assay_id,confidence_score,assay_organism,description,assay_type,assay_tax_id,assay_tissue,assay_subcellular_fraction,assay_category,chembl_id,doc_id,relationship_type,bao_format,src_id,tissue_id,assay_test_type,assay_strain,assay_cell_type,tid
1,8,,The compound was tested for the in vitro inhibition of platelet 12-lipoxygenase at a concentration of 30 uM,B,,,,,CHEMBL615117,11087,H,BAO_0000019,1,,,,,12052
2,0,,Compound was evaluated for its ability to mobilize calcium in 1321NI cells,F,,,,,CHEMBL615118,684,U,BAO_0000219,1,,,,,22226
3,0,,,B,,,,,CHEMBL615119,15453,U,BAO_0000019,1,,,,,22226
4,4,Bos taurus,Binding affinity against A2 adenosine receptor in bovine striatal membranes using [3H]CGS-21680,B,9913.0,,,,CHEMBL615120,17841,H,BAO_0000249,1,,,,,104729
5,1,Homo sapiens,In vitro cell cytotoxicity against 143-B cell lines (Human osteosarcoma cell line),F,9606.0,,,,CHEMBL615121,17430,N,BAO_0000219,1,,,,143B,80001
6,1,Homo sapiens,In vitro cell cytotoxicity against 143-B cell lines (Human osteosarcoma cell line),F,9606.0,,,,CHEMBL615122,17430,N,BAO_0000219,1,,,,143B,80001
7,1,Mus musculus,Cytotoxic Activity was evaluated against 143B (TK-) tumor cells,F,10090.0,,,,CHEMBL615123,13799,N,BAO_0000219,1,,,,143B,80001
8,1,Homo sapiens,In vitro cell cytotoxicity was determined against 143B cell line,F,9606.0,,,,CHEMBL615124,17774,N,BAO_0000219,1,,,,143B,80001
9,1,Homo sapiens,Inhibitory activity against tumor osteosarcoma cell line 143B after 72 hr continuous exposure to compound,F,9606.0,,,,CHEMBL615125,3801,N,BAO_0000219,1,,,,143B,80001
10,1,Homo sapiens,In vitro cell cytotoxicity against 143B-LTK cell lines expressed in HSV-1 TK,F,9606.0,,,,CHEMBL615126,17430,N,BAO_0000219,1,,,,143B,80001
11,1,Homo sapiens,In vitro cell cytotoxicity against 143B-LTK cell lines expressed in HSV-1 TK,F,9606.0,,,,CHEMBL615127,17430,N,BAO_0000219,1,,,,143B,80001
12,1,Homo sapiens,In vitro cell cytotoxicity was determined against 143B-LTK cell line,F,9606.0,,,,CHEMBL615128,17774,N,BAO_0000219,1,,,,143B,80001
13,1,Staphylococcus aureus,"The compound was tested for minimum inhibitory concentration in Staphylococcus aureus,147N penicillin sensitive Staphylococcus aureus",F,1280.0,,,,CHEMBL857900,11324,N,BAO_0000218,1,,,,,50185
14,1,Staphylococcus aureus,"The compound was tested for minimum inhibitory concentration in Staphylococcus aureus,147N penicillin sensitive Staphylococcus aureus",F,1280.0,,,,CHEMBL615129,11324,N,BAO_0000218,1,,,,,50185
15,1,Staphylococcus aureus,"The compound was tested for minimum inhibitory concentration in Staphylococcus aureus,147N penicillin sensitive Staphylococcus aureus",F,1280.0,,,,CHEMBL615130,11324,N,BAO_0000218,1,,,,,50185
16,1,Staphylococcus aureus,"The compound was tested for minimum inhibitory concentration in Staphylococcus aureus,147N penicillin sensitive Staphylococcus aureus",F,1280.0,,,,CHEMBL615131,11324,N,BAO_0000218,1,,,,,50185
17,9,Rattus norvegicus,Inhibition of cytochrome P450 progesterone 15-alpha hydroxylase,A,10116.0,,,,CHEMBL884521,11347,D,BAO_0000357,1,,,,,100122
18,8,,Concentration that cause 50% activation of human reticulocyte 15-lipoxygenase (15-HLO),B,,,,,CHEMBL615132,16474,H,BAO_0000357,1,,,,,12054
19,8,,Inhibition of partially purified 15-lipoxygenase from human leukocytes,B,,,,,CHEMBL615133,10091,H,BAO_0000019,1,,,,,12054
20,8,,Inhibitory activity against human reticulocyte 15-lipoxygenase (15-HLO),B,,,,,CHEMBL615134,16474,H,BAO_0000357,1,,,,,12054
21,8,,Compound was evaluated for the percent increase in activation concentration of human reticulocyte 15-lipoxygenase (15-HLO),B,,,,,CHEMBL615135,16474,H,BAO_0000357,1,,,,,12054
22,8,,Inhibitory activity against human reticulocyte 15-lipoxygenase (15-HLO),B,,,,,CHEMBL615136,16474,H,BAO_0000357,1,,,,,12054
23,8,,Inhibitory activity against human reticulocyte 15-lipoxygenase (15-HLO); NI is no inhibition,B,,,,,CHEMBL615137,16474,H,BAO_0000357,1,,,,,12054
24,8,,Inhibitory activity against human reticulocyte 15-lipoxygenase (15-HLO); NI is no inhibition,B,,,,,CHEMBL615138,16474,H,BAO_0000357,1,,,,,12054
25,0,,"Inhibitory concentration against 15-lipoxygenase, by inhibiting 15-HETE production by human umbilical vein endothelial cells (HUVEC) stimulated by calcium ionophore A 23187 at concentration of 10e-5 M.",B,,,,,CHEMBL836324,14352,U,BAO_0000219,1,,,,,22226
26,8,Oryctolagus cuniculus,In vitro inhibitory activity of compound on rabbit reticulocyte 15-lipoxygenase,B,9986.0,,,,CHEMBL615139,5646,H,BAO_0000357,1,,,,,12054
27,8,Oryctolagus cuniculus,Inhibition of rabbit reticulocyte 15-lipoxygenase by compound (30 uM),B,9986.0,,,,CHEMBL615140,5646,H,BAO_0000357,1,,,,,12054
28,8,,Inhibitory activity against 15-lipoxygenase in rat polymorphonuclear leukocytes,B,,,,,CHEMBL615141,10997,H,BAO_0000219,1,,,,,12426
29,8,soya bean,Inhibitory activity against 15-lipoxygenase was determined obtained from soya bean,B,3847.0,,,,CHEMBL615142,6309,H,BAO_0000357,1,,,,,12054
30,8,Glycine max,Inhibitory activity against soybean 15-lipoxygenase was evaluated,B,3847.0,,,,CHEMBL615143,167,H,BAO_0000357,1,,,,,12054
31,8,Glycine max,Inhibitory activity against soybean 15-lipoxygenase was evaluated at 100 uM,B,3847.0,,,,CHEMBL615144,167,H,BAO_0000357,1,,,,,12054
32,8,Glycine max,The compound was tested for the in vitro inhibition of 15-lipoxygenase of soybean at a concentration of 10 uM,B,3847.0,,,,CHEMBL872867,11087,H,BAO_0000357,1,,,,,12054
33,8,Glycine max,The compound was tested for the in vitro inhibition of 15-lipoxygenase of soybean at a concentration of 100 uM,B,3847.0,,,,CHEMBL615145,11087,H,BAO_0000357,1,,,,,12054
34,8,Glycine max,Compound was tested in vitro for inhibition of 15-lipoxygenase soybean,B,3847.0,,,,CHEMBL615146,13622,H,BAO_0000357,1,,,,,12054
35,8,Glycine max,Compound at 100 uM was tested in vitro for inhibition of 15-lipoxygenase soybean,B,3847.0,,,,CHEMBL615147,13622,H,BAO_0000357,1,,,,,12054
36,0,Rattus norvegicus,Inhibition of cytochrome P450 progesterone 16-alpha hydroxylase,A,10116.0,,,,CHEMBL615148,11347,U,BAO_0000019,1,,,,,22226
37,0,Escherichia coli,Binding affinity against bacterial 16S rRNA using mass spectrometry based assay,B,562.0,,,,CHEMBL615149,5926,U,BAO_0000019,1,,,,,22226
38,0,,Dissociation constant with dimeric 16S rRNA RNA construct B,B,,,,,CHEMBL615150,4567,U,BAO_0000019,1,,,,,22226
39,3,,Dissociation constant towards 16S rRNA construct A,B,,,,,CHEMBL615151,3782,M,BAO_0000225,1,,,,,22222
40,3,,Dissociation constant towards 16S rRNA construct B,B,,,,,CHEMBL615152,3782,M,BAO_0000225,1,,,,,22222
41,3,Escherichia coli,Binding affinity of aminoglycoside to 16S ribosomal RNA A-site in Escherichia coli,B,562.0,,,,CHEMBL615153,4466,M,BAO_0000225,1,,,,,100263
42,3,Escherichia coli,Binding affinity for the 16S ribosomal RNA A-site of Escherichia coli,B,562.0,,,,CHEMBL615154,6592,M,BAO_0000225,1,,,,,100263
43,8,,Inhibitory activity against human placenta 17-beta-hydroxysteroid dehydrogenase type 2 (17-beta-HSD type 2),B,,,,,CHEMBL615155,898,H,BAO_0000019,1,,,,,13053
44,8,,Inhibitory constant against human placenta 17-beta-hydroxysteroid dehydrogenase type 2 (17-beta-HSD type 2),B,,,,,CHEMBL615156,898,H,BAO_0000019,1,,,,,13053
45,8,Homo sapiens,The compound was tested at a concentration of 1 uM for inhibitory activity against 17 beta-hydroxysteroid dehydrogenase from human placental microsomes,B,9606.0,,,,CHEMBL615157,13163,H,BAO_0000019,1,,,,,20001
46,8,Homo sapiens,The compound was tested at a concentration of 1 uM for inhibitory activity against 17 beta-hydroxysteroid dehydrogenase from human placental microsomes,B,9606.0,,,,CHEMBL615158,13163,H,BAO_0000019,1,,,,,20001
47,9,Rattus norvegicus,"Inhibition of 17-alpha-hydroxylase/17,20 lyase from rat testes microsomal preparation",B,10116.0,,,,CHEMBL615159,10691,D,BAO_0000019,1,,,,,12971
48,9,Rattus norvegicus,"Inhibition of 17-alpha-hydroxylase/17,20 lyase from rat testes microsomal preparation",B,10116.0,,,,CHEMBL615172,10691,D,BAO_0000019,1,,,,,12971
49,9,Rattus norvegicus,"Percent inhibition of 17-alpha-hydroxylase/17,20 lyase of rat testes microsomes at 100 uM",B,10116.0,,,,CHEMBL615173,10691,D,BAO_0000019,1,,,,,12971
50,9,Rattus norvegicus,"Percent inhibition of Steroid 17-alpha-hydroxylase/17,20 lyase of rat testes microsomes at 100 uM",B,10116.0,,,,CHEMBL615174,10691,D,BAO_0000019,1,,,,,12971
51,8,,Inhibitory activity against human placenta 17-beta-hydroxysteroid dehydrogenase type 2 (17-beta-HSD type 2),B,,,,,CHEMBL884518,898,H,BAO_0000019,1,,,,,13053
52,8,,Compound was tested for the inhibition of 17-beta-hydroxysteroid dehydrogenase type 1(17-beta-HSD type 1),B,,,,,CHEMBL615175,912,H,BAO_0000357,1,,,,,11512
53,8,,Compound was tested for the inhibition of 17-beta-hydroxysteroid dehydrogenase type 1(17-beta-HSD type 1) at 1 uM concentration,B,,,,,CHEMBL615176,912,H,BAO_0000357,1,,,,,11512
54,8,,Compound was tested for the inhibition of 17-beta-hydroxysteroid dehydrogenase type 1(17-beta-HSD type 1) at 10 uM concentration,B,,,,,CHEMBL615177,912,H,BAO_0000357,1,,,,,11512
55,5,Rattus norvegicus,Selectivity ratio of binding affinity towards mu to delta receptors of rat brain membranes,B,10116.0,,Membranes,,CHEMBL615178,15103,D,BAO_0000249,1,,,,,104740
56,1,Homo sapiens,Cytotoxicity against ovarian cancer cell line (1A-9) of humans was determined,F,9606.0,,,,CHEMBL615179,5116,N,BAO_0000219,1,,,,1A9,80002
57,7,Rattus norvegicus,Functional antagonism by electrical assays in Xenopus oocytes expressing 1A/2A NMDA receptor subtype,F,10116.0,,,,CHEMBL615180,14578,D,BAO_0000219,1,,,,Oocytes,104835
58,7,Rattus norvegicus,Functional antagonism by electrical assays in Xenopus oocytes expressing the 1A/2B NMDA receptor,F,10116.0,,,,CHEMBL615181,14578,D,BAO_0000219,1,,,,Oocytes,104821
59,7,Rattus norvegicus,Functional antagonism by electrical assays in Xenopus oocytes expressing the 1A/2C NMDA receptor,F,10116.0,,,,CHEMBL615182,14578,D,BAO_0000219,1,,,,Oocytes,104848
60,1,Homo sapiens,In vitro effective concentration required to reduce the number of human ovarian cancer (1A9) after 3-day incubation,F,9606.0,,,,CHEMBL615183,4787,N,BAO_0000219,1,,,,1A9,80002
61,1,Homo sapiens,In vitro effective concentration required to reduce the number of human ovarian cancer cells (1A9) after 3-day incubation,F,9606.0,,,,CHEMBL615184,4787,N,BAO_0000219,1,,,,1A9,80002
62,1,Homo sapiens,Cytotoxic activity against human ovarian cancer (1A9) cell line,F,9606.0,,,,CHEMBL615185,3547,N,BAO_0000219,1,,,,1A9,80002
63,1,Homo sapiens,Cytotoxic activity against human ovarian cancer (1A9) cell line; ND=Not determined,F,9606.0,,,,CHEMBL615186,3547,N,BAO_0000219,1,,,,1A9,80002
64,1,Homo sapiens,Effective dose of compound against replication of 1A9 cell line was evaluated,F,9606.0,,,,CHEMBL615187,6726,N,BAO_0000219,1,,,,1A9,80002
65,1,Homo sapiens,In vitro cytotoxic activity was determined against ovarian cancer (1A9) cell line,F,9606.0,,,,CHEMBL885343,3455,N,BAO_0000219,1,,,,1A9,80002
66,1,Homo sapiens,In vitro cytotoxicity evaluated against human ovarian cancer (1A9 cell line),F,9606.0,,,,CHEMBL615188,5726,N,BAO_0000219,1,,,,1A9,80002
67,1,Homo sapiens,In vitro cytotoxicity evaluated against human ovarian cancer (1A9 cell line); NA is not active,F,9606.0,,,,CHEMBL615189,5726,N,BAO_0000219,1,,,,1A9,80002
68,1,Homo sapiens,In vitro percent inhibition evaluated against human ovarian cancer (1A9 cell line) at >20 ug/mL,F,9606.0,,,,CHEMBL615190,5726,N,BAO_0000219,1,,,,1A9,80002
69,1,Homo sapiens,Inhibitory activity against Taxol resistant 1A9 cell lines,F,9606.0,,,,CHEMBL615191,3395,N,BAO_0000219,1,,,,1A9,80002
70,1,Homo sapiens,Cytotoxicity against human ovarian cancer (1A9) cell lines.,F,9606.0,,,,CHEMBL615192,3415,N,BAO_0000219,1,,,,1A9,80002
71,1,Homo sapiens,Percentage inhibition of human ovarian cancer (1A9) cell lines.,F,9606.0,,,,CHEMBL827083,3415,N,BAO_0000219,1,,,,1A9,80002
72,1,Homo sapiens,Effective dose required for inhibitory activity against 1A9 human tumor cell line.,F,9606.0,,,,CHEMBL615193,17099,N,BAO_0000219,1,,,,1A9,80002
73,1,Homo sapiens,Percent inhibition against 1A9 human tumor cell line at 0.10 ug/mL,F,9606.0,,,,CHEMBL615194,17099,N,BAO_0000219,1,,,,1A9,80002
74,1,Homo sapiens,Percent inhibition against 1A9 human tumor cell line at <0.00008 ug/mL,F,9606.0,,,,CHEMBL615195,17099,N,BAO_0000219,1,,,,1A9,80002
75,1,Homo sapiens,Percent inhibition against 1A9 human tumor cell line at >10 ug/mL,F,9606.0,,,,CHEMBL615196,17099,N,BAO_0000219,1,,,,1A9,80002
76,1,Homo sapiens,Inhibitory concentration against Jurkat cells,F,9606.0,,,,CHEMBL615197,17721,N,BAO_0000219,1,,,,Jurkat,81072
77,0,,In vitro anticancer activity against 2 NCI SCLC cell lines; inactive,F,,,,,CHEMBL615198,1229,U,BAO_0000019,1,,,,,22226
78,9,Rattus norvegicus,Inhibition of cytochrome P450 progesterone 2-alpha-hydroxylase,A,10116.0,,,,CHEMBL615199,11347,D,BAO_0000357,1,,,,,100121
79,8,,"In vitro inhibition of human 2,3-oxidosqualene cyclase.",B,,,,,CHEMBL615200,17117,H,BAO_0000357,1,,,,,11231
80,8,,"In vitro inhibition of human 2,3-oxidosqualene cyclase.",B,,,,,CHEMBL615201,17117,H,BAO_0000357,1,,,,,11231
81,8,,"In vitro inhibition of human 2,3-oxidosqualene cyclase at 100 nM.",B,,,,,CHEMBL615202,17117,H,BAO_0000357,1,,,,,11231
82,8,Candida albicans,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene cyclase in Candida albicans microsomes",B,5476.0,,Microsomes,,CHEMBL615203,11375,H,BAO_0000251,1,,,,,11231
83,8,Candida albicans,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene-lanosterol cyclase in Candida albicans microsomes",B,5476.0,,Microsomes,,CHEMBL615204,11375,H,BAO_0000251,1,,,,,11231
84,8,Saccharomyces cerevisiae,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene cyclase in Saccharomyces cerevisiae microsomes",B,4932.0,,Microsomes,,CHEMBL615205,11375,H,BAO_0000251,1,,,,,11231
85,8,Saccharomyces cerevisiae,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene-lanosterol cyclase in Saccharomyces cerevisiae microsomes",B,4932.0,,Microsomes,,CHEMBL615206,11375,H,BAO_0000251,1,,,,,11231
86,8,Sus scrofa,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene-lanosterol cyclase in pig liver microsomes",B,9823.0,Liver,Microsomes,,CHEMBL615207,11375,H,BAO_0000251,1,2107.0,,,,12083
87,8,Rattus norvegicus,"Concentration required to inhibit rat liver 2,3-oxidosqualene-lanosterol cyclase",B,10116.0,,,,CHEMBL827084,791,H,BAO_0000019,1,,,,,11231
88,8,Rattus norvegicus,"Concentration required to inhibit rat liver 2,3-oxidosqualene-lanosterol cyclase (OSC)",B,10116.0,,,,CHEMBL615208,791,H,BAO_0000019,1,,,,,11231
89,8,Rattus norvegicus,"Evaluated for its activity to inhibit rat liver 2,3-oxidosqualene-lanosterol cyclase, activity expressed as Ki",B,10116.0,,,,CHEMBL615209,791,H,BAO_0000019,1,,,,,11231
90,9,Rattus norvegicus,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene cyclase in rat liver microsomes",B,10116.0,Liver,Microsomes,,CHEMBL615210,11375,D,BAO_0000251,1,2107.0,,,,12083
91,9,Rattus norvegicus,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene-lanosterol cyclase in rat liver microsomes",B,10116.0,Liver,Microsomes,,CHEMBL615211,11375,D,BAO_0000251,1,2107.0,,,,12083
92,9,Rattus norvegicus,"Compound was evaluated for inhibitory activity against 2,3-oxidosqualene-lanosterol cyclase in rat liver microsomes",B,10116.0,Liver,Microsomes,,CHEMBL615212,153,D,BAO_0000251,1,2107.0,,,,12083
93,8,,Molar concentration needed to give 50% prevention of 2-5A (Adenosine dependent endoribonuclease),B,,,,,CHEMBL615213,8269,H,BAO_0000357,1,,,,,11377
94,8,,Molar concentration required to displace 50% of the radiolabeled probe from 2-5A (Adenosine dependent endoribonuclease) in endonuclease-nitrocellulose complex,B,,,,,CHEMBL615273,8269,H,BAO_0000357,1,,,,,11377
95,1,Homo sapiens,In vitro cytotoxic concentration required to inhibit hepatitisB virus (HBV) replication in 2.2.15 cell line,F,9606.0,,,,CHEMBL615274,17653,N,BAO_0000219,1,,,,HepG2,81020
96,1,Homo sapiens,50% Effective concentration of compound required for inhibiting intracellular viral replicative intermediate DNA in HBV-transfected 2.2.15 cell line.,F,9606.0,,,,CHEMBL615275,14277,N,BAO_0000219,1,,,,HepG2,81020
97,1,Homo sapiens,Antiviral activity against Hepatitis B virus in 2.2.15 cell line,F,9606.0,,,,CHEMBL615276,1717,N,BAO_0000219,1,,,,HepG2,81020
98,1,Homo sapiens,In vitro effective concentration against hepatitis B virus was determined in 2.2.15 cells,F,9606.0,,,,CHEMBL615277,14091,N,BAO_0000219,1,,,,HepG2,81020
99,1,Homo sapiens,In vitro effective concentration against hepatitis B virus was determined in 2.2.15 cells; Not determined,F,9606.0,,,,CHEMBL615326,14091,N,BAO_0000219,1,,,,HepG2,81020
100,1,Hepatitis B virus,In vitro effective concentration required to inhibit hepatitisB virus (HBV) replication in 2.2.15 cell line,F,10407.0,,,,CHEMBL883130,17653,N,BAO_0000218,1,,,,,50606
101,1,Homo sapiens,Ability to inhibit the episomal HBV-DNA in 2.2.15 cells.,F,9606.0,,,,CHEMBL884519,13105,N,BAO_0000219,1,,,,HepG2,81020
102,1,Homo sapiens,Concentration required to inhibit 50% of 2.2.15 cell line,F,9606.0,,,,CHEMBL615327,1717,N,BAO_0000219,1,,,,HepG2,81020
103,1,Homo sapiens,Anti viral activity against 2.2.15 cells (concentration required to reduce the log phase cell growth by 50%).,A,9606.0,,,,CHEMBL615328,13105,N,BAO_0000219,1,,,,HepG2,81020
104,1,Homo sapiens,Cytotoxic activity of compound against uninfected 2.2.15 cells.,F,9606.0,,,,CHEMBL615329,13600,N,BAO_0000218,1,,,,2.2.15,50587
105,1,Homo sapiens,Anti hepatitis-B virus activity was evaluated in 2.2.15 cells.,F,9606.0,,,,CHEMBL615330,13467,N,BAO_0000218,1,,,,2.2.15,50587
106,1,Hepatitis B virus,"Inhibition of the replication of HBV in 2.2.15 cells, by DNA hybridization assay",F,10407.0,,,,CHEMBL615331,17477,N,BAO_0000218,1,,,,2.2.15,50606
107,1,Homo sapiens,In vitro anti-HBV activity in 2.2.15 cells,F,9606.0,,,,CHEMBL615332,1593,N,BAO_0000218,1,,,,2.2.15,50587
108,1,Homo sapiens,In vitro anti-HBV activity in 2.2.15 cells; Not determined,F,9606.0,,,,CHEMBL615333,1593,N,BAO_0000218,1,,,,2.2.15,50587
109,1,Homo sapiens,The compound was tested in vitro for the anti-HBV activity against 2.2.15 cells,F,9606.0,,,,CHEMBL615334,15089,N,BAO_0000218,1,,,,2.2.15,50587
110,1,Homo sapiens,The compound was tested in vitro for the anti-HBV activity in 2.2.15 cells,F,9606.0,,,,CHEMBL615335,15089,N,BAO_0000218,1,,,,2.2.15,50587
111,1,Homo sapiens,Cytotoxicity in 2.2.15 cells,F,9606.0,,,,CHEMBL615336,1593,N,BAO_0000218,1,,,,2.2.15,50587
112,1,Homo sapiens,Cytotoxicity in 2.2.15 cells; Not determined,F,9606.0,,,,CHEMBL615337,1593,N,BAO_0000218,1,,,,2.2.15,50587
113,1,Homo sapiens,Inhibitory activity of compound against hepatitis B virus (HBV) in growing cultures of 2.2.15 cells,F,9606.0,,,,CHEMBL615338,13600,N,BAO_0000218,1,,,,2.2.15,50587
114,1,Homo sapiens,The growth inhibition activity for the compound was evaluated in 2.2.15 cells.,F,9606.0,,,,CHEMBL615339,13467,N,BAO_0000218,1,,,,2.2.15,50587
115,1,Homo sapiens,Selectivity index was determined from the ratio of IC50 to the EC50 values evaluated in 2.2.15 cells.,F,9606.0,,,,CHEMBL615340,13467,N,BAO_0000218,1,,,,2.2.15,50587
116,1,Homo sapiens,Antiviral activity against HBV was determined in 2.215 cell line,F,9606.0,,,,CHEMBL615341,14764,N,BAO_0000219,1,,,,HepG2,81020
117,0,Homo sapiens,Inhibition of 20-HETE synthesis in human renal microsomes,B,9606.0,,Microsomes,,CHEMBL615342,6531,U,BAO_0000251,1,,,,,22226
118,0,,Inhibitory activity against 20-HETE production from arachidonic acid using human renal microsome 20-HETE synthase.,B,,,,,CHEMBL615343,17322,U,BAO_0000019,1,,,,,22226
119,1,Homo sapiens,Inhibitory concentration against 2008 (ovarian) cells,F,9606.0,,,,CHEMBL615344,17072,N,BAO_0000219,1,,,,2008,80612
120,1,Homo sapiens,50% Growth inhibitory concentration( GI 50 ) by using 2008 human ovarian carcinoma cell lines.,F,9606.0,,,,CHEMBL615345,16936,N,BAO_0000219,1,,,,2008,80612
121,1,Homo sapiens,Compound was tested for 50% growth inhibitory concentration by using human ovarian carcinoma cell lines (2008),F,9606.0,,,,CHEMBL615346,16936,N,BAO_0000219,1,,,,2008,80612
122,1,Homo sapiens,Direct cytotoxicity against the selected tumor cell line 2008 was determined especially on ovarian adenocarcinoma derived cells,F,9606.0,,,,CHEMBL615347,17146,N,BAO_0000219,1,,,,2008,80612
123,1,Homo sapiens,Direct cytotoxicity against the selected tumor cell line 2008 was determined especially on ovarian adenocarcinoma derived cells; not detected,F,9606.0,,,,CHEMBL615348,17146,N,BAO_0000219,1,,,,2008,80612
124,1,Homo sapiens,In vitro inhibition of 2008/R ovarian cancer cell line,F,9606.0,,,,CHEMBL827085,10797,N,BAO_0000219,1,,,,2008/R,80613
125,1,Homo sapiens,In vitro inhibition of 2008/R ovarian cancer cell line; NA= Not achievable,F,9606.0,,,,CHEMBL615349,10797,N,BAO_0000219,1,,,,2008/R,80613
126,1,Homo sapiens,In vitro inhibition of 2008/S ovarian cancer cell line,F,9606.0,,,,CHEMBL615350,10797,N,BAO_0000219,1,,,,2008/S,80614
127,1,Homo sapiens,In vitro inhibition of 2008/S ovarian cancer cell line; NA= Not achievable,F,9606.0,,,,CHEMBL615351,10797,N,BAO_0000219,1,,,,2008/S,80614
128,2,Homo sapiens,Tested in vitro for inhibition of chymotrypsin like activity of purified human 20S proteasome,B,9606.0,,,,CHEMBL615352,4823,S,BAO_0000220,1,,,,,100256
129,2,Homo sapiens,Compound was evaluated for inhibitory activity against 20S proteasome from human liver and brain,B,9606.0,,,,CHEMBL615353,12912,S,BAO_0000220,1,,,,,100256
130,2,,Inhibition of chymotrypsin-like activity of 20S proteasome,B,,,,,CHEMBL615354,2957,S,BAO_0000220,1,,,,,100256
131,2,,Inhibition of chymotrypsin-like activity of 20S proteasome; value ranges from 10-20 uM,B,,,,,CHEMBL615355,2957,S,BAO_0000220,1,,,,,100256
132,2,,Inhibitory activity against 20S proteosome,B,,,,,CHEMBL615356,3260,S,BAO_0000220,1,,,,,100256
133,0,Homo sapiens,Compound was tested for inhibitory activity against tryptase,B,9606.0,,,,CHEMBL615357,3451,U,BAO_0000019,1,,,,,22226
134,1,Homo sapiens,Concentration required to inhibit 50% of extracellular circular replication of HBV DNA using 2215 cell line,F,9606.0,,,,CHEMBL615358,13885,N,BAO_0000219,1,,,,HepG2,81020
135,1,Homo sapiens,Concentration required to inhibit 50% of intracellular circular replication of HBV DNA using 2215 cell line,F,9606.0,,,,CHEMBL827086,13885,N,BAO_0000219,1,,,,HepG2,81020
136,0,,Compound was tested for the inhibition of Alpha-glucosidase,B,,,,,CHEMBL615359,3676,U,BAO_0000019,1,,,,,22226
137,8,,Inhibitory concentration against human neutrophil elastase (HNE),B,,,,,CHEMBL615360,6043,H,BAO_0000357,1,,,,,235
138,0,Rattus norvegicus,Change in heart rate was expressed in percent at at a dose 0.002 mg/kg iv in anesthetized rat,F,10116.0,Heart,,,CHEMBL615361,11140,U,BAO_0000218,1,948.0,,,,22226
139,8,,90% inhibition of the 20 Mycobacterium avium complex (MAC) clinical isolates,F,,,,,CHEMBL615362,10543,H,BAO_0000019,1,,,,,19640
140,8,,Minimum inhibitory concentration of compound against 20 Mycobacterium avium complex (MAC) clinical isolates,F,,,,,CHEMBL615363,10543,H,BAO_0000019,1,,,,,19640
141,8,,Minimum inhibitory concentration of compound against 20 Mycobacterium avium complex (MAC) clinical isolates,B,,,,,CHEMBL615364,10543,H,BAO_0000357,1,,,,,19640
142,8,,90% inhibition of the 20 Mycobacterium avium complex (MAC) clinical isolates,F,,,,,CHEMBL615365,10543,H,BAO_0000019,1,,,,,19640
143,1,Mus musculus,In Vitro evaluation for the growth inhibition of Subline (P388/AMSA) Leukemia cell lines,F,10090.0,,,,CHEMBL615366,11365,N,BAO_0000219,1,,,,P338,80360
144,1,Mus musculus,In Vitro evaluation for the growth inhibition of Subline (P388/CP) Leukemia cell lines,F,10090.0,,,,CHEMBL615367,11365,N,BAO_0000219,1,,,,P338,80360
145,1,Homo sapiens,Compound was evaluated for the inhibition of cell replication human peripheral blood lymphocytes (PBL's).,F,9606.0,,,,CHEMBL615368,11803,N,BAO_0000219,1,,,,PBL,80384
146,0,Ovis aries,Compound was evaluated for the inhibition of cell replication sheep choroid plexus (SCP) cells,F,9940.0,,,,CHEMBL615369,11803,U,BAO_0000019,1,,,,,22226
147,0,Ovis aries,Compound was evaluated for the inhibition of cell replication sheep choroid plexus (SCP) cells.,F,9940.0,,,,CHEMBL615370,11803,U,BAO_0000019,1,,,,,22226
148,8,,Compound is evaluated in vitro for the inhibition single mutant of HIV-1 RT (Y181C),B,,,,,CHEMBL615673,12278,H,BAO_0000357,1,,,,,191
149,0,Homo sapiens,Compound was evaluated for its inhibitory effect on thymidine [3H]dThd) incorporation into DNA of CEM/MTX cells in culture at conc. 10e-5,F,9606.0,,,,CHEMBL615674,8249,U,BAO_0000019,1,,,,,22226
150,0,Homo sapiens,Compound was evaluated for its inhibitory effect on thymidine [3H]-dThd) incorporation into DNA of CEM/MTX cells in culture at conc. 10e-6,F,9606.0,,,,CHEMBL615675,8249,U,BAO_0000019,1,,,,,22226
151,0,Homo sapiens,Compound was evaluated for its inhibitory effect on thymidine ([3H]dThd) incorporation into DNA of CEM cells in at conc. 10e-7,F,9606.0,,,,CHEMBL615676,8249,U,BAO_0000219,1,,,,CCRF-CEM,22226
152,0,Homo sapiens,Compound was evaluated for its inhibitory effect on thymidine ([3H]-dThd) incorporation into DNA of CEM cells in culture at conc. 10e-4,F,9606.0,,,,CHEMBL615677,8249,U,BAO_0000219,1,,,,CCRF-CEM,22226
153,0,Homo sapiens,Compound was evaluated for its inhibitory effect on thymidine ([3H]dThd) incorporation into DNA of CEM cells in culture at conc. 10e-5,F,9606.0,,,,CHEMBL615678,8249,U,BAO_0000219,1,,,,CCRF-CEM,22226
154,0,Homo sapiens,Compound was evaluated for its inhibitory effect on thymidine ([3H]dThd) incorporation into DNA of CEM cells in culture at conc. 10e-6,F,9606.0,,,,CHEMBL615679,8249,U,BAO_0000219,1,,,,CCRF-CEM,22226
155,0,Homo sapiens,Compound was evaluated for its inhibitory effect on thymidine ([3H]-dThd) incorporation into DNA of CEM/MTX cells in at conc. 10e-7.,F,9606.0,,,,CHEMBL615680,8249,U,BAO_0000019,1,,,,,22226
156,0,Homo sapiens,Compound was evaluated for its inhibitory effect on thymidine ([3H]dThd) incorporation into DNA of CEM/MTX cells in culture at conc. 10e-4,F,9606.0,,,,CHEMBL615681,8249,U,BAO_0000019,1,,,,,22226
157,6,,In vitro binding affinity towards (alpha-4)2(beta-2)3 neuronal nicotinic acetylcholine receptor in P2 membrane fractions of rat forebrain,B,,,,,CHEMBL857972,16992,H,BAO_0000249,1,,,,,104290
158,1,Streptococcus pyogenes,Minimum inhibitory concentration of compound against Streptococcus pyogenus septicemia in the mouse,F,1314.0,,,,CHEMBL857899,10543,N,BAO_0000218,1,,,,,50264
159,1,Human herpesvirus 3,Antiviral activity against 07/1 strain of thymidine kinase negative (TK-) Varicella-Zoster Virus (VZV),F,10335.0,,,,CHEMBL615371,17833,N,BAO_0000218,1,,,,,50527
160,1,vericilla zoster virus,Antiviral activity against 07/1 strain of VZV in HEL (human erythroleukemia) cells.,F,10335.0,,,,CHEMBL615372,17290,N,BAO_0000218,1,,,,HEL,50527
161,1,vericilla zoster virus,Antiviral activity against 07/1 strain of VZV; ND: No data,F,10335.0,,,,CHEMBL615373,17290,N,BAO_0000218,1,,,,,50527
162,1,vericilla zoster virus,Antiviral activity against 07/1 strain of VZV; ND=No data,F,10335.0,,,,CHEMBL615374,17290,N,BAO_0000218,1,,,,,50527
163,1,escherichia cloac,"Antibacterial activity was determined against gram negative organism, Enterobacter cloacae (MA2646)",F,561.0,,,,CHEMBL615375,10932,N,BAO_0000218,1,,,,,50145
164,0,,Ratio of Ki at A2 to Ki at A1 receptors,B,,,,,CHEMBL615376,9707,U,BAO_0000019,1,,,,,22226
165,8,Candida albicans,"In vitro inhibition of 1,3-beta-glucan synthase in Candida albicans membrane assay.",B,5476.0,,,,CHEMBL615377,2346,H,BAO_0000249,1,,,,,11143
166,8,Candida glabrata CBS 138,"Inhibition of 1,3-beta-glucan synthase",B,284593.0,,,,CHEMBL615378,2205,H,BAO_0000357,1,,,,,18077
167,1,Homo sapiens,Inhibition of growth of 1-87 human tumor cell line,F,9606.0,,,,CHEMBL615379,11900,N,BAO_0000219,1,,,,1-87 tumor cell line,80609
168,9,Rattus norvegicus,Inhibition of 1-lipoxygenase (LOX)in RBL cells,B,10116.0,,,,CHEMBL615380,14864,D,BAO_0000219,1,,,,,12166
169,9,Glycine max,Inhibitory activity against soybean 1-lipoxygenase (SLO),B,3847.0,,,,CHEMBL615381,16474,D,BAO_0000357,1,,,,,100171
170,9,Glycine max,Inhibitory activity against soybean 1-lipoxygenase (SLO); no effect,B,3847.0,,,,CHEMBL615382,16474,D,BAO_0000357,1,,,,,100171
171,9,Glycine max,% inhibition against soybean 1-lipoxygenase (SLO),B,3847.0,,,,CHEMBL615383,16474,D,BAO_0000357,1,,,,,100171
172,9,Glycine max,percent inhibition against soybean 1-lipoxygenase (SLO);NI is no inhibition,B,3847.0,,,,CHEMBL615384,16474,D,BAO_0000357,1,,,,,100171
173,9,Glycine max,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 10:90,B,3847.0,,,,CHEMBL615385,3094,D,BAO_0000357,1,,,,,100171
174,9,Glycine max,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 1:99,B,3847.0,,,,CHEMBL615386,3094,D,BAO_0000357,1,,,,,100171
175,9,Glycine max,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 25:75,B,3847.0,,,,CHEMBL615387,3094,D,BAO_0000357,1,,,,,100171
176,9,Glycine max,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 35:65,B,3847.0,,,,CHEMBL615388,3094,D,BAO_0000357,1,,,,,100171
177,9,Glycine max,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 50:50,B,3847.0,,,,CHEMBL615214,3094,D,BAO_0000357,1,,,,,100171
178,9,Glycine max,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 76:24,B,3847.0,,,,CHEMBL827087,3094,D,BAO_0000357,1,,,,,100171
179,9,Glycine max,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 87:13,B,3847.0,,,,CHEMBL615215,3094,D,BAO_0000357,1,,,,,100171
180,9,Glycine max,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 89:11,B,3847.0,,,,CHEMBL615216,3094,D,BAO_0000357,1,,,,,100171
181,9,Glycine max,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 95:5,B,3847.0,,,,CHEMBL615217,3094,D,BAO_0000357,1,,,,,100171
182,9,Glycine max,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 97:3,B,3847.0,,,,CHEMBL615218,3094,D,BAO_0000357,1,,,,,100171
183,9,Glycine max,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 99:1,B,3847.0,,,,CHEMBL615219,3094,D,BAO_0000357,1,,,,,100171
184,0,Mus musculus,Evaluated for inhibitory activity on 10-formyltetrahydrofolate synthetase(L cell) at folate substrate concentration of 100 uM,B,10090.0,,,,CHEMBL615220,10413,U,BAO_0000019,1,,,,,22226
185,1,Mus musculus,Cells were harvested and were assayed for luciferase and -galactosidase activities (Transcriptional activity),F,10090.0,,,,CHEMBL615221,16929,N,BAO_0000219,1,,,,C3H 10T1/2,80049
186,0,,In vitro anticancer activity against 11 NCI NSCLC cell lines; inactive,F,,,,,CHEMBL615222,1229,U,BAO_0000019,1,,,,,22226
187,8,,In vitro inhibitory activity against human 11 beta hydroxysteroid dehydrogenase type 1 using scintillation proximity assay (SPA),B,,,,,CHEMBL615223,16587,H,BAO_0000357,1,,,,,11489
188,8,,In vitro inhibitory activity against mouse 11 beta hydroxysteroid dehydrogenase type 1 using scintillation proximity assay (SPA),B,,,,,CHEMBL615224,16587,H,BAO_0000357,1,,,,,11862
189,8,,In vitro inhibitory activity against mouse 11 beta hydroxysteroid dehydrogenase type 1 using scintillation proximity assay (SPA).,B,,,,,CHEMBL615225,16587,H,BAO_0000357,1,,,,,11862
190,8,,Ability to convert [3H]cortisol to the tritium labeled cortisone in the presence of human 11 beta hydroxysteroid dehydrogenase type 2,B,,,,,CHEMBL615226,16587,H,BAO_0000357,1,,,,,11489
191,8,,Inhibitory activity against mouse 11 beta hydroxysteroid dehydrogenase type 2 at a concentration of 0.2 mM; NI means no inhibition,B,,,,,CHEMBL615227,16587,H,BAO_0000357,1,,,,,11862
192,9,Bos taurus,Evaluated for inhibition of bovine adrenal cortical mitochondrial 11 beta-hydroxylase,F,9913.0,,,,CHEMBL615228,8058,D,BAO_0000019,1,,,,,12347
193,9,Rattus norvegicus,Effect on adrenal 11-beta-hydroxylase activity at 10e-4 M; No significant effect,B,10116.0,,,,CHEMBL615229,9065,D,BAO_0000357,1,,,,,100120
194,9,Rattus norvegicus,Inhibition of 11 beta-hydroxylase from rat adrenal gland,B,10116.0,Adrenal gland,,,CHEMBL615230,8865,D,BAO_0000357,1,2369.0,,,,100120
195,9,Rattus norvegicus,Inhibition of rat adrenal 11-beta-hydroxylase,B,10116.0,,,,CHEMBL615231,9066,D,BAO_0000357,1,,,,,100120
196,9,Rattus norvegicus,Inhibition of rat adrenal 11-beta-hydroxylase,B,10116.0,,,,CHEMBL884520,8394,D,BAO_0000357,1,,,,,100120
197,9,Rattus norvegicus,Inhibition of rat adrenal 11-beta-hydroxylase at 10e-5 M,B,10116.0,,,,CHEMBL615232,8394,D,BAO_0000357,1,,,,,100120
198,8,,Percent inhibition against 11-beta-hydroxysteroid dehydrogenase 1 of wistar rat liver cytosol at 10 uM was determined using [3H]cortisone,B,,,,,CHEMBL615233,6431,H,BAO_0000019,1,,,,,10328
199,8,,Percent inhibition against 11-beta-hydroxysteroid dehydrogenase 2 of wistar rat kidney at 10 uM was determined using [3H]cortisol,B,,,,,CHEMBL827088,6431,H,BAO_0000357,1,,,,,11490
200,8,,Percent inhibition against 11-beta-hydroxysteroid dehydrogenase 2 of wistar rat kidney at 10 uM was determined using [3H]cortisol,B,,,,,CHEMBL615234,6431,H,BAO_0000357,1,,,,,11490
201,8,,Compound was tested for the percent of inhibition against 12-LO at 10 uM,F,,,,,CHEMBL615235,9295,H,BAO_0000019,1,,,,,11134
202,8,,In vitro inhibitory activity against rat platelet 12-lipoxygenase at 10 uM,B,,,,,CHEMBL615236,10193,H,BAO_0000019,1,,,,,12052
203,8,,Compound was tested in vitro for inhibition of 12-LO human platelet,B,,,,,CHEMBL615237,13622,H,BAO_0000019,1,,,,,11134
204,8,,Inhibitory concentration against human platelet 12-lipoxygenase,F,,,,,CHEMBL615238,12079,H,BAO_0000019,1,,,,,11134
205,8,,Compound at 100 uM was tested in vitro for inhibition of 12-LO human platelet,B,,,,,CHEMBL615239,13622,H,BAO_0000019,1,,,,,11134
206,9,Homo sapiens,Inhibitory concentration against human platelet 12-lipoxygenase,F,9606.0,,,,CHEMBL615240,12079,D,BAO_0000019,1,,,,,11134
207,8,,Tested for inhibition of 12-LO (12-lipoxygenase) as an inhibitor of 12(S)-HETE biosynthesis in mouse epidermal homogenates,B,,,,,CHEMBL615241,13500,H,BAO_0000019,1,,,,,11835
208,8,,Inhibitory activity against conversion of [1-14C]arachidonic acid to 12-HPETE and its reduction product 12-HETE by porcine leukocyte type 12-lipoxygenase,B,,,,,CHEMBL615242,13723,H,BAO_0000357,1,,,,,11601
209,8,,Inhibitory activity against human platelet 12-lipoxygenase (12-HLO),B,,,,,CHEMBL615243,16474,H,BAO_0000019,1,,,,,11134
210,8,,Inhibitory activity against human platelet 12-lipoxygenase,B,,,,,CHEMBL615244,1630,H,BAO_0000019,1,,,,,11134
211,8,,Inhibitory activity against human platelet 12-lipoxygenase was evaluated,B,,,,,CHEMBL615245,167,H,BAO_0000019,1,,,,,11134
212,8,,% inhibition against human platelet 12-lipoxygenase (12-HLO),B,,,,,CHEMBL615246,16474,H,BAO_0000019,1,,,,,11134
213,8,,Inhibitory activity against human platelet 12-lipoxygenase was evaluated at 100 uM,B,,,,,CHEMBL615247,167,H,BAO_0000019,1,,,,,11134
214,8,,percent inhibition against human platelet 12-lipoxygenase (12-HLO); NI is no inhibition,B,,,,,CHEMBL615248,16474,H,BAO_0000019,1,,,,,11134
215,8,,Inhibitory activity towards porcine 12-lipoxygenase,B,,,,,CHEMBL615249,10091,H,BAO_0000357,1,,,,,11601
216,8,,Tested for inhibition against porcine 12-LO,B,,,,,CHEMBL615250,11966,H,BAO_0000357,1,,,,,11601
217,8,,Inhibition of 12-lipoxygenase was evaluated in rat platelets stimulated by thrombin up to a concentration of 10 uM; NE means No effect,B,,,,,CHEMBL615251,951,H,BAO_0000019,1,,,,,12052
218,8,,Inhibitory activity against 12-lipoxygenase in rat platelet rich plasma,B,,,,,CHEMBL615252,10997,H,BAO_0000019,1,,,,,12052
219,8,,In vitro inhibition of rat platelet 12-lipoxygenase,B,,,,,CHEMBL828340,10193,H,BAO_0000019,1,,,,,12052
220,8,,In vitro inhibitory activity against rat platelet 12-lipoxygenase at 10 uM,B,,,,,CHEMBL615253,10193,H,BAO_0000019,1,,,,,12052
221,8,,In vitro inhibitory activity against rat platelet 12-lipoxygenase at 100 uM,B,,,,,CHEMBL615254,10193,H,BAO_0000019,1,,,,,12052
222,8,,In vitro inhibitory activity against rat platelet 12-lipoxygenase at 30 uM,B,,,,,CHEMBL615255,10193,H,BAO_0000019,1,,,,,12052
223,8,,In vitro inhibitory activity against rat platelet 12-lipoxygenase at 10 uM,B,,,,,CHEMBL615256,10193,H,BAO_0000019,1,,,,,12052
224,8,,In vitro inhibitory activity against rat platelet 12-lipoxygenase,B,,,,,CHEMBL615257,10193,H,BAO_0000019,1,,,,,12052
225,8,,The compound was tested for the in vitro inhibition of platelet 12-lipoxygenase at a concentration of 100 uM,B,,,,,CHEMBL615258,11087,H,BAO_0000019,1,,,,,12052
226,1,Homo sapiens,Cytotoxic activity in a panel of Human ovarian tumor 41M cell line after 96h of drug exposure,F,9606.0,,,,CHEMBL615259,15569,N,BAO_0000219,1,,,,41M,80007
227,1,Homo sapiens,In vitro antitumor activity against 41M cell line.,F,9606.0,,,,CHEMBL615260,12989,N,BAO_0000219,1,,,,41M,80007
228,1,Homo sapiens,cytotoxicity against 41M cells incubated for 24 hr in MTT assay.,F,9606.0,,,,CHEMBL615261,16745,N,BAO_0000219,1,,,,41M,80007
229,1,Homo sapiens,Cytotoxic activity in a panel of Human ovarian tumor 41M/CDDP cell line after 96h of drug exposure,F,9606.0,,,,CHEMBL615262,15569,N,BAO_0000219,1,,,,41M,80007
230,1,Homo sapiens,In vitro antitumor activity against 41McisR cell line.,F,9606.0,,,,CHEMBL615263,12989,N,BAO_0000219,1,,,,41M,80007
231,1,Homo sapiens,Resistant factor was determined between IC50 of cisplatin-resistant human tumor cell lines to that of 41McisR cell line,F,9606.0,,,,CHEMBL838393,12989,N,BAO_0000219,1,,,,41M,80007
232,1,Homo sapiens,cytotoxicity against 41McisR cells incubated for 24 hr in MTT assay,F,9606.0,,,,CHEMBL615264,16745,N,BAO_0000219,1,,,,41M,80007
233,9,Homo sapiens,Inhibition of 5'-inosine monophosphate dehydrogenase type I (IMPDH I),B,9606.0,,,,CHEMBL615265,6210,D,BAO_0000357,1,,,,,84
234,9,Homo sapiens,Inhibition of 5'-inosine monophosphate dehydrogenase type II (IMPDH II),B,9606.0,,,,CHEMBL615266,6210,D,BAO_0000357,1,,,,,68
235,8,,Inhibitory activity against inosine 5'-inosine monophosphate dehydrogenase type II (IMPDH II),B,,,,,CHEMBL615267,6226,H,BAO_0000357,1,,,,,68
236,8,,Equilibrium dissociation constant towards human 5'-methylthioadenosine phosphorylase,B,,,,,CHEMBL615268,17855,H,BAO_0000357,1,,,,,10201
237,8,,Equilibrium dissociation constant towards human 5'-methylthioadenosine phosphorylase; nd = Not determined,B,,,,,CHEMBL615269,17855,H,BAO_0000357,1,,,,,10201
238,8,,Initial dissociation constant towards human 5'-methylthioadenosine phosphorylase,B,,,,,CHEMBL615270,17855,H,BAO_0000357,1,,,,,10201
239,8,,"Evaluated for inhibitory activity on 5,10-Methenyl Tetrahydrofolate Cyclohydrolase(L cell) at folate substrate concentration of 100 uM",B,,,,,CHEMBL615271,10413,H,BAO_0000357,1,,,,,12220
240,8,Escherichia coli,"Inhibitory activity against 5,10-methylenetetrahydrofolate dehydrogenase from Escherichia coli at a concentration of 0.1 mM; NT=Not tested",B,562.0,,,,CHEMBL615272,10413,H,BAO_0000357,1,,,,,11303
241,8,Escherichia coli,"Inhibitory activity against 5,10-Methylene Tetrahydrofolate Cyclohydrolase from Escherichia coli at a concentration of 0.1 mM; NT=Not tested",B,562.0,,,,CHEMBL615103,10413,H,BAO_0000357,1,,,,,11303
242,8,Escherichia coli,"Inhibitory activity against 5,10-Methylene Tetrahydrofolate Cyclohydrolase from Escherichia coli at a concentration of 0.1 mM;NT=Not tested",B,562.0,,,,CHEMBL615104,10413,H,BAO_0000357,1,,,,,11303
243,8,,"Evaluated for inhibitory activity on 5,10-Methylene Tetrahydrofolate Cyclohydrolase(L cell) at folate substrate concentration of 100 uM",B,,,,,CHEMBL615105,10413,H,BAO_0000357,1,,,,,12220
244,8,,"Evaluated for inhibitory activity on 5,10-methylenetetrahydrofolate dehydrogenase(L cell) at folate substrate concentration of 100 uM",B,,,,,CHEMBL872866,10413,H,BAO_0000357,1,,,,,12220
245,8,Sus scrofa,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (L1210 tumor tissue) enzyme at 10E-6 M inhibitory concentration",B,9823.0,,,,CHEMBL615106,7587,H,BAO_0000357,1,,,,,11303
246,8,Sus scrofa,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (A,porcine liver) enzyme.",B,9823.0,,,,CHEMBL615107,7587,H,BAO_0000019,1,,,,,11303
247,8,Sus scrofa,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (L1210 tumor tissue) enzyme at 10E-4 M inhibitory concentration",B,9823.0,,,,CHEMBL615108,7587,H,BAO_0000357,1,,,,,11303
248,8,Sus scrofa,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (L1210 tumor tissue) enzyme at 10E-5 M inhibitory concentration",B,9823.0,,,,CHEMBL615109,7587,H,BAO_0000357,1,,,,,11303
249,8,Sus scrofa,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (L1210 tumor tissue) enzyme at 10E-6 M inhibitory concentration",B,9823.0,,,,CHEMBL615110,7587,H,BAO_0000357,1,,,,,11303
250,8,Sus scrofa,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (porcine liver) enzyme at 10E-4 M inhibitory concentration",B,9823.0,,,,CHEMBL840105,7587,H,BAO_0000019,1,,,,,11303
251,8,Sus scrofa,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (porcine liver) enzyme at 10E-5 M inhibitory concentration",B,9823.0,,,,CHEMBL615111,7587,H,BAO_0000019,1,,,,,11303
252,8,Sus scrofa,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (porcine liver) enzyme at 10E-6 M inhibitory concentration",B,9823.0,,,,CHEMBL615112,7587,H,BAO_0000019,1,,,,,11303
253,8,Sus scrofa,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (porcine liver) enzyme at 10E-7 M inhibitory concentration",B,9823.0,,,,CHEMBL615113,7587,H,BAO_0000019,1,,,,,11303
254,8,Sus scrofa,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (porcine liver) enzyme.",B,9823.0,,,,CHEMBL615114,7587,H,BAO_0000019,1,,,,,11303
255,8,Sus scrofa,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (L1210 tumor tissue) enzyme at 10E-6 M inhibitory concentration",B,9823.0,,,,CHEMBL615115,7587,H,BAO_0000357,1,,,,,11303
256,8,Sus scrofa,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (porcine liver) enzyme at 10E-4 M inhibitory concentration",B,9823.0,,,,CHEMBL615116,7587,H,BAO_0000019,1,,,,,11303
257,8,,"Compound was tested for in vitro inhibition of 5,10-Methylene Tetrahydrofolate Cyclohydrolase, competitive against (+)-L-5,10-methenyltetrahydrofolate",B,,,,,CHEMBL615698,7323,H,BAO_0000357,1,,,,,11303
258,0,Sus scrofa,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Reductase (porcine kidney) enzyme at 10E-4 M inhibitory concentration",B,9823.0,,,,CHEMBL615699,7587,U,BAO_0000019,1,,,,,22226
259,0,Sus scrofa,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Reductase (porcine kidney) enzyme.",B,9823.0,,,,CHEMBL615700,7587,U,BAO_0000019,1,,,,,22226
260,8,Saccharomyces cerevisiae,Inhibition of 5-Desaturase involved in ergosterol biosynthesis,B,4932.0,,,,CHEMBL615701,13750,H,BAO_0000357,1,,,,,100249
261,0,Rattus norvegicus,Ability for reversible inhibition of Walker 256 5-Fluoro-2'-deoxyuridine Phosphorylase,B,10116.0,,,,CHEMBL615702,7662,U,BAO_0000019,1,,,,,22226
262,0,Rattus norvegicus,Ability for reversible inhibition of Walker 256 5-Fluoro-2'-deoxyuridine Phosphorylase,B,10116.0,,,,CHEMBL615703,7662,U,BAO_0000019,1,,,,,22226
263,0,Rattus norvegicus,"Irreversible inhibition of Walker 256 FUDR phosphorylase; expressed as Vo/Vi, velocity without inhibitor to that of velocity with inhibitor",B,10116.0,,,,CHEMBL615704,7662,U,BAO_0000019,1,,,,,22226
264,6,,"Tested for 5-HT 3 receptor antagonist potency by ability to inhibit the reflex bradycardia, the Bezold-Jarisch reflex in the rat",F,,,,,CHEMBL615705,12211,H,BAO_0000019,1,,,,,104698
265,6,,"Compound was tested for its 5-HT 3 receptor antagonist potency by their ability to inhibit the reflex bradycardia, the Bezold-Jarisch reflex in the rat",F,,,,,CHEMBL615706,12211,H,BAO_0000019,1,,,,,104698
266,9,Cavia porcellus,Relative ability to increase cholinergically mediated contractions in isolated ileum of guinea pig,F,10141.0,Ileum,,,CHEMBL615707,12211,D,BAO_0000221,1,2116.0,,,,20033
267,8,,Stimulatory activity of intragastric pressure was tested in the rat,F,,,,,CHEMBL615708,12211,H,BAO_0000019,1,,,,,10623
268,8,,% Decrease of 5-HT carrier-receptor -bound radioactivity using paroxetine as a radioligand.,B,,,,,CHEMBL615709,15453,H,BAO_0000357,1,,,,,121
269,0,Rattus norvegicus,Dose to reduce neuronal firing against 5-HT cells in rats (iv),F,10116.0,,,,CHEMBL615710,11884,U,BAO_0000218,1,,,,,22226
270,8,,Antagonistic activity of corresponding methoxy compound against serotonin 5-HT receptor,F,,,,,CHEMBL615711,7185,H,BAO_0000019,1,,,,,12688
271,9,Homo sapiens,Binding affinity at 5-HT reuptake site labeled with [3H]paroxetine,B,9606.0,,,,CHEMBL615712,6876,D,BAO_0000357,1,,,,,121
272,9,Homo sapiens,Binding affinity at 5-HT reuptake site labeled with [3H]paroxetine; No data,B,9606.0,,,,CHEMBL836325,6876,D,BAO_0000357,1,,,,,121
273,8,,Inhibition of high affinity 5-HT uptake at concentration of 1 uM,F,,,,,CHEMBL615713,11863,H,BAO_0000019,1,,,,,12198
274,8,,Inhibition constant of high-affinity 5-HT uptake,B,,,,,CHEMBL615714,11863,H,BAO_0000357,1,,,,,12198
275,8,,Michaelis-Menten constant was reported for high affinity transport of 5-HT,F,,,,,CHEMBL615715,11863,H,BAO_0000019,1,,,,,12198
276,8,,Maximum rate was determined for high affinity transport of 5-HT,F,,,,,CHEMBL615716,11863,H,BAO_0000019,1,,,,,12198
277,4,,Compound was tested for agonistic activity against 5-HT uptake,F,,,,,CHEMBL615717,4639,H,BAO_0000019,1,,,,,104714
278,8,,Inhibition affinity against 5-HT-1B receptor in rat frontal cortex using radio binding assay,B,,,,,CHEMBL881818,15796,H,BAO_0000019,1,,,,,10577
279,8,Bos taurus,Inhibition affinity against 5-HT-1D receptor in bovine caudate nucleus using radio binding assay,B,9913.0,,,,CHEMBL884540,15796,H,BAO_0000357,1,,,,,105
280,5,Rattus norvegicus,Binding affinity towards 5-hydroxytryptamine 1 receptor using [3H]5-HT as radioligand,B,10116.0,,,,CHEMBL615718,12801,D,BAO_0000224,1,,,,,104744
281,4,,The compound was evaluated for the binding affinity towards 5-hydroxytryptamine 1 using [3H]5-HT as radioligand,B,,,,,CHEMBL615719,12801,H,BAO_0000224,1,,,,,104744
282,4,,Percent inhibition of binding of 3.0 nM [3H]5-HT to 5-hydroxytryptamine 1 receptor in rat caudate membranes at 10 e -5 M,B,,,Membranes,,CHEMBL615720,12120,H,BAO_0000249,1,,,,,104744
283,4,,Percent inhibition of binding of 3.0 nM [3H]5-HT to 5-hydroxytryptamine 1 receptor in rat caudate membranes at 10 e -5 M.,B,,,Membranes,,CHEMBL615721,12120,H,BAO_0000249,1,,,,,104744
284,4,,Displacement of binding of [3H]-5-HT to 5-hydroxytryptamine 1 receptor in rat cerebral cortex,B,,,,,CHEMBL615722,11963,H,BAO_0000019,1,,,,,104744
285,8,,Dose required to reduce neuronal firing of 5-HT1A cells by 50%,F,,,,,CHEMBL615723,11701,H,BAO_0000019,1,,,,,51
286,8,,In vitro inhibition of [3H]5-HT (2 nM) binding to 5-hydroxytryptamine 1A receptor from bovine hippocampus,B,,Hippocampus,,,CHEMBL615724,9995,H,BAO_0000221,1,10000000.0,,,,51
287,8,,In vitro inhibition of [3H]DPAT (1 nM) binding to 5-HT1A receptor from bovine hippocampus,B,,Hippocampus,,,CHEMBL615725,9995,H,BAO_0000221,1,10000000.0,,,,51
288,8,,In vitro inhibition of [3H]DPAT (1 nM) binding to 5-hydroxytryptamine 1A receptor from bovine hippocampus,B,,Hippocampus,,,CHEMBL615726,9995,H,BAO_0000221,1,10000000.0,,,,51
289,8,,Antagonistic activity at postsynaptic 5-HT1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (.26-3.52),F,,,,,CHEMBL615727,16394,H,BAO_0000218,1,,In vivo,,,10576
290,9,Cavia porcellus,Effect on forskolin stimulated adenylate cyclase activity at 5-HT1D receptor of guinea pig substantia nigra.,F,10141.0,,,,CHEMBL615728,11574,D,BAO_0000019,1,,,,,105570
291,8,,Binding affinity towards 5-HT1F (human cloned receptor) in CHO cells using [3H]5-HT as radioligand.,B,,,,,CHEMBL857971,15779,H,BAO_0000219,1,,,,CHO,279
292,8,,Compound was tested for the displacement of [125I]DOI from clone human 5-hydroxytryptamine 2A receptor,B,,,,,CHEMBL615729,15363,H,BAO_0000357,1,,,,,107
293,9,Rattus norvegicus,Efficacy against 5-hydroxytryptamine 2A receptor,F,10116.0,,,,CHEMBL615730,15363,D,BAO_0000019,1,,,,,12687
294,8,,Intrinsic activity towards 5-HT2A receptor of rat tail artery,F,,,,,CHEMBL615731,15329,H,BAO_0000019,1,,,,,12687
295,8,,Relative potency towards 5-HT2A receptor of rat tail artery,F,,,,,CHEMBL615732,15329,H,BAO_0000019,1,,,,,12687
296,8,,Blocking 5-HT2A receptor-mediated contractions of rat tail artery,F,,,,,CHEMBL615733,15329,H,BAO_0000019,1,,,,,12687
297,8,,Partial agonism at 5-HT2A receptor was evaluated in presence of ketanserin (3-10 nM) in isolated rat tail artery,F,,,,,CHEMBL615734,15329,H,BAO_0000019,1,,,,,12687
298,8,,Compound was tested for the intrinsic activity against 5-HT2A receptors of rat tail artery.,F,,,,,CHEMBL615735,15329,H,BAO_0000019,1,,,,,12687
299,8,,Effectiveness in blocking 5-HT2A receptor-mediated contractions of rat tail artery,F,,,,,CHEMBL615736,15329,H,BAO_0000019,1,,,,,12687
300,9,Cavia porcellus,Evaluated for the agonistic activity against 5-HT4 receptor in non-electrically stimulated guinea-pig ileum.,F,10141.0,Ileum,,,CHEMBL615737,273,D,BAO_0000221,1,2116.0,,,,20033
301,9,Cavia porcellus,Agonistic activity against Serotonin 5-HT4 receptor in low frequency field stimulation of guinea-pig ileum (FSGPI),F,10141.0,Ileum,,,CHEMBL615738,273,D,BAO_0000221,1,2116.0,,,,20033
302,9,Cavia porcellus,Evaluated for the agonistic activity against Serotonin 5-HT4 receptor in non-electrically stimulated guinea-pig ileum.,F,10141.0,Ileum,,,CHEMBL615739,273,D,BAO_0000221,1,2116.0,,,,20033
303,8,,The binding affinity was measured on 5-hydroxytryptamine 4 receptor using [3H]- GR-113808 as radioligand.,B,,,,,CHEMBL615278,12092,H,BAO_0000357,1,,,,,10623
304,9,Rattus norvegicus,Antagonist activity against 5-HT4 receptor mediated relaxation of rat carbachol contracted esophageal muscularis mucosae,F,10116.0,,,,CHEMBL615279,1317,D,BAO_0000019,1,,,,,10623
305,8,,Binding affinity against 5-hydroxytryptamine 4 receptor,B,,,,,CHEMBL615280,12409,H,BAO_0000357,1,,,,,168
306,0,Gallus gallus,Relative competitive index values for binding to 25-OH-D3-1-hydroxylase of chick intestine,B,9031.0,,,,CHEMBL615281,11126,U,BAO_0000019,1,,,,,22226
307,0,Homo sapiens,Inhibitory effect (10e-6 M) on the 25-OH-D3-1-hydroxylase activity,F,9606.0,,,,CHEMBL615282,11126,U,BAO_0000019,1,,,,,22226
308,0,Homo sapiens,25-OH-D3-1-hydroxylase activity (10e-6 M) was measured as %control,F,9606.0,,,,CHEMBL615283,11126,U,BAO_0000019,1,,,,,22226
309,1,Homo sapiens,Relative competitive index values for binding to 25-OH-D3-1-hydroxylase of human HL-60 cells,B,9606.0,,,,CHEMBL615284,11126,N,BAO_0000219,1,,,,HL-60,80156
310,0,Homo sapiens,Inhibitory effect (10e-6 M) on the 25-hydroxyvitamin D3-1-hydroxylase activity,B,9606.0,,,,CHEMBL615285,11126,U,BAO_0000019,1,,,,,22226
311,0,Homo sapiens,25-hydroxyvitamin D3-1-hydroxylase activity (10e-6 M) was measured as %control,B,9606.0,,,,CHEMBL615286,11126,U,BAO_0000019,1,,,,,22226
312,7,Homo sapiens,Displacement of [3H]-Ro- 15-1788 from human GABA-A alpha-1-beta-3-gamma-2 receptor subunits expressed in Xenopus oocytes,B,9606.0,,,,CHEMBL615287,17807,D,BAO_0000219,1,,,,Oocytes,104703
313,2,,Chymotryptic inhibitory activity against 26S proteasome,F,,,,,CHEMBL615288,16575,S,BAO_0000220,1,,,,,100256
314,2,,Inhibitory activity against 26S proteasome degradation of IkB,B,,,,,CHEMBL615289,15407,S,BAO_0000220,1,,,,,100256
315,1,Homo sapiens,In vitro inhibition of 2780/DOX ovarian cancer cell line,F,9606.0,,,,CHEMBL615290,10797,N,BAO_0000219,1,,,,A2780,81034
316,1,Homo sapiens,In vitro inhibition of 2780/S ovarian cancer cell line,F,9606.0,,,,CHEMBL884522,10797,N,BAO_0000219,1,,,,A2780,81034
317,0,Homo sapiens,Relative activity on the cellular accumulation of vincristine in multidrug-resistant (MDR) human ovarian cancer 2780AD cells,F,9606.0,,,,CHEMBL615291,3469,U,BAO_0000019,1,,,,,22226
318,3,,Association constant for binding to AATT 28-mer AATT hairpin,B,,,,,CHEMBL615292,16037,M,BAO_0000225,1,,,,,22222
319,3,,Kinetically Defined Association Constant for 28-mer AATT hairpin.,B,,,,,CHEMBL615293,16037,M,BAO_0000225,1,,,,,22222
320,3,,Reaction Rate Parameter for 28-mer AATT hairpin,B,,,,,CHEMBL615294,16037,M,BAO_0000225,1,,,,,22222
321,3,,Reaction Rate Parameter for 28-mer AATT hairpin,B,,,,,CHEMBL615295,16037,M,BAO_0000225,1,,,,,22222
322,0,Homo sapiens,Antiviral activity against envelope deficient HIV-1 in a single cycle replication assay (experiment 1),F,9606.0,,,,CHEMBL825021,16524,U,BAO_0000019,1,,,,,22226
323,0,Homo sapiens,Antiviral activity against envelope deficient HIV-1 in a single cycle replication assay (experiment 2),F,9606.0,,,,CHEMBL615296,16524,U,BAO_0000019,1,,,,,22226
324,0,Homo sapiens,Inhibitory concentration by single cycle replication assay using envelope deficient HIV-1,F,9606.0,,,,CHEMBL615297,16524,U,BAO_0000019,1,,,,,22226
325,0,Cricetulus griseus,Cytotoxicity against cell line 2SC/20 determined by MTT test,F,10029.0,,,,CHEMBL615298,16758,U,BAO_0000019,1,,,,,22226
326,0,Cricetulus griseus,Cytotoxicity against cell line 2SC/20 of hamster determined by MTT test,F,10029.0,,,,CHEMBL615299,16758,U,BAO_0000019,1,,,,,22226
327,0,Cricetulus griseus,Inhibitory concentration against the growth of 2SC/20 cell line after 72 hr of drug exposure by MTT test,F,10029.0,,,,CHEMBL615300,16758,U,BAO_0000019,1,,,,,22226
328,8,,Binding affinity on 3 beta-hydroxysteroid dehydrogenase,B,,,,,CHEMBL615301,14360,H,BAO_0000357,1,,,,,241
329,9,Homo sapiens,Binding affinity for 3-beta-hydroxysteroid dehydrogenase,B,9606.0,,,,CHEMBL615302,14360,D,BAO_0000357,1,,,,,241
330,0,Rattus norvegicus,Selectivity ratio of ID50 in liver and heart,B,10116.0,,,,CHEMBL615303,9964,U,BAO_0000019,1,,,,,22226
331,8,,"Selectivity, ratio of relative ID50 in liver and heart",B,,,,,CHEMBL615304,9964,H,BAO_0000019,1,,,,,12132
332,8,,Binding affinity to the receptor was determined in isolated nuclei of heart(In vitro) relative to T3,B,,,,,CHEMBL615305,9964,H,BAO_0000019,1,,,,,12132
333,8,,"Binding affinity to the receptor was determined in nuclei of heart In vivo 1 hour after intravenous administration relative to 3,5,3' triiodothyronine receptor",B,,,,,CHEMBL615306,9964,H,BAO_0000218,1,,,,,12132
334,8,,"Binding affinity to the receptor was determined in nuclei of liver In vivo 1 hour after intravenous administration relative to 3,5,3' triiodothyronine receptor",B,,,,,CHEMBL615307,9964,H,BAO_0000218,1,,,,,12132
335,8,,"Binding affinity to the receptor was determined in nuclei of liver in vivo 1 hour after intravenous administration relative to 3,5,3' triiodothyronine receptor",B,,,,,CHEMBL615308,9964,H,BAO_0000218,1,,In vivo,,,12132
336,8,,"Binding affinity to the receptor was determined in nuclei of liver in vivo 1 hour after intravenous administration relative to 3,5,3' triiodothyronine receptor",F,,,,,CHEMBL615309,9964,H,BAO_0000218,1,,In vivo,,,12132
337,0,,"Binding affinity to the thyroid hormone receptor was determined in vitro in isolated nuclei of rat liver relative to 3,5,3' triiodothyronine",B,,,,,CHEMBL615310,9964,U,BAO_0000019,1,,,,,22226
338,8,,Binding affinity to the receptor was determined in vitro in isolated nuclei of rat liver relative to T3,B,,,,,CHEMBL615311,9964,H,BAO_0000019,1,,,,,12132
339,0,Homo sapiens,"Binding affinity to thyroid hormone receptor beta, relative to 3,5,3' triiodothyronine receptor, in isolated nuclei of heart",B,9606.0,,,,CHEMBL615312,9964,U,BAO_0000019,1,,,,,22226
340,8,,In vitro binding affinity to the receptor was determined in isolated nuclei of heart relative to T3,B,,,,,CHEMBL615313,9964,H,BAO_0000019,1,,,,,12132
341,8,,In vitro binding affinity to the receptor was determined in isolated nuclei of heart relative to T3,F,,,,,CHEMBL615314,9964,H,BAO_0000019,1,,,,,12132
342,8,,"Binding affinity to the receptor was determined in isolated nuclei of heart(In vitro) relative to 3,5,3' triiodothyronine receptor",B,,,,,CHEMBL615315,9964,H,BAO_0000019,1,,,,,12132
343,0,Rattus norvegicus,"In vivo binding affinity for 3,5,3'' triiodothyronine receptor of heart nuclei 1 hr after intravenous administration",B,10116.0,,,,CHEMBL615316,9964,U,BAO_0000218,1,,,,,22226
344,8,,Binding affinity to the receptor was determined in nuclei of heart in vivo 1 hour after intravenous administration relative to T3,B,,,,,CHEMBL615317,9964,H,BAO_0000218,1,,In vivo,,,12132
345,8,,"Binding affinity to the receptor was determined in nuclei of liver In vivo 1 hour after intravenous administration relative to 3,5,3' triiodothyronine receptor",B,,,,,CHEMBL615318,9964,H,BAO_0000218,1,,,,,12132
346,0,Rattus norvegicus,"In vivo binding affinity for 3,5,3' triiodothyronine receptor of liver nuclei 1 hour after intravenous administration",B,10116.0,,,,CHEMBL615319,9964,U,BAO_0000218,1,,,,,22226
347,8,,"In vitro binding affinity to the receptor was determined in isolated nuclei of heart relative to 3,5,3' triiodothyronine receptor",B,,,,,CHEMBL615320,9964,H,BAO_0000019,1,,,,,12132
348,8,,"In vitro binding affinity to the receptor was determined in isolated nuclei of heart relative to 3,5,3' triiodothyronine receptor",F,,,,,CHEMBL615321,9964,H,BAO_0000019,1,,,,,12132
349,0,Rattus norvegicus,"Inhibition of [125I]L-T3 binding to rat hepatic 3,5,3''-triiodo-L-thyronine receptor",B,10116.0,,,,CHEMBL615322,3796,U,BAO_0000019,1,,,,,22226
350,8,Escherichia coli,Inhibition constant for binding to Co2+ form of 3-dehydroquinate synthase (DHQ) purified from Escherichia coli,B,562.0,,,,CHEMBL615323,4251,H,BAO_0000357,1,,,,,19690
351,8,Escherichia coli,Inhibition constant for binding to Zn2+ form of 3-dehydroquinate synthase (DHQ) purified from Escherichia coli,B,562.0,,,,CHEMBL615407,4251,H,BAO_0000357,1,,,,,19690
352,8,Escherichia coli,Kinetics expressed as Michaelis-Menten constant against Co2+ form of 3-dehydroquinate synthase purified from Escherichia coli,B,562.0,,,,CHEMBL857267,4251,H,BAO_0000357,1,,,,,19690
353,8,Escherichia coli,Kinetics expressed as Michaelis-Menten constant against Zn2+ form of 3-dehydroquinate synthase purified from Escherichia coli,B,562.0,,,,CHEMBL615408,4251,H,BAO_0000357,1,,,,,19690
354,8,,Type of inhibition of 3-dehydroquinate synthase was determined; R - Slowly reversible,B,,,,,CHEMBL615409,166,H,BAO_0000357,1,,,,,19690
355,8,,Compound was evaluated for its inhibitory constant against 3-dehydroquinate synthase,B,,,,,CHEMBL615410,17861,H,BAO_0000357,1,,,,,19690
356,8,,Inhibition constant against 3-dehydroquinate synthase,B,,,,,CHEMBL615411,166,H,BAO_0000357,1,,,,,19690
357,8,,Association rate constant against 3-dehydroquinate synthase,B,,,,,CHEMBL615412,166,H,BAO_0000357,1,,,,,19690
358,8,,Rate constant against 3-dehydroquinate synthase,B,,,,,CHEMBL615413,166,H,BAO_0000357,1,,,,,19690
359,0,,Inhibitory activity against fuc-TVII,B,,,,,CHEMBL615414,3548,U,BAO_0000019,1,,,,,22226
360,9,Rattus norvegicus,Ability of compound (2.5 uM) to inhibit the activity of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) using [14C]mevalonate in rat liver microsomes,B,10116.0,Liver,Microsomes,,CHEMBL615415,9877,D,BAO_0000251,1,2107.0,,,,12236
361,9,Rattus norvegicus,Ability of compound (2500 uM) to inhibit the activity of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) using [14C]mevalonate in rat liver microsomes,B,10116.0,Liver,Microsomes,,CHEMBL615416,9877,D,BAO_0000251,1,2107.0,,,,12236
362,9,Rattus norvegicus,Ability of compound (250 uM) to inhibit the activity of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) using [14C]mevalonate in rat liver microsomes,B,10116.0,Liver,Microsomes,,CHEMBL615417,9877,D,BAO_0000251,1,2107.0,,,,12236
363,9,Rattus norvegicus,Ability of compound (25 uM) to inhibit the activity of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) using [14C]mevalonate in rat liver microsomes,B,10116.0,Liver,Microsomes,,CHEMBL615418,9877,D,BAO_0000251,1,2107.0,,,,12236
364,9,Rattus norvegicus,Ability of compound at 0 uM to inhibit the activity of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) using [14C]mevalonate in rat liver microsomes,B,10116.0,Liver,Microsomes,,CHEMBL615419,9877,D,BAO_0000251,1,2107.0,,,,12236
365,9,Rattus norvegicus,Ability of compound to inhibit the activity of 3-hydroxy-3-methylglutarylcoenzyme A(HMGR) reductase in rat liver microsomes,B,10116.0,Liver,Microsomes,,CHEMBL615420,9877,D,BAO_0000251,1,2107.0,,,,12236
366,9,Rattus norvegicus,Percentage inhibition of 3-hydroxy-3-methyl glutaryl coenzyme A reductase in rat liver microsomes at 250 uM,B,10116.0,Liver,Microsomes,,CHEMBL615421,9877,D,BAO_0000251,1,2107.0,,,,12236
367,9,Rattus norvegicus,Percentage inhibition of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) in rat liver microsomes at 0 uM,B,10116.0,Liver,Microsomes,,CHEMBL615422,9877,D,BAO_0000251,1,2107.0,,,,12236
368,9,Rattus norvegicus,Percentage inhibition of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) in rat liver microsomes at 2.5 uM,B,10116.0,Liver,Microsomes,,CHEMBL615423,9877,D,BAO_0000251,1,2107.0,,,,12236
369,9,Rattus norvegicus,Percentage inhibition of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) in rat liver microsomes at 2500 uM,B,10116.0,Liver,Microsomes,,CHEMBL872868,9877,D,BAO_0000251,1,2107.0,,,,12236
370,9,Rattus norvegicus,Percentage inhibition of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) in rat liver microsomes at 25 uM,B,10116.0,Liver,Microsomes,,CHEMBL615424,9877,D,BAO_0000251,1,2107.0,,,,12236
371,4,,Inhibitory activity against 3-phosphoglycerate kinase.,B,,,,,CHEMBL825022,3003,H,BAO_0000224,1,,,,,104832
372,4,,Binding affinity was evaluated towards 3-phosphoglycerate kinase at 37 degrees Celsius in 0.1 m NaCl pH 7.1,B,,,,,CHEMBL615425,3003,H,BAO_0000224,1,,,,,104832
373,4,,"Michaelis-Menten constant with 1,3-bisphosphoglyceric acid (1,3-BPG) against 3-phosphoglycerate kinase",B,,,,,CHEMBL615426,3003,H,BAO_0000224,1,,,,,104832
374,9,Homo sapiens,Inhibition of human 3-phosphoinositide-dependent protein kinase 1 at 10 uM,B,9606.0,,,,CHEMBL615427,17185,D,BAO_0000357,1,,,,,10612
375,1,Homo sapiens,Cytotoxicity on 3677 melanoma cells,F,9606.0,,,,CHEMBL615428,6072,N,BAO_0000219,1,,,,3677 melanoma cell line,80616
376,1,Homo sapiens,Cytotoxicity on 3677 melanoma cells in combination with L-49-sFv-bL,F,9606.0,,,,CHEMBL615429,6072,N,BAO_0000219,1,,,,3677 melanoma cell line,80616
377,1,Mus musculus,Antitumor activity against Mouse colon 38 at 500 ug/disk in disk diffusion assay,F,10090.0,,,,CHEMBL615430,5018,N,BAO_0000219,1,,,,MC-38,80617
378,0,Homo sapiens,Compound was evaluated for inhibition of tumor cell growth using sulforhodamine-B assay in 38 human cell lines,F,9606.0,,,,CHEMBL615431,2852,U,BAO_0000019,1,,,,,22226
379,0,,In vivo antitumor activity against 3B131 intraperitoneally implanted B16 melanoma cells; NT= Not tested,F,,,,,CHEMBL615432,8663,U,BAO_0000218,1,,,,B16,22226
380,0,,In vivo antitumor activity against 3B131 intraperitoneally implanted B16 melanoma cells; reproducible significant activity.,F,,,,,CHEMBL615433,8663,U,BAO_0000218,1,,,,B16,22226
381,9,Human rhinovirus 14,Inhibitory activity against Human RhinoVirus serotype-14 3C Protease,F,12131.0,,,,CHEMBL615434,3245,D,BAO_0000019,1,,,,,12464
382,1,Human rhinovirus sp.,Inhibitory activity against Human RhinoVirus serotype-14 3C Protease; NI means No inhibition to 50 uM,F,169066.0,,,,CHEMBL615435,3245,N,BAO_0000218,1,,,,,50085
383,1,human rhinovirus type 14,Compound was evaluated for the inactivation of HRV 14 3C protease activity expressed as KI,F,169066.0,,,,CHEMBL615436,3877,N,BAO_0000218,1,,,,,50679
384,1,human rhinovirus type 14,Compound was evaluated for the inactivation of HRV 14 3C protease activity expressed as kinact,F,169066.0,,,,CHEMBL615437,3877,N,BAO_0000218,1,,,,,50679
385,9,Human rhinovirus 14,Antiviral activity against human rhinovirus-14 (HRV-14) 3C protease using enzyme assay,F,12131.0,,,,CHEMBL615438,5861,D,BAO_0000019,1,,,,,12464
386,9,Human rhinovirus 14,Antiviral activity against human rhinovirus-14 (HRV-14) 3C protease using enzyme assay,F,12131.0,,,,CHEMBL615439,5861,D,BAO_0000019,1,,,,,12464
387,9,Human rhinovirus 14,Antiviral activity against human rhinovirus-14 (HRV-14) 3C protease using enzyme assay,F,12131.0,,,,CHEMBL615440,5861,D,BAO_0000019,1,,,,,12464
388,9,Human rhinovirus 14,Antiviral activity against human rhinovirus-14 (HRV-14) 3C protease using enzyme assay; inactive,F,12131.0,,,,CHEMBL615441,5861,D,BAO_0000019,1,,,,,12464
389,1,Enterovirus,Compound was tested for the inhibitory activity of compound towards human rhinovirus 3C protease,F,12059.0,,,,CHEMBL615641,13748,N,BAO_0000218,1,,,,,50665
390,1,Enterovirus,Compound was tested for the inhibitory activity of compound towards human rhinovirus-16 3C protease,F,12059.0,,,,CHEMBL872065,13748,N,BAO_0000218,1,,,,,50665
391,1,Enterovirus,Compound was tested for the inhibitory activity of compound towards human rhinovirus-2 3C protease,F,12059.0,,,,CHEMBL825023,13748,N,BAO_0000218,1,,,,,50665
392,1,Enterovirus,Compound was tested for the inhibitory activity of compound towards human rhinovirus-89 3C protease,F,12059.0,,,,CHEMBL615642,13748,N,BAO_0000218,1,,,,,50665
393,8,Human rhinovirus B,Inhibition of human rhinovirus 3C protease,B,147712.0,,,,CHEMBL615643,13748,H,BAO_0000357,1,,,,,12464
394,0,Homo sapiens,Compound was tested for inhibition of a proteinase 3CL pro of human coronavirus; Inhibited,B,9606.0,,,,CHEMBL615644,17699,U,BAO_0000019,1,,,,,22226
395,1,Mus musculus,Compound tested for activity against 3EM 37 mouse ependymoblastoma after single ip injection on day 1 at optimal dose of 100 mg/kg (Dose range 200-12.5),F,10090.0,,,,CHEMBL615645,7145,N,BAO_0000218,1,,,,3EM 37,80619
396,1,Mus musculus,Compound tested for activity against 3EM 37 mouse ependymoblastoma after single ip injection on day 1 at optimal dose of 128 mg/kg (Dose range 256-16),F,10090.0,,,,CHEMBL615646,7145,N,BAO_0000218,1,,,,3EM 37,80619
397,1,Mus musculus,Compound tested for toxicity against 3EM 37 Mouse Ependymoblastoma after single ip injection on day 1 at optimal dose (OD) of 100 mg/kg on the 5th day after the injection of the compound; (10/10),F,10090.0,,,,CHEMBL615647,7145,N,BAO_0000218,1,,,,3EM 37,80619
398,1,Mus musculus,Compound tested for toxicity against 3EM 37 mouse ependymoblastoma after single ip injection on day 1 at optimal dose (OD) of 100 mg/kg on the 5th day after the injection of the compound; (6/6),F,10090.0,,,,CHEMBL615648,7145,N,BAO_0000218,1,,,,3EM 37,80619
399,1,Mus musculus,Effect of compound on 3EM 37 mouse ependymoblastoma after single ip injection on day 1 recorded as animal weight difference of the treated and the control (T-C) at OD of 100 mg/kg,F,10090.0,,,,CHEMBL615649,7145,N,BAO_0000218,1,,,,3EM 37,80619
400,1,Mus musculus,Effect of compound on 3EM 37 mouse ependymoblastoma after single ip injection on day 1 recorded as percentage of cured animals at OD of 100 mg/kg,F,10090.0,,,,CHEMBL615650,7145,N,BAO_0000218,1,,,,3EM 37,80619
401,1,Mus musculus,In vivo anti-tumor and anti-metastatic activity was measured after oral dosing 15 mg/kg b.i.d. to B6D2F1 mice bearing metastatic 3LL Lewis lung tumor,F,10090.0,,,,CHEMBL615651,5325,N,BAO_0000218,1,,,,3LL cell line,80620
402,1,Mus musculus,In vivo anti-tumor and anti-metastatic activity was measured after oral dosing b.i.d. to B6D2F1 mice bearing metastatic 3LL Lewis lung tumor,F,10090.0,,,,CHEMBL615652,5325,N,BAO_0000218,1,,,,3LL cell line,80620
403,1,Mus musculus,In vivo anti-tumor and anti-metastatic activity following p.o. administration b.i.d. to B6D2F1 mice bearing metastatic 3LL Lewis lung tumor; Not tested.,F,10090.0,,,,CHEMBL615653,5325,N,BAO_0000218,1,,,,3LL cell line,80620
404,1,Mus musculus,accumulation of compound in 3LL cells was measured with DFMO by HPLC at 1 uM dose,F,10090.0,,,,CHEMBL615654,16169,N,BAO_0000219,1,,,,3LL cell line,80620
405,1,Mus musculus,accumulation of compound in 3LL cells was measured with DFMO by HPLC at 10 uM dose,F,10090.0,,,,CHEMBL615655,16169,N,BAO_0000219,1,,,,3LL cell line,80620
406,1,Mus musculus,accumulation of compound in 3LL cells was measured with DFMO by HPLC at 250 uM dose,F,10090.0,,,,CHEMBL825024,16169,N,BAO_0000219,1,,,,3LL cell line,80620
407,1,Mus musculus,accumulation of compound in 3LL cells was measured with DFMO by HPLC at 50 uM dose,F,10090.0,,,,CHEMBL615656,16169,N,BAO_0000219,1,,,,3LL cell line,80620
408,1,Mus musculus,accumulation of compound in 3LL cells was measured with DFMO by ICP-AES at 50 uM dose,F,10090.0,,,,CHEMBL615657,16169,N,BAO_0000219,1,,,,3LL cell line,80620
409,1,Mus musculus,accumulation of compound in 3LL cells was measured without DFMO by HPLC at 1 uM dose,F,10090.0,,,,CHEMBL615658,16169,N,BAO_0000219,1,,,,3LL cell line,80620
410,1,Mus musculus,accumulation of compound in 3LL cells was measured without DFMO by HPLC at 10 uM dose,F,10090.0,,,,CHEMBL615659,16169,N,BAO_0000219,1,,,,3LL cell line,80620
411,1,Mus musculus,accumulation of compound in 3LL cells was measured without DFMO by HPLC at 250 uM dose,F,10090.0,,,,CHEMBL615660,16169,N,BAO_0000219,1,,,,3LL cell line,80620
412,1,Mus musculus,accumulation of compound in 3LL cells was measured without DFMO by HPLC at 50 uM dose,F,10090.0,,,,CHEMBL615661,16169,N,BAO_0000219,1,,,,3LL cell line,80620
413,1,Mus musculus,accumulation of compound in 3LL cells was measured without DFMO by ICP-AES at 50 uM dose,F,10090.0,,,,CHEMBL615662,16169,N,BAO_0000219,1,,,,3LL cell line,80620
414,1,Mus musculus,Effect on the growth of 3LL cells by DFMO pretreatment at 48 hr incubation,F,10090.0,,,,CHEMBL615663,16169,N,BAO_0000219,1,,,,3LL cell line,80620
415,1,Mus musculus,Effect on the growth of 3LL cells was evaluated using an MTT assay at 48 hour incubation,F,10090.0,,,,CHEMBL615664,16169,N,BAO_0000219,1,,,,3LL cell line,80620
416,1,Mus musculus,Effect on the growth of 3LL cells was evaluated using an MTT assay at 72 hour incubation,F,10090.0,,,,CHEMBL615665,16169,N,BAO_0000219,1,,,,3LL cell line,80620
417,1,Mus musculus,accumulation of compound in 3LL cells was measured without DFMO by HPLC at 50 uM dose,F,10090.0,,,,CHEMBL615666,16169,N,BAO_0000219,1,,,,3LL cell line,80620
418,1,Mus musculus,putrescine levels in 3LL cells after the treatment of 1 uM of Compound,F,10090.0,,,,CHEMBL615667,16169,N,BAO_0000219,1,,,,3LL cell line,80620
419,1,Mus musculus,putrescine levels in 3LL cells after the treatment of 10 uM of Compound,F,10090.0,,,,CHEMBL615668,16169,N,BAO_0000219,1,,,,3LL cell line,80620
420,1,Mus musculus,putrescine levels in 3LL cells after the treatment of 250 uM of Compound,F,10090.0,,,,CHEMBL615669,16169,N,BAO_0000219,1,,,,3LL cell line,80620
421,1,Mus musculus,putrescine levels in 3LL cells after the treatment of 50 uM of Compound,F,10090.0,,,,CHEMBL615670,16169,N,BAO_0000219,1,,,,3LL cell line,80620
422,1,Mus musculus,spermidine levels in 3LL cells after the treatment of 1 uM of Compound,F,10090.0,,,,CHEMBL836739,16169,N,BAO_0000219,1,,,,3LL cell line,80620
423,1,Mus musculus,spermidine levels in 3LL cells after the treatment of 10 uM of Compound,F,10090.0,,,,CHEMBL615671,16169,N,BAO_0000219,1,,,,3LL cell line,80620
424,1,Mus musculus,spermidine levels in 3LL cells after the treatment of 250 uM of Compound,F,10090.0,,,,CHEMBL615672,16169,N,BAO_0000219,1,,,,3LL cell line,80620
425,1,Mus musculus,spermidine levels in 3LL cells after the treatment of 50 uM of Compound,F,10090.0,,,,CHEMBL615791,16169,N,BAO_0000219,1,,,,3LL cell line,80620
426,1,Mus musculus,spermine levels in 3LL cells after the treatment of 1 uM of Compound,F,10090.0,,,,CHEMBL615792,16169,N,BAO_0000219,1,,,,3LL cell line,80620
427,1,Mus musculus,spermine levels in 3LL cells after the treatment of 10 uM of Compound,F,10090.0,,,,CHEMBL615793,16169,N,BAO_0000219,1,,,,3LL cell line,80620
428,1,Mus musculus,spermine levels in 3LL cells after the treatment of 250 uM of Compound,F,10090.0,,,,CHEMBL615794,16169,N,BAO_0000219,1,,,,3LL cell line,80620
429,1,Mus musculus,spermine levels in 3LL cells after the treatment of 50 uM of Compound,F,10090.0,,,,CHEMBL615795,16169,N,BAO_0000219,1,,,,3LL cell line,80620
430,1,Homo sapiens,Concentration required to inhibit the colony formation of lung carcinoma (3LLD122) cell lines by 50%,F,9606.0,,,,CHEMBL615590,15547,N,BAO_0000219,1,,,,3LLD122,80621
431,0,,In vivo antitumor activity against 3M531 is the sarcoma M5076; reproducible minimal activity,F,,,,,CHEMBL615591,8663,U,BAO_0000218,1,,,,,22226
432,0,,In vivo antitumor activity against 3M531 is the sarcoma M5076; reproducible significant activity.,F,,,,,CHEMBL615592,8663,U,BAO_0000218,1,,,,,22226
433,0,,In vivo antitumor activity against 3MBG5 subrenal capsule mammary carcinoma MX-1 xenograft; NT= Not tested,F,,,,,CHEMBL615593,8663,U,BAO_0000218,1,,,,,22226
434,0,,In vivo antitumor activity against 3MBG5 subrenal capsule mammary carcinoma MX-1 xenograft; reproducible significant activity.,F,,,,,CHEMBL615594,8663,U,BAO_0000218,1,,,,,22226
435,1,Mus musculus,Effective dose required against Trypanosoma cruzi amastigotes in 3T3 Fibroblasts,F,10090.0,,,,CHEMBL615595,4504,N,BAO_0000219,1,,,,NIH3T3,80951
436,1,Mus musculus,Effective dose required against Trypanosoma cruzi amastigotes in 3T3 Fibroblasts,F,10090.0,,,,CHEMBL615596,4504,N,BAO_0000219,1,,,,NIH3T3,80951
437,8,,Inhibition of 6 nM bombesin induced [3H]thymidine incorporation measured in swiss 3T3 cells using a mitogenicity assay,F,,,,,CHEMBL615597,12695,H,BAO_0000219,1,,,,NIH3T3,11169
438,1,Mus musculus,Ability of the peptide to inhibit 6 nM bombesin induced [3H]thymidine incorporation was measured in swiss 3T3 cells using mitogenicity assay; na=Not active,F,10090.0,,,,CHEMBL615598,12695,N,BAO_0000219,1,,,,NIH3T3,80951
439,1,Mus musculus,Ability of the peptide to inhibit 6 nM bombesin induced [3H]thymidine incorporation was measured in swiss 3T3 cells using mitogenicity assay; nt=Not tested,F,10090.0,,,,CHEMBL615599,12695,N,BAO_0000219,1,,,,NIH3T3,80951
440,1,Mus musculus,Effective dose against murine 3T3 fibroblasts cells,F,10090.0,,,,CHEMBL615600,17642,N,BAO_0000219,1,,,,NIH3T3,80951
441,1,Mus musculus,Dose required against murine 3T3 fibroblasts cells; 1-10 uM,F,10090.0,,,,CHEMBL615601,17642,N,BAO_0000219,1,,,,NIH3T3,80951
442,1,Mus musculus,Cytotoxic effect on 3T3 cells,F,10090.0,,,,CHEMBL615602,12340,N,BAO_0000219,1,,,,NIH3T3,80951
443,1,Mus musculus,Cytotoxic effect on 3T3 cells,F,10090.0,,,,CHEMBL615603,12340,N,BAO_0000219,1,,,,NIH3T3,80951
444,1,Mus musculus,Compound was tested for the concentration necessary to inhibit swiss 3T3 Mouse Fibroblast cell growth rate by 50%.,F,10090.0,,,,CHEMBL615604,12716,N,BAO_0000219,1,,,,NIH3T3,80951
445,1,Mus musculus,Concentration of NO in supernatant generated by mouse fibroblasts (3T3) cell line in the presence of compound was determined using NR coloration,F,10090.0,,,,CHEMBL615605,6277,N,BAO_0000219,1,,,,NIH3T3,80951
446,1,Mus musculus,Concentration of NO in supernatant generated by mouse fibroblasts (3T3) cell line in the presence of compound was determined using NR coloration; nd=No data,F,10090.0,,,,CHEMBL615606,6277,N,BAO_0000219,1,,,,NIH3T3,80951
447,1,Mus musculus,In vitro cytotoxic concentration against mouse fibroblasts (3T3) cell line using MTT coloration,F,10090.0,,,,CHEMBL884526,6277,N,BAO_0000219,1,,,,NIH3T3,80951
448,1,Mus musculus,In vitro cytotoxic concentration against mouse fibroblasts (3T3) cell line using MTT coloration; n.d.=no data,F,10090.0,,,,CHEMBL615607,6277,N,BAO_0000219,1,,,,NIH3T3,80951
449,1,Mus musculus,In vitro cytotoxic concentration against mouse fibroblasts (3T3) cell line using MTT coloration; n.t.=not tested,F,10090.0,,,,CHEMBL615608,6277,N,BAO_0000219,1,,,,NIH3T3,80951
450,1,Mus musculus,In vitro inhibitory activity against mouse fibroblasts (3T3) cell line using CV coloration,F,10090.0,,,,CHEMBL615609,6277,N,BAO_0000219,1,,,,NIH3T3,80951
451,1,Mus musculus,In vitro inhibitory activity against mouse fibroblasts (3T3) cell line using CV coloration; n.d.=no data,F,10090.0,,,,CHEMBL615682,6277,N,BAO_0000219,1,,,,NIH3T3,80951
452,1,Mus musculus,In vitro inhibitory activity against mouse fibroblasts (3T3) cell line using CV coloration; n.t.=not tested,F,10090.0,,,,CHEMBL615683,6277,N,BAO_0000219,1,,,,NIH3T3,80951
453,1,Mus musculus,In vivo inhibition of H-ras-transformed 3T3 fibroblasts in nude mouse tumor models,F,10090.0,,,,CHEMBL615684,17780,N,BAO_0000218,1,,,,NIH3T3,80951
454,7,Mus musculus,Inhibition of PDGF-dependent autophosphorylation of PDGF-R in mouse BALB/c3T3 cells,F,10090.0,,,,CHEMBL615685,12751,D,BAO_0000219,1,,,,,104860
455,1,Mus musculus,Inhibition of Swiss 3T3 Mouse fibroblast proliferation,F,10090.0,,,,CHEMBL615686,12380,N,BAO_0000219,1,,,,NIH3T3,80951
456,1,Mus musculus,Inhibitory activity against 3T3 cell line,F,10090.0,,,,CHEMBL615687,14892,N,BAO_0000219,1,,,,NIH3T3,80951
457,1,Mus musculus,The ability of the peptide to inhibit the binding of 10 pM [125I]gastrin releasing peptide to S-3T3 cell membrane was measured,F,10090.0,,,,CHEMBL884523,12695,N,BAO_0000219,1,,,,NIH3T3,80951
458,8,,Ability of peptide to inhibit binding of 10 pM [125I]gastrin releasing peptide to S-3T3 cell membrane.,F,,,,,CHEMBL615688,12695,H,BAO_0000019,1,,,,,11169
459,1,Mus musculus,The ability of the peptide to inhibit the binding of 10 pM [125I]gastrin releasing peptide to S-3T3 cell membrane was measured; nt=Not tested,F,10090.0,,,,CHEMBL615689,12695,N,BAO_0000219,1,,,,NIH3T3,80951
460,1,Mus musculus,The ability of the peptide to inhibit the binding of 50 pM [125I]gastrin releasing peptide to intact S-3T3 cells was measured,F,10090.0,,,,CHEMBL615690,12695,N,BAO_0000219,1,,,,NIH3T3,80951
461,8,,The ability of the peptide to inhibit the binding of 50 pM [125I]gastrin releasing peptide to intact S-3T3 cells,F,,,,,CHEMBL615691,12695,H,BAO_0000019,1,,,,,11169
462,8,,The ability of the peptide to inhibit the binding of 50 pM [125I]gastrin releasing peptide to intact S-3T3 cells; nt=Not tested,F,,,,,CHEMBL615692,12695,H,BAO_0000019,1,,,,,11169
463,1,Mus musculus,Concentration of NO in supernatant generated by mouse fibroblasts (3T3) cell line in the presence of compound was determined using NR coloration,F,10090.0,,,,CHEMBL615693,6277,N,BAO_0000219,1,,,,NIH3T3,80951
464,1,Mus musculus,Concentration of NO in supernatant generated by mouse fibroblasts (3T3) cell line was determined using NR coloration; n.d.=no data,F,10090.0,,,,CHEMBL615324,6277,N,BAO_0000219,1,,,,NIH3T3,80951
465,9,Homo sapiens,Inhibition of ligand-induced proliferation in human EGF-R Kinase expressing 3T3 cells,F,9606.0,,,,CHEMBL615325,4959,D,BAO_0000219,1,,,,NIH3T3,9
466,9,Homo sapiens,Inhibition of ligand-induced proliferation in human EGF-R Kinase expressing 3T3 cells (Not tested),F,9606.0,,,,CHEMBL615490,4959,D,BAO_0000219,1,,,,NIH3T3,9
467,9,Homo sapiens,Inhibition of ligand induced proliferation in human Her-2 (p185erbB) tyrosine kinase expressing 3T3 cells,F,9606.0,,,,CHEMBL615491,4959,D,BAO_0000219,1,,,,NIH3T3,188
468,9,Homo sapiens,Inhibition of ligand-induced proliferation in human Her-2 (p185erbB) tyrosine kinase expressing 3T3 cells (Not tested),F,9606.0,,,,CHEMBL615492,4959,D,BAO_0000219,1,,,,NIH3T3,188
469,1,Mus musculus,Inhibitory concentration of compound rwas calculated on 3T3 cells by [3H]Thd incorporation,F,10090.0,,,,CHEMBL615493,12082,N,BAO_0000219,1,,,,NIH3T3,80951
470,1,Mus musculus,Inhibitory concentration of compound was calculated on 3T3 cells by [14C]Leu incorporation,F,10090.0,,,,CHEMBL615494,12082,N,BAO_0000219,1,,,,NIH3T3,80951
471,1,Mus musculus,Inhibitory concentration of compound was calculated on 3T3 cells by using clonal assay,F,10090.0,,,,CHEMBL615495,12082,N,BAO_0000219,1,,,,NIH3T3,80951
472,1,Mus musculus,Inhibitory concentration was calculated on 3T3 cells by using growth assay,F,10090.0,,,,CHEMBL615496,12082,N,BAO_0000219,1,,,,NIH3T3,80951
473,1,Mus musculus,In vitro cytotoxicity was evaluated in mouse embryo BALB/c 3T3 cells,F,10090.0,,,,CHEMBL615497,2643,N,BAO_0000219,1,,,,NIH3T3,80951
474,1,Mus musculus,Inhibition of Swiss 3T3 mouse fibroblast proliferation,F,10090.0,,,,CHEMBL615498,11926,N,BAO_0000219,1,,,,NIH3T3,80951
475,1,Mus musculus,The compound was tested for cytotoxicity against 3T3 fibroblast murine cell line.,A,10090.0,,,,CHEMBL615499,15204,N,BAO_0000219,1,,,,NIH3T3,80951
476,1,Mus musculus,Effective concentration required to inhibit the growth of murine 3T3 fibroblasts,F,10090.0,,,,CHEMBL835522,15992,N,BAO_0000219,1,,,,NIH3T3,80951
477,1,Mus musculus,Cytotoxicity on 3T3 fibroblasts (3T3F) murine cell line (O.D.=0.131+/-0.014); Not tested,F,10090.0,,,,CHEMBL615500,16279,N,BAO_0000219,1,,,,NIH3T3,80951
478,1,Mus musculus,Cytotoxicity against 3T3 fibroblasts (3T3F) murine cell line (O.D.=0.131+/-0.014),F,10090.0,,,,CHEMBL615501,16279,N,BAO_0000219,1,,,,NIH3T3,80951
479,1,Mus musculus,Cytotoxicity on 3T3 fibroblasts (3T3F) murine cell line (O.D.=0.131+/-0.014),F,10090.0,,,,CHEMBL615502,16279,N,BAO_0000219,1,,,,NIH3T3,80951
480,1,Mus musculus,cytotoxicity on 3T3 fibroblasts (3T3F) murine cell line (O.D.=0.131+/-0.014),F,10090.0,,,,CHEMBL615503,16279,N,BAO_0000219,1,,,,NIH3T3,80951
481,1,Mus musculus,Cytotoxicity on 3T3 fibroblasts (3T3F) murine cell line (O.D.=0.131+/-0.014),F,10090.0,,,,CHEMBL615504,16279,N,BAO_0000219,1,,,,NIH3T3,80951
482,1,Mus musculus,Cytotoxicity against 3T3 fibroblasts (3T3F) murine cell line (O.D.=0.131+/-0.014),F,10090.0,,,,CHEMBL615505,16279,N,BAO_0000219,1,,,,NIH3T3,80951
483,1,Mus musculus,Inhibition of swiss 3T3 mouse fibroblast proliferation,F,10090.0,,,,CHEMBL615506,12831,N,BAO_0000219,1,,,,NIH3T3,80951
484,1,Mus musculus,Compound was tested for sublethal concentrations in 3T3 mouse fibroblast lysis.,F,10090.0,,,,CHEMBL615507,13497,N,BAO_0000219,1,,,,NIH3T3,80951
485,1,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 30 uM dose.,F,,,,,CHEMBL615508,13715,N,BAO_0000218,1,,,,3T3-L1,80006
486,1,Mus musculus,Concentration required to stimulate glucose uptake in 3T3-L1 adipocytes after 48 hr incubation,F,10090.0,,,,CHEMBL615509,13618,N,BAO_0000219,1,,,,3T3-L1,80006
487,1,Mus musculus,Effect on GLUT 1 glucose transporter expression in 3T3-L1 adipocytes at dose of 0.3 uM,F,10090.0,,,,CHEMBL615510,11902,N,BAO_0000219,1,,,,3T3-L1,80006
488,1,Mus musculus,Effect on GLUT 1 glucose transporter expression in 3T3-L1 adipocytes at dose of 3 uM,F,10090.0,,,,CHEMBL615511,11902,N,BAO_0000219,1,,,,3T3-L1,80006
489,1,Mus musculus,Effect on GLUT 1 glucose transporter expression in 3T3-L1 adipocytes at dose of 30 uM,F,10090.0,,,,CHEMBL615512,11902,N,BAO_0000219,1,,,,3T3-L1,80006
490,1,Mus musculus,"In vitro ability to stimulate glucose transport in 3T3-L1 adipocytes, given at 100 mg/kg in mouse, after 24 hr",F,10090.0,,,,CHEMBL615513,14840,N,BAO_0000218,1,,,,3T3-L1,80006
491,1,Mus musculus,"In vitro ability to stimulate glucose transport in 3T3-L1 adipocytes, given at 100 mg/kg in mouse, after 3 hr",F,10090.0,,,,CHEMBL615514,14840,N,BAO_0000218,1,,,,3T3-L1,80006
492,1,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes,F,,,,,CHEMBL615515,13715,N,BAO_0000219,1,,,,3T3-L1,80006
493,1,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 10 micro M,F,,,,,CHEMBL615516,13715,N,BAO_0000219,1,,,,3T3-L1,80006
494,1,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 3 micro M,F,,,,,CHEMBL615517,13715,N,BAO_0000219,1,,,,3T3-L1,80006
495,1,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 30 micro M,F,,,,,CHEMBL615518,13715,N,BAO_0000219,1,,,,3T3-L1,80006
496,1,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 3 micro M,F,,,,,CHEMBL615519,13715,N,BAO_0000219,1,,,,3T3-L1,80006
497,1,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 0.3 uM dose.,F,,,,,CHEMBL615520,13715,N,BAO_0000218,1,,,,3T3-L1,80006
498,1,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 0.5 uM dose.,F,,,,,CHEMBL615521,13715,N,BAO_0000218,1,,,,3T3-L1,80006
499,1,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 1 uM dose.,F,,,,,CHEMBL615522,13715,N,BAO_0000218,1,,,,3T3-L1,80006
500,1,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 10 uM dose.,F,,,,,CHEMBL615523,13715,N,BAO_0000218,1,,,,3T3-L1,80006
501,1,,In vitro measurements 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 100 uM dose.,F,,,,,CHEMBL615524,13715,N,BAO_0000218,1,,,,3T3-L1,80006
502,1,,Acute effects in vitro by measuring 2-deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 10 uM dose.,F,,,,,CHEMBL615525,13715,N,BAO_0000218,1,,,,3T3-L1,80006
503,1,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 1 uM dose.,F,,,,,CHEMBL615526,13715,N,BAO_0000218,1,,,,3T3-L1,80006
504,1,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 3 uM dose.,F,,,,,CHEMBL615527,13715,N,BAO_0000218,1,,,,3T3-L1,80006
505,1,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 300 uM dose.,F,,,,,CHEMBL615528,13715,N,BAO_0000218,1,,,,3T3-L1,80006
506,1,,Acute effects in vitro by measuring 2-deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 30 uM dose.,F,,,,,CHEMBL615529,13715,N,BAO_0000218,1,,,,3T3-L1,80006
507,1,,In vitro by measurements of 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 3 uM dose.,F,,,,,CHEMBL615530,13715,N,BAO_0000218,1,,,,3T3-L1,80006
508,1,,In vitro measurements of 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 60 uM dose.,F,,,,,CHEMBL615531,13715,N,BAO_0000218,1,,,,3T3-L1,80006
509,1,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 10 micro M,F,,,,,CHEMBL615532,13715,N,BAO_0000219,1,,,,3T3-L1,80006
510,1,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 3 micro M,F,,,,,CHEMBL615533,13715,N,BAO_0000219,1,,,,3T3-L1,80006
511,1,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 30 micro M,F,,,,,CHEMBL615534,13715,N,BAO_0000219,1,,,,3T3-L1,80006
512,1,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 100 uM dose.,F,,,,,CHEMBL615535,13715,N,BAO_0000218,1,,,,3T3-L1,80006
513,1,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 10 uM dose.,F,,,,,CHEMBL615536,13715,N,BAO_0000218,1,,,,3T3-L1,80006
514,1,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 30 uM dose.,F,,,,,CHEMBL615537,13715,N,BAO_0000218,1,,,,3T3-L1,80006
515,1,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 3 uM dose.,F,,,,,CHEMBL615538,13715,N,BAO_0000218,1,,,,3T3-L1,80006
516,1,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 60 uM dose.,F,,,,,CHEMBL836166,13715,N,BAO_0000218,1,,,,3T3-L1,80006
517,8,,Inhibition of forskolin-stimulated lipolysis in differentiated 3T3-L1 cells,F,,,,,CHEMBL615539,6411,H,BAO_0000219,1,,,,3T3-L1,11214
518,1,Mus musculus,Evaluated for the inhibition of forskolin-stimulated lipolysis in differentiated 3T3-L1 cells; ND = No data,F,10090.0,,,,CHEMBL615540,6411,N,BAO_0000219,1,,,,3T3-L1,80006
519,8,,Evaluated for the inhibition of forskolin-stimulated lipolysis in differentiated 3T3-L1 cells; Na = Not active,F,,,,,CHEMBL615541,6411,H,BAO_0000219,1,,,,3T3-L1,11214
520,1,Mus musculus,Insulin-sensitizing activity; triglyceride accumulation from insulin regulated differentiation of 3T3-L1 cells at 1 uM expressed as percent activity of pioglitazone,F,10090.0,,,,CHEMBL615542,3966,N,BAO_0000219,1,,,,3T3-L1,80006
521,1,Mus musculus,Compound was tested for insulin-sensitizing activity by measuring triglyceride accumulation from insulin regulated differentiation of 3T3-L1 cells at 10 uM expressed as percent activity of pioglitazone,F,10090.0,,,,CHEMBL615543,3966,N,BAO_0000219,1,,,,3T3-L1,80006
522,1,Mus musculus,Stimulation of adipogenesis in 3T3-L1 cells is expressed as concentration equivalent to the [ 1-14C] uptake counts after treatment with 0.2 ug/mL troglitazone,F,10090.0,,,,CHEMBL615544,15556,N,BAO_0000219,1,,,,3T3-L1,80006
523,1,Mus musculus,Effective concentration for enhancement of insulin-induced triglyceride accumulation in 3T3-L1 cells,F,10090.0,,,,CHEMBL615545,5845,N,BAO_0000219,1,,,,3T3-L1,80006
524,1,Mus musculus,Effective concentration for 50% enhancement of insulin-induced triglyceride accumulation in 3T3-L1 cells,F,10090.0,,,,CHEMBL615546,14422,N,BAO_0000219,1,,,,3T3-L1,80006
525,1,Mus musculus,Percentage of rosiglitazone response for insulin-sensitizing activity at 1 uM concentration in 3T3-L1 cells,F,10090.0,,,,CHEMBL615547,5845,N,BAO_0000219,1,,,,3T3-L1,80006
526,1,Mus musculus,In vitro glucose transport activity in 3T3-LI adipocytes at 10 uM concentration.,F,10090.0,,,,CHEMBL615548,14508,N,BAO_0000219,1,,,,3T3-L1,80006
527,1,Mus musculus,In vitro glucose transport activity in 3T3-LI adipocytes at 3 uM concentration.,F,10090.0,,,,CHEMBL615549,14508,N,BAO_0000219,1,,,,3T3-L1,80006
528,1,Mus musculus,In vitro glucose transport activity in 3T3-LI adipocytes at 30 uM concentration.,F,10090.0,,,,CHEMBL615550,14508,N,BAO_0000219,1,,,,3T3-L1,80006
529,1,Rattus norvegicus,Inhibitory activity against rat fibroblast (3Y1) cell line,F,10116.0,,,,CHEMBL615551,6349,N,BAO_0000219,1,,,,3Y1 cell line,80622
530,1,Rattus norvegicus,Mean concentration causing inhibition of cell growth in 3Y1 cells.,F,10116.0,,,,CHEMBL615552,15899,N,BAO_0000219,1,,,,3Y1 cell line,80622
531,1,Rattus norvegicus,Cytotoxicity in 3Y1 cells.,F,10116.0,,,,CHEMBL615553,15899,N,BAO_0000219,1,,,,3Y1 cell line,80622
532,1,Rattus norvegicus,Cytostatic effect in 3Y1 cells.,F,10116.0,,,,CHEMBL615554,15899,N,BAO_0000219,1,,,,3Y1 cell line,80622
533,1,Rattus norvegicus,"Mean averaged concentration for total growth inhibition, which signifies cytostatic effect",F,10116.0,,,,CHEMBL615555,15899,N,BAO_0000219,1,,,,3Y1 cell line,80622
534,1,Rattus norvegicus,Concentration to inhibit growth of normal rat fibroblast cells (3Y1-B cells) after 72 h exposure,F,10116.0,,,,CHEMBL615556,17038,N,BAO_0000219,1,,,,3Y1 cell line,80622
535,0,,In vitro inhibitory activity against human adrenal 3-beta hydroxy-delta 5-teroid isomerase,B,,,,,CHEMBL615557,12421,U,BAO_0000019,1,,,,,22226
536,0,,Inhibition of recombinant human adrenal 3-beta-hydroxy-delta-5-steroid dehydrogenase,B,,,,,CHEMBL615558,12947,U,BAO_0000019,1,,,,,22226
537,0,,Inhibition of recombinant rat adrenal 3-beta-hydroxy-delta-5-steroid dehydrogenase,B,,,,,CHEMBL872066,12947,U,BAO_0000019,1,,,,,22226
538,9,Sus scrofa,In vitro inhibition against of 4-Hydroxyphenylpyruvate dioxygenase (4-HPPD) from pig liver by the enol borate method,B,9823.0,,,,CHEMBL615559,4896,D,BAO_0000019,1,,,,,11607
539,8,,In vitro inhibitory concentration required against 4-hydroxyphenylpyruvate dioxygenase (4-HPPD) taken from pig liver,B,,,,,CHEMBL615560,6148,H,BAO_0000019,1,,,,,11607
540,8,,Inhibition of pig liver 4-Hydroxyphenylpyruvate dioxygenase (4-HPPD) enzyme,B,,,,,CHEMBL615561,16432,H,BAO_0000019,1,,,,,11607
541,8,,Concentration required to achieve 50% inhibition against 4-Hydroxyphenylpyruvate dioxygenase (HPPD) from pig liver,B,,,,,CHEMBL857062,4978,H,BAO_0000019,1,,,,,11607
542,8,,Concentration required to achieve 50% inhibition against 4-Hydroxyphenylpyruvate dioxygenase (HPPD) from pig liver; (observed value),B,,,,,CHEMBL615562,4978,H,BAO_0000019,1,,,,,11607
543,8,,In vitro inhibitory activity against HPPD(4-hydroxyphenylpyruvate Dioxygenase) from pig liver using enol borate assay method,B,,,,,CHEMBL615563,3723,H,BAO_0000019,1,,,,,11607
544,8,,Compound was evaluated for complete competitive inhibition of 4-hydroxyphenylpyruvate dioxygenase (HPPD),B,,,,,CHEMBL615564,3518,H,BAO_0000357,1,,,,,11607
545,8,,In vitro inhibition of 4-hydroxyphenylpyruvate dioxygenase obtained from purified pig liver by enol-borate method,B,,,,,CHEMBL615565,4164,H,BAO_0000019,1,,,,,11607
546,8,,Inhibitory activity on pig liver 4-hydroxyphenylpyruvate dioxygenase (HPPD) was evaluated,B,,,,,CHEMBL615566,3518,H,BAO_0000019,1,,,,,11607
547,9,Sus scrofa,Inhibition of 4-hydroxyphenylpyruvate dioxygenase of purified pig liver by enol-borate method,B,9823.0,,,,CHEMBL615567,4164,D,BAO_0000019,1,,,,,11607
548,8,,The inhibitory activity on pig liver 4-hydroxyphenylpyruvate dioxygenase (HPPD) was evaluated.,B,,,,,CHEMBL615568,3518,H,BAO_0000019,1,,,,,11607
549,8,,Compound was evaluated for competitive inhibition of 4-hydroxyphenylpyruvate dioxygenase (HPPD) (complete inhibition was observed at a concentration of 0.5-1.0 mM),B,,,,,CHEMBL615569,3518,H,BAO_0000357,1,,,,,11607
550,8,,Concentration required to achieve 50% inhibition against 4-hydroxyphenylpyruvate dioxygenase from pig liver,B,,,,,CHEMBL615570,4978,H,BAO_0000019,1,,,,,11607
551,8,,Concentration required to achieve 50% inhibition against 4-hydroxyphenylpyruvate dioxygenase from pig liver; (observed value),B,,,,,CHEMBL615571,4978,H,BAO_0000019,1,,,,,11607
552,4,,Binding affinity against melatonin (MT1) receptor (pC1),B,,,,,CHEMBL615572,6455,H,BAO_0000224,1,,,,,104733
553,0,,Compound was tested for inhibitory activity against 5-hydroxytryptamine 1 receptor,B,,,,,CHEMBL615573,2222,U,BAO_0000019,1,,,,,22226
554,0,,Inhibition of [3H]- 5-HT binding to 5-hydroxytryptamine 1 receptor at 10e-5 M,B,,,,,CHEMBL615574,13020,U,BAO_0000019,1,,,,,22226
555,0,,Inhibition of [3H]5-HT binding to 5-hydroxytryptamine 1 receptor of central nervous system,B,,,,,CHEMBL615575,13021,U,BAO_0000019,1,,,,,22226
556,8,,Inhibitory activity against 5-hydroxytryptamine 1 receptor using [3H]5-HT as radioligand at 10e-5 M concentration,B,,,,,CHEMBL615576,14532,H,BAO_0000357,1,,,,,10619
557,8,,Binding affinity against 5-hydroxytryptamine 1 receptor using [3H]5-HT as radioligand,B,,,,,CHEMBL615577,14118,H,BAO_0000357,1,,,,,10619
558,8,,Binding affinity at 5-hydroxytryptamine 1A receptor in bovine hippocampal preparation using [3H]8-OH-DPAT,B,,Hippocampus,,,CHEMBL615578,11884,H,BAO_0000221,1,10000000.0,,,,51
559,8,,Binding affinity against 5-hydroxytryptamine 1A receptor was measured using [3H]8-OH-DPAT as radioligand,B,,,,,CHEMBL615579,13969,H,BAO_0000357,1,,,,,51
560,8,,Binding affinity for 5-hydroxytryptamine 1A receptor,B,,,,,CHEMBL615580,13392,H,BAO_0000357,1,,,,,51
561,8,,Affinity towards 5-hydroxytryptamine 1A receptor in membranes from bovine hippocampus using [3H]OH-DPAT,B,,,,,CHEMBL615581,14430,H,BAO_0000019,1,,,,,51
562,8,,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in bovine hippocampus,B,,Hippocampus,,,CHEMBL615582,12248,H,BAO_0000221,1,10000000.0,,,,51
563,8,,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in bovine hippocampus,B,,Hippocampus,,,CHEMBL615583,12249,H,BAO_0000221,1,10000000.0,,,,51
564,8,,In vitro inhibition of [3H]5-HT (2 nM) binding to 5-HT1A receptor from bovine hippocampus,B,,Hippocampus,,,CHEMBL615584,9995,H,BAO_0000221,1,10000000.0,,,,51
565,8,,In vitro inhibition of [3H]5-HT (2 nM) binding to 5-hydroxytryptamine 1A receptor from bovine hippocampus,B,,Hippocampus,,,CHEMBL833691,9995,H,BAO_0000221,1,10000000.0,,,,51
566,8,,In vitro inhibition of azido-[125I]-IPAPP (0.25 nM) binding to 5-HT1A receptor from bovine hippocampus,B,,Hippocampus,,,CHEMBL615585,9995,H,BAO_0000221,1,10000000.0,,,,51
567,8,,In vitro inhibition of [125I]IPAPP (0.25 nM) binding to 5-HT1A receptor from bovine hippocampus,B,,Hippocampus,,,CHEMBL615586,9995,H,BAO_0000221,1,10000000.0,,,,51
568,8,,In vitro inhibition of [125I]IPAPP (2.5 nM) binding to 5-hydroxytryptamine 1A receptor from bovine hippocampus,B,,Hippocampus,,,CHEMBL884524,9995,H,BAO_0000221,1,10000000.0,,,,51
569,8,,Inhibitory concentration against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in bovine hippocampus,B,,Hippocampus,,,CHEMBL615587,12249,H,BAO_0000221,1,10000000.0,,,,51
570,8,,"Compound was tested for binding affinity against 5-hydroxytryptamine 1A receptor from bovine hippocampus, used [3H]8-OH-DPAT as radioligand",B,,Hippocampus,,,CHEMBL615588,11799,H,BAO_0000221,1,10000000.0,,,,51
571,9,Rattus norvegicus,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of rat hippocampal membranes,B,10116.0,,Membranes,,CHEMBL615589,14331,D,BAO_0000249,1,,,,,10576
572,8,Bos taurus,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of bovine hippocampus.,B,9913.0,Hippocampus,,,CHEMBL615442,11884,H,BAO_0000221,1,10000000.0,,,,51
573,8,,Binding affinity of compound towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT (0.5 nM) ligand in hippocampus + frontal bovine was determined,B,,Hippocampus,,,CHEMBL615443,14331,H,BAO_0000221,1,10000000.0,,,,51
574,8,,Compound was evaluated for its ability to displace [3H]DPAT from 5-HT1A receptor in homogenates of bovine hippocampus,B,,Hippocampus,,,CHEMBL615444,11701,H,BAO_0000221,1,10000000.0,,,,51
575,8,,Ability to displace [3H]-DPAT from 5-hydroxytryptamine 1A receptor in homogenates of bovine hippocampus.,B,,Hippocampus,,,CHEMBL615445,11701,H,BAO_0000221,1,10000000.0,,,,51
576,8,,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor in bovine hippocampus,B,,Hippocampus,,,CHEMBL615446,12248,H,BAO_0000221,1,10000000.0,,,,51
577,8,,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in CHO cells,B,,,,,CHEMBL615447,12248,H,BAO_0000219,1,,,,CHO,51
578,8,,Binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in bovine hippocampus,B,,Hippocampus,,,CHEMBL615448,12248,H,BAO_0000221,1,10000000.0,,,,51
579,8,,Binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in bovine hippocampus,B,,Hippocampus,,,CHEMBL615449,12249,H,BAO_0000221,1,10000000.0,,,,51
580,8,,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in cloned CHO cells,B,,,,,CHEMBL615450,12248,H,BAO_0000219,1,,,,CHO,51
581,8,,"Binding affinity against 5-hydroxytryptamine 1A receptor from bovine hippocampus, used [3H]8-OH-DPAT as radioligand",B,,Hippocampus,,,CHEMBL615451,11799,H,BAO_0000221,1,10000000.0,,,,51
582,8,,Compound was tested for its binding affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT radioligand,B,,,,,CHEMBL615452,634,H,BAO_0000357,1,,,,,51
583,8,,In vitro inhibition of [3H]5-HT (2 nM) binding to 5-HT1A receptor from bovine hippocampus,B,,Hippocampus,,,CHEMBL615453,9995,H,BAO_0000221,1,10000000.0,,,,51
584,8,,In vitro inhibition of [3H]5-HT (2 nM) binding to 5-hydroxytryptamine 1A receptor from bovine hippocampus,B,,Hippocampus,,,CHEMBL615454,9995,H,BAO_0000221,1,10000000.0,,,,51
585,8,,In vitro inhibition of [3H]DPAT (1 nM) binding to 5-HT1A receptor from bovine hippocampus,B,,Hippocampus,,,CHEMBL615455,9995,H,BAO_0000221,1,10000000.0,,,,51
586,8,,In vitro inhibition of [3H]DPAT (1 nM) binding to 5-hydroxytryptamine 1A receptor from bovine hippocampus,B,,Hippocampus,,,CHEMBL615456,9995,H,BAO_0000221,1,10000000.0,,,,51
587,8,,In vitro inhibition of [3H]DPAT (1 nM) binding to 5-HT1A receptor from bovine hippocampus,B,,Hippocampus,,,CHEMBL615457,9995,H,BAO_0000221,1,10000000.0,,,,51
588,8,,In vivo binding affinity towards [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in bovine hippocampus.,B,,Hippocampus,,,CHEMBL615458,12210,H,BAO_0000218,1,10000000.0,,,,51
589,8,,Tested for activity against 5-hydroxytryptamine 1A receptor from bovine hippocampus,B,,Hippocampus,,,CHEMBL615459,13311,H,BAO_0000221,1,10000000.0,,,,51
590,9,Homo sapiens,"Tested in vitro for the inhibition of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor, expressed in cloned CHO cells.",B,9606.0,,,,CHEMBL615460,2331,D,BAO_0000219,1,,,,CHO,51
591,8,Cavia porcellus,Compound was tested for the inhibition of forskolin-stimulated adenylate cyclase at 5-hydroxytryptamine 1A receptor in guinea pig,F,10141.0,,,,CHEMBL615461,1375,H,BAO_0000019,1,,,,,51
592,8,Cavia porcellus,Compound was tested for the inhibition of forskolin-stimulated adenylate cyclase at 5-hydroxytryptamine 1A receptor in guinea pig; NT means not tested,F,10141.0,,,,CHEMBL615462,1375,H,BAO_0000019,1,,,,,51
593,8,Cavia porcellus,Effect on forskolin stimulated adenylate cyclase activity at 5-hydroxytryptamine 1A receptor of guinea pig hippocampus.,F,10141.0,Hippocampus,,,CHEMBL615463,11574,H,BAO_0000221,1,10000000.0,,,,51
594,8,Cavia porcellus,Ability to antagonize Acetylcholine induced contractile responses in Guinea pig ileum for 5-HT1A receptor.,B,10141.0,Ileum,,,CHEMBL615464,12867,H,BAO_0000221,1,2116.0,,,,51
595,8,Cavia porcellus,Ability to antagonize Acetylcholine induced contractile responses in Guinea pig ileum for 5-HT1A receptor. Inactive at dose level of 1.0 uM,B,10141.0,Ileum,,,CHEMBL615465,12867,H,BAO_0000221,1,2116.0,,,,51
596,8,Cavia porcellus,Ability to antagonize electrical induced contractile responses in Guinea pig ileum for 5-HT1A receptor.,B,10141.0,Ileum,,,CHEMBL615466,12867,H,BAO_0000221,1,2116.0,,,,51
597,8,Cavia porcellus,Ability to antagonize electrical induced contractile responses in Guinea pig ileum for 5-HT1A receptor. Inactive at dose level of 1.0 uM,B,10141.0,Ileum,,,CHEMBL615467,12867,H,BAO_0000221,1,2116.0,,,,51
598,8,Cavia porcellus,Ability to antagonize electrical induced contractile responses in Guinea pig ileum for 5-HT1A receptor. Inactive at dose level of 1.0 uM,B,10141.0,Ileum,,,CHEMBL615468,12867,H,BAO_0000221,1,2116.0,,,,51
599,8,Cavia porcellus,Ability to antagonize electrical induced contractile responses in Guinea pig ileum for 5-HT1A receptor; Inactive at dose level of 1.0 uM,B,10141.0,Ileum,,,CHEMBL615469,12867,H,BAO_0000221,1,2116.0,,,,51
600,8,Cavia porcellus,Binding affinity against 5-hydroxytryptamine 1A receptor,B,10141.0,,,,CHEMBL615470,11574,H,BAO_0000357,1,,,,,51
601,8,Cavia porcellus,Compound is evaluated for in vitro receptor binding affinity against 5-hydroxytryptamine 1A receptor,B,10141.0,,,,CHEMBL615471,13114,H,BAO_0000357,1,,,,,51
602,8,Cavia porcellus,Binding affinity was determined against 5-hydroxytryptamine 1A receptor,B,10141.0,,,,CHEMBL615472,13181,H,BAO_0000357,1,,,,,51
603,8,Cavia porcellus,Inhibition of Forskolin-stimulated adenylate cyclase activity against 5-hydroxytryptamine 1A receptor of guinea pig hippocampus,B,10141.0,Hippocampus,,,CHEMBL883242,10639,H,BAO_0000221,1,10000000.0,,,,106
604,8,Cavia porcellus,Inhibition of Forskolin-stimulated adenylate cyclase activity against 5-hydroxytryptamine 1A receptor of guinea pig hippocampus,F,10141.0,Hippocampus,,,CHEMBL615473,10639,H,BAO_0000221,1,10000000.0,,,,106
605,8,Cricetulus griseus,In vitro binding affinity against 5-hydroxytryptamine 1A receptor using [3H]-8-OH-DPAT as radioligand in CHO cells (sc),B,10029.0,,,,CHEMBL615474,11883,H,BAO_0000218,1,,,,CHO,11863
606,8,,Fraction involved in salt bridge interactions with Asp3:11 part of the 5-hydroxytryptamine 1A receptor,B,,,,,CHEMBL615475,17785,H,BAO_0000357,1,,,,,51
607,8,,Compound was tested for its ability to inhibit forskolin-stimulated activity of adenylate cyclase coupled to human 5-HT 1A receptor in HeLa cells; value ranges from 85-370,F,,,,,CHEMBL615476,1558,H,BAO_0000219,1,,,,HeLa,51
608,8,,Compound was tested for its ability to inhibit forskolin-stimulated activity of adenylate cyclase coupled to human 5-hydroxytryptamine 1A receptor in HeLa cells; value ranges from 95-320,F,,,,,CHEMBL615477,1558,H,BAO_0000219,1,,,,HeLa,51
609,8,,EC50 for inhibition of 50 uM forskolin-stimulated cAMP accumulation against 5-hydroxytryptamine 1A receptor,F,,,,,CHEMBL615478,15740,H,BAO_0000019,1,,,,,51
610,8,,Effective concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing human 5-hydroxytryptamine 1A receptor,F,,,,,CHEMBL615160,17624,H,BAO_0000219,1,,,,CHO,51
611,8,,Effective concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing human 5-hydroxytryptamine 1A receptor,F,,,,,CHEMBL615161,17624,H,BAO_0000219,1,,,,CHO,51
612,8,,Effective concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing human 5-hydroxytryptamine 1A receptor; nd=Not determined,F,,,,,CHEMBL615162,17624,H,BAO_0000219,1,,,,CHO,51
613,8,,Effective concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing human 5-hydroxytryptamine 1A receptor; nd=not determined,F,,,,,CHEMBL615163,17624,H,BAO_0000219,1,,,,CHO,51
614,8,,Effective concentration against human 5-hydroxytryptamine 1A receptor using cAMP as radioligand in CHO cells,B,,,,,CHEMBL615164,17624,H,BAO_0000219,1,,,,CHO,51
615,8,,Effective concentration against human 5-hydroxytryptamine 1A receptor using cAMP as radioligand in CHO cells,B,,,,,CHEMBL615165,17624,H,BAO_0000219,1,,,,CHO,51
616,8,,Effective concentration against human 5-hydroxytryptamine 1A receptor using cAMP as radioligand in CHO cells; nd=not determined,B,,,,,CHEMBL615166,17624,H,BAO_0000219,1,,,,CHO,51
617,8,,In vitro potency at human 5-hydroxytryptamine 1A receptor in inhibiting forskolin-stimulated accumulation of intracellular cAMP,F,,,,,CHEMBL615167,14256,H,BAO_0000219,1,,,,,51
618,9,Homo sapiens,Stimulation of [35S]- GIPyS binding to cloned human 5-hydroxytryptamine 1A receptor stably expressed in HeLa cells,B,9606.0,,,,CHEMBL615168,3445,D,BAO_0000219,1,,,,HeLa,51
619,9,Homo sapiens,Stimulation of [35S]- GIPyS binding to cloned human 5-hydroxytryptamine 1A receptor stably expressed in HeLa cells; Inverse,B,9606.0,,,,CHEMBL615169,3445,D,BAO_0000219,1,,,,HeLa,51
620,9,Homo sapiens,Tested for functional response on CHO cells expressing cloned human 5-hydroxytryptamine 1A receptor,B,9606.0,,,,CHEMBL615170,17200,D,BAO_0000219,1,,,,CHO,51
621,9,Homo sapiens,Tested for functional response on CHO cells expressing cloned human 5-hydroxytryptamine 1A receptor; Not determined,B,9606.0,,,,CHEMBL615171,17200,D,BAO_0000219,1,,,,CHO,51
622,8,,Eudisimic ratio(ER) is the antilog of the defference between the pKb and pD2 values against 5-hydroxytryptamine 1A receptor,F,,,,,CHEMBL615694,15180,H,BAO_0000019,1,,,,,51
623,8,,Eudisimic ratio(ER) is the antilog of the difference between the pKb and pD2 values against 5-hydroxytryptamine 1A receptor,F,,,,,CHEMBL615695,15180,H,BAO_0000019,1,,,,,51
624,8,,"Percent of maximum effect on binding of [35S]GTP-gamma-S, to HeLa cell membranes expressing the human 5-hydroxytryptamine 1A receptor",F,,,,,CHEMBL615696,16026,H,BAO_0000019,1,,,,,51
625,8,,Agonistic efficacy was evaluated by adenylyl cyclase assay in CHO cells stably expressing the human 5-HT1A receptor,F,,,,,CHEMBL615697,2759,H,BAO_0000219,1,,,,CHO,51
626,9,Homo sapiens,Agonistic efficacy as adenylyl cyclase assay in CHO cells expressing human 5-HT1A receptor (experiment 1),F,9606.0,,,,CHEMBL859410,2759,D,BAO_0000219,1,,,,CHO,51
627,8,,Agonistic efficacy was evaluated by adenylyl cyclase assay in CHO cells stably expressing the human 5-HT1A receptor (experiment 2),F,,,,,CHEMBL615841,2759,H,BAO_0000219,1,,,,CHO,51
628,9,Homo sapiens,Agonistic efficacy in adenylyl cyclase assay in CHO cells expressing human 5-HT1A receptor (experiment 2),F,9606.0,,,,CHEMBL615842,2759,D,BAO_0000219,1,,,,CHO,51
629,8,,Antagonistic efficacy was evaluated by adenylyl cyclase assay in CHO cells stably expressing the human 5-HT1A receptor,F,,,,,CHEMBL835003,2759,H,BAO_0000219,1,,,,CHO,51
630,8,,Antagonistic efficacy was evaluated by adenylyl cyclase assay in CHO cells stably expressing the human 5-HT1A receptor (experiment 1),F,,,,,CHEMBL615843,2759,H,BAO_0000219,1,,,,CHO,51
631,9,Homo sapiens,Antagonistic efficacy as adenylyl cyclase assay in CHO cells expressing human 5-HT1A receptor (experiment 1),F,9606.0,,,,CHEMBL615979,2759,D,BAO_0000219,1,,,,CHO,51
632,8,,Antagonistic efficacy was evaluated by adenylyl cyclase assay in CHO cells stably expressing the human 5-HT1A receptor (experiment 2),F,,,,,CHEMBL615980,2759,H,BAO_0000219,1,,,,CHO,51
633,9,Homo sapiens,Antagonistic efficacy as adenylyl cyclase assay in CHO cells expressing human 5-HT1A receptor (experiment 2),F,9606.0,,,,CHEMBL615981,2759,D,BAO_0000219,1,,,,CHO,51
634,9,Homo sapiens,Percent efficacy against cloned human 5-hydroxytryptamine 1A receptor normalized to the maximal 5-HT response,F,9606.0,,,,CHEMBL615982,3445,D,BAO_0000019,1,,,,,51
635,9,Homo sapiens,"Agonist activity at the 5-hydroxytryptamine 1A receptor was determined in vitro using a [35S]GTP-gamma-S,",F,9606.0,,,,CHEMBL615983,5272,D,BAO_0000019,1,,,,,51
636,9,Homo sapiens,"Agonist activity at the 5-hydroxytryptamine 1A receptor in vitro using a [35S]GTP-gamma-S, No data",F,9606.0,,,,CHEMBL615984,5272,D,BAO_0000019,1,,,,,51
637,9,Homo sapiens,"Agonist activity at the 5-hydroxytryptamine 1A receptor determined in vitro using a [35S]GTP-gamma-S,",F,9606.0,,,,CHEMBL615985,5272,D,BAO_0000019,1,,,,,51
638,8,,Agonistic effect against 5-HT1A receptor using cAMP as radioligand relative to 5-HT in inhibiting forskolin-stimulated adenylate cyclase activity in CHO cells,F,,,,,CHEMBL615986,17624,H,BAO_0000219,1,,,,CHO,51
639,8,,Agonistic effect against 5-hydroxytryptamine 1A receptor using cAMP as radioligand relative to 5-HT in inhibiting forskolin-stimulated adenylate cyclase activity in CHO cells,F,,,,,CHEMBL615987,17624,H,BAO_0000219,1,,,,CHO,51
640,8,,Agonistic effect against 5-hydroxytryptamine 1A receptor using cAMP as radioligand relative to 5-HT in inhibiting forskolin-stimulated adenylate cyclase activity in CHO cells; nd=Not determined,F,,,,,CHEMBL615988,17624,H,BAO_0000219,1,,,,CHO,51
641,8,,Agonistic effect against 5-hydroxytryptamine 1A receptor using cAMP as radioligand relative to 5-HT in inhibiting forskolin-stimulated adenylate cyclase activity in CHO cells,F,,,,,CHEMBL615989,17624,H,BAO_0000219,1,,,,CHO,51
642,8,,Agonistic effect against 5-hydroxytryptamine 1A receptor using cAMP as radioligand relative to 5-HT in inhibiting forskolin-stimulated adenylate cyclase activity in CHO cells; nd=Not determined,F,,,,,CHEMBL615990,17624,H,BAO_0000219,1,,,,CHO,51
643,8,,Agonistic effect against 5-hydroxytryptamine 1A receptor using cAMP as radioligand relative to 5-HT in inhibiting forskolin-stimulated adenylate cyclase activity in CHO cells; nd=not determined,F,,,,,CHEMBL615991,17624,H,BAO_0000219,1,,,,CHO,51
644,8,,Agonistic effect against 5-HT 1A receptor using [35S]GTP-gamma-S as radioligand in CHO cells relative to 5-HT,F,,,,,CHEMBL615992,17624,H,BAO_0000219,1,,,,CHO,51
645,8,,Agonistic effect against 5-HT 1A receptor using [35S]GTP-gamma-S as radioligand in CHO cells relative to 5-HT; nd=Not determined,F,,,,,CHEMBL615993,17624,H,BAO_0000219,1,,,,CHO,51
646,8,,Agonistic effect against 5-hydroxytryptamine 1A receptor using [35S]GTP-gamma-S as radioligand in CHO cells relative to 5-HT,F,,,,,CHEMBL615994,17624,H,BAO_0000219,1,,,,CHO,51
647,8,,Agonistic effect against 5-hydroxytryptamine 1A receptor using [35S]GTP-gamma-S as radioligand in CHO cells relative to 5-HT; nd=not determined,F,,,,,CHEMBL615995,17624,H,BAO_0000219,1,,,,CHO,51
648,8,,Agonistic effect against 5-hydroxytryptamine 1A receptor using [35S]GTP-gamma-S as radioligand in CHO cells relative to 5-HT,F,,,,,CHEMBL615996,17624,H,BAO_0000219,1,,,,CHO,51
649,8,,Agonistic effect against 5-hydroxytryptamine 1A receptor using [35]GTPgammaS as radioligand in CHO cells relative to 5-HT; nd=Not determined,F,,,,,CHEMBL615997,17624,H,BAO_0000219,1,,,,CHO,51
650,8,,"Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by [35S]GTP-gamma-S, stimulated cAMP assay",F,,,,,CHEMBL615998,6563,H,BAO_0000019,1,,,,,51
651,8,,"Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by [35S]GTP-gamma-S, stimulated cAMP assay",F,,,,,CHEMBL615999,6563,H,BAO_0000019,1,,,,,51
652,8,,Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by forskolin stimulated cAMP assay,F,,,,,CHEMBL616000,6563,H,BAO_0000019,1,,,,,51
653,8,,Binding affinity against human 5-hydroxytryptamine 1A receptors HEK 293 cell membranes using [35S]GTP gamma-S,F,,,,,CHEMBL616001,17296,H,BAO_0000219,1,,,,HEK293,51
654,9,Homo sapiens,"Evaluated for stimulation at 1 uM concentration expressed as percent of the maximal [35S]GTP-gamma-S, binding induced by 5-hydroxytryptamine",F,9606.0,,,,CHEMBL616002,6876,D,BAO_0000019,1,,,,,51
655,8,,"Stimulation of percent maximal [35S]GTP-gamma-S, binding induced by 5-hydroxytryptamine at 1 uM; nd = not determined",F,,,,,CHEMBL616003,6876,H,BAO_0000019,1,,,,,51
656,9,Homo sapiens,In vitro agonist activity at the 5-hydroxytryptamine 1A receptor,F,9606.0,,,,CHEMBL616004,5272,D,BAO_0000019,1,,,,,51
657,9,Homo sapiens,In vitro agonist activity at the 5-hydroxytryptamine 1A receptor; No data,F,9606.0,,,,CHEMBL616005,5272,D,BAO_0000019,1,,,,,51
658,8,,"Maximal response as a result of 5-HT1A receptor-mediated stimulation of [35S]GTP-gamma-S, binding; Not determined",F,,,,,CHEMBL616006,5548,H,BAO_0000019,1,,,,,51
659,8,,"Maximal response as a result of 5-hydroxytryptamine 1A receptor-mediated stimulation of [35S]GTP-gamma-S, binding",F,,,,,CHEMBL616007,5548,H,BAO_0000019,1,,,,,51
660,8,,"Maximal response as a result of 5-hydroxytryptamine 1A receptor-mediated stimulation of [35S]GTP-gamma-S, binding; Not determined",F,,,,,CHEMBL616008,5548,H,BAO_0000019,1,,,,,51
661,8,,"Maximal response as a result of 5-hydroxytryptamine 1A receptor-mediated stimulation of [35S]GTP-gamma-S, binding; Not determined",F,,,,,CHEMBL616009,5548,H,BAO_0000019,1,,,,,51
662,8,,"Maximal stimulation of expressed human 5-hydroxytryptamine 1A receptor assayed by [35S]GTP-gamma-S, binding",F,,,,,CHEMBL616010,5929,H,BAO_0000019,1,,,,,51
663,9,Homo sapiens,"Maximal response towards 5-hydroxytryptamine 1A receptor in human using [35S]GTP-gamma-S, as radioligand; ND means not determined",F,9606.0,,,,CHEMBL616011,5929,D,BAO_0000019,1,,,,,51
664,9,Homo sapiens,"Maximal response towards 5-hydroxytryptamine 1A receptor in human using [35S]GTP-gamma-S, as radioligand; ND=Not determined",F,9606.0,,,,CHEMBL615740,5929,D,BAO_0000019,1,,,,,51
665,8,,"Maximal stimulation was expressed as percentage of the maximal 5-HT response in the [35S]GTP-gamma-S, binding assay on 5-hydroxytryptamine 1A receptor",F,,,,,CHEMBL615741,16245,H,BAO_0000019,1,,,,,51
666,8,,"Inhibition of 5-HT induced [35S]GTP-gamma-S, binding at human cloned 5-HT 1A receptors.",F,,,,,CHEMBL615742,5640,H,BAO_0000019,1,,,,,51
667,8,,"5-hydroxytryptamine 1A receptor antagonism was evaluated by the ability to inhibit [35S]GTP-gamma-S, binding that was induced by 5-HT; Emin (%): not determined",F,,,,,CHEMBL615743,5640,H,BAO_0000019,1,,,,,51
668,8,,Antagonist activity was measured against CHO cells expressing the human 5-hydroxytryptamine 1A receptor in a forskolin stimulated adenylate cyclase (FSC) assay,F,,,,,CHEMBL615744,14509,H,BAO_0000219,1,,,,CHO,51
669,8,,Antagonist activity against CHO cells expressing the human 5-hydroxytryptamine 1A receptor in a forskolin stimulated adenylate cyclase (FSC) assay.,F,,,,,CHEMBL615745,14509,H,BAO_0000219,1,,,,CHO,51
670,8,,Affinity of compound towards 5-hydroxytryptamine 1A receptor was evaluated using radioligand binding technique,B,,,,,CHEMBL615746,15331,H,BAO_0000357,1,,,,,51
671,8,,Affinity of compound towards 5-hydroxytryptamine 1A receptor was evaluated using radioligand binding technique,B,,,,,CHEMBL615747,15331,H,BAO_0000357,1,,,,,51
672,8,,"Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by [35S]GTP-gamma-S, stimulated cAMP assay",F,,,,,CHEMBL615748,6563,H,BAO_0000019,1,,,,,51
673,8,,"Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by [35S]GTP-gamma-S, stimulated cAMP assay; NA indicates not available",F,,,,,CHEMBL615749,6563,H,BAO_0000019,1,,,,,51
674,8,,Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by forskolin stimulated cAMP assay,F,,,,,CHEMBL615750,6563,H,BAO_0000019,1,,,,,51
675,9,Homo sapiens,Forskolin stimulated cAMP assessment of agonist activity for 5-hydroxytryptamine 1A receptor,F,9606.0,,,,CHEMBL616259,6563,D,BAO_0000019,1,,,,,51
676,8,,"Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by [35S]GTP-gamma-S, stimulated cAMP assay",F,,,,,CHEMBL616260,6563,H,BAO_0000019,1,,,,,51
677,9,Homo sapiens,Antagonism of 5-hydroxytryptamine 1A receptor determined in vitro,F,9606.0,,,,CHEMBL616261,5272,D,BAO_0000019,1,,,,,51
678,9,Homo sapiens,"Antagonism of 5-hydroxytryptamine 1A receptor was determined in vitro using a [35S]GTP-gamma-S,",F,9606.0,,,,CHEMBL616262,5272,D,BAO_0000019,1,,,,,51
679,9,Homo sapiens,"Antagonism at the 5-hydroxytryptamine 1A receptor determined in vitro using a [35S]GTP-gamma-S, No data",F,9606.0,,,,CHEMBL616263,5272,D,BAO_0000019,1,,,,,51
680,9,Homo sapiens,Antagonism at the 5-hydroxytryptamine 1A receptor was determined in vitro; No data,F,9606.0,,,,CHEMBL616264,5272,D,BAO_0000019,1,,,,,51
681,9,Homo sapiens,Antagonism at the 5-hydroxytryptamine 1A receptor in vitro,F,9606.0,,,,CHEMBL616265,5272,D,BAO_0000019,1,,,,,51
682,9,Homo sapiens,"Antagonism at the 5-hydroxytryptamine 1A receptor was determined in vitro using a [35S]GTP-gamma-S,",F,9606.0,,,,CHEMBL616266,5272,D,BAO_0000019,1,,,,,51
683,9,Homo sapiens,"Antagonism at the 5-hydroxytryptamine 1A receptor determined in vitro using a [35S]GTP-gamma-S, No data",F,9606.0,,,,CHEMBL616267,5272,D,BAO_0000019,1,,,,,51
684,9,Homo sapiens,Antagonism at the 5-hydroxytryptamine 1A receptor determined in vitro; No data,F,9606.0,,,,CHEMBL616268,5272,D,BAO_0000019,1,,,,,51
685,9,Homo sapiens,Inhibition of human 5-hydroxytryptamine 1A receptor,B,9606.0,,,,CHEMBL616269,16146,D,BAO_0000357,1,,,,,51
686,8,,Binding affinity against 5-hydroxytryptamine 1A receptor using cAMP as radioligand in CHO cells,B,,,,,CHEMBL884528,17624,H,BAO_0000219,1,,,,CHO,51
687,9,,Displacement of [3H]-5-HT from human 5-hydroxytryptamine 1D receptor alpha expressed in HEK 293 cells,B,,,,,CHEMBL616270,13706,D,BAO_0000219,1,,,,HEK293,105
688,8,,Compound was tested for the displacement of [3H]5-HT binding to cloned 5-hydroxytryptamine 1A receptor stably expressed in CHO cells,B,,,,,CHEMBL616271,15250,H,BAO_0000219,1,,,,CHO,51
689,8,,Effective concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing 5-hydroxytryptamine 1A receptor,F,,,,,CHEMBL616272,17624,H,BAO_0000219,1,,,,CHO,51
690,8,,In vitro binding affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT in human CYP3A4 assay,B,,,,,CHEMBL616273,6861,H,BAO_0000357,1,,,,,51
691,9,Homo sapiens,In vitro inhibitory concentration required against [3H]8-OH-DPAT binding to cloned human 5-hydroxytryptamine 1A receptor,B,9606.0,,,,CHEMBL616274,17200,D,BAO_0000357,1,,,,,51
692,8,,Inhibition concentration against 5-HT 1A receptor using cAMP as radioligand in CHO cells,B,,,,,CHEMBL616275,17624,H,BAO_0000219,1,,,,CHO,51
693,8,,Inhibition concentration against 5-hydroxytryptamine 1A receptor using cAMP as radioligand in CHO cells,B,,,,,CHEMBL616276,17624,H,BAO_0000219,1,,,,CHO,51
694,0,Rattus norvegicus,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by po administration,F,10116.0,,,,CHEMBL616277,12058,U,BAO_0000218,1,,In vivo,,,22226
695,0,Rattus norvegicus,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by po administration; Inactive,F,10116.0,,,,CHEMBL616278,12058,U,BAO_0000218,1,,In vivo,,,22226
696,0,Rattus norvegicus,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by sc administration,F,10116.0,,,,CHEMBL616279,12058,U,BAO_0000218,1,,In vivo,,,22226
697,0,Rattus norvegicus,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by sc administration; Inactive,F,10116.0,,,,CHEMBL616280,12058,U,BAO_0000218,1,,In vivo,,,22226
698,0,Rattus norvegicus,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by sc administration; Partial response at the highest dose tested,F,10116.0,,,,CHEMBL616281,12058,U,BAO_0000218,1,,In vivo,,,22226
699,0,Rattus norvegicus,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by sc administration; Inactive,F,10116.0,,,,CHEMBL616282,12058,U,BAO_0000218,1,,In vivo,,,22226
700,0,Rattus norvegicus,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain limbic area by po administration,F,10116.0,,,,CHEMBL616283,12058,U,BAO_0000218,1,,In vivo,,,22226
701,0,Rattus norvegicus,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain limbic area by po administration; Inactive,F,10116.0,,,,CHEMBL616284,12058,U,BAO_0000218,1,,In vivo,,,22226
702,0,Rattus norvegicus,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain limbic area by sc administration,F,10116.0,,,,CHEMBL616285,12058,U,BAO_0000218,1,,In vivo,,,22226
703,0,Rattus norvegicus,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain limbic area by sc administration; Inactive,F,10116.0,,,,CHEMBL616286,12058,U,BAO_0000218,1,,In vivo,,,22226
704,0,Rattus norvegicus,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain limbic area by sc administration; partial response at the highest dose tested,F,10116.0,,,,CHEMBL616287,12058,U,BAO_0000218,1,,In vivo,,,22226
705,0,Rattus norvegicus,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by po administration,F,10116.0,,,,CHEMBL616288,12058,U,BAO_0000218,1,,In vivo,,,22226
706,0,Rattus norvegicus,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by po administration; Inactive,F,10116.0,,,,CHEMBL616289,12058,U,BAO_0000218,1,,In vivo,,,22226
707,0,Rattus norvegicus,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by po administration; Partial response at the highest dose tested,F,10116.0,,,,CHEMBL615610,12058,U,BAO_0000218,1,,In vivo,,,22226
708,0,Rattus norvegicus,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by sc administration,F,10116.0,,,,CHEMBL615611,12058,U,BAO_0000218,1,,In vivo,,,22226
709,0,Rattus norvegicus,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by sc administration; Inactive,F,10116.0,,,,CHEMBL615612,12058,U,BAO_0000218,1,,In vivo,,,22226
710,0,Rattus norvegicus,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by sc administration; Partial response at the highest dose tested,F,10116.0,,,,CHEMBL615613,12058,U,BAO_0000218,1,,In vivo,,,22226
711,0,Rattus norvegicus,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by sc administration; partial response at the highest dose tested,F,10116.0,,,,CHEMBL615614,12058,U,BAO_0000218,1,,In vivo,,,22226
712,0,Rattus norvegicus,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by po administration,F,10116.0,,,,CHEMBL615615,12058,U,BAO_0000218,1,,In vivo,,,22226
713,4,,Affinity in displacing [125I](R)-DOI from rat cortical homogenate 5-HT2 receptor.,B,,,,,CHEMBL615616,11440,H,BAO_0000019,1,,,,,105093
714,8,,Binding affinity towards 5-HT 7 receptor in rat hypothalamus membranes using [3H]5-CT as radioligand,B,,Hypothalamus,,,CHEMBL615617,6238,H,BAO_0000249,1,1898.0,,,,11923
715,8,,Inhibitory activity against 5-HT1B receptor of rat striatal membrane homogenate using [3H]5-HT as the radioligand; nd is No Data,B,,,,,CHEMBL615618,10046,H,BAO_0000019,1,,,,,10577
716,8,,Inhibitory activity against 5-hydroxytryptamine 1B receptor of rat striatal membrane homogenate using [3H]5-HT as the radioligand; nd is No Data.,B,,,,,CHEMBL615619,10046,H,BAO_0000019,1,,,,,10577
717,8,,Inhibitory activity against 5-hydroxytryptamine 1B receptor of rat striatal membrane homogenate using [3H]5-HT as the radioligand.,B,,,,,CHEMBL615620,10046,H,BAO_0000019,1,,,,,10577
718,8,,"Inhibitory activity against human whole blood, LTB4 5-lipoxygenase was evaluated",B,,,,,CHEMBL615621,167,H,BAO_0000357,1,,,,,55
719,8,,"Inhibitory activity against intact human PMNL, LTB4 5-lipoxygenase was evaluated",B,,,,,CHEMBL615622,167,H,BAO_0000357,1,,,,,55
720,8,,Compound was evaluated for the inhibition of 5-LO (lipoxygenase),F,,,,,CHEMBL615623,11520,H,BAO_0000019,1,,,,,12166
721,8,,Compound was evaluated for the inhibition of 5-LO (5-lipoxygenase).,F,,,,,CHEMBL615624,11520,H,BAO_0000019,1,,,,,12166
722,8,,Compound was evaluated for the inhibition of 5-LO (5-lipoxygenase).,F,,,,,CHEMBL615625,11520,H,BAO_0000019,1,,,,,12166
723,8,,Compound was evaluated for the inhibition of 5-LO (5-lipoxygenase).,F,,,,,CHEMBL767045,11520,H,BAO_0000019,1,,,,,12166
724,8,Cavia porcellus,Inhibition of [14C]arachidonic acid conversion to 5-HETE by broken cell 5-LO isolated from guinea pig PMN,F,10141.0,,,,CHEMBL615626,135,H,BAO_0000019,1,,,,,55
725,8,Cavia porcellus,Inhibition of [14C]arachidonic acid conversion to 5-HETE by broken cell 5-LO isolated from guinea pig PMN; not active at the highest concentration (3 ug/mL) tested; No activity,F,10141.0,,,,CHEMBL615627,135,H,BAO_0000019,1,,,,,55
726,8,Cavia porcellus,The compound was tested for inhibitory activity against 5-Lipoxygenase in guinea pig polymorphonuclear leukocytes,B,10141.0,,,,CHEMBL615628,11311,H,BAO_0000019,1,,,,,55
727,8,Cavia porcellus,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase using guinea pig supernatant at 10 uM,B,10141.0,,,,CHEMBL615629,10193,H,BAO_0000357,1,,,,,55
728,9,Homo sapiens,Inhibitory concentration against 5-lipoxygenase from human whole blood,B,9606.0,,,,CHEMBL615630,12281,D,BAO_0000357,1,,,,,55
729,8,,The compound was tested for inhibitory activity against 5-Lipoxygenase in human polymorphonuclear leukocytes[PMNS],B,,,,,CHEMBL615631,11311,H,BAO_0000219,1,,,,,55
730,8,,In vivo inhibition of 5-lipoxygenase (LTC4) in the mouse zymosan peritonitis assay at an oral dose of 30 mg/Kg,F,,,,,CHEMBL615632,12576,H,BAO_0000218,1,,,,,17087
731,8,,Inhibitory concentration against 5-lipoxygenase from mouse macrophage,B,,,,,CHEMBL615633,12281,H,BAO_0000357,1,,,,,17087
732,8,,In vivo inhibition of 5-lipoxygenase (LTC4) in the mouse zymosan peritonitis assay at an oral dose of 30 mg/Kg,F,,,,,CHEMBL615634,12576,H,BAO_0000218,1,,,,,17087
733,8,Sus scrofa,Inhibition of arachidonate 5-lipoxygenase purified from porcine leukocytes.,B,9823.0,,,,CHEMBL615635,11089,H,BAO_0000019,1,,,,,55
734,8,,In vitro inhibition of rat 5-Lipoxygenase,B,,,,,CHEMBL615636,11006,H,BAO_0000357,1,,,,,12166
735,9,Rattus norvegicus,Inhibitory activity against 5-Lipoxygenase,B,10116.0,,,,CHEMBL615637,11481,D,BAO_0000357,1,,,,,12166
736,8,,Inhibitory activity against 5-lipoxygenase in rat basophilic leukemia cells,B,,,,,CHEMBL615638,10864,H,BAO_0000219,1,,,,RBL-1,12166
737,8,,Inhibitory activity against 5-lipoxygenase (5-LO) in intact rat barophilic leukemia cells (RBL-1),B,,,,,CHEMBL615639,3595,H,BAO_0000219,1,,,,RBL-1,12166
738,8,,The compound was tested for inhibitory activity against 5-Lipoxygenase in rat RBL-1,B,,,,,CHEMBL615640,11311,H,BAO_0000219,1,,,,RBL-1,12166
739,8,,The compound was tested for inhibitory activity against 5-Lipoxygenase in rat blood,B,,,,,CHEMBL615796,11311,H,BAO_0000019,1,,,,,12166
740,8,,The compound was tested for inhibitory activity against 5-Lipoxygenase receptor in rat polymorphonuclear leukocytes[PMNS],B,,,,,CHEMBL615845,11311,H,BAO_0000219,1,,,,,12166
741,8,,Compound was evaluated for the inhibition of 5-Lipoxygenase (5-LO) in vitro at 1 uM,B,,,,,CHEMBL615846,11006,H,BAO_0000357,1,,,,,12166
742,8,,Inhibitory activity against 5-lipoxygenase (5-LO) using broken rat barophilic leukemia cells (RBL-1)at 10 uM,B,,,,,CHEMBL615847,3595,H,BAO_0000219,1,,,,RBL-1,12166
743,8,,The compound was tested for inhibition of isolated 5-Lipoxygenase,B,,,,,CHEMBL615848,11311,H,BAO_0000357,1,,,,,12166
744,0,Rattus norvegicus,Ratio of IC50 against 5-LO and COX,B,10116.0,,,,CHEMBL615849,11481,U,BAO_0000019,1,,,,,22226
745,8,,Compound was evaluated for the inhibition of 5-Lipoxygenase (5-LO) in vitro at 1 uM,B,,,,,CHEMBL615850,11006,H,BAO_0000357,1,,,,,12166
746,8,,Compound was evaluated for the inhibition of 5-Lipoxygenase (5-LO) in vitro at 1 uM; range is 20-35%,B,,,,,CHEMBL615851,11006,H,BAO_0000357,1,,,,,12166
747,8,,The compound was tested for inhibition against 5-Lipoxygenase in rat polymorphonuclear leukocytes at 10 uM concentration,B,,,,,CHEMBL615852,11311,H,BAO_0000219,1,,,,,12166
748,8,,Compound was evaluated for the inhibition of 5-Lipoxygenase (5-LO) ex vivo,F,,,,,CHEMBL615853,11006,H,BAO_0000019,1,,,,,12166
749,8,,Compound was tested for the inhibition of type 2 5-alpha-reductase of human prostates,B,,Prostate gland,,,CHEMBL884527,4288,H,BAO_0000357,1,2367.0,,,,120
750,0,Columba livia,Percent inhibition was measured against 5-amino-4-imidazolecarboxamide ribotide transformylase(pigeon liver) enzyme at 10E-4 M inhibitory concentration,B,8932.0,,,,CHEMBL872871,7587,U,BAO_0000019,1,,,,,22226
751,0,Columba livia,Percent inhibition was measured against 5-amino-4-imidazolecarboxamide ribotide transformylase(pigeon liver) enzyme at 10E-5 M inhibitory concentration,B,8932.0,,,,CHEMBL615854,7587,U,BAO_0000019,1,,,,,22226
752,0,Columba livia,Percent inhibition was measured against 5-amino-4-imidazolecarboxamide ribotide transformylase(pigeon liver) enzyme.,B,8932.0,,,,CHEMBL767046,7587,U,BAO_0000019,1,,,,,22226
753,8,,Compound was evaluated for the inhibition of 5-aminoimidazole-4-carboxamide ribonucleotide transformylase obtained from human at 100 uM,B,,,,,CHEMBL615855,11249,H,BAO_0000357,1,,,,,10732
754,9,Rattus norvegicus,Effect on synaptosomal uptake inhibition of 5-hydroxytryptamine (5-HT); NT = Not Tested,F,10116.0,,,,CHEMBL615856,8003,D,BAO_0000019,1,,,,,12198
755,9,Rattus norvegicus,Effect on synaptosomal uptake inhibition of 5-hydroxytryptamine (5-HT),F,10116.0,,,,CHEMBL615857,8003,D,BAO_0000019,1,,,,,12198
756,9,Rattus norvegicus,Effect on synaptosomal uptake inhibition of 5-hydroxytryptamine (5-HT),F,10116.0,,,,CHEMBL615858,8003,D,BAO_0000019,1,,,,,12198
757,8,,In vitro affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand in hippocampus,B,,Hippocampus,,,CHEMBL615859,12416,H,BAO_0000221,1,10000000.0,,,,10576
758,8,,Binding affinity towards human 5-hydroxytryptamine 1 receptor,B,,,,,CHEMBL615860,16293,H,BAO_0000357,1,,,,,51
759,0,Oryctolagus cuniculus,Intrinsic activity against 5-hydroxytryptamine 1 receptor using rabbit saphenous vein assay.,B,9986.0,,,,CHEMBL615861,13047,U,BAO_0000019,1,,,,,22226
760,0,Oryctolagus cuniculus,Binding affinity against 5-hydroxytryptamine 1 receptor using rabbit saphenous vein assay.,B,9986.0,,,,CHEMBL615862,13047,U,BAO_0000019,1,,,,,22226
761,0,Oryctolagus cuniculus,Binding affinity against 5-hydroxytryptamine 1D receptor using rabbit saphenous vein assay.,B,9986.0,,,,CHEMBL615863,13047,U,BAO_0000019,1,,,,,22226
762,0,Oryctolagus cuniculus,Binding affinity against 5-hydroxytryptamine 4 receptor using rabbit saphenous vein assay.,B,9986.0,,,,CHEMBL615864,13047,U,BAO_0000019,1,,,,,22226
763,4,,Ability to bind at 5-hydroxytryptamine 1 receptor of rat hippocampus by displacing [3H]5-HT,B,,Hippocampus,,,CHEMBL615865,10085,H,BAO_0000221,1,10000000.0,,,,104744
764,4,,Ability to bind at 5-hydroxytryptamine 1 receptor of rat hippocampus by displacing [3H]5-HT,B,,Hippocampus,,,CHEMBL615866,10085,H,BAO_0000221,1,10000000.0,,,,104744
765,4,,Ability to bind at serotonin 5-hydroxytryptamine 1 receptor of rat hippocampus by displacing [3H]5-HT,B,,Hippocampus,,,CHEMBL615867,10085,H,BAO_0000221,1,10000000.0,,,,104744
766,4,,Ability to inhibit binding of titreated serotonin to the 5-hydroxytryptamine 1 receptor in rat brain frontal cortex membranes,B,,,Membranes,,CHEMBL615868,9841,H,BAO_0000249,1,,,,,104744
767,5,Rattus norvegicus,Binding affinity towards 5-hydroxytryptamine 1 receptor in brain cortical membranes of rat,B,10116.0,,,,CHEMBL615869,8822,D,BAO_0000249,1,,,,,104744
768,5,Rattus norvegicus,Binding affinity towards 5-hydroxytryptamine 1 receptor in rat frontal cortex homogenates using [3H]5-HT as a radioligand,B,10116.0,,,,CHEMBL615870,9806,D,BAO_0000019,1,,,,,104744
769,5,Rattus norvegicus,Binding affinity towards 5-hydroxytryptamine 1 receptor using [3H]5-HT as a radioligand from rat frontal cortex homogenates,B,10116.0,,,,CHEMBL615871,9806,D,BAO_0000019,1,,,,,104744
770,4,,Binding affinity towards 5-hydroxytryptamine 1 receptor was measured using radioligand ([3H]5-HT) binding assay,B,,,,,CHEMBL615872,8868,H,BAO_0000224,1,,,,,104744
771,4,,Binding affinity towards hippocampus 5-hydroxytryptamine 1 receptor was measured using radioligand [3H]5-HT,B,,Hippocampus,,,CHEMBL833492,9036,H,BAO_0000221,1,10000000.0,,,,104744
772,4,,Compound was evaluated for the inhibition of [3H]5-HT (concentration of 12 nM) specific binding to rat hippocampus,B,,Hippocampus,,,CHEMBL615873,11374,H,BAO_0000221,1,10000000.0,,,,104744
773,4,,Inhibitory activity against 5-hydroxytryptamine 1 receptor by 3H ligand binding experiments.,B,,,,,CHEMBL615479,10881,H,BAO_0000224,1,,,,,104744
774,4,,Tested for its binding affinity towards 5-hydroxytryptamine 1 receptor in rat,B,,,,,CHEMBL615480,8822,H,BAO_0000019,1,,,,,104744
775,5,Rattus norvegicus,Tested for its binding affinity towards 5-hydroxytryptamine 1 receptor in rat cortical membrane homogenates using radioligand ([3H]5-HT) binding assay.,B,10116.0,,,,CHEMBL615481,9806,D,BAO_0000249,1,,,,,104744
776,4,,Compound at 1 uM was tested for the inhibition of radioligand [3H]5-HT binding to 5-hydroxytryptamine 1 receptor in rat cerebral cortex,B,,,,,CHEMBL872869,15463,H,BAO_0000019,1,,,,,104744
777,4,,Compound at 1 uM was tested for the inhibition of radioligand [3H]5-HT binding to 5-hydroxytryptamine 1 receptor in rat cerebral cortex,B,,,,,CHEMBL615482,15463,H,BAO_0000019,1,,,,,104744
778,4,,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 1 receptor using [3H]5-HT in rat brain cortex at 10 uM,B,,Brain,,,CHEMBL615483,14542,H,BAO_0000221,1,955.0,,,,104744
779,4,,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 1 receptor using [3H]5-HT in rat brain cortex at 10 uM,B,,Brain,,,CHEMBL615484,14542,H,BAO_0000221,1,955.0,,,,104744
780,4,,Percent inhibition of 5-hydroxytryptamine 1 receptor from rat cortex membrane using [3H]- serotonin as radioligand at 33 uM,B,,,,,CHEMBL615485,8569,H,BAO_0000019,1,,,,,104744
781,5,Rattus norvegicus,Inhibition of [3H]5-HT radioligand binding against 5-hydroxytryptamine 1 receptor,B,10116.0,,,,CHEMBL615486,10062,D,BAO_0000224,1,,,,,104744
782,4,,Ancillary Binding affinity towards rat 5-hydroxytryptamine 1 receptor,B,,,,,CHEMBL615487,4771,H,BAO_0000224,1,,,,,104744
783,4,,Binding affinity determined in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 1 receptor,B,,,,,CHEMBL615488,10062,H,BAO_0000224,1,,,,,104744
784,4,,Binding affinity in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 1 receptor,B,,,,,CHEMBL615489,10062,H,BAO_0000224,1,,,,,104744
785,4,,Binding affinity in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 1 receptor,B,,,,,CHEMBL615389,10062,H,BAO_0000224,1,,,,,104744
786,4,,Binding affinity towards 5-hydroxytryptamine 1 receptor was determined in rat cerebral cortex using [3H]5-HT as radioligand,B,,,,,CHEMBL615390,15463,H,BAO_0000019,1,,,,,104744
787,4,,Binding affinity towards central 5-hydroxytryptamine 1 receptor was determined in rat cerebral cortex using [3H]5-HT as radioligand,B,,,,,CHEMBL615391,15463,H,BAO_0000019,1,,,,,104744
788,4,,Binding affinity towards 5-hydroxytryptamine 1 receptor was determined,B,,,,,CHEMBL615392,9098,H,BAO_0000224,1,,,,,104744
789,0,Rattus norvegicus,Affinity for 5-hydroxytryptamine 1 receptor,B,10116.0,,,,CHEMBL615393,3070,U,BAO_0000019,1,,,,,22226
790,4,,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 1 receptor using [3H]5-HT in rat brain cortex,B,,Brain,,,CHEMBL615394,14542,H,BAO_0000221,1,955.0,,,,104744
791,4,,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 1 receptor using [3H]5-HT in rat brain cortex at 10 uM,B,,Brain,,,CHEMBL615395,14542,H,BAO_0000221,1,955.0,,,,104744
792,4,,Compound was evaluated for 5-hydroxytryptamine 1 receptor binding,B,,,,,CHEMBL615396,6398,H,BAO_0000224,1,,,,,104744
793,4,,Compound was evaluated for its binding affinity to 5-hydroxytryptamine 1 receptor in rat brain using [3H]HT radioligand assay,B,,Brain,,,CHEMBL615397,1344,H,BAO_0000221,1,955.0,,,,104744
794,4,,Displacement of binding of [3H]5-HT to 5-hydroxytryptamine 1 receptor in rat cerebral cortex,B,,,,,CHEMBL615398,11963,H,BAO_0000019,1,,,,,104744
795,0,Rattus norvegicus,Displacement of [3H]spiperone from 5-hydroxytryptamine 1 receptor of rat cortex,B,10116.0,,,,CHEMBL615399,8908,U,BAO_0000019,1,,,,,22226
796,4,,Evaluated for binding affinity towards rat cortical membranes at 5-hydroxytryptamine 1 receptor binding site by using [3H]-5-HT as a radioligand.,B,,,,,CHEMBL615400,9098,H,BAO_0000019,1,,,,,104744
797,5,Rattus norvegicus,Binding affinity for 5-hydroxytryptamine 1 receptor of rat prefrontal cortex,B,10116.0,,,,CHEMBL615401,8841,D,BAO_0000019,1,,,,,104744
798,0,Rattus norvegicus,Displacement of [3H]5-HT from 5-hydroxytryptamine 1 receptor of rat cortical membrane homogenates,B,10116.0,,,,CHEMBL615402,8814,U,BAO_0000019,1,,,,,22226
799,4,,The ability to inhibit [3H]5-HT binding to 5-hydroxytryptamine 1 receptor in rat cortex,B,,,,,CHEMBL615403,11752,H,BAO_0000019,1,,,,,104744
800,4,,The binding affinity was measured on serotonin 5-hydroxytryptamine 1 receptor in rat brain tissue,B,,Brain,,,CHEMBL615404,11642,H,BAO_0000221,1,955.0,,,,104744
801,4,,The compound was tested for its binding affinity towards 5-hydroxytryptamine 1 receptor by displacing [3H]5-HT radioligand in rat cerebral cortex,B,,,,,CHEMBL615781,11642,H,BAO_0000019,1,,,,,104744
802,4,,Tested for 5-hydroxytryptamine 1 receptor binding ability by displacement of [3H]5-HT from rat brain synaptosomes,B,,Brain,,,CHEMBL615782,9231,H,BAO_0000220,1,955.0,,,,104744
803,4,,Inhibition constant (1 uM) was measured on 5-hydroxytryptamine 1 receptor/uptake using [3H]- serotonin as radioligand in rat brain cortex.,B,,Brain,,,CHEMBL615783,11351,H,BAO_0000221,1,955.0,,,,104744
804,0,,Compound was tested for binding affinity against 5-HT1 receptor,B,,,,,CHEMBL873481,4639,U,BAO_0000019,1,,,,,22226
805,0,,Inhibitory concentration against 5-hydroxytryptamine 1 receptor,B,,,,,CHEMBL615784,1205,U,BAO_0000019,1,,,,,22226
806,8,,Concentration necessary to achieve half maximal inhibition of [3H]8-Hydroxy-2-(di-n-propylamino)tetralin binding to 5-hydroxytryptamine 1A receptor at 1 uM,B,,,,,CHEMBL615785,10025,H,BAO_0000357,1,,,,,10576
807,8,,"Ability to inhibit 5-HT sensitive,forskolin-stimulated adenylyl cyclase(FSC) activity in rat hippocampal membranes mediated through 5-hydroxytryptamine 1A receptor",F,,,,,CHEMBL615786,13241,H,BAO_0000249,1,,,,,10576
808,8,,Agonistic activity (induction of forepaw treading in rats)on postsynaptic 5-hydroxytryptamine 1A receptor while iv administration,F,,,,,CHEMBL615787,16245,H,BAO_0000218,1,,In vivo,,,10576
809,8,,Agonistic activity (induction of forepaw treading in rats)on postsynaptic 5-hydroxytryptamine 1A receptor while subcutaneous administration,F,,,,,CHEMBL615788,16245,H,BAO_0000218,1,,In vivo,,,10576
810,8,,Inhibition of forskolin stimulated adenylate cyclase at 5-hydroxytryptamine 1A receptor,F,,,,,CHEMBL767044,12438,H,BAO_0000019,1,,,,,10576
811,8,,Agonistic activity (induction of forepaw treading in rats)on postsynaptic 5-hydroxytryptamine 1A receptor while iv administration,F,,,,,CHEMBL615789,16245,H,BAO_0000218,1,,In vivo,,,10576
812,8,,Agonistic activity (induction of forepaw treading in rats)on postsynaptic 5-hydroxytryptamine 1A receptor while subcutaneous administration,F,,,,,CHEMBL615790,16245,H,BAO_0000218,1,,In vivo,,,10576
813,8,,Evaluated for the 5-hydroxytryptamine 1A receptor agonist activity in LY-293284 trained rats,F,,,,,CHEMBL615813,15740,H,BAO_0000019,1,,,,,10576
814,8,,Percent of maximum response by 5-HT when tested for inhibition of vasoactive intestinal polypeptide-induced (VIP-induced) cAMP formation assessed in GH4ZD10 cells at 10 uM concentration,F,,,,,CHEMBL615814,15535,H,BAO_0000219,1,,,,,10576
815,8,,Percent inhibition of vasoactive intestinal polypeptide-induced (VIP-induced) cAMP formation in GH4ZD10 cells expressing 5-HT1A receptor at 50 uM relative to 5-HT,F,,,,,CHEMBL615815,15535,H,BAO_0000219,1,,,,,51
816,8,,Percent of maximum response by 5-HT when tested for inhibition of vasoactive intestinal polypeptide-induced (VIP-induced) cAMP formation assessed in GH4ZD10 cells at 50 uM concentration; No effect,F,,,,,CHEMBL615816,15535,H,BAO_0000219,1,,,,,10576
817,8,,Binding affinity at [3H]8-OH-DPAT-Labeled 5-hydroxytryptamine 1A receptor sites in rat brain hippocampal membranes expressed as Hill values,B,,,,,CHEMBL615817,9888,H,BAO_0000249,1,,,,,10576
818,8,,Ability to bind at 5-hydroxytryptamine 1A receptor of rat hippocampus by displacing [3H]8-OH-DPAT,B,,Hippocampus,,,CHEMBL615818,10085,H,BAO_0000221,1,10000000.0,,,,10576
819,8,,Ability to bind at serotonin 5-hydroxytryptamine 1A receptors of rat hippocampus by displacing [3H]8-OH-DPAT,B,,Hippocampus,,,CHEMBL615819,10085,H,BAO_0000221,1,10000000.0,,,,10576
820,8,,Binding affinity against 5-hydroxytryptamine 1A receptor (5-HT1A) by displacement of [3H]8-OH-DPAT from rat hippocampus membranes,B,,,Membranes,,CHEMBL615820,17331,H,BAO_0000249,1,,,,,10576
821,9,Rattus norvegicus,Binding affinity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue with [3H]8-OH-DPAT,B,10116.0,Hippocampus,,,CHEMBL615821,10845,D,BAO_0000221,1,10000000.0,,,,10576
822,9,Rattus norvegicus,Binding affinity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue with [3H]5-HT,B,10116.0,Hippocampus,,,CHEMBL615822,10845,D,BAO_0000221,1,10000000.0,,,,10576
823,8,,Binding affinity against 5-hydroxytryptamine 1A receptor using in rat hippocampal tissue using [3H]8-OH-DPAT as radioligand,B,,Hippocampus,,,CHEMBL615823,10845,H,BAO_0000221,1,10000000.0,,,,10576
824,9,Rattus norvegicus,Displacement of [3H]8-OH-DPAT from rat hippocampal 5-hydroxytryptamine 1A receptor; IA-Inactive,B,10116.0,Hippocampus,,,CHEMBL615824,10845,D,BAO_0000221,1,10000000.0,,,,10576
825,9,Rattus norvegicus,Binding affinity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue with [3H]5-HT,B,10116.0,Hippocampus,,,CHEMBL615825,10845,D,BAO_0000221,1,10000000.0,,,,10576
826,8,,Binding affinity towards rat 5-hydroxytryptamine 1A receptor was evaluated using [3H]8-OH-DPAT as radioligand,B,,,,,CHEMBL615826,13730,H,BAO_0000357,1,,,,,10576
827,8,,Binding affinity against 5-hydroxytryptamine 1A receptor in rat hippocampus membranes using [3H]8-OH-DPAT as radioligand,B,,,,,CHEMBL615827,13508,H,BAO_0000249,1,,,,,10576
828,8,,Binding affinity against serotonin 5-hydroxytryptamine 1A receptor in rat hippocampus membrane using [3H]8-OH-DPAT as radioligand,B,,Hippocampus,,,CHEMBL615828,13508,H,BAO_0000249,1,10000000.0,,,,10576
829,8,,Binding affinity by measuring displacement of [3H]-8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampus,B,,Hippocampus,,,CHEMBL615829,12073,H,BAO_0000221,1,10000000.0,,,,10576
830,8,,Binding affinity to 5-hydroxytryptamine 1A receptor of rat hippocampus with [3H]8-OH-DPAT as radioligand,B,,Hippocampus,,,CHEMBL615830,4671,H,BAO_0000221,1,10000000.0,,,,10576
831,8,,Binding affinity towards serotonin 5-HT1A receptor was determined in rat hippocampus using [3H]8-OH-DPAT as ligand,B,,Hippocampus,,,CHEMBL615831,13631,H,BAO_0000221,1,10000000.0,,,,10576
832,8,,Binding affinity was measured against serotonin 5-hydroxytryptamine 1A receptor,B,,,,,CHEMBL615832,12438,H,BAO_0000357,1,,,,,10576
833,8,,Binding affinity to 5-hydroxytryptamine 1A receptor in rat cortex using [3H]-8-OH- DPAT as radioligand,B,,,,,CHEMBL615833,10483,H,BAO_0000019,1,,,,,10576
834,8,,Binding affinity to 5-hydroxytryptamine 1A receptor in rat hippocampus using [3H]-8-OH- DPAT as radioligand,B,,Hippocampus,,,CHEMBL615834,10483,H,BAO_0000221,1,10000000.0,,,,10576
835,8,,Binding affinity against 5-hydroxytryptamine 1A (5-HT1A) receptor in rat hippocampus membranes,B,,,,,CHEMBL615835,12352,H,BAO_0000249,1,,,,,10576
836,8,,Binding affinity was measured at the serotonin 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand in rat hippocampal membrane.,B,,Hippocampus,,,CHEMBL615836,14732,H,BAO_0000249,1,10000000.0,,,,10576
837,9,Rattus norvegicus,Binding affinity to 5-hydroxytryptamine 1A receptor in the rat brain using [3H]8-hydroxy-2-(di-n-propylamine)tetralin as radioligand.,B,10116.0,,,,CHEMBL615837,11049,D,BAO_0000019,1,,,,,10576
838,9,Rattus norvegicus,Binding affinity to 5-hydroxytryptamine 1A receptor in the rat brain using [3H]8-hydroxy-2-(di-n-propylamine)tetralin as radioligand; ND-Not determined,B,10116.0,,,,CHEMBL615838,11049,D,BAO_0000019,1,,,,,10576
839,8,,"Binding affinity to 5-hydroxytryptamine 1A receptor in rat hippocampus membranes,3H-8-OH-DPAT and buspirone for nonspecific binding (NSB)",B,,,,,CHEMBL615839,13657,H,BAO_0000249,1,,,,,10576
840,8,,Compound was evaluated for binding affinity towards 5-hydroxytryptamine 1A receptor in rat cortex using [3H]-8-OH-DPAT as radioligand,B,,,,,CHEMBL884525,11473,H,BAO_0000019,1,,,,,10576
841,8,,Compound was evaluated for its ability to displace [3H]8-OH-DPAT from serotonin 5-hydroxytryptamine 1A receptor in rat cerebral cortex membranes,B,,,,,CHEMBL615840,2014,H,BAO_0000249,1,,,,,10576
842,8,,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampus,B,,Hippocampus,,,CHEMBL615405,3086,H,BAO_0000221,1,10000000.0,,,,10576
843,8,,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat frontal cortex using [125I]iodocyanopindolol as radio-ligand.,B,,,,,CHEMBL615406,15854,H,BAO_0000019,1,,,,,10576
844,8,,Affinity for 5-hydroxytryptamine 1A receptor labeled with [3H]8-OH-DPAT radioligand in hippocampus tissue,B,,Hippocampus,,,CHEMBL615900,10922,H,BAO_0000221,1,10000000.0,,,,10576
845,8,,Inhibition of [3H]8-OH-DPAT binding at serotonin 5-hydroxytryptamine 1A receptor from rat hippocampus tissue.,B,,Hippocampus,,,CHEMBL615901,13346,H,BAO_0000221,1,10000000.0,,,,10576
846,8,,In vitro inhibition of [3H]8-OH-DPAT binding to rat 5-HT 1a receptors.,B,,,,,CHEMBL615902,15311,H,BAO_0000357,1,,,,,10576
847,8,,Compound was measured for affinity at 5-hydroxytryptamine 1A receptor labeled with [3H]8-OH-DPAT radioligand in hippocampus tissue,B,,Hippocampus,,,CHEMBL615903,10922,H,BAO_0000221,1,10000000.0,,,,10576
848,8,,Concentration necessary to achieve half maximal inhibition of [3H]8-Hydroxy-2-(di-n-propylamino)tetralin binding to 5-hydroxytryptamine 1A receptor<br>at 1 uM,B,,,,,CHEMBL615904,10025,H,BAO_0000357,1,,,,,10576
849,8,,Concentration necessary to achieve half maximal inhibition of [3H]8-Hydroxy-2-(di-n-propylamino)tetralin binding to 5-hydroxytryptamine 1A receptor at 1 uM,B,,,,,CHEMBL615905,10025,H,BAO_0000357,1,,,,,10576
850,8,,In vitro Inhibitory activity tested at 5-hydroxytryptamine 1A receptor binding site in rat,B,,,,,CHEMBL615906,9742,H,BAO_0000019,1,,,,,10576
851,8,,In vitro Inhibitory activity tested at 5-hydroxytryptamine 1A receptor binding site in rat,F,,,,,CHEMBL615907,9742,H,BAO_0000019,1,,,,,10576
852,8,,In vitro ability to inhibit binding of radioligand [3H]8-OH-DPAT to 5-hydroxytryptamine 1A receptor in rat cerebral cortex,B,,,,,CHEMBL615908,12304,H,BAO_0000019,1,,,,,10576
853,8,,In vitro affinity against 5-hydroxytryptamine 1A receptor using [3H]-8-OH-DPAT in rat hippocampus,B,,Hippocampus,,,CHEMBL615909,15789,H,BAO_0000221,1,10000000.0,,,,10576
854,8,,"In vitro binding activity against 5-hydroxytryptamine 1A receptor from homogenized rat brain, using [3H]-8-OH-DPAT as the radioligand",B,,,,,CHEMBL615910,9912,H,BAO_0000019,1,,,,,10576
855,8,,"In vitro binding activity against 5-hydroxytryptamine 1A receptor from homogenized rat brain, using [3H]8-OH-DPAT as the radioligand.",B,,,,,CHEMBL615911,9912,H,BAO_0000019,1,,,,,10576
856,8,,"In vitro binding activity against 5-hydroxytryptamine 1A receptor from homogenized rat brain, using [3H]8-OH-DPAT as the radioligand",B,,,,,CHEMBL615912,9912,H,BAO_0000019,1,,,,,10576
857,8,,In vitro binding affinity for serotonin 5-hydroxytryptamine 1A receptor fof rat cerebral cortex using [3H]8-OH-DPAT as radioligand,B,,,,,CHEMBL615913,16693,H,BAO_0000019,1,,,,,10576
858,8,,In vitro binding affinity measured on serotonin 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand.,B,,,,,CHEMBL615914,13276,H,BAO_0000357,1,,,,,10576
859,8,,In vitro binding affinity to 5-hydroxytryptamine 1A receptor using [125I](R)-(+)-trans-8-OH-PIPAT as radioligand in rat hippocampal homogenate,B,,Hippocampus,,,CHEMBL615915,12678,H,BAO_0000221,1,10000000.0,,,,10576
860,8,,In vitro binding affinity towards the 5-hydroxytryptamine 1A receptor was evaluated,B,,,,,CHEMBL615916,11825,H,BAO_0000357,1,,,,,10576
861,8,,In vitro binding affinity was measured on serotonergic 5-hydroxytryptamine 1A receptor by displacement of [3H]- tetralin,B,,,,,CHEMBL615917,12443,H,BAO_0000357,1,,,,,10576
862,8,,In vitro inhibitory activity against [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor,B,,,,,CHEMBL615918,13830,H,BAO_0000357,1,,,,,10576
863,8,,In vitro inhibitory concentration against radioligand [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor in rat hippocampal membrane.,B,,Hippocampus,,,CHEMBL615919,14286,H,BAO_0000249,1,10000000.0,,,,10576
864,9,Rattus norvegicus,In vitro radioligand binding assay on 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT in rat hippocampus,B,10116.0,Hippocampus,,,CHEMBL615920,14356,D,BAO_0000221,1,10000000.0,,,,10576
865,8,,Inhibition concentration against 5-hydroxytryptamine 1A receptor,B,,,,,CHEMBL615921,15306,H,BAO_0000357,1,,,,,10576
866,8,,Inhibitory concentration against 5-hydroxytryptamine 1A receptor (Inactive at >1000 nM concentration),B,,,,,CHEMBL615922,15306,H,BAO_0000357,1,,,,,10576
867,9,Rattus norvegicus,"Inhibition of (+)-8-OH-DPAT stimulated [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor in hippocampal membranes",F,10116.0,,,,CHEMBL881290,16616,D,BAO_0000249,1,,,,,10576
868,8,,"Inhibition of [3H]8-hydroxy-2-dipropylamino-1,2,3,4-tetrahydronaphthalene binding to 5-hydroxytryptamine 1A receptor in hippocampus region of rat brain; Residual radioligand binding higher than 50%",B,,Hippocampus,,,CHEMBL615923,3651,H,BAO_0000221,1,10000000.0,,,,10576
869,8,,Inhibition of forskolin-activated adenylate cyclase (cAMP) activity at 5-hydroxytryptamine 1A receptor in rat hippocampus,F,,Hippocampus,,,CHEMBL615924,14331,H,BAO_0000221,1,10000000.0,,,,10576
870,8,,Inhibition of forskolin-activated adenylate cyclase (cAMP) activity at 5-hydroxytryptamine 1A receptor in rat hippocampus,F,,Hippocampus,,,CHEMBL615925,14331,H,BAO_0000221,1,10000000.0,,,,10576
871,9,Rattus norvegicus,Inhibition of radiolabeled [3H]-8-OH-DPAT ligand binding to 5-hydroxytryptamine 1A receptor,B,10116.0,,,,CHEMBL615926,14178,D,BAO_0000357,1,,,,,10576
872,9,Rattus norvegicus,Displacement of [3H]8-OH-DPAT from rat cortex 5-hydroxytryptamine 1A receptor,B,10116.0,,,,CHEMBL615927,10639,D,BAO_0000019,1,,,,,10576
873,8,,Inhibitory activity against 5-hydroxytryptamine 1A receptor of rat hippocampal homogenates,B,,Hippocampus,,,CHEMBL615928,12306,H,BAO_0000221,1,10000000.0,,,,10576
874,9,Rattus norvegicus,Inhibitory activity against 5-hydroxytryptamine 1A receptor subtype,B,10116.0,,,,CHEMBL615929,1348,D,BAO_0000357,1,,,,,10576
875,8,,Inhibitory activity against [3H]DPAT binding to 5-HT1A receptor in rat hippocampus,B,,Hippocampus,,,CHEMBL615930,13605,H,BAO_0000221,1,10000000.0,,,,10576
876,8,,Inhibition concentration against 5-hydroxytryptamine 1A receptor using cAMP as radioligand in CHO cells,B,,,,,CHEMBL615931,17624,H,BAO_0000219,1,,,,CHO,51
877,8,,Inhibition concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing 5-hydroxytryptamine 1A receptor,F,,,,,CHEMBL615932,17624,H,BAO_0000219,1,,,,CHO,51
878,8,,Inhibition concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing 5-hydroxytryptamine 1A receptor,F,,,,,CHEMBL615933,17624,H,BAO_0000219,1,,,,CHO,51
879,8,,Inhibition of [3H]- 8-OH-DAPT binding against human recombinant 5-hydroxytryptamine 1A receptor,B,,,,,CHEMBL615934,15267,H,BAO_0000357,1,,,,,51
880,8,,The binding affinity at the 5-hydroxytryptamine 1A receptor determined using [3H]5-CT; Not tested,B,,,,,CHEMBL615935,16532,H,BAO_0000357,1,,,,,51
881,8,,"Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by [35S]GTP-gamma-S, stimulated cAMP assay",F,,,,,CHEMBL615936,6563,H,BAO_0000019,1,,,,,51
882,8,,Ability to displace [3H]-8-OH-DPAT from CHO cells stably transfected with human 5-hydroxytryptamine 1A receptor at a concentration of 1 uM,B,,,,,CHEMBL615937,4751,H,BAO_0000219,1,,,,CHO,51
883,8,,Compound at 1 uM was tested for the inhibition of radioligand [3H]8-OH-DPAT binding to recombinant human 5-hydroxytryptamine 1A receptor,B,,,,,CHEMBL615938,15463,H,BAO_0000357,1,,,,,51
884,8,,In vitro binding affinity against human 5-hydroxytryptamine 1A receptor at a concentration of 100 (nM),B,,,,,CHEMBL615797,3805,H,BAO_0000357,1,,,,,51
885,8,,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,B,,,,,CHEMBL615798,5640,H,BAO_0000357,1,,,,,51
886,8,,Inhibition of [3H]8-OH-DPAT binding to human 5-hydroxytryptamine 1A receptor at 1000 nM compound concentration,B,,,,,CHEMBL872870,6563,H,BAO_0000357,1,,,,,51
887,8,,Inhibitory activity against 5-hydroxytryptamine 1A receptor using [3H]-8-OH-DPAT as radioligand at 100 nM concentration,B,,,,,CHEMBL615799,5548,H,BAO_0000357,1,,,,,51
888,8,,Percent binding affinity against 5-hydroxytryptamine 1A receptor,B,,,,,CHEMBL615800,6347,H,BAO_0000357,1,,,,,51
889,8,,Intrinsic activity for human 5-hydroxytryptamine 1A receptors HEK 293 cell membranes using [35S]GTP gamma-S,F,,,,,CHEMBL615801,17296,H,BAO_0000219,1,,,,HEK293,51
890,8,,Binding affinity against 5-hydroxytryptamine 1 receptor using rabbit jugular vein assay in the absence of endothelium,B,,,,,CHEMBL615802,13047,H,BAO_0000019,1,,,,,51
891,8,,Dissociation constant against human 5-hydroxytryptamine 1A receptor receptor,B,,,,,CHEMBL615803,15740,H,BAO_0000357,1,,,,,51
892,8,,"Inhibition of 5-HT induced [35S]GTP-gamma-S, binding at human cloned 5-HT 1A receptors.",F,,,,,CHEMBL835002,5640,H,BAO_0000019,1,,,,,51
893,8,,"5-hydroxytryptamine 1A receptor antagonism was evaluated by the ability to inhibit [35S]GTP-gamma-S, binding that was induced by 5-HT; Ki (nM): not determined",F,,,,,CHEMBL615804,5640,H,BAO_0000019,1,,,,,51
894,8,,Ability to displace [3H]5-CT (2.0 nM) from HeLa cells of human 5-hydroxytryptamine 1A receptor,B,,,,,CHEMBL615805,17211,H,BAO_0000219,1,,,,HeLa,51
895,8,,Ability to displace [3H]8-OH-DPAT from CHO cells stably transfected with human 5-hydroxytryptamine 1A receptor,B,,,,,CHEMBL615806,4751,H,BAO_0000219,1,,,,CHO,51
896,9,Homo sapiens,Affinity towards human 5-hydroxytryptamine 1A serotonin receptor,B,9606.0,,,,CHEMBL615807,6491,D,BAO_0000357,1,,,,,51
897,8,,Binding affinity towards human 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT-as radioligand,B,,,,,CHEMBL615808,4707,H,BAO_0000357,1,,,,,51
898,9,Homo sapiens,Binding affinity against 5-hydroxytryptamine 1A receptor,B,9606.0,,,,CHEMBL615809,13910,D,BAO_0000357,1,,,,,51
899,8,,Binding affinity against 5-hydroxytryptamine 1A receptor in HeLa cells was determined using [3H]5-HT,B,,,,,CHEMBL615810,16190,H,BAO_0000219,1,,,,HeLa,51
900,8,,Binding affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,B,,,,,CHEMBL615811,16633,H,BAO_0000357,1,,,,,51
901,8,,Binding affinity against [3H]- -8-OH-DPAT -labeled 5-hydroxytryptamine 1A sites in cloned CHO cells,B,,,,,CHEMBL615812,11898,H,BAO_0000219,1,,,,CHO,51
902,8,,Binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in cloned CHO cells,B,,,,,CHEMBL615751,11898,H,BAO_0000219,1,,,,CHO,51
903,8,,Binding affinity against human 5-hydroxytryptamine 1A receptor,B,,,,,CHEMBL615752,14331,H,BAO_0000357,1,,,,,51
904,8,,Binding affinity against human 5-hydroxytryptamine 1A receptor in CHO cells labeled with [3H]8-OH-DPAT radioligand,B,,,,,CHEMBL615753,17624,H,BAO_0000219,1,,,,CHO,51
905,8,,Binding affinity against human 5-hydroxytryptamine 1A receptor in CHO cells labeled with [3H]8-OH-DPAT radioligand; nd=not determined,B,,,,,CHEMBL615754,17624,H,BAO_0000219,1,,,,CHO,51
906,8,,Binding affinity of compound to human 5-hydroxytryptamine 1A receptor,B,,,,,CHEMBL615755,3307,H,BAO_0000357,1,,,,,51
907,9,Homo sapiens,Displacement of [3H]8-OH-DPAT from human 5-hydroxytryptamine 1A receptor expressed in CHO cells,B,9606.0,,,,CHEMBL615756,6563,D,BAO_0000219,1,,,,CHO,51
908,8,,Binding affinity for 5-hydroxytryptamine 1A receptor in HeLa transfected cell type using [3H]8-OH-DPAT as radioligand,B,,,,,CHEMBL615757,14165,H,BAO_0000019,1,,,,,51
909,8,,Binding affinity towards cloned human 5-hydroxytryptamine 1A receptor was determined,B,,,,,CHEMBL615758,5732,H,BAO_0000357,1,,,,,51
910,8,,In vitro affinity at human cloned 5-hydroxytryptamine 1A receptor by [3H]8-OH-DPAT displacement.,B,,,,,CHEMBL615759,13366,H,BAO_0000357,1,,,,,51
911,8,,Binding affinity towards human 5-hydroxytryptamine 1A receptor,B,,,,,CHEMBL615760,17626,H,BAO_0000357,1,,,,,51
912,8,,Binding affinity towards human 5-hydroxytryptamine 1A receptor by the displacement of [3H]5-HT radioligand from the cloned receptor expressed in HeLa cells,B,,,,,CHEMBL615761,6588,H,BAO_0000219,1,,,,HeLa,51
913,8,,Binding affinity towards human 5-hydroxytryptamine 1A receptor was determined using [3H]-5-HT as radioligand,B,,,,,CHEMBL872104,16209,H,BAO_0000357,1,,,,,51
914,8,,Binding affinity towards recombinant human 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand,B,,,,,CHEMBL615762,15463,H,BAO_0000357,1,,,,,51
915,8,,Binding affinity towards recombinant human Compound at 1 uM was tested for the inhibition of radioligand [3H]8-OH-DPAT binding to recombinant human 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand,B,,,,,CHEMBL615763,15463,H,BAO_0000357,1,,,,,51
916,8,,Binding affinity for recombinant human 5-hydroxytryptamine 1A receptor using [3H]5-HT as radioligand.,B,,,,,CHEMBL615764,14770,H,BAO_0000357,1,,,,,51
917,8,,Binding affinity on human cloned 5-hydroxytryptamine 1A receptor transfected in human cell lines (He La),B,,,,,CHEMBL615765,16245,H,BAO_0000219,1,,,,Cell line,51
918,8,,Binding affinity on human cloned 5-hydroxytryptamine 1A receptor transfected in human cell lines(He La),B,,,,,CHEMBL615766,16245,H,BAO_0000019,1,,,,,51
919,8,,Binding affinity towards 5-HT1A receptor using [3H]8-OH-DPAT as radioligand,B,,,,,CHEMBL615767,5548,H,BAO_0000357,1,,,,,51
920,8,,Binding affinity was determined towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,B,,,,,CHEMBL615768,5548,H,BAO_0000357,1,,,,,51
921,8,,Binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,B,,,,,CHEMBL615769,5548,H,BAO_0000357,1,,,,,51
922,8,,Binding affinity was evaluated at 5-hydroxytryptamine 1A receptor labeled with [3H]-8-OH-DPAT,B,,,,,CHEMBL615770,6876,H,BAO_0000357,1,,,,,51
923,8,,Binding affinity was evaluated at human recombinant 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,B,,,,,CHEMBL615771,2598,H,BAO_0000357,1,,,,,51
924,8,,Binding affinity to human 5-hydroxytryptamine 1A receptor was measured using [3H]-8-hydroxy-2-(di-n-propylamine) tetraline [3H]8-OH-DPAT) as radioligand,B,,,,,CHEMBL615772,17785,H,BAO_0000357,1,,,,,51
925,8,,Binding affinity towards 5-hydroxytryptamine 1A receptor,B,,,,,CHEMBL615773,6013,H,BAO_0000357,1,,,,,51
926,8,,Binding affinity towards 5-hydroxytryptamine 1A receptor in human using [3H]8-OH-DPAT as radioligand,B,,,,,CHEMBL615774,5929,H,BAO_0000357,1,,,,,51
927,8,,Binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,B,,,,,CHEMBL615775,16633,H,BAO_0000357,1,,,,,51
928,8,,Binding affinity towards cloned human 5-hydroxytryptamine 1A receptor was determined,B,,,,,CHEMBL615776,1558,H,BAO_0000357,1,,,,,51
929,8,,Binding affinity towards human cloned 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,B,,,,,CHEMBL615777,16026,H,BAO_0000357,1,,,,,51
930,8,,Binding affinity was measured on 5-hydroxytryptamine 1A receptor in AK cells transfected with human 5-HT1A gene labeled with [3H]-8-OH-DPAT,B,,,,,CHEMBL615778,12469,H,BAO_0000219,1,,,,,51
931,9,Homo sapiens,Binding affinity was measured on cloned Human 5-hydroxytryptamine 1A receptor which is labeled by [3H]8-OH-DPAT,B,9606.0,,,,CHEMBL615779,15874,D,BAO_0000357,1,,,,,51
932,8,,Binding affinity was measured on cloned human 5-hydroxytryptamine 1A receptor which is labeled by [3H]8-OH-DPAT,B,,,,,CHEMBL615780,15874,H,BAO_0000357,1,,,,,51
933,8,,Compound was evaluated for its binding affinity for human 5-hydroxytryptamine 1A receptor,B,,,,,CHEMBL616298,3935,H,BAO_0000357,1,,,,,51
934,8,,Compound was evaluated for its binding affinity towards human 5-hydroxytryptamine 1A receptor,B,,,,,CHEMBL616299,15818,H,BAO_0000357,1,,,,,51
935,8,,Compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1A receptor expressed in CHO-K1 cells.,B,,,,,CHEMBL616300,13706,H,BAO_0000219,1,,,,CHO-K1,51
936,8,,Ability to inhibit the forskolin-stimulated c-AMP formation mediated by human 5-hydroxytryptamine 1A receptor in CHO-K1 cells,F,,,,,CHEMBL616301,13729,H,BAO_0000219,1,,,,CHO-K1,51
937,8,,In vitro inhibition of [3H]- 8-OH-DPAT binding to cloned cell line containing human 5-hydroxytryptamine 1A receptor,B,,,,,CHEMBL616302,15413,H,BAO_0000019,1,,,,,51
938,8,,In vitro inhibition of [3H]- 8-OH-DPAT binding to cloned cell line containing human 5-hydroxytryptamine 1A receptor (Experiment 1),B,,,,,CHEMBL616117,15413,H,BAO_0000019,1,,,,,51
939,8,,In vitro inhibition of [3H]- 8-OH-DPAT binding to cloned cell line containing human 5-hydroxytryptamine 1A receptor (Experiment 2),B,,,,,CHEMBL616118,15413,H,BAO_0000019,1,,,,,51
940,8,,In vitro inhibition of [3H]- 8-OH-DPAT binding to cloned cell line containing human 5-hydroxytryptamine 1A receptor by Panlabs assay,B,,,,,CHEMBL616119,15413,H,BAO_0000019,1,,,,,51
941,9,Homo sapiens,Displacement of specific [3H]- 5-HT binding to cloned human 5-hydroxytryptamine 1A receptor stably expressed in HeLa cells,B,9606.0,,,,CHEMBL616120,3445,D,BAO_0000219,1,,,,HeLa,51
942,8,,Evaluated for the binding constant at [3H]8-OH-DPAT-labeled human 5-hydroxytryptamine 1A receptor,B,,,,,CHEMBL616121,15740,H,BAO_0000357,1,,,,,51
943,8,,Evaluated for the binding constant at [3H]8-OH-DPAT-labeled human 5-hydroxytryptamine 1A receptor receptor,B,,,,,CHEMBL616122,15740,H,BAO_0000357,1,,,,,51
944,8,,In vitro binding affinity tested on human 5-hydroxytryptamine 1A receptor,B,,,,,CHEMBL616123,17626,H,BAO_0000357,1,,,,,51
945,9,Homo sapiens,In vitro binding affinity to human 5-hydroxytryptamine 1A receptor,B,9606.0,,,,CHEMBL616124,4234,D,BAO_0000357,1,,,,,51
946,8,,In vitro binding affinity at 5-hydroxytryptamine 1A receptor by [3H]8-OH-DPAT displacement.,B,,,,,CHEMBL616125,5640,H,BAO_0000357,1,,,,,51
947,8,Rattus norvegicus,In vitro binding affinity towards Human 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT,B,10116.0,,,,CHEMBL616126,5272,H,BAO_0000357,1,,,,,51
948,8,,In vitro binding affinity towards cloned human 5-hydroxytryptamine 1A receptor expressed in Chinese hamster ovary (CHO) cells using [3H]8-OH-DPAT as radioligand,B,,,,,CHEMBL616127,4622,H,BAO_0000219,1,,,,CHO,51
949,8,,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1A receptor,B,,,,,CHEMBL616128,17085,H,BAO_0000019,1,,,,,51
950,8,,In vitro binding affinity was determined towards cloned human 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT radioligand,B,,,,,CHEMBL616129,3025,H,BAO_0000357,1,,,,,51
951,8,,In vitro receptor binding affinity for cloned human 5-hydroxytryptamine 1A receptor,B,,,,,CHEMBL616130,15315,H,BAO_0000357,1,,,,,51
952,8,,Inhibition of [3H]- OH-DPAT binding against 5-hydroxytryptamine 1A receptor from human recombinant,B,,,,,CHEMBL616131,15267,H,BAO_0000357,1,,,,,51
953,8,,Inhibition of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor serotonergic receptor in human HeLa cells,B,,,,,CHEMBL616132,17158,H,BAO_0000219,1,,,,HeLa,51
954,9,Homo sapiens,Receptor binding affinity for cloned human 5-hydroxytryptamine 1A receptor in HeLa cells,B,9606.0,,,,CHEMBL616133,14214,D,BAO_0000219,1,,,,HeLa,51
955,8,,Tested in vitro for its ability to bind to 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,B,,,,,CHEMBL616134,17133,H,BAO_0000357,1,,,,,51
956,8,,The binding affinity at the 5-hydroxytryptamine 1A receptor determined using [3H]5-CT,B,,,,,CHEMBL616135,16532,H,BAO_0000357,1,,,,,51
957,9,Homo sapiens,Affinity for 5-hydroxytryptamine 1A receptor subtype,B,9606.0,,,,CHEMBL616136,2391,D,BAO_0000357,1,,,,,51
958,8,,The compound was tested for CNS binding affinity towards 5-hydroxytryptamine 1A receptor from cloned Human membranes,B,,,,,CHEMBL616137,14447,H,BAO_0000019,1,,,,,51
959,8,,The compound was tested for CNS binding affinity towards 5-hydroxytryptamine 1A receptor from cloned Human membranes.,B,,,,,CHEMBL872105,14447,H,BAO_0000019,1,,,,,51
960,8,,The compound was tested for binding affinity against 5-hydroxytryptamine 1A receptor receptor,B,,,,,CHEMBL616138,15086,H,BAO_0000357,1,,,,,51
961,9,Homo sapiens,Binding affinity for cloned human 5-hydroxytryptamine 1A receptor,B,9606.0,,,,CHEMBL616139,13051,D,BAO_0000357,1,,,,,51
962,8,,"Ability to influence the binding of [35S]GTP-gamma-S, to HeLa cell membranes expressing the human 5-hydroxytryptamine 1A receptor; Not active",F,,,,,CHEMBL616140,16026,H,BAO_0000019,1,,,,,51
963,8,,In vitro binding affinity was determined by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1A receptor; ND means not determined,B,,,,,CHEMBL616141,17085,H,BAO_0000019,1,,,,,51
964,8,,Tested in vitro for its ability to bind to 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,B,,,,,CHEMBL616142,17133,H,BAO_0000357,1,,,,,51
965,8,,Tested in vitro for its ability to bind to 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand; ND means Not determined,B,,,,,CHEMBL616143,17133,H,BAO_0000357,1,,,,,51
966,8,,Ability to displace [3H]5-CT (2.0 nM) from HeLa cells of human 5-hydroxytryptamine 1A receptor; NT denotes not tested,B,,,,,CHEMBL616144,17211,H,BAO_0000219,1,,,,HeLa,51
967,8,,Ability to displace [3H]5-CT (2.0 nM) from HeLa cells of human 5-hydroxytryptamine 1A receptor; NT=not tested,B,,,,,CHEMBL616145,17211,H,BAO_0000219,1,,,,HeLa,51
968,8,,Ability to displace [3H]5-CT (2.0 nM) from HeLa cells of human 5-hydroxytryptamine 1A receptor; NT denotes not tested,B,,,,,CHEMBL616012,17211,H,BAO_0000219,1,,,,HeLa,51
969,8,,Ability to displace [3H]5-CT (2.0 nM) from HeLa cells of human 5-hydroxytryptamine 1A receptor; NT denotes not tested,B,,,,,CHEMBL616013,17211,H,BAO_0000219,1,,,,HeLa,51
970,8,,"Agonist efficacy of [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor compared with 5-HT.; NT is not tested",F,,,,,CHEMBL616014,16394,H,BAO_0000019,1,,,,,51
971,8,,"Agonist efficacy of [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor compared with 5-HT.; NT is not tested",F,,,,,CHEMBL616015,16394,H,BAO_0000019,1,,,,,51
972,8,,"Agonist efficacy of [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor compared with 5-HT.; NT is not tested",F,,,,,CHEMBL616016,16394,H,BAO_0000019,1,,,,,51
973,8,,Antagonist induction of hypothermia by 8-OH-DPAT in 5-hydroxytryptamine 1A receptor after subcutaneous administration; NT is not tested,F,,,,,CHEMBL616017,16394,H,BAO_0000218,1,,In vivo,,,51
974,8,,Binding affinity at human 5-hydroxytryptamine 1A receptor by inhibition of [3H]-8-OH-DPAT binding in Chinese hamster ovary cell line; NT is not tested,B,,,,,CHEMBL616018,16394,H,BAO_0000019,1,,,,,51
975,8,,EC50 for inhibition of 50 uM forskolin-stimulated cAMP accumulation against 5-hydroxytryptamine 1A receptor receptor; Not tested,F,,,,,CHEMBL616019,15740,H,BAO_0000019,1,,,,,51
976,8,,EC50 for inhibition of 50 uM forskolin-stimulated cAMP accumulation against 5-hydroxytryptamine 1A receptor; Not tested,F,,,,,CHEMBL616020,15740,H,BAO_0000019,1,,,,,51
977,8,,Evaluated for the binding constant at [3H]8-OH-DPAT-labeled human 5-hydroxytryptamine 1A receptor,B,,,,,CHEMBL858018,15740,H,BAO_0000357,1,,,,,51
978,8,,Binding affinity against human 5-hydroxytryptamine 1A receptors HEK 293 cell membranes using [35S]GTP gamma-S,F,,,,,CHEMBL616021,17296,H,BAO_0000219,1,,,,HEK293,51
979,8,,"Stimulation of binding of [35S]GTP-gamma-S, to G protein mediated by human cloned 5-hydroxytryptamine 1A receptor tested in vitro at 1 uM.",F,,,,,CHEMBL616022,5640,H,BAO_0000019,1,,,,,51
980,8,,"Stimulation of binding of [35S]GTP-gamma-S, to G protein mediated by human cloned 5-hydroxytryptamine 1A receptor tested in vitro at a concentration of 1 uM; ND means Not determined",F,,,,,CHEMBL616023,5640,H,BAO_0000019,1,,,,,51
981,8,,"Stimulation of binding of [35S]GTP-gamma-S, to G protein mediated by human cloned 5-hydroxytryptamine 1A receptor tested in vitro at a concentration of 1 uM; ND means not determined",F,,,,,CHEMBL616024,5640,H,BAO_0000019,1,,,,,51
982,8,,"Stimulation of binding of [35S]GTP-gamma-S, to G protein mediated by human cloned 5-hydroxytryptamine 1A receptor tested in vitro at a concentration of 1 uM; Not determined",F,,,,,CHEMBL616025,5640,H,BAO_0000019,1,,,,,51
983,8,,Antagonistic efficacy was evaluated by adenylyl cyclase assay in CHO cells stably expressing the human 5-HT1A receptor,F,,,,,CHEMBL616026,2759,H,BAO_0000219,1,,,,CHO,51
984,8,,"Agonist efficacy of [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor compared with 5-HT",F,,,,,CHEMBL616027,16394,H,BAO_0000019,1,,,,,51
985,9,Homo sapiens,"Agonist efficacy of [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor compared to 5-HT",F,9606.0,,,,CHEMBL616028,16394,D,BAO_0000019,1,,,,,51
986,9,Homo sapiens,Percent efficacy against human 5-hydroxytryptamine 1A receptor relative to maximal 5-HT response,F,9606.0,,,,CHEMBL616029,3445,D,BAO_0000019,1,,,,,51
987,8,,Binding affinity for 5-hydroxytryptamine 1A receptor was determined by incubating human 5-hydroxytryptamine 1A receptor transfected CHO cells with [3H]8-OH-DPAT,B,,,,,CHEMBL616030,4316,H,BAO_0000219,1,,,,CHO,51
988,8,,In vitro inhibition of [3H]8-OH-DPAT binding to human cloned 5-hydroxytryptamine 1A receptor on CHO cell membranes.,B,,,,,CHEMBL616031,4316,H,BAO_0000019,1,,,,,51
989,9,Homo sapiens,Agonist efficacy on 5-hydroxytryptamine 1A receptor subtype,F,9606.0,,,,CHEMBL616032,15180,D,BAO_0000019,1,,,,,51
990,9,Homo sapiens,Agonist efficacy on 5-hydroxytryptamine 1A receptor subtype,F,9606.0,,,,CHEMBL616033,15180,D,BAO_0000019,1,,,,,51
991,8,,Maximum binding affinity was evaluated as ([35S]GTP binding on 5-hydroxytryptamine 1A serotonergic receptors.,F,,,,,CHEMBL616034,15042,H,BAO_0000019,1,,,,,51
992,8,,Maximum binding affinity was evaluated as ([35S]GTP binding on 5-hydroxytryptamine 1A serotonergic receptors.,F,,,,,CHEMBL616035,15042,H,BAO_0000019,1,,,,,51
993,8,,Maximum binding affinity was evaluated as ([35S]GTP binding on cloned human 5-hydroxytryptamine 1A receptor,F,,,,,CHEMBL616036,15042,H,BAO_0000019,1,,,,,51
994,8,,Agonist efficacy was evaluated as ([35S]GTP binding on 5-hydroxytryptamine 1A serotonergic receptors.,F,,,,,CHEMBL616037,15042,H,BAO_0000019,1,,,,,51
995,8,,Agonist efficacy was evaluated as ([35S]GTP binding on 5-hydroxytryptamine 1A serotonergic receptors.,F,,,,,CHEMBL616038,15042,H,BAO_0000019,1,,,,,51
996,8,,Agonist efficacy was evaluated as ([35S]GTP binding on 5-hydroxytryptamine 1A serotonergic receptors.,F,,,,,CHEMBL616039,15042,H,BAO_0000019,1,,,,,51
997,8,,Agonist efficacy was evaluated as [35S]GTP binding on cloned human 5-hydroxytryptamine 1A receptor,F,,,,,CHEMBL616040,15042,H,BAO_0000019,1,,,,,51
998,9,Homo sapiens,Concentration required to obtain 50% maximal stimulation of [35S]GTP gamma-S binding to human cloned 5-HT1A receptors of cell membranes from HeLa cells,F,9606.0,,,,CHEMBL616041,15180,D,BAO_0000219,1,,,,HeLa,51
999,9,Homo sapiens,Negative logarithm of concentration required to obtain 50% maximal stimulation of [35S]GTP gamma-S binding to human cloned 5-HT1A receptors of cell membranes from HeLa cells,F,9606.0,,,,CHEMBL616042,15180,D,BAO_0000219,1,,,,HeLa,51
1000,9,Homo sapiens,Negative logarithm of concentration required to obtain 50% maximal stimulation of [35S]GTP gamma-S binding to human cloned 5-HT1A receptors of cell membranes from HeLa cells,F,9606.0,,,,CHEMBL616043,15180,D,BAO_0000219,1,,,,HeLa,51
1001,8,,"Potency (pD2) for the stimulation of [35S]GTP-gamma-S, binding on 5-hydroxytryptamine 1A receptor",F,,,,,CHEMBL616044,16245,H,BAO_0000019,1,,,,,51
1002,8,,"Ability to influence the binding of [35S]GTP-gamma-S, to HeLa cell membranes expressing the human 5-hydroxytryptamine 1A receptor",F,,,,,CHEMBL616045,16026,H,BAO_0000019,1,,,,,51
1003,8,,Binding affinity against human 5-hydroxytryptamine 1A receptors HEK 293 cell membranes using [35S]GTP gamma-S,F,,,,,CHEMBL616046,17296,H,BAO_0000219,1,,,,HEK293,51
1004,8,,Compound was tested for its potency against 5-hydroxytryptamine 1A receptor expressed in CHO cells (experiment 2),F,,,,,CHEMBL616047,2759,H,BAO_0000219,1,,,,CHO,51
1005,8,,Compound was tested for its potency against human 5-hydroxytryptamine 1A receptor expressed in CHO cells,F,,,,,CHEMBL616048,2759,H,BAO_0000219,1,,,,CHO,51
1006,9,Homo sapiens,Potency against human 5-hydroxytryptamine 1A receptor expressed in CHO cells (experiment 1),F,9606.0,,,,CHEMBL616049,2759,D,BAO_0000219,1,,,,CHO,51
1007,8,,Compound was tested for its potency against human 5-hydroxytryptamine 1A receptor expressed in CHO cells (experiment 2),F,,,,,CHEMBL616050,2759,H,BAO_0000219,1,,,,CHO,51
1008,8,,In vitro effective concentration required to inhibit forskolin-stimulated cAMP levels in HA7 cells expressing human 5-HT1A receptor,F,,,,,CHEMBL616051,15419,H,BAO_0000219,1,,,,,51
1009,8,,In vitro effective concentration required to inhibit forskolin-stimulated cAMP levels in HA7 cells expressing human 5-HT1A receptor; Not tested,F,,,,,CHEMBL616212,15419,H,BAO_0000219,1,,,,,51
1010,8,,"ability to influence the binding of [35S]GTP-gamma-S, to HeLa cell membranes expressing the human 5-hydroxytryptamine 1A receptor",F,,,,,CHEMBL616213,16026,H,BAO_0000019,1,,,,,51
1011,8,,Ability to bind to 5-hydroxytryptamine 1A receptor from cloned human expressed in Ha7 cells,B,,,,,CHEMBL616214,1414,H,BAO_0000219,1,,In vitro,,,51
1012,8,,Ability to bind to 5-hydroxytryptamine 1A receptor subtype from cloned human expressed in Ha7 cells,B,,,,,CHEMBL616215,1414,H,BAO_0000219,1,,In vitro,,,51
1013,8,,Binding activity radioligand.,B,,,,,CHEMBL616216,12861,H,BAO_0000357,1,,,,,51
1014,8,,Binding activity against 5-hydroxytryptamine 3 receptor from rat cortex homogenate using [3H]-Q-ICS 205-930 as radioligand.,B,,,,,CHEMBL616217,12861,H,BAO_0000019,1,,,,,51
1015,8,,Binding affinity for human cloned 5-hydroxytryptamine 1A receptor,B,,,,,CHEMBL616218,5104,H,BAO_0000357,1,,,,,51
1016,8,,Binding affinity for human cloned 5-hydroxytryptamine 1A receptor,B,,,,,CHEMBL616219,5105,H,BAO_0000357,1,,,,,51
1017,8,,binding affinity towards human recombinant 5-hydroxytryptamine 1A receptor,B,,,,,CHEMBL616220,16312,H,BAO_0000357,1,,,,,51
1018,9,Homo sapiens,Displacement of [3H]8-hydroxy-2-(di-n-propylamino)tetralin from human 5-hydroxytryptamine 1A receptor,B,9606.0,,,,CHEMBL833493,15180,D,BAO_0000357,1,,,,,51
1019,8,,Ability to displace the radioligand [3H]-8-OH-DPAT from human 5-hydroxytryptamine 1A receptor,B,,,,,CHEMBL616221,5033,H,BAO_0000357,1,,,,,51
1020,9,Homo sapiens,Affinity constant on CHO cells expressing Human recombinant 5-hydroxytryptamine receptor 1A,B,9606.0,,,,CHEMBL616222,16909,D,BAO_0000219,1,,,,CHO,51
1021,8,,Antagonistic affinity against cloned human 5-hydroxytryptamine 1A receptor,F,,,,,CHEMBL616223,2590,H,BAO_0000019,1,,,,,51
1022,8,,Antagonistic affinity against cloned human 5-hydroxytryptamine 1A receptor; Not determined,F,,,,,CHEMBL616224,2590,H,BAO_0000019,1,,,,,51
1023,8,,Binding affinity at human 5-hydroxytryptamine 1A receptor by inhibition of [3H]8-OH-DPAT binding in Chinese hamster ovary cell line,B,,,,,CHEMBL616225,16394,H,BAO_0000019,1,,,,,51
1024,9,Homo sapiens,Binding affinity to human cloned 5-hydroxytryptamine 1A receptor in HEK 293 cells using [3H]-8-OH- DPAT as radioligand,B,9606.0,,,,CHEMBL616226,4540,D,BAO_0000219,1,,,,HEK293,51
1025,8,,Binding affinity against 5-hydroxytryptamine 1A human cloned receptors in HEK293 cells,B,,,,,CHEMBL616227,17296,H,BAO_0000219,1,,,,HEK293,51
1026,8,,Binding affinity against 5-hydroxytryptamine 1A human cloned receptors in HEK293 cells using [3H]8-OH-DPAT as radioligand,B,,,,,CHEMBL616228,17296,H,BAO_0000219,1,,,,HEK293,51
1027,8,,Binding affinity towards 5-hydroxytryptamine 1A receptor (human cloned receptor) in HEK293 cells using [3H]8-OH-DPAT as radioligand;,B,,,,,CHEMBL616229,15779,H,BAO_0000219,1,,,,HEK293,51
1028,8,,Binding affinity towards 5-hydroxytryptamine 1A receptor (human cloned receptor) in HEK293 cells using [3H]8-OH-DPAT as radioligand; ND means no data,B,,,,,CHEMBL616230,15779,H,BAO_0000219,1,,,,HEK293,51
1029,8,,Binding affinity towards 5-hydroxytryptamine 1A receptor (human cloned receptor) in HEK293 cells using [3H]8-OH-DPAT as radioligand;ND means no data.,B,,,,,CHEMBL616231,15779,H,BAO_0000219,1,,,,HEK293,51
1030,8,,Binding affinity towards 5-hydroxytryptamine 1A receptor in human using [3H]8-OH-DPAT as radioligand,B,,,,,CHEMBL616232,6166,H,BAO_0000357,1,,,,,51
1031,8,,Binding affinity towards 5-hydroxytryptamine 1A receptor (human cloned receptor) in HEK293 cells using [3H]8-OH-DPAT as radioligand;,B,,,,,CHEMBL616233,15779,H,BAO_0000219,1,,,,HEK293,51
1032,8,,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 1A receptor in HEK 293 cells using [3H]8-OH-DPAT as the radioligand,B,,,,,CHEMBL857973,4199,H,BAO_0000219,1,,,,HEK293,51
1033,8,,Compound was evaluated for its ability to displace [3H]8-OH-DPAT binding from human 5-hydroxytryptamine 1A receptor in mammalian cells,B,,,,,CHEMBL616234,15316,H,BAO_0000219,1,,,,,51
1034,8,,Compound was tested for binding affinity against human 5-hydroxytryptamine 1A receptor,B,,,,,CHEMBL616235,14875,H,BAO_0000357,1,,,,,51
1035,8,,Binding affinity at human cloned 5-hydroxytryptamine 1A receptor expressed in HeLa cells by [3H]8-hydroxy-2-(di-n-propylamino)tetraline displacement.,B,,,,,CHEMBL616236,14727,H,BAO_0000219,1,,,,HeLa,51
1036,8,,Binding affinity at native 5-hydroxytryptamine 1A receptor in rat by [3H]8-hydroxy-2-(di-n-propylamino)tetraline displacement.,B,,,,,CHEMBL616237,14727,H,BAO_0000019,1,,,,,51
1037,8,,Compound was tested for its binding affinity against 5-hydroxytryptamine 1A receptor in human cloned receptors in HEK 293 cells using [3H]8-OH-DPAT,B,,,,,CHEMBL616238,15146,H,BAO_0000219,1,,,,HEK293,51
1038,8,,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 1A receptor in HEK 293 using [3H]5-CT as a radioligand,B,,,,,CHEMBL616239,5213,H,BAO_0000219,1,,,,HEK293,51
1039,8,,In vitro binding affinity at human recombinant 5-hydroxytryptamine 1A receptor in mammalian cells using 3[H]8-OH-DPAT as the radioligand,B,,,,,CHEMBL616240,16429,H,BAO_0000219,1,,,,,51
1040,9,Homo sapiens,The binding affinity was evaluated on cloned human 5-hydroxytryptamine 1A receptor expressed in HeLa cells by using DPAT as radioligand.,B,9606.0,,,,CHEMBL616241,15042,D,BAO_0000219,1,,,,HeLa,51
1041,8,,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 1A receptor in HEK 293 cells using [3H]8-OH-DPAT.,B,,,,,CHEMBL616242,14818,H,BAO_0000219,1,,,,HEK293,51
1042,8,,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 1A receptor in HEK293 cells, using [3H]8-OH-DPAT as radioligand",B,,,,,CHEMBL616243,4829,H,BAO_0000219,1,,,,HEK293,51
1043,9,,In vitro inhibitory concentration required against [3H]8-OH-DPAT binding to cloned human 5-hydroxytryptamine 1A receptor,B,,,,,CHEMBL616244,17200,D,BAO_0000357,1,,,,,51
1044,9,Homo sapiens,The compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1A receptor,B,9606.0,,,,CHEMBL616245,13051,D,BAO_0000357,1,,,,,51
1045,8,,Binding affinity towards 5-HT1B receptor by the displacement of [3H]-5-CT] in human recombinant receptors in mammalian cell,B,,,,,CHEMBL616246,5486,H,BAO_0000357,1,,,,,106
1046,8,,Binding affinity against 5-HT1D receptor,B,,,,,CHEMBL616247,5254,H,BAO_0000357,1,,,,,105
1047,8,,Binding affinity against 5-hydroxytryptamine 1A receptor,B,,,,,CHEMBL616248,5254,H,BAO_0000357,1,,,,,105
1048,8,,Affinity of compound towards 5-hydroxytryptamine 1A receptor was evaluated using radioligand binding technique,B,,,,,CHEMBL616249,15331,H,BAO_0000357,1,,,,,107
1049,8,Homo sapiens,Binding affinity against serotonin 5-hydroxytryptamine 1A receptor using radioligand [3H]8-OH-DPAT binding assay,B,9606.0,,,,CHEMBL616250,13506,H,BAO_0000357,1,,,,,10576
1050,8,,Inhibition of [3H]- 8-OH-DAPT binding against human recombinant 5-hydroxytryptamine 1A receptor,B,,,,,CHEMBL616251,15267,H,BAO_0000357,1,,,,,51
1051,8,,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice 15 min after administration of the compound,F,,,,,CHEMBL616252,16616,H,BAO_0000218,1,,In vivo,,,11863
1052,8,,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice 30 min after administration of the compound,F,,,,,CHEMBL616253,16616,H,BAO_0000218,1,,In vivo,,,11863
1053,8,,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice 60 min after administration of the compound,F,,,,,CHEMBL616254,16616,H,BAO_0000218,1,,In vivo,,,11863
1054,9,Mus musculus,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice at 10 mg/kg after 15 min,F,10090.0,,,,CHEMBL616255,16616,D,BAO_0000218,1,,,,,11863
1055,9,Mus musculus,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice at 10 mg/kg after 30 min,F,10090.0,,,,CHEMBL832872,16616,D,BAO_0000218,1,,,,,11863
1056,9,Mus musculus,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice at 10 mg/kg after 60 min,F,10090.0,,,,CHEMBL616256,16616,D,BAO_0000218,1,,,,,11863
1057,9,Mus musculus,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice at 1 mg/kg after 15 min,F,10090.0,,,,CHEMBL616257,16616,D,BAO_0000218,1,,,,,11863
1058,9,Mus musculus,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice at 1 mg/kg after 30 min,F,10090.0,,,,CHEMBL616258,16616,D,BAO_0000218,1,,,,,11863
1059,9,Mus musculus,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice at 1 mg/kg after 60 min,F,10090.0,,,,CHEMBL616384,16616,D,BAO_0000218,1,,,,,11863
1060,8,,Hill number was determined for inhibition of of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor in mouse hippocampus,B,,Hippocampus,,,CHEMBL616385,10297,H,BAO_0000221,1,10000000.0,,,,11863
1061,8,,Inhibitory activity against serotonin 5-hydroxytryptamine 1A receptor from mice.,B,,,,,CHEMBL616386,13704,H,BAO_0000357,1,,,,,11863
1062,9,Mus musculus,Inhibitory activity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in mouse hippocampus,B,10090.0,Hippocampus,,,CHEMBL616387,10297,D,BAO_0000221,1,10000000.0,,,,11863
1063,8,,Binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in mouse hippocampus; Not determined,B,,Hippocampus,,,CHEMBL616388,10297,H,BAO_0000221,1,10000000.0,,,,11863
1064,9,Mus musculus,Binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in mouse hippocampus,B,10090.0,Hippocampus,,,CHEMBL616389,10297,D,BAO_0000221,1,10000000.0,,,,11863
1065,8,,Binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in mouse hippocampus; Not determined,B,,Hippocampus,,,CHEMBL616390,10297,H,BAO_0000221,1,10000000.0,,,,11863
1066,8,,Compound was tested for binding affinity to 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as a radioligand,B,,,,,CHEMBL616391,217,H,BAO_0000357,1,,,,,11863
1067,9,Mus musculus,Hill number was determined for inhibition of of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor in mouse hippocampus,B,10090.0,Hippocampus,,,CHEMBL616392,10297,D,BAO_0000221,1,10000000.0,,,,11863
1068,8,Sus scrofa,Ability to displace [3H]8-OH-DPAT radioligand from porcine 5-hydroxytryptamine 1A receptor,B,9823.0,,,,CHEMBL616393,4921,H,BAO_0000357,1,,,,,51
1069,8,Sus scrofa,Ability to displace [3H]8-OH-DPAT radioligand from porcine 5-hydroxytryptamine 1A receptor; ND denotes not determined,B,9823.0,,,,CHEMBL616394,4921,H,BAO_0000357,1,,,,,51
1070,8,Sus scrofa,Binding affinity of compound measured for 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT-labeled porcine brain homogenates,B,9823.0,,,,CHEMBL616395,4996,H,BAO_0000019,1,,,,,51
1071,8,Sus scrofa,Compound was evaluated for the binding affinity at 5- HT1A receptor,B,9823.0,,,,CHEMBL616396,12918,H,BAO_0000357,1,,,,,51
1072,8,Sus scrofa,Compound was tested in vitro for its ability to compete with [3H]8-OH-DPAT at 5-hydroxytryptamine 1A receptor in porcine brain homogenate,B,9823.0,,,,CHEMBL872907,5333,H,BAO_0000019,1,,,,,51
1073,8,Sus scrofa,In vitro for its ability to displace [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in porcine brain homogenate,B,9823.0,,,,CHEMBL616397,4437,H,BAO_0000019,1,,,,,51
1074,8,Sus scrofa,Compound was tested for its ability to displace [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in pig cortex,B,9823.0,,,,CHEMBL616398,1742,H,BAO_0000019,1,,,,,51
1075,8,Sus scrofa,Displacement of [3H]- 8-OH-DPAT from porcine 5-hydroxytryptamine 1A receptor,B,9823.0,,,,CHEMBL616399,16688,H,BAO_0000357,1,,,,,51
1076,8,Sus scrofa,Binding activity radioligand.,B,9823.0,,,,CHEMBL857065,12861,H,BAO_0000357,1,,,,,51
1077,8,Sus scrofa,Binding activity against 5-hydroxytryptamine 1A receptor from pig cortex membrane using [3H]8-OH-DPAT-HT as radioligand.,B,9823.0,,,,CHEMBL616400,12861,H,BAO_0000019,1,,,,,51
1078,8,Sus scrofa,Binding activity against 5-hydroxytryptamine 1A receptor from pig cortex membrane using [3H]8-OH-DPAT-HT as radioligand.,B,9823.0,,,,CHEMBL616401,12861,H,BAO_0000019,1,,,,,51
1079,8,,Displacement of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor from pig cortex,B,,,,,CHEMBL616402,12490,H,BAO_0000019,1,,,,,10624
1080,8,Sus scrofa,Displacement of [3H]8-OH-DPAT from pig cortex 5-hydroxytryptamine 1A receptor,B,9823.0,,,,CHEMBL616403,11828,H,BAO_0000019,1,,,,,51
1081,8,Sus scrofa,Binding affinity for 5-hydroxytryptamine 1A receptor in piglet hippocampus using [3H]8-OH-DPAT,B,9823.0,Hippocampus,,,CHEMBL616404,11866,H,BAO_0000221,1,10000000.0,,,,51
1082,8,Sus scrofa,Binding affinity towards 5-hydroxytryptamine 1A receptor in pig frontal cortex membranes using [8H]-OH-DPAT,B,9823.0,,,,CHEMBL616405,12827,H,BAO_0000249,1,,,,,51
1083,8,Sus scrofa,Binding affinity was evaluated by 5-hydroxytryptamine 1A receptor agonism in the pig cortex by displacing 8-OH-DPAT,B,9823.0,,,,CHEMBL616406,12918,H,BAO_0000019,1,,,,,51
1084,8,Sus scrofa,Agonistic activity against 5-hydroxytryptamine 1A receptor in pig cortex using [3H]8-OH-DPAT,F,9823.0,,,,CHEMBL616407,12919,H,BAO_0000019,1,,,,,51
1085,8,Oryctolagus cuniculus,Binding affinity against 5-hydroxytryptamine 1 receptor using rabbit jugular vein assay in the presence of endothelium,B,9986.0,,,,CHEMBL616408,13047,H,BAO_0000019,1,,,,,51
1086,9,Rattus norvegicus,Inhibition activity against 5-hydroxytryptamine 1A receptor in rat hippocampus membranes using radio binding assays,B,10116.0,,,,CHEMBL616409,15796,D,BAO_0000249,1,,,,,10576
1087,9,Rattus norvegicus,"Inhibition of [3H]8-hydroxy-2-dipropylamino-1,2,3,4-tetrahydronaphthalene binding to 5-hydroxytryptamine 1A receptor in hippocampus region of rat brain; Less active",B,10116.0,Hippocampus,,,CHEMBL616410,3651,D,BAO_0000221,1,10000000.0,,,,10576
1088,8,,Tested for the effect on binding at 5-hydroxytryptamine 1A receptor; No activity,B,,,,,CHEMBL616411,188,H,BAO_0000357,1,,,,,10576
1089,9,Rattus norvegicus,"Antagonist activity to stimulate binding of [35S]GTP-gamma-S, to 5-hydroxytryptamine 1A receptor in isolated rat hippocampal membranes",F,10116.0,,Membranes,,CHEMBL616412,16616,D,BAO_0000249,1,,,,,10576
1090,9,Rattus norvegicus,"Inhibition of (+)-8-OH-DPAT stimulated [35S]GTP-gamma-S, binding in rat hippocampal membranes",F,10116.0,Hippocampus,Membranes,,CHEMBL616413,16616,D,BAO_0000249,1,10000000.0,,,,10576
1091,8,,The binding of [125I]MPPI ligand to 5-hydroxytryptamine 1A receptor of rat hippocampal homogenates,B,,Hippocampus,,,CHEMBL616414,12306,H,BAO_0000221,1,10000000.0,,,,10576
1092,9,Rattus norvegicus,Binding affinity for rat hippocampus 5-hydroxytryptamine 1A receptor by inhibition of [3H]8-OH-DPAT binding,B,10116.0,Hippocampus,,,CHEMBL616415,17167,D,BAO_0000221,1,10000000.0,,,,10576
1093,8,,Binding affinity measured at the 5-hydroxytryptamine 1A receptor by the inhibition of [3H]8-OH-DPAT binding to rat cortex using unlabeled buspirone for nonspecific binding.,B,,,,,CHEMBL616416,14776,H,BAO_0000019,1,,,,,10576
1094,8,,Binding affinity of 5-hydroxytryptamine 1A receptor using [3H]-8-OH-DPAT as radioligand.,B,,,,,CHEMBL616417,12158,H,BAO_0000357,1,,,,,10576
1095,8,,Binding affinity of [3H]- -8-OH-DPAT labelled towards Rat Hippocampal 5-hydroxytryptamine 1A receptor using radioligand binding assay,B,,,,,CHEMBL616418,13481,H,BAO_0000357,1,,,,,10576
1096,8,,Binding affinity of [3H]-8-OH-DPAT towards 5-hydroxytryptamine 1A receptor in cloned mammalian receptor expressed in cultured cells or from rat whole brain.,B,,,,,CHEMBL616419,13427,H,BAO_0000219,1,,In vitro,,,10576
1097,8,,Binding affinity of compound against 5-hydroxytryptamine 1A receptor binding site using radioligand [3H]8-OH-DPAT,B,,,,,CHEMBL616420,10210,H,BAO_0000357,1,,,,,10576
1098,8,,Binding affinity of compound towards 5-HT 1A receptor by measuring ability to displace [3H]OH-DPAT from 5-hydroxytryptamine 1A receptor in rat striatal membranes,B,,,Membranes,,CHEMBL616421,10205,H,BAO_0000249,1,,,,,10576
1099,8,,Binding affinity of compound towards 5-HT 1A receptor by measuring ability to displace [3H]OH-DPAT from 5-hydroxytryptamine 1A receptor in rat striatal membranes,B,,,Membranes,,CHEMBL616422,10205,H,BAO_0000249,1,,,,,10576
1100,8,,Binding affinity of compound towards 5-hydroxytryptamine 1A receptor in rat striatal membranes by [3H]OH-DPAT displacement.,B,,,Membranes,,CHEMBL616423,10205,H,BAO_0000249,1,,,,,10576
1101,9,Rattus norvegicus,Binding affinity for 5-hydroxytryptamine 1A receptor with [3H]5-HT,B,10116.0,,,,CHEMBL616424,12280,D,BAO_0000357,1,,,,,10576
1102,8,,Binding affinity to the rat 5-hydroxytryptamine 1A receptor,B,,,,,CHEMBL616425,17386,H,BAO_0000357,1,,,,,10576
1103,8,,Binding affinity was tested on 5-hydroxytryptamine 1A receptor using radioligand [3H]5-HT binding assay.,B,,,,,CHEMBL616426,13654,H,BAO_0000357,1,,,,,10576
1104,8,,Binding affinity against 5-hydroxytryptamine 1A receptor from rat hippocampus using [3H]8-OH-DPAT as the radioligand.,B,,Hippocampus,,,CHEMBL616427,14423,H,BAO_0000221,1,10000000.0,,,,10576
1105,8,,Binding affinity against 5-hydroxytryptamine 1A receptor of rat hippocampus tissue.,B,,Hippocampus,,,CHEMBL616428,15412,H,BAO_0000221,1,10000000.0,,,,10576
1106,8,,Binding affinity by measuring displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampus,B,,Hippocampus,,,CHEMBL616290,12073,H,BAO_0000221,1,10000000.0,,,,10576
1107,9,Rattus norvegicus,Displacement of [3H]8-OH-DPAT from rat striata 5-hydroxytryptamine 1A receptor,B,10116.0,,,,CHEMBL616052,4101,D,BAO_0000357,1,,,,,10576
1108,8,,Binding affinity in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 1A receptor,B,,,,,CHEMBL616053,10062,H,BAO_0000357,1,,,,,10576
1109,8,,Binding affinity towards 5-HT 1A receptor in rat cerebral cortex membranes using [3H]8-OH-DPAT as radioligand,B,,,,,CHEMBL616054,6238,H,BAO_0000249,1,,,,,10576
1110,8,,Binding affinity towards 5-hydroxytryptamine 1A receptor,B,,,,,CHEMBL616055,16273,H,BAO_0000357,1,,,,,10576
1111,8,,Binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand in competitive binding assay,B,,,,,CHEMBL616056,11139,H,BAO_0000357,1,,,,,10576
1112,8,,Binding affinity towards 5-hydroxytryptamine 1A receptor from rat hippocampal membranes,B,,,,,CHEMBL616057,16796,H,BAO_0000019,1,,,,,10576
1113,9,Rattus norvegicus,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat brain,B,10116.0,Brain,,,CHEMBL616058,9548,D,BAO_0000221,1,955.0,,,,10576
1114,8,,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat brain,B,,Brain,,,CHEMBL616059,10381,H,BAO_0000221,1,955.0,,,,10576
1115,8,,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat hypocampus membrane using [3H]8-OH-DPAT as radioligand,B,,,,,CHEMBL616060,13408,H,BAO_0000249,1,,,,,10576
1116,9,Rattus norvegicus,Binding affinity towards 5-hydroxytryptamine 1A receptor in the rat brain (hippocampus) using [3H]8-OH-DPAT,B,10116.0,Hippocampus,,,CHEMBL616061,13825,D,BAO_0000221,1,10000000.0,,,,10576
1117,8,,Binding affinity towards 5-hydroxytryptamine 1A receptor of rat hippocampus using [3H]-8-hydroxy-2-(di-n-propylamine) tetralin (8-OH-DPAT) as a radioligand,B,,Hippocampus,,,CHEMBL616062,11147,H,BAO_0000221,1,10000000.0,,,,10576
1118,8,,Binding affinity towards 5-hydroxytryptamine 1A receptor sites in cortical membranes using [3H]8-OH-DPAT as radioligand,B,,,,,CHEMBL616063,10552,H,BAO_0000249,1,,,,,10576
1119,8,,"Binding affinity towards 5-hydroxytryptamine 1A receptor sites, in rat striatum membranes using [3H]- sandoz 205-501 as radioligand",B,,Striatum,,,CHEMBL616064,10552,H,BAO_0000249,1,2435.0,,,,10576
1120,9,Rattus norvegicus,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of rat cortex membranes,B,10116.0,,Membranes,,CHEMBL616065,17136,D,BAO_0000249,1,,,,,10576
1121,9,Rattus norvegicus,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of rat cerebral cortex membranes,B,10116.0,,Membranes,,CHEMBL616066,5778,D,BAO_0000249,1,,,,,10576
1122,8,,Binding affinity towards rat hippocampal 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,B,,Hippocampus,,,CHEMBL616067,13481,H,BAO_0000221,1,10000000.0,,,,10576
1123,8,,Binding affinity towards rat hippocampal 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand; Not tested,B,,Hippocampus,,,CHEMBL616068,13481,H,BAO_0000221,1,10000000.0,,,,10576
1124,8,,Binding affinity against rat hippocampal 5-hydroxytryptamine 1A (5-HT1A) receptor determined using [3H]8-OH-DPAT as radioligand,B,,Hippocampus,,,CHEMBL616069,13630,H,BAO_0000221,1,10000000.0,,,,10576
1125,8,,Binding was determined on 5-hydroxytryptamine 1A receptor in rat hippocampal membranes,B,,,,,CHEMBL616070,16245,H,BAO_0000249,1,,,,,10576
1126,8,,Binding affinity was evaluated against 5-hydroxytryptamine 1A receptor on rat hippocampus using [3H]8-OH-DPAT as radioligand,B,,Hippocampus,,,CHEMBL616071,14509,H,BAO_0000221,1,10000000.0,,,,10576
1127,8,,Binding affinity against 5-hydroxytryptamine 1A receptor on rat hippocampus using [3H]8-OH-DPAT as radioligand.,B,,Hippocampus,,,CHEMBL616072,14509,H,BAO_0000221,1,10000000.0,,,,10576
1128,8,,Binding affinity was evaluated against 5-hydroxytryptamine 1A receptor on rat hippocampus using [3H]8-OH-DPAT as radioligand.; ND = Not determined,B,,Hippocampus,,,CHEMBL616073,14509,H,BAO_0000221,1,10000000.0,,,,10576
1129,8,,Binding affinity was evaluated against 5-hydroxytryptamine 1A receptor on rat hippocampus using [3H]8-OH-DPAT as radioligand; ND = Not determined,B,,Hippocampus,,,CHEMBL616074,14509,H,BAO_0000221,1,10000000.0,,,,10576
1130,8,,Binding affinity was evaluated by determining in vitro displacement of [3H]8-OH-DPAT from the central 5-hydroxytryptamine 1A receptor recognition site in rat frontal cortex homogenate.,B,,,,,CHEMBL616075,14256,H,BAO_0000019,1,,,,,10576
1131,8,,Binding affinity was evaluated by using [3H]8-OH-DPAT radioligand by using competitive binding assay on 5-hydroxytryptamine 1A receptor,B,,,,,CHEMBL616076,11139,H,BAO_0000357,1,,,,,10576
1132,9,Rattus norvegicus,Binding affinity for 5-HT1A measured by displacing [3H]8-OH-DPAT from rat cortical membranes; Not determined,B,10116.0,,,,CHEMBL616077,11047,D,BAO_0000019,1,,,,,10576
1133,9,Rattus norvegicus,Binding affinity for 5-hydroxytryptamine 1A receptor measured by displacing [3H]8-OH-DPAT from rat cortical membranes,B,10116.0,,,,CHEMBL616078,11047,D,BAO_0000019,1,,,,,10576
1134,9,Rattus norvegicus,Binding affinity for 5-hydroxytryptamine 1A receptor measured by displacing [3H]8-OH-DPAT from rat cortical membranes;ND-Not determined,B,10116.0,,,,CHEMBL616079,11047,D,BAO_0000019,1,,,,,10576
1135,9,Rattus norvegicus,Binding affinity against [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor expressed in CHO-K1 cells,B,10116.0,,,,CHEMBL616080,2395,D,BAO_0000219,1,,,,CHO-K1,10576
1136,8,,Binding affinity towards 5-hydroxytryptamine 1A receptor,B,,,,,CHEMBL616081,9699,H,BAO_0000357,1,,,,,10576
1137,9,Rattus norvegicus,Binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [125I]trans-8-OH-PIPAT in membrane homogenates of hippocampal tissue of rat brain,B,10116.0,Hippocampus,,,CHEMBL616082,12028,D,BAO_0000221,1,10000000.0,,,,10576
1138,8,,Binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in membrane homogenates of hippocampal tissue of rat brain,B,,Hippocampus,,,CHEMBL616083,12028,H,BAO_0000221,1,10000000.0,,,,10576
1139,8,,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat cerebral cortex,B,,,,,CHEMBL616084,5815,H,BAO_0000019,1,,,,,10576
1140,8,,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat frontal cortex homogenates,B,,,,,CHEMBL616085,16616,H,BAO_0000019,1,,,,,10576
1141,8,,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat cerebral cortex using [3H]-8-OH-DPAT,B,,,,,CHEMBL616086,5815,H,BAO_0000019,1,,,,,10576
1142,8,,"Binding affinity towards 5-hydroxytryptamine 1A receptor using 0.1 nM [3H]-8-OH-DPAT (8-hydroxy-2-(di-n-propylamino)tet-ralin), from rat hippocampal homogenate",B,,Hippocampus,,,CHEMBL616087,2761,H,BAO_0000221,1,10000000.0,,,,10576
1143,8,,Binding affinity was determined against 5-hydroxytryptamine 1A receptor using [3H]WB-4101,B,,,,,CHEMBL616088,13133,H,BAO_0000357,1,,,,,10576
1144,8,,Binding affinity was determined against 5-hydroxytryptamine 1A receptor was determined in male Sprague-Dawley rat brain.,B,,,,,CHEMBL616089,10444,H,BAO_0000019,1,,,,,10576
1145,9,Rattus norvegicus,Binding affinity was measured against 5-hydroxytryptamine 1A receptor by displacement of [3H]8-OH-DPAT by lysergic acid amides,B,10116.0,,,,CHEMBL616090,13278,D,BAO_0000357,1,,,,,10576
1146,8,,Binding affinity was measured on cloned rat 5-hydroxytryptamine 1A receptor which is labeled by [3H]8-OH-DPAT,B,,,,,CHEMBL616091,15874,H,BAO_0000357,1,,,,,10576
1147,8,,"Binding affinity of the compound towards 5-hydroxytryptamine 1A receptor sites, in rat striatum membranes using [3H]- sandoz 205-501 as radioligand",B,,Striatum,Membranes,,CHEMBL616092,10552,H,BAO_0000249,1,2435.0,,,,10576
1148,8,,Binding constant against 5-hydroxytryptamine 1A receptor (in vitro),B,,,,,CHEMBL616093,11130,H,BAO_0000357,1,,,,,10576
1149,8,,Binding constant against 5-hydroxytryptamine 1A receptor (in vivo),B,,,,,CHEMBL616094,11130,H,BAO_0000218,1,,In vivo,,,10576
1150,8,,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]-8-OH- -DPAT in rat brain cortex,B,,Brain,,,CHEMBL616095,14542,H,BAO_0000221,1,955.0,,,,10576
1151,9,Rattus norvegicus,Inhibition of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor,B,10116.0,,,,CHEMBL616096,13670,D,BAO_0000357,1,,,,,10576
1152,8,,Binding affinity at [3H]8-OH-DPAT-Labeled 5-hydroxytryptamine 1A receptor sites in rat brain hippocampal membranes,B,,,,,CHEMBL616097,9888,H,BAO_0000249,1,,,,,10576
1153,9,Rattus norvegicus,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of rat hippocampus membranes,B,10116.0,,Membranes,,CHEMBL616098,3678,D,BAO_0000249,1,,,,,10576
1154,8,,Compound was evaluated for in vitro binding affinity towards 5-hydroxytryptamine 1A receptor in rat hippocampus using [3H]8-OH-DPAT as radioligand,B,,Hippocampus,,,CHEMBL616099,11332,H,BAO_0000221,1,10000000.0,,,,10576
1155,8,,Compound was evaluated for in vitro binding affinity towards serotonin 5-hydroxytryptamine 1A receptor receptor in rat hippocampus using [3H]8-OH-DPAT as radioligand,B,,Hippocampus,,,CHEMBL616100,11332,H,BAO_0000221,1,10000000.0,,,,10576
1156,8,,Ability to displace [3H]-8-OH-DPAT from serotonergic 5-hydroxytryptamine 1A receptor,B,,,,,CHEMBL616101,1185,H,BAO_0000357,1,,,,,10576
1157,8,,Binding affinity at 5-hydroxytryptamine 1A receptor in rat cerebral cortex membranes by [3H]8-OH-DPAT displacement.,B,,,,,CHEMBL616102,2014,H,BAO_0000249,1,,,,,10576
1158,8,,Compound was evaluated for its ability to displace [3H]8-OH-DPAT from serotonergic 5-hydroxytryptamine 1A receptor,B,,,,,CHEMBL616103,1185,H,BAO_0000357,1,,,,,10576
1159,8,,Compound was evaluated for its binding affinity against 5-hydroxytryptamine 1A receptor from rat cerebral cortex,B,,,,,CHEMBL616104,14429,H,BAO_0000019,1,,,,,10576
1160,8,,"Binding affinity to 5-hydroxytryptamine 1A receptor (5-HT 1A receptor, serotonin receptor) from rat cortex using [3H]8-OH-DPAT as radioligand",B,,,,,CHEMBL616105,16288,H,BAO_0000019,1,,,,,10576
1161,9,Rattus norvegicus,Displacement of [3H]prazosin from rat cortex membrane 5-hydroxytryptamine 1A receptor,B,10116.0,,,,CHEMBL616106,5432,D,BAO_0000019,1,,,,,10576
1162,8,,Compound was evaluated for its binding affinity with 5-hydroxytryptamine 1A receptor using membranes prepared from rat cerebral cortex,B,,,,,CHEMBL616107,14429,H,BAO_0000019,1,,,,,10576
1163,8,,Binding affinity towards rat 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT radioligand.,B,,,,,CHEMBL616108,13672,H,BAO_0000357,1,,,,,10576
1164,8,,In vitro ability to displace [3H]8-hydroxy-2-(di-n-propylamino) tetralin binding from 5-hydroxytryptamine 1A receptor site in rat brain hippocampus,B,,Hippocampus,,,CHEMBL616109,11296,H,BAO_0000221,1,10000000.0,,,,10576
1165,8,,In vitro ability to displace [3H]8-hydroxy-2-(di-n-propylamino) tetralin binding from 5-hydroxytryptamine 1A receptor site.,B,,,,,CHEMBL616110,11296,H,BAO_0000357,1,,,,,10576
1166,8,,Binding affinity against rat 5-hydroxytryptamine 1A receptor in CHO cells.,B,,,,,CHEMBL616111,14749,H,BAO_0000219,1,,,,CHO,10576
1167,8,,Binding affinity towards 5-hydroxytryptamine 1A receptor from rat brain using [3H]-8-OH-DPAT as radioligand,B,,,,,CHEMBL616112,15086,H,BAO_0000019,1,,,,,10576
1168,8,,Compound was tested for the Binding affinity against rat hippocampal 5-hydroxytryptamine 1A receptor by Radio ligand [3H]8-OH-DPAT binding assay.,B,,Hippocampus,,,CHEMBL616113,13462,H,BAO_0000221,1,10000000.0,,,,10576
1169,8,,Compound was tested for the displacement of [3H]-8-OH- DPAT from rat brain 5-hydroxytryptamine 1A receptor,B,,,,,CHEMBL616114,15363,H,BAO_0000019,1,,,,,10576
1170,8,,Compound was tested for the displacement of [3H]-8-OH- DPAT from rat brain 5-hydroxytryptamine 1A receptor,B,,,,,CHEMBL616115,15363,H,BAO_0000019,1,,,,,10576
1171,8,,Compound was tested in vitro for binding affinity for 5-hydroxytryptamine 1A receptor,B,,,,,CHEMBL616116,10796,H,BAO_0000357,1,,,,,10576
1172,8,,Binding affinity for 5-hydroxytryptamine 1A receptor in rat brain tissue using [3H]8-OH-DPAT as radioligand,B,,Brain,,,CHEMBL615844,12816,H,BAO_0000221,1,955.0,,,,10576
1173,8,,In vitro displacement of [3H]8-OH-DPAT binding to rat hippocampal 5-hydroxytryptamine 1A receptor,B,,Hippocampus,,,CHEMBL615939,13542,H,BAO_0000221,1,10000000.0,,,,10576
1174,8,,In vitro ability to displace [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor sites of rat brain cortex.,B,,,,,CHEMBL615940,13308,H,BAO_0000019,1,,,,,10576
1175,8,,In vitro affinity at 5-hydroxytryptamine 1A receptor of rat hippocampus by [3H]8-OH-DPAT displacement.,B,,Hippocampus,,,CHEMBL615941,13541,H,BAO_0000221,1,10000000.0,,,,10576
1176,8,,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-HT1A receptor of rat hippocampus and the value ranges from 9 - 12,B,,Hippocampus,,,CHEMBL615942,10058,H,BAO_0000221,1,10000000.0,,,,10576
1177,8,,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus,B,,Hippocampus,,,CHEMBL615943,10058,H,BAO_0000221,1,10000000.0,,,,10576
1178,8,,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus (94%CI) from 12 to 17,B,,Hippocampus,,,CHEMBL615944,10058,H,BAO_0000221,1,10000000.0,,,,10576
1179,8,,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus (94%CI) from 391-841,B,,Hippocampus,,,CHEMBL615945,10058,H,BAO_0000221,1,10000000.0,,,,10576
1180,8,,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and the value ranges from 12 to 17.,B,,Hippocampus,,,CHEMBL615946,10058,H,BAO_0000221,1,10000000.0,,,,10576
1181,8,,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and the value ranges from 12 to 20.,B,,Hippocampus,,,CHEMBL615947,10058,H,BAO_0000221,1,10000000.0,,,,10576
1182,8,,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and the value ranges from 245 to 736,B,,Hippocampus,,,CHEMBL615948,10058,H,BAO_0000221,1,10000000.0,,,,10576
1183,8,,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and the value ranges from 25 - 84,B,,Hippocampus,,,CHEMBL615949,10058,H,BAO_0000221,1,10000000.0,,,,10576
1184,8,,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and the value ranges from 48 to 59,B,,Hippocampus,,,CHEMBL615950,10058,H,BAO_0000221,1,10000000.0,,,,10576
1185,8,,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and the value ranges from 3 -5,B,,Hippocampus,,,CHEMBL615951,10058,H,BAO_0000221,1,10000000.0,,,,10576
1186,8,,In vitro ability to inhibit [3H]-8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and value ranges from 15 - 31,B,,Hippocampus,,,CHEMBL615952,10058,H,BAO_0000221,1,10000000.0,,,,10576
1187,8,,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and value ranges from 27 - 42,B,,Hippocampus,,,CHEMBL615953,10058,H,BAO_0000221,1,10000000.0,,,,10576
1188,8,,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and value ranges from 6 - 13,B,,Hippocampus,,,CHEMBL615954,10058,H,BAO_0000221,1,10000000.0,,,,10576
1189,9,Rattus norvegicus,Inhibition of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus,B,10116.0,Hippocampus,,,CHEMBL615955,10058,D,BAO_0000221,1,10000000.0,,,,10576
1190,8,,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus.; ND is No Data.,B,,Hippocampus,,,CHEMBL615956,10058,H,BAO_0000221,1,10000000.0,,,,10576
1191,8,,In vitro ability to inhibit [3H]-8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus. and the value ranges from 16 - 27,B,,Hippocampus,,,CHEMBL615957,10058,H,BAO_0000221,1,10000000.0,,,,10576
1192,8,,Displacement of [3H]2-(di-N-propylamino)-8-hydroxytetralin from central 5-hydroxytryptamine 1A receptor recognition sites in rat frontal cortex homogenates.,B,,,,,CHEMBL615958,12879,H,BAO_0000019,1,,,,,10576
1193,8,,Displacement of radioligand [3H]2-(di-N-propylamino)-8-hydroxytetralin from 5-hydroxytryptamine 1A receptor in rat frontal cortex homogenate,B,,,,,CHEMBL615959,11964,H,BAO_0000019,1,,,,,10576
1194,8,,Displacement of radioligand [3H]2-(di-N-propylamino)-8-hydroxytetralin from 5-hydroxytryptamine 1A receptor in rat frontal cortex homogenate (experiment 1),B,,,,,CHEMBL615960,11964,H,BAO_0000019,1,,,,,10576
1195,8,,Displacement of radioligand [3H]2-(di-N-propylamino)-8-hydroxytetralin from 5-hydroxytryptamine 1A receptor in rat frontal cortex homogenate (experiment 2),B,,,,,CHEMBL615961,11964,H,BAO_0000019,1,,,,,10576
1196,8,,Evaluated for binding affinity towards 5-hydroxytryptamine 1A receptor in rat brain,B,,Brain,,,CHEMBL615962,9548,H,BAO_0000221,1,955.0,,,,10576
1197,8,,Evaluated for the binding affinity to hippocampus striatal membranes at 5-hydroxytryptamine 1A receptor binding site by using [3H]-8-OH- DPAT as a radioligand.,B,,,,,CHEMBL615963,9098,H,BAO_0000019,1,,,,,10576
1198,8,,Evaluated for the binding affinity to hippocampus striatal membranes at 5-hydroxytryptamine 1A receptor binding site by using [3H]-8-OH- DPAT as a radioligand; ND is no data.,B,,,,,CHEMBL615964,9098,H,BAO_0000019,1,,,,,10576
1199,8,,Evaluated for the binding affinity to hippocampus striatal membranes at 5-hydroxytryptamine 1A receptor binding site by using [3H]-8-OH- DPAT as a radioligand;ND means no data,B,,,,,CHEMBL615965,9098,H,BAO_0000019,1,,,,,10576
1200,8,,In vitro displacement of radioactively labeled ligand [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor site in CHO cells,B,,,,,CHEMBL615966,13248,H,BAO_0000219,1,,,,CHO,10576
1201,8,,In vitro ability to inhibit [3H]-8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor in rat cortical membranes,B,,,,,CHEMBL615967,3147,H,BAO_0000249,1,,,,,10576
1202,8,,In vitro binding affinity against 5-hydroxytryptamine 1A receptor of rat cerebral cortex using [3H]8-OH-DPAT as radioligand.,B,,,,,CHEMBL615968,13949,H,BAO_0000019,1,,,,,10576
1203,8,,In vitro binding affinity against 5-hydroxytryptamine 1A receptor using [3H]-8-OH-DPAT as radioligand in CHO cells (sc),B,,,,,CHEMBL615969,11883,H,BAO_0000218,1,,,,CHO,10576
1204,8,,In vitro binding affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT (agonist) as radioligand (sc),B,,,,,CHEMBL615970,11883,H,BAO_0000218,1,,,,,10576
1205,9,Rattus norvegicus,In vitro binding affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT,B,10116.0,,,,CHEMBL615971,11883,D,BAO_0000357,1,,,,,10576
1206,8,,In vitro binding affinity at 5-HT1A receptors assayed by displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampal membranes,B,,,Membranes,,CHEMBL615972,15535,H,BAO_0000249,1,,,,,10576
1207,8,,In vitro binding affinity at 5-HT1A receptor by measuring its ability to displace [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampal membranes + cortex,B,,,,,CHEMBL615973,15535,H,BAO_0000249,1,,,,,10576
1208,8,,In vitro binding affinity at 5-HT1A receptor by measuring its ability to displace [3H]-8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampal membranes+cortex,B,,,,,CHEMBL615974,15535,H,BAO_0000249,1,,,,,10576
1209,9,Homo sapiens,Displacement of [3H]8-OH-DPAT from human 5-hydroxytryptamine 1A receptor expressed in CHO cells,B,9606.0,,,,CHEMBL615975,16372,D,BAO_0000219,1,,,,CHO,51
1210,8,,In vitro binding affinity for 5-hydroxytryptamine 1A receptor in rat hippocampal membranes by [125I]-labeled agonist displacement.,B,,,,,CHEMBL615976,14608,H,BAO_0000249,1,,,,,10576
1211,9,Rattus norvegicus,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of rat hippocampus,B,10116.0,Hippocampus,,,CHEMBL872106,4795,D,BAO_0000221,1,10000000.0,,,,10576
1212,8,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand,B,,,,,CHEMBL615977,13863,H,BAO_0000357,1,,,,,10576
1213,8,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=100-230,B,,,,,CHEMBL615978,13863,H,BAO_0000357,1,,,,,10576
1214,8,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=12-14,B,,,,,CHEMBL616166,13863,H,BAO_0000357,1,,,,,10576
1215,8,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=16-20,B,,,,,CHEMBL616167,13863,H,BAO_0000357,1,,,,,10576
1216,8,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=160-430,B,,,,,CHEMBL616168,13863,H,BAO_0000357,1,,,,,10576
1217,8,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=174-224,B,,,,,CHEMBL616169,13863,H,BAO_0000357,1,,,,,10576
1218,8,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=184-503,B,,,,,CHEMBL616170,13863,H,BAO_0000357,1,,,,,10576
1219,8,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=19-23,B,,,,,CHEMBL616171,13863,H,BAO_0000357,1,,,,,10576
1220,8,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]-8-OH-DPAT as radioligand; range=2.2-3.2,B,,,,,CHEMBL616172,13863,H,BAO_0000357,1,,,,,10576
1221,8,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=2.7-3.6,B,,,,,CHEMBL616173,13863,H,BAO_0000357,1,,,,,10576
1222,8,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=20-23,B,,,,,CHEMBL616174,13863,H,BAO_0000357,1,,,,,10576
1223,8,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]-8-OH-DPAT as radioligand; range=21-28,B,,,,,CHEMBL616175,13863,H,BAO_0000357,1,,,,,10576
1224,8,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=240-760,B,,,,,CHEMBL616176,13863,H,BAO_0000357,1,,,,,10576
1225,8,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]-8-OH-DPAT as radioligand; range=39-87,B,,,,,CHEMBL616177,13863,H,BAO_0000357,1,,,,,10576
1226,8,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=4.6-5.2,B,,,,,CHEMBL616178,13863,H,BAO_0000357,1,,,,,10576
1227,8,,Inhibitory activity tested in vitro at 5-hydroxytryptamine 1A receptor binding site in rat,B,,,,,CHEMBL616179,9742,H,BAO_0000019,1,,,,,10576
1228,8,,Inhibitory concentration against 5-hydroxytryptamine 1A receptor,B,,,,,CHEMBL616180,12073,H,BAO_0000357,1,,,,,10576
1229,8,,Inhibitory concentration against binding of 5-hydroxytryptamine 1A receptor from striata of male Wistar rats by displacement of [3H]8-OH-DPAT,B,,,,,CHEMBL616181,4101,H,BAO_0000357,1,,,,,10576
1230,8,,Inhibitory concentration against radioligand [3H]hydroxy-2-(di-n-propylamino)-tetralin binding to 5-hydroxytryptamine 1A receptor in rat,B,,,,,CHEMBL616182,15360,H,BAO_0000019,1,,,,,10576
1231,8,,Inhibitory concentration against radioligand [3H]8-OH-DPAT binding to rat hippocampal 5-hydroxytryptamine 1A receptor,B,,Hippocampus,,,CHEMBL616183,11576,H,BAO_0000221,1,10000000.0,,,,10576
1232,8,,Inhibition of the 5-hydroxytryptamine 1A receptor in rat dorsal raphe,B,,,,,CHEMBL615874,5834,H,BAO_0000019,1,,,,,10576
1233,9,Rattus norvegicus,Inhibitory concentration against [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor expressed in CHO-K1 cells,B,10116.0,,,,CHEMBL615875,2395,D,BAO_0000219,1,,,,CHO-K1,10576
1234,8,,Tested in vitro for receptor binding affinity to 5-hydroxytryptamine 1A receptor in rat cortex using [3H]OH-DPAT radioligand,B,,,,,CHEMBL615876,1375,H,BAO_0000019,1,,,,,10576
1235,8,,Tested in vitro for receptor binding affinity to 5-hydroxytryptamine 1A receptor in rat cortex using [3H]OH-DPAT radioligand; NT means not tested,B,,,,,CHEMBL615877,1375,H,BAO_0000019,1,,,,,10576
1236,8,,The compound was evaluated for the ability to displace [3H]- 8-OH -DPAT from 5-hydroxytryptamine 1A receptor ( striata of male wistar rats),B,,,,,CHEMBL615878,3967,H,BAO_0000357,1,,,,,10576
1237,8,,Binding affinity towards 5-hydroxytryptamine 1A receptor binding site using [3H]8-OH-DPAT. ,B,,,,,CHEMBL615879,12884,H,BAO_0000357,1,,,,,10576
1238,8,,Binding affinity towards 5-hydroxytryptamine 1A receptor using receptor binding assay,B,,,,,CHEMBL615880,2343,H,BAO_0000357,1,,,,,10576
1239,8,,"The compound was tested in vitro for inhibitory activity against 5-HT1A receptor in rats, using [3H]8-OH-DPAT as radioligand",B,,,,,CHEMBL615881,11511,H,BAO_0000019,1,,,,,10576
1240,9,Rattus norvegicus,"Inhibitory activity against 5-hydroxytryptamine 1A receptor in rats, using [3H]8-OH-DPAT as radioligand",B,10116.0,,,,CHEMBL615882,11511,D,BAO_0000019,1,,,,,10576
1241,8,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat,F,,,,,CHEMBL615883,16394,H,BAO_0000218,1,,In vivo,,,10576
1242,8,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.10-6.20),F,,,,,CHEMBL615884,16394,H,BAO_0000218,1,,In vivo,,,10576
1243,8,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.20-1.60),F,,,,,CHEMBL615885,16394,H,BAO_0000218,1,,In vivo,,,10576
1244,8,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.20-1.80),F,,,,,CHEMBL615886,16394,H,BAO_0000218,1,,In vivo,,,10576
1245,8,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.37-4.27),F,,,,,CHEMBL615887,16394,H,BAO_0000218,1,,In vivo,,,10576
1246,8,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.40-2.70),F,,,,,CHEMBL615888,16394,H,BAO_0000218,1,,In vivo,,,10576
1247,8,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.40-4),F,,,,,CHEMBL615889,16394,H,BAO_0000218,1,,In vivo,,,10576
1248,8,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.45-4.51),F,,,,,CHEMBL615890,16394,H,BAO_0000218,1,,In vivo,,,10576
1249,8,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.50-5.30),F,,,,,CHEMBL615891,16394,H,BAO_0000218,1,,In vivo,,,10576
1250,8,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.60-1.60),F,,,,,CHEMBL615892,16394,H,BAO_0000218,1,,In vivo,,,10576
1251,8,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.72-2.87),F,,,,,CHEMBL615893,16394,H,BAO_0000218,1,,In vivo,,,10576
1252,8,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.80-5.80),F,,,,,CHEMBL615894,16394,H,BAO_0000218,1,,In vivo,,,10576
1253,8,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (1.50-16.5),F,,,,,CHEMBL615895,16394,H,BAO_0000218,1,,In vivo,,,10576
1254,8,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (2.20-30.5),F,,,,,CHEMBL615896,16394,H,BAO_0000218,1,,In vivo,,,10576
1255,8,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges is not computable,F,,,,,CHEMBL615897,16394,H,BAO_0000218,1,,In vivo,,,10576
1256,9,Rattus norvegicus,"Percent increase of R(+)-8-OH-DPAT stimulated [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor in isolated rat hippocampal membranes",F,10116.0,,Membranes,,CHEMBL615898,16616,D,BAO_0000249,1,,,,,10576
1257,8,,% inhibition towards 5-HT1A receptor from rat hippocampal membranes,B,,,,,CHEMBL615899,16796,H,BAO_0000019,1,,,,,10576
1258,8,,% inhibition towards 5-hydroxytryptamine 1A receptor from rat hippocampal membranes,B,,,,,CHEMBL616291,16796,H,BAO_0000019,1,,,,,10576
1259,8,,Tested in vitro for % inhibition against (serotonin)5-HT 1A receptor.,B,,,,,CHEMBL616292,15629,H,BAO_0000357,1,,,,,10576
1260,8,,"Ability to inhibit 5-HT sensitive,forskolin-stimulated adenylyl cyclase(FSC) activity in rat hippocampal membranes mediated through 5-hydroxytryptamine 1A receptor",F,,,,,CHEMBL616293,13241,H,BAO_0000249,1,,,,,10576
1261,8,,Measurement of binding affinity by displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampus,B,,Hippocampus,,,CHEMBL616294,12073,H,BAO_0000221,1,10000000.0,,,,10576
1262,8,,Compound at 10E-5 M was tested in vitro for the inhibition of radioligand [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor in rat hippocampal membrane,B,,Hippocampus,,,CHEMBL616295,14286,H,BAO_0000249,1,10000000.0,,,,10576
1263,8,,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]-8-OH- -DPAT in rat brain cortex at 10 uM,B,,Brain,,,CHEMBL616296,14542,H,BAO_0000221,1,955.0,,,,10576
1264,8,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.1 uM + 10 uM 5-HT.,F,,,,,CHEMBL616297,13630,H,BAO_0000019,1,,,,,10576
1265,8,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0+ 1 uM 5-HT.,F,,,,,CHEMBL616605,13630,H,BAO_0000019,1,,,,,10576
1266,8,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.01 uM+ 1 uM 5-HT.,F,,,,,CHEMBL616606,13630,H,BAO_0000019,1,,,,,10576
1267,8,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.05 uM,F,,,,,CHEMBL616607,13630,H,BAO_0000019,1,,,,,10576
1268,8,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.05 uM,F,,,,,CHEMBL616608,13630,H,BAO_0000019,1,,,,,10576
1269,8,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.05 uM+ 1 uM 5-HT.,F,,,,,CHEMBL616609,13630,H,BAO_0000019,1,,,,,10576
1270,9,Rattus norvegicus,Effect against 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at 0.1 uM dose,F,10116.0,,,,CHEMBL616610,13630,D,BAO_0000019,1,,,,,10576
1271,8,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.1 uM + 10 uM 5-HT.,F,,,,,CHEMBL616611,13630,H,BAO_0000019,1,,,,,10576
1272,8,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.1 uM + 1 uM 5-HT.,F,,,,,CHEMBL616612,13630,H,BAO_0000019,1,,,,,10576
1273,8,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.1 uM + 0.1 uM 5-HT.,F,,,,,CHEMBL616613,13630,H,BAO_0000019,1,,,,,10576
1274,8,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 10 uM,F,,,,,CHEMBL616614,13630,H,BAO_0000019,1,,,,,10576
1275,8,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 10 uM+ 10 uM 5-HT.,F,,,,,CHEMBL616615,13630,H,BAO_0000019,1,,,,,10576
1276,8,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM,F,,,,,CHEMBL616616,13630,H,BAO_0000019,1,,,,,10576
1277,8,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 0.1 uM 5-HT.,F,,,,,CHEMBL616617,13630,H,BAO_0000019,1,,,,,10576
1278,8,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 10 uM 5-HT.,F,,,,,CHEMBL616618,13630,H,BAO_0000019,1,,,,,10576
1279,8,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 1 uM 5-HT.,F,,,,,CHEMBL616619,13630,H,BAO_0000019,1,,,,,10576
1280,8,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 3 uM 5-HT.,F,,,,,CHEMBL616620,13630,H,BAO_0000019,1,,,,,10576
1281,8,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 50 uM 5-HT.,F,,,,,CHEMBL616621,13630,H,BAO_0000019,1,,,,,10576
1282,8,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 30 uM,F,,,,,CHEMBL616622,13630,H,BAO_0000019,1,,,,,10576
1283,8,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 50 uM,F,,,,,CHEMBL616146,13630,H,BAO_0000019,1,,,,,10576
1284,8,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 50 uM+ 50 uM 5-HT.,F,,,,,CHEMBL832873,13630,H,BAO_0000019,1,,,,,10576
1285,8,,Effect on 5-hydroxytryptamine 1A receptor-mediated inhibition of VIP-stimulated cAMP production at dose of 0.1 uM,F,,,,,CHEMBL616147,13630,H,BAO_0000019,1,,,,,10576
1286,8,,Effect on 5-hydroxytryptamine 1A receptor-mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 10 uM 5-HT.,F,,,,,CHEMBL872872,13630,H,BAO_0000019,1,,,,,10576
1287,8,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM,F,,,,,CHEMBL616148,13630,H,BAO_0000019,1,,,,,10576
1288,8,,In vitro inhibition of [3H]spiperone binding to 5-hydroxytryptamine 1A receptor from rat hippocampal tissue,B,,Hippocampus,,,CHEMBL616149,9783,H,BAO_0000221,1,10000000.0,,,,10576
1289,8,,In vitro inhibition of [3H]spiperone binding to 5-hydroxytryptamine 1A receptor from rat hippocampal tissue at 1 uM,B,,Hippocampus,,,CHEMBL616150,9783,H,BAO_0000221,1,10000000.0,,,,10576
1290,9,Rattus norvegicus,Inhibition of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor in rat hippocampal membranes at 10e-7 M,B,10116.0,,Membranes,,CHEMBL616151,14331,D,BAO_0000249,1,,,,,10576
1291,8,,Inhibitory activity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue at 1 uM,B,,Hippocampus,,,CHEMBL872873,15260,H,BAO_0000221,1,10000000.0,,,,10576
1292,8,,Inhibitory activity against rat hippocampal tissue 5-hydroxytryptamine 1A receptor at 0.1 uM concentration,B,,Hippocampus,,,CHEMBL616670,15260,H,BAO_0000221,1,10000000.0,,,,10576
1293,8,,Inhibitory activity against rat hippocampal tissue 5-hydroxytryptamine 1A receptor at 1 uM concentration,B,,Hippocampus,,,CHEMBL616671,15260,H,BAO_0000221,1,10000000.0,,,,10576
1294,9,Rattus norvegicus,"Percent inhibition of (+)-8-OH-DPAT stimulated [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor in hippocampal membranes",F,10116.0,,,,CHEMBL884861,16616,D,BAO_0000249,1,,,,,10576
1295,8,,Tested in vitro for % inhibition against (serotonin)5-HT 1A receptor,B,,,,,CHEMBL616672,15629,H,BAO_0000357,1,,,,,10576
1296,8,,The compound was tested binding affinity against 5-hydroxytryptamine 1A receptor from rat brain using [3H]8-OH-DPAT as radioligand at 10e-6 M.,B,,,,,CHEMBL616673,15086,H,BAO_0000019,1,,,,,10576
1297,8,,Antagonistic activity against 5-hydroxytryptamine 1A receptor in rat cerebral cortex using [3H]8-OH-DPAT as radioligand.,F,,,,,CHEMBL616674,5717,H,BAO_0000019,1,,,,,10576
1298,8,,Binding affinity against the site labelled by the 5-hydroxytryptamine 1A receptor agonist [3H]- 8-OH-DPAT,B,,,,,CHEMBL616675,12652,H,BAO_0000357,1,,,,,10576
1299,8,,In vitro binding affinity for 5-hydroxytryptamine 1A receptor was determined by measuring specific inhibition of [125I]-binding to rat hippocampal membrane preparations,B,,Hippocampus,,,CHEMBL616676,14608,H,BAO_0000221,1,10000000.0,,,,10576
1300,8,,Inhibition of binding of [125I]-8-OH-PIPAT ligand to 5-hydroxytryptamine 1A receptor of rat hippocampal homogenates,B,,Hippocampus,,,CHEMBL616677,12306,H,BAO_0000221,1,10000000.0,,,,10576
1301,8,,The binding of [125I]MPPI ligand to 5-hydroxytryptamine 1A receptor of rat hippocampal homogenates,B,,Hippocampus,,,CHEMBL616678,12306,H,BAO_0000221,1,10000000.0,,,,10576
1302,9,Rattus norvegicus,Ability to displace [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor,B,10116.0,,,,CHEMBL616679,15247,D,BAO_0000357,1,,,,,10576
1303,8,,Ability to bind to central serotonin 5-hydroxytryptamine 1A receptor in vitro in hippocampus of the rat brain using [3H]8-OH-DPAT radioligand,B,,Hippocampus,,,CHEMBL616680,17529,H,BAO_0000221,1,10000000.0,,,,10576
1304,8,,Ability to displace [3H]- -OH-DPAT bound to 5-hydroxytryptamine 1A receptor in rat hippocampus,B,,Hippocampus,,,CHEMBL616681,14826,H,BAO_0000221,1,10000000.0,,,,10576
1305,8,,Ability to displace [3H]- -(OH)-DPAT bound to 5-hydroxytryptamine 1A receptor in rat hippocampus,B,,Hippocampus,,,CHEMBL616682,14826,H,BAO_0000221,1,10000000.0,,,,10576
1306,8,,Ability to displace [3H]8-OH-DPAT binding to rat hippocampal 5-hydroxytryptamine 1A receptor,B,,Hippocampus,,,CHEMBL616683,13241,H,BAO_0000221,1,10000000.0,,,,10576
1307,8,,Ability to displace [3H]-8-OH-DPAT from rat hippocampal homogenate 5-hydroxytryptamine 1A receptor,B,,Hippocampus,,,CHEMBL616684,14093,H,BAO_0000221,1,10000000.0,,,,10576
1308,8,,Ability to displace [3H]-8-OH-DPAT from rat hippocampal homogenate 5-hydroxytryptamine 1A receptor; Not tested,B,,Hippocampus,,,CHEMBL616685,14093,H,BAO_0000221,1,10000000.0,,,,10576
1309,8,,Affinity at [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor in rat brain homogenate was determined,B,,Brain,,,CHEMBL616686,14442,H,BAO_0000221,1,955.0,,,,10576
1310,8,,Affinity for 5-hydroxytryptamine 1A receptor site,B,,,,,CHEMBL616687,9919,H,BAO_0000357,1,,,,,10576
1311,8,,Affinity for 5-hydroxytryptamine 1A receptor site,B,,,,,CHEMBL616688,9919,H,BAO_0000357,1,,,,,10576
1312,8,,Affinity in displacing [3H]8-OH-DPAT from rat hippocampal 5-HT1A receptor.,B,,Hippocampus,,,CHEMBL616689,11440,H,BAO_0000221,1,10000000.0,,,,10576
1313,8,,Affinity on 5-hydroxytryptamine 1A receptor labeled by [3H]8-OH-DPAT,B,,,,,CHEMBL616690,11257,H,BAO_0000357,1,,,,,10576
1314,8,,Binding affinity against 5-hydroxytryptamine 1A receptor using [3H]-8-OH-DPAT as radioligand,B,,,,,CHEMBL616691,10330,H,BAO_0000357,1,,,,,10576
1315,9,Rattus norvegicus,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of rat hippocampus mambranes,B,10116.0,Hippocampus,,,CHEMBL616692,17331,D,BAO_0000221,1,10000000.0,,,,10576
1316,8,,Binding affinity against 5-hydroxytryptamine 1A receptor by displacing [3H]8-OH-DPAT radioligand in rat cortex membrane,B,,,,,CHEMBL616693,16567,H,BAO_0000249,1,,,,,10576
1317,9,Rattus norvegicus,"Binding affinity against 5-hydroxytryptamine 1A receptor in homogenated rat brain tissue, using by [3H]8-OH-DPAT as radioligand",B,10116.0,,,,CHEMBL616694,12058,D,BAO_0000019,1,,,,,10576
1318,8,,Binding affinity against 5-hydroxytryptamine 1A receptor in rat hippocampal tissue,B,,Hippocampus,,,CHEMBL616695,9699,H,BAO_0000221,1,10000000.0,,,,10576
1319,8,,Binding affinity against 5-hydroxytryptamine 1A receptor of rat was determined using [3H]8-OH-DPAT in binding assay,B,,,,,CHEMBL616696,9547,H,BAO_0000357,1,,,,,10576
1320,8,,Binding affinity against 5-hydroxytryptamine 1A receptor using [3H]DOB as radioligand,B,,,,,CHEMBL616697,10330,H,BAO_0000357,1,,,,,10576
1321,8,,Binding affinity against rat 5-hydroxytryptamine 1A receptor,B,,,,,CHEMBL616698,14331,H,BAO_0000357,1,,,,,10576
1322,9,Rattus norvegicus,Binding affinity against rat brain 5-hydroxytryptamine 1A receptor,B,10116.0,,,,CHEMBL616949,14060,D,BAO_0000019,1,,,,,10576
1323,8,,Binding affinity against the 5-hydroxytryptamine 1A receptor labelled with [3H]8-OH-DPAT in rat hippocampal homogenates,B,,Hippocampus,,,CHEMBL616950,14744,H,BAO_0000221,1,10000000.0,,,,10576
1324,8,,Binding affinity against serotonin 5-hydroxytryptamine 1A receptor using radioligand [3H]8-OH-DPAT binding assay,B,,,,,CHEMBL832875,13506,H,BAO_0000357,1,,,,,10576
1325,8,,Binding affinity at 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in rat brain.,B,,Brain,,,CHEMBL616951,10862,H,BAO_0000221,1,955.0,,,,10576
1326,8,,Binding affinity at 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in rat brain.,B,,Brain,,,CHEMBL616952,10862,H,BAO_0000221,1,955.0,,,,10576
1327,8,,Binding affinity at rat 5-hydroxytryptamine 1A receptor by [3H]WB-4101 displacement.,B,,,,,CHEMBL616953,10062,H,BAO_0000357,1,,,,,10576
1328,8,,Binding affinity for 5-hydroxytryptamine 1A receptor by use of [3H]8-OH-DPAT in male rat,B,,,,,CHEMBL616954,12073,H,BAO_0000357,1,,,,,10576
1329,8,,GTPgammaS radioligand binding assay,B,,,,,CHEMBL616955,14875,H,BAO_0000357,1,,,,,106
1330,8,,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor; Not determined,B,,,,,CHEMBL616956,2391,H,BAO_0000357,1,,,,,106
1331,8,,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor; Partial agonist,F,,,,,CHEMBL616957,2391,H,BAO_0000019,1,,,,,106
1332,8,,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor; Slient antagonist,F,,,,,CHEMBL616958,2391,H,BAO_0000019,1,,,,,106
1333,8,,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor,B,,,,,CHEMBL616959,2391,H,BAO_0000357,1,,,,,106
1334,8,,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor; Not determined,B,,,,,CHEMBL616960,2391,H,BAO_0000357,1,,,,,106
1335,8,,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor; silent antagonist,F,,,,,CHEMBL616961,2391,H,BAO_0000019,1,,,,,106
1336,8,,Ability to displace [3H]5-CT (1.5 nM) from HeLa cells of human 5-hydroxytryptamine 1B receptor,B,,,,,CHEMBL616962,17211,H,BAO_0000219,1,,,,HeLa,106
1337,8,,Ability to displace [3H]5-CT (1.5 nM) from HeLa cells of human 5-hydroxytryptamine 1B receptor receptor,B,,,,,CHEMBL616963,17211,H,BAO_0000219,1,,,,HeLa,106
1338,9,Homo sapiens,Affinity towards human 5-hydroxytryptamine 1B serotonin receptor,B,9606.0,,,,CHEMBL616524,6491,D,BAO_0000357,1,,,,,106
1339,8,,Binding affinity against 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-HT as radioligand,B,,,,,CHEMBL616525,16190,H,BAO_0000219,1,,,,CHO,106
1340,8,,Binding affinity for 5-hydroxytryptamine 1B receptor in C6-glial transfected cell type using [3H]5-CT as radioligand,B,,,,,CHEMBL872908,14165,H,BAO_0000019,1,,,,,106
1341,8,,Binding affinity for 5-hydroxytryptamine 1B receptor in C6-glial transfected cell type using [3H]GR-125743 as radioligand,B,,,,,CHEMBL616526,14165,H,BAO_0000019,1,,,,,106
1342,9,Homo sapiens,Binding affinity to cloned human 5-hydroxytryptamine 1B receptor,B,9606.0,,,,CHEMBL616527,4234,D,BAO_0000357,1,,,,,106
1343,8,,Binding affinity towards human 5-hydroxytryptamine 1B receptor in L-M(tk-) cells using [3H]GR-125743 as radioligand,B,,,,,CHEMBL616528,6328,H,BAO_0000219,1,,,,,106
1344,8,,Binding affinity for recombinant human 5-hydroxytryptamine 1B receptor using [3H]5-HT as radioligand.,B,,,,,CHEMBL616529,14770,H,BAO_0000357,1,,,,,106
1345,8,,Binding affinity was evaluated at human recombinant 5-hydroxytryptamine 1B receptor using [3H]5-CT as radioligand,B,,,,,CHEMBL616530,2598,H,BAO_0000357,1,,,,,106
1346,8,,Binding affinity was evaluated at the cloned human 5-hydroxytryptamine 1B receptor,B,,,,,CHEMBL616531,6897,H,BAO_0000357,1,,,,,106
1347,8,,Binding affinity was evaluated at the cloned human 5-hydroxytryptamine 1B receptor,B,,,,,CHEMBL616532,6897,H,BAO_0000357,1,,,,,106
1348,8,,Binding affinity towards 5-hydroxytryptamine 1B receptor,B,,,,,CHEMBL616533,6013,H,BAO_0000357,1,,,,,106
1349,8,,Binding affinity towards cloned human 5-hydroxytryptamine 1B receptor,B,,,,,CHEMBL616534,5843,H,BAO_0000357,1,,,,,106
1350,8,,Binding affinity towards human 5-hydroxytryptamine 1B receptor using [3H]5-HT trifluoroacetate as radioligand,B,,,,,CHEMBL616535,14454,H,BAO_0000357,1,,,,,106
1351,8,,Binding affinity towards human 5-hydroxytryptamine 1B receptor using [3H]5-HT radioligand,B,,,,,CHEMBL616536,16209,H,BAO_0000357,1,,,,,106
1352,8,,Compound was evaluated for its binding affinity for human 5-hydroxytryptamine 1B receptor,B,,,,,CHEMBL616537,3935,H,BAO_0000357,1,,,,,106
1353,8,,Ability to inhibit the forskolin-stimulated c-AMP formation mediated by human 5-hydroxytryptamine 1B receptor in CHO-K1 cells,F,,,,,CHEMBL616538,13729,H,BAO_0000219,1,,,,CHO-K1,106
1354,8,,Agonist activity to the human recombinant 5-hydroxytryptamine 1B receptor,F,,,,,CHEMBL616539,14251,H,BAO_0000019,1,,,,,106
1355,8,,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1B receptor,B,,,,,CHEMBL616540,17085,H,BAO_0000019,1,,,,,106
1356,8,,In vitro binding affinity was determined towards cloned human 5-hydroxytryptamine 1B receptor using [3H]5-CT radioligand,B,,,,,CHEMBL616429,3025,H,BAO_0000357,1,,,,,106
1357,8,,In vitro receptor binding affinity for cloned human 5-hydroxytryptamine 1B receptor,B,,,,,CHEMBL616430,15315,H,BAO_0000357,1,,,,,106
1358,9,Homo sapiens,Receptor binding affinity for cloned human 5-hydroxytryptamine 1B receptor in Cos-7 cells,B,9606.0,,,,CHEMBL616431,14214,D,BAO_0000219,1,,,,,106
1359,9,Homo sapiens,Binding affinity towards cloned human 5-hydroxytryptamine 1B receptor,B,9606.0,,,,CHEMBL616432,3804,D,BAO_0000357,1,,,,,106
1360,9,Homo sapiens,Affinity for 5-hydroxytryptamine 1B receptor subtype,B,9606.0,,,,CHEMBL616433,2391,D,BAO_0000357,1,,,,,106
1361,9,Homo sapiens,Binding affinity for human 5-hydroxytryptamine 1B receptor,B,9606.0,,,,CHEMBL616434,4175,D,BAO_0000357,1,,,,,106
1362,8,,Binding affinity against cloned human 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-CT as radioligand; Not determined,B,,,,,CHEMBL616435,17296,H,BAO_0000219,1,,,,CHO,106
1363,8,,In vitro binding affinity was determined by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1B receptor; ND means not determined,B,,,,,CHEMBL616436,17085,H,BAO_0000019,1,,,,,106
1364,8,,Ability to displace [3H]5-CT (1.5 nM) from HeLa cells of human 5-hydroxytryptamine 1B receptor; NT denotes not tested,B,,,,,CHEMBL616437,17211,H,BAO_0000219,1,,,,HeLa,106
1365,8,,Ability to displace [3H]5-CT (1.5 nM) from HeLa cells of human 5-hydroxytryptamine 1B receptor; NT=not tested,B,,,,,CHEMBL616438,17211,H,BAO_0000219,1,,,,HeLa,106
1366,8,,Ability to displace [3H]-5-CT (1.5 nM) from HeLa cells of human 5-hydroxytryptamine 1B receptor; NT denotes not tested,B,,,,,CHEMBL616439,17211,H,BAO_0000219,1,,,,HeLa,106
1367,9,Homo sapiens,Binding activity against human 5-hydroxytryptamine 1B receptor; NT means not tested,B,9606.0,,,,CHEMBL616440,15926,D,BAO_0000357,1,,,,,106
1368,8,,Binding affinity in CHO-K1 cells transfected with human recombinant 5-hydroxytryptamine 1B receptor; not tested,B,,,,,CHEMBL616441,16312,H,BAO_0000219,1,,,,CHO-K1,106
1369,8,,Selectivity ratio against cloned human 5-HT1B receptor to that of h5-HT1D receptor,B,,,,,CHEMBL616442,5843,H,BAO_0000357,1,,,,,106
1370,8,,Selectivity ratio against cloned human 5-hydroxytryptamine 1B receptor to that of human 5-hydroxytryptamine 1D receptor,B,,,,,CHEMBL616443,5843,H,BAO_0000357,1,,,,,106
1371,8,,Binding affinity in CHO-K1 cells transfected with human recombinant 5-hydroxytryptamine 1B receptor,B,,,,,CHEMBL616444,16312,H,BAO_0000219,1,,,,CHO-K1,106
1372,9,Homo sapiens,Binding activity against human 5-hydroxytryptamine 1B receptor,B,9606.0,,,,CHEMBL616445,15926,D,BAO_0000357,1,,,,,106
1373,9,Homo sapiens,Binding activity against human 5-hydroxytryptamine 1B receptor,B,9606.0,,,,CHEMBL616446,15926,D,BAO_0000357,1,,,,,106
1374,9,Homo sapiens,Binding affinity to human cloned 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-HT as radioligand,B,9606.0,,,,CHEMBL616447,4540,D,BAO_0000219,1,,,,CHO,106
1375,8,,Binding affinity towards cloned human 5-hydroxytryptamine 1B receptor was determined,B,,,,,CHEMBL616448,6166,H,BAO_0000357,1,,,,,106
1376,8,,Binding affinity against cloned human 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-CT as radioligand,B,,,,,CHEMBL616449,17296,H,BAO_0000219,1,,,,CHO,106
1377,8,,Binding affinity against human 5-hydroxytryptamine 1B receptor cloned receptors in CHO cells,B,,,,,CHEMBL616450,17296,H,BAO_0000219,1,,,,CHO,106
1378,8,,Binding affinity against human 5-hydroxytryptamine 1B receptor cloned receptors in CHO cells using [3H]5-CT as radioligand,B,,,,,CHEMBL857974,17296,H,BAO_0000219,1,,,,CHO,106
1379,8,,Binding affinity towards 5-hydroxytryptamine 1B (human cloned receptor) in CHO cells using [3H]5-HT as radioligand,B,,,,,CHEMBL616451,15779,H,BAO_0000219,1,,,,CHO,106
1380,8,,Binding affinity towards 5-hydroxytryptamine 1B receptor (human cloned receptor) in CHO cells using [3H]5-HT as radioligand,B,,,,,CHEMBL616452,15779,H,BAO_0000219,1,,,,CHO,106
1381,8,,Binding affinity towards 5-hydroxytryptamine 1B receptor (human cloned receptor) in CHO cells using [3H]5-HT as radioligand;ND means no data.,B,,,,,CHEMBL616453,15779,H,BAO_0000219,1,,,,CHO,106
1382,8,,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-HT as the radioligand,B,,,,,CHEMBL616454,4199,H,BAO_0000219,1,,,,CHO,106
1383,9,Homo sapiens,Binding affinity for human 5-hydroxytryptamine 1B receptor,B,9606.0,,,,CHEMBL616455,14875,D,BAO_0000357,1,,,,,106
1384,8,,Compound was tested for its binding affinity against human cloned 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-HT,B,,,,,CHEMBL616456,15146,H,BAO_0000219,1,,,,CHO,106
1385,8,,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 1B receptor in CHO using [3H]5-HT as a radioligand,B,,,,,CHEMBL616457,5213,H,BAO_0000357,1,,,,,106
1386,8,,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-HT,B,,,,,CHEMBL616458,14818,H,BAO_0000219,1,,,,CHO,106
1387,8,,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 1B receptor in CHO cells, using [3H]5-HT as radioligand",B,,,,,CHEMBL616459,4829,H,BAO_0000219,1,,,,CHO,106
1388,8,,Adenyl cyclase activity was expressed as percent forskolin response against 5-hydroxytryptamine 1B receptor at concentration 1 uM,F,,,,,CHEMBL616460,14454,H,BAO_0000019,1,,,,,106
1389,8,,Adenyl cyclase activity was expressed as percent forskolin response against 5-hydroxytryptamine 1B receptor at concentration 10 uM,F,,,,,CHEMBL616461,14454,H,BAO_0000019,1,,,,,106
1390,8,,"Effect of compound on [35S]GTP-gamma-S, radioligand binding CHO cells expressing human 5-hydroxytryptamine 1B receptor",F,,,,,CHEMBL616462,14875,H,BAO_0000219,1,,,,CHO,106
1391,8,,"Effect of compound on [35S]GTP-gamma-S, radioligand binding in CHO cells expressing human 5-hydroxytryptamine 1B receptor",F,,,,,CHEMBL616463,14875,H,BAO_0000219,1,,,,CHO,106
1392,8,,"Compound was tested for maximum stimulation of [35S]GTP-gamma-S, binding expressed relative to the maximal effect produced by 5-HT.",F,,,,,CHEMBL616464,15250,H,BAO_0000019,1,,,,,105
1393,8,,Compound was tested for the displacement of [3H]5-HT binding to cloned 5-hydroxytryptamine 1D receptor stably expressed in CHO cells.,B,,,,,CHEMBL616465,15250,H,BAO_0000219,1,,,,CHO,105
1394,8,,The compound was tested for binding affinity against 5-hydroxytryptamine 1B receptor,B,,,,,CHEMBL832874,15086,H,BAO_0000357,1,,,,,17105
1395,8,Oryctolagus cuniculus,5-hydroxytryptamine 1B receptor agonist potency determined in rabbit saphenous vein contraction model,F,9986.0,,,,CHEMBL616184,3025,H,BAO_0000019,1,,,,,106
1396,8,Oryctolagus cuniculus,The vascular 5-hydroxytryptamine 1B receptor affinity was assessed using ring preparations of rabbit saphenous vein (RbSV).,B,9986.0,,,,CHEMBL616185,14998,H,BAO_0000019,1,,,,,106
1397,8,Oryctolagus cuniculus,"Binding affinity against vascular 5-hydroxytryptamine 1B receptor, measured using ring preparations of rabbit saphenous vein (RbSV)",B,9986.0,,,,CHEMBL616186,14998,H,BAO_0000019,1,,,,,106
1398,8,Oryctolagus cuniculus,The vascular 5-hydroxytryptamine 1B receptor affinity was assessed using ring preparations of rabbit saphenous vein(RbSV).,B,9986.0,,,,CHEMBL616187,14998,H,BAO_0000019,1,,,,,106
1399,8,,Binding affinity towards 5-hydroxytryptamine 1B receptor was measured using [3H]5-HT as radioligand,B,,,,,CHEMBL616188,13969,H,BAO_0000357,1,,,,,10577
1400,9,,Binding affinity for 5-hydroxytryptamine 1B receptor,B,,,,,CHEMBL873475,13392,D,BAO_0000357,1,,,,,10577
1401,9,Rattus norvegicus,Inhibition of [3H]5-HT binding to 5-hydroxytryptamine 1B receptor in rat striatum; Less active,B,10116.0,Striatum,,,CHEMBL616189,3651,D,BAO_0000019,1,2435.0,,,,10577
1402,8,,Concentration necessary to achieve half maximal inhibition of [125I]- Iodocyanopindolol binding to 5-hydroxytryptamine 1B receptor at 1 uM,B,,,,,CHEMBL616190,10025,H,BAO_0000357,1,,,,,10577
1403,8,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]-8-OH-DPAT as radioligand; range=48-77,B,,,,,CHEMBL616191,13863,H,BAO_0000357,1,,,,,10576
1404,8,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=63-95,B,,,,,CHEMBL616192,13863,H,BAO_0000357,1,,,,,10576
1405,8,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=710-980,B,,,,,CHEMBL616193,13863,H,BAO_0000357,1,,,,,10576
1406,8,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=78-140,B,,,,,CHEMBL616194,13863,H,BAO_0000357,1,,,,,10576
1407,8,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=85-130,B,,,,,CHEMBL616195,13863,H,BAO_0000357,1,,,,,10576
1408,8,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=89-280,B,,,,,CHEMBL616196,13863,H,BAO_0000357,1,,,,,10576
1409,8,,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand in rat hippocampus membrane.,B,,Hippocampus,,,CHEMBL616197,4622,H,BAO_0000249,1,10000000.0,,,,10576
1410,8,,Binding affinity at 5-hydroxytryptamine 1A (5-HT1A) receptor in rat cerebral cortex using [3H]8-OH-DPAT as radioligand,B,,,,,CHEMBL616198,14911,H,BAO_0000019,1,,,,,10576
1411,8,,In vitro binding affinity to 5-hydroxytryptamine 1A receptor using [125I](R)-(+)-trans-8-OH-PIPAT as radioligand in rat hippocampal homogenate,B,,Hippocampus,,,CHEMBL616199,12678,H,BAO_0000221,1,10000000.0,,,,10576
1412,8,,In vitro binding affinity to 5-hydroxytryptamine 1A receptor in rat hippocampal homogenate by [125I](R)-(+)-trans-8-OH-PIPAT displacement.,B,,Hippocampus,,,CHEMBL616200,12678,H,BAO_0000221,1,10000000.0,,,,10576
1413,8,,In vitro binding affinity to rat hippocampal 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand,B,,Hippocampus,,,CHEMBL616201,14235,H,BAO_0000221,1,10000000.0,,,,10576
1414,8,,In vitro binding affinity towards 5-hydroxytryptamine 1A r receptor by the displacement of [3H]8-OH-DPAT radioligand in rat hippocampal homogenates,B,,Hippocampus,,,CHEMBL616202,14949,H,BAO_0000221,1,10000000.0,,,,10576
1415,8,,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT radioligand in rat hippocampal homogenates,B,,Hippocampus,,,CHEMBL616203,14949,H,BAO_0000221,1,10000000.0,,,,10576
1416,8,,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT radioligand in rat hippocampal homogenates; ND=not determined,B,,Hippocampus,,,CHEMBL616204,14949,H,BAO_0000221,1,10000000.0,,,,10576
1417,8,,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT radioligand in rat hippocampal homogenates; Not determined,B,,Hippocampus,,,CHEMBL616205,14949,H,BAO_0000221,1,10000000.0,,,,10576
1418,8,,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT radioligand in rat hippocampal homogenates; not determined,B,,Hippocampus,,,CHEMBL616206,14949,H,BAO_0000221,1,10000000.0,,,,10576
1419,8,,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor in rat cerebral cortex membranes,B,,,,,CHEMBL616207,16118,H,BAO_0000249,1,,,,,10576
1420,8,,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand in rat cerebral cortex membranes,B,,,,,CHEMBL616208,3268,H,BAO_0000249,1,,,,,10576
1421,8,,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand in rat cerebral cortex membranes; Inactive,B,,,,,CHEMBL616209,3268,H,BAO_0000249,1,,,,,10576
1422,8,,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor was determined using radioligand [3H]-8-OH-DPAT,B,,,,,CHEMBL616210,16117,H,BAO_0000357,1,,,,,10576
1423,8,,In vitro inhibition of [3H]spiperone binding to 5-hydroxytryptamine 1A receptor from rat hippocampal tissue.,B,,Hippocampus,,,CHEMBL616211,9783,H,BAO_0000221,1,10000000.0,,,,10576
1424,8,,In vitro inhibition of [3H]spiperone binding to 5-hydroxytryptamine 1A receptor from rat hippocampal tissue; NT=Not tested,B,,Hippocampus,,,CHEMBL616504,9783,H,BAO_0000221,1,10000000.0,,,,10576
1425,9,Rattus norvegicus,Displacement of [3H]8-OH-DPAT from rat hippocampal 5-hydroxytryptamine 1A receptor,B,10116.0,Hippocampus,,,CHEMBL616505,14356,D,BAO_0000221,1,10000000.0,,,,10576
1426,8,,Inhibition constant of 50 uM forskolin-stimulated cAMP accumulation against 5-hydroxytryptamine 1A receptor,F,,,,,CHEMBL616506,15740,H,BAO_0000019,1,,,,,10576
1427,8,,Inhibition of binding of [125I]8-OH-PIPAT ligand to 5-hydroxytryptamine 1A receptor of rat hippocampal homogenates,B,,Hippocampus,,,CHEMBL872107,12306,H,BAO_0000221,1,10000000.0,,,,10576
1428,9,Rattus norvegicus,Displacement of [3H]5-HT from rat hippocampal 5-hydroxytryptamine 1A receptor with 10e-6 M ketanserin,B,10116.0,Hippocampus,,,CHEMBL616507,13348,D,BAO_0000221,1,10000000.0,,,,10576
1429,8,,Inhibitory activity against 5-hydroxytryptamine 1A receptor in rat cortical membranes using [3H]8-OH-DPAT as a radioligand,B,,,,,CHEMBL616303,10394,H,BAO_0000249,1,,,,,10576
1430,8,,Inhibitory activity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue,B,,Hippocampus,,,CHEMBL616304,15260,H,BAO_0000221,1,10000000.0,,,,10576
1431,8,,Inhibitory activity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue using [3H]OH-DPAT as radioligand.,B,,Hippocampus,,,CHEMBL616305,10046,H,BAO_0000221,1,10000000.0,,,,10576
1432,8,,Antagonist activity against rat hippocampal tissue 5-hydroxytryptamine 1A receptor,F,,Hippocampus,,,CHEMBL616306,15260,H,BAO_0000221,1,10000000.0,,,,10576
1433,8,,Inhibitory affinity constant against 5-hydroxytryptamine 1A receptor,B,,,,,CHEMBL616307,12851,H,BAO_0000357,1,,,,,10576
1434,9,Rattus norvegicus,Displacement of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat brain hippocampus,B,10116.0,Hippocampus,,,CHEMBL881829,2148,D,BAO_0000221,1,10000000.0,,,,10576
1435,8,,Affinity against the 5-hydroxytryptamine receptor 1A using [3H]WB-4101.,B,,,,,CHEMBL616308,13134,H,BAO_0000357,1,,,,,10576
1436,8,,Tested for affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT in homogenized rat brain,B,,,,,CHEMBL616309,12462,H,BAO_0000019,1,,,,,10576
1437,8,,Tested for affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT in homogenized rat brain tissue,B,,,,,CHEMBL616310,12462,H,BAO_0000019,1,,,,,10576
1438,8,,Tested for affinity against 5-hydroxytryptamine 1A receptors using [3H]8-OH-DPAT in homogenized rat cloned CHO cells,B,,,,,CHEMBL616311,12462,H,BAO_0000219,1,,,,CHO,10576
1439,8,,Tested for binding affinity against 5-hydroxytryptamine 1A receptor from rat frontal cortical regions using [3H]8-OH-DPAT as radioligand,B,,,,,CHEMBL616312,11933,H,BAO_0000357,1,,,,,10576
1440,8,,Tested for binding affinity against 5-hydroxytryptamine 1A receptor from rat frontal cortical regions using [3H]8-OH-DPAT as radioligand; ND is Not Determined,B,,,,,CHEMBL616313,11933,H,BAO_0000357,1,,,,,10576
1441,9,Rattus norvegicus,Displacement of [3H]8-OH-DPAT from rat hippocampal 5-hydroxytryptamine 1A receptor,B,10116.0,Hippocampus,,,CHEMBL616314,403,D,BAO_0000221,1,10000000.0,,,,10576
1442,8,,Tested for binding affinity by measuring displacement of [3H]8-OH-DPAT from rat serotonin 5-hydroxytryptamine 1A receptor in rat hippocampus,B,,Hippocampus,,,CHEMBL616315,15538,H,BAO_0000221,1,10000000.0,,,,10576
1443,8,,Tested for binding affinity by measuring displacement of [3H]8-OH-DPAT from rat serotonin 5-hydroxytryptamine 1A receptor in rat hippocampus; NA means Not Active,B,,Hippocampus,,,CHEMBL616567,15538,H,BAO_0000221,1,10000000.0,,,,10576
1444,8,,Tested for binding affinity by measuring displacement of [3H]-8-OH-DPAT from rat serotonin 5-hydroxytryptamine 1A receptor in rat hippocampus; ND means Not Determined,B,,Hippocampus,,,CHEMBL616568,15538,H,BAO_0000221,1,10000000.0,,,,10576
1445,8,,Binding affinity to displace [3H]2-(di-N-propylamino)-8-hydroxy-tetralin from 5-hydroxytryptamine 1A (5-HT1A) receptor in rat frontal cortex homogenates,B,,,,,CHEMBL616569,12464,H,BAO_0000019,1,,,,,10576
1446,8,,Binding affinity to 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT radioligand assay.,B,,,,,CHEMBL616570,1455,H,BAO_0000357,1,,,,,10576
1447,8,,Tested for the binding affinity against the site labelled by the 5-hydroxytryptamine 1A receptor agonist [3H]- 8-OH-DPAT,B,,,,,CHEMBL616571,12652,H,BAO_0000357,1,,,,,10576
1448,8,,Tested for the inhibitory activity against 5-hydroxytryptamine 1A receptor in rat hippocampal,B,,Hippocampus,,,CHEMBL616572,12639,H,BAO_0000221,1,10000000.0,,,,10576
1449,8,,Tested in vitro for binding affinity by measuring its ability to inhibit [3H]8-OH-DPAT binding at 5-hydroxytryptamine 1A receptor in rat cerebral cortex membranes.,B,,,,,CHEMBL616573,13949,H,BAO_0000249,1,,,,,10576
1450,9,Rattus norvegicus,Tested in vitro for receptor binding affinity against 5-hydroxytryptamine 1A receptor using radioligand [3H]8-OH-DPAT,B,10116.0,,,,CHEMBL616574,12463,D,BAO_0000357,1,,,,,10576
1451,8,,The binding affinity by measuring its ability to displace [3H]8-OH-DPAT radioligand in 5-hydroxytryptamine 1A receptor on rat hippocampal preparation,B,,Hippocampus,,,CHEMBL616575,14829,H,BAO_0000221,1,10000000.0,,,,10576
1452,8,,The binding affinity by measuring its ability to displace [3H]8-OH-DPAT radioligand in 5-hydroxytryptamine 1A receptor on rat hippocampal preparation; ND=not determined,B,,Hippocampus,,,CHEMBL872108,14829,H,BAO_0000221,1,10000000.0,,,,10576
1453,8,,The binding affinity was measured on 5-hydroxytryptamine 1A receptor using [3H]- 8-OH-DPAT as radioligand.,B,,,,,CHEMBL616576,12092,H,BAO_0000357,1,,,,,10576
1454,8,,The compound was evaluated for binding affinity against 5-hydroxytryptamine 1A receptor in rat hippocampal membranes using [3H]8-OH-DPAT as radioligand in the presence of 1 mM of MnCl2,B,,,,,CHEMBL616577,403,H,BAO_0000249,1,,,,,10576
1455,8,,The compound was evaluated for binding affinity against 5-hydroxytryptamine 1A receptor in rat hippocampal membranes using [3H]8-OH-DPAT as radioligand in the presence of 3*10e-5 M GTP gamma S,B,,,,,CHEMBL616578,403,H,BAO_0000249,1,,,,,10576
1456,8,,Binding affinity at 5-hydroxytryptamine 1A receptor from striata of wistar rats by [3H]- 8-OH -DPAT displacement.,B,,,,,CHEMBL616579,3967,H,BAO_0000357,1,,,,,10576
1457,9,Rattus norvegicus,Binding affinity towards 5-hydroxytryptamine 1A receptor of rat brain synaptosomal preparations,B,10116.0,,,,CHEMBL616580,12771,D,BAO_0000019,1,,,,,10576
1458,8,,The compound was tested binding affinity against 5-hydroxytryptamine 1A receptor from rat brain using [3H]8-OH-DPAT as radioligand at 10e-6 M.,B,,,,,CHEMBL616581,15086,H,BAO_0000019,1,,,,,10576
1459,8,,The compound was tested for binding affinity on [3H]8-OH-DPAT as specific ligand on 5-hydroxytryptamine 1A receptor in rat hippocampus,B,,Hippocampus,,,CHEMBL616582,14909,H,BAO_0000221,1,10000000.0,,,,10576
1460,8,,The compound was tested for binding affinity on [3H]8-OH-DPAT as specific ligand on 5-hydroxytryptamine 1A receptor in rat hippocampus,B,,Hippocampus,,,CHEMBL616583,14949,H,BAO_0000221,1,10000000.0,,,,10576
1461,9,Rattus norvegicus,Binding affinity against 5-hydroxytryptamine 1A receptor of rat hippocampus using [3H]8-OH-DPAT,B,10116.0,Hippocampus,,,CHEMBL616584,2309,D,BAO_0000221,1,10000000.0,,,,10576
1462,8,,Binding affinity towards 5-hydroxytryptamine 1A receptor,B,,,,,CHEMBL616585,4170,H,BAO_0000357,1,,,,,10576
1463,9,Rattus norvegicus,Binding affinity towards 5-hydroxytryptamine 1A receptor by displacing [3H]WB-4101 from rat hippocampus,B,10116.0,Hippocampus,,,CHEMBL616586,11642,D,BAO_0000221,1,10000000.0,,,,10576
1464,8,,The compound was tested for its binding affinity towards 5-hydroxytryptamine 1A receptor by displacing [3H]WB-4101 radioligand in rat hippocampus,B,,Hippocampus,,,CHEMBL616587,11642,H,BAO_0000221,1,10000000.0,,,,10576
1465,8,,The compound was tested for their binding affinity towards 5-hydroxytryptamine 1A receptor from rat hippocampus using [3H]-8-OH-DPAT as radioligand,B,,Hippocampus,,,CHEMBL616588,12953,H,BAO_0000221,1,10000000.0,,,,10576
1466,8,,The compound was tested for their binding affinity towards 5-hydroxytryptamine 1A receptor from rat hippocampus using [3H]8-OH-DPAT as radioligand.,B,,Hippocampus,,,CHEMBL616589,12953,H,BAO_0000221,1,10000000.0,,,,10576
1467,8,,Binding affinity for 5-hydroxytryptamine 1A receptor from rat hippocampus using [3H]8-OH-DPAT as radioligand,B,,Hippocampus,,,CHEMBL616590,12953,H,BAO_0000221,1,10000000.0,,,,10576
1468,8,,"In vitro binding affinity against cloned mammalian 5-hydroxytryptamine 1A receptor expressed in CHO cells, by using [3H]8-OH-DPAT as radioligand.",B,,,,,CHEMBL616591,12903,H,BAO_0000219,1,,,,CHO,10576
1469,8,,Displacement of the radioligand [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor,B,,,,,CHEMBL616592,12536,H,BAO_0000357,1,,,,,10576
1470,8,,The inhibition activity of 5-HT1A at 1 uM,B,,,,,CHEMBL616593,10058,H,BAO_0000357,1,,,,,10576
1471,8,,"Binding affinity against 5-hydroxytryptamine 1A receptor from CHO-K1 cells, using [3H]8-OH-DPAT as the radioligand.",B,,,,,CHEMBL616594,12902,H,BAO_0000219,1,,,,CHO-K1,10576
1472,8,,Binding affinities against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand in rat cerebral cortex membrane,B,,,,,CHEMBL616595,14057,H,BAO_0000249,1,,,,,10576
1473,8,,Compound was evaluated for its ability to displace the protonated form of [3H]8-hydroxy-2-(di-n-propylamino)tetralin binding from labeled 5-HT 1A receptor site.,B,,,,,CHEMBL616596,11296,H,BAO_0000357,1,,,,,10576
1474,8,,Compound was evaluated for its ability to displace the protonated form of [3H]8-hydroxy-2-(di-n-propylamino)tetralin binding from labeled 5-hydroxytryptamine 1A receptor site in rat brain hippocampus,B,,Hippocampus,,,CHEMBL616597,11296,H,BAO_0000221,1,10000000.0,,,,10576
1475,8,,Ability to displace the protonated form of [3H]8-hydroxy-2-(di-n-propylamino)tetralin binding from labeled 5-hydroxytryptamine 1A receptor site in rat brain hippocampus,B,,Hippocampus,,,CHEMBL616598,11296,H,BAO_0000221,1,10000000.0,,,,10576
1476,9,Rattus norvegicus,Antagonist activity to stimulate binding of [35S]-GTP-gamma S binding to 5-hydroxytryptamine 1A receptor in isolated rat hippocampal membranes,F,10116.0,,Membranes,,CHEMBL616599,16616,D,BAO_0000249,1,,,,,10576
1477,9,Rattus norvegicus,"Inhibition of (+)-8-OH-DPAT stimulated [35S]GTP-gamma-S, binding in rat hippocampal membranes",F,10116.0,Hippocampus,Membranes,,CHEMBL616600,16616,D,BAO_0000249,1,10000000.0,,,,10576
1478,8,,Binding affinity against 5-hydroxytryptamine 1A receptor by displacing [3H]8-OH-DPAT radioligand in rat cortex membrane;ND is defined as not -determined.,B,,,,,CHEMBL616601,16567,H,BAO_0000019,1,,,,,10576
1479,8,,Binding affinity against 5-hydroxytryptamine 1A receptor by displacing [3H]8-OH-DPAT radioligand in rat cortex membrane;ND is defined as not defined.,B,,,,,CHEMBL616602,16567,H,BAO_0000019,1,,,,,10576
1480,8,,Binding affinity against 5-hydroxytryptamine 1A receptor by displacing [3H]8-OH-DPAT radioligand in rat cortex membrane;ND is defined as not determined.,B,,,,,CHEMBL616603,16567,H,BAO_0000019,1,,,,,10576
1481,8,,Binding affinity against 5-hydroxytryptamine 1A receptor by displacing [3H]8-OH-DPAT radioligand in rat cortex membrane;ND means not determined.,B,,,,,CHEMBL616604,16567,H,BAO_0000019,1,,,,,10576
1482,8,,Binding affinity towards 5-hydroxytryptamine 1A receptor was determined in rat cortex membranes using [3H]8-OH-DPAT as radioligand; No data,B,,,,,CHEMBL616316,17136,H,BAO_0000249,1,,,,,10576
1483,8,,Binding affinity towards 5-hydroxytryptamine 1A receptor was determined in rat cortex membranes using [3H]8-OH-DPAT as radioligand; Not determined,B,,,,,CHEMBL616317,17136,H,BAO_0000249,1,,,,,10576
1484,9,Rattus norvegicus,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat frontal cortex homogenates; ND means No data,B,10116.0,,,,CHEMBL616318,16616,D,BAO_0000019,1,,,,,10576
1485,8,,Binding affinity against 5-hydroxytryptamine 1A receptor by displacement of [3H]8-OH-DPAT from rat hippocampus mambranes,B,,Hippocampus,,,CHEMBL616319,17331,H,BAO_0000221,1,10000000.0,,,,10576
1486,8,,Binding affinity against 5-hydroxytryptamine 1A receptor by displacement of [3H]8-OH-DPAT from rat hippocampus mambranes; Not tested,B,,Hippocampus,,,CHEMBL616320,17331,H,BAO_0000221,1,10000000.0,,,,10576
1487,9,Rattus norvegicus,Binding affinity for rat hippocampus 5-hydroxytryptamine 1A receptor by inhibition of [3H]8-OH-DPAT binding; Not tested,B,10116.0,Hippocampus,,,CHEMBL616321,17167,D,BAO_0000221,1,10000000.0,,,,10576
1488,8,,Evaluated for the 5-hydroxytryptamine 1A receptor agonist activity in LY-293284 trained rats; Not tested,F,,,,,CHEMBL616322,15740,H,BAO_0000019,1,,,,,10576
1489,8,,Evaluated for the 5-hydroxytryptamine 1A receptor agonist activity in LY-293284 trained rats; not tested,F,,,,,CHEMBL616323,15740,H,BAO_0000019,1,,,,,10576
1490,8,,Ratio of binding affinity to 5-HT 1A and D2 receptor,B,,,,,CHEMBL616324,4671,H,BAO_0000357,1,,,,,10576
1491,8,,In vitro ability to inhibit [3H]-8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus at 1 uM,B,,Hippocampus,,,CHEMBL616325,10058,H,BAO_0000221,1,10000000.0,,,,10576
1492,8,,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus at 1 uM,B,,Hippocampus,,,CHEMBL616326,10058,H,BAO_0000221,1,10000000.0,,,,10576
1493,8,,In vitro ability to inhibit [3H]-8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus.,B,,Hippocampus,,,CHEMBL616327,10058,H,BAO_0000221,1,10000000.0,,,,10576
1494,8,,Percentage inhibition against 5-hydroxytryptamine 1A receptor,B,,,,,CHEMBL616328,12073,H,BAO_0000357,1,,,,,10576
1495,8,,Compound was tested for its potency against 5-hydroxytryptamine 1A receptor in rat frontal cortex membranes (experiment 1),B,,,,,CHEMBL858110,2759,H,BAO_0000249,1,,,,,10576
1496,8,,Compound was tested for its potency against 5-hydroxytryptamine 1A receptor in rat frontal cortex membranes (experiment 1),F,,,,,CHEMBL616329,2759,H,BAO_0000249,1,,,,,10576
1497,8,,Compound was tested for its potency against 5-hydroxytryptamine 1A receptor in rat frontal cortex membranes (experiment 2),B,,,,,CHEMBL616330,2759,H,BAO_0000249,1,,,,,10576
1498,8,,Compound was tested for its potency against 5-hydroxytryptamine 1A receptor in rat frontal cortex membranes (experiment 2),F,,,,,CHEMBL616331,2759,H,BAO_0000249,1,,,,,10576
1499,8,,Compound was tested for its potency against 5-hydroxytryptamine 1A receptor in rat frontal cortex membranes.,F,,,,,CHEMBL616332,2759,H,BAO_0000249,1,,,,,10576
1500,8,,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat brain membrane using [3H]8-OH-DPAT as a selective ligand.,B,,Brain,,,CHEMBL857063,9737,H,BAO_0000249,1,955.0,,,,10576
1501,8,,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat frontal cortex using [3H]8-OH-DPAT as a radioligand,B,,,,,CHEMBL616333,9737,H,BAO_0000019,1,,,,,10576
1502,8,,Antagonistic activity against 5-hydroxytryptamine 1A receptor in rat cerebral cortex using [3H]-8-OH-DPAT as radioligand.,F,,,,,CHEMBL616334,5717,H,BAO_0000019,1,,,,,10576
1503,8,,Binding affinity of 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT in rat hippocampus,B,,Hippocampus,,,CHEMBL616335,12253,H,BAO_0000221,1,10000000.0,,,,10576
1504,8,,Affinity pKi for 5-hydroxytryptamine 1A receptor was measured in rat cortex homogenates.,B,,,,,CHEMBL616336,14025,H,BAO_0000019,1,,,,,10576
1505,8,,Binding affinity against 5-hydroxytryptamine 1A receptor in rat cerebral cortical membrane using [3H]-8-OH-DPAT as radioligand.,B,,,,,CHEMBL616337,10425,H,BAO_0000249,1,,,,,10576
1506,8,,Binding affinity against 5-hydroxytryptamine 1A receptor in rat cortex homogenates.,B,,,,,CHEMBL616338,14998,H,BAO_0000019,1,,,,,10576
1507,8,,Binding affinity against native 5-HT1A-receptors from rat hippocampus using radioligand ([3H]- 8-hydri\oxy-2-(di-n-propylamino)tetraline) binding assay,B,,Hippocampus,,,CHEMBL616339,13694,H,BAO_0000221,1,10000000.0,,,,10576
1508,8,,Binding affinity against native 5-HT1A-receptors from rat hippocampus using radioligand ([3H]8-hydroxy-2-(di-n-propylamino)-tetraline) binding assay,B,,Hippocampus,,,CHEMBL616340,13694,H,BAO_0000221,1,10000000.0,,,,10576
1509,8,,Binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined,B,,,,,CHEMBL616341,4342,H,BAO_0000357,1,,,,,10576
1510,9,Rattus norvegicus,Binding affinity against rat 5-hydroxytryptamine 1A receptor,B,10116.0,,,,CHEMBL616342,12936,D,BAO_0000357,1,,,,,10576
1511,9,Rattus norvegicus,Inhibition of [3H]2-(di-N-propylamino)-8-hydroxytetralin binding to 5-HT1A receptor of rat frontal cortex homogenates,B,10116.0,,,,CHEMBL616343,13144,D,BAO_0000019,1,,,,,10576
1512,8,,Binding affinity of a compound to rat brain 5-hydroxytryptamine 1A (serotonin) receptor assayed by radiolabeled [3H]-8-OH-DPAT ligand displacement,B,,,,,CHEMBL616344,13343,H,BAO_0000019,1,,,,,10576
1513,8,,Binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand.,B,,,,,CHEMBL616345,12132,H,BAO_0000357,1,,,,,10576
1514,8,,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat cortex using [3H]8-OH-DPAT as a radioligand,B,,,,,CHEMBL616346,15419,H,BAO_0000019,1,,,,,10576
1515,8,,Binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT in rat hippocampus,B,,Hippocampus,,,CHEMBL616347,1479,H,BAO_0000221,1,10000000.0,,,,10576
1516,8,,In vitro by displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor on rat cortical membrane,B,,,,,CHEMBL616348,14287,H,BAO_0000019,1,,,,,10576
1517,8,,Binding affinity at 5-hydroxytryptamine 1A receptor,B,,,,,CHEMBL616349,13116,H,BAO_0000357,1,,,,,10576
1518,9,Rattus norvegicus,Inhibition of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat frontal cortex membranes,B,10116.0,,Membranes,,CHEMBL616152,2759,D,BAO_0000249,1,,,,,10576
1519,8,,Compound was tested for inhibition constant against 5-hydroxytryptamine 1A receptor in rat frontal cortex membranes.,B,,,,,CHEMBL616153,2759,H,BAO_0000249,1,,,,,10576
1520,8,,"Binding affinity for rat cortex 5-hydroxytryptamine 1A receptor, by displacement of 0.2 nM [3H]8-OH-DPAT radioligand",B,,,,,CHEMBL616154,14748,H,BAO_0000019,1,,,,,10576
1521,8,,In vitro ability to inhibit binding of radioligand [3H]8-OH-DPAT to 5-hydroxytryptamine 1A receptor in rat cerebral cortex,B,,,,,CHEMBL616155,12304,H,BAO_0000019,1,,,,,10576
1522,9,Rattus norvegicus,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat hippocampus using [3H]8-OH-DPAT,B,10116.0,Hippocampus,,,CHEMBL616156,12409,D,BAO_0000221,1,10000000.0,,,,10576
1523,9,Rattus norvegicus,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat hippocampus with [3H]8-OH-DPAT,B,10116.0,Hippocampus,,,CHEMBL616157,12409,D,BAO_0000221,1,10000000.0,,,,10576
1524,8,,The binding affinity (pKi) was measured against 5-hydroxytryptamine 4 receptor of piglet hippocampus using [125I]-SB 207710 as radioligand,B,,Hippocampus,,,CHEMBL616158,13267,H,BAO_0000221,1,10000000.0,,,,10576
1525,8,,The compound was tested for the binding affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand.,B,,,,,CHEMBL616159,15194,H,BAO_0000357,1,,,,,10576
1526,8,,pKi value against rat 5-hydroxytryptamine 1A receptor.,B,,,,,CHEMBL616160,14256,H,BAO_0000357,1,,,,,10576
1527,8,,Binding affinity against 5-hydroxytryptamine 1A receptor by displacing [3H]8-OH-DPAT radioligand in rat cortex membrane;ND is define as non-determined.,B,,,,,CHEMBL616161,16567,H,BAO_0000019,1,,,,,10576
1528,8,,Evaluated for the 5-hydroxytryptamine 1A receptor agonist activity in LY-293284 trained rats; Not tested,F,,,,,CHEMBL616162,15740,H,BAO_0000019,1,,,,,10576
1529,9,Rattus norvegicus,Binding affinity was measured against 5-hydroxytryptamine 2A receptor by displacement of [3H]- ketanserin by lysergic acid amides,B,10116.0,,,,CHEMBL616163,13278,D,BAO_0000357,1,,,,,12687
1530,8,,Inhibition of specific [3H]OH-DPAT binding at 5-hydroxytryptamine 1A receptor in rat hippocampal membranes,B,,,Membranes,,CHEMBL616164,1970,H,BAO_0000249,1,,,,,10626
1531,8,,Concentration of compound required to inhibit cortical 5-hydroxytryptamine 1A receptor binding sites in rat brain was evaluated,B,,Brain,,,CHEMBL616165,10034,H,BAO_0000221,1,955.0,,,,10576
1532,8,Rattus norvegicus,Inhibitory activity against 5-hydroxytryptamine 1A receptor isolated from rat hippocampus membranes membrane using [3H]5-HT as radioligand in the presence of 10e-6 M ketanserin as 5-HT2 blocker,B,10116.0,,,,CHEMBL616355,13348,H,BAO_0000019,1,,,,,51
1533,8,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 50 uM 5-HT.,F,,,,,CHEMBL616356,13630,H,BAO_0000019,1,,,,,10576
1534,8,,Binding affinity at 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in rat brain.,B,,Brain,,,CHEMBL616357,10862,H,BAO_0000221,1,955.0,,,,10576
1535,8,,"Binding affinity against 5-hydroxytryptamine 1A receptor in homogenated rat brain tissue, using by [3H]8-OH-DPAT as radioligand",B,,,,,CHEMBL616358,12058,H,BAO_0000019,1,,,,,10576
1536,8,,Compound was tested for binding affinity against 5-hydroxytryptamine 1A receptor,B,,,,,CHEMBL616359,4639,H,BAO_0000357,1,,,,,51
1537,8,,Percent decrease in 5-hydroxytryptamine 1A receptor binding using 8-OH-DPAT,B,,,,,CHEMBL616360,15453,H,BAO_0000357,1,,,,,51
1538,8,,Binding affinity towards 5-hydroxytryptamine 1A receptor,B,,,,,CHEMBL616361,4820,H,BAO_0000357,1,,,,,51
1539,8,,Tested for binding affinity for 5-hydroxytryptamine 1A receptor,B,,,,,CHEMBL616362,1089,H,BAO_0000357,1,,,,,51
1540,8,,The compound was evaluated for its ability to displace [3H]-8-OH-DPAT from 5-hydroxytryptamine 1A receptor in cellular brain membranes,B,,,Brain membranes,,CHEMBL616363,386,H,BAO_0000249,1,,,,,51
1541,8,,Inhibition of binding towards 5-hydroxytryptamine 1A receptor at 100 nM concentration,B,,,,,CHEMBL616364,6011,H,BAO_0000357,1,,,,,51
1542,8,,Percent inhibition (at 1 uM) against 5-hydroxytryptamine 1A receptor,B,,,,,CHEMBL616365,5014,H,BAO_0000357,1,,,,,51
1543,8,,Binding affinity for 5-hydroxytryptamine 1A receptor determined using [3H]8-OH-DPAT as radioligand,B,,,,,CHEMBL616366,4402,H,BAO_0000357,1,,,,,51
1544,8,,Binding affinity towards 5-hydroxytryptamine 1A receptor,B,,,,,CHEMBL872906,17066,H,BAO_0000357,1,,,,,51
1545,8,,Binding affinity of compound towards serotonin 5-hydroxytryptamine 1A receptor; inactive at 10 uM,B,,,,,CHEMBL616367,17515,H,BAO_0000357,1,,,,,51
1546,8,,Binding affinity against 5-hydroxytryptamine 1A receptor,B,,,,,CHEMBL616368,2474,H,BAO_0000357,1,,,,,51
1547,8,,Binding affinity to 5-hydroxytryptamine 1A receptor was determined,B,,,,,CHEMBL616369,4775,H,BAO_0000357,1,,,,,51
1548,9,Homo sapiens,Binding affinity towards Serotonin 5-hydroxytryptamine 1A receptor by displacement of [3H]-(+)-8-OH-DPAT.,B,9606.0,,,,CHEMBL616370,14294,D,BAO_0000357,1,,,,,51
1549,9,Homo sapiens,Binding affinity towards Serotonin 5-hydroxytryptamine 1A receptor by displacement of [3H](+)-8-OH-DPAT; inactive,B,9606.0,,,,CHEMBL616371,14294,D,BAO_0000357,1,,,,,51
1550,8,,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in cloned CHO cells,B,,,,,CHEMBL616372,12249,H,BAO_0000219,1,,,,CHO,51
1551,8,,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor expressed in CHO cell membranes,B,,,,,CHEMBL616373,11376,H,BAO_0000219,1,,,,,51
1552,8,,Compound was measured in vivo for its binding affinity at 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,B,,,,,CHEMBL616374,2474,H,BAO_0000218,1,,In vivo,,,51
1553,8,,Tested for activity against 5-hydroxytryptamine 1A receptor from bovine hippocampus,B,,Hippocampus,,,CHEMBL616375,13311,H,BAO_0000221,1,10000000.0,,,,51
1554,8,,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 1A receptor was determined,B,,,,,CHEMBL616376,4373,H,BAO_0000357,1,,,,,51
1555,8,,Binding affinity towards 5-hydroxytryptamine 1A receptor by displacement of [3H]8-OH-DPAT.,B,,,,,CHEMBL857064,1633,H,BAO_0000357,1,,,,,51
1556,8,,Binding affinity for 5-hydroxytryptamine 1A receptor was determined,B,,,,,CHEMBL616377,11866,H,BAO_0000357,1,,,,,51
1557,8,,Binding affinity for 5-hydroxytryptamine 1A receptor was determined,B,,,,,CHEMBL616378,4373,H,BAO_0000357,1,,,,,51
1558,8,,Evaluated for the binding affinity to 5-hydroxytryptamine 1A receptor,B,,,,,CHEMBL616379,4687,H,BAO_0000357,1,,,,,51
1559,8,,Ability to displace [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor,B,,,,,CHEMBL616380,16946,H,BAO_0000357,1,,,,,11863
1560,8,,Binding affinity against 5-hydroxytryptamine 1A receptor was determined using [3H]-8-OH-DPAT radioligand,B,,,,,CHEMBL616381,13291,H,BAO_0000357,1,,,,,11863
1561,8,,Compound was evaluated for the affinity at 5-hydroxytryptamine 1A receptor,B,,,,,CHEMBL616382,14159,H,BAO_0000357,1,,,,,11863
1562,8,,Compound was tested for the binding affinity against 5-hydroxytryptamine 1A receptor by using [3H]DPAT as radioligand,B,,,,,CHEMBL616383,10812,H,BAO_0000357,1,,,,,11863
1563,9,Mus musculus,In vitro binding affinity against 5-hydroxytryptamine 1A receptor in CHO cells,B,10090.0,,,,CHEMBL616350,3032,D,BAO_0000219,1,,,,CHO,11863
1564,8,,Inhibition of 5-OH-DPAT binding to 5-hydroxytryptamine 1A receptor,B,,,,,CHEMBL616351,16655,H,BAO_0000357,1,,,,,11863
1565,8,,Inhibitory activity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand at 10e-5 M concentration,B,,,,,CHEMBL616352,14532,H,BAO_0000357,1,,,,,11863
1566,8,,Binding affinity against 5-hydroxytryptamine 1A receptor,B,,,,,CHEMBL616353,13944,H,BAO_0000357,1,,,,,11863
1567,8,,Binding affinity against serotonergic 5-HT1a receptor,B,,,,,CHEMBL616354,13033,H,BAO_0000357,1,,,,,11863
1568,8,,Binding affinity for 5-hydroxytryptamine 1A receptor was determined by using [3H]8-OH-DPAT as radioligand,B,,,,,CHEMBL616508,10321,H,BAO_0000357,1,,,,,11863
1569,9,Mus musculus,Binding affinity for 5-hydroxytryptamine 1A receptor,B,10090.0,,,,CHEMBL616559,2968,D,BAO_0000357,1,,,,,11863
1570,8,,Binding affinity at 5-hydroxytryptamine 1A receptor,B,,,,,CHEMBL616560,13964,H,BAO_0000357,1,,,,,11863
1571,8,,"Binding affinity towards 5-hydroxytryptamine 1A receptor receptor, using [3H]5-HT as radioligand.",B,,,,,CHEMBL616561,15527,H,BAO_0000357,1,,,,,11863
1572,8,,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in cloned CHO cells,B,,,,,CHEMBL616562,12248,H,BAO_0000219,1,,,,CHO,11863
1573,8,,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in cloned CHO cells,B,,,,,CHEMBL616563,12249,H,BAO_0000219,1,,,,CHO,11863
1574,8,,Compound was tested for binding affinity using [3H]8-OH-DPAT against 5-hydroxytryptamine 1A receptor,B,,,,,CHEMBL616564,15120,H,BAO_0000357,1,,,,,11863
1575,8,,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor by using [3H]-8-OH-DPAT as radioligand,B,,,,,CHEMBL616565,13313,H,BAO_0000357,1,,,,,11863
1576,8,,In vivo binding affinity was evaluated against 5-hydroxytryptamine 1A receptor,B,,,,,CHEMBL616566,2613,H,BAO_0000218,1,,,,,11863
1577,8,,The binding affinity towards 5-hydroxytryptamine 1A receptor; No affinity,B,,,,,CHEMBL616989,16700,H,BAO_0000357,1,,,,,11863
1578,8,,Ability to displace [125I]iodosulpiride from 5-hydroxytryptamine 1A receptor,B,,,,,CHEMBL857975,2201,H,BAO_0000357,1,,,,,11863
1579,9,Mus musculus,Binding affinity against 5-hydroxytryptamine 1A receptor,B,10090.0,,,,CHEMBL616990,1274,D,BAO_0000357,1,,,,,11863
1580,8,,Compound was evaluated for binding affinity against 5-hydroxytryptamine 1A receptor using radioligand binding assay,B,,,,,CHEMBL616991,1317,H,BAO_0000357,1,,,,,11863
1581,8,,Tested against 5-hydroxytryptamine 1A receptor,B,,,,,CHEMBL616992,12146,H,BAO_0000357,1,,,,,11863
1582,8,,The compound's binding affinity against 5-hydroxytryptamine 1A receptor,B,,,,,CHEMBL616993,14059,H,BAO_0000357,1,,,,,11863
1583,8,Oryctolagus cuniculus,Dissociation equilibrium constant against the vascular 5-hydroxytryptamine 1B like receptor in the rabbit saphenous vein,B,9986.0,,,,CHEMBL616994,14025,H,BAO_0000019,1,,,,,106
1584,8,Oryctolagus cuniculus,The dissociation equilibrium constant (pKB=-log KB) of compound was determined against the vascular 5-hydroxytryptamine 1B like receptor in the rabbit saphenous vein(RbSV); NS=non surmountable,B,9986.0,,,,CHEMBL616995,14025,H,BAO_0000019,1,,,,,106
1585,9,Gorilla gorilla,The compound was tested for CNS binding affinity towards 5-hydroxytryptamine 1B receptor from cloned gorilla membranes expressed in cultured HEK 293 cells,B,9593.0,,,,CHEMBL616996,14447,D,BAO_0000219,1,,,,HEK293,105571
1586,8,Cavia porcellus,5-HT1B agonist potency was evaluated as effective dose that induced hypothermia in the guinea-pig upon intraperitoneal administration,F,10141.0,,,,CHEMBL616997,3025,H,BAO_0000218,1,,In vivo,,,106
1587,8,Cavia porcellus,5-hydroxytryptamine 1B receptor agonist potency was evaluated as effective dose that induced hypothermia in the guinea-pig upon intraperitoneal administration,F,10141.0,,,,CHEMBL616998,3025,H,BAO_0000218,1,,In vivo,,,106
1588,8,Cavia porcellus,Affinity of compound towards 5-hydroxytryptamine 1B receptor in isolated guinea-pig iliac artery,F,10141.0,,,,CHEMBL616999,15329,H,BAO_0000019,1,,,,,106
1589,8,Cavia porcellus,Affinity of compound towards 5-hydroxytryptamine 1B receptor in isolated guinea-pig iliac artery; n.d. indicates Not determined,F,10141.0,,,,CHEMBL617000,15329,H,BAO_0000019,1,,,,,106
1590,8,Cavia porcellus,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 1B receptor of guinea pig,F,10141.0,,,,CHEMBL617001,15847,H,BAO_0000019,1,,,,,106
1591,8,Cavia porcellus,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 1B receptor of guinea pig; ND means not done,F,10141.0,,,,CHEMBL858111,15847,H,BAO_0000019,1,,,,,106
1592,8,,Intrinsic activity for Antagonism of 5-hydroxytryptamine 1B receptor-mediated stimulation of [35S]GTP gamma S binding,F,,,,,CHEMBL617002,14165,H,BAO_0000019,1,,,,,106
1593,8,,Antagonism tested at 1 uM against the agonist-induced inhibitory effect of 10 nM 5-carbamoyltryptamine (5-CT),F,,,,,CHEMBL617003,14214,H,BAO_0000019,1,,,,,106
1594,8,,Antagonism tested at 1 uM against the agonist-induced inhibitory effect of 10 nM 5-carbamoyltryptamine(5-CT),F,,,,,CHEMBL617004,14214,H,BAO_0000019,1,,,,,106
1595,9,Homo sapiens,Agonist activity at 5-hydroxytryptamine 1B receptor by measuring the inhibition of forskolin-stimulated cAMP formation,F,9606.0,,,,CHEMBL617005,14214,D,BAO_0000019,1,,,,,106
1596,9,Homo sapiens,Inhibition of forskolin-stimulated c-AMP formation by human 5-hydroxytryptamine 1B receptor expressed in CHO-K1 cells,F,9606.0,,,,CHEMBL616623,13729,D,BAO_0000219,1,,,,CHO-K1,106
1597,8,,Effective concentration determined by measuring inhibition of forskolin-stimulated c-AMP formation at 5-hydroxytryptamine 1B receptor stably transfected in CHO cell lines,F,,,,,CHEMBL616624,3025,H,BAO_0000219,1,,,,CHO,106
1598,8,,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor,B,,,,,CHEMBL883243,2391,H,BAO_0000357,1,,,,,106
1599,8,,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor; full agonist,F,,,,,CHEMBL616625,2391,H,BAO_0000019,1,,,,,106
1600,8,,"Agonist-induced [35S]GTP-gamma-S, binding in CHO cells stably transfected with human 5-hydroxytryptamine 1B receptor",F,,,,,CHEMBL616626,14956,H,BAO_0000219,1,,,,CHO,106
1601,8,,The intrinsic activity was evaluated for its ability to inhibit forskolin-stimulated c-AMP formation mediated by cloned 5-hydroxytryptamine 1B receptor in CHO cell line,F,,,,,CHEMBL616627,2598,H,BAO_0000219,1,,,,CHO,106
1602,8,,The intrinsic activity was evaluated for its ability to inhibit forskolin-stimulated c-AMP formation mediated by cloned 5-hydroxytryptamine 1B receptor in CHO cell line; Antagonist,F,,,,,CHEMBL616628,2598,H,BAO_0000219,1,,,,CHO,106
1603,8,,The intrinsic activity was evaluated for its ability to inhibit forskolin-stimulated c-AMP formation mediated by cloned 5-hydroxytryptamine 1B receptor in CHO cell line; Full Agonist,F,,,,,CHEMBL616629,2598,H,BAO_0000219,1,,,,CHO,106
1604,8,,The intrinsic activity was evaluated for its ability to inhibit forskolin-stimulated c-AMP formation mediated by cloned 5-hydroxytryptamine 1B receptor in CHO cell line; Partial Agonist,F,,,,,CHEMBL616630,2598,H,BAO_0000219,1,,,,CHO,106
1605,8,,"Efficacy was evaluated relative to human 5-HT1B receptor using [35S]GTP-gamma-S, as radioligand",F,,,,,CHEMBL616631,14956,H,BAO_0000019,1,,,,,106
1606,8,,"Efficacy of compound was evaluated relative to human 5-hydroxytryptamine 1B receptor using [35S]GTP-gamma-S, as radioligand",F,,,,,CHEMBL616632,14956,H,BAO_0000019,1,,,,,106
1607,9,Homo sapiens,Percentage Maximal inhibition obtained with 1 uM 5-HT against 5-hydroxytryptamine 1B receptor,B,9606.0,,,,CHEMBL616633,14214,D,BAO_0000357,1,,,,,106
1608,8,,Ability to displace [3H]5-HT from recombinant human 5-hydroxytryptamine 1B receptor stably expressed in CHO cells determined in vitro,B,,,,,CHEMBL616634,3463,H,BAO_0000219,1,,,,CHO,106
1609,8,,Affinity of compound towards 5-hydroxytryptamine 1B receptor was evaluated using radioligand binding technique,B,,,,,CHEMBL616635,15331,H,BAO_0000357,1,,,,,106
1610,9,Homo sapiens,Binding affinity against 5-hydroxytryptamine 1B receptor,B,9606.0,,,,CHEMBL885358,16146,D,BAO_0000357,1,,,,,106
1611,9,Homo sapiens,Displacement of [3H]5-HT from human 5-hydroxytryptamine 1B receptor expressed in CHO cells,B,9606.0,,,,CHEMBL616636,14159,D,BAO_0000219,1,,,,CHO,106
1612,8,,Binding affinity to human cloned 5-hydroxytryptamine 1B receptor in CHO cells by [3H]5-HT binding displacement.,B,,,,,CHEMBL616637,14158,H,BAO_0000219,1,,,,CHO,106
1613,8,,Compound was evaluated for the affinity at 5-hydroxytryptamine 1B receptor,B,,,,,CHEMBL616638,14159,H,BAO_0000357,1,,,,,106
1614,8,,Displacement of [3H]5-HT binding to cloned 5-hydroxytryptamine 1B receptor stably expressed in CHO cells,B,,,,,CHEMBL616639,15250,H,BAO_0000219,1,,,,CHO,106
1615,8,,Binding affinity at cloned human 5-hydroxytryptamine 1B receptor stably expressed in CHO cells by [3H]5-HT displacement.,B,,,,,CHEMBL616640,15250,H,BAO_0000219,1,,,,CHO,106
1616,8,,Displacement of [3H]5-HT binding from the cloned human 5-hydroxytryptamine 1B receptor stably expressed in CHO cells,B,,,,,CHEMBL616641,15331,H,BAO_0000219,1,,,,CHO,106
1617,8,,Displacement of [3H]5-HT binding from cloned human 5-hydroxytryptamine 1B receptor stably expressed in CHO cells.,B,,,,,CHEMBL616642,15332,H,BAO_0000219,1,,,,CHO,106
1618,8,,Displacement of specific [3H]5-HT binding to cloned human 5-hydroxytryptamine 1B receptor expressed in CHO cells,B,,,,,CHEMBL616643,14956,H,BAO_0000219,1,,,,CHO,106
1619,8,,In vitro binding affinity against human 5-hydroxytryptamine 1B receptor at a concentration of 100 (nM),B,,,,,CHEMBL616644,3805,H,BAO_0000357,1,,,,,106
1620,8,,Intrinsic activity for each compound is calculated as a percentage of the 5-hydroxytryptamine 1B receptor response,B,,,,,CHEMBL616645,14875,H,BAO_0000357,1,,,,,106
1621,8,Oryctolagus cuniculus,Compound was tested for 5-hydroxytryptamine 1D like receptor-mediated vascular effect in rabbit saphenous vein (RSV),F,9986.0,,,,CHEMBL616646,14454,H,BAO_0000019,1,,,,,105
1622,8,Oryctolagus cuniculus,Tested for 5-hydroxytryptamine 1D like receptor-mediated vascular effect in rabbit saphenous vein (RSV),F,9986.0,,,,CHEMBL616647,14454,H,BAO_0000019,1,,,,,105
1623,8,,Affinity at 5-hydroxytryptamine 1D receptor (For sumatriptan = Ki (nM)-12+/-1.9),B,,,,,CHEMBL616509,16288,H,BAO_0000357,1,,,,,105
1624,8,,Affinity at 5-hydroxytryptamine 1D receptor from calf caudate using [3H]5-HT as radioligand (For sumatriptan = Ki(nM)-12+/-1.9),B,,,,,CHEMBL616510,16288,H,BAO_0000357,1,,,,,105
1625,8,,Binding affinity against calf caudate 5-hydroxytryptamine 1D receptor,B,,,,,CHEMBL616511,16312,H,BAO_0000357,1,,,,,105
1626,8,Bos taurus,Inhibitory activity against 5-hydroxytryptamine 1D receptor subtype,B,9913.0,,,,CHEMBL616512,1348,H,BAO_0000357,1,,,,,105
1627,8,Bos taurus,Inhibitory concentration required against 5-hydroxytryptamine 1D receptor in bovine caudate using [3H]5-HT,B,9913.0,,,,CHEMBL616513,5834,H,BAO_0000357,1,,,,,105
1628,8,Bos taurus,Binding affinity towards 5-hydroxytryptamine 1D receptor was determined in calf striatum homogenate,B,9913.0,Striatum,,,CHEMBL616514,13366,H,BAO_0000019,1,2435.0,,,,105
1629,8,Bos taurus,Ability to bind to 5-hydroxytryptamine 1D receptor of calf substantia nigra,B,9913.0,,,,CHEMBL616515,1414,H,BAO_0000357,1,,,,,105
1630,8,Bos taurus,Binding affinity against 5-hydroxytryptamine 1D receptor in calf caudate homogenates.,B,9913.0,,,,CHEMBL616516,14998,H,BAO_0000019,1,,,,,105
1631,8,Bos taurus,Compound was evaluated for binding affinity towards 5-hydroxytryptamine 1D receptor in bovine caudate using [3H]- serotonin as radioligand,B,9913.0,,,,CHEMBL616517,11473,H,BAO_0000357,1,,,,,105
1632,8,Bos taurus,Compound was evaluated for binding affinity towards 5-hydroxytryptamine 1D receptor in bovine caudate using [3H]- serotonin as radioligand,B,9913.0,,,,CHEMBL616518,11473,H,BAO_0000357,1,,,,,105
1633,8,Bos taurus,Compound was evaluated for its inhibitory activity against 5-hydroxytryptamine 1D receptor of bovine caudate using [3H]5-HT as the radioligand,B,9913.0,,,,CHEMBL616519,10639,H,BAO_0000357,1,,,,,105
1634,8,Bos taurus,Inhibitory activity against 5-hydroxytryptamine 1D receptor of bovine caudate using [3H]5-HT as the radioligand,B,9913.0,,,,CHEMBL616520,10639,H,BAO_0000357,1,,,,,105
1635,8,Bos taurus,Tested in vitro for receptor binding affinity to 5-hydroxytryptamine 1D receptor in bovine caudate using [3H]5-HT radioligand,B,9913.0,,,,CHEMBL616521,1375,H,BAO_0000357,1,,,,,105
1636,8,Bos taurus,Tested in vitro for receptor binding affinity to 5-hydroxytryptamine 1D receptor in bovine caudate using [3H]5-HT radioligand; NT means not tested,B,9913.0,,,,CHEMBL616522,1375,H,BAO_0000357,1,,,,,105
1637,8,Bos taurus,The binding affinity at 5-hydroxytryptamine 1D receptor was determined using [3H]5-CT; Not tested,B,9913.0,,,,CHEMBL884531,16532,H,BAO_0000357,1,,,,,105
1638,8,Bos taurus,Binding affinity towards 5-hydroxytryptamine 1D receptor using [3H]5-HT as radioligand,B,9913.0,,,,CHEMBL616523,11147,H,BAO_0000357,1,,,,,105
1639,8,Bos taurus,Binding affinity towards 5-hydroxytryptamine 1D receptor was determined in calf striatum homogenate,B,9913.0,Striatum,,,CHEMBL616731,13366,H,BAO_0000019,1,2435.0,,,,105
1640,8,Bos taurus,Binding affinity was determined against 5-hydroxytryptamine 1D receptor in bovine caudate homogenate,B,9913.0,,,,CHEMBL616732,10444,H,BAO_0000019,1,,,,,105
1641,8,Bos taurus,The binding affinity at 5-hydroxytryptamine 1D receptor was determined using [3H]5-CT,B,9913.0,,,,CHEMBL616733,16532,H,BAO_0000357,1,,,,,105
1642,8,Bos taurus,The binding affinity at 5-hydroxytryptamine 1D receptor was determined using [3H]5-CT; Not tested,B,9913.0,,,,CHEMBL616734,16532,H,BAO_0000357,1,,,,,105
1643,8,Bos taurus,Binding affinity towards 5-hydroxytryptamine 1B receptor in rat frontal cortex membranes using [125]ICYP,B,9913.0,,,,CHEMBL616735,12827,H,BAO_0000249,1,,,,,105
1644,8,Bos taurus,Binding affinity towards 5-hydroxytryptamine 1B receptor in rat frontal cortex membranes using [125]ICYP; Not determined,B,9913.0,,,,CHEMBL616736,12827,H,BAO_0000249,1,,,,,105
1645,8,Bos taurus,Agonistic activity against 5-hydroxytryptamine 1D receptor in calf caudate using [3H]-GTI,F,9913.0,,,,CHEMBL616737,12919,H,BAO_0000019,1,,,,,105
1646,8,Bos taurus,Affinity pKi for 5-hydroxytryptamine 1D receptor was measured in calf caudate homogenate,B,9913.0,,,,CHEMBL616738,14025,H,BAO_0000019,1,,,,,105
1647,8,Bos taurus,Agonistic activity against 5-hydroxytryptamine 1D receptor in calf caudate using [3H]-GTI,F,9913.0,,,,CHEMBL616739,12919,H,BAO_0000019,1,,,,,105
1648,8,Bos taurus,Agonistic activity against 5-hydroxytryptamine 1D receptor in calf caudate using [3H]-GTI,F,9913.0,,,,CHEMBL616740,12919,H,BAO_0000019,1,,,,,105
1649,8,Bos taurus,Agonistic activity against 5-hydroxytryptamine 1D receptor in calf caudate using [3H]-GTI,F,9913.0,,,,CHEMBL616741,12919,H,BAO_0000019,1,,,,,105
1650,8,Gorilla gorilla,The compound was tested for CNS binding affinity towards 5-hydroxytryptamine 1D receptor from cloned gorilla membranes expressed in cultured HEK 293 cells,B,9593.0,,,,CHEMBL616742,14447,H,BAO_0000219,1,,,,HEK293,105
1651,9,Cavia porcellus,Compound was tested for the inhibition of forskolin-stimulated adenylate cyclase at 5-hydroxytryptamine 1D receptor in guinea pig substantia nigra,B,10141.0,,,,CHEMBL616743,1375,D,BAO_0000019,1,,,,,105570
1652,9,Cavia porcellus,Compound was tested for the inhibition of forskolin-stimulated adenylate cyclase at 5-hydroxytryptamine 1D receptor in guinea pig substantia nigra; NT means not tested,B,10141.0,,,,CHEMBL616744,1375,D,BAO_0000019,1,,,,,105570
1653,9,Cavia porcellus,Oral effective dose against hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptor by the agonist GR-46611,F,10141.0,,,,CHEMBL616745,12409,D,BAO_0000019,1,,,,,105570
1654,9,Cavia porcellus,Oral effective dose against hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611,F,10141.0,,,,CHEMBL616746,12409,D,BAO_0000019,1,,,,,105570
1655,9,Cavia porcellus,Oral effective dose against hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611; range is 2-9,F,10141.0,,,,CHEMBL616747,12409,D,BAO_0000019,1,,,,,105570
1656,9,Cavia porcellus,Oral effective dose against hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611;range is 0.2-0.4,F,10141.0,,,,CHEMBL616748,12409,D,BAO_0000019,1,,,,,105570
1657,9,Cavia porcellus,Oral effective dose against hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611;range is 0.2-1.2,F,10141.0,,,,CHEMBL616648,12409,D,BAO_0000019,1,,,,,105570
1658,9,Cavia porcellus,Binding affinity against 5-hydroxytryptamine 1D receptor,B,10141.0,,,,CHEMBL616649,11574,D,BAO_0000357,1,,,,,105570
1659,9,Cavia porcellus,Binding affinity towards guinea pig 5-hydroxytryptamine 1D receptor was determined,B,10141.0,,,,CHEMBL616650,1558,D,BAO_0000357,1,,,,,105570
1660,9,Cavia porcellus,Compound at 3 mg/kg was tested for the inhibition of hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611,F,10141.0,,,,CHEMBL616651,12409,D,BAO_0000218,1,,,,,105570
1661,9,Cavia porcellus,Compound at 45 mg/kg was tested for the inhibition of hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611,F,10141.0,,,,CHEMBL616652,12409,D,BAO_0000218,1,,,,,105570
1662,9,Cavia porcellus,Compound at 50 mg/kg was tested for the inhibition of hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611,F,10141.0,,,,CHEMBL616653,12409,D,BAO_0000218,1,,,,,105570
1663,9,Cavia porcellus,Compound at oral dose of 45 mg/kg was tested for percent inhibition against 5-hydroxytryptamine 1D receptor causes hypothermia in guinea pig,F,10141.0,,,,CHEMBL616654,12409,D,BAO_0000218,1,,,,,105570
1664,9,Cavia porcellus,Binding affinity of 5-hydroxytryptamine 1D receptor using [3H]-8-HT in guinea pig cortex,B,10141.0,,,,CHEMBL616655,12253,D,BAO_0000019,1,,,,,105570
1665,9,Cavia porcellus,Binding affinity against guinea pig 5-hydroxytryptamine 1D receptor,B,10141.0,,,,CHEMBL616656,12936,D,BAO_0000357,1,,,,,105570
1666,8,Cavia porcellus,Binding affinity was determined against 5-hydroxytryptamine 4 receptor using [125I]SB 207710 as radioligand from piglet hippocampal membranes,B,10141.0,,,,CHEMBL616657,13181,H,BAO_0000019,1,,,,,105
1667,9,Cavia porcellus,In vitro binding affinity towards 5-hydroxytryptamine 1D receptor in guinea-pig striatum in presence of BMY-7378 and mesulergine,B,10141.0,Striatum,,,CHEMBL616658,12409,D,BAO_0000357,1,2435.0,,,,105570
1668,9,Cavia porcellus,Inhibition of Forskolin-stimulated adenylate cyclase activity against 5-hydroxytryptamine 1D receptor of guinea pig substantia nigra,B,10141.0,,,,CHEMBL616659,10639,D,BAO_0000357,1,,,,,105570
1669,8,,Binding affinity against 5-hydroxytryptamine 1D receptor,B,,,,,CHEMBL616660,5254,H,BAO_0000357,1,,,,,51
1670,8,,The compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1D receptor beta,B,,,,,CHEMBL616661,13051,H,BAO_0000357,1,,,,,106
1671,8,,Maximum stimulation of [35S]GTP gamma-S binding expressed relative to the maximal effect produced by 5-hydroxytryptamine 1D receptor,F,,,,,CHEMBL616662,3463,H,BAO_0000019,1,,,,,105
1672,8,,Ability to inhibit forskolin-stimulated adenylate cyclase in a cell line expressing human 5-hydroxytryptamine 1D receptor,F,,,,,CHEMBL616663,15315,H,BAO_0000019,1,,,,,105
1673,8,,Ability to inhibit forskolin-stimulated adenylate cyclase activity in Chinese hamster ovary (CHO) stable cell lines expressing human 5-hydroxytryptamine 1D receptor,F,,,,,CHEMBL616664,6011,H,BAO_0000019,1,,,,,105
1674,9,Homo sapiens,"Stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing 5-hydroxytryptamine 1D receptor",F,9606.0,,,,CHEMBL881820,14159,D,BAO_0000219,1,,,,CHO,105
1675,8,,"Compound was evaluated for the stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing the 5-hydroxytryptamine 1D receptor.",F,,,,,CHEMBL616665,14159,H,BAO_0000219,1,,,,CHO,105
1676,8,,Agonist-induced [35S]- GTPgammaS binding in CHO cells stably transfected with 5-hydroxytryptamine 1D receptor,B,,,,,CHEMBL616666,15250,H,BAO_0000219,1,,,,CHO,105
1677,8,,Compound was tested for measuring agonist-induced [35S]- GTPgammaS binding in CHO cells stably transfected with human 5-hydroxytryptamine 1D receptor,B,,,,,CHEMBL616667,15250,H,BAO_0000219,1,,,,CHO,105
1678,8,,"Stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing the 5-hydroxytryptamine 1D receptor",F,,,,,CHEMBL616668,15331,H,BAO_0000219,1,,,,CHO,105
1679,9,Homo sapiens,"Stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing the 5-hydroxytryptamine 1D receptor",F,9606.0,,,,CHEMBL616669,15332,D,BAO_0000219,1,,,,CHO,105
1680,8,,"Stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing the human 5-hydroxytryptamine 1D receptor.",F,,,,,CHEMBL617040,15332,H,BAO_0000219,1,,,,CHO,105
1681,8,,"Measurement of agonist induced [35S]GTP-gamma-S, binding in CHO cells stably transfected with 5-hydroxytryptamine 1D receptor",F,,,,,CHEMBL617041,3294,H,BAO_0000219,1,,,,CHO,105
1682,8,,"Measurement of agonist induced [35S]GTP-gamma-S, binding in CHO cells stably transfected with 5-hydroxytryptamine 1D receptor.",F,,,,,CHEMBL617042,14158,H,BAO_0000219,1,,,,CHO,105
1683,8,,"Agonist-induced [35S]GTP-gamma-S, binding in CHO cells stably transfected with human 5-hydroxytryptamine 1D receptor",F,,,,,CHEMBL617043,14956,H,BAO_0000219,1,,,,CHO,105
1684,8,,Compound was evaluated for its agonistic activity on 5-hydroxytryptamine 1D receptor,F,,,,,CHEMBL617044,12469,H,BAO_0000019,1,,,,,105
1685,8,,Measurement of agonist-induced [35S]-GTP gamma-S binding in CHO cells stably transfected with 5-hydroxytryptamine 1D receptor,F,,,,,CHEMBL617045,3463,H,BAO_0000219,1,,,,CHO,105
1686,9,Homo sapiens,"Maximum stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing human 5-HT-1d relative to 5-HT",F,9606.0,,,,CHEMBL617046,15250,D,BAO_0000219,1,,,,CHO,105
1687,9,Homo sapiens,"Maximum stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing human 5-HT-1d relative to 5-HT",F,9606.0,,,,CHEMBL617047,15250,D,BAO_0000219,1,,,,CHO,105
1688,8,,"Efficacy was evaluated relative to human 5-hydroxytryptamine 1D receptor using [35S]GTP-gamma-S, as radioligand",F,,,,,CHEMBL617048,14956,H,BAO_0000019,1,,,,,105
1689,8,,"Maximum stimulation of [35S]GTP-gamma-S, binding expressed relative to the maximal effect produced by 5-hydroxytryptamine 1D receptor.",F,,,,,CHEMBL616897,14159,H,BAO_0000019,1,,,,,105
1690,9,Homo sapiens,"Maximum stimulation of [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1D receptor relative to 5-HT",F,9606.0,,,,CHEMBL616898,14159,D,BAO_0000019,1,,,,,105
1691,9,Homo sapiens,Percent efficacy relative to 5-HT treatment of CHO cells expressing 5-HT 1d receptor,F,9606.0,,,,CHEMBL858201,14499,D,BAO_0000219,1,,,,CHO,105
1692,8,,Intrinsic activity for 5-hydroxytryptamine 1D receptor,F,,,,,CHEMBL616899,15315,H,BAO_0000019,1,,,,,105
1693,8,,Ability to displace [3H]- -5-HT binding to cloned 5-hydroxytryptamine 1D receptor stably expressed in chinese hamster cells (CHO cells),B,,,,,CHEMBL616900,3294,H,BAO_0000219,1,,In vitro,,,105
1694,8,,Ability to displace [3H]-5-HT from recombinant human 5-hydroxytryptamine 1D receptor stably expressed in CHO cells determined in vitro,B,,,,,CHEMBL616901,3463,H,BAO_0000219,1,,,,CHO,105
1695,8,,Affinity of compound towards 5-hydroxytryptamine 1D receptor was evaluated using radioligand binding technique,B,,,,,CHEMBL616902,15331,H,BAO_0000357,1,,,,,105
1696,9,Homo sapiens,Displacement of [3H]5-HT from human 5-hydroxytryptamine 1D receptor expressed in CHO cells,B,9606.0,,,,CHEMBL616903,14159,D,BAO_0000219,1,,,,CHO,105
1697,8,,Binding affinity by displacement to human cloned 5-hydroxytryptamine 1D receptor in CHO cells by [3H]5-HT displacement.,B,,,,,CHEMBL616904,14158,H,BAO_0000219,1,,,,CHO,105
1698,8,,Compound was evaluated for the affinity at 5-hydroxytryptamine 1D receptor,B,,,,,CHEMBL616905,14159,H,BAO_0000357,1,,,,,105
1699,8,,Binding affinity at human cloned 5-hydroxytryptamine 1D receptor stably expressed in CHO cells by [3H]5-HT displacement.,B,,,,,CHEMBL616906,15250,H,BAO_0000219,1,,,,CHO,105
1700,8,,Displacement of [3H]5-HT binding to cloned human 5-hydroxytryptamine 1D receptor stably expressed in CHO cells,B,,,,,CHEMBL616907,15250,H,BAO_0000219,1,,,,CHO,105
1701,8,,Displacement of [3H]5-HT binding from the cloned human 5-hydroxytryptamine 1D receptor stably expressed in CHO cells,B,,,,,CHEMBL616908,15331,H,BAO_0000219,1,,,,CHO,105
1702,9,Homo sapiens,Displacement of [3H]5-HT binding from human 5-hydroxytryptamine 1D receptor expressed in CHO cells,B,9606.0,,,,CHEMBL616909,15332,D,BAO_0000219,1,,,,CHO,105
1703,9,Homo sapiens,Displacement of [3H]5-HT from human 5-hydroxytryptamine 1D receptor expressed in CHO cells,B,9606.0,,,,CHEMBL616910,14499,D,BAO_0000219,1,,,,CHO,105
1704,8,,Displacement of [3H]5-HT binding to the cloned human 5-hydroxytryptamine 1D receptor stably expressed in CHO cells,B,,,,,CHEMBL616911,15332,H,BAO_0000219,1,,,,CHO,105
1705,8,,Displacement of specific [3H]5-HT binding to cloned human 5-hydroxytryptamine 1D receptor expressed in CHO cells,B,,,,,CHEMBL616912,14956,H,BAO_0000219,1,,,,CHO,105
1706,8,,In vitro binding affinity against human 5-hydroxytryptamine 1D receptor at a concentration of 100 (nM),B,,,,,CHEMBL616913,3805,H,BAO_0000357,1,,,,,105
1707,9,Homo sapiens,Inhibition of [3H]5-HT binding to human 5-hydroxytryptamine 1D receptor expressed in CHO cells at 1 uM,B,9606.0,,,,CHEMBL616914,6011,D,BAO_0000219,1,,,,CHO,105
1708,8,,Binding affinity against 5-hydroxytryptamine 1D receptor in CHO cells using [3H]5-HT as radioligand,B,,,,,CHEMBL616915,16190,H,BAO_0000219,1,,,,CHO,105
1709,8,,Binding affinity for 5-hydroxytryptamine 1D receptor in Cos-7 transfected cell type using [3H]5-CT as radioligand,B,,,,,CHEMBL616916,14165,H,BAO_0000019,1,,,,,105
1710,9,Homo sapiens,Binding affinity to cloned human 5-hydroxytryptamine 1D receptor,B,9606.0,,,,CHEMBL616917,4234,D,BAO_0000357,1,,,,,105
1711,8,,"Binding affinity towards 5-HT1D receptor, using [3H]5-HT as radioligand.",B,,,,,CHEMBL616918,15527,H,BAO_0000357,1,,,,,105
1712,8,,Binding affinity towards human 5-hydroxytryptamine 1D receptor in L-M(tk-) cells using [3H]GR-125743 as radioligand,B,,,,,CHEMBL616919,6328,H,BAO_0000219,1,,,,,105
1713,8,,Binding affinity towards human 5-hydroxytryptamine 1D receptor was determined using [3H]5-HT as radioligand,B,,,,,CHEMBL616920,16209,H,BAO_0000357,1,,,,,105
1714,8,,Binding affinity for recombinant human 5-hydroxytryptamine 1D receptor using [3H]5-HT as radioligand.,B,,,,,CHEMBL872914,14770,H,BAO_0000357,1,,,,,105
1715,8,,Binding affinity was evaluated at human recombinant 5-hydroxytryptamine 1D receptor using [3H]-5-CT as radioligand,B,,,,,CHEMBL616921,2598,H,BAO_0000357,1,,,,,105
1716,8,,Binding affinity was evaluated at the cloned human 5-hydroxytryptamine 1D receptor,B,,,,,CHEMBL616922,6897,H,BAO_0000357,1,,,,,105
1717,8,,Binding affinity towards 5-hydroxytryptamine 1D receptor,B,,,,,CHEMBL616923,6013,H,BAO_0000357,1,,,,,105
1718,8,,Binding affinity towards cloned human 5-hydroxytryptamine 1D receptor,B,,,,,CHEMBL616924,5843,H,BAO_0000357,1,,,,,105
1719,8,,Binding affinity towards human 5-hydroxytryptamine 1D receptor using [3H]5-HT trifluoroacetate as radioligand,B,,,,,CHEMBL875909,14454,H,BAO_0000357,1,,,,,105
1720,8,,Binding affinity towards human 5-hydroxytryptamine 1D receptor using [3H]5-HT trifluoroacetate as radioligand; Not determined,B,,,,,CHEMBL616925,14454,H,BAO_0000357,1,,,,,105
1721,8,,Binding affinity towards human 5-hydroxytryptamine 1D receptor using [3H]5-HT trifluoroacetate as radioligand; not determined,B,,,,,CHEMBL616926,14454,H,BAO_0000357,1,,,,,105
1722,8,,Compound was evaluated for its binding affinity towards human 5-hydroxytryptamine 1D receptor,B,,,,,CHEMBL616927,15818,H,BAO_0000357,1,,,,,105
1723,8,,Ability to inhibit the forskolin-stimulated c-AMP formation mediated by human 5-hydroxytryptamine 1D receptor in CHO-K1 cells,F,,,,,CHEMBL616928,13729,H,BAO_0000219,1,,,,CHO-K1,105
1724,9,Homo sapiens,Displacement of [3H]5-HT from human 5-hydroxytryptamine 1D receptor expressed in Chinese hamster ovary cells (CHO cells),B,9606.0,,,,CHEMBL616929,6011,D,BAO_0000219,1,,In vitro,,,105
1725,9,Homo sapiens,In vitro binding affinity to human 5-hydroxytryptamine 1D receptor,B,9606.0,,,,CHEMBL616930,4234,D,BAO_0000357,1,,,,,105
1726,8,,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1D receptor,B,,,,,CHEMBL616931,17085,H,BAO_0000019,1,,,,,105
1727,8,,In vitro binding affinity was determined towards cloned human 5-hydroxytryptamine 1D receptor using [3H]5-CT radioligand,B,,,,,CHEMBL616932,3025,H,BAO_0000357,1,,,,,105
1728,8,,In vitro receptor binding affinity for cloned human 5-hydroxytryptamine 1D receptor,B,,,,,CHEMBL616933,15315,H,BAO_0000357,1,,,,,105
1729,9,Homo sapiens,Receptor binding affinity for cloned human 5-hydroxytryptamine 1D receptor in Cos-7 cells,B,9606.0,,,,CHEMBL616934,14214,D,BAO_0000219,1,,,,,105
1730,9,Homo sapiens,Binding affinity for human 5-hydroxytryptamine 1D receptor,B,9606.0,,,,CHEMBL616935,3804,D,BAO_0000357,1,,,,,105
1731,8,,The binding affinity towards the 5-hydroxytryptamine 1D receptor; No affinity,B,,,,,CHEMBL616936,16700,H,BAO_0000357,1,,,,,105
1732,9,Homo sapiens,Affinity for 5-hydroxytryptamine 1D receptor subtype,B,9606.0,,,,CHEMBL616937,2391,D,BAO_0000357,1,,,,,105
1733,9,Homo sapiens,Binding affinity for human 5-hydroxytryptamine 1D receptor,B,9606.0,,,,CHEMBL616938,4175,D,BAO_0000357,1,,,,,105
1734,8,,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1D receptor,B,,,,,CHEMBL616939,17085,H,BAO_0000019,1,,,,,105
1735,8,,In vitro binding affinity was determined by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1D receptor; ND means not determined,B,,,,,CHEMBL616940,17085,H,BAO_0000019,1,,,,,105
1736,9,Homo sapiens,Binding activity against human 5-hydroxytryptamine 1D receptor; NT means not tested,B,9606.0,,,,CHEMBL616941,15926,D,BAO_0000357,1,,,,,105
1737,8,,Binding affinity in CHO-K1 cells transfected with human 5-hydroxytryptamine 1D receptor; Not tested,B,,,,,CHEMBL616942,16312,H,BAO_0000219,1,,,,CHO-K1,105
1738,8,,Binding affinity in CHO-K1 cells transfected with human 5-hydroxytryptamine 1D receptor; not tested,B,,,,,CHEMBL616943,16312,H,BAO_0000219,1,,,,CHO-K1,105
1739,4,,Selectivity towards 5-HT1D and to that of 5-HT1B in CHO cells,B,,,,,CHEMBL616944,14956,H,BAO_0000219,1,,,,CHO,104802
1740,8,,"Maximum stimulation of [35S]GTP-gamma-S, binding expressed relative to the maximal effect produced by the 5-HT",F,,,,,CHEMBL616945,3294,H,BAO_0000019,1,,,,,105
1741,8,,Binding activity radioligand.,B,,,,,CHEMBL616946,12861,H,BAO_0000357,1,,,,,105
1742,8,,Binding activity against 5-hydroxytryptamine 3 receptor from rat cortex homogenate using [3H]-Q-ICS 205-930 as radioligand.,B,,,,,CHEMBL616947,12861,H,BAO_0000019,1,,,,,105
1743,8,,Binding affinity in CHO-K1 cells transfected with human 5-hydroxytryptamine 1D receptor,B,,,,,CHEMBL616948,16312,H,BAO_0000219,1,,,,CHO-K1,105
1744,8,,Binding affinity for human cloned 5-hydroxytryptamine 1D receptor,B,,,,,CHEMBL616851,5104,H,BAO_0000357,1,,,,,105
1745,8,,Binding affinity for human cloned 5-hydroxytryptamine 1D receptor,B,,,,,CHEMBL616852,5105,H,BAO_0000357,1,,,,,105
1746,8,,Measured as -log Ka on 5-hydroxytryptamine 1D receptor,B,,,,,CHEMBL616853,14499,H,BAO_0000357,1,,,,,105
1747,9,Homo sapiens,Binding activity against human 5-hydroxytryptamine 1D receptor,B,9606.0,,,,CHEMBL616854,15926,D,BAO_0000357,1,,,,,105
1748,9,Homo sapiens,Binding affinity to human cloned 5-hydroxytryptamine 1D receptor in CHO cells using [3H]5-HT as radioligand,B,9606.0,,,,CHEMBL616855,4540,D,BAO_0000219,1,,,,CHO,105
1749,8,,Binding affinity towards 5-hydroxytryptamine 1D (human cloned receptor) in CHO cells using [3H]-5-HT as radioligand.,B,,,,,CHEMBL616856,15779,H,BAO_0000219,1,,,,CHO,105
1750,8,,Binding affinity towards 5-hydroxytryptamine 1D (human cloned receptor) in CHO cells using [3H]5-HT as radioligand.,B,,,,,CHEMBL616857,15779,H,BAO_0000219,1,,,,CHO,105
1751,8,,Binding affinity towards cloned human 5-hydroxytryptamine 1D receptor,B,,,,,CHEMBL616858,6166,H,BAO_0000357,1,,,,,105
1752,8,,Binding affinity towards human cloned 5-hydroxytryptamine 1D receptor in CHO cells using [3H]5-HT as radioligand.,B,,,,,CHEMBL616859,15779,H,BAO_0000219,1,,,,CHO,105
1753,8,,Binding affinity towards human cloned 5-hydroxytryptamine 1D receptor in CHO cells using [3H]-5-HT as radioligand.;ND means no data.,B,,,,,CHEMBL616860,15779,H,BAO_0000219,1,,,,CHO,105
1754,8,,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 1D receptor expressed in HEK 293 cells using [3H]LSD as radioligand,B,,,,,CHEMBL616861,17451,H,BAO_0000219,1,,,,HEK293,105
1755,8,,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 1D receptor expressed in HEK 293 cells using [3H]LSD as radioligand,B,,,,,CHEMBL616541,17451,H,BAO_0000219,1,,,,HEK293,105
1756,8,,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 1D receptor expressed in HEK 293 cells using [3H]LSD as radioligand; Not determined,B,,,,,CHEMBL616542,17451,H,BAO_0000219,1,,,,HEK293,105
1757,8,,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 1D receptor in CHO cells using [3H]5-HT as the radioligand,B,,,,,CHEMBL616543,4199,H,BAO_0000219,1,,,,CHO,105
1758,9,Homo sapiens,Binding affinity for human 5-hydroxytryptamine 1D receptor,B,9606.0,,,,CHEMBL616544,14875,D,BAO_0000357,1,,,,,105
1759,8,,Compound was tested for its binding affinity against human cloned 5-hydroxytryptamine 1D receptor in CHO cells using [3H]5-HT,B,,,,,CHEMBL616545,15146,H,BAO_0000219,1,,,,CHO,105
1760,8,,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 1D receptor in CHO using [3H]5-HT as a radioligand,B,,,,,CHEMBL616546,5213,H,BAO_0000357,1,,,,,105
1761,8,,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 1D receptor in CHO cells using [3H]5-HT.,B,,,,,CHEMBL616547,14818,H,BAO_0000219,1,,,,CHO,105
1762,8,,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 1D receptor in CHO cells, using [3H]5-HT as radioligand",B,,,,,CHEMBL616548,4829,H,BAO_0000219,1,,,,CHO,105
1763,8,,Adenyl cyclase activity was expressed as percent forskolin response against 5-hydroxytryptamine 1D receptor at concentration 1 uM,F,,,,,CHEMBL616549,14454,H,BAO_0000019,1,,,,,105
1764,8,,Adenyl cyclase activity was expressed as percent forskolin response against 5-hydroxytryptamine 1D receptor at concentration 10 uM,F,,,,,CHEMBL616550,14454,H,BAO_0000019,1,,,,,105
1765,8,,Binding affinity against 5-HT2C receptor,B,,,,,CHEMBL857066,5254,H,BAO_0000357,1,,,,,108
1766,8,,Binding affinity against 5-hydroxytryptamine 1D receptor,B,,,,,CHEMBL616551,5254,H,BAO_0000357,1,,,,,108
1767,8,,Inhibition of Forskolin-stimulated adenylate cyclase activity against 5-hydroxytryptamine 1B receptor of rat substantia nigra,B,,,,,CHEMBL616552,10639,H,BAO_0000357,1,,,,,10577
1768,8,,Inhibition of Forskolin-stimulated adenylate cyclase activity against 5-hydroxytryptamine 1B receptor of rat substantia nigra,F,,,,,CHEMBL832876,10639,H,BAO_0000019,1,,,,,10577
1769,8,,"Binding affinity for 5-hydroxytryptamine 1B receptor in rat cortex, striatum and globus pallidus",B,,,,,CHEMBL616553,12352,H,BAO_0000019,1,,,,,10577
1770,8,,Binding affinity towards 5-HT1B was determined,B,,,,,CHEMBL616554,9098,H,BAO_0000357,1,,,,,10577
1771,8,,Affinity towards 5-hydroxytryptamine 1B receptor in membranes from rat frontal cortex using [3H]5-HT,B,,,,,CHEMBL616555,14430,H,BAO_0000019,1,,,,,10577
1772,8,,"Binding affinity to 5-HT1B receptors using rat cortex+striatum + globus pallidus,[3H]-5-OH-tryptamine, and serotonin for NSB",B,,,,,CHEMBL616556,13657,H,BAO_0000019,1,,,,,10577
1773,8,,"Compound was evaluated for binding affinity on 5-HT1B receptors using rat cortex+striatum+ globus pallidus,[ 3H]-5-OH-tryptamine, and serotonin for NSB.",B,,,,,CHEMBL616557,13657,H,BAO_0000019,1,,,,,10577
1774,8,,Binding affinity towards 5-hydroxytryptamine 1B receptor in rat frontal cortex using [125I]iodocyanopindolol as radio-ligand.,B,,,,,CHEMBL616558,15854,H,BAO_0000019,1,,,,,10577
1775,9,Rattus norvegicus,Inhibitory activity against 5-hydroxytryptamine 1B receptor of rat cortex using [3H]5-HT,B,10116.0,,,,CHEMBL616749,10639,D,BAO_0000019,1,,,,,10577
1776,8,,Concentration necessary to achieve half maximal inhibition of [125I]- Iodocyanopindolol binding to 5-hydroxytryptamine 1B receptor at 1 uM,B,,,,,CHEMBL616750,10025,H,BAO_0000357,1,,,,,10577
1777,8,,"Concentration necessary to achieve half maximal inhibition of [125I]- Iodocyanopindolol, binds to 5-hydroxytryptamine 1B receptor at 1 uM",B,,,,,CHEMBL616751,10025,H,BAO_0000357,1,,,,,10577
1778,8,,In vitro inhibitory concentration against radioligand [3H]5-HT binding to 5-hydroxytryptamine 1B receptor in rat striatal membrane,B,,,,,CHEMBL616752,14286,H,BAO_0000249,1,,,,,10577
1779,8,,Inhibition of [3H]-5-HT binding to 5-hydroxytryptamine 1B receptor in rat striatum; Residual radioligand binding higher than 50%,B,,Striatum,,,CHEMBL616753,3651,H,BAO_0000019,1,2435.0,,,,10577
1780,9,Rattus norvegicus,Inhibition of radiolabeled [3H]-5-HT ligand binding to 5-hydroxytryptamine 1B receptor,B,10116.0,,,,CHEMBL616754,14178,D,BAO_0000357,1,,,,,10577
1781,8,,Inhibitory activity against 5-hydroxytryptamine 1B receptor of rat cortex using [3H]5-HT as the radioligand.,B,,,,,CHEMBL616755,10639,H,BAO_0000019,1,,,,,10577
1782,8,,Inhibitory activity against [3H]5-HT binding to 5-HT1B receptor in rat striatum,B,,Striatum,,,CHEMBL616756,13605,H,BAO_0000019,1,2435.0,,,,10577
1783,8,,Inhibitory concentration required against 5-hydroxytryptamine 1B receptor in rat striatum using [3H]5-HT,B,,Striatum,,,CHEMBL616757,5834,H,BAO_0000019,1,2435.0,,,,10577
1784,8,,compound was measured for affinity against 5-hydroxytryptamine 1B receptor labelled with [3H]5-HT radioligand in striatum tissue,B,,Striatum,,,CHEMBL616758,10922,H,BAO_0000357,1,2435.0,,,,10577
1785,8,,Compound at 10E-5 M was tested in vitro for the inhibition of radioligand [3H]5-HT binding to 5-hydroxytryptamine 1B receptor in rat striatal membrane,B,,,,,CHEMBL616759,14286,H,BAO_0000249,1,,,,,10577
1786,8,,In vitro binding affinity towards the 5-hydroxytryptamine 1B receptor at 10 e-6 M,B,,,,,CHEMBL616760,11825,H,BAO_0000357,1,,,,,10577
1787,8,,Ability to displace [3H]5-HT bound to 5-hydroxytryptamine 1B receptor in rat striatum,B,,Striatum,,,CHEMBL616761,14826,H,BAO_0000019,1,2435.0,,,,10577
1788,8,,Binding affinity against 5-HT1B serotonin receptor in rat striatum,B,,Striatum,,,CHEMBL616762,9699,H,BAO_0000019,1,2435.0,,,,10577
1789,8,,Binding affinity against 5-hydroxytryptamine 1B receptor in membranes of Rat cerebral cortex,B,,,,,CHEMBL616763,14423,H,BAO_0000019,1,,,,,10577
1790,8,,Binding affinity at rat 5-hydroxytryptamine 1B receptor by [3H]5-HT displacement.,B,,,,,CHEMBL872909,10062,H,BAO_0000357,1,,,,,10577
1791,8,,Binding affinity determined in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 1B receptor,B,,,,,CHEMBL616764,10062,H,BAO_0000357,1,,,,,10577
1792,9,Rattus norvegicus,Inhibition of [3H]5-HT binding to 5-hydroxytryptamine 1B receptor,B,10116.0,,,,CHEMBL616765,12280,D,BAO_0000357,1,,,,,10577
1793,8,,Binding affinity against 5-hydroxytryptamine 1B receptor of rat striatum,B,,Striatum,,,CHEMBL616766,15412,H,BAO_0000357,1,2435.0,,,,10577
1794,8,,Binding affinity against 5-hydroxytryptamine 1B receptor of rat striatum.,B,,Striatum,,,CHEMBL616767,15412,H,BAO_0000357,1,2435.0,,,,10577
1795,8,,Binding affinity in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 1B receptor,B,,,,,CHEMBL616768,10062,H,BAO_0000357,1,,,,,10577
1796,8,,Binding affinity towards 5-hydroxytryptamine 1B receptor using [3H]5-HT as radioligand,B,,,,,CHEMBL616769,11147,H,BAO_0000357,1,,,,,10577
1797,8,,Binding affinity towards 5-hydroxytryptamine 1B receptor in rat was determined using 50 uL of [125I]ICYP in binding assay,B,,,,,CHEMBL616770,9547,H,BAO_0000019,1,,,,,10577
1798,8,,Binding affinity was determined against 5-hydroxytryptamine 1B receptor was determined in male Sprague-Dawley rat brain.,B,,,,,CHEMBL616771,10444,H,BAO_0000019,1,,,,,10577
1799,8,,Binding affinity was measured on 5-hydroxytryptamine 1B receptor in rat striatum labeled with [3H]5-HT,B,,Striatum,,,CHEMBL616772,12469,H,BAO_0000019,1,2435.0,,,,10577
1800,8,,Binding affinity (Ki) to rat cortical membranes at 5-HT1B binding site by using [125 I] ICYP as a radioligand.,B,,,,,CHEMBL616773,9098,H,BAO_0000019,1,,,,,10577
1801,8,,Compound was evaluated for the binding affinity (Ki) to rat cortical membranes at 5-HT1B binding site by using [125 I] ICYP as a radioligand; ND is no data.,B,,,,,CHEMBL616774,9098,H,BAO_0000019,1,,,,,10577
1802,8,,Evaluated for binding affinity towards 5-hydroxytryptamine 1B receptor,B,,,,,CHEMBL616775,9699,H,BAO_0000357,1,,,,,10577
1803,8,,Inhibitory activity against 5-hydroxytryptamine 1B receptor in rat cortical membranes using [3H]5-HT as a radioligand,B,,,,,CHEMBL616776,10394,H,BAO_0000249,1,,,,,10577
1804,8,,The binding affinity was measured on 5-hydroxytryptamine 1B receptor using [3H]- serotonin as radioligand.,B,,,,,CHEMBL616777,12092,H,BAO_0000357,1,,,,,10577
1805,8,,The binding affinity towards the receptor rat 5-hydroxytryptamine 1B receptor; No affinity,B,,,,,CHEMBL616778,16700,H,BAO_0000357,1,,,,,10577
1806,9,Rattus norvegicus,Binding affinity against 5-hydroxytryptamine 1B receptor in rat striatal membranes using [3H]5-HT as radioligand,B,10116.0,,,,CHEMBL616779,403,D,BAO_0000249,1,,,,,10577
1807,9,Rattus norvegicus,Binding affinity towards 5-hydroxytryptamine 1B receptor,B,10116.0,,,,CHEMBL616780,12771,D,BAO_0000357,1,,,,,10577
1808,8,,The compound was tested for its binding affinity towards 5-hydroxytryptamine 1B receptor by displacing [3H]serotonin radioligand in rat cerebral cortex,B,,,,,CHEMBL616781,11642,H,BAO_0000019,1,,,,,10577
1809,8,,The compound was tested for their binding affinity towards 5-hydroxytryptamine 1B receptor from rat striatum using [3H]5-HT as radioligand,B,,,,,CHEMBL616782,12953,H,BAO_0000357,1,,,,,10577
1810,8,,The compound was tested for their binding affinity towards 5-hydroxytryptamine 1B receptor from rat striatum using [3H]5-HT as radioligand.,B,,,,,CHEMBL616783,12953,H,BAO_0000357,1,,,,,10577
1811,8,,Binding affinity for 5-hydroxytryptamine 1B receptor in rat striatum using [3H]5-HT as radioligand,B,,Striatum,,,CHEMBL616784,12953,H,BAO_0000019,1,2435.0,,,,10577
1812,8,,The compound was tested for their binding affinity towards 5-hydroxytryptamine 1B receptor from rat striatum using [3H]5-HT as radioligand; Nonactive at 10 uM,B,,,,,CHEMBL616785,12953,H,BAO_0000357,1,,,,,10577
1813,8,,Binding affinity against 5-HT1B receptor in rat brain membrane using [3H]8-OH-DPAT as a selective ligand.,B,,Brain,,,CHEMBL857067,9737,H,BAO_0000249,1,955.0,,,,10577
1814,8,,Binding affinity against 5-HT1B receptor in rat frontal cortex using [3H]-5-HT in presence of 0.1 uM [3H]-8-OH-DPAT as a radioligand,B,,,,,CHEMBL616786,9737,H,BAO_0000019,1,,,,,10577
1815,8,,Binding affinity towards 5-HT1B receptor in rat brain membrane using [3H]8-OH-DPAT as a selective ligand.,B,,Brain,,,CHEMBL616787,9737,H,BAO_0000249,1,955.0,,,,10577
1816,8,,Binding affinity towards 5-hydroxytryptamine 2C receptor of porcine choroid plexus using [3H]mesulergine,B,,,,,CHEMBL616788,12827,H,BAO_0000357,1,,,,,10577
1817,8,,Ability to displace the radioligand [125I](-)-iodocyanopindolol from rat striatal 5-hydroxytryptamine 1B receptor,B,,,,,CHEMBL616789,5033,H,BAO_0000357,1,,,,,10577
1818,9,Rattus norvegicus,Displacement of [3H]5-HT from 5-HT1B receptor of rat frontal cortex homogenate,B,10116.0,,,,CHEMBL616790,9786,D,BAO_0000019,1,,,,,10577
1819,8,,Binding affinity at 5-hydroxytryptamine 1B receptor,B,,,,,CHEMBL616791,13116,H,BAO_0000357,1,,,,,10577
1820,8,,In vitro binding affinity at 5-hydroxytryptamine 1B receptor in rat striatal muscles using [125I](-)-iodocyanopindolol as the radioligand,B,,,,,CHEMBL616792,16429,H,BAO_0000019,1,,,,,10577
1821,9,Rattus norvegicus,In vitro binding affinity towards 5-hydroxytryptamine 1B receptor in rat striatal membrane with [125I]- iodocyanopindolol,B,10116.0,,,,CHEMBL616793,12409,D,BAO_0000249,1,,,,,10577
1822,8,,The compound was tested for the binding affinity against 5-hydroxytryptamine 1B receptor using [3H]5-HT as radioligand,B,,,,,CHEMBL616794,15194,H,BAO_0000357,1,,,,,10577
1823,8,,The compound was tested for the binding affinity against 5-hydroxytryptamine 1B receptor using [3H]5-HT as radioligand.,B,,,,,CHEMBL616795,15194,H,BAO_0000357,1,,,,,10577
1824,4,,Binding affinity towards 5-HT2 receptor by the displacement of [3H]-ketanserin] in rat cerebral cortex,B,,,,,CHEMBL616796,5486,H,BAO_0000019,1,,,,,104686
1825,8,,Compound was tested for binding affinity against 5-hydroxytryptamine 1B receptor,B,,,,,CHEMBL616797,4639,H,BAO_0000357,1,,,,,106
1826,8,,The compound was evaluated for its ability to displace [3H]5-HT from 5-hydroxytryptamine 1B receptor in cellular brain membranes,B,,,Brain membranes,,CHEMBL616798,386,H,BAO_0000249,1,,,,,106
1827,8,,Compound was measured for its binding affinity at 5-hydroxytryptamine 1B receptor at a concentration of 100 nM using [125I]CYP as radioligand,B,,,,,CHEMBL616799,2474,H,BAO_0000357,1,,,,,106
1828,8,,Inhibition of binding towards 5-hydroxytryptamine 1B receptor at 100 nM concentration,B,,,,,CHEMBL616800,6011,H,BAO_0000357,1,,,,,106
1829,8,,Percent inhibition (at 1 uM) against 5-hydroxytryptamine 1B receptor,B,,,,,CHEMBL616801,5014,H,BAO_0000357,1,,,,,106
1830,8,,Binding affinity of compound towards serotonin 5-hydroxytryptamine 1B receptor; inactive at 10 uM,B,,,,,CHEMBL616802,17515,H,BAO_0000357,1,,,,,106
1831,8,,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 1B receptor was determined,B,,,,,CHEMBL616803,4373,H,BAO_0000357,1,,,,,106
1832,8,,Binding affinity towards 5-hydroxytryptamine 1B receptor by displacement of [3H]5-HT.,B,,,,,CHEMBL857068,1633,H,BAO_0000357,1,,,,,106
1833,8,,Compound was evaluated for the binding affinity towards 5-hydroxytryptamine 1B receptor by displacement of [3H]ketanserin.,B,,,,,CHEMBL616804,1633,H,BAO_0000357,1,,,,,106
1834,8,,Binding affinity for 5-hydroxytryptamine 1B receptor was determined,B,,,,,CHEMBL616805,4373,H,BAO_0000357,1,,,,,106
1835,8,,Evaluated for the binding affinity to 5-hydroxytryptamine 1B receptor,B,,,,,CHEMBL616806,4687,H,BAO_0000357,1,,,,,106
1836,8,,Binding affinity against 5-hydroxytryptamine 1B receptor,B,,,,,CHEMBL616807,11574,H,BAO_0000357,1,,,,,106
1837,8,,Binding affinity for 5-hydroxytryptamine 1B receptor was determined by using [3H]5-HT as radioligand,B,,,,,CHEMBL616808,10321,H,BAO_0000357,1,,,,,106
1838,8,,Binding affinity towards 5-hydroxytryptamine 1B receptor using [3H]5-HT as radioligand.,B,,,,,CHEMBL616809,15527,H,BAO_0000357,1,,,,,106
1839,8,,Inhibitory constant against 5-hydroxytryptamine 1B receptor using with [125I]- cyanopindolol radioligand,B,,,,,CHEMBL616810,17200,H,BAO_0000357,1,,,,,106
1840,4,,Binding affinity against 5-hydroxytryptamine 1B receptor - 5-hydroxytryptamine 1D receptor using [3H]5-HT as the radioligand.,B,,,,,CHEMBL616811,14423,H,BAO_0000224,1,,,,,104802
1841,8,Bos taurus,Inhibitory concentration required against 5-hydroxytryptamine 1C receptor in bovine choroid plexus using [3H]mesulergine,B,9913.0,,,,CHEMBL616812,5834,H,BAO_0000357,1,,,,,108
1842,8,Sus scrofa,Binding affinity towards 5-hydroxytryptamine 1C receptor using [3H]mesulergine as radioligand,B,9823.0,,,,CHEMBL616813,11473,H,BAO_0000357,1,,,,,108
1843,8,Sus scrofa,Compound was evaluated for binding affinity towards 5-hydroxytryptamine 1C receptor in pig choroid plexus using [3H]mesulergine as radioligand,B,9823.0,,,,CHEMBL616814,11473,H,BAO_0000357,1,,,,,108
1844,8,Sus scrofa,Compound was evaluated for its inhibitory activity against 5-hydroxytryptamine 1C receptor of pig choroid plexus using [3H]mesulergine as the radioligand,B,9823.0,,,,CHEMBL616815,10639,H,BAO_0000357,1,,,,,108
1845,8,Sus scrofa,inhibitory activity against 5-hydroxytryptamine 1C receptor of pig choroid plexus using [3H]mesulergine as the radioligand,B,9823.0,,,,CHEMBL616816,10639,H,BAO_0000357,1,,,,,108
1846,8,Sus scrofa,Binding affinity of compound towards 5-hydroxytryptamine 1C receptor using [3H]mesulergine (1.2 nM) ligand in choroid Plexus pig was determined,B,9823.0,,,,CHEMBL616817,14331,H,BAO_0000357,1,,,,,108
1847,8,Sus scrofa,Compound was tested in vitro for binding affinity for 5-hydroxytryptamine 1C receptor,B,9823.0,,,,CHEMBL616818,10796,H,BAO_0000357,1,,,,,108
1848,8,Sus scrofa,Evaluated for the binding affinity to porcine choroid plexus at 5-hydroxytryptamine 2C receptor binding site by using [3H]-MES as a radioligand.,B,9823.0,,,,CHEMBL616819,9098,H,BAO_0000357,1,,,,,108
1849,8,Sus scrofa,Inhibition of [3H]mesulergine binding to 5-hydroxytryptamine 1C receptor of pig choroid Plexus,B,9823.0,,,,CHEMBL616820,14331,H,BAO_0000357,1,,,,,108
1850,8,Sus scrofa,Displacement of [3H]mesulergine from pig cortex 5-hydroxytryptamine 1C receptor,B,9823.0,,,,CHEMBL616821,11828,H,BAO_0000019,1,,,,,108
1851,8,Sus scrofa,Binding affinity for 5-hydroxytryptamine 1C receptor in piglet choroid plexus using [3H]5-HT,B,9823.0,,,,CHEMBL616822,11866,H,BAO_0000357,1,,,,,108
1852,8,Oryctolagus cuniculus,Binding affinity against 5-hydroxytryptamine 1D receptor alpha using rabbit saphenous vein assay.,B,9986.0,,,,CHEMBL616823,13047,H,BAO_0000019,1,,,,,108
1853,9,Rattus norvegicus,Tested for the effect on binding at 5-hydroxytryptamine 1C receptor; No activity,B,10116.0,,,,CHEMBL616824,188,D,BAO_0000357,1,,,,,12689
1854,9,Rattus norvegicus,In vitro binding affinity towards the 5-hydroxytryptamine 1C receptor at 10 e-6 M,B,10116.0,,,,CHEMBL616825,11825,D,BAO_0000357,1,,,,,12689
1855,9,Rattus norvegicus,In vitro binding affinity towards the 5-hydroxytryptamine 1C receptor at 10 e-6 M,B,10116.0,,,,CHEMBL616826,11825,D,BAO_0000357,1,,,,,12689
1856,9,Rattus norvegicus,Binding affinity against 5-hydroxytryptamine 1C receptor in rat using [3H]mesulergine as radioligand,B,10116.0,,,,CHEMBL616827,11624,D,BAO_0000019,1,,,,,12689
1857,9,Rattus norvegicus,Binding affinity towards 5-hydroxytryptamine 1C receptor using [125 I]-SCH23982 as radioligand in competitive binding assay,B,10116.0,,,,CHEMBL616828,11139,D,BAO_0000357,1,,,,,12689
1858,9,Rattus norvegicus,Binding affinity towards 5-hydroxytryptamine 1C receptor using [3H]mesulergine as radioligand,B,10116.0,,,,CHEMBL616829,11147,D,BAO_0000357,1,,,,,12689
1859,9,Rattus norvegicus,Binding affinity was determined against 5-hydroxytryptamine 1C receptor was determined in male Sprague-Dawley rat brain.,B,10116.0,,,,CHEMBL616830,10444,D,BAO_0000019,1,,,,,12689
1860,9,Rattus norvegicus,Binding affinity against 5-hydroxytryptamine 1C receptor,B,10116.0,,,,CHEMBL616831,11624,D,BAO_0000357,1,,,,,12689
1861,9,Rattus norvegicus,"Compound was tested for binding affinity towards 5-HT1C (5-HT1C) receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]mesulergine as radioligand",B,10116.0,,,,CHEMBL616832,11662,D,BAO_0000019,1,,,,,12689
1862,9,Rattus norvegicus,"Compound was tested for binding affinity towards 5-hydroxytryptamine 1C receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]mesulergine as radioligand",B,10116.0,,,,CHEMBL616833,11662,D,BAO_0000019,1,,,,,12689
1863,9,Rattus norvegicus,"Binding affinity towards 5-hydroxytryptamine 1C receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]mesulergine as radioligand",B,10116.0,,,,CHEMBL616834,11662,D,BAO_0000019,1,,,,,12689
1864,9,Rattus norvegicus,"Compound was tested for binding affinity towards 5-hydroxytryptamine 1C receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]mesulergine as radioligand",B,10116.0,,,,CHEMBL829595,11662,D,BAO_0000019,1,,,,,12689
1865,9,Rattus norvegicus,Evaluated for the binding affinity to porcine choroid plexus at 5-hydroxytryptamine 1C receptor binding site by using [3H]- MES as a radioligand.,B,10116.0,,,,CHEMBL616835,9098,D,BAO_0000357,1,,,,,12689
1866,9,Rattus norvegicus,Inhibitory activity against 5-hydroxytryptamine 1C receptor in rat cortical membranes using [3H]mesulergine as a radioligand,B,10116.0,,,,CHEMBL872910,10394,D,BAO_0000249,1,,,,,12689
1867,8,,Tested for binding affinity against 5-hydroxytryptamine 1C receptor from rat frontal cortical regions using [3H]mesulergine as radioligand,B,,,,,CHEMBL616836,11933,H,BAO_0000357,1,,,,,12689
1868,9,Rattus norvegicus,The binding affinity was measured on 5-hydroxytryptamine 1C receptor using [3H]- serotonin as radioligand.,B,10116.0,,,,CHEMBL616837,12092,D,BAO_0000357,1,,,,,12689
1869,9,Rattus norvegicus,Binding affinity of 5-hydroxytryptamine 1C receptor using [3H]- ketanserin in rat frontal cortex,B,10116.0,,,,CHEMBL616466,12253,D,BAO_0000019,1,,,,,12689
1870,9,Rattus norvegicus,Binding affinity towards rat 5-hydroxytryptamine 1C receptor using [3H]mesulergine as radioligand expressed in 293 cells,B,10116.0,,,,CHEMBL616467,12253,D,BAO_0000219,1,,,,HEK293,12689
1871,8,,Compound was tested for its affinity towards 5-hydroxytryptamine 1C receptor,B,,,,,CHEMBL616468,1558,H,BAO_0000357,1,,,,,108
1872,8,,Compound was measured for its binding affinity at 5-hydroxytryptamine 1C receptor at a concentration of 100 nM using [3H]mesulergine as radioligand,B,,,,,CHEMBL616469,2474,H,BAO_0000357,1,,,,,108
1873,8,,Compound was measured for its binding affinity at 5-hydroxytryptamine 1C receptor at a concentration of 100 nM using [3H]mesulergine as radioligand,B,,,,,CHEMBL616470,2474,H,BAO_0000357,1,,,,,108
1874,8,,Binding affinity against 5-hydroxytryptamine 1C receptor,B,,,,,CHEMBL616471,11574,H,BAO_0000357,1,,,,,12689
1875,8,,Compound was tested for its affinity towards 5-hydroxytryptamine 1C receptor,B,,,,,CHEMBL616472,1558,H,BAO_0000357,1,,,,,12689
1876,8,,Binding affinity against 5-hydroxytryptamine 1C receptor,B,,,,,CHEMBL616473,13944,H,BAO_0000357,1,,,,,12689
1877,8,,Binding affinity against serotonergic 5-HT1c receptor,B,,,,,CHEMBL616474,13033,H,BAO_0000357,1,,,,,12689
1878,8,,Binding affinity for 5-hydroxytryptamine 1C receptor was determined by using [3H]- mesulergine as radioligand,B,,,,,CHEMBL616475,10321,H,BAO_0000357,1,,,,,12689
1879,8,,Binding affinity for 5-hydroxytryptamine 1C receptor was determined,B,,,,,CHEMBL616476,11866,H,BAO_0000357,1,,,,,12689
1880,8,Oryctolagus cuniculus,Compound was tested for 5-hydroxytryptamine 1D like receptor-mediated vascular effect in rabbit saphenous vein (RSV),B,9986.0,,,,CHEMBL616477,14454,H,BAO_0000019,1,,,,,105
1881,4,,Binding affinity against 5-hydroxytryptamine 2 receptor using [125I]DOI as radioligand.,B,,,,,CHEMBL616478,11574,H,BAO_0000224,1,,,,,104686
1882,4,,Binding affinity against 5-hydroxytryptamine 2 receptor using [3H]ket as radioligand.,B,,,,,CHEMBL616479,11574,H,BAO_0000224,1,,,,,104686
1883,4,,Binding affinity towards serotonin 5-HT2 receptor was determined in rat cortex using [3H]spiperone as ligand,B,,,,,CHEMBL616480,13631,H,BAO_0000019,1,,,,,104686
1884,5,Rattus norvegicus,Binding affinity towards 5-hydroxytryptamine 2 receptor as antagonism of serotonin-induced contractions in rat jugular vein,B,10116.0,,,,CHEMBL616481,9630,D,BAO_0000019,1,,,,,104686
1885,5,Rattus norvegicus,Binding affinity towards 5-hydroxytryptamine 2 receptor in rat brain cortical membranes,B,10116.0,,,,CHEMBL616482,8822,D,BAO_0000249,1,,,,,104686
1886,5,Rattus norvegicus,Binding affinity towards 5-hydroxytryptamine 2 receptor in rat brain using [3H]spiroperidol,B,10116.0,Brain,,,CHEMBL884713,9064,D,BAO_0000221,1,955.0,,,,104686
1887,4,,Binding affinity towards 5-hydroxytryptamine 2 receptor measured using radioligand ([3H]spiperone) binding assay,B,,,,,CHEMBL616483,8868,H,BAO_0000224,1,,,,,104686
1888,4,,Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]- spiroperidol,B,,,,,CHEMBL616484,9064,H,BAO_0000224,1,,,,,104686
1889,4,,Binding affinity at 5-hydroxytryptamine 2 receptor from rat frontal cortex homogenates by [3H]-spiperone displacement.,B,,,,,CHEMBL616485,9806,H,BAO_0000019,1,,,,,104686
1890,4,,Binding affinity towards 5-hydroxytryptamine 2 receptor was determined,B,,,,,CHEMBL616486,9098,H,BAO_0000224,1,,,,,104686
1891,4,,Binding affinity towards 5-hydroxytryptamine 2 receptor was measured using radioligand ([3H]spiperone) binding assay,B,,,,,CHEMBL616487,8868,H,BAO_0000224,1,,,,,104686
1892,4,,Binding affinity at serotonin 5-hydroxytryptamine 2 receptor by [3H]ketanserin displacement.,B,,,,,CHEMBL616488,12765,H,BAO_0000224,1,,,,,104686
1893,4,,Compound was evaluated In vitro for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]ketanserin as radioligand.,B,,,,,CHEMBL616489,11049,H,BAO_0000019,1,,,,,104686
1894,4,,Compound was evaluated In vitro for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]ketanserin as radioligand.,B,,,,,CHEMBL616490,11049,H,BAO_0000019,1,,,,,104686
1895,4,,Compound was evaluated In vitro for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]-Ketanserin as radioligand; not determined,B,,,,,CHEMBL616491,11049,H,BAO_0000019,1,,,,,104686
1896,4,,Compound was evaluated In vitro for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]ketanserin as radioligand; ND-Not determined,B,,,,,CHEMBL616492,11049,H,BAO_0000019,1,,,,,104686
1897,4,,Compound was evaluated In vitro for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]ketanserin as radioligand.,B,,,,,CHEMBL616493,11049,H,BAO_0000019,1,,,,,104686
1898,4,,Compound was evaluated for binding affinity towards 5-hydroxytryptamine 2 receptor in rat anterior cortex using [125I]DOI as radioligand,B,,,,,CHEMBL616494,11473,H,BAO_0000019,1,,,,,104686
1899,4,,Compound was evaluated for binding affinity towards 5-hydroxytryptamine 2 receptor in rat anterior cortex using [3H]ketanserin as radioligand,B,,,,,CHEMBL616495,11473,H,BAO_0000019,1,,,,,104686
1900,4,,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor in rat pre frontal cortex,B,,,,,CHEMBL616496,3086,H,BAO_0000019,1,,,,,104686
1901,4,,Compound was evaluated for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]ketanserin as radioligand.,B,,,,,CHEMBL616497,11049,H,BAO_0000019,1,,,,,104686
1902,4,,Compound was evaluated for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]ketanserin as radioligand.,B,,,,,CHEMBL616498,11049,H,BAO_0000019,1,,,,,104686
1903,4,,Compound was evaluated for its inhibitory activity against 5-hydroxytryptamine 2 receptor of rat anterior cortex using [3H]ketanserin as the radioligand,B,,,,,CHEMBL616499,10639,H,BAO_0000019,1,,,,,104686
1904,4,,Compound was measured for affinity at 5-hydroxytryptamine 2 receptor in rat cortical by [3H]spiroperidol displacement.,B,,,,,CHEMBL616500,10922,H,BAO_0000019,1,,,,,104686
1905,5,Rattus norvegicus,Binding affinity against serotonin-2 receptor in rat brain using [3H]spiroperidol,B,10116.0,Brain,,,CHEMBL616501,9064,D,BAO_0000221,1,955.0,,,,104686
1906,4,,Compound was tested for its inhibitory effect on the binding profile in 5-hydroxytryptamine 2 receptor using [3H]spiroperidol in rat brain.,B,,Brain,,,CHEMBL616502,10748,H,BAO_0000221,1,955.0,,,,104686
1907,4,,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor from rat cortical membranes.,B,,,Membranes,,CHEMBL884529,11614,H,BAO_0000249,1,,,,,104686
1908,4,,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor in rat cortical membranes,B,,,Membranes,,CHEMBL616503,11615,H,BAO_0000249,1,,,,,104686
1909,4,,Compound was tested for the displacement of [3H]ketanserin from serotonin 5-hydroxytryptamine 2 receptor,B,,,,,CHEMBL616964,11615,H,BAO_0000224,1,,,,,104686
1910,4,,Compound was tested for the displacement of [3H]ketanserin from serotonin 5-hydroxytryptamine 2 receptor from rat cortical membranes.,B,,,Membranes,,CHEMBL616965,11614,H,BAO_0000249,1,,,,,104686
1911,4,,Inhibition of [3H]ketanserin binding to rat 5-hydroxytryptamine 2 receptors.,B,,,,,CHEMBL616966,11702,H,BAO_0000224,1,,,,,104686
1912,4,,Compound was tested for the inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor; NT=Not tested,B,,,,,CHEMBL616967,11702,H,BAO_0000224,1,,,,,104686
1913,5,Rattus norvegicus,Inhibition of [3H]ketanserin binding to dopamine 5-hydroxytryptamine 2 receptor,B,10116.0,,,,CHEMBL616968,11702,D,BAO_0000224,1,,,,,104686
1914,4,,Compound was tested for the inhibition of [3H]ketanserin binding to dopamine 5-hydroxytryptamine 2 receptor; NT=Not tested,B,,,,,CHEMBL616969,11702,H,BAO_0000224,1,,,,,104686
1915,4,,Inhibition of [3H]ketanserin binding at 5-hydroxytryptamine 2 receptor from rat frontal cortex.,B,,,,,CHEMBL884530,13346,H,BAO_0000019,1,,,,,104686
1916,4,,Concentration necessary to achieve half maximal inhibition of [3H]-ketanserin binding to 5-hydroxytryptamine 2 receptor,B,,,,,CHEMBL616970,10025,H,BAO_0000224,1,,,,,104686
1917,4,,Concentration necessary to achieve half maximal inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor at 1 uM,B,,,,,CHEMBL616971,10025,H,BAO_0000224,1,,,,,104686
1918,4,,"Concentration necessary to achieve half maximal inhibition of [3H]ketanserin, binds to 5-hydroxytryptamine 2 receptor at 1 uM",B,,,,,CHEMBL616972,10025,H,BAO_0000224,1,,,,,104686
1919,4,,Evaluated for binding affinity towards 5-hydroxytryptamine 2 receptor using radioligand [3H]-spiperone,B,,,,,CHEMBL616973,9036,H,BAO_0000224,1,,,,,104686
1920,4,,Evaluated for binding affinity towards 5-hydroxytryptamine 2 receptor using radioligand [3H]spiperone; IA=Inactive,B,,,,,CHEMBL616974,9036,H,BAO_0000224,1,,,,,104686
1921,4,,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue.,B,,,,,CHEMBL616975,9161,H,BAO_0000019,1,,,,,104686
1922,4,,Inhibition of binding of radioligand [3H]ketanserin to 5-hydroxytryptamine 2 receptor in rat cerebral cortex,B,,,,,CHEMBL616976,12304,H,BAO_0000019,1,,,,,104686
1923,4,,In vitro binding affinity measured on serotonin 5-hydroxytryptamine 2 receptor using [3H]ketanserin as radioligand.,B,,,,,CHEMBL616977,13276,H,BAO_0000224,1,,,,,104686
1924,4,,In vitro binding affinity towards the 5-hydroxytryptamine 2 receptor at 10 e-6 M,B,,,,,CHEMBL616978,11825,H,BAO_0000224,1,,,,,104686
1925,4,,In vitro binding affinity was measured on serotonergic 5-hydroxytryptamine 2 receptor by displacement of [3H]- ketanserin,B,,,,,CHEMBL616979,12443,H,BAO_0000224,1,,,,,104686
1926,4,,In vitro inhibitory activity against [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor,B,,,,,CHEMBL616980,13830,H,BAO_0000224,1,,,,,104686
1927,4,,Inhibition of [3H]spiperone binding to 5-hydroxytryptamine 2 receptor from rat cortical membranes,B,,,Membranes,,CHEMBL616981,9592,H,BAO_0000249,1,,,,,104686
1928,4,,Inhibition of [3H]spiperone binding to 5-hydroxytryptamine 2 receptor from rat cortical membranes; Not tested,B,,,Membranes,,CHEMBL616982,9592,H,BAO_0000249,1,,,,,104686
1929,4,,Inhibitory activity against 5-hydroxytryptamine 2 receptor by 3H ligand binding experiments.,B,,,,,CHEMBL616983,10881,H,BAO_0000224,1,,,,,104686
1930,4,,Inhibitory activity against [3H]spiroperidol binding to 5-HT2 receptor in rat cortex,B,,,,,CHEMBL616984,13605,H,BAO_0000019,1,,,,,104686
1931,5,Rattus norvegicus,Inhibitory activity against 5-hydroxytryptamine 2 receptor,B,10116.0,,,,CHEMBL616985,11624,D,BAO_0000224,1,,,,,104686
1932,4,,Inhibitory concentration against 5-hydroxytryptamine 2 receptor from striata of male Wistar rats by displacement of [3H]-ketanserin,B,,,,,CHEMBL616986,4101,H,BAO_0000224,1,,,,,104686
1933,4,,Inhibitory concentration against binding of 5-hydroxytryptamine 2 receptor from striata of male Wistar rats by displacement of [3H]-ketanserin,B,,,,,CHEMBL616987,4101,H,BAO_0000224,1,,,,,104686
1934,4,,Inhibitory concentration against radioligand [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor in rat,B,,,,,CHEMBL616988,15360,H,BAO_0000019,1,,,,,104686
1935,4,,Inhibitory concentration against radioligand [3H]spiperone binding to 5-hydroxytryptamine 2 receptor in rat cortex,B,,,,,CHEMBL617243,11576,H,BAO_0000019,1,,,,,104686
1936,4,,Inhibitory concentration required against 5-hydroxytryptamine 2 receptor in rat cortex using [3H]spiperone,B,,,,,CHEMBL617244,5834,H,BAO_0000019,1,,,,,104686
1937,5,Rattus norvegicus,Inhibitory concentration against [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor expressed in CHO-K1 cells,B,10116.0,,,,CHEMBL617245,2395,D,BAO_0000219,1,,,,CHO-K1,104686
1938,4,,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor in rat cortical membranes,B,,,Membranes,,CHEMBL617246,11965,H,BAO_0000249,1,,,,,104686
1939,4,,The compound was evaluated for the ability to displace [3H]ketanserin from 5-hydroxytryptamine 2 receptor ( striata of male wistar rats),B,,,,,CHEMBL617546,3967,H,BAO_0000224,1,,,,,104686
1940,4,,The concentration required to inhibit [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor in rat brain membranes (in vitro),B,,,Brain membranes,,CHEMBL617547,11130,H,BAO_0000249,1,,,,,104686
1941,4,,Binding affinity of [3H]ketanserin towards 5-hydroxytryptamine 2 receptor in cloned mammalian receptor expressed in cultured cells or from rat whole brain.,B,,,,,CHEMBL617548,13427,H,BAO_0000219,1,,In vitro,,,104686
1942,4,,Binding affinity towards 5-hydroxytryptamine 2 receptor,B,,,,,CHEMBL617549,9443,H,BAO_0000224,1,,,,,104686
1943,4,,Binding affinity towards 5-hydroxytryptamine 2 receptor at 1.0 uM concentration,B,,,,,CHEMBL617550,9443,H,BAO_0000224,1,,,,,104686
1944,4,,In vitro binding affinity towards the 5-hydroxytryptamine 2 receptor at 10 e-6 M,B,,,,,CHEMBL617551,11825,H,BAO_0000224,1,,,,,104686
1945,4,,Percent inhibition of binding of 1.0 nM [3H]ketanserin to 5-hydroxytryptamine 2 receptor in rat cortical membranes at 10 e -5 M,B,,,Membranes,,CHEMBL617552,12120,H,BAO_0000249,1,,,,,104686
1946,4,,Percent inhibition of binding of 1.0 nM [3H]-ketanserin to 5-hydroxytryptamine 2 receptor in rat cortical membranes at 10 e-5 M.,B,,,Membranes,,CHEMBL617553,12120,H,BAO_0000249,1,,,,,104686
1947,4,,Tested for antagonistic activity against 5-hydroxytryptamine 2 receptor from rat thoracic aorta,F,,Thoracic aorta,,,CHEMBL617554,11963,H,BAO_0000019,1,1515.0,,,,104686
1948,4,,Binding affinity for membrane-bound 5-hydroxytryptamine 2 receptor,B,,,,,CHEMBL617555,9069,H,BAO_0000019,1,,,,,104686
1949,4,,Compound was tested for its effect on 5-hydroxytryptamine 2 receptor saturation analysis,B,,,,,CHEMBL617556,8868,H,BAO_0000224,1,,,,,104686
1950,8,,Inhibitory constant against human 5-hydroxytryptamine 1B receptor using [3H]5-CT radioligand,B,,,,,CHEMBL617557,17200,H,BAO_0000357,1,,,,,10624
1951,8,,Inhibitory constant against human 5-hydroxytryptamine 1D receptor using [3H]5-CT radioligand,B,,,,,CHEMBL617558,17200,H,BAO_0000357,1,,,,,10624
1952,8,,Binding affinity against 5-hydroxytryptamine 1D receptor was measured using [3H]5-HT as radioligand,B,,,,,CHEMBL617559,13969,H,BAO_0000357,1,,,,,17106
1953,9,,Binding affinity for 5-hydroxytryptamine 1D receptor,B,,,,,CHEMBL617560,13392,D,BAO_0000357,1,,,,,17106
1954,8,,Compound was tested for its ability to displace [125I]GTI binding to 5-hydroxytryptamine 1D receptor recognition sites in pig caudate membranes,B,,,,,CHEMBL617561,1742,H,BAO_0000249,1,,,,,17106
1955,8,,Compound was tested for its ability to displace [3H]-5-HT binding to 5-hydroxytryptamine 1D receptor recognition sites in pig caudate membranes,B,,,,,CHEMBL617562,1742,H,BAO_0000249,1,,,,,17106
1956,8,,Binding affinity against 5-hydroxytryptamine 1D receptor using [3H]5-HT in pig striatum + frontalCortex,B,,Striatum,,,CHEMBL617563,14331,H,BAO_0000357,1,2435.0,,,,17106
1957,8,,Relative agonist efficacy against 1 uM 5-hydroxytryptamine 1D receptor,F,,,,,CHEMBL617564,12861,H,BAO_0000019,1,,,,,17106
1958,8,,Binding activity against 5-hydroxytryptamine 1D receptor from pig caudate membrane using [3H]5-HT as radioligand,B,,,,,CHEMBL617565,12861,H,BAO_0000019,1,,,,,17106
1959,8,,Binding activity radioligand.,B,,,,,CHEMBL856076,12861,H,BAO_0000357,1,,,,,17106
1960,8,,Binding activity against 5-hydroxytryptamine 2C receptor from human brain cortex using [3H]mesulergine as radioligand.,B,,,,,CHEMBL617566,12861,H,BAO_0000019,1,,,,,17106
1961,8,,Binding activity against 5-hydroxytryptamine 3 receptor from rat cortex homogenate using [3H]-Q-ICS 205-930 as radioligand.,B,,,,,CHEMBL875911,12861,H,BAO_0000019,1,,,,,17106
1962,8,,Binding activity against 5-hydroxytryptamine 3 receptor from rat cortex homogenate using [3H]-Q-ICS 205-930 as radioligand; NA Not Available,B,,,,,CHEMBL617567,12861,H,BAO_0000019,1,,,,,17106
1963,8,,Compound was tested for the displacement of [3H]-5-HT to 5-hydroxytryptamine 1D receptor recognition sites in pig caudate membranes,B,,,,,CHEMBL617568,675,H,BAO_0000249,1,,,,,17106
1964,8,,Displacement of [3H]5-HT binding to 5-hydroxytryptamine 1D receptor from pig caudate membrane,B,,,,,CHEMBL617569,12490,H,BAO_0000019,1,,,,,17106
1965,8,,Displacement of radioligand [3H]5-HT binding to 5-hydroxytryptamine 1D receptor in pig caudate membrane,B,,,,,CHEMBL617570,11828,H,BAO_0000249,1,,,,,17106
1966,8,,Binding affinity for 5-hydroxytryptamine 1D receptor in piglet caudate using [3H]5-HT,B,,,,,CHEMBL617571,11866,H,BAO_0000357,1,,,,,17106
1967,8,Sus scrofa,In Vitro Binding affinity againist 5-hydroxytryptamine 1D receptor by displacing [125I]GTI from pig caudate,B,9823.0,,,,CHEMBL617572,773,H,BAO_0000357,1,,,,,105
1968,8,Oryctolagus cuniculus,The compound was tested for intrinsic activity against 5-HT1D receptor,B,9986.0,,,,CHEMBL617573,13047,H,BAO_0000357,1,,,,,105
1969,8,Oryctolagus cuniculus,Intrinsic activity against 5-hydroxytryptamine 1 receptor using rabbit saphenous vein assay.,B,9986.0,,,,CHEMBL617574,13047,H,BAO_0000019,1,,,,,105
1970,8,Oryctolagus cuniculus,The compound was tested for binding affinity against 5-HT1D receptor,B,9986.0,,,,CHEMBL617575,13047,H,BAO_0000357,1,,,,,105
1971,8,,Tested for the effect on binding at 5-hydroxytryptamine 1D receptor; No activity,B,,,,,CHEMBL617576,188,H,BAO_0000357,1,,,,,10578
1972,8,,Inhibition of Forskolin-stimulated adenylate cyclase activity against 5-hydroxytryptamine 1D receptor of rat substantia nigra,F,,,,,CHEMBL617577,10639,H,BAO_0000019,1,,,,,10578
1973,8,,Inhibition of forskolin stimulated adenylate cyclase at 5-hydroxytryptamine 1D receptor,F,,,,,CHEMBL617578,12438,H,BAO_0000019,1,,,,,10578
1974,8,,Binding affinity was measured against serotonin 5-hydroxytryptamine 1D receptor,B,,,,,CHEMBL617579,12438,H,BAO_0000357,1,,,,,10578
1975,8,,Binding affinity towards 5-hydroxytryptamine 1D receptor in rat frontal cortex using [125I]iodocyanopindolol as radio-ligand.,B,,,,,CHEMBL617580,15854,H,BAO_0000019,1,,,,,10578
1976,8,,Inhibitory activity against 5-hydroxytryptamine 1D receptor in rat cortical membranes using [3H]5-HT as a radioligand,B,,,,,CHEMBL617581,10394,H,BAO_0000249,1,,,,,10578
1977,8,,The binding affinity was measured on 5-hydroxytryptamine 1D receptor using [3H]- serotonin as radioligand.,B,,,,,CHEMBL617582,12092,H,BAO_0000357,1,,,,,10578
1978,8,,Binding affinity to 5-hydroxytryptamine 1D receptor in the rat forebrain by [3H]- SB-204269 displacement.,B,,,,,CHEMBL617583,3389,H,BAO_0000019,1,,,,,10578
1979,8,,Inhibition of binding towards 5-hydroxytryptamine 1D receptor at 100 nM concentration,B,,,,,CHEMBL617584,6011,H,BAO_0000357,1,,,,,105
1980,8,,Compound was tested for binding affinity against 5-hydroxytryptamine 1D receptor,B,,,,,CHEMBL617585,4639,H,BAO_0000357,1,,,,,105
1981,8,,Compound was measured for its binding affinity at 5-hydroxytryptamine 1D receptor at a concentration of 10 uM using [3H]5-HT as radioligand,B,,,,,CHEMBL875912,2474,H,BAO_0000357,1,,,,,105
1982,8,,Percent inhibition (at 1 uM) against 5-hydroxytryptamine 1D receptor,B,,,,,CHEMBL617586,5014,H,BAO_0000357,1,,,,,105
1983,8,,Binding affinity of compound towards serotonin 5-hydroxytryptamine 1D receptor; inactive at 10 uM,B,,,,,CHEMBL617587,17515,H,BAO_0000357,1,,,,,105
1984,8,,Binding affinity for 5-hydroxytryptamine 1D receptor was determined,B,,,,,CHEMBL617588,11866,H,BAO_0000357,1,,,,,105
1985,8,,Evaluated for the binding affinity against 5-hydroxytryptamine 1D receptor,B,,,,,CHEMBL857980,4687,H,BAO_0000357,1,,,,,105
1986,8,,Tested against 5-hydroxytryptamine 1D receptor,B,,,,,CHEMBL617589,12146,H,BAO_0000357,1,,,,,105
1987,8,,Binding affinity for 5-hydroxytryptamine 1D receptor was determined by using [3H]5-HT as radioligand,B,,,,,CHEMBL617590,10321,H,BAO_0000357,1,,,,,105
1988,8,,Antagonistic binding affinity measured against 5-hydroxytryptamine 2A receptor (human clone expressed in 293 cells) using [3H]ketanserin as radioligand,B,,,,,CHEMBL617591,13267,H,BAO_0000219,1,,,,HEK293,105
1989,9,Homo sapiens,Binding affinity against 5-Hydroxytryptamine 1D receptor,B,9606.0,,,,CHEMBL617592,1274,D,BAO_0000357,1,,,,,105
1990,8,,,B,,,,,CHEMBL617593,15250,H,BAO_0000357,1,,,,,105
1991,8,,Compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1D receptor alpha expressed in CHO-K1 cells.,B,,,,,CHEMBL617594,13706,H,BAO_0000219,1,,,,CHO-K1,106
1992,8,,Compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1D receptor alpha expressed in CHO-K1 cells.,B,,,,,CHEMBL617595,13706,H,BAO_0000219,1,,,,CHO-K1,105
1993,8,,Compound was tested for binding affinity against human 5-hydroxytryptamine 1D receptor alpha clones expressed in human embryonic kidney (HEK 293) cells line.,B,,,,,CHEMBL617596,13706,H,BAO_0000219,1,,,,HEK293,105
1994,8,,Compound was tested for binding affinity against human 5-hydroxytryptamine 1D receptor alpha clones expressed in human embryonic kidney (HEK 293) cells line; NT= not tested,B,,,,,CHEMBL617597,13706,H,BAO_0000219,1,,,,HEK293,105
1995,8,,Binding affinity against 5-hydroxytryptamine 1D receptor beta using rabbit saphenous vein assay.,B,,,,,CHEMBL617598,13047,H,BAO_0000019,1,,,,,105
1996,8,,Binding affinity of compound against 5-HT1Dalpha Binding affinity of compound against 5-HT1D alpha receptors in human,B,,,,,CHEMBL872916,13366,H,BAO_0000357,1,,,,,105
1997,8,,In vitro affinity human cloned 5-hydroxytryptamine 1D receptor alpha by [3H]5-HT displacement.,B,,,,,CHEMBL617599,13366,H,BAO_0000357,1,,,,,105
1998,8,,Binding affinity towards cloned human 5-hydroxytryptamine 1D receptor alpha was determined,B,,,,,CHEMBL617091,1558,H,BAO_0000357,1,,,,,105
1999,8,,"Binding affinity against 5-hydroxytryptamine 1D receptor alpha expressed in CHO-K1 cells, using [3H]-5-HT as the radioligand.",B,,,,,CHEMBL617092,12902,H,BAO_0000219,1,,,,CHO-K1,105
2000,8,,Compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1D receptor alpha expressed in CHO-K1 cells.,B,,,,,CHEMBL617093,13706,H,BAO_0000219,1,,,,CHO-K1,105
2001,8,,Compound was tested for intrinsic efficacy against human 5-hydroxytryptamine 1D receptor alpha measured as the reduction of forskolin-stimulated cAMP.,F,,,,,CHEMBL617094,13706,H,BAO_0000019,1,,,,,105
2002,8,,Compound was tested for intrinsic efficacy against human 5-hydroxytryptamine 1D receptor beta measured as the reduction of forskolin-stimulated cAMP.,F,,,,,CHEMBL617095,13706,H,BAO_0000019,1,,,,,105
2003,8,,Compound was tested for its agonist activity against human 5-hydroxytryptamine 1D receptor alpha for comparison purpose.,F,,,,,CHEMBL617096,14251,H,BAO_0000019,1,,,,,105
2004,8,,Compound was tested for its agonist activity against human recombinant 5-hydroxytryptamine 1D receptor alpha for comparison purpose.,F,,,,,CHEMBL617097,14251,H,BAO_0000019,1,,,,,105
2005,8,,Compound was tested for its agonist activity against human recombinant 5-hydroxytryptamine 1D receptor alpha for comparison purpose.,F,,,,,CHEMBL617098,14251,H,BAO_0000019,1,,,,,105
2006,8,,In vitro binding affinity towards 5-HT1D alpha receptor by using [3H]5-HT as radioligand,B,,,,,CHEMBL617301,13313,H,BAO_0000357,1,,,,,105
2007,8,,In vitro binding affinity towards 5-hydroxytryptamine 1D receptor alpha by using [3H]5-HT as radioligand,B,,,,,CHEMBL617302,13313,H,BAO_0000357,1,,,,,105
2008,8,,Selectivity towards 5-hydroxytryptamine 1D receptor beta to that of 5-hydroxytryptamine 1D receptor alpha,B,,,,,CHEMBL617303,13366,H,BAO_0000357,1,,,,,105
2009,8,,Binding affinity to recombinant human 5-hydroxytryptamine 1D receptor alpha,B,,,,,CHEMBL617304,13051,H,BAO_0000357,1,,,,,105
2010,8,,"In vitro binding affinity against cloned mammalian 5-hydroxytryptamine 1D receptor alpha expressed in CHO cells, by using [3H]5-HT as radioligand",B,,,,,CHEMBL617305,12903,H,BAO_0000219,1,,,,CHO,105
2011,9,Homo sapiens,Binding affinity was measured on 5-hydroxytryptamine 1D receptor alpha in COS cells transfected with human 5-HT1D alpha gene labeled with [3H]5-HT,B,9606.0,,,,CHEMBL617306,12469,D,BAO_0000219,1,,,,,105
2012,8,,Binding affinity (in vitro) against 5-hydroxytryptamine 1D receptor alpha using radio-ligand binding assay,B,,,,,CHEMBL617307,5619,H,BAO_0000357,1,,,,,17106
2013,8,Oryctolagus cuniculus,Binding affinity against 5-hydroxytryptamine 4 receptor using rabbit saphenous vein assay.,B,9986.0,,,,CHEMBL617308,13047,H,BAO_0000019,1,,,,,105
2014,8,,Binding affinities against 5-hydroxytryptamine 1D receptor alpha,B,,,,,CHEMBL617309,16633,H,BAO_0000357,1,,,,,105
2015,8,,Binding affinities towards 5-hydroxytryptamine 1D receptor alpha,B,,,,,CHEMBL617310,16633,H,BAO_0000357,1,,,,,105
2016,8,,Binding affinities towards 5-hydroxytryptamine 1D receptor alpha,B,,,,,CHEMBL617311,16633,H,BAO_0000357,1,,,,,105
2017,8,,Binding affinity towards 5-hydroxytryptamine 1D receptor alpha using [3H]8-OH-DPAT as radioligand,B,,,,,CHEMBL617312,16633,H,BAO_0000357,1,,,,,105
2018,8,,Affinity against 5-hydroxytryptamine 1D receptor alpha,B,,,,,CHEMBL617313,3269,H,BAO_0000357,1,,,,,105
2019,8,,Binding affinity against 5-hydroxytryptamine 1D receptor alpha,B,,,,,CHEMBL617314,12409,H,BAO_0000357,1,,,,,105
2020,8,,Compound was tested for intrinsic efficacy against human 5-hydroxytryptamine 1D receptor beta measured as the reduction of forskolin-stimulated cAMP.,F,,,,,CHEMBL617315,13706,H,BAO_0000019,1,,,,,106
2021,8,,Compound was tested for binding affinity against human 5-hydroxytryptamine 1D receptor beta clones expressed in human embryonic kidney (HEK 293) cells line.,B,,,,,CHEMBL617316,13706,H,BAO_0000219,1,,,,HEK293,106
2022,8,,Compound was tested for binding affinity against human 5-hydroxytryptamine 1D receptor beta clones expressed in human embryonic kidney (HEK 293) cells line; NT= not tested,B,,,,,CHEMBL617317,13706,H,BAO_0000219,1,,,,HEK293,106
2023,8,,"The compound was tested in vitro for binding affinity against cloned mammalian 5-hydroxytryptamine 1D receptor beta expressed in CHO cells, by using [3H]5-HT as radioligand",B,,,,,CHEMBL617318,12903,H,BAO_0000219,1,,,,CHO,106
2024,8,,Binding affinity against 5-hydroxytryptamine 1D receptor beta using rabbit saphenous vein assay.,B,,,,,CHEMBL617319,13047,H,BAO_0000019,1,,,,,106
2025,9,,Displacement of [3H]-5-HT from human 5-hydroxytryptamine 1D receptor beta,B,,,,,CHEMBL617320,13366,D,BAO_0000357,1,,,,,106
2026,9,,Displacement of [3H]-5-HT from human 5-hydroxytryptamine 1D receptor beta,B,,,,,CHEMBL617321,13366,D,BAO_0000357,1,,,,,106
2027,9,,Displacement of [3H]-5-HT from human 5-hydroxytryptamine 1D receptor beta,B,,,,,CHEMBL617322,13366,D,BAO_0000357,1,,,,,106
2028,8,,Binding affinity towards cloned human 5-hydroxytryptamine 1D receptor beta was determined using [3H]8-OH-DPAT as radioligand,B,,,,,CHEMBL616862,13366,H,BAO_0000357,1,,,,,106
2029,8,,Binding affinity towards cloned human 5-hydroxytryptamine 1D receptor was determined using [3H]8-OH-DPAT as radioligand,B,,,,,CHEMBL616863,13366,H,BAO_0000357,1,,,,,106
2030,8,,Binding affinity was measured on 5-hydroxytryptamine 1D receptor beta in CHO cells transfected with human 5-HT1D beta gene labeled with [3H]5-HT,B,,,,,CHEMBL616864,12469,H,BAO_0000219,1,,,,CHO,106
2031,8,,Compound was tested for binding affinity against cloned human 5-HT1D beta receptor expressed in CHO-K1 cells.,B,,,,,CHEMBL616865,13706,H,BAO_0000219,1,,,,CHO-K1,106
2032,8,,Compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1D receptor beta expressed in CHO-K1 cells.,B,,,,,CHEMBL616866,13706,H,BAO_0000219,1,,,,CHO-K1,106
2033,8,,Compound was tested for intrinsic efficacy against human 5-hydroxytryptamine 1D receptor beta measured as the reduction of forskolin-stimulated cAMP.,F,,,,,CHEMBL616867,13706,H,BAO_0000019,1,,,,,106
2034,8,,"Binding affinity against 5-hydroxytryptamine 1D receptor beta expressed in CHO-K1 cells, using [3H]5-HT as the radioligand.",B,,,,,CHEMBL616868,12902,H,BAO_0000219,1,,,,CHO-K1,106
2035,8,,Binding affinity for cloned human 5-hydroxytryptamine 1D receptor beta,B,,,,,CHEMBL616869,13051,H,BAO_0000357,1,,,,,105
2036,8,,"In vitro binding affinity against cloned mammalian 5-hydroxytryptamine 1D receptor beta expressed in CHO cells, by using [3H]5-HT as radioligand",B,,,,,CHEMBL616870,12903,H,BAO_0000219,1,,,,CHO,106
2037,8,,Compound was tested for its ability inhibit forskolin-stimulated activity of adenylate cyclase coupled to human 5-hydroxytryptamine 1D receptor beta in CHO-K1 cells; value ranges from 0.24-0.55,F,,,,,CHEMBL616871,1558,H,BAO_0000219,1,,,,CHO-K1,105
2038,8,,Compound was tested for its ability inhibit forskolin-stimulated activity of adenylate cyclase coupled to human 5-hydroxytryptamine 1D receptor beta in CHO-K1 cells; value ranges from 0.6-2.0,F,,,,,CHEMBL616872,1558,H,BAO_0000219,1,,,,CHO-K1,105
2039,8,,Compound was tested for its ability inhibit forskolin-stimulated activity of adenylate cyclase coupled to human 5-hydroxytryptamine 1D receptor beta in CHO-K1 cells; value ranges from 2.8-6.5,F,,,,,CHEMBL616873,1558,H,BAO_0000219,1,,,,CHO-K1,105
2040,8,,Compound was tested for its ability inhibit forskolin-stimulated activity of adenylate cyclase coupled to human 5-hydroxytryptamine 1D receptor beta in CHO-K1 cells; value ranges from 30-70,F,,,,,CHEMBL616838,1558,H,BAO_0000219,1,,,,CHO-K1,105
2041,8,,Binding affinity towards cloned human 5-hydroxytryptamine 1D receptor beta was determined,B,,,,,CHEMBL616839,1558,H,BAO_0000357,1,,,,,105
2042,8,Oryctolagus cuniculus,Binding affinity against 5-hydroxytryptamine 3 receptor using rabbit saphenous vein assay.,B,9986.0,,,,CHEMBL616840,13047,H,BAO_0000019,1,,,,,106
2043,8,,In vitro binding affinity towards 5-hydroxytryptamine 1D receptor alpha by using [3H]-5-HT as radioligand,B,,,,,CHEMBL616841,13313,H,BAO_0000357,1,,,,,105
2044,8,,In vitro binding affinity towards 5-hydroxytryptamine 1D receptor beta by using [3H]5-HT as radioligand,B,,,,,CHEMBL616842,13313,H,BAO_0000357,1,,,,,105
2045,8,,Binding affinity against 5-hydroxytryptamine 1D receptor beta,B,,,,,CHEMBL857976,12409,H,BAO_0000357,1,,,,,105
2046,8,,Compound was tested for the displacement of [3H]5-HT binding to cloned human 5-hydroxytryptamine 1E receptor stably expressed in CHO cells,B,,,,,CHEMBL616843,15250,H,BAO_0000219,1,,,,CHO,10618
2047,9,Homo sapiens,Inhibitory activity against 5-hydroxytryptamine 1E receptor subtype,B,9606.0,,,,CHEMBL616844,1348,D,BAO_0000357,1,,,,,10618
2048,8,,Inhibitory activity against 5-hydroxytryptamine 1E receptor subtype; NA denotes data not available,B,,,,,CHEMBL616845,1348,H,BAO_0000357,1,,,,,10618
2049,9,Homo sapiens,Binding affinity to cloned human 5-hydroxytryptamine 1E receptor,B,9606.0,,,,CHEMBL616846,4234,D,BAO_0000357,1,,,,,10618
2050,8,,Binding affinity towards human 5-hydroxytryptamine 1E receptor was determined using [3H]5-HT as radioligand,B,,,,,CHEMBL616847,16209,H,BAO_0000357,1,,,,,10618
2051,8,,Binding affinity was determined against 5-hydroxytryptamine 1E receptor in human cortical homogenate,B,,,,,CHEMBL616848,10444,H,BAO_0000019,1,,,,,10618
2052,8,,Compound was evaluated for its binding affinity for human 5-hydroxytryptamine 1E receptor,B,,,,,CHEMBL616849,3935,H,BAO_0000357,1,,,,,10618
2053,8,,Compound was evaluated for its binding affinity towards human 5-hydroxytryptamine 1E receptor,B,,,,,CHEMBL872911,15818,H,BAO_0000357,1,,,,,10618
2054,8,,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1E receptor,B,,,,,CHEMBL616850,17085,H,BAO_0000019,1,,,,,10618
2055,9,Homo sapiens,Binding affinity against human 5-hydroxytryptamine 1E receptor expressed in CHO cells,B,9606.0,,,,CHEMBL616699,12936,D,BAO_0000219,1,,,,CHO,10618
2056,8,,Binding affinity towards cloned human 5-hydroxytryptamine 1E receptor was determined,B,,,,,CHEMBL616700,6166,H,BAO_0000357,1,,,,,10618
2057,8,,Binding affinity towards 5-hydroxytryptamine 1E receptor (human cloned receptor) in CHO cells using [3H]5-HT as radioligand.,B,,,,,CHEMBL616701,15779,H,BAO_0000219,1,,,,CHO,10618
2058,8,,Binding affinity towards human cloned 5-hydroxytryptamine 1E receptor in CHO cells using [3H]5-HT as radioligand.,B,,,,,CHEMBL616702,15779,H,BAO_0000219,1,,,,CHO,10618
2059,8,,Binding affinity towards human cloned 5-hydroxytryptamine 1E receptor in CHO cells using [3H]5-HT as radioligand;ND means no data.,B,,,,,CHEMBL616703,15779,H,BAO_0000219,1,,,,CHO,10618
2060,8,,Binding affinity was determined against 5-hydroxytryptamine 1D receptor,B,,,,,CHEMBL616704,13181,H,BAO_0000357,1,,,,,10618
2061,8,,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 1E receptor in CHO cells using [3H]5-HT as the radioligand,B,,,,,CHEMBL616705,4199,H,BAO_0000219,1,,,,CHO,10618
2062,8,,Compound was tested for binding affinity against human 5-hydroxytryptamine 1E receptor,B,,,,,CHEMBL616706,14875,H,BAO_0000357,1,,,,,10618
2063,8,,Compound was tested for its binding affinity against cloned human 5-hydroxytryptamine 1E receptor in CHO cells using [3H]-5-HT,B,,,,,CHEMBL616707,15146,H,BAO_0000219,1,,,,CHO,10618
2064,8,,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 1E receptor in CHO using [3H]5-HT as a radioligand,B,,,,,CHEMBL616708,5213,H,BAO_0000357,1,,,,,10618
2065,8,,Tested for binding affinity towards cloned human 5-hydroxytryptamine 1E receptor using [3H]5-HT as radioligand,B,,,,,CHEMBL616709,12146,H,BAO_0000357,1,,,,,10618
2066,8,,The binding affinity (pKi) measured against 5-hydroxytryptamine 1E receptor (cloned human receptors in CHO cells) using [3H]5-HT1E as radioligand,B,,,,,CHEMBL616710,13267,H,BAO_0000219,1,,,,CHO,10618
2067,8,,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 1E receptor in CHO cells using [3H]5-HT.,B,,,,,CHEMBL616711,14818,H,BAO_0000219,1,,,,CHO,10618
2068,8,,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 1E receptor in CHO cells, using [3H]5-HT as radioligand",B,,,,,CHEMBL616712,4829,H,BAO_0000219,1,,,,CHO,10618
2069,8,,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 1E receptor was determined,B,,,,,CHEMBL616713,4373,H,BAO_0000357,1,,,,,10618
2070,8,,Binding affinity for 5-hydroxytryptamine 1E receptor was determined,B,,,,,CHEMBL616714,4373,H,BAO_0000357,1,,,,,10618
2071,8,,Compound was evaluated for the affinity at 5-hydroxytryptamine 1E receptor,B,,,,,CHEMBL616715,14159,H,BAO_0000357,1,,,,,10618
2072,8,,Binding affinity towards 5-hydroxytryptamine 1E receptor,B,,,,,CHEMBL616716,16633,H,BAO_0000357,1,,,,,10618
2073,8,,"In vitro effective concentration for stimulation of [35S]GTP-gamma-S, binding in mouse LM(tk-)cells expressing the human 5-HT1F receptor",F,,,,,CHEMBL616717,17085,H,BAO_0000019,1,,,,,279
2074,8,,"In vitro effective concentration for stimulation of [35S]GTP-gamma-S, binding in mouse LM(tk-)cells expressing the human 5-hydroxytryptamine 1F receptor",F,,,,,CHEMBL616718,17085,H,BAO_0000019,1,,,,,279
2075,8,,In vitro effective concentration for inhibition of skolin-stimulated adenylate cyclase in cell line expressing human 5-hydroxytryptamine 1F receptor,F,,,,,CHEMBL875905,16209,H,BAO_0000019,1,,,,,279
2076,8,,In vitro agonist potency against human 5-hydroxytryptamine 1F receptor,F,,,,,CHEMBL616719,16209,H,BAO_0000019,1,,,,,279
2077,8,,"Maximum stimulation of of [35S]GTP-gamma-S, binding expressed relative to the maximal effect of 5-hydroxytryptamine 1F receptor",F,,,,,CHEMBL616720,17085,H,BAO_0000019,1,,,,,279
2078,8,,Compound was evaluated for the affinity at 5-hydroxytryptamine 1F receptor,B,,,,,CHEMBL616721,14159,H,BAO_0000357,1,,,,,279
2079,8,,Compound was tested for the displacement of [3H]5-HT binding to cloned human 5-hydroxytryptamine 1F receptor stably expressed in CHO cells,B,,,,,CHEMBL616722,15250,H,BAO_0000219,1,,,,CHO,279
2080,8,,In vitro binding affinity against human 5-hydroxytryptamine 1F receptor at a concentration of 100 (nM),B,,,,,CHEMBL616723,3805,H,BAO_0000357,1,,,,,279
2081,8,,Binding affinity against 5-hydroxytryptamine 1F receptor in CHO cells using [3H]5-HT radioligand,B,,,,,CHEMBL616724,16190,H,BAO_0000219,1,,,,CHO,279
2082,8,,Binding affinity against 5-hydroxytryptamine 1F receptor in CHO using [3H]5-HT radioligand,B,,,,,CHEMBL616725,16190,H,BAO_0000357,1,,,,,279
2083,8,,Binding affinity towards human 5-hydroxytryptamine 1F receptor,B,,,,,CHEMBL616726,16209,H,BAO_0000357,1,,,,,279
2084,8,,Binding affinity towards human 5-hydroxytryptamine 1F receptor was determined,B,,,,,CHEMBL616727,16209,H,BAO_0000357,1,,,,,279
2085,8,,Binding affinity towards human 5-hydroxytryptamine 1F receptor using [3H]-5-HT radioligand,B,,,,,CHEMBL616728,16209,H,BAO_0000357,1,,,,,279
2086,8,,In vitro binding affinity for human 5-hydroxytryptamine 1F receptor,B,,,,,CHEMBL616729,6866,H,BAO_0000357,1,,,,,279
2087,8,,In vitro binding affinity was determined by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1F receptor,B,,,,,CHEMBL616730,17085,H,BAO_0000019,1,,,,,279
2088,8,,Binding affinity towards human recombinant 5-hydroxytryptamine 1F receptor,B,,,,,CHEMBL617125,16312,H,BAO_0000357,1,,,,,279
2089,8,,Binding affinity towards cloned human 5-hydroxytryptamine 1F receptor was determined,B,,,,,CHEMBL857977,6166,H,BAO_0000357,1,,,,,279
2090,8,,Binding affinity towards 5-hydroxytryptamine 1F receptor (human cloned receptor) in CHO cells using [3H]5-HT as radioligand.,B,,,,,CHEMBL617126,15779,H,BAO_0000219,1,,,,CHO,279
2091,8,,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 1F receptor in CHO cells using [3H]-5-HT as the radioligand,B,,,,,CHEMBL617127,4199,H,BAO_0000219,1,,,,CHO,279
2092,8,,Compound was tested for binding affinity against human 5-hydroxytryptamine 1F receptor,B,,,,,CHEMBL617128,14875,H,BAO_0000357,1,,,,,279
2093,8,,Compound was tested for its binding affinity against 5-hydroxytryptamine 1F receptor in human cloned receptors in CHO cells using [3H]5-HT,B,,,,,CHEMBL617129,15146,H,BAO_0000219,1,,,,CHO,279
2094,8,,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 1F receptor in CHO using [3H]5-HT as a radioligand,B,,,,,CHEMBL617130,5213,H,BAO_0000357,1,,,,,279
2095,8,,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 1F receptor in CHO cells using [3H]5-HT.,B,,,,,CHEMBL617131,14818,H,BAO_0000219,1,,,,CHO,279
2096,8,,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 1F receptor in CHO cells, using [3H]5-HT as radioligand",B,,,,,CHEMBL617132,4829,H,BAO_0000219,1,,,,CHO,279
2097,8,,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 1F receptor in CHO cells, using [3H]5-HT as radioligand",B,,,,,CHEMBL617133,4829,H,BAO_0000219,1,,,,CHO,279
2098,8,,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 1F receptor was determined,B,,,,,CHEMBL617134,4373,H,BAO_0000357,1,,,,,279
2099,8,,Binding affinity for 5-hydroxytryptamine 1F receptor was determined,B,,,,,CHEMBL617135,4373,H,BAO_0000357,1,,,,,279
2100,8,,Percent inhibition (at 1 uM) against 5-hydroxytryptamine 1F receptor,B,,,,,CHEMBL617136,5014,H,BAO_0000357,1,,,,,279
2101,4,,"Compound was tested for binding affinity towards 5-hydroxytryptamine 2 (5-hydroxytryptamine-2) receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]-ketanserin as radioligand",B,,,,,CHEMBL617137,11662,H,BAO_0000019,1,,,,,104686
2102,4,,"Compound was tested for binding affinity towards 5-hydroxytryptamine 2 receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]ketanserin as radioligand",B,,,,,CHEMBL617138,11662,H,BAO_0000019,1,,,,,104686
2103,4,,"Compound was tested for binding affinity towards 5-hydroxytryptamine 2 (5-hydroxytryptamine-2) receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]ketanserin as radioligand; Not Determined",B,,,,,CHEMBL617139,11662,H,BAO_0000019,1,,,,,104686
2104,8,,Ability to displace [3H]ketanserin from rat cortical homogenate 5-hydroxytryptamine 2A receptor,B,,,,,CHEMBL617140,14093,H,BAO_0000019,1,,,,,12687
2105,4,,"In vivo inhibitory activity of 10 mg/kg compound in rats against elevation of BP caused by 5-HT (300 ug/kg, iv) through 5-HT2 receptor 1 hr after oral administration",F,,,,,CHEMBL617141,11200,H,BAO_0000218,1,,In vivo,,,104686
2106,4,,In vitro antagonistic activity against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips,F,,,,,CHEMBL858112,11200,H,BAO_0000019,1,,,,,104686
2107,8,,Binding affinity towards 5-hydroxytryptamine 2 receptor in calf frontal cortex,B,,,,,CHEMBL617142,12352,H,BAO_0000019,1,,,,,17005
2108,0,Bos taurus,"Binding affinity to 5-hydroxytryptamine 2 receptor using calf frontal cortex, [3H]- ketanserin, and spiperone for NSB",B,9913.0,,,,CHEMBL617143,13657,U,BAO_0000019,1,,,,,22226
2109,0,Bos taurus,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor of bovine frontal cortex at 10e-7 M,B,9913.0,,,,CHEMBL617144,14331,U,BAO_0000019,1,,,,,22226
2110,0,Bos taurus,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor of bovine frontal cortex,B,9913.0,,,,CHEMBL617145,14331,U,BAO_0000019,1,,,,,22226
2111,0,,Binding affinity of compound towards 5-hydroxytryptamine 2 receptor using [3H]ketanserin (0.8 nM) ligand in frontal cortex bovine was determined,B,,,,,CHEMBL617146,14331,U,BAO_0000019,1,,,,,22226
2112,4,Cavia porcellus,Binding affinity for serotonin 5-hydroxytryptamine 2 receptor using [3H]ketanserin in guinea pig frontal cortex,B,10141.0,,,,CHEMBL617147,12685,H,BAO_0000019,1,,,,,104784
2113,4,Cavia porcellus,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor of guinea pig frontal cortex membranes,B,10141.0,,,,CHEMBL617148,14389,H,BAO_0000019,1,,,,,104784
2114,4,Cavia porcellus,Compound was tested for its binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]ketanserin from guinea pig frontal cortex,B,10141.0,,,,CHEMBL617149,14386,H,BAO_0000019,1,,,,,104784
2115,4,,Binding affinity towards cloned human 5-hydroxytryptamine 2 receptor was determined,B,,,,,CHEMBL617150,5732,H,BAO_0000224,1,,,,,104784
2116,4,,Binding affinity towards 5-hydroxytryptamine 2 receptor was determined,B,,,,,CHEMBL617151,16293,H,BAO_0000224,1,,,,,104784
2117,4,,In vitro binding affinity of compound against neuronal 5-hydroxytryptamine 2 receptor,B,,,,,CHEMBL617201,2078,H,BAO_0000224,1,,,,,104784
2118,8,,Binding affinity towards 5-HT7 receptor by the displacement of [3H]-5-CT] in human recombinant receptors in mammalian cell,B,,,,,CHEMBL617202,5486,H,BAO_0000357,1,,,,,10209
2119,4,,Effective dose through peroral route for in vivo inhibition against 5-hydroxytryptamine 2 receptor in male CF-1 mice by using radioligand [3H]ketanserin,B,,,,,CHEMBL617203,11820,H,BAO_0000218,1,,In vivo,,,104826
2120,4,,Hill number was determined for inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor in mouse cerebral cortex,B,,,,,CHEMBL617204,10297,H,BAO_0000019,1,,,,,104826
2121,4,,Inhibitory activity against serotonin 5-hydroxytryptamine 2 receptor from mice.,B,,,,,CHEMBL617205,13704,H,BAO_0000224,1,,,,,104826
2122,5,Mus musculus,Inhibitory activity towards 5-hydroxytryptamine 2 receptor by the displacement of [3H]ketanserin in mouse cerebral cortex,B,10090.0,,,,CHEMBL617206,10297,D,BAO_0000019,1,,,,,104826
2123,4,,Effective dose through peroral route for in vivo inhibition against 5-hydroxytryptamine 2 receptor in male CF-1 mice by using radioligand [3H]ketanserin,B,,,,,CHEMBL617207,11820,H,BAO_0000218,1,,In vivo,,,104826
2124,5,Mus musculus,Binding affinity towards 5-hydroxytryptamine 2 receptor by the displacement of [3H]-ketanserin in mouse cerebral cortex,B,10090.0,,,,CHEMBL617208,10297,D,BAO_0000019,1,,,,,104826
2125,4,,The compound was tested in vitro for its binding affinity towards 5-hydroxytryptamine 2 receptor,B,,,,,CHEMBL617209,11555,H,BAO_0000224,1,,,,,104826
2126,4,,In vitro binding affinity for serotonin 5-hydroxytryptamine (5-HT) 2 receptors,B,,,,,CHEMBL617210,11555,H,BAO_0000224,1,,,,,104826
2127,4,,The compound was tested in vitro for its binding affinity towards serotonin 5-hydroxytryptamine 2 receptor; nd = no data,B,,,,,CHEMBL617211,11555,H,BAO_0000224,1,,,,,104826
2128,5,Mus musculus,Hill number was determined for inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor in mouse cerebral cortex,B,10090.0,,,,CHEMBL617212,10297,D,BAO_0000019,1,,,,,104826
2129,4,Sus scrofa,Binding affinity for porcine 5-hydroxytryptamine 2 receptor using [3H]- ketanserin,B,9823.0,,,,CHEMBL617213,16688,H,BAO_0000224,1,,,,,104784
2130,4,Sus scrofa,Binding affinity for porcine 5-hydroxytryptamine 2 receptor using [3H]- ketanserin with 10 uM prazosin,B,9823.0,,,,CHEMBL617214,16688,H,BAO_0000224,1,,,,,104784
2131,0,,Compound was tested in vitro for its ability to compete with [3H]-ketanserin at 5-hydroxytryptamine 2 receptor in porcine brain homogenate,B,,,,,CHEMBL617215,5333,U,BAO_0000221,1,,,,,22226
2132,0,,In vitro for its ability to displace [3H]- ketanserin from 5-hydroxytryptamine 2 receptor in porcine brain homogenate,B,,,,,CHEMBL617216,4437,U,BAO_0000221,1,,,,,22226
2133,8,Sus scrofa,Ability to displace the radioligand [3H]mesulergine from pig choroid plexus 5-hydroxytryptamine 2 receptor,B,9823.0,,,,CHEMBL617217,5033,H,BAO_0000357,1,,,,,17005
2134,4,,Inhibition of [3H]- Ketanserin binding against rat brain 5-hydroxytryptamine 2 receptor,B,,,,,CHEMBL617218,15267,H,BAO_0000019,1,,,,,104686
2135,4,,Inhibition of [3H]- Ketanserin binding against rat brain 5-hydroxytryptamine 2 receptor,B,,,,,CHEMBL872913,15267,H,BAO_0000019,1,,,,,104686
2136,4,,Binding affinity against 5-hydroxytryptamine 2 receptor from rat cortical synaptosomal membrane using radioligand [3H]ketanserin.,B,,,,,CHEMBL617219,11820,H,BAO_0000019,1,,,,,104826
2137,4,,Evaluated for binding activity against [3H]ketanserin as radioligand for 5-hydroxytryptamine 2 receptor,B,,,,,CHEMBL873482,9069,H,BAO_0000224,1,,,,,104686
2138,5,Rattus norvegicus,Affinity towards 5-hydroxytryptamine 2 receptor by measuring its ability to antagonize serotonin-induced contractions in the rat jugular vein; ND means no data,B,10116.0,,,,CHEMBL617220,9162,D,BAO_0000019,1,,,,,104686
2139,4,,Affinity towards 5-hydroxytryptamine 2 receptor by measuring its ability to antagonize serotonin-induced contractions in the rat jugular vein.,B,,,,,CHEMBL617221,9162,H,BAO_0000019,1,,,,,104686
2140,4,,Affinity towards 5-hydroxytryptamine 2 receptor by measuring its ability to antagonize serotonin-induced contractions in the rat jugular vein; no appreciable 5-HT2 receptor affinity,B,,,,,CHEMBL617222,9162,H,BAO_0000019,1,,,,,104686
2141,4,,Antagonistic activity against (5-hydroxytryptamine 2 receptor) serotonin-induced contractions in the rat jugular vein,F,,,,,CHEMBL875906,10428,H,BAO_0000019,1,,,,,104686
2142,4,,Binding affinity to the 5-hydroxytryptamine 2 receptor assayed by antagonism of serotonin-induced contractions in the rat jugular vein,B,,,,,CHEMBL617223,9628,H,BAO_0000019,1,,,,,104686
2143,4,,Binding affinity against serotonin 5-hydroxytryptamine 2 receptor,B,,,,,CHEMBL617224,12704,H,BAO_0000224,1,,,,,104686
2144,5,Rattus norvegicus,Percent decrease in 5-hydroxytryptamine 2 receptor binding using ketanserin,B,10116.0,,,,CHEMBL617225,15453,D,BAO_0000224,1,,,,,104686
2145,4,,Tested for the effect on binding at 5-hydroxytryptamine 2 receptor; No activity,B,,,,,CHEMBL617226,188,H,BAO_0000224,1,,,,,104686
2146,4,,Effect of 2 week administration of compound on 5-hydroxytryptamine 2 receptor binding by using 0.4 nM dose of [3H]- spiperone as a radioligand.,B,,,,,CHEMBL617227,10349,H,BAO_0000224,1,,,,,104686
2147,4,,Effect of 2 week administration of compound on 5-hydroxytryptamine 2 receptor binding by using 0.6 nM dose of [3H]- spiperone as a radioligand.,B,,,,,CHEMBL617228,10349,H,BAO_0000224,1,,,,,104686
2148,4,,Compound was tested for its effect on 5-hydroxytryptamine 2 receptor saturation analysis,B,,,,,CHEMBL617229,8868,H,BAO_0000224,1,,,,,104686
2149,4,,Concentration necessary to achieve half maximal inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor at 1 uM,B,,,,,CHEMBL617230,10025,H,BAO_0000224,1,,,,,104686
2150,4,,"Concentration necessary to achieve half maximal inhibition of [3H]ketanserin, binds to 5-hydroxytryptamine 2 receptor at 1 uM",B,,,,,CHEMBL617231,10025,H,BAO_0000224,1,,,,,104686
2151,4,,Compound was tested for the inhibition of quipazine binding at 5-HT2 receptor,B,,,,,CHEMBL617232,11702,H,BAO_0000224,1,,,,,104686
2152,4,,Compound was tested for the inhibition of quipazine binding at 5-hydroxytryptamine 2 receptor,B,,,,,CHEMBL617233,11702,H,BAO_0000224,1,,,,,104686
2153,4,,Compound was tested for the inhibition of quipazine binding at 5-hydroxytryptamine 2 receptor; NT=Not tested,B,,,,,CHEMBL617234,11702,H,BAO_0000224,1,,,,,104686
2154,4,,Compound was tested for the inhibition of quipazine induced head twitches in rats,F,,,,,CHEMBL617235,11702,H,BAO_0000019,1,,,,,104686
2155,4,,Compound was tested for the inhibition of quipazine induced head twitches in rats; NT=Not tested,F,,,,,CHEMBL617236,11702,H,BAO_0000019,1,,,,,104686
2156,4,,Ability to bind at 5-hydroxytryptamine 2 receptor of rat hippocampus by displacing [3H]spiperone,B,,Hippocampus,,,CHEMBL617237,10085,H,BAO_0000221,1,10000000.0,,,,104686
2157,4,,Ability to bind at serotonin 5-hydroxytryptamine 2 receptors of rat hippocampus by displacing [3H]spiperone,B,,Hippocampus,,,CHEMBL617238,10085,H,BAO_0000221,1,10000000.0,,,,104686
2158,5,Rattus norvegicus,Displacement of [3H]spiroperidol from 5-hydroxytryptamine 2 receptor in rat brain,B,10116.0,Brain,,,CHEMBL617239,9630,D,BAO_0000221,1,955.0,,,,104686
2159,4,,Ability to inhibit binding of [3H]KET to 5-hydroxytryptamine 2 receptor in rat cortex,B,,,,,CHEMBL617240,11070,H,BAO_0000019,1,,,,,104686
2160,4,,Ability to inhibit binding of titreated spiperone to 5-hydroxytryptamine 2 receptor in rat brain frontal cortex membranes,B,,,Membranes,,CHEMBL617241,9841,H,BAO_0000249,1,,,,,104686
2161,4,,Ability to inhibit binding of titreated spiperone to the 5-hydroxytryptamine 2 receptor in rat brain frontal cortex membranes,B,,,Membranes,,CHEMBL875907,9841,H,BAO_0000249,1,,,,,104686
2162,4,,Affinity for 5-hydroxytryptamine 2 receptor binding sites by its ability to displace [3H]spiperone from rat frontal cortex.,B,,,,,CHEMBL617242,13291,H,BAO_0000019,1,,,,,104686
2163,4,,Antagonistic activity against 5-hydroxytryptamine 2 receptor on rat frontal cortex membrane.,F,,,,,CHEMBL617152,10590,H,BAO_0000019,1,,,,,104686
2164,5,Rattus norvegicus,Binding affinity against serotonin-2 receptor in rat brain using [3H]spiroperidol,B,10116.0,Brain,,,CHEMBL617153,9064,D,BAO_0000221,1,955.0,,,,104686
2165,5,Rattus norvegicus,Binding affinity at 5-hydroxytryptamine 2 receptor by the inhibition of binding to [3H]ketanserin in rat cortical membranes,B,10116.0,,Membranes,,CHEMBL617154,12268,D,BAO_0000249,1,,,,,104686
2166,4,,Binding affinity against 5-hydroxytryptamine 2 receptor in rat brain using [3H]ketanserin as radioligand,B,,Brain,,,CHEMBL617155,13508,H,BAO_0000221,1,955.0,,,,104686
2167,4,,5-hydroxytryptamine 2 receptor antagonistic activity on the rat tail artery determined by Schild plot.,F,,,,,CHEMBL617156,11279,H,BAO_0000019,1,,,,,104686
2168,4,,In vitro antagonistic activity against the contraction induced by 5-HT through 5-HT2 receptor in rat thoracic aortic strips,F,,,,,CHEMBL617157,11200,H,BAO_0000019,1,,,,,104686
2169,4,,In vitro antagonistic activity tested against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips,F,,,,,CHEMBL617158,11200,H,BAO_0000019,1,,,,,104686
2170,4,,In vitro antagonistic activity against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips; NC=non competitive antagonism,F,,,,,CHEMBL617159,11200,H,BAO_0000019,1,,,,,104686
2171,4,,In vitro antagonistic activity against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips; NC=non competitive antagonism,F,,,,,CHEMBL617160,11200,H,BAO_0000019,1,,,,,104686
2172,4,,In vitro antagonistic activity against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips,F,,,,,CHEMBL858113,11200,H,BAO_0000019,1,,,,,104686
2173,4,,Tested for 5-hydroxytryptamine 2 receptor binding ability by displacement of [3H]spiperone from rat brain frontal cortex synaptosomes,B,,Brain,,,CHEMBL617247,9231,H,BAO_0000220,1,955.0,,,,104686
2174,4,,Binding affinity towards 5-hydroxytryptamine 2 receptor in rat frontal cortex using [3H]ketanserin as radioligand,B,,,,,CHEMBL617248,9737,H,BAO_0000019,1,,,,,104686
2175,4,,Binding affinity towards 5-hydroxytryptamine 2 receptor in rat brain membrane using [3H]8-OH-DPAT as a selective ligand.,B,,Brain,,,CHEMBL617249,9737,H,BAO_0000249,1,955.0,,,,104686
2176,4,,Binding affinity towards 5-hydroxytryptamine 2 receptor in rat frontal cortex,B,,,,,CHEMBL617250,9737,H,BAO_0000019,1,,,,,104686
2177,4,,Binding affinity towards 5-hydroxytryptamine 2 receptor in rat frontal cortex using [3H]ketanserin as radioligand,B,,,,,CHEMBL617251,9737,H,BAO_0000019,1,,,,,104686
2178,5,Rattus norvegicus,isplacement of [3H]DOB from rat cortex homogenate 5-hydroxytryptamine 2 receptor,B,10116.0,,,,CHEMBL617252,11828,D,BAO_0000019,1,,,,,104686
2179,4,,Binding affinity of 5-hydroxytryptamine 2 receptor using [3H]- ketanserin in rat frontal cortex,B,,,,,CHEMBL617006,12253,H,BAO_0000019,1,,,,,104686
2180,4,,Binding affinity against 5-hydroxytryptamine 2 receptor using [3H]ketanserin in rat frontal cortex,B,,,,,CHEMBL617007,12253,H,BAO_0000019,1,,,,,104686
2181,4,,"5-hydroxytryptamine 2 receptor antagonistic activity at concentrations of<br>3,10 and 30 uM on the rat tail artery.",F,,,,,CHEMBL617008,11279,H,BAO_0000019,1,,,,,104686
2182,4,,Binding affinity for 5-hydroxytryptamine 2 receptor in rat cortex using [3H]- ketanserin,B,,,,,CHEMBL617009,11866,H,BAO_0000019,1,,,,,104686
2183,5,Rattus norvegicus,Binding affinity against 5-hydroxytryptamine 2 receptor in serotonin-induced contraction of the rat aorta,B,10116.0,,,,CHEMBL617010,14424,D,BAO_0000224,1,,,,,104686
2184,5,Rattus norvegicus,Displacement of [3H]ketanserin from rat brain 5-hydroxytryptamine 2 receptor,B,10116.0,,,,CHEMBL857978,15180,D,BAO_0000019,1,,,,,104686
2185,5,Rattus norvegicus,Displacement of [3H]ketanserin from rat brain 5-hydroxytryptamine 2 receptor,B,10116.0,,,,CHEMBL617011,15180,D,BAO_0000019,1,,,,,104686
2186,5,Rattus norvegicus,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor of rat frontal cortex homogenate,B,10116.0,,,,CHEMBL617012,9786,D,BAO_0000019,1,,,,,104686
2187,4,,Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]-ketanserin as radioligand.,B,,,,,CHEMBL617013,12132,H,BAO_0000224,1,,,,,104686
2188,4,,Binding affinity towards 5-hydroxytryptamine 2 receptor by the displacement of [3H]ketanserin in rat cerebral cortex membrane,B,,,,,CHEMBL617014,5486,H,BAO_0000249,1,,,,,104686
2189,4,,Compound was evaluated for its ability to displace [3H]ketanserin binding from cloned rat cerebral cortex membranes 5-hydroxytryptamine 2 receptor,B,,,,,CHEMBL617015,15316,H,BAO_0000019,1,,,,,104686
2190,4,,In vitro binding affinity to 5-hydroxytryptamine 2 receptor of rat cerebral cortex membranes using [3H]ketanserin as the radioligand,B,,,,,CHEMBL617016,16429,H,BAO_0000019,1,,,,,104686
2191,4,,pKi value for 5-hydroxytryptamine 2 receptor binding site,B,,,,,CHEMBL617017,14617,H,BAO_0000224,1,,,,,104686
2192,4,,Inhibitory constant (1 uM) was measured on 5-hydroxytryptamine 2 receptor/uptake using [3H]- ketanserin as radioligand in rat brain cortex.,B,,Brain,,,CHEMBL617018,11351,H,BAO_0000221,1,955.0,,,,104686
2193,4,,5-hydroxytryptamine 2 receptor antagonistic activity on the rat tail artery determined by Schild plot.,F,,,,,CHEMBL617019,11279,H,BAO_0000019,1,,,,,104686
2194,4,,Binding affinity at 5-hydroxytryptamine 2 receptor determined using [125I]- DOI as radioligand in rat frontal cortex,B,,,,,CHEMBL617020,9523,H,BAO_0000019,1,,,,,105075
2195,4,,Binding affinity at 5-hydroxytryptamine 2 receptor was determined using [125I]- DOI as radioligand in rat frontal cortex,B,,,,,CHEMBL617021,9523,H,BAO_0000019,1,,,,,105075
2196,4,,Binding affinity at [3H]DOB labeled sites of 5-hydroxytryptamine 2 receptor determined using [125I]- DOI as radioligand in rat frontal cortex,B,,,,,CHEMBL617022,9523,H,BAO_0000019,1,,,,,105075
2197,4,,Binding affinity at [3H]DOB labeled sites of 5-hydroxytryptamine 2 receptor was determined using [125I]- DOI as radioligand in rat frontal cortex,B,,,,,CHEMBL617023,9523,H,BAO_0000019,1,,,,,105075
2198,4,,Binding affinity at [3H]KET labeled sites of 5-hydroxytryptamine 2 receptor determined using [125I]- DOI as radioligand in rat frontal cortex,B,,,,,CHEMBL617024,9523,H,BAO_0000019,1,,,,,105075
2199,4,,Binding affinity at [3H]KET labeled sites of 5-hydroxytryptamine 2 receptor was determined using [125I]- DOI as radioligand in rat frontal cortex,B,,,,,CHEMBL617025,9523,H,BAO_0000019,1,,,,,105075
2200,4,,Hill coefficient of compound was determined,B,,,,,CHEMBL617026,9523,H,BAO_0000224,1,,,,,105075
2201,0,,Ancillary Binding affinity towards rat 5-hydroxytryptamine 2 receptor,B,,,,,CHEMBL617027,4771,U,BAO_0000019,1,,,,,22226
2202,5,Rattus norvegicus,Ability to displace the radioligand [3H]5-carboximidotryptamine ([3H]-ketanserin) from 5-hydroxytryptamine 2 receptor of rat cerebral cortex membrane,B,10116.0,,,,CHEMBL617028,5033,D,BAO_0000019,1,,,,,104686
2203,8,,Binding affinity against rat 5-hydroxytryptamine 2 receptor in rat cerebral cortex tissue using [3H]spiperone as radioligand,B,,,,,CHEMBL617029,10845,H,BAO_0000019,1,,,,,12687
2204,8,,Binding affinity against rat 5-hydroxytryptamine 2 receptor in rat cerebral cortex tissue using [3H]spiperone as radioligand; IA-Inactive,B,,,,,CHEMBL875908,10845,H,BAO_0000019,1,,,,,12687
2205,8,,Affinity at 5-hydroxytryptamine 2 receptor (For ketanserin = Ki(nM)= 0.7+/-0.09),B,,,,,CHEMBL617030,16288,H,BAO_0000357,1,,,,,12687
2206,8,,Affinity at 5-hydroxytryptamine 2 receptor from rat frontal cortex using [3H]ketanserin as radioligand (For ketanserin = Ki(nM)=0.7+/-0.09),B,,,,,CHEMBL617031,16288,H,BAO_0000019,1,,,,,12687
2207,8,,Binding affinity for 5-hydroxytryptamine 2 receptor of rat cortical membrane using [3H]DOB radioligand,B,,,,,CHEMBL617032,16190,H,BAO_0000019,1,,,,,12687
2208,5,Rattus norvegicus,Tested in vitro for receptor binding affinity against 5-hydroxytryptamine 2 receptor using radioligand [3H]ketanserin,B,10116.0,,,,CHEMBL617033,12463,D,BAO_0000224,1,,,,,104686
2209,4,,"Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]- 1-(4-bromo-2,5-dimethoxy-phenyl)-2-aminopropane (D) as radioligand",B,,,,,CHEMBL617034,9699,H,BAO_0000224,1,,,,,104686
2210,4,,Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]- ketanserin as radioligand,B,,,,,CHEMBL617035,9699,H,BAO_0000224,1,,,,,104686
2211,4,,"Compound was tested for binding affinity towards 5-hydroxytryptamine 2 receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]ketanserin as radioligand; Not Determined",B,,,,,CHEMBL617036,11662,H,BAO_0000019,1,,,,,104686
2212,4,,Inhibitory concentration against 5-hydroxytryptamine 2 receptor,B,,,,,CHEMBL617037,1205,H,BAO_0000224,1,,,,,104784
2213,0,,Compound was evaluated for the binding affinity towards 5-hydroxytryptamine 2 receptor from mammalian clones expressed in CHO cell membranes using [3H]-ketanserin as radioligand,B,,,,,CHEMBL617038,11376,U,BAO_0000219,1,,,,,22226
2214,4,,"Binding affinity towards 5-hydroxytryptamine 2 receptor expressed in CHO cell membranes using [3H]ketanserin (60 Ci/mmol, 1 nM)",B,,,,,CHEMBL617039,11376,H,BAO_0000219,1,,,,,104784
2215,4,,Compound was tested for binding affinity against 5-hydroxytryptamine 2 receptor,B,,,,,CHEMBL617161,4639,H,BAO_0000224,1,,,,,104784
2216,4,,Compound was tested for inhibitory activity against 5-hydroxytryptamine 2 receptor,B,,,,,CHEMBL617162,2222,H,BAO_0000224,1,,,,,104784
2217,4,,Compound was tested for its affinity towards 5-hydroxytryptamine 2 receptor,B,,,,,CHEMBL617163,1558,H,BAO_0000224,1,,,,,104784
2218,4,,Tested for binding affinity for 5-hydroxytryptamine 2 receptor,B,,,,,CHEMBL617164,1089,H,BAO_0000224,1,,,,,104784
2219,4,,The compound was evaluated for its ability to displace [3H]ketanserin from 5-hydroxytryptamine 2 receptor in cellular brain membranes,B,,,Brain membranes,,CHEMBL617165,386,H,BAO_0000249,1,,,,,104784
2220,4,,Compound was measured for its binding affinity at 5-hydroxytryptamine 2 receptor at a concentration of 10 uM using [3H]ketanserin as radioligand,B,,,,,CHEMBL617166,2474,H,BAO_0000224,1,,,,,104784
2221,4,,Binding affinity towards 5-HT2 receptor,B,,,,,CHEMBL617167,17066,H,BAO_0000224,1,,,,,104784
2222,4,,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor,B,,,,,CHEMBL872912,959,H,BAO_0000224,1,,,,,104784
2223,4,,Compound was evaluated for 5-hydroxytryptamine 2 receptor binding,B,,,,,CHEMBL617168,6398,H,BAO_0000224,1,,,,,104784
2224,4,,In vitro binding affinity against rat 5-hydroxytryptamine 2 receptor.,B,,,,,CHEMBL617169,11889,H,BAO_0000224,1,,,,,104686
2225,4,,In vitro binding affinity for 5-hydroxytryptamine 2 receptor,B,,,,,CHEMBL617170,4221,H,BAO_0000224,1,,,,,104784
2226,4,,The compound was tested for binding affinity against 5-hydroxytryptamine 2 receptor using ketanserin as radioligand,B,,,,,CHEMBL617171,11026,H,BAO_0000224,1,,,,,104784
2227,4,,Binding affinity for 5-hydroxytryptamine 2 receptor was determined,B,,,,,CHEMBL617172,11866,H,BAO_0000224,1,,,,,104784
2228,4,,In vitro binding affinity for 5-hydroxytryptamine 2 receptor,B,,,,,CHEMBL617173,4221,H,BAO_0000224,1,,,,,104784
2229,0,,In Vitro binding affinity for 5-hydroxytryptamine 2 receptor,B,,,,,CHEMBL617174,13950,U,BAO_0000019,1,,,,,22226
2230,4,,5-hydroxytryptamine 2 receptor binding affinity,B,,,,,CHEMBL617175,1263,H,BAO_0000224,1,,,,,104784
2231,8,,Binding affinity against 5-hydroxytryptamine 2 receptor was determined using [ [3H]spiperone radioligand,B,,,,,CHEMBL617176,13291,H,BAO_0000357,1,,,,,17005
2232,8,,Compound was tested for the binding affinity against 5-hydroxytryptamine 2 receptor by using [3H]ketanserin as radioligand,B,,,,,CHEMBL617177,10812,H,BAO_0000357,1,,,,,17005
2233,4,,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor at 10e-5 M,B,,,,,CHEMBL617178,13020,H,BAO_0000224,1,,,,,104784
2234,4,,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor of central nervous system,B,,,,,CHEMBL617179,13021,H,BAO_0000224,1,,,,,104784
2235,4,,Ketanserin binding to 5-hydroxytryptamine 2 receptor at 10e-5 M,B,,,,,CHEMBL617180,13020,H,BAO_0000224,1,,,,,104784
2236,8,,Inhibitory activity against 5-hydroxytryptamine 2 receptor using [3H]-ketanserin as radioligand at 10e-5 M concentration,B,,,,,CHEMBL617181,14532,H,BAO_0000357,1,,,,,17005
2237,8,,Binding affinity against 5-hydroxytryptamine 2 receptor,B,,,,,CHEMBL617182,13944,H,BAO_0000357,1,,,,,17005
2238,8,,Binding affinity against 5-hydroxytryptamine 2 receptor,B,,,,,CHEMBL617183,14331,H,BAO_0000357,1,,,,,17005
2239,8,,Binding affinity against 5-hydroxytryptamine 2 receptor using [3H]ketanserin as radioligand,B,,,,,CHEMBL617184,14118,H,BAO_0000357,1,,,,,17005
2240,8,,Binding affinity against serotonergic 5-HT2 receptor,B,,,,,CHEMBL617185,13033,H,BAO_0000357,1,,,,,17005
2241,8,,Binding affinity for 5-hydroxytryptamine 2 receptor was determined by using [3H]ketanserin as radioligand,B,,,,,CHEMBL617186,10321,H,BAO_0000357,1,,,,,17005
2242,8,,Compound was evaluated for the binding affinity at 5- HT2 receptor,B,,,,,CHEMBL617187,12918,H,BAO_0000357,1,,,,,17005
2243,8,,Compound was tested for binding affinity using [3H]ketanserin against 5-hydroxytryptamine 2 receptor,B,,,,,CHEMBL617188,15120,H,BAO_0000357,1,,,,,17005
2244,8,,In vivo binding affinity was evaluated against 5-hydroxytryptamine 2 receptor,B,,,,,CHEMBL617189,2613,H,BAO_0000218,1,,,,,17005
2245,5,Homo sapiens,Inhibitory activity against cloned human 5-HT2 receptor,B,9606.0,,,,CHEMBL617190,13378,D,BAO_0000224,1,,,,,104784
2246,5,Homo sapiens,"Tested in vitro for the inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor, expressed in cloned CHO cells",B,9606.0,,,,CHEMBL617191,2331,D,BAO_0000219,1,,,,CHO,104784
2247,5,Homo sapiens,"Tested in vitro for the inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor, expressed in cloned CHO cells.",B,9606.0,,,,CHEMBL617192,2331,D,BAO_0000219,1,,,,CHO,104784
2248,5,Homo sapiens,"Tested in vitro for the inhibition of [3H]-ketanserin binding to 5-hydroxytryptamine 2 receptor, expressed in cloned CHO cells; Inactive",B,9606.0,,,,CHEMBL617193,2331,D,BAO_0000219,1,,,,CHO,104784
2249,5,Homo sapiens,"Tested in vitro for the inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor, expressed in cloned CHO cells; not tested",B,9606.0,,,,CHEMBL617194,2331,D,BAO_0000219,1,,,,CHO,104784
2250,4,,Binding affinity towards 5-hydroxytryptamine 2 receptor,B,,,,,CHEMBL617195,4170,H,BAO_0000224,1,,,,,104784
2251,4,,Percent decrease in 5-hydroxytryptamine 2 receptor binding using ketanserin,B,,,,,CHEMBL881830,15453,H,BAO_0000224,1,,,,,104784
2252,8,,Binding affinity towards 5-hydroxytryptamine 2 receptor,B,,,,,CHEMBL617196,1479,H,BAO_0000357,1,,,,,17005
2253,4,,Binding affinity towards 5-hydroxytryptamine 2- receptor using [3H]ketanserin as radioligand in competitive binding assay,B,,,,,CHEMBL617197,11139,H,BAO_0000224,1,,,,,104686
2254,8,,Binding affinity against 5-hydroxytryptamine 2A receptor was measured using [3H]ketanserin as radioligand,B,,,,,CHEMBL617198,13969,H,BAO_0000357,1,,,,,17005
2255,8,,Binding affinity towards 5-hydroxytryptamine 2A receptor,B,,,,,CHEMBL873476,13392,H,BAO_0000357,1,,,,,17005
2256,8,,Affinity towards 5-hydroxytryptamine 2A receptor in membranes from bovine frontal cortex using [3H]ketanserin,B,,,,,CHEMBL617199,14430,H,BAO_0000019,1,,,,,17005
2257,8,Cavia porcellus,Binding affinity was determined against 5-hydroxytryptamine 2A receptor,B,10141.0,,,,CHEMBL617200,13181,H,BAO_0000357,1,,,,,107
2258,8,,Inhibitory constant against cloned human 5-hydroxytryptamine 2A receptor using with [125I]- DOI radioligand,B,,,,,CHEMBL617484,17200,H,BAO_0000357,1,,,,,51
2259,8,,Inhibitory constant against cloned human 5-hydroxytryptamine 2A receptor using with [125I]- DOI radioligand,B,,,,,CHEMBL617485,17200,H,BAO_0000357,1,,,,,107
2260,8,,Inhibitory constant against cloned human 5-hydroxytryptamine 2A receptor using with [125I]- DOI radioligand,B,,,,,CHEMBL617486,17200,H,BAO_0000357,1,,,,,51
2261,8,,Binding affinity analysed on 5-HT 2A human clone using [3H]ketanserin as radioligand,B,,,,,CHEMBL858022,13463,H,BAO_0000357,1,,,,,107
2262,8,,Effective concentration against human 5-hydroxytryptamine 2A receptor in CHO cells using 8-OH-DPA radioligand,B,,,,,CHEMBL617049,6347,H,BAO_0000219,1,,,,CHO,107
2263,9,Homo sapiens,Functional activity against human 5-hydroxytryptamine 2A receptor expressed in CHO cells using fluorometric imaging plate reader,F,9606.0,,,,CHEMBL617050,6857,D,BAO_0000219,1,,,,CHO,107
2264,8,,Functional agonist activity of compound was determined by fluorescence-based assay measuring intracellular calcium mobilization for 5-HT2a receptor cell line,F,,,,,CHEMBL617051,4176,H,BAO_0000219,1,,,,,107
2265,8,,Functional agonist activity of compound was determined by fluorescence-based assay measuring intracellular calcium mobilization for 5-HT2a receptor cell line; no data,F,,,,,CHEMBL617052,4176,H,BAO_0000219,1,,,,,107
2266,8,,Functional antagonist activity of compound was determined by fluorescence-based assay measuring intracellular calcium mobilization for 5-HT2a receptor cell line,F,,,,,CHEMBL617053,4176,H,BAO_0000219,1,,,,,107
2267,8,,"Agonistic binding affinity against human 5-hydroxytryptamine 2A receptor in CHO cells using 8-OH-DPA radioligand, expressed as Emax",B,,,,,CHEMBL617054,6347,H,BAO_0000219,1,,,,CHO,107
2268,8,,"Agonistic binding affinity against human 5-hydroxytryptamine 2A receptor in CHO cells, expressed as Emax",B,,,,,CHEMBL617055,6347,H,BAO_0000219,1,,,,CHO,107
2269,8,,Affinity of compound towards human 5-hydroxytryptamine 2A receptor was evaluated using radioligand binding technique,B,,,,,CHEMBL882924,15331,H,BAO_0000357,1,,,,,107
2270,9,Homo sapiens,Inhibition of human 5-hydroxytryptamine 2A receptor,B,9606.0,,,,CHEMBL617056,16146,D,BAO_0000357,1,,,,,107
2271,8,,Compound was tested for the displacement of [3H]5-HT binding to cloned human 5-hydroxytryptamine 2A receptor stably expressed in CHO cells,B,,,,,CHEMBL617057,15250,H,BAO_0000219,1,,,,CHO,107
2272,8,,Inhibitory concentration against human 5-HT2A receptor in BEK cells,B,,,,,CHEMBL617058,13631,H,BAO_0000219,1,,,,,107
2273,8,,In vitro binding affinity against human 5-hydroxytryptamine 2A receptor at a concentration of 100 (nM),B,,,,,CHEMBL617059,3805,H,BAO_0000357,1,,,,,107
2274,8,,Ability to displace [3H]ketanserin from CHO cells expressing human 5-hydroxytryptamine 2A receptor was determined,B,,,,,CHEMBL617060,4011,H,BAO_0000219,1,,,,CHO,107
2275,8,,Displacement of [3H]ketanserin from CHO cells expressing human 5-hydroxytryptamine 2A receptor.,B,,,,,CHEMBL617061,4012,H,BAO_0000219,1,,,,CHO,107
2276,8,,Ability to displace [125I]R91150 from human cloned 5-hydroxytryptamine 2A receptor expressed in L929 cells,B,,,,,CHEMBL617062,6366,H,BAO_0000219,1,,,,L929,107
2277,8,,Ability to displace [3H]ketanserin binding to human 5-hydroxytryptamine 2A receptor stably expressed in CHO cells,B,,,,,CHEMBL617063,15949,H,BAO_0000219,1,,,,CHO,107
2278,8,,Agonist activity at cloned human 5-hydroxytryptamine 2A receptor using [125I]DOI radioligand,F,,,,,CHEMBL617064,14093,H,BAO_0000019,1,,,,,107
2279,8,,Agonistic activity at cloned human 5-hydroxytryptamine 2A receptor using [125I]DOI as radioligand,F,,,,,CHEMBL617065,13481,H,BAO_0000019,1,,,,,107
2280,8,,Agonistic binding affinity against human 5-hydroxytryptamine 2A receptor in CHO cells using 8-OH-DPA radioligand,B,,,,,CHEMBL617066,6347,H,BAO_0000219,1,,,,CHO,107
2281,8,,Agonistic binding affinity against human 5-hydroxytryptamine 2A receptor in CHO cells using 8-OH-DPA radioligand; Nd means not done,B,,,,,CHEMBL617067,6347,H,BAO_0000219,1,,,,CHO,107
2282,8,,Antagonist activity at cloned human 5-hydroxytryptamine 2A receptor using [3H]-Ketanserin radioligand,F,,,,,CHEMBL617068,14093,H,BAO_0000019,1,,,,,107
2283,8,,Antagonist activity at cloned human 5-hydroxytryptamine 2A receptor using [3H]ketanserin radioligand; Not tested,F,,,,,CHEMBL617069,14093,H,BAO_0000019,1,,,,,107
2284,8,,Antagonistic activity at cloned human 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand,F,,,,,CHEMBL617070,13481,H,BAO_0000019,1,,,,,107
2285,8,,Binding ability of compound at cloned human 5-hydroxytryptamine 2A receptor using [125 I]DOI as radioligand,B,,,,,CHEMBL617071,14442,H,BAO_0000357,1,,,,,107
2286,8,,Binding ability of compound at cloned human 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand,B,,,,,CHEMBL872915,14442,H,BAO_0000357,1,,,,,107
2287,8,,Binding activity against cloned human 5-hydroxytryptamine 2A receptor using [125I]DOI as the radioligand.,B,,,,,CHEMBL617072,14755,H,BAO_0000357,1,,,,,107
2288,8,,Binding affinity against 5-hydroxytryptamine 2A receptor in humans,B,,,,,CHEMBL617073,16441,H,BAO_0000357,1,,,,,107
2289,8,,Binding affinity against the cloned human 5-hydroxytryptamine 2A receptor using [125I]DOI as the radioligand,B,,,,,CHEMBL617074,14744,H,BAO_0000357,1,,,,,107
2290,8,,Binding affinity for displacement of [3H]ketanserin to human 5-hydroxytryptamine 2A receptor stably expressed in CHO cells,B,,,,,CHEMBL617075,16659,H,BAO_0000219,1,,,,CHO,107
2291,8,,Binding affinity of compound to human 5-hydroxytryptamine 2A receptor,B,,,,,CHEMBL617076,3307,H,BAO_0000357,1,,,,,107
2292,9,Homo sapiens,Affinity for human 5-hydroxytryptamine 2A receptor expressed in mammalian cell line,B,9606.0,,,,CHEMBL617077,6857,D,BAO_0000019,1,,,,,107
2293,8,,Binding affinity against 5-hydroxytryptamine 2A receptor using [125I]DOI radioligand.,B,,,,,CHEMBL617078,5635,H,BAO_0000357,1,,,,,107
2294,9,Homo sapiens,Binding affinity to cloned human 5-hydroxytryptamine 2A receptor,B,9606.0,,,,CHEMBL617079,4234,D,BAO_0000357,1,,,,,107
2295,8,,Binding affinity towards 5-hydroxytryptamine 2A receptor using [3H]5-HT as radioligand.,B,,,,,CHEMBL617080,15527,H,BAO_0000357,1,,,,,107
2296,8,,Binding affinity towards human 5-hydroxytryptamine 2A receptor by the displacement of [3H]ketanserin radioligand from the cloned receptor expressed in CHO cells,B,,,,,CHEMBL617081,6588,H,BAO_0000219,1,,,,CHO,107
2297,8,,Binding affinity towards human 5-HT2A receptor in BEK cells,B,,,,,CHEMBL617082,13631,H,BAO_0000219,1,,,,,107
2298,8,,Binding affinity towards human serotonin 5-hydroxytryptamine 2A receptor,B,,,,,CHEMBL617083,17723,H,BAO_0000357,1,,,,,107
2299,8,,Binding affinity for recombinant human 5-hydroxytryptamine 2A receptor using [3H]5-HT as radioligand.,B,,,,,CHEMBL617084,14770,H,BAO_0000357,1,,,,,107
2300,9,Homo sapiens,Binding affinity for human 5-hydroxytryptamine 2A receptor,B,9606.0,,,,CHEMBL617085,16293,D,BAO_0000357,1,,,,,107
2301,8,,Binding affinity towards human 5-hydroxytryptamine 2A receptor using [125I]DOI as radioligand,B,,,,,CHEMBL617086,16209,H,BAO_0000357,1,,,,,107
2302,8,,Binding affinity was measured on 5-hydroxytryptamine 2A receptor in GF6 cells transfected with human 5-HT2A gene labeled with [3H]ketanserin,B,,,,,CHEMBL617087,12469,H,BAO_0000219,1,,,,,107
2303,8,,Compound was tested for the displacement of [125I]-DOI from clone human 5-hydroxytryptamine 2A receptor,B,,,,,CHEMBL617088,15363,H,BAO_0000357,1,,,,,107
2304,8,,Compound was tested for the displacement of [125I]DOI from cloned human 5-hydroxytryptamine 2A receptor,B,,,,,CHEMBL617089,15363,H,BAO_0000357,1,,,,,107
2305,8,,"Tested on genetically transfected COS7 cell membranes selectively expressing human 5-hydroxytryptamine 2A receptor, using [3H]ketanserin as radioligand",B,,,,,CHEMBL617090,16441,H,BAO_0000019,1,,,,,107
2306,8,,In vitro binding affinity towards 5-hydroxytryptamine 2A receptor in human using [3H]ketanserin as radioligand,B,,,,,CHEMBL617513,8,H,BAO_0000357,1,,,,,107
2307,8,,In vitro binding affinity towards human 5-hydroxytryptamine 2A receptor expressed in HEK293 cells was determined using [3H]ketanserin as radioligand,B,,,,,CHEMBL617514,4176,H,BAO_0000219,1,,,,HEK293,107
2308,8,,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 2A receptor,B,,,,,CHEMBL617515,17085,H,BAO_0000019,1,,,,,107
2309,8,,Inhibitory constant against cloned human 5-hydroxytryptamine 2A receptor using with [125I]- DOI radioligand,B,,,,,CHEMBL617516,17200,H,BAO_0000357,1,,,,,107
2310,9,Homo sapiens,Inhibitory constant determined against cloned human 5-hydroxytryptamine 2A receptor using with [125I]- DOI radioligand,B,9606.0,,,,CHEMBL617517,17200,D,BAO_0000357,1,,,,,107
2311,9,Homo sapiens,Displacement of [3H]ketanserin from human 5-hydroxytryptamine 2A receptor expressed in CHO cells,B,9606.0,,,,CHEMBL617518,4013,D,BAO_0000219,1,,,,CHO,107
2312,8,,Tested for binding affinity towards 5-hydroxytryptamine 2A receptor,B,,,,,CHEMBL617519,5088,H,BAO_0000357,1,,,,,107
2313,9,Homo sapiens,Displacement of [3H]DOB from human 5-hydroxytryptamine 2A receptor,B,9606.0,,,,CHEMBL617520,5088,D,BAO_0000357,1,,,,,107
2314,8,,Tested for binding affinity towards 5-hydroxytryptamine 2A receptor using [3H]DOB as labeled ligand; binding data not obtained,B,,,,,CHEMBL617521,5088,H,BAO_0000357,1,,,,,107
2315,9,Homo sapiens,Displacement of [3H]ketanserin from human 5-hydroxytryptamine 2A receptor,B,9606.0,,,,CHEMBL617522,5088,D,BAO_0000357,1,,,,,107
2316,8,,Tested for binding affinity towards human 5-hydroxytryptamine 2A receptor using [3H]5-HT as radioligand,B,,,,,CHEMBL617523,5088,H,BAO_0000357,1,,,,,107
2317,8,,Tested for binding affinity towards human 5-hydroxytryptamine 2A receptor using [3H]DOB as radioligand,B,,,,,CHEMBL617524,5088,H,BAO_0000357,1,,,,,107
2318,4,,Ability to displace 0.75 nM [3H]ketanserin in 5-hydroxytryptamine 2 receptor from rat frontal cortex homogenate,B,,,,,CHEMBL617525,9786,H,BAO_0000019,1,,,,,104686
2319,5,Rattus norvegicus,Ability to inhibit [3H]spiperone binding to 5-hydroxytryptamine 2 receptor determined in rat,B,10116.0,,,,CHEMBL617526,9205,D,BAO_0000019,1,,,,,104686
2320,4,,Affinity on 5-hydroxytryptamine 2 receptor labeled by [125I]DOI,B,,,,,CHEMBL617527,11257,H,BAO_0000224,1,,,,,104686
2321,4,,Affinity towards [3H]- DOB -labeled 5-hydroxytryptamine 2 receptor sites in rat cortical homogenates,B,,,,,CHEMBL617528,9362,H,BAO_0000019,1,,,,,104686
2322,4,,Affinity towards [3H]- ketanserin-labeled 5-hydroxytryptamine 2 receptor sites in rat cortical homogenates,B,,,,,CHEMBL617529,9362,H,BAO_0000019,1,,,,,104686
2323,4,,Inhibition of 5-hydroxytryptamine 2 induced vasoconstriction of rat caudal artery.,B,,,,,CHEMBL617530,10590,H,BAO_0000224,1,,,,,104686
2324,4,,Binding affinity against 5-hydroxytryptamine 2 receptor of rat frontal cortex using [3H]ketanserin radioligand,B,,,,,CHEMBL617531,10468,H,BAO_0000019,1,,,,,104686
2325,4,,Binding affinity against 5-hydroxytryptamine 2 receptor from rat frontal cortex using [125]-(R)-DOI as radioligand,B,,,,,CHEMBL617532,13050,H,BAO_0000019,1,,,,,104686
2326,4,,Binding affinity against 5-hydroxytryptamine 2 receptor in rat using [3H]ketanserin as radioligand,B,,,,,CHEMBL617533,11624,H,BAO_0000019,1,,,,,104686
2327,4,,Binding affinity against 5-hydroxytryptamine 2 receptor of rat frontal cortex using [3H]ketanserin radioligand,B,,,,,CHEMBL617534,10468,H,BAO_0000019,1,,,,,104686
2328,4,,Binding affinity against 5-hydroxytryptamine 2 receptor using [3H]ketanserin as radioligand,B,,,,,CHEMBL617535,10330,H,BAO_0000224,1,,,,,104686
2329,4,,Binding affinity at rat 5-hydroxytryptamine 2 receptor by [3H]ketanserin displacement.,B,,,,,CHEMBL617536,10062,H,BAO_0000224,1,,,,,104686
2330,4,,Binding affinity determined in radioreceptor binding assay by using [3H]ketanserin radioligand against 5-hydroxytryptamine 2 receptor,B,,,,,CHEMBL617537,11642,H,BAO_0000224,1,,,,,104686
2331,4,,Binding affinity determined in radioreceptor binding assay by using [3H]ketanserin radioligand against 5-hydroxytryptamine 2 receptor,B,,,,,CHEMBL617538,10062,H,BAO_0000224,1,,,,,104686
2332,4,,Binding affinity of [3H]ketanserin towards 5-hydroxytryptamine 2 receptor in cloned mammalian receptor expressed in cultured cells or from rat whole brain.,B,,,,,CHEMBL617539,13427,H,BAO_0000219,1,,In vitro,,,104686
2333,5,Rattus norvegicus,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor,B,10116.0,,,,CHEMBL617540,12280,D,BAO_0000224,1,,,,,104686
2334,5,Rattus norvegicus,Binding affinity for 5-hydroxytryptamine 2 receptor from striata of male Wistar rats by displacement of [3H]ketanserin,B,10116.0,,,,CHEMBL617541,4101,D,BAO_0000224,1,,,,,104686
2335,4,,Binding affinity in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 2 receptor,B,,,,,CHEMBL617542,10062,H,BAO_0000224,1,,,,,104686
2336,4,,Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]DOB as,B,,,,,CHEMBL617543,11147,H,BAO_0000224,1,,,,,104686
2337,5,Rattus norvegicus,Binding affinity against [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor expressed in CHO-K1 cells,B,10116.0,,,,CHEMBL617544,2395,D,BAO_0000219,1,,,,CHO-K1,104686
2338,5,Rattus norvegicus,Binding affinity against [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor expressed in CHO-K1 cells,B,10116.0,,,,CHEMBL617545,2395,D,BAO_0000219,1,,,,CHO-K1,104686
2339,5,Rattus norvegicus,Binding affinity to rat cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- DOB as a radioligand,B,10116.0,,,,CHEMBL617413,9098,D,BAO_0000019,1,,,,,104686
2340,4,,Binding affinity to rat cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- DOB as a radioligand.,B,,,,,CHEMBL617414,9098,H,BAO_0000019,1,,,,,104686
2341,5,Rattus norvegicus,Binding affinity to 5-hydroxytryptamine 2 receptor of rat cortical membranes using [3H]- DOB; ND means no data.,B,10116.0,,,,CHEMBL617415,9098,D,BAO_0000019,1,,,,,104686
2342,4,,Binding affinity towards 5-hydroxytryptamine 2 receptor,B,,,,,CHEMBL617416,9443,H,BAO_0000224,1,,,,,104686
2343,4,,Binding affinity towards 5-hydroxytryptamine 2 receptor at 1.0 uM concentration,B,,,,,CHEMBL617417,9443,H,BAO_0000224,1,,,,,104686
2344,4,,"Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]- 1-(4-bromo-2,5-dimethoxy-phenyl)-2-aminopropane (D) as radioligand in rat frontal cortex",B,,,,,CHEMBL617418,9699,H,BAO_0000019,1,,,,,104686
2345,4,,Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]- ketanserin as radioligand in rat frontal cortex,B,,,,,CHEMBL617419,9699,H,BAO_0000019,1,,,,,104686
2346,4,,Binding affinity towards 5-hydroxytryptamine 2 receptor was determined,B,,,,,CHEMBL617420,9098,H,BAO_0000224,1,,,,,104686
2347,5,Rattus norvegicus,Affinity for 5-hydroxytryptamine 2 receptor,B,10116.0,,,,CHEMBL617421,3070,D,BAO_0000224,1,,,,,104686
2348,4,,Binding affinity towards serotonin 5-hydroxytryptamine 2 receptor of rat determined using 0.5 nM of [3H]ketanserin in binding assay,B,,,,,CHEMBL617422,9547,H,BAO_0000224,1,,,,,104686
2349,4,,Binding affinity was determined against 5-hydroxytryptamine 2 receptor from male Sprague-Dawley rat brain.,B,,,,,CHEMBL617423,10444,H,BAO_0000019,1,,,,,104686
2350,4,,Binding affinity which represents concentration giving half-maximal inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor from rat tissue homogenate,B,,,,,CHEMBL617424,14617,H,BAO_0000019,1,,,,,104686
2351,4,,Binding affinity which represents concentration giving half-maximal inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor rat tissue homogenate,B,,,,,CHEMBL617425,14617,H,BAO_0000019,1,,,,,104686
2352,4,,Binding constant against 5-hydroxytryptamine 2 receptor (in vitro),B,,,,,CHEMBL617426,11130,H,BAO_0000224,1,,,,,104686
2353,4,,Binding constant against 5-hydroxytryptamine 2 receptor (in vivo),B,,,,,CHEMBL617427,11130,H,BAO_0000218,1,,In vivo,,,104686
2354,4,,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]ketanserin in rat brain,B,,Brain,,,CHEMBL617428,14542,H,BAO_0000221,1,955.0,,,,104686
2355,4,,Compound was evaluated for binding affinity against 5-hydroxytryptamine 2 receptor from rat,B,,,,,CHEMBL617429,2797,H,BAO_0000224,1,,,,,104686
2356,4,,Compound was evaluated for in vitro binding affinity towards 5-hydroxytryptamine 2 receptor in rat cortex using [3H]- spiperone as radioligand,B,,,,,CHEMBL617430,11332,H,BAO_0000019,1,,,,,104686
2357,4,,Compound was evaluated for in vitro binding affinity towards serotonin 5-hydroxytryptamine 2 receptor in rat cortex using [3H]- spiperone as radioligand,B,,,,,CHEMBL617431,11332,H,BAO_0000019,1,,,,,104686
2358,4,,Compound was evaluated for its ability to displace 0.25 nM [125I](R)-DOI from binding sites in rat frontal cortex.,B,,Frontal cortex,,,CHEMBL617432,10752,H,BAO_0000019,1,1870.0,,,,104686
2359,4,,Ability to displace [3H]ketanserin from serotonergic 5-hydroxytryptamine 2 receptor,B,,,,,CHEMBL617433,1185,H,BAO_0000224,1,,,,,104686
2360,4,,Compound was evaluated for its ability to displace [3H]ketanserin from serotonergic 5-hydroxytryptamine 2 receptor,B,,,,,CHEMBL617434,1185,H,BAO_0000224,1,,,,,104686
2361,5,Rattus norvegicus,Binding affinity against 5-Hydroxy tryptamine 2 (5-hydroxytryptamine 2)receptor,B,10116.0,,,,CHEMBL617435,11624,D,BAO_0000224,1,,,,,104686
2362,4,,Compound was evaluated for its binding affinity to 5-hydroxytryptamine 2 receptor in rat cortex using [3H]ketanserin radioligand assay,B,,,,,CHEMBL617436,1344,H,BAO_0000019,1,,,,,104686
2363,5,Rattus norvegicus,Binding affinity against 5-hydroxytryptamine 2 receptor in rat striatum using [3H]-RP62203,B,10116.0,Striatum,,,CHEMBL617437,15453,D,BAO_0000019,1,2435.0,,,,104686
2364,4,,"Binding affinity towards 5-hydroxytryptamine 2 receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]ketanserin as radioligand",B,,,,,CHEMBL617438,11662,H,BAO_0000019,1,,,,,104686
2365,4,,"Compound was tested for binding affinity towards 5-hydroxytryptamine 2 receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]ketanserin as radioligand; Not Determined",B,,,,,CHEMBL617439,11662,H,BAO_0000019,1,,,,,104686
2366,4,,Compound was tested in vitro for binding affinity for 5-hydroxytryptamine 2 receptor,B,,,,,CHEMBL617440,10796,H,BAO_0000224,1,,,,,104686
2367,4,,Evaluated for binding activity against [3H]ketanserin as radioligand for 5-hydroxytryptamine 2 receptor,B,,,,,CHEMBL617441,9069,H,BAO_0000224,1,,,,,104686
2368,5,Rattus norvegicus,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor of rat cortical membrane homogenates,B,10116.0,,,,CHEMBL872918,8814,D,BAO_0000019,1,,,,,104686
2369,5,Rattus norvegicus,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor of rat cortex,B,10116.0,,,,CHEMBL617442,8908,D,BAO_0000019,1,,,,,104686
2370,4,,Evaluated for the binding affinity to rat cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- KET as a radioligand; ND means no data.,B,,,,,CHEMBL617443,9098,H,BAO_0000019,1,,,,,104686
2371,4,,Binding affinity to rat cortical membranes at 5-hydroxytryptamine 2 (5-HT2) receptor using [3H]KET as a radioligand,B,,,,,CHEMBL617444,9098,H,BAO_0000019,1,,,,,104686
2372,4,,Evaluated for the binding affinity to rat cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- KET as a radioligand; ND means no data.,B,,,,,CHEMBL617445,9098,H,BAO_0000019,1,,,,,104686
2373,4,,Evaluated for the binding affinity to rat cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- KET as a radioligand.,B,,,,,CHEMBL617446,9098,H,BAO_0000019,1,,,,,104686
2374,4,,Binding affinity to 5-hydroxytryptamine 2 receptor in rat frontal cortical membranes by [3H]- KET displacement.,B,,,,,CHEMBL617447,9098,H,BAO_0000249,1,,,,,104686
2375,4,,Evaluated for the binding affinity to rat frontal cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- KET as a radioligand.;ND is not determined,B,,,,,CHEMBL617448,9098,H,BAO_0000019,1,,,,,104686
2376,4,,Evaluated for the binding affinity to rat frontal cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- KET as a radioligand;ND means no data,B,,,,,CHEMBL617449,9098,H,BAO_0000019,1,,,,,104686
2377,4,,In vitro binding affinity at 5-hydroxytryptamine 2 receptor in rat cortical tissue by [3H]spiperone displacement; No data.,B,,,,,CHEMBL617450,9161,H,BAO_0000019,1,,,,,104686
2378,4,,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 165 to 263,B,,,,,CHEMBL617451,9161,H,BAO_0000019,1,,,,,104686
2379,4,,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 2.4 to 5.3,B,,,,,CHEMBL617452,9161,H,BAO_0000019,1,,,,,104686
2380,4,,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]-Spiperone as the radioligand in rat cortical tissue.,B,,,,,CHEMBL617453,9161,H,BAO_0000019,1,,,,,104686
2381,4,,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue.; value may range from 140 to 980,B,,,,,CHEMBL617660,9161,H,BAO_0000019,1,,,,,104686
2382,4,,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue.; value may range from 76 to 299,B,,,,,CHEMBL617661,9161,H,BAO_0000019,1,,,,,104686
2383,4,,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]-Spiperone as the radioligand in rat cortical tissue; value may range from 12 to 66,B,,,,,CHEMBL617662,9161,H,BAO_0000019,1,,,,,104686
2384,4,,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 136 to 220,B,,,,,CHEMBL872919,9161,H,BAO_0000019,1,,,,,104686
2385,4,,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 197 to 341,B,,,,,CHEMBL617663,9161,H,BAO_0000019,1,,,,,104686
2386,4,,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 23 to 187,B,,,,,CHEMBL617664,9161,H,BAO_0000019,1,,,,,104686
2387,4,,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 29 to 132,B,,,,,CHEMBL617665,9161,H,BAO_0000019,1,,,,,104686
2388,4,,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 6 to 75,B,,,,,CHEMBL617666,9161,H,BAO_0000019,1,,,,,104686
2389,4,,In vitro binding affinity on 5-hydroxytryptamine 2 receptor is inhibition of binding of [125I]- I-LSD to P11 cells,B,,,,,CHEMBL617667,12094,H,BAO_0000019,1,,,,,104686
2390,4,,In vitro binding affinity towards 5-hydroxytryptamine 2 receptor in rat striatal membranes by [3H]ketanserin displacement.,B,,,,,CHEMBL617668,12018,H,BAO_0000249,1,,,,,104686
2391,4,,Inhibitory activity against 5-hydroxytryptamine 2 receptor in rat cortical membranes using [3H]ketanserin as a radioligand,B,,,,,CHEMBL617669,10394,H,BAO_0000249,1,,,,,104686
2392,4,,Inhibitory activity against rat cortical 5-hydroxytryptamine 2 receptor,B,,,,,CHEMBL617670,15260,H,BAO_0000224,1,,,,,104686
2393,5,Rattus norvegicus,Inhibitory constant against 5-hydroxytryptamine 2 receptor,B,10116.0,,,,CHEMBL617671,11624,D,BAO_0000224,1,,,,,104686
2394,4,,Percentage specific displacement of radioligand [3H]-ketanserin from 5-hydroxytryptamine 2 receptor,B,,,,,CHEMBL617672,13654,H,BAO_0000224,1,,,,,104686
2395,4,,Potency to displace [3H]- Spiperone from 5-hydroxytryptamine 2 receptor in rat striatum,B,,,,,CHEMBL617673,9541,H,BAO_0000019,1,,,,,104686
2396,4,,Tested for binding affinity against 5-hydroxytryptamine 2 receptor from rat frontal cortical regions using [3H]ketanserin as radioligand,B,,,,,CHEMBL617674,11933,H,BAO_0000224,1,,,,,104686
2397,4,,Tested for binding affinity by measuring displacement of [3H]ketanserin from rat serotonin 5-hydroxytryptamine 2 receptor in rat cortex,B,,,,,CHEMBL617675,15538,H,BAO_0000019,1,,,,,104686
2398,4,,Tested for binding affinity by measuring displacement of [3H]ketanserin from rat serotonin 5-hydroxytryptamine 2 receptor in rat cortex; NA means Not Active,B,,,,,CHEMBL617676,15538,H,BAO_0000019,1,,,,,104686
2399,4,,Tested for binding affinity by measuring displacement of [3H]ketanserin from rat serotonin 5-hydroxytryptamine 2 receptor in rat cortex; not determined,B,,,,,CHEMBL617677,15538,H,BAO_0000019,1,,,,,104686
2400,5,,Displacement of [3H]ketanserin from rat prefrontal cortex 5-hydroxytryptamine 2 receptor,B,,,,,CHEMBL617678,8841,D,BAO_0000019,1,,,,,104686
2401,4,,Binding affinity to 5-hydroxytryptamine 2 receptor using [3H]ketanserin radioligand assay.,B,,,,,CHEMBL617679,1455,H,BAO_0000224,1,,,,,104686
2402,4,,Tested for its binding affinity to Tested for its binding affinity to 5-hydroxytryptamine 2 receptor using [3H]-ketanserin radioligand assay using [3H]-ketanserin radioligand assay,B,,,,,CHEMBL617680,1455,H,BAO_0000224,1,,,,,104686
2403,4,,The ability to inhibit [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor in rat whole brain,B,,,,,CHEMBL617681,11752,H,BAO_0000019,1,,,,,104686
2404,4,,The binding affinity was measured on 5-hydroxytryptamine 2 receptor in rat brain tissue,B,,Brain,,,CHEMBL617682,11642,H,BAO_0000221,1,955.0,,,,104686
2405,4,,The binding affinity was measured on 5-hydroxytryptamine 2 receptor using [3H]- spiperone as radioligand.,B,,,,,CHEMBL617683,12092,H,BAO_0000224,1,,,,,104686
2406,4,,Binding affinity at 5-hydroxytryptamine 2 receptor from striata wistar rats by [3H]ketanserin displacement.,B,,,,,CHEMBL617684,3967,H,BAO_0000224,1,,,,,104686
2407,5,Rattus norvegicus,Binding affinity towards 5-hydroxytryptamine 2 receptor,B,10116.0,,,,CHEMBL617685,12771,D,BAO_0000224,1,,,,,104686
2408,4,,The compound was tested for its binding affinity towards 5-hydroxytryptamine 2 receptor by displacing [3H]ketanserin radioligand in rat cerebral cortex,B,,,,,CHEMBL617686,11642,H,BAO_0000019,1,,,,,104686
2409,4,,The compound was tested in vitro for binding affinity towards 5-hydroxytryptamine 2 receptor by displacing [125]I-LSD radioligand,B,,,,,CHEMBL617687,11628,H,BAO_0000224,1,,,,,104686
2410,4,,Percentage specific displacement of radioligand [3H]ketanserin from 5-hydroxytryptamine 2 receptor,B,,,,,CHEMBL617688,13654,H,BAO_0000224,1,,,,,104686
2411,4,,In vitro antagonistic activity against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips,F,,,,,CHEMBL617689,11200,H,BAO_0000019,1,,,,,104686
2412,4,,In vitro antagonistic activity against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips,F,,,,,CHEMBL617690,11200,H,BAO_0000019,1,,,,,104686
2413,4,,"In vivo inhibitory activity of 10 mg/kg compound in rats against elevation of BP caused by 5-HT (300 ug/kg, iv) through 5-hydroxytryptamine 2 receptor 1 hr after oral administration",F,,,,,CHEMBL617691,11200,H,BAO_0000218,1,,In vivo,,,104686
2414,4,,"In vivo inhibitory activity of 10 mg/kg compound in rats against elevation of BP caused by 5-HT (300 ug/kg, iv) through 5-hydroxytryptamine 2 receptor 3h after oral administration",F,,,,,CHEMBL617692,11200,H,BAO_0000218,1,,In vivo,,,104686
2415,4,,"In vivo inhibitory activity of 3 mg/kg compound in rats against elevation of BP caused by 5-HT (300 ug/kg, iv) through 5-hydroxytryptamine 2 receptor 1 hr after oral administration",F,,,,,CHEMBL617693,11200,H,BAO_0000218,1,,In vivo,,,104686
2416,4,,"In vivo inhibitory activity of 3 mg/kg compound in rats against elevation of BP caused by 5-HT (300 ug/kg, iv) through 5-hydroxytryptamine 2 receptor 3h after oral administration",F,,,,,CHEMBL617694,11200,H,BAO_0000218,1,,In vivo,,,104686
2417,8,,Affinity for 5-hydroxytryptamine 2A receptor in rat brain cortex by ability to displace [3H]ketanserin,B,,Brain,,,CHEMBL857985,15436,H,BAO_0000221,1,955.0,,,,12687
2418,9,Rattus norvegicus,Affinity at 5-hydroxytryptamine 2A receptor of the rat brain cortex was assessed on the basis of their ability to displace [3H]ketanserin,B,10116.0,,,,CHEMBL617695,15436,D,BAO_0000019,1,,,,,12687
2419,8,,Affinity pKi for 5-hydroxytryptamine 2A receptor was measured in rat cortex homogenates,B,,,,,CHEMBL617696,14025,H,BAO_0000019,1,,,,,12687
2420,8,,Binding affinity of compound towards serotonin 5-hydroxytryptamine 2A receptor was determined,B,,,,,CHEMBL617697,4342,H,BAO_0000357,1,,,,,12687
2421,9,Rattus norvegicus,Displacement of [3H]ketanserin from 5-HT2A receptor of rat frontal cortex,B,10116.0,,,,CHEMBL617257,13735,D,BAO_0000019,1,,,,,12687
2422,9,Rattus norvegicus,Binding affinity towards 5-hydroxytryptamine 2A receptor using [3H]ketanserin,B,10116.0,,,,CHEMBL617258,5816,D,BAO_0000357,1,,,,,12687
2423,8,,Binding affinity was evaluated in vitro by displacement of [3H]ketanserin from 5-hydroxytryptamine 2A receptor on rat cortical membrane,B,,,,,CHEMBL617259,14287,H,BAO_0000019,1,,,,,12687
2424,8,,In vitro affinity against serotonin ( 5-hydroxytryptamine 2A receptor ) receptor,B,,,,,CHEMBL617260,15738,H,BAO_0000357,1,,,,,12687
2425,9,Rattus norvegicus,In vitro affinity against serotonin 5-hydroxytryptamine 2A receptor,B,10116.0,,,,CHEMBL617261,15738,D,BAO_0000357,1,,,,,12687
2426,8,,Compound was tested in vitro for its binding affinity towards 5-hydroxytryptamine 2A receptor from rat frontal cortex using [3H]-ketanserin as radioligand,B,,,,,CHEMBL617262,15026,H,BAO_0000019,1,,,,,12687
2427,8,,Half-maximal inhibition of [3H]- Ketanserin binding to 5-hydroxytryptamine 2A receptor in rat cerebral cortex homogenate,B,,,,,CHEMBL617263,16647,H,BAO_0000019,1,,,,,12687
2428,8,,Half-maximal inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor in rat tissue homogenate,B,,,,,CHEMBL617264,16647,H,BAO_0000019,1,,,,,12687
2429,9,Rattus norvegicus,Displacement of [3H]-ketanserin from rat brain 5-hydroxytryptamine 2A receptor,B,10116.0,,,,CHEMBL617265,13345,D,BAO_0000019,1,,,,,12687
2430,8,,Inhibition constant for in vitro inhibition of [3H]ketanserin binding to rat frontal cortex membranes 5-hydroxytryptamine 2A receptor,B,,,Membranes,,CHEMBL617266,1543,H,BAO_0000249,1,,,,,12687
2431,8,,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor rat frontal cortex membrane,B,,,,,CHEMBL617267,12444,H,BAO_0000019,1,,,,,12687
2432,8,,Inhibitory constant on 5-hydroxytryptamine 2A receptor of Rat frontal cortex,B,,,,,CHEMBL617268,16404,H,BAO_0000019,1,,,,,12687
2433,8,,Inhibitory constant on human 5-hydroxytryptamine 2A receptor transfected in to CHO cells,B,,,,,CHEMBL617269,16404,H,BAO_0000219,1,,,,CHO,12687
2434,8,,Kinetic inhibition constant evaluated by measuring serotonergic activity,B,,,,,CHEMBL617323,15577,H,BAO_0000357,1,,,,,12687
2435,8,,Serotonergic activity of the compound.,B,,,,,CHEMBL617324,15577,H,BAO_0000357,1,,,,,12687
2436,8,,Tested in vitro for its ability to inhibit [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor in rat frontal cortex membranes,B,,,,,CHEMBL617325,2495,H,BAO_0000249,1,,,,,12687
2437,9,Rattus norvegicus,The binding affinity was evaluated on 5-hydroxytryptamine 2A receptor expressed in rat cortex by using [3H]ketanserin as radioligand.,B,10116.0,,,,CHEMBL617326,15042,D,BAO_0000019,1,,,,,12687
2438,8,,In vitro ability to displace [3H]ketanserin binding from 5-hydroxytryptamine 2A receptor in rat striatal membrane.,B,,,,,CHEMBL617327,15026,H,BAO_0000249,1,,,,,12687
2439,9,Rattus norvegicus,Agonistic activity against 5-hydroxytryptamine 2A receptor in rat cortex using [3H]ketanserin,F,10116.0,,,,CHEMBL617328,12919,D,BAO_0000019,1,,,,,12687
2440,9,Rattus norvegicus,Agonistic activity against 5-hydroxytryptamine 2A receptor in rat cortex using [3H]ketanserin,F,10116.0,,,,CHEMBL617329,12919,D,BAO_0000019,1,,,,,12687
2441,9,Rattus norvegicus,Agonistic activity against 5-hydroxytryptamine 2A receptor in rat cortex using [3H]ketanserin,F,10116.0,,,,CHEMBL617330,12919,D,BAO_0000019,1,,,,,12687
2442,8,,The compound was tested for the binding affinity against 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand,B,,,,,CHEMBL617331,15194,H,BAO_0000357,1,,,,,12687
2443,8,,The compound was tested for the binding affinity against 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand.,B,,,,,CHEMBL617332,15194,H,BAO_0000357,1,,,,,12687
2444,8,,Binding affinity towards 5-hydroxytryptamine 2A receptor,B,,,,,CHEMBL617333,4820,H,BAO_0000357,1,,,,,107
2445,8,,Binding affinity against serotonin 5-hydroxytryptamine 2A receptor was determined using human [125I]-eotaxin,B,,,,,CHEMBL617334,6736,H,BAO_0000357,1,,,,,107
2446,8,,Binding affinity towards 5-hydroxytryptamine 2A receptor was determined at a concentration of 0.000001 mol/L,B,,,,,CHEMBL617335,5163,H,BAO_0000357,1,,,,,107
2447,8,,Binding affinity towards 5-hydroxytryptamine 2A receptor was determined at a concentration of 0.00001 mol/L,B,,,,,CHEMBL617336,5163,H,BAO_0000357,1,,,,,107
2448,8,,Inhibition of binding towards 5-hydroxytryptamine 2A receptor at 100 nM concentration,B,,,,,CHEMBL617337,6011,H,BAO_0000357,1,,,,,107
2449,9,Homo sapiens,Percent inhibition against 5-hydroxytryptamine 2A receptor using [3H]ketanserin at 1 uM,B,9606.0,,,,CHEMBL617338,14294,D,BAO_0000357,1,,,,,107
2450,8,,Percent inhibition (at 1 uM) against 5-hydroxytryptamine 2A receptor,B,,,,,CHEMBL617339,5014,H,BAO_0000357,1,,,,,107
2451,8,,Binding affinity towards 5-hydroxytryptamine 2A receptor,B,,,,,CHEMBL617340,17066,H,BAO_0000357,1,,,,,107
2452,8,,Binding affinity of compound towards serotonin 5-hydroxytryptamine 2A receptor; inactive at 10 uM,B,,,,,CHEMBL617341,17515,H,BAO_0000357,1,,,,,107
2453,8,,Inhibition of [125I]-eotaxin binding to serotonin 5-hydroxytryptamine 2A receptor,B,,,,,CHEMBL617342,6736,H,BAO_0000357,1,,,,,107
2454,8,,Affinity for 5-hydroxytryptamine 2A receptor,B,,,,,CHEMBL617343,5163,H,BAO_0000357,1,,,,,107
2455,8,,Binding affinity was performed using [3H]ketanserin as the radioligand and stably transfected NIH3T3 cells expressing the 5-hydroxytryptamine 2A receptor (GF-62 cells).,B,,,,,CHEMBL617344,16911,H,BAO_0000219,1,,,,NIH3T3,107
2456,8,,Binding affinity towards 5-hydroxytryptamine 2A receptor using [3H]ketanserin,B,,,,,CHEMBL617345,6841,H,BAO_0000357,1,,,,,107
2457,8,,Binding affinity towards 5-hydroxytryptamine 2A receptor using [125I]DOI as radioligand.,B,,,,,CHEMBL617346,6119,H,BAO_0000357,1,,,,,107
2458,8,,Compound was evaluated for its binding against 5-hydroxytryptamine 2A receptor,B,,,,,CHEMBL617347,3962,H,BAO_0000357,1,,,,,107
2459,8,,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 2A receptor was determined,B,,,,,CHEMBL617348,4373,H,BAO_0000357,1,,,,,107
2460,8,,Binding affinity relative to indolopiperidine (compound 1)for 5-hydroxytryptamine 2A receptor was determined,B,,,,,CHEMBL617349,4373,H,BAO_0000357,1,,,,,107
2461,8,,Compound was evaluated for its inverse agonist activity against 5-hydroxytryptamine 2A receptor,F,,,,,CHEMBL617350,3962,H,BAO_0000019,1,,,,,107
2462,8,,Binding affinity towards 5-hydroxytryptamine 2A receptor by displacement of [3H]ketanserin,B,,,,,CHEMBL872339,1633,H,BAO_0000357,1,,,,,107
2463,8,,Binding affinity for 5-hydroxytryptamine 2A receptor was determined,B,,,,,CHEMBL617351,4373,H,BAO_0000357,1,,,,,107
2464,8,,Binding affinity towards serotonin 5-hydroxytryptamine 2A receptor,B,,,,,CHEMBL617352,6576,H,BAO_0000357,1,,,,,107
2465,8,,Evaluated for the binding affinity towards 5-hydroxytryptamine 2A receptor,B,,,,,CHEMBL617353,4687,H,BAO_0000357,1,,,,,107
2466,8,,Ability to displace [3H]-ketanserin from 5-hydroxytryptamine 2A receptor,B,,,,,CHEMBL617354,16946,H,BAO_0000357,1,,,,,107
2467,8,,Compound was evaluated for the affinity at 5-hydroxytryptamine 2A receptor,B,,,,,CHEMBL617355,14159,H,BAO_0000357,1,,,,,107
2468,8,Mus musculus,In vitro binding affinity against 5-hydroxytryptamine 2A receptor in CHO cells,B,10090.0,,,,CHEMBL617356,3032,H,BAO_0000219,1,,,,CHO,107
2469,8,,Inhibition of ketanserin binding to 5-hydroxytryptamine 2A receptor,B,,,,,CHEMBL617357,16655,H,BAO_0000357,1,,,,,107
2470,8,,Binding affinity at 5-hydroxytryptamine 2A receptor,B,,,,,CHEMBL617358,13964,H,BAO_0000357,1,,,,,107
2471,8,,Binding affinity towards Serotonin 5-hydroxytryptamine 2A receptor,B,,,,,CHEMBL617359,16989,H,BAO_0000357,1,,,,,107
2472,8,,In vitro binding affinity towards 5-hydroxytryptamine 2A receptor was determined,B,,,,,CHEMBL617360,16117,H,BAO_0000357,1,,,,,107
2473,8,,The binding affinity towards 5-hydroxytryptamine 2A receptor; No affinity,B,,,,,CHEMBL875913,16700,H,BAO_0000357,1,,,,,107
2474,8,,Affinity against 5-hydroxytryptamine 2A receptor,B,,,,,CHEMBL617361,3269,H,BAO_0000357,1,,,,,107
2475,9,Homo sapiens,Binding affinity against 5-Hydroxytryptamine 2A receptor,B,9606.0,,,,CHEMBL617362,1274,D,BAO_0000357,1,,,,,107
2476,8,,Compound was evaluated for binding affinity against 5-hydroxytryptamine 2A receptor using radioligand binding assay,B,,,,,CHEMBL617363,1317,H,BAO_0000357,1,,,,,107
2477,8,,Tested against 5-hydroxytryptamine 2A receptor,B,,,,,CHEMBL617364,12146,H,BAO_0000357,1,,,,,107
2478,4,,Binding affinity against the site labelled by the 5-hydroxytryptamine 2A receptor - 5-hydroxytryptamine 2C receptor antagonist [3H]- ketanserin,B,,,,,CHEMBL617365,12652,H,BAO_0000224,1,,,,,105075
2479,4,,Tested for the binding affinity against the site labelled by the 5-hydroxytryptamine 2A receptor - 5-hydroxytryptamine 2C receptor antagonist [3H] ketanserin,B,,,,,CHEMBL617366,12652,H,BAO_0000224,1,,,,,105075
2480,4,,Tested for the binding affinity against the site labelled by the 5-hydroxytryptamine 2A receptor - 5-hydroxytryptamine 2C receptor agonist [125I]- - (+/-)DOI,B,,,,,CHEMBL617367,12652,H,BAO_0000224,1,,,,,105075
2481,4,,Tested for the binding affinity against the site labelled by the 5-hydroxytryptamine 2A receptor - 5-hydroxytryptamine 2C receptor antagonist [3H]- ketanserin,B,,,,,CHEMBL617368,12652,H,BAO_0000224,1,,,,,105075
2482,8,,Selectivity ratio towards 5-hydroxytryptamine 2A receptor to Dopamine receptor D2 (5-HT2A/D2 ),B,,,,,CHEMBL617369,16647,H,BAO_0000357,1,,,,,107
2483,9,Homo sapiens,Displacement of [3H]ketanserin from human 5-hydroxytryptamine 2B receptor expressed in HEK293 cells; ND means no data,B,9606.0,,,,CHEMBL617370,15851,D,BAO_0000219,1,,,,HEK293,227
2484,9,Homo sapiens,Functional activity against human 5-hydroxytryptamine 2B receptor expressed in CHO cells using fluorometric imaging plate reader,F,9606.0,,,,CHEMBL617371,6857,D,BAO_0000219,1,,,,CHO,227
2485,8,,In vitro binding affinity against human 5-HT2B receptor at a concentration of 100 (nM),B,,,,,CHEMBL617372,3805,H,BAO_0000357,1,,,,,227
2486,9,Homo sapiens,Affinity towards human 5-hydroxytryptamine 2B serotonin receptor,B,9606.0,,,,CHEMBL617373,6491,D,BAO_0000357,1,,,,,227
2487,8,,Agonist activity at cloned human 5-hydroxytryptamine 2B receptor using [3H]5-HT radioligand,F,,,,,CHEMBL617374,14093,H,BAO_0000019,1,,,,,227
2488,8,,Agonistic activity at cloned human 5-hydroxytryptamine 2B receptor using [3H]-5-HT as radioligand,F,,,,,CHEMBL617375,13481,H,BAO_0000019,1,,,,,227
2489,8,,Antagonist activity at cloned human 5-hydroxytryptamine 2B receptor using [3H]- rauwolscine radioligand,F,,,,,CHEMBL617376,14093,H,BAO_0000019,1,,,,,227
2490,8,,Antagonist activity at cloned human 5-hydroxytryptamine 2B receptor using [3H]- rauwolscine radioligand; Not tested,F,,,,,CHEMBL617377,14093,H,BAO_0000019,1,,,,,227
2491,8,,Antagonist activity at cloned human 5-hydroxytryptamine 2B receptor using [3H]rauwolscine radioligand,F,,,,,CHEMBL617378,14093,H,BAO_0000019,1,,,,,227
2492,8,,Antagonistic activity at cloned human 5-hydroxytryptamine 2B receptor using [3H]rauwolscine as radioligand,F,,,,,CHEMBL617379,13481,H,BAO_0000019,1,,,,,227
2493,8,,Binding ability of compound at cloned human 5-hydroxytryptamine 2B receptor using [3H]- rauwolscine as radioligand,B,,,,,CHEMBL617380,14442,H,BAO_0000357,1,,,,,227
2494,8,,Binding ability of compound at cloned human 5-hydroxytryptamine 2B receptor using [3H]5-HT 2B as radioligand,B,,,,,CHEMBL617381,14442,H,BAO_0000357,1,,,,,227
2495,8,,Binding ability of compound at cloned human 5-hydroxytryptamine 2B receptor using [3H]rauwolscine as radioligand,B,,,,,CHEMBL617382,14442,H,BAO_0000357,1,,,,,227
2496,8,,The compound evaluated for its affinity against 5-hydroxytryptamine 2A receptor,B,,,,,CHEMBL617383,12369,H,BAO_0000357,1,,,,,107
2497,8,,Affinity against 5-hydroxytryptamine 2A receptor (D) labeled with [125I]DOI.,B,,,,,CHEMBL617384,12369,H,BAO_0000357,1,,,,,107
2498,8,,Affinity against 5-hydroxytryptamine 2A receptor (K) labeled with [3H]ketanserin.,B,,,,,CHEMBL617385,12369,H,BAO_0000357,1,,,,,107
2499,8,,The compound was tested for CNS binding affinity towards 5-hydroxytryptamine 2A receptor from cloned Human membranes,B,,,,,CHEMBL617386,14447,H,BAO_0000019,1,,,,,107
2500,8,,The compound was tested for CNS binding affinity towards 5-hydroxytryptamine 2A receptor from cloned Human membranes.,B,,,,,CHEMBL617387,14447,H,BAO_0000019,1,,,,,107
2501,8,,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 2A receptor expressed in 3T3 cells using [3H]5-HT as radioligand; Not determined,B,,,,,CHEMBL617388,17451,H,BAO_0000219,1,,,,NIH3T3,107
2502,8,,Relative efficacy against human 5-hydroxytryptamine 2A receptor expressed in CHO cells using fluorometric imaging plate reader relative to 10 uM 5-HT,F,,,,,CHEMBL617389,6857,H,BAO_0000219,1,,,,CHO,107
2503,9,Homo sapiens,Relative efficacy against human 5-hydroxytryptamine 2A receptor expressed in CHO cells using fluorometric imaging plate reader relative to 10 uM 5-HT,F,9606.0,,,,CHEMBL617390,6857,D,BAO_0000219,1,,,,CHO,107
2504,4,,Selectivity ratio of binding affinity of 5-hydroxytryptamine 2A receptor to that of 5-hydroxytryptamine 2C receptor.,B,,,,,CHEMBL617391,5635,H,BAO_0000224,1,,,,,104817
2505,8,,Binding activity radioligand.,B,,,,,CHEMBL617392,12861,H,BAO_0000357,1,,,,,107
2506,8,,Binding activity against 5-hydroxytryptamine 2C receptor from human brain cortex using [3H]mesulergine as radioligand.,B,,,,,CHEMBL617393,12861,H,BAO_0000019,1,,,,,107
2507,8,,Binding affinity for human cloned 5-HT2A receptor expressed in L929 cells using [125I]R91150 as radioligand,B,,,,,CHEMBL617394,5105,H,BAO_0000219,1,,,,L929,107
2508,8,,Binding affinity for human cloned 5-hydroxytryptamine 2A receptor expressed in L929 cells using [125I]R91150 as radioligand,B,,,,,CHEMBL617395,5104,H,BAO_0000219,1,,,,L929,107
2509,8,,Binding affinity at human cloned 5-hydroxytryptamine 2A receptor expressed in L929 cells by [125I]R91150 displacement.,B,,,,,CHEMBL617396,5105,H,BAO_0000219,1,,,,L929,107
2510,8,,Binding affinity for human cloned 5-hydroxytryptamine 2A receptor expressed in L929 cells using [125I]R91150 as radioligand; Not tested,B,,,,,CHEMBL617397,5105,H,BAO_0000219,1,,,,L929,107
2511,8,,Binding affinity against 5-HT2A receptor,B,,,,,CHEMBL617398,5254,H,BAO_0000357,1,,,,,107
2512,8,,Binding affinity against 5-hydroxytryptamine 2A receptor,B,,,,,CHEMBL617399,5254,H,BAO_0000357,1,,,,,107
2513,8,,Antagonistic binding affinity measured against 5-hydroxytryptamine 2A receptor (human clone expressed in 293 cells) using [3H]ketanserin as radioligand,B,,,,,CHEMBL617400,13267,H,BAO_0000219,1,,,,HEK293,107
2514,8,,Antagonistic binding affinity measured against 5-hydroxytryptamine 2C receptor (human clone expressed in 293 cells) using [3H]mesulergine as radioligand,B,,,,,CHEMBL617401,13267,H,BAO_0000219,1,,,,HEK293,107
2515,9,Homo sapiens,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2A receptor expressed in HEK 293 cells,B,9606.0,,,,CHEMBL617402,14157,D,BAO_0000219,1,,,,HEK293,107
2516,9,Homo sapiens,Binding affinity against human 5-hydroxytryptamine 2A receptor expressed in 293 cells using [3H]ketanserin,B,9606.0,,,,CHEMBL617403,12936,D,BAO_0000219,1,,,,HEK293,107
2517,8,,Binding affinity against human 5-hydroxytryptamine 2A receptor using displacement of [3H]5-HT,B,,,,,CHEMBL617404,14068,H,BAO_0000357,1,,,,,107
2518,9,Homo sapiens,Binding affinity against human 5-hydroxytryptamine 2A receptor expressed in 293 cells using [3H]ketanserin,B,9606.0,,,,CHEMBL857981,12936,D,BAO_0000219,1,,,,HEK293,107
2519,9,Homo sapiens,Binding affinity against human 5-hydroxytryptamine 2A receptor expressed in 293 cells using [3H]ketanserin,B,9606.0,,,,CHEMBL617405,12936,D,BAO_0000219,1,,,,HEK293,107
2520,9,Homo sapiens,Binding affinity to human cloned 5-hydroxytryptamine 2A receptor in HEK 293 cells using [3H]- ketanserin as radioligand,B,9606.0,,,,CHEMBL617253,4540,D,BAO_0000219,1,,,,HEK293,107
2521,8,,Binding affinity at human cloned 5-hydroxytryptamine 2A receptor.,B,,,,,CHEMBL617254,6166,H,BAO_0000357,1,,,,,107
2522,8,,Binding affinity against 5-hydroxytryptamine 2A receptor human cloned receptors in HEK 293 cells using [3H]ketanserin as radioligand,B,,,,,CHEMBL617255,17296,H,BAO_0000219,1,,,,HEK293,107
2523,8,,Binding affinity against 5-hydroxytryptamine 2A receptor human cloned receptors in HEK 293 cells using [3H]ketanserin as radioligand,B,,,,,CHEMBL617256,17296,H,BAO_0000219,1,,,,HEK293,107
2524,8,,Binding affinity against 5-hydroxytryptamine 2A receptor human cloned receptorswithouteffect in HEK 293 cells using [3H]ketanserin as radioligand,B,,,,,CHEMBL616874,17296,H,BAO_0000219,1,,,,HEK293,107
2525,9,Homo sapiens,Binding affinity towards 5-hydroxytryptamine 2A receptor (human cloned receptor) in HEK 293 cells using [3H]ketanserin as radioligand.,B,9606.0,,,,CHEMBL616875,15779,D,BAO_0000219,1,,,,HEK293,107
2526,8,,Binding affinity towards human 5-hydroxytryptamine 2A receptor expressed in HEK 293 cells using [3H]ketanserin as radioligand,B,,,,,CHEMBL616876,14391,H,BAO_0000219,1,,,,HEK293,107
2527,8,,"Binding affinity towards human cloned 5-hydroxytryptamine receptor 2A in HEK293 cells, using [3H]ketanserin as radioligand.",B,,,,,CHEMBL616877,15851,H,BAO_0000219,1,,,,HEK293,107
2528,9,Homo sapiens,Displacement of [3H]ketanserin from human 5-hydroxytryptamine 2A receptor expressed in HEK293 cells; compound is insoluble,B,9606.0,,,,CHEMBL616878,15851,D,BAO_0000219,1,,,,HEK293,107
2529,8,,Binding affinity towards human cloned 5-hydroxytryptamine 2A receptor of HEK293 cells by displacement of [3H]ketanserin,B,,,,,CHEMBL616879,3832,H,BAO_0000219,1,,,,HEK293,107
2530,8,,In vitro binding affinity at human cloned 5-hydroxytryptamine 2A receptor of HEK293 cells by [3H]ketanserin displacement.,B,,,,,CHEMBL616880,3833,H,BAO_0000219,1,,,,HEK293,107
2531,9,Homo sapiens,Binding affinity against human 5-hydroxytryptamine 2A receptor expressed in 293 cells using [3H]ketanserin,B,9606.0,,,,CHEMBL616881,12936,D,BAO_0000219,1,,,,HEK293,107
2532,8,,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 2A receptor expressed in 3T3 cells using [3H]5-HT as radioligand,B,,,,,CHEMBL616882,17451,H,BAO_0000219,1,,,,NIH3T3,107
2533,8,,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 2A receptor expressed in 3T3 cells using [3H]5-HT as radioligand; Not determined,B,,,,,CHEMBL616883,17451,H,BAO_0000219,1,,,,NIH3T3,107
2534,8,,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 2A receptor expressed in 3T3 cells using [3H]5-HT as radioligand; Not determined,B,,,,,CHEMBL616884,17451,H,BAO_0000219,1,,,,NIH3T3,107
2535,8,,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 2A receptor in HEK 293 cells using [3H]ketanserin as the radioligand,B,,,,,CHEMBL616885,4199,H,BAO_0000219,1,,,,HEK293,107
2536,8,,Compound was evaluated for displacement of [3H]ketanserin from human cloned 5-hydroxytryptamine 2A receptor in transfected CHO-K1 cells,B,,,,,CHEMBL616886,1883,H,BAO_0000219,1,,,,CHO-K1,107
2537,8,,Displacement of [3H]-ketanserin from human cloned 5-hydroxytryptamine 2A receptor expressed in CHO-K1 cells.,B,,,,,CHEMBL616887,1883,H,BAO_0000219,1,,,,CHO-K1,107
2538,9,Homo sapiens,Binding affinity for human 5-hydroxytryptamine 2A receptor,B,9606.0,,,,CHEMBL616888,14875,D,BAO_0000357,1,,,,,107
2539,8,,Compound was tested for its binding affinity against 5-hydroxytryptamine 2A receptor in human cloned receptors in HEK 293 cells using [3H]ketanserin,B,,,,,CHEMBL616889,15146,H,BAO_0000219,1,,,,HEK293,107
2540,8,,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 2A receptor in HEK 293 using [3H]ketanserin as a radioligand,B,,,,,CHEMBL616890,5213,H,BAO_0000219,1,,,,HEK293,107
2541,9,Homo sapiens,Inhibitory constant for human 5-hydroxytryptamine 2A receptor transfected in to CHO cells,B,9606.0,,,,CHEMBL616891,16404,D,BAO_0000219,1,,,,CHO,107
2542,8,,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 2A receptor in HEK293 cells using [3H]-ketanserin.,B,,,,,CHEMBL616892,14818,H,BAO_0000219,1,,,,HEK293,107
2543,8,,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 2A receptor in HEK293 cells, using [3H]ketanserin as radioligand",B,,,,,CHEMBL616893,4829,H,BAO_0000219,1,,,,HEK293,107
2544,8,,Percent of maximum stimulation of phosphatidylinositol turnover at cloned 5-hydroxytryptamine 2A receptor in 3T3 cells,F,,,,,CHEMBL616894,12652,H,BAO_0000219,1,,,,NIH3T3,10620
2545,8,,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2A receptor expressed NIH3T3 cells,B,,,,,CHEMBL616895,4682,H,BAO_0000219,1,,,,NIH3T3,107
2546,8,,The maximum responses of [3H]- inositol monophosphate accumulation in cells expressing the 5-hydroxytryptamine 2A receptor,F,,,,,CHEMBL616896,12652,H,BAO_0000019,1,,,,,10620
2547,8,,Ability to displace [3H]-Ketanserin radioligand from porcine 5-hydroxytryptamine 2A receptor,B,,,,,CHEMBL617099,4921,H,BAO_0000357,1,,,,,10621
2548,8,,Ability to displace [3H]ketanserin radioligand from porcine 5-hydroxytryptamine 2A receptor; ND denotes not determined,B,,,,,CHEMBL617100,4921,H,BAO_0000357,1,,,,,10621
2549,8,Oryctolagus cuniculus,Binding affinity against rabbit aorta 5-HT2A receptor,B,9986.0,,,,CHEMBL884532,16312,H,BAO_0000357,1,,,,,107
2550,8,Oryctolagus cuniculus,Binding affinity for 5-hydroxytryptamine 2A receptor of rabbit aorta ring preparations,B,9986.0,,,,CHEMBL617101,14998,H,BAO_0000357,1,,,,,107
2551,8,Oryctolagus cuniculus,Dissociation equilibrium constant against the vascular 5-hydroxytryptamine 2A receptor in the rabbit saphenous aorta,B,9986.0,,,,CHEMBL617102,14025,H,BAO_0000357,1,,,,,107
2552,8,Oryctolagus cuniculus,Binding affinity against 5-hydroxytryptamine 1D receptor alpha using rabbit saphenous vein assay.,B,9986.0,,,,CHEMBL617103,13047,H,BAO_0000019,1,,,,,107
2553,8,Oryctolagus cuniculus,The compound was tested for binding affinity against 5-HT2A receptor,B,9986.0,,,,CHEMBL617104,13047,H,BAO_0000357,1,,,,,107
2554,8,,Compound was evaluated for displacement of [3H]ketanserin from cloned rat 5-hydroxytryptamine 2A receptor in transfected CHO-K1 cells.,B,,,,,CHEMBL857979,1883,H,BAO_0000219,1,,,,CHO-K1,10576
2555,8,,Binding affinity analysed towards 5-HT 2A in rat jugular vein,B,,,,,CHEMBL857502,13463,H,BAO_0000019,1,,,,,12687
2556,8,,Binding affinity analysed towards 5-HT 2A in rat jugular vein.,B,,,,,CHEMBL617105,13463,H,BAO_0000019,1,,,,,12687
2557,8,,Binding affinity analysed on 5-HT 2A in rat stomach fundus.,B,,Stomach,,,CHEMBL858021,13463,H,BAO_0000019,1,945.0,,,,12687
2558,9,Rattus norvegicus,Binding affinity for 5-HT 2A in rat stomach fundus,B,10116.0,Stomach,,,CHEMBL875910,13463,D,BAO_0000019,1,945.0,,,,12687
2559,8,,Binding affinity analysed towards 5-HT 2A in rat jugular vein.,B,,,,,CHEMBL617106,13463,H,BAO_0000019,1,,,,,12687
2560,8,,Ability to stimulate phosphoinositide hydrolysis in NIH3T3 cells expressing the 5-hydroxytryptamine 2A receptor,B,,,,,CHEMBL617107,16326,H,BAO_0000219,1,,,,NIH3T3,12687
2561,8,,Effect on phosphoinositide hydrolysis in NIH 3T3 fibroblast 5-hydroxytryptamine 2A receptor,F,,,,,CHEMBL617108,14093,H,BAO_0000019,1,,,,,12687
2562,8,,Effect on phosphoinositide hydrolysis in NIH 3T3 fibroblast expressing 5-hydroxytryptamine 2A receptor,F,,,,,CHEMBL617109,14093,H,BAO_0000019,1,,,,,12687
2563,8,,Evaluated for the effective concentration at [125I]-DOI-labeled rat 5-hydroxytryptamine 2A receptor,B,,,,,CHEMBL617110,15740,H,BAO_0000357,1,,,,,12687
2564,8,,Functional potency at the rat 5-hydroxytryptamine 2A receptor as effective concentration EC50 for stimulating Phosphoinositide accumulation,B,,,,,CHEMBL617111,16633,H,BAO_0000357,1,,,,,12687
2565,9,Rattus norvegicus,In vitro relative agonist activity against 5-hydroxytryptamine 2A using PI assay in rat vascular smooth muscle cells,F,10116.0,,,,CHEMBL617112,17200,D,BAO_0000019,1,,,,,12687
2566,8,,Tested for its ability to activate phospholipase C by quantification of IP3 at cloned rat 5-hydroxytryptamine 2A receptor,B,,,,,CHEMBL617113,17133,H,BAO_0000357,1,,,,,12687
2567,8,,Tested for its ability to activate phospholipase C by quantification of IP3 at cloned rat 5-hydroxytryptamine 2A receptor,B,,,,,CHEMBL617114,17133,H,BAO_0000357,1,,,,,12687
2568,8,,Tested for its ability to activate phospholipase c by quantification of IP3 at cloned rat 5-hydroxytryptamine 2A receptor,B,,,,,CHEMBL617115,17133,H,BAO_0000357,1,,,,,12687
2569,8,,The receptor (5-hydroxytryptamine 2A ) mediated mobilization of intracellular calcium [Ca2+] was studied in rat smooth muscle cells,F,,,,,CHEMBL617116,17200,H,BAO_0000219,1,,,,,12687
2570,8,,Efficacy at 5-hydroxytryptamine 2A receptor,F,,,,,CHEMBL617117,15363,H,BAO_0000019,1,,,,,12687
2571,8,,In vitro efficacy against rat 5-hydroxytryptamine 2A receptor was determined by using CA+ assay (Emax),B,,,,,CHEMBL617118,17200,H,BAO_0000357,1,,,,,12687
2572,9,Rattus norvegicus,In vitro efficacy against rat 5-hydroxytryptamine 2A receptor was determined by using CA+ assay (Emax),B,10116.0,,,,CHEMBL617119,17200,D,BAO_0000357,1,,,,,12687
2573,9,Rattus norvegicus,In vitro efficacy against rat 5-hydroxytryptamine 2A receptor determined by using PI assay (Emax),B,10116.0,,,,CHEMBL617120,17200,D,BAO_0000357,1,,,,,12687
2574,9,Rattus norvegicus,The receptor (5-hydroxytryptamine 2A ) mediated mobilization of intracellular calcium [Ca2+] was studied in rat smooth muscle cells,F,10116.0,,,,CHEMBL617121,17200,D,BAO_0000219,1,,,,,12687
2575,8,,The receptor (5-hydroxytryptamine 2A) mediated mobilization of intracellular calcium [Ca2+] was studied in rat smooth muscle cells,F,,,,,CHEMBL617122,17200,H,BAO_0000219,1,,,,,12687
2576,8,,Ability to displace [3H]ketanserin (0.5 nM) from cerebral cortex of rat 5-hydroxytryptamine 2A receptor,B,,,,,CHEMBL617123,17211,H,BAO_0000019,1,,,,,12687
2577,8,,Binding affinity against 5-hydroxytryptamine 2A receptor by displacement of [3H]-ketanserin from rat prefrontal cerebral cortex mambranes,B,,,,,CHEMBL617124,17331,H,BAO_0000019,1,,,,,12687
2578,8,,Binding affinity to serotonin 5-hydroxytryptamine 2A receptors using a radioligand [3H]ketanserin binding assay in rat cortical membranes,B,,,,,CHEMBL617600,13565,H,BAO_0000249,1,,,,,12687
2579,8,,Binding affinity towards rat 5-hydroxytryptamine 2A receptor was evaluated using [3H]- ketanserin as radioligand,B,,,,,CHEMBL617601,13730,H,BAO_0000357,1,,,,,12687
2580,8,,In vitro affinity towards 5-hydroxytryptamine 2A receptor using [3H]spiroperidol as radioligand in cortex,B,,,,,CHEMBL882923,12416,H,BAO_0000019,1,,,,,12687
2581,8,,Compound was tested for it's binding affinity towards 5-hydroxytryptamine 2A receptor,B,,,,,CHEMBL617602,15295,H,BAO_0000357,1,,,,,12687
2582,8,,Compound was tested for its ability to displace [3H]DOB from 5-hydroxytryptamine 2A receptor in rat cortex homogenates,B,,,,,CHEMBL617603,1742,H,BAO_0000019,1,,,,,12687
2583,8,,Compound was tested for the inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor,B,,,,,CHEMBL617604,15295,H,BAO_0000357,1,,,,,12687
2584,8,,Binding affinity towards 5-hydroxytryptamine 2A receptor from rat frontal cortex using [3H]ketanserin as radioligand,B,,,,,CHEMBL617605,14970,H,BAO_0000019,1,,,,,12687
2585,8,,In vitro binding affinity for serotonin 5-hydroxytryptamine 2A receptor of rat cerebral cortex using [3H]ketanserin as radioligand,B,,,,,CHEMBL617606,16693,H,BAO_0000019,1,,,,,12687
2586,9,Rattus norvegicus,Inhibition of [3H]ketanserin binding to rat frontal cortex membrane 5-hydroxytryptamine 2A receptor,B,10116.0,,,,CHEMBL617607,14776,D,BAO_0000019,1,,,,,12687
2587,8,,In vitro inhibitory concentration against radioligand [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor in rat cortical membrane,B,,,,,CHEMBL617455,14286,H,BAO_0000249,1,,,,,12687
2588,9,Rattus norvegicus,In vitro inhibition of [125I]DOI binding to 5-hydroxytryptamine 2A receptor in rat cerebral cortex,B,10116.0,,,,CHEMBL617456,17200,D,BAO_0000019,1,,,,,12687
2589,8,,Inhibitory concentration against 5-hydroxytryptamine 2A receptor (Inactive at >1000 nM concentration),B,,,,,CHEMBL617457,15306,H,BAO_0000357,1,,,,,12687
2590,9,Rattus norvegicus,Inhibition of radiolabeled [3H]-Ketanserin ligand binding to 5-hydroxytryptamine 2A receptor,B,10116.0,,,,CHEMBL617458,14178,D,BAO_0000357,1,,,,,12687
2591,9,Rattus norvegicus,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor from rat brain,B,10116.0,,,,CHEMBL617459,14229,D,BAO_0000019,1,,,,,12687
2592,8,,Binding affinity towards 5-hydroxytryptamine 2A receptor binding site using [3H]ketanserin. ,B,,,,,CHEMBL617460,12884,H,BAO_0000357,1,,,,,12687
2593,8,,"Binding affinity for 5-hydroxytryptamine 2A receptor, activity is expressed as IC50 values.",B,,,,,CHEMBL617461,13149,H,BAO_0000357,1,,,,,12687
2594,9,Rattus norvegicus,Displacement of [3H]ketanserin from rat cortical membrane 5-hydroxytryptamine 2A receptor at 10e-7 M,B,10116.0,,,,CHEMBL617462,15295,D,BAO_0000019,1,,,,,12687
2595,8,,Intrinsic activity was determined at 5-hydroxytryptamine 2A receptor which is percentage response given compared with the response produced by 10 uM serotonin.,B,,,,,CHEMBL617463,15740,H,BAO_0000357,1,,,,,12687
2596,8,,"Compound was tested for binding affinity at 5-hydroxytryptamine 2A receptor sites in rat cortical homogenate using [125I]-2,5-Dimethoxy -4-iodoamphetamine (DOI).",B,,,,,CHEMBL617464,15185,H,BAO_0000019,1,,,,,12687
2597,8,,"Compound was tested for binding affinity using [3H]MDL-100,907 at 5-hydroxytryptamine 2A receptor sites in rat cortical homogenate.",B,,,,,CHEMBL617465,15185,H,BAO_0000019,1,,,,,12687
2598,8,,Ability to bind to central serotonin 5-hydroxytryptamine 2A receptor in vitro in cortex of the rat brain using [3H]ketanserin radioligand,B,,,,,CHEMBL617466,17529,H,BAO_0000019,1,,,,,12687
2599,8,,Ability to displace [3H]- ketanserin bound to 5-hydroxytryptamine 2A receptor in rat pre-frontal cortex,B,,,,,CHEMBL617467,14826,H,BAO_0000019,1,,,,,12687
2600,8,,Displacement of [3H]ketanserin (0.5 nM) from rat cerebral cortex 5-hydroxytryptamine 2A receptors,B,,,,,CHEMBL617468,17211,H,BAO_0000019,1,,,,,12687
2601,8,,Ability to displace [3H]ketanserin bound to 5-hydroxytryptamine 2A receptor in rat pre-frontal cortex,B,,,,,CHEMBL617469,14826,H,BAO_0000019,1,,,,,12687
2602,8,,Ability to displace [3H]ketanserin from rat cortical homogenate 5-hydroxytryptamine 2A receptor,B,,,,,CHEMBL617470,14093,H,BAO_0000019,1,,,,,12687
2603,8,,Ability to displace [3H]ketanserin from rat cortical homogenate 5-hydroxytryptamine 2A receptor; Not tested,B,,,,,CHEMBL617471,14093,H,BAO_0000019,1,,,,,12687
2604,8,,Ability to inhibit the binding of iodine-125-labelled lysergic acid diethylamide([125I]-LSD) to the S-2A serotonin receptor in NIH3T3 cell line membranes,B,,,,,CHEMBL617472,13246,H,BAO_0000219,1,,,,NIH3T3,12687
2605,8,,Ability to inhibit the binding of iodine-125-labelled lysergic acid diethylamide([125I]-LSD) to the S-2A serotonin receptor.,B,,,,,CHEMBL617473,13246,H,BAO_0000357,1,,,,,12687
2606,9,Rattus norvegicus,Affinity 5-hydroxytryptamine 2A receptor of the rat brain cortex was assessed on the basis of their ability to displace [3H]ketanserin,B,10116.0,,,,CHEMBL617474,15436,D,BAO_0000019,1,,,,,12687
2607,9,Rattus norvegicus,Affinity at 5-hydroxytryptamine 2A receptor of the rat brain cortex was assessed on the basis of their ability to displace [3H]ketanserin,B,10116.0,,,,CHEMBL617475,15436,D,BAO_0000019,1,,,,,12687
2608,8,,Affinity at [3H]ketanserin-labeled 5-hydroxytryptamine 2A receptor in rat brain homogenate was determined,B,,Brain,,,CHEMBL617476,14442,H,BAO_0000221,1,955.0,,,,12687
2609,8,,Affinity was evaluated as inhibition constant for serotonin 5-hydroxytryptamine 2A receptor,B,,,,,CHEMBL617477,12457,H,BAO_0000357,1,,,,,12687
2610,8,,Affinity was evaluated by inhibition of [125I]LSD binding to NIH 3T3 cells transfected with cloned rat 5-hydroxytryptamine 2A receptor,B,,,,,CHEMBL617478,12457,H,BAO_0000219,1,,,,NIH3T3,12687
2611,8,,"Antagonistic activity measured for 5-hydroxytryptamine 2A receptor using [3H]-MDL- 100,907 as radioligand in rat cortical homogenates.",F,,,,,CHEMBL617479,14755,H,BAO_0000221,1,,,,,12687
2612,8,,Binding affinity towards rat 5-hydroxytryptamine 2A receptor was determined using [125I]- DOI as radioligand,B,,,,,CHEMBL617480,4707,H,BAO_0000357,1,,,,,12687
2613,8,,Binding affinity against 5-hydroxytryptamine 2A receptor,B,,,,,CHEMBL617481,13297,H,BAO_0000357,1,,,,,12687
2614,8,,Binding affinity against 5-hydroxytryptamine 2A receptor by displacement of [3H]ketanserin from rat prefrontal cerebral cortex mambranes,B,,,,,CHEMBL617482,17331,H,BAO_0000019,1,,,,,12687
2615,8,,Binding affinity against 5-hydroxytryptamine 2A receptor from rat forebrain using [3H]ketanserin as radioligand,B,,,,,CHEMBL617483,4664,H,BAO_0000019,1,,,,,12687
2616,8,,Binding affinity against 5-hydroxytryptamine 2A receptor using [125I]DOI as radioligand,B,,,,,CHEMBL621528,16633,H,BAO_0000357,1,,,,,12687
2617,9,Rattus norvegicus,Binding affinity against 5-hydroxytryptamine 2A receptor expressed NIH3T3 cells using [3H]ketanserin,B,10116.0,,,,CHEMBL621529,4664,D,BAO_0000219,1,,,,NIH3T3,12687
2618,8,,Binding affinity against rat 5-hydroxytryptamine 2A receptor using [3H]DOB as radioligand,B,,,,,CHEMBL621530,16133,H,BAO_0000357,1,,,,,12687
2619,8,,Binding affinity against rat 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand,B,,,,,CHEMBL621531,16133,H,BAO_0000357,1,,,,,12687
2620,9,Rattus norvegicus,Binding affinity against rat brain 5-hydroxytryptamine 2A receptor,B,10116.0,,,,CHEMBL621532,14060,D,BAO_0000019,1,,,,,12687
2621,8,,Binding affinity at cloned rat 5-hydroxytryptamine 2A receptor using [3H]DOB as radioligand,B,,,,,CHEMBL621533,16326,H,BAO_0000357,1,,,,,12687
2622,8,,Binding affinity for displacement of [3H]ketanserin to rat 5-hydroxytryptamine 2A receptor stably expressed in CHO cells,B,,,,,CHEMBL621534,16659,H,BAO_0000219,1,,,,CHO,12687
2623,8,,Binding affinity measured at the 5-hydroxytryptamine 2A receptor by the inhibition of [3H]ketanserin binding to rat cortex using unlabeled mianserin for nonspecific binding.,B,,,,,CHEMBL621535,14776,H,BAO_0000019,1,,,,,12687
2624,8,,Binding affinity of [3H]- ketanserin labelled towards Rat cortical 5-hydroxytryptamine 2A receptor using radioligand binding assay,B,,,,,CHEMBL621536,13481,H,BAO_0000357,1,,,,,12687
2625,8,,Binding affinity of compound was tested for 5-hydroxytryptamine 2A receptor,B,,,,,CHEMBL621537,17386,H,BAO_0000357,1,,,,,12687
2626,9,Rattus norvegicus,Binding affinity for 5-hydroxytryptamine 2A receptor,B,10116.0,,,,CHEMBL621538,6611,D,BAO_0000357,1,,,,,12687
2627,8,,Binding affinity against 5-hydroxytryptamine 2A receptor from rat cortex using [3H]ketanserin as the radioligand.,B,,,,,CHEMBL621539,14423,H,BAO_0000019,1,,,,,12687
2628,8,,Binding affinity against 5-hydroxytryptamine 2A receptor of rat pre-frontal cortex,B,,,,,CHEMBL621540,15412,H,BAO_0000019,1,,,,,12687
2629,8,,Binding affinity against 5-hydroxytryptamine 2A receptor of rat pre-frontal cortex.,B,,,,,CHEMBL621541,15412,H,BAO_0000019,1,,,,,12687
2630,8,,Binding affinity towards 5-HT 2A receptor in rat cerebral frontal cortex membranes using [3H]ketanserin as radioligand,B,,,,,CHEMBL621542,6238,H,BAO_0000019,1,,,,,12687
2631,8,,Binding affinity at 5-hydroxytryptamine 2A receptor of rat.,B,,,,,CHEMBL621543,6648,H,BAO_0000357,1,,,,,12687
2632,8,,Binding affinity towards 5-hydroxytryptamine 2A receptor sites by using [3H]ketanserin as radioligand,B,,,,,CHEMBL621544,5667,H,BAO_0000357,1,,,,,12687
2633,9,Rattus norvegicus,Binding affinity for 5-hydroxytryptamine 2A serotonin receptor,B,10116.0,,,,CHEMBL621545,6611,D,BAO_0000357,1,,,,,12687
2634,8,,Binding affinity towards rat cortical 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand,B,,,,,CHEMBL621546,13481,H,BAO_0000357,1,,,,,12687
2635,8,,Binding affinity towards rat cortical 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand; Not tested,B,,,,,CHEMBL621547,13481,H,BAO_0000357,1,,,,,12687
2636,8,,Displacement of [3H]ketanserin from NIH3T3 cells stably expressing rat 5-hydroxytryptamine 2A receptor,B,,,,,CHEMBL618692,15558,H,BAO_0000219,1,,,,NIH3T3,12687
2637,8,,Binding affinity towards 5-hydroxytryptamine 2A receptor,B,,,,,CHEMBL618693,6013,H,BAO_0000357,1,,,,,12687
2638,8,,Binding affinity towards 5-hydroxytryptamine 2A receptor using [125I]DOI as radioligand,B,,,,,CHEMBL872922,16633,H,BAO_0000357,1,,,,,12687
2639,8,,Binding affinity towards cloned rat 5-hydroxytryptamine 2A receptor from fundus tissue was determined using [3H]mesulergine as radioligand,B,,,,,CHEMBL618694,6013,H,BAO_0000357,1,,,,,12687
2640,9,Rattus norvegicus,Binding affinity for rat 5-hydroxytryptamine 2A receptor using [3H]DOB,B,10116.0,,,,CHEMBL618695,6013,D,BAO_0000357,1,,,,,12687
2641,8,,Binding affinity towards cloned rat 5-hydroxytryptamine 2A receptor was determined using [3H]DOB as radioligand; ND=No data,B,,,,,CHEMBL618696,6013,H,BAO_0000357,1,,,,,12687
2642,8,,Binding affinity towards cloned rat 5-hydroxytryptamine 2A receptor by [3H]ketanserin displacement.,B,,,,,CHEMBL618697,6013,H,BAO_0000357,1,,,,,12687
2643,8,,Binding affinity towards cloned rat Inhibition of binding towards 5-hydroxytryptamine 2A receptor at 100 nM concentration was determined using [3H]DOB as radioligand,B,,,,,CHEMBL618892,6013,H,BAO_0000357,1,,,,,12687
2644,8,,Binding affinity towards cloned rat Inhibition of binding towards 5-hydroxytryptamine 2A receptor at 100 nM concentration was determined using [3H]ketanserin as radioligand,B,,,,,CHEMBL618893,6013,H,BAO_0000357,1,,,,,12687
2645,8,,Binding affinity towards rat 5-hydroxytryptamine 2A receptor,B,,,,,CHEMBL618894,16293,H,BAO_0000357,1,,,,,12687
2646,8,,Binding affinity towards rat 5-hydroxytryptamine 2A receptor expressed in NIH3T3 cells using [3H]ketanserin as radioligand,B,,,,,CHEMBL618895,17175,H,BAO_0000219,1,,,,NIH3T3,12687
2647,9,Rattus norvegicus,Binding affinity was measured against 5-hydroxytryptamine 2A receptor by displacement of [3H]- ketanserin by lysergic acid amides,B,10116.0,,,,CHEMBL618896,13278,D,BAO_0000357,1,,,,,12687
2648,8,,Compound was evaluated for affinity towards cerebral 5-hydroxytryptamine 2A receptor in homogenate of caudate putamen tissue from rat brain,B,,Caudate-putamen,,,CHEMBL618897,3682,H,BAO_0000019,1,5383.0,,,,12687
2649,8,,Compound was evaluated for binding affinity against 5-hydroxytryptamine 2A receptor using [3H]ketanserin as a radioligand,B,,,,,CHEMBL618898,2014,H,BAO_0000357,1,,,,,12687
2650,8,,Compound was evaluated for binding affinity against 5-hydroxytryptamine 2A receptor using [3H]ketanserin as a radioligand; Not determined,B,,,,,CHEMBL618899,2014,H,BAO_0000357,1,,,,,12687
2651,8,,Compound was evaluated for its ability to displace (+/-)[125I]-DOI from 5-hydroxytryptamine 2A receptor in cloned rat cell culture,B,,,,,CHEMBL618900,4932,H,BAO_0000357,1,,,,,12687
2652,8,,Compound was evaluated for its ability to displace [125I](R)-DOI from 5-hydroxytryptamine 2A receptor in cloned rat prefrontal cortex homogenate,B,,,,,CHEMBL618901,4932,H,BAO_0000019,1,,,,,12687
2653,8,,Compound was evaluated for its binding affinity for rat 5-hydroxytryptamine 2A receptor,B,,,,,CHEMBL618902,3935,H,BAO_0000357,1,,,,,12687
2654,9,Rattus norvegicus,Displacement of [3H]8-OH-DPAT from rat hippocampus membrane 5-hydroxytryptamine 2A receptor,B,10116.0,Hippocampus,,,CHEMBL618903,5432,D,BAO_0000221,1,10000000.0,,,,12687
2655,8,,Compound was evaluated for its binding affinity towards rat 5-hydroxytryptamine 2A receptor,B,,,,,CHEMBL618904,15818,H,BAO_0000357,1,,,,,12687
2656,8,,Compound was evaluated for the binding affinity towards 5-hydroxytryptamine 2A receptor using [3H]ketanserin radioligand.,B,,,,,CHEMBL618905,13672,H,BAO_0000357,1,,,,,12687
2657,8,,Compound was evaluated for the binding affinity towards 5-hydroxytryptamine 2A receptor using [3H]-ketanserin radioligand.,B,,,,,CHEMBL618906,13672,H,BAO_0000357,1,,,,,12687
2658,8,,Binding affinity against rat 5-hydroxytryptamine 2A receptor in NIH3T3 cells.,B,,,,,CHEMBL618907,14749,H,BAO_0000219,1,,,,NIH3T3,12687
2659,8,,Compound was tested for the Binding affinity against rat frontal cortex 5-hydroxytryptamine 2A receptor by Radio ligand [3H]ketanserin binding assay.,B,,,,,CHEMBL618908,13462,H,BAO_0000019,1,,,,,12687
2660,8,,Evaluated for the binding constant at [125I]-DOI-labeled rat 5-hydroxytryptamine 2A receptor,B,,,,,CHEMBL617909,15740,H,BAO_0000357,1,,,,,12687
2661,8,,Half-maximal inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor in rat cerebral cortex homogenate,B,,,,,CHEMBL617910,16647,H,BAO_0000019,1,,,,,12687
2662,8,,In vitro ability to displace [3H]ketanserin from 5-hydroxytryptamine 2A receptor in rat brain.,B,,Brain,,,CHEMBL617911,13345,H,BAO_0000221,1,955.0,,,,12687
2663,8,,In vitro binding affinity at 5-hydroxytryptamine 2A receptor in rat cortical membrane,B,,,,,CHEMBL872923,16740,H,BAO_0000249,1,,,,,12687
2664,8,,In vitro binding affinity at 5-hydroxytryptamine 2A receptor in rat cortical membrane,B,,,,,CHEMBL617912,16740,H,BAO_0000249,1,,,,,12687
2665,9,Rattus norvegicus,In vitro binding affinity at 5-hydroxytryptamine 2A receptor by displacement of [3H]ketanserin from rat cortex,B,10116.0,,,,CHEMBL617913,15535,D,BAO_0000019,1,,,,,12687
2666,8,,In vitro binding affinity at 5-hydroxytryptamine 2A receptor in rat cortical membrane,B,,,,,CHEMBL617914,16740,H,BAO_0000249,1,,,,,12687
2667,8,,In vitro binding affinity at 5-hydroxytryptamine 2A receptor in rat cortical membrane,B,,,,,CHEMBL617915,16740,H,BAO_0000249,1,,,,,12687
2668,8,,In vitro binding affinity at serotonin 5-hydroxytryptamine 2A receptor in rat cortical membrane,B,,,,,CHEMBL617916,16740,H,BAO_0000249,1,,,,,12687
2669,9,Rattus norvegicus,Displacement of [3H]- Ketanserin from rat cortex 5-hydroxytryptamine 2A receptor,B,10116.0,,,,CHEMBL617917,4795,D,BAO_0000019,1,,,,,12687
2670,8,,In vitro binding affinity towards 5-hydroxytryptamine 2A receptor in rat tissue homogenate using [3H]ketanserin as radioligand,B,,,,,CHEMBL617918,8,H,BAO_0000019,1,,,,,12687
2671,8,,In vitro binding affinity towards 5-hydroxytryptamine 2A receptor in rat tissue homogenate using [3H]ketanserin as radioligand; Not active at 10-5 M,B,,,,,CHEMBL617919,8,H,BAO_0000019,1,,,,,12687
2672,9,Rattus norvegicus,In vitro inhibitory constant against [125I]DOI binding to 5-hydroxytryptamine 2A receptor in rat cerebral cortex,B,10116.0,,,,CHEMBL617920,17200,D,BAO_0000019,1,,,,,12687
2673,9,Rattus norvegicus,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2A receptor of rat brain cortex,B,10116.0,,,,CHEMBL617921,2148,D,BAO_0000019,1,,,,,12687
2674,5,Rattus norvegicus,"Relative binding affinity for D2 receptor and 5-hydroxytryptamine 2A receptor, ratio of Ki",B,10116.0,,,,CHEMBL617922,13345,D,BAO_0000224,1,,,,,105102
2675,8,,Tested for binding affinity towards rat 5-hydroxytryptamine 2A receptor using [3H]DOB as radioligand,B,,,,,CHEMBL617923,5088,H,BAO_0000357,1,,,,,12687
2676,8,,Tested for binding affinity towards rat 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand,B,,,,,CHEMBL617924,5088,H,BAO_0000357,1,,,,,12687
2677,8,,Tested in vitro for its ability to bind to 5-hydroxytryptamine 2A receptor using [125 I]-DOI as radioligand,B,,,,,CHEMBL617925,17133,H,BAO_0000357,1,,,,,12687
2678,9,Rattus norvegicus,In vitro binding to 5-hydroxytryptamine 2A receptor using [125 I]-DOI,B,10116.0,,,,CHEMBL617926,17133,D,BAO_0000357,1,,,,,12687
2679,8,,The binding affinity at 5-hydroxytryptamine 2A receptor was determined using [3H]ketanserin,B,,,,,CHEMBL617927,16532,H,BAO_0000357,1,,,,,12687
2680,8,,The compound was tested for binding affinity against 5-hydroxytryptamine 2A receptor,B,,,,,CHEMBL617928,15086,H,BAO_0000357,1,,,,,12687
2681,9,Rattus norvegicus,Binding affinity for 5-hydroxytryptamine 2A receptor in rat cortex using [3H]ketanserin,B,10116.0,,,,CHEMBL617929,2309,D,BAO_0000019,1,,,,,12687
2682,8,,Binding affinity to 5-hydroxytryptamine 2A receptor from rat cortex assayed using [3H]ketanserin as radioligand.,B,,,,,CHEMBL617930,12953,H,BAO_0000019,1,,,,,12687
2683,8,,The compound was tested for its binding affinity towards 5-hydroxytryptamine 2A receptor from rat cortex using [3H]ketanserin as radioligand.; Nonactive at 10 uM,B,,,,,CHEMBL617931,12953,H,BAO_0000019,1,,,,,12687
2684,8,,The compound was tested for its binding affinity towards 5-hydroxytryptamine 2A receptor from rat cortex using [3H]-ketanserin as radioligand; Nonactive at 10 uM,B,,,,,CHEMBL617932,12953,H,BAO_0000019,1,,,,,12687
2685,8,,Binding affinity for displacement of [3H]ketanserin to rat 5-hydroxytryptamine 2A receptor stably expressed in CHO cells; ND is No Data,B,,,,,CHEMBL617933,16659,H,BAO_0000219,1,,,,CHO,12687
2686,8,,In vitro binding affinity at 5-hydroxytryptamine 2A receptor in rat cortical membrane; ND means no data,B,,,,,CHEMBL617934,16740,H,BAO_0000019,1,,,,,12687
2687,8,,In vitro binding affinity at serotonin 5-hydroxytryptamine 2A receptor in rat cortical membrane; ND means no data,B,,,,,CHEMBL617935,16740,H,BAO_0000019,1,,,,,12687
2688,8,,Tested for its ability to activate phospholipase C by quantification of IP3 at cloned rat 5-hydroxytryptamine 2A receptor; Not determined,B,,,,,CHEMBL617936,17133,H,BAO_0000357,1,,,,,12687
2689,8,,Ability to displace [3H]ketanserin (0.5 nM) from cerebral cortex of rat 5-hydroxytryptamine 2A receptor; NT=not tested,B,,,,,CHEMBL617937,17211,H,BAO_0000019,1,,,,,12687
2690,8,,Binding affinity against 5-hydroxytryptamine 2A receptor by displacement of [3H]-ketanserin from rat prefrontal cerebral cortex mambranes; Not tested,B,,,,,CHEMBL617938,17331,H,BAO_0000019,1,,,,,12687
2691,8,,Compound was evaluated for effective dose measured in nmol/kg following a dose of 0.04 mg/kg and 0.093 uM/kg (95%CI); range 32-63,B,,,,,CHEMBL617939,16633,H,BAO_0000218,1,,,,,12687
2692,8,,Compound was evaluated for the percentage of rats disrupted following a dose of 0.04 mg/kg and 0.097 uM/kg,B,,,,,CHEMBL617940,16633,H,BAO_0000218,1,,,,,12687
2693,8,,Compound was evaluated for the percentage of rats disrupted following a dose of 0.08 mg/kg and 0.194 uM/kg,B,,,,,CHEMBL617941,16633,H,BAO_0000218,1,,,,,12687
2694,8,,Ratio of pKi of 5-HT2A to that of 5-HT2C receptor,B,,,,,CHEMBL617942,15026,H,BAO_0000357,1,,,,,12687
2695,8,,Ratio of pKi of 5-HT2A to that of D2 receptor,B,,,,,CHEMBL617943,15026,H,BAO_0000357,1,,,,,12687
2696,4,,Selectivity ratio towards KB of 5-hydroxytryptamine 2A receptor to 5-hydroxytryptamine 2B receptor,B,,,,,CHEMBL617944,16404,H,BAO_0000224,1,,,,,105093
2697,4,,Selectivity ratio towards KB of 5-hydroxytryptamine 2A receptor to 5-hydroxytryptamine 2B receptor,B,,,,,CHEMBL617945,16404,H,BAO_0000224,1,,,,,105093
2698,4,,Selectivity ratio towards Ki of 5-hydroxytryptamine 2A receptor to 5-hydroxytryptamine 2C receptor,B,,,,,CHEMBL617946,16404,H,BAO_0000224,1,,,,,105075
2699,8,,Selectivity ratio towards Ki of 5-hydroxytryptamine 2A receptor to 5-hydroxytryptamine 2C receptor; ND is no data,B,,,,,CHEMBL617947,16404,H,BAO_0000357,1,,,,,12687
2700,8,,Percent maximal 5-HT stimulation at cloned rat 5-hydroxytryptamine 2A receptor (phosphoinositide hydrolysis study) at a conc of 100 uM,B,,,,,CHEMBL617948,16326,H,BAO_0000357,1,,,,,12687
2701,8,,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 2A receptor of rat,F,,,,,CHEMBL858116,15847,H,BAO_0000019,1,,,,,12687
2702,8,,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 2A receptor of rat; ND means not done,F,,,,,CHEMBL617949,15847,H,BAO_0000019,1,,,,,12687
2703,8,,Effectiveness of compound in blocking 5-hydroxytryptamine 2A receptor-mediated contractions of rat tail artery,F,,,,,CHEMBL617950,15329,H,BAO_0000019,1,,,,,12687
2704,8,,Negative log concentration of antagonist on 5-hydroxytryptamine 2A receptor in rat thoracic aorta,F,,Thoracic aorta,,,CHEMBL617951,16404,H,BAO_0000019,1,1515.0,,,,12687
2705,8,,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2A receptor of Rat thoracic aorta,F,,Thoracic aorta,,,CHEMBL617952,16404,H,BAO_0000019,1,1515.0,,,,12687
2706,8,,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2A receptor of Rat thoracic aorta; ND is not determined.,F,,Thoracic aorta,,,CHEMBL617953,16404,H,BAO_0000019,1,1515.0,,,,12687
2707,8,,Binding activity radioligand.,B,,,,,CHEMBL617954,12861,H,BAO_0000357,1,,,,,12687
2708,8,,Binding activity against 5-hydroxytryptamine 2C receptor from pig cortex membrane using [3H]mesulergine as radioligand.,B,,,,,CHEMBL617955,12861,H,BAO_0000019,1,,,,,12687
2709,8,,Binding activity against 5-hydroxytryptamine 2C receptor from pig cortex membrane using [3H]mesulergine as radioligand; NA Not Available,B,,,,,CHEMBL857071,12861,H,BAO_0000019,1,,,,,12687
2710,8,,Displacement of [3H]DOB binding to 5-hydroxytryptamine 2A receptor from rat cortex homogenate,B,,,,,CHEMBL617270,12490,H,BAO_0000019,1,,,,,12687
2711,8,,Binding affinity towards 5-hydroxytryptamine 3 receptor in membranes of N1E-115 neuroblastoma cells using [3H]-ICS 205-930,B,,,,,CHEMBL617271,12827,H,BAO_0000219,1,,,,N1E-115,12687
2712,8,,Binding affinity towards 5-hydroxytryptamine 3 receptor in membranes of N1E-115 neuroblastoma cells using [3H]-ICS 205-930; Not determined,B,,,,,CHEMBL617272,12827,H,BAO_0000219,1,,,,N1E-115,12687
2713,8,,Binding affinity was evaluated by 5-hydroxytryptamine 2A receptor agonism in the rat cortex by displacing ketanserin,B,,,,,CHEMBL617273,12918,H,BAO_0000019,1,,,,,12687
2714,9,Rattus norvegicus,Agonistic activity against 5-hydroxytryptamine 2A receptor in rat cortex using [3H]-ketanserin,F,10116.0,,,,CHEMBL617274,12919,D,BAO_0000019,1,,,,,12687
2715,8,,Binding affinity towards human serotonin 5-hydroxytryptamine 2C receptor,B,,,,,CHEMBL617275,17723,H,BAO_0000357,1,,,,,108
2716,8,,Binding affinity towards 5-hydroxytryptamine 2C receptor,B,,,,,CHEMBL617276,6013,H,BAO_0000357,1,,,,,108
2717,8,,Binding affinity towards human 5-hydroxytryptamine 2C receptor,B,,,,,CHEMBL617277,16293,H,BAO_0000357,1,,,,,108
2718,8,,Binding affinity using [125I]DOI as radioligand with membranes isolated from a CHO-k cell line expressing the human 5-hydroxytryptamine 2C receptor,B,,,,,CHEMBL617278,3857,H,BAO_0000019,1,,,,,108
2719,8,,Binding affinity using [125I]DOI as radioligand with membranes isolated from a CHO-k cell line expressing the human 5-hydroxytryptamine 2C receptor; Not determined,B,,,,,CHEMBL617279,3857,H,BAO_0000019,1,,,,,108
2720,8,,Binding affinity using [3H]mesulergine as radioligand with receptor membranes isolated from a CHO-k cell line expressing the human 5-hydroxytryptamine 2C receptor,B,,,,,CHEMBL617280,3857,H,BAO_0000019,1,,,,,108
2721,8,,Compound was tested for the displacement of [125I]DOI from cloned human 5-hydroxytryptamine 2C receptor,B,,,,,CHEMBL617281,15363,H,BAO_0000357,1,,,,,108
2722,8,,Compound was tested for the displacement of [125I]DOI from cloned human 5-hydroxytryptamine 2C receptor,B,,,,,CHEMBL617282,15363,H,BAO_0000357,1,,,,,108
2723,8,,Tested on transfected cell membranes selectively expressing human 5-hydroxytryptamine 2C receptor using [3H]mesulergine,B,,,,,CHEMBL617283,16441,H,BAO_0000019,1,,,,,108
2724,8,,Tested on transfected cell membranes selectively expressing human 5-hydroxytryptamine 2C receptor using [3H]-mesulergine; ND is No Data.,B,,,,,CHEMBL617284,16441,H,BAO_0000019,1,,,,,108
2725,8,,In vitro binding affinity towards human 5-hydroxytryptamine 2C receptor expressed in HEK293 cells was determined using [3H]mesulergine as radioligand,B,,,,,CHEMBL617285,4176,H,BAO_0000219,1,,,,HEK293,108
2726,8,,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 2C receptor,B,,,,,CHEMBL617286,17085,H,BAO_0000019,1,,,,,108
2727,9,Homo sapiens,Inhibitory constant against cloned human 5-hydroxytryptamine 2C receptor using with [125I]- DOI radioligand,B,9606.0,,,,CHEMBL617287,17200,D,BAO_0000357,1,,,,,108
2728,8,,Binding affinity towards human 5-hydroxytryptamine 2C receptor.,B,,,,,CHEMBL617288,5088,H,BAO_0000357,1,,,,,108
2729,8,,Tested for binding affinity towards human 5-hydroxytryptamine 2C receptor using [3H]DOB as radioligand,B,,,,,CHEMBL617289,5088,H,BAO_0000357,1,,,,,108
2730,8,,Tested for binding affinity towards human 5-hydroxytryptamine 2C receptor using [3H]mesulergine as radioligand,B,,,,,CHEMBL872917,5088,H,BAO_0000357,1,,,,,108
2731,8,,Tested for binding affinity towards human 5-hydroxytryptamine 2C receptor using [3H]5-HT as radioligand,B,,,,,CHEMBL617290,5088,H,BAO_0000357,1,,,,,108
2732,8,,Binding affinity for displacement of [3H]mesulergine to human 5-hydroxytryptamine 2C receptor stably expressed in CHO cells,B,,,,,CHEMBL617291,16659,H,BAO_0000219,1,,,,CHO,108
2733,8,,Binding affinity for displacement of [3H]mesulergine to human 5-hydroxytryptamine 2C receptor stably expressed in CHO cells; ND is no data,B,,,,,CHEMBL617292,16659,H,BAO_0000219,1,,,,CHO,108
2734,8,,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 2C receptor expressed in 3T3 cells using [3H]5-HT as radioligand; Not determined,B,,,,,CHEMBL617293,17451,H,BAO_0000219,1,,,,NIH3T3,108
2735,9,Homo sapiens,Relative efficacy against human 5-hydroxytryptamine 2B receptor expressed in CHO cells using fluorometric imaging plate reader relative to 10 uM 5-HT,F,9606.0,,,,CHEMBL617294,6857,D,BAO_0000219,1,,,,CHO,108
2736,8,,Inhibitory activity using [3H]mesulergine as radioligand with receptor membranes isolated from a CHO-k cell line expressing the human 5-hydroxytryptamine 2C receptor at a concentration of 1 uM,B,,,,,CHEMBL617295,3857,H,BAO_0000019,1,,,,,108
2737,8,,Binding activity radioligand.,B,,,,,CHEMBL617296,12861,H,BAO_0000357,1,,,,,108
2738,8,,Binding activity against 5-hydroxytryptamine 2C receptor from human brain cortex using [3H]mesulergine as radioligand.,B,,,,,CHEMBL617297,12861,H,BAO_0000019,1,,,,,108
2739,8,,Binding affinity for human cloned 5-hydroxytryptamine 2C receptor expressed in CHO cells using [3H]mesulergine as radioligand,B,,,,,CHEMBL617298,5104,H,BAO_0000219,1,,,,CHO,108
2740,8,,Binding affinity at human cloned 5-hydroxytryptamine 2C receptor expressed in CHO cells by [3H]mesulergine displacement.,B,,,,,CHEMBL617299,5105,H,BAO_0000219,1,,,,CHO,108
2741,8,,Binding affinity for human cloned 5-hydroxytryptamine 2C receptor expressed in CHO cells using [3H]mesulergine as radioligand; NT means not tested,B,,,,,CHEMBL617300,5105,H,BAO_0000219,1,,,,CHO,108
2742,8,,Binding affinity against 5-HT2C receptor,B,,,,,CHEMBL617454,5254,H,BAO_0000357,1,,,,,108
2743,8,,Antagonistic binding affinity measured against 5-hydroxytryptamine 2C receptor (human clone expressed in 293 cells) using [3H]mesulergine as radioligand,B,,,,,CHEMBL617505,13267,H,BAO_0000219,1,,,,HEK293,108
2744,9,Homo sapiens,Displacement of [3H]mesulergine from 5-hydroxytryptamine 2C receptor expressed in HEK 293 cells,B,9606.0,,,,CHEMBL617506,14157,D,BAO_0000219,1,,,,HEK293,108
2745,9,Homo sapiens,Binding affinity against human 5-hydroxytryptamine 2C receptor expressed in 293 cells using [3H]mesulergine,B,9606.0,,,,CHEMBL617507,12936,D,BAO_0000219,1,,,,HEK293,108
2746,8,,Binding affinity against human 5-hydroxytryptamine 2C receptor using displacement of [3H]DOB,B,,,,,CHEMBL617508,14068,H,BAO_0000357,1,,,,,108
2747,9,Homo sapiens,Binding affinity against human 5-hydroxytryptamine 2C receptor expressed in 293 cells using [3H]mesulergine,B,9606.0,,,,CHEMBL857982,12936,D,BAO_0000219,1,,,,HEK293,108
2748,9,Homo sapiens,Binding affinity to human cloned 5-hydroxytryptamine 2C receptor in HEK 293 cells using [3H]- mesulergine as radioligand,B,9606.0,,,,CHEMBL617509,4540,D,BAO_0000219,1,,,,HEK293,108
2749,9,Homo sapiens,Binding affinity to human cloned 5-hydroxytryptamine 2C receptor in HEK 293 cells using [3H]- mesulergine as radioligand; Nd means not determined,B,9606.0,,,,CHEMBL617510,4540,D,BAO_0000219,1,,,,HEK293,108
2750,8,,Binding affinity towards cloned human 5-hydroxytryptamine 2C receptor was determined,B,,,,,CHEMBL617511,6166,H,BAO_0000357,1,,,,,108
2751,8,,Binding affinity against 5-hydroxytryptamine 2C receptor human cloned receptors in HEK 293 cells using [3H]mesulergine as radioligand,B,,,,,CHEMBL617512,17296,H,BAO_0000219,1,,,,HEK293,108
2752,8,,Binding affinity against 5-hydroxytryptamine 2C receptor human cloned receptorswithouteffect in HEK 293 cells using [3H]mesulergine as radioligand,B,,,,,CHEMBL617749,17296,H,BAO_0000219,1,,,,HEK293,108
2753,8,,Binding affinity towards 5-HT2C (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand.,B,,,,,CHEMBL617750,15779,H,BAO_0000219,1,,,,HEK293,108
2754,8,,Binding affinity towards 5-hydroxytryptamine 2C receptor (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand.,B,,,,,CHEMBL617751,15779,H,BAO_0000219,1,,,,HEK293,108
2755,8,,Binding affinity towards cloned human 5-hydroxytryptamine 2C receptor expressed in HEK 293 cells using [3H]mesulergine as radioligand,B,,,,,CHEMBL617752,14391,H,BAO_0000219,1,,,,HEK293,108
2756,8,,"Binding affinity towards human cloned 5-hydroxytryptamine 2C receptor in HEK293 cells, using [3H]mesulergine as radioligand",B,,,,,CHEMBL617753,15779,H,BAO_0000219,1,,,,HEK293,108
2757,8,,"Binding affinity towards human cloned 5-hydroxytryptamine receptor 2C in HEK293 cells, using [3H]mesulergine as radioligand.",B,,,,,CHEMBL617754,15851,H,BAO_0000219,1,,,,HEK293,108
2758,9,Homo sapiens,Displacement of [3H]mesulergine from human 5-hydroxytryptamine 2C receptor expressed in HEK293 cells; compound insoluble,B,9606.0,,,,CHEMBL617755,15851,D,BAO_0000219,1,,,,HEK293,108
2759,8,,"Binding affinity towards human cloned 5-hydroxytryptamine 2C receptor in HEK293 cells, using [3H]mesulergine as radioligand; no data",B,,,,,CHEMBL617756,15779,H,BAO_0000219,1,,,,HEK293,108
2760,8,,Binding affinity towards human cloned 5-hydroxytryptamine 2C receptor of HEK293 cells by displacement of [3H]mesulergine,B,,,,,CHEMBL617757,3832,H,BAO_0000219,1,,,,HEK293,108
2761,8,,In vitro binding affinity at human cloned 5-hydroxytryptamine 2C receptor of HEK293 cells by [3H]mesulergine displacement.,B,,,,,CHEMBL617758,3833,H,BAO_0000219,1,,,,HEK293,108
2762,8,,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 2C receptor expressed in 3T3 cells using [3H]5-HT as radioligand,B,,,,,CHEMBL617759,17451,H,BAO_0000219,1,,,,NIH3T3,108
2763,8,,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 2C receptor in HEK 293 cells using [3H]mesulergine as the radioligand,B,,,,,CHEMBL617760,4199,H,BAO_0000219,1,,,,HEK293,108
2764,8,,Displacement of [3H]mesulergine from human cloned 5-hydroxytryptamine 2C receptor expressed in CHO-K1 cells,B,,,,,CHEMBL617761,1883,H,BAO_0000219,1,,,,CHO-K1,108
2765,9,Homo sapiens,Binding affinity against 5-hydroxytryptamine 2C receptor,B,9606.0,,,,CHEMBL617762,4321,D,BAO_0000357,1,,,,,108
2766,8,,Compound was tested for binding affinity against human 5-hydroxytryptamine 2C receptor,B,,,,,CHEMBL617763,14875,H,BAO_0000357,1,,,,,108
2767,8,,Compound was tested for its binding affinity against human cloned 5-hydroxytryptamine 2C receptor in HEK 293 cells using [3H]mesulergine,B,,,,,CHEMBL857983,15146,H,BAO_0000219,1,,,,HEK293,108
2768,8,,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 2C receptor in HEK 293 using [3H]mesulergine as a radioligand,B,,,,,CHEMBL617764,5213,H,BAO_0000219,1,,,,HEK293,108
2769,8,,Inhibitory constant on human 5-hydroxytryptamine 2C receptor transfected in to HeLa cells,B,,,,,CHEMBL617765,16404,H,BAO_0000219,1,,,,HeLa,108
2770,8,,Selectivity as the ratio of Ki value towards 5-hydroxytryptamine 2C receptor to that of pA2 value towards 5-hydroxytryptamine 2B receptor,F,,,,,CHEMBL617766,13267,H,BAO_0000019,1,,,,,108
2771,8,,The binding affinity (pKi) measured against 5-hydroxytryptamine 3 receptor of rat hippocampus and entorhinal cortex using [3H]granisetron as radioligand,F,,Hippocampus,,,CHEMBL617767,13267,H,BAO_0000221,1,10000000.0,,,,108
2772,8,,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 2C receptor in HEK293 cells using [3H]mesulergine.,B,,,,,CHEMBL617768,14818,H,BAO_0000219,1,,,,HEK293,108
2773,8,,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 2C receptor in HEK293 cells, using [3H]5-mesulergine as radioligand",B,,,,,CHEMBL617769,4829,H,BAO_0000219,1,,,,HEK293,108
2774,8,,Binding affinity analysed on 5-HT 2C in human clone using [3H]mesulergine as radioligand,B,,,,,CHEMBL858023,13463,H,BAO_0000357,1,,,,,11864
2775,8,,Binding affinity analysed on 5-HT 2C in rat stomach fundus,B,,Stomach,,,CHEMBL617770,13463,H,BAO_0000019,1,945.0,,,,11864
2776,8,,Binding affinity analysed towards 5-HT 2C in rat stomach fundus,B,,Stomach,,,CHEMBL617771,13463,H,BAO_0000019,1,945.0,,,,11864
2777,8,,Percent of maximum stimulation of phosphatidylinositol turnover at cloned 5-hydroxytryptamine 2C receptor in A9 cells,F,,,,,CHEMBL617772,12652,H,BAO_0000219,1,,,,A9,11864
2778,8,,Binding affinity to 5-hydroxytryptamine 2C receptor using [3H]Mesulergine as radioligand in stably transfected NIH3T3 cells,B,,,,,CHEMBL617773,4682,H,BAO_0000219,1,,,,NIH3T3,11864
2779,8,,Binding affinity to 5-hydroxytryptamine 2C receptor measured using radioligand [3H]Mesulergine in stably transfected NIH3T3 cells,B,,,,,CHEMBL617850,4682,H,BAO_0000219,1,,,,NIH3T3,11864
2780,8,,Binding affinity to 5-hydroxytryptamine 2C receptor using [3H]Mesulergine as radioligand in stably transfected NIH3T3 cells,B,,,,,CHEMBL617851,4682,H,BAO_0000219,1,,,,NIH3T3,11864
2781,8,,The maximum responses of [3H]- inositol monophosphate accumulation in cells expressing the 5-hydroxytryptamine 2C receptor,F,,,,,CHEMBL617852,12652,H,BAO_0000019,1,,,,,11864
2782,8,Mus musculus,Binding affinity analysed on 5-HT 2C in rat stomach fundus.,B,10090.0,Stomach,,,CHEMBL858024,13463,H,BAO_0000019,1,945.0,,,,12689
2783,9,Rattus norvegicus,Binding affinity towards 5-HT 2C receptor in rat stomach fundus,B,10116.0,Stomach,,,CHEMBL617853,13463,D,BAO_0000019,1,945.0,,,,12689
2784,8,,Binding affinity against 5-Hydroxytryptamine 2C Receptor was measured using [3H]N-methyl-mesulergine as radioligand,B,,,,,CHEMBL617854,13969,H,BAO_0000357,1,,,,,108
2785,8,Sus scrofa,Binding affinity for 5-hydroxytryptamine 2C receptor,B,9823.0,,,,CHEMBL873477,13392,H,BAO_0000357,1,,,,,108
2786,8,,Binding affinity towards 5-hydroxytryptamine 2C receptor,B,,,,,CHEMBL617855,13392,H,BAO_0000357,1,,,,,108
2787,8,,Affinity towards 5-hydroxytryptamine 2C receptor in membranes from pig choroid plexus using [3H]N-methyl-mesulergine,B,,,,,CHEMBL617856,14430,H,BAO_0000019,1,,,,,108
2788,8,,Compound was tested for its ability to displace [3H]mesulergine from 5-hydroxytryptamine 2C receptor in pig cortex,B,,,,,CHEMBL617857,1742,H,BAO_0000019,1,,,,,108
2789,8,,In vitro inhibitory concentration against radioligand [3H]mesulergine binding to 5-hydroxytryptamine 2C receptor in pig cortical membrane,B,,,,,CHEMBL617858,14286,H,BAO_0000249,1,,,,,108
2790,8,,Binding affinity towards pig 5-hydroxytryptamine 2C receptor,B,,,,,CHEMBL617859,5619,H,BAO_0000357,1,,,,,108
2791,8,,The compound was tested for binding affinity against 5-hydroxytryptamine 2C receptor,B,,,,,CHEMBL617860,15086,H,BAO_0000357,1,,,,,108
2792,8,,Binding activity radioligand.,B,,,,,CHEMBL617861,12861,H,BAO_0000357,1,,,,,108
2793,8,,Binding activity against 5-hydroxytryptamine 2C receptor from pig cortex membrane using [3H]mesulergine as radioligand.,B,,,,,CHEMBL617862,12861,H,BAO_0000019,1,,,,,108
2794,8,,Binding activity against 5-hydroxytryptamine 3 receptor from pig cortex membrane using [3H]mesulergine as radioligand; NA Not Available,B,,,,,CHEMBL617863,12861,H,BAO_0000019,1,,,,,108
2795,8,,Binding affinity towards 5-hydroxytryptamine 1D receptor in calf caudate membranes using [3H]5-HT,B,,,,,CHEMBL617864,12827,H,BAO_0000249,1,,,,,108
2796,8,,Binding affinity towards 5-hydroxytryptamine 1D receptor in calf caudate membranes using [3H]5-HT; Not determined,B,,,,,CHEMBL617649,12827,H,BAO_0000249,1,,,,,108
2797,8,Sus scrofa,Agonistic activity against 5-hydroxytryptamine 2C receptor in pig choroid plexus using [3H]mesulergine,F,9823.0,,,,CHEMBL617650,12919,H,BAO_0000019,1,,,,,108
2798,8,Sus scrofa,Agonistic activity against 5-hydroxytryptamine 2C receptor in pig choroid plexus using [3H]mesulergine,F,9823.0,,,,CHEMBL617651,12919,H,BAO_0000019,1,,,,,108
2799,8,Sus scrofa,In vitro binding affinity at 5-hydroxytryptamine 2C receptor in pig choroid plexus using 3[H]mesulergine as the radioligand,B,9823.0,,,,CHEMBL617652,16429,H,BAO_0000357,1,,,,,108
2800,8,Sus scrofa,In Vitro Binding affinity againist 5-hydroxytryptamine 2C receptor by displacing [3H]mesulergine from pig cortex,B,9823.0,,,,CHEMBL857072,773,H,BAO_0000019,1,,,,,108
2801,8,Sus scrofa,Ability to displace the radioligand [3H]mesulergine from pig choroid plexus 5-hydroxytryptamine 2C receptor,B,9823.0,,,,CHEMBL617653,5033,H,BAO_0000357,1,,,,,108
2802,8,,Binding activity against 5-hydroxytryptamine 2C receptor from pig cortex membrane using [3H]mesulergine as radioligand.,B,,,,,CHEMBL617654,12861,H,BAO_0000019,1,,,,,12687
2803,8,,Effect on phosphoinositide hydrolysis in NIH 3T3 fibroblast 5-hydroxytryptamine 2C receptor,F,,,,,CHEMBL617655,14093,H,BAO_0000019,1,,,,,12689
2804,8,,Binding affinity towards 5-HT2C receptor from rat using [3H]mesulergine as radioligand,B,,,,,CHEMBL617656,14970,H,BAO_0000357,1,,,,,12689
2805,8,,Compound was tested in vitro for its binding affinity towards 5-hydroxytryptamine 2C receptor from rat using [3H]mesulergine as radioligand,B,,,,,CHEMBL617657,14970,H,BAO_0000357,1,,,,,12689
2806,8,,Compound was tested in vitro for its binding affinity towards 5-hydroxytryptamine 2C receptor from rat using [3H]mesulergine as radioligand; Not tested,B,,,,,CHEMBL617658,14970,H,BAO_0000357,1,,,,,12689
2807,9,Rattus norvegicus,Inhibition of radiolabeled [3H]-Ketanserin ligand binding to 5-hydroxytryptamine 2C receptor,B,10116.0,,,,CHEMBL617659,14178,D,BAO_0000357,1,,,,,12689
2808,9,Rattus norvegicus,Inhibition of radiolabeled [3H]mesulergine ligand binding to 5-hydroxytryptamine 2C receptor,B,10116.0,,,,CHEMBL617838,14178,D,BAO_0000357,1,,,,,12689
2809,9,Rattus norvegicus,Inhibition of [3H]mesulergine binding to 5-hydroxytryptamine 2C receptor in rat brain membranes,B,10116.0,,Brain membranes,,CHEMBL617839,14229,D,BAO_0000249,1,,,,,12689
2810,8,,The binding affinity at 5-hydroxytryptamine 2C receptor was determined using [3H]mesulergine; Not tested,B,,,,,CHEMBL617840,16532,H,BAO_0000357,1,,,,,12689
2811,8,,Ability to displace [3H]mesulergine bound to 5-hydroxytryptamine 2C receptor in rat cortex,B,,,,,CHEMBL617841,14826,H,BAO_0000019,1,,,,,12689
2812,8,,Ability to displace [3H]mesulergine (0.5 nM) from SR-3T3 cells of rat 5-HT2C receptor,B,,,,,CHEMBL875915,17211,H,BAO_0000019,1,,,,,12689
2813,8,,Displacement of [3H]mesulergine (0.5 nM) from rat 5-hydroxytryptamine 2C receptor expressed in SR-3T3 cells,B,,,,,CHEMBL617842,17211,H,BAO_0000219,1,,In vitro,,,12689
2814,8,,Ability to inhibit the binding of iodine-125-labelled lysergic acid diethylamide([125I]-LSD) to the S-2C serotonin receptor in NIH3T3 cell line membranes,B,,,,,CHEMBL617843,13246,H,BAO_0000219,1,,,,NIH3T3,12689
2815,8,,Ability to inhibit the binding of iodine-125-labelled lysergic acid diethylamide([125I]-LSD) to the S-2C serotonin receptor.,B,,,,,CHEMBL617844,13246,H,BAO_0000357,1,,,,,12689
2816,8,,Affinity was evaluated as inhibition constant for serotonin 5-hydroxytryptamine 2C receptor,B,,,,,CHEMBL617845,12457,H,BAO_0000357,1,,,,,12689
2817,8,,Affinity was evaluated by inhibition of [125I]LSD binding to NIH 3T3 cells transfected with cloned rat 5-hydroxytryptamine 2C receptor,B,,,,,CHEMBL617846,12457,H,BAO_0000219,1,,,,NIH3T3,12689
2818,8,,Binding affinity towards rat 5-hydroxytryptamine 2C receptor was determined using [125I]- DOI as radioligand,B,,,,,CHEMBL617847,4707,H,BAO_0000357,1,,,,,12689
2819,8,,Binding affinity against 5-hydroxytryptamine 2C receptor,B,,,,,CHEMBL617848,13297,H,BAO_0000357,1,,,,,12689
2820,8,,Binding affinity against 5-hydroxytryptamine 2C receptor using [125I]DOI as radioligand,B,,,,,CHEMBL617849,16633,H,BAO_0000357,1,,,,,12689
2821,8,,Binding affinity against rat 5-hydroxytryptamine 2C receptor using [3H]mesulergine as radioligand,B,,,,,CHEMBL621507,16133,H,BAO_0000357,1,,,,,12689
2822,8,,Binding affinity at cloned rat 5-hydroxytryptamine 2C receptor using [3H]DOI as radioligand,B,,,,,CHEMBL621508,16326,H,BAO_0000357,1,,,,,12689
2823,8,,Binding affinity against 5-hydroxytryptamine 2C receptor from rat cortex using [3H]mesulergine as the radioligand.,B,,,,,CHEMBL621509,14423,H,BAO_0000019,1,,,,,12689
2824,8,,Binding affinity against 5-hydroxytryptamine 2C receptor of rat cortex,B,,,,,CHEMBL621510,15412,H,BAO_0000019,1,,,,,12689
2825,8,,Binding affinity against 5-hydroxytryptamine 2C receptor of rat cortex.,B,,,,,CHEMBL621511,15412,H,BAO_0000019,1,,,,,12689
2826,8,,Displacement of [3H]mesulergine from A9 cells stably expressing rat 5-hydroxytryptamine 2C receptor,B,,,,,CHEMBL621512,15558,H,BAO_0000219,1,,,,A9,12689
2827,8,,Binding affinity towards 5-hydroxytryptamine 2C receptor using [125I]DOI as radioligand,B,,,,,CHEMBL621513,16633,H,BAO_0000357,1,,,,,12689
2828,8,,Binding affinity towards cloned rat 5-hydroxytryptamine 2C receptor from fundus tissue by [3H]mesulergine displacement.,B,,,,,CHEMBL621514,6013,H,BAO_0000357,1,,,,,12689
2829,8,,Binding affinity towards rat 5-hydroxytryptamine 2C receptor expressed in A-9 cells using [3H]mesulergine as radioligand,B,,,,,CHEMBL621515,17175,H,BAO_0000219,1,,In vitro,,,12689
2830,8,,Binding affinity was measured on 5-hydroxytryptamine 2C receptor in J1 cells transfected with rat 5-HT2C gene labeled with [3H]mesulergine,B,,,,,CHEMBL621516,12469,H,BAO_0000219,1,,,,,12689
2831,8,,Compound was evaluated for affinity towards cerebral 5-hydroxytryptamine 2C receptor in homogenate of caudate putamen tissue from rat brain,B,,Caudate-putamen,,,CHEMBL621517,3682,H,BAO_0000019,1,5383.0,,,,12689
2832,8,,Compound was evaluated for its ability to displace (+/-)[125I]-DOI from 5-hydroxytryptamine 2C receptor in cloned rat cell culture,B,,,,,CHEMBL621518,4932,H,BAO_0000357,1,,,,,12689
2833,8,,Compound was evaluated for its ability to displace [125I](R)-DOI from 5-hydroxytryptamine 2C receptor in cloned rat prefrontal cortex homogenate; ND denotes no data,B,,,,,CHEMBL621519,4932,H,BAO_0000019,1,,,,,12689
2834,8,,Compound was evaluated for its binding affinity for rat 5-hydroxytryptamine 2C receptor,B,,,,,CHEMBL621520,3935,H,BAO_0000357,1,,,,,12689
2835,8,,Compound was evaluated for its binding affinity towards rat 5-hydroxytryptamine 2C receptor,B,,,,,CHEMBL621521,15818,H,BAO_0000357,1,,,,,12689
2836,8,,Compound was evaluated for its binding affinity towards rat r5-hydroxytryptamine 2C receptor,B,,,,,CHEMBL621522,15818,H,BAO_0000357,1,,,,,12689
2837,8,,Binding affinity against rat 5-hydroxytryptamine 2C receptor in A-9 cells.,B,,,,,CHEMBL621523,14749,H,BAO_0000219,1,,,,,12689
2838,8,,Evaluated for the binding constant at [125I]-DOI-labeled rat 5-hydroxytryptamine 2C receptor,B,,,,,CHEMBL621524,15740,H,BAO_0000357,1,,,,,12689
2839,9,Rattus norvegicus,In vitro binding to 5-hydroxytryptamine 2C receptor using [125 I]-DOI,B,10116.0,,,,CHEMBL621525,17133,D,BAO_0000357,1,,,,,12689
2840,8,,The binding affinity at 5-hydroxytryptamine 2C receptor was determined using [3H]mesulergine,B,,,,,CHEMBL872921,16532,H,BAO_0000357,1,,,,,12689
2841,8,,The compound evaluated for its affinity against 5-hydroxytryptamine 2C receptor,B,,,,,CHEMBL621526,12369,H,BAO_0000357,1,,,,,12689
2842,8,,Affinity against 5-hydroxytryptamine 2C receptor in J1 cells transfected with the rat 5-HT2C gene labeled with [3H]mesulergine.,B,,,,,CHEMBL621527,12369,H,BAO_0000219,1,,,,,12689
2843,9,Rattus norvegicus,Binding affinity against 5-hydroxytryptamine 2C receptor in rat choroid plexus using [3H]N-methyl-mesulergine,B,10116.0,,,,CHEMBL617865,2309,D,BAO_0000019,1,,,,,12689
2844,8,,The compound was tested for their binding affinity towards 5-hydroxytryptamine 2C receptor,B,,,,,CHEMBL617866,12953,H,BAO_0000357,1,,,,,12689
2845,8,,The compound was tested for their binding affinity towards 5-hydroxytryptamine 2C receptor from rat cortex using [3H]-citalopram as radioligand; Nonactive at 10 uM,B,,,,,CHEMBL617867,12953,H,BAO_0000019,1,,,,,12689
2846,8,,The compound was tested for their binding affinity towards 5-hydroxytryptamine 2C receptor using [3H]mesulergine as radioligand; Nonactive at 10 uM,B,,,,,CHEMBL617487,12953,H,BAO_0000357,1,,,,,12689
2847,8,,Binding affinity for 5-hydroxytryptamine 2C receptor,B,,,,,CHEMBL617488,12953,H,BAO_0000357,1,,,,,12689
2848,8,,Tested in vitro for its ability to bind to 5-hydroxytryptamine 2C receptor using [125 I]-DOI as radioligand; Not determined,B,,,,,CHEMBL617489,17133,H,BAO_0000357,1,,,,,12689
2849,8,,Ability to displace [3H]mesulergine (0.5 nM) from SR-3T3 cells of rat 5-hydroxytryptamine 2C receptor; NT denotes not tested,B,,,,,CHEMBL617490,17211,H,BAO_0000019,1,,,,,12689
2850,8,,Ability to displace [3H]mesulergine (0.5 nM) from SR-3T3 cells of rat 5-hydroxytryptamine 2C receptor; NT=not tested,B,,,,,CHEMBL617491,17211,H,BAO_0000019,1,,,,,12689
2851,8,,Affinity pKi for 5-hydroxytryptamine 2C receptor was measured in rat cortex homogenates.,B,,,,,CHEMBL617492,14025,H,BAO_0000019,1,,,,,12689
2852,8,,Binding affinity against 5-hydroxytryptamine 2C receptor in rat cortex homogenates.,B,,,,,CHEMBL617493,14998,H,BAO_0000019,1,,,,,12689
2853,8,,Binding affinity of compound towards serotonin 5-hydroxytryptamine 2C receptor was determined,B,,,,,CHEMBL617494,4342,H,BAO_0000357,1,,,,,12689
2854,9,Rattus norvegicus,Displacement of [3H]mesulergine from rat 5-HT2C receptor expressed in HEK293,B,10116.0,,,,CHEMBL617495,13735,D,BAO_0000019,1,,,,,12689
2855,8,,Binding affinity was determined against cloned human 5-hydroxytryptamine 2C receptor using [3H]5-HT as radioligand,B,,,,,CHEMBL617496,13181,H,BAO_0000357,1,,,,,12689
2856,8,,Compound was evaluated for displacement of [3H]mesulergine from cloned rat 5-hydroxytryptamine 2C receptor in transfected CHO-K1 cells.,B,,,,,CHEMBL617497,1883,H,BAO_0000219,1,,,,CHO-K1,12689
2857,8,,The compound was tested for the binding affinity against 5-hydroxytryptamine 2C receptor using [3H]mesulergine as radioligand,B,,,,,CHEMBL617498,15194,H,BAO_0000357,1,,,,,12689
2858,8,,The compound was tested for the binding affinity against 5-hydroxytryptamine 2C receptor using [3H]Mesulergine as radioligand.,B,,,,,CHEMBL617499,15194,H,BAO_0000357,1,,,,,12689
2859,8,,Compound tested for relative response using 0.1 uM 5-HT as agonist against 5-hydroxytryptamine 2C receptor,F,,,,,CHEMBL617500,14579,H,BAO_0000019,1,,,,,12689
2860,8,,Compound was tested for binding affinity against 5-hydroxytryptamine 2C receptor,B,,,,,CHEMBL617501,4639,H,BAO_0000357,1,,,,,108
2861,8,,Binding affinity towards 5-hydroxytryptamine 2C receptor,B,,,,,CHEMBL617502,4820,H,BAO_0000357,1,,,,,108
2862,8,,Binding ability of compound at cloned human 5-hydroxytryptamine 2B receptor using [3H]rauwolscine as radioligand; Not Tested,B,,,,,CHEMBL617503,14442,H,BAO_0000357,1,,,,,227
2863,8,,Binding activity against cloned human 5-hydroxytryptamine 2B receptor using [3H]5-HT as the radioligand.,B,,,,,CHEMBL617504,14755,H,BAO_0000357,1,,,,,227
2864,8,,Binding affinity against the cloned human 5-hydroxytryptamine 2B receptor using [3H]5-HT as the radioligand,B,,,,,CHEMBL617406,14744,H,BAO_0000357,1,,,,,227
2865,9,Homo sapiens,Affinity for human 5-hydroxytryptamine 2B receptor expressed in mammalian cell line,B,9606.0,,,,CHEMBL617407,6857,D,BAO_0000019,1,,,,,227
2866,8,,Binding affinity towards human 5-hydroxytryptamine 2B receptor using [3H]5-HT as radioligand,B,,,,,CHEMBL617408,16209,H,BAO_0000357,1,,,,,227
2867,8,,Compound was tested for the displacement of [3H]5-HT from clone human 5-hydroxytryptamine 2B receptor,B,,,,,CHEMBL617409,15363,H,BAO_0000357,1,,,,,227
2868,8,,Compound was tested for the displacement of [3H]5-HT from clone human 5-hydroxytryptamine 2B receptor,B,,,,,CHEMBL617410,15363,H,BAO_0000357,1,,,,,227
2869,8,,Compound was tested for the displacement of [3H]5-HT from cloned human 5-hydroxytryptamine 2B receptor,B,,,,,CHEMBL617411,15363,H,BAO_0000357,1,,,,,227
2870,8,,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 2B receptor,B,,,,,CHEMBL617412,17085,H,BAO_0000019,1,,,,,227
2871,9,Homo sapiens,Inhibitory constant against cloned human 5-hydroxytryptamine 2B receptor using with [125I]- DOI radioligand,B,9606.0,,,,CHEMBL617774,17200,D,BAO_0000357,1,,,,,227
2872,9,Homo sapiens,Displacement of [3H]5-HT from human 5-hydroxytryptamine 2B receptor expressed in HEK293 cells; ND = no data,B,9606.0,,,,CHEMBL617775,15851,D,BAO_0000219,1,,,,HEK293,227
2873,9,Homo sapiens,Displacement of [3H]ketanserin from human 5-hydroxytryptamine 2B receptor expressed in HEK293 cells; ND = no data,B,9606.0,,,,CHEMBL617776,15851,D,BAO_0000219,1,,,,HEK293,227
2874,9,Homo sapiens,Relative efficacy against human 5-hydroxytryptamine 2B receptor expressed in CHO cells using fluorometric imaging plate reader relative to 10 uM 5-HT,F,9606.0,,,,CHEMBL617777,6857,D,BAO_0000219,1,,,,CHO,227
2875,9,Homo sapiens,Rleative efficacy against human 5-hydroxytryptamine 2B receptor expressed in CHO cells using fluorometric imaging plate reader relative to 10 uM 5-HT,F,9606.0,,,,CHEMBL617778,6857,D,BAO_0000219,1,,,,CHO,227
2876,8,,"Binding affinities towards human cloned 5-hydroxytryptamine 2B receptor in HEK293 cells, using [3H]5-HT as radioligand",B,,,,,CHEMBL617779,15779,H,BAO_0000219,1,,,,HEK293,227
2877,8,,Binding affinities towards human cloned 5-hydroxytryptamine 2B receptor in HEK293 cells using [3H]5-HT as radioligand.,B,,,,,CHEMBL617780,15851,H,BAO_0000219,1,,,,HEK293,227
2878,8,,"Binding affinities towards human cloned 5-hydroxytryptamine 2B receptor in HEK293 cells, using [3H]5-HT as radioligand; no data",B,,,,,CHEMBL617781,15779,H,BAO_0000219,1,,,,HEK293,227
2879,9,Homo sapiens,Displacement of [3H]5-HT from 5-hydroxytryptamine 2B receptor expressed in HEK 293 cells,B,9606.0,,,,CHEMBL617782,14157,D,BAO_0000219,1,,,,HEK293,227
2880,9,Homo sapiens,Binding affinity to human cloned 5-HT2B receptor in HEK 293 cells using [3H]- -5-HT as radioligand,B,9606.0,,,,CHEMBL617783,4540,D,BAO_0000219,1,,,,HEK293,227
2881,8,,Binding affinity towards cloned human 5-hydroxytryptamine 2B receptor was determined,B,,,,,CHEMBL617784,6166,H,BAO_0000357,1,,,,,227
2882,8,,Binding affinity towards 5-hydroxytryptamine 2B receptor (human cloned receptor) in HEK 293 cells using [3H]5-HT as radioligand.,B,,,,,CHEMBL617785,15779,H,BAO_0000219,1,,,,HEK293,227
2883,8,,Binding affinity towards cloned human 5-hydroxytryptamine 2B receptor expressed in HEK 293 cells using [3H]5-HT as radioligand,B,,,,,CHEMBL857984,14391,H,BAO_0000219,1,,,,HEK293,227
2884,8,,Binding affinity towards human cloned 5-HT2B receptor of HEK293 cells by displacement of [3H]5-HT,B,,,,,CHEMBL617786,3832,H,BAO_0000219,1,,,,HEK293,227
2885,8,,In vitro binding affinity at human cloned 5-hydroxytryptamine 2B receptor of HEK293 cells by [3H]5-HT displacement.,B,,,,,CHEMBL617787,3833,H,BAO_0000219,1,,,,HEK293,227
2886,9,Homo sapiens,Displacement of [3H]5-HT from human 5-hydroxytryptamine 2B receptor expressed in HEK293 cells,B,9606.0,,,,CHEMBL617788,15851,D,BAO_0000219,1,,,,HEK293,227
2887,9,Homo sapiens,Displacement of [3H]5-HT from human 5-hydroxytryptamine 2B receptor expressed in HEK293 cells; compound is insoluble,B,9606.0,,,,CHEMBL617789,15851,D,BAO_0000219,1,,,,HEK293,227
2888,8,,Compound was evaluated for binding affinity against human cloned 5-HT2B receptor in HEK 293 cells using [3H]5-HT as the radioligand,B,,,,,CHEMBL617790,4199,H,BAO_0000219,1,,,,HEK293,227
2889,8,,Displacement of [3H]-5-5HT from human cloned 5-hydroxytryptamine 2B receptor expressed in CHO-K1 cells,B,,,,,CHEMBL617791,1883,H,BAO_0000219,1,,,,CHO-K1,227
2890,8,,Binding affinity against 5-hydroxytryptamine 2B receptor,B,,,,,CHEMBL617608,4321,H,BAO_0000357,1,,,,,227
2891,8,,Compound was tested for its binding affinity against cloned human 5-hydroxytryptamine 2B receptor in HEK 293 cells using [3H]5-HT,B,,,,,CHEMBL617609,15146,H,BAO_0000219,1,,,,HEK293,227
2892,8,,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 2B receptor in HEK 293 using [3H]ketanserin as a radioligand,B,,,,,CHEMBL617610,5213,H,BAO_0000219,1,,,,HEK293,227
2893,8,,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 2B receptors in HEK293 cells using [3H]5-HT.,B,,,,,CHEMBL617611,14818,H,BAO_0000219,1,,,,HEK293,227
2894,8,,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 2B receptor in HEK293 cells, using [3H]5-HT as radioligand",B,,,,,CHEMBL617612,4829,H,BAO_0000219,1,,,,HEK293,227
2895,8,,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 2B receptor in HEK293 cells, using [3H]5-HT as radioligand",B,,,,,CHEMBL617613,4829,H,BAO_0000219,1,,,,HEK293,227
2896,8,Oryctolagus cuniculus,The dissociation equilibrium constant (pKB=-log KB) of compound was determined against the vascular 5-hydroxytryptamine 2B receptor in the endothelium intact rabbit jugular vein.,B,9986.0,,,,CHEMBL617614,14025,H,BAO_0000019,1,,,,,227
2897,8,,Binding affinity analysed for 5-HT 2B receptor in rat stomach fundus,B,,Stomach,,,CHEMBL617615,13463,H,BAO_0000019,1,945.0,,,,12688
2898,8,,Affinity against 5-hydroxytryptamine 2B receptor in the isolated rat stomach fundus,B,,Stomach,,,CHEMBL858114,7259,H,BAO_0000357,1,945.0,,,,12688
2899,8,,Affinity against serotonergic receptor in the isolated rat stomach fundus,B,,Stomach,,,CHEMBL617616,7259,H,BAO_0000357,1,945.0,,,,12688
2900,9,Rattus norvegicus,Antagonistic activity against 5-hydroxytryptamine 2B receptor obtained from rat stomach fundus preparation,F,10116.0,Stomach,,,CHEMBL617617,7185,D,BAO_0000019,1,945.0,,,,12688
2901,9,Rattus norvegicus,Antagonistic against 5-hydroxytryptamine 2B receptor,F,10116.0,,,,CHEMBL875914,7185,D,BAO_0000019,1,,,,,12688
2902,8,,Antagonistic affinity measured as pA2 value on 5-hydroxytryptamine 2B receptor of the rat stomach fundus,F,,Stomach,,,CHEMBL617618,13267,H,BAO_0000019,1,945.0,,,,12688
2903,9,Rattus norvegicus,Inhibition of 5-HT binding to 5-HT2B receptor of Rat stomach fundus,B,10116.0,Stomach,,,CHEMBL617619,13735,D,BAO_0000357,1,945.0,,,,12688
2904,8,,Compound was evaluated for antagonism against serotonin (5-hydroxytryptamine 2B receptor ) receptor,F,,,,,CHEMBL617620,15738,H,BAO_0000019,1,,,,,12688
2905,8,,Compound was evaluated for antagonism against serotonin (5-hydroxytryptamine 2B receptor ) receptor; No data,F,,,,,CHEMBL617621,15738,H,BAO_0000019,1,,,,,12688
2906,8,,Compound was evaluated for antagonism against serotonin (5-hydroxytryptamine 2B) receptor,F,,,,,CHEMBL617622,15738,H,BAO_0000019,1,,,,,12688
2907,9,Rattus norvegicus,Inhibitory potency against rat stomach fundus 5-hydroxytryptamine 2B receptor,B,10116.0,Stomach,,,CHEMBL617623,12936,D,BAO_0000357,1,945.0,,,,12688
2908,9,Rattus norvegicus,Inhibitory potency against rat stomach fundus 5-hydroxytryptamine 2B receptor,B,10116.0,Stomach,,,CHEMBL617624,12936,D,BAO_0000357,1,945.0,,,,12688
2909,9,Rattus norvegicus,Inhibitory potency against rat stomach fundus 5-hydroxytryptamine 2B receptor,B,10116.0,Stomach,,,CHEMBL617625,12936,D,BAO_0000357,1,945.0,,,,12688
2910,9,Rattus norvegicus,Inhibitory potency against rat stomach fundus 5-hydroxytryptamine 2B receptor,B,10116.0,Stomach,,,CHEMBL617626,12936,D,BAO_0000357,1,945.0,,,,12688
2911,8,,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2B receptor of Rat stomach fundus,F,,Stomach,,,CHEMBL617627,16404,H,BAO_0000019,1,945.0,,,,12688
2912,8,,Negative log concentration of antagonist was determined on 5-hydroxytryptamine 2B receptor of Rat stomach fundus,F,,Stomach,,,CHEMBL617628,16404,H,BAO_0000019,1,945.0,,,,12688
2913,8,,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2B receptor of Rat stomach fundus; ND is No Data.,F,,Stomach,,,CHEMBL617629,16404,H,BAO_0000019,1,945.0,,,,12688
2914,8,,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2B receptor of Rat stomach fundus; ND is not determined.,F,,Stomach,,,CHEMBL858115,16404,H,BAO_0000019,1,945.0,,,,12688
2915,9,Rattus norvegicus,Antagonistic activity on 5-hydroxytryptamine 2B receptor of Rat stomach fundus;ND is not determined,F,10116.0,Stomach,,,CHEMBL617630,16404,D,BAO_0000019,1,945.0,,,,12688
2916,8,,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2B receptor of Rat thoracic aorta; ND is not determined,F,,Thoracic aorta,,,CHEMBL617631,16404,H,BAO_0000019,1,1515.0,,,,12688
2917,8,,The binding affinity of compound to 5-HT receptor of rat fundus was expressed as pA2 value; Unable to determine valid PA2 value due to slope of Schild plot,B,,,,,CHEMBL617632,7483,H,BAO_0000357,1,,,,,12688
2918,8,,The binding affinity to 5-hydroxytryptamine 2B receptor of rat fundus,B,,,,,CHEMBL617633,7483,H,BAO_0000357,1,,,,,12688
2919,8,,The binding affinity of compound to 5-hydroxytryptamine 2B receptor of rat fundus was expressed as pA2 value; Unable to determine valid PA2 value due to slope of Schild plot,B,,,,,CHEMBL617634,7483,H,BAO_0000357,1,,,,,12688
2920,8,,The binding affinity of compound to 5-hydroxytryptamine 2B receptor of rat fundus; Unable to determine valid PA2 value due to slope of Schild plot,B,,,,,CHEMBL617635,7483,H,BAO_0000357,1,,,,,12688
2922,9,Rattus norvegicus,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2B receptor of Rat stomach fundus,F,10116.0,Stomach,,,CHEMBL617637,16404,D,BAO_0000019,1,945.0,,,,12688
2923,8,,Binding affinity against 5-hydroxytryptamine 1A receptor,B,,,,,CHEMBL617638,6347,H,BAO_0000357,1,,,,,227
2924,8,,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 2B receptor was determined,B,,,,,CHEMBL617639,4373,H,BAO_0000357,1,,,,,227
2925,8,,Binding affinity for 5-hydroxytryptamine 2B receptor was determined,B,,,,,CHEMBL617640,4373,H,BAO_0000357,1,,,,,227
2926,8,,Evaluated for the binding affinity to 5-HT 2B receptor,B,,,,,CHEMBL617641,4687,H,BAO_0000357,1,,,,,227
2927,8,,Ability to displace [3H]5-HT from 5-hydroxytryptamine 2B receptor,B,,,,,CHEMBL617642,16946,H,BAO_0000357,1,,,,,227
2928,8,,Binding affinities against 5-hydroxytryptamine 2B receptor,B,,,,,CHEMBL617643,16633,H,BAO_0000357,1,,,,,227
2929,8,,Binding affinities towards 5-hydroxytryptamine 2B receptor,B,,,,,CHEMBL617644,16633,H,BAO_0000357,1,,,,,227
2930,8,,Binding affinity towards 5-hydroxytryptamine 2B receptor using [125I]DOI as radioligand,B,,,,,CHEMBL617645,16633,H,BAO_0000357,1,,,,,227
2931,8,,In vitro ability to displace [3H]mesulergine binding from 5-hydroxytryptamine 2C receptor from bovine choroid plexus.,B,,,,,CHEMBL617646,15026,H,BAO_0000357,1,,,,,108
2932,8,Bos taurus,In vitro affinity against serotonin (5-hydroxytryptamine 2C) receptor,B,9913.0,,,,CHEMBL617647,15738,H,BAO_0000357,1,,,,,108
2933,8,Bos taurus,In vitro affinity against serotonin (5-hydroxytryptamine 2C) receptor at a concentration of 10E-6 M,B,9913.0,,,,CHEMBL617648,15738,H,BAO_0000357,1,,,,,108
2934,8,Bos taurus,In vitro affinity against serotonin (5-hydroxytryptamine 2C) receptor at a concentration of 10e-6 M,B,9913.0,,,,CHEMBL617875,15738,H,BAO_0000357,1,,,,,108
2935,8,Bos taurus,In vitro affinity against serotonin (5-hydroxytryptamine 2C) receptor at concentration of 10e-6 M,B,9913.0,,,,CHEMBL617876,15738,H,BAO_0000357,1,,,,,108
2936,8,Bos taurus,Inhibitory constant was determined on 5-hydroxytryptamine 2C receptor of Bovine choroid plexus,B,9913.0,,,,CHEMBL617877,16404,H,BAO_0000357,1,,,,,108
2937,8,Bos taurus,In vitro ability to displace [3H]mesulergine binding from 5-hydroxytryptamine 2C receptor from bovine choroid plexus.,B,9913.0,,,,CHEMBL617878,15026,H,BAO_0000357,1,,,,,108
2938,8,Bos taurus,In vitro affinity against serotonin (5-hydroxytryptamine 2C) receptor,B,9913.0,,,,CHEMBL617879,15738,H,BAO_0000357,1,,,,,108
2939,8,Cavia porcellus,Binding affinity against guinea pig cortex 5-HT2C receptor in the presence of [3H]mesulergine,B,10141.0,,,,CHEMBL617880,16312,H,BAO_0000019,1,,,,,108
2940,9,Cavia porcellus,Binding affinity towards 5-HT4 receptor by the displacement of [3H]GR-113808 in guinea-pig striatum,B,10141.0,Striatum,,,CHEMBL617881,5486,D,BAO_0000357,1,2435.0,,,,20033
2941,8,,Binding affinity against 5-HT1A receptor,B,,,,,CHEMBL857073,5254,H,BAO_0000357,1,,,,,51
2942,8,,Agonistic activity for 5-HT2c (5-HT2C) by measuring [3H]inositol monophosphate fromation in CHO cells in which the human 5-HT2C receptor subtype was stably expressed,F,,,,,CHEMBL617882,3857,H,BAO_0000219,1,,,,CHO,108
2943,9,Homo sapiens,Functional activity against human 5-hydroxytryptamine 2C receptor expressed in CHO cells using fluorometric imaging plate reader,F,9606.0,,,,CHEMBL617883,6857,D,BAO_0000219,1,,,,CHO,108
2944,8,,Functional agonist activity of compound was determined by fluorescence-based assay measuring intracellular calcium mobilization for 5-HT2c receptor cell line,F,,,,,CHEMBL617884,4176,H,BAO_0000219,1,,,,,108
2945,8,,Agonistic binding efficacy against human 5-hydroxytryptamine 2C receptor in CHO cells using [125I]- DOI radioligand,B,,,,,CHEMBL617885,6347,H,BAO_0000219,1,,,,CHO,108
2946,8,,"Agonistic binding affinity against human 5-hydroxytryptamine 2C receptor in CHO cells using [125I]- DOI radioligand, expressed as Emax",B,,,,,CHEMBL617886,6347,H,BAO_0000219,1,,,,CHO,108
2947,9,Homo sapiens,Inhibition of human 5-hydroxytryptamine 2C receptor,B,9606.0,,,,CHEMBL617887,16146,D,BAO_0000357,1,,,,,108
2948,8,,In vitro binding affinity against human 5-hydroxytryptamine 2C receptor at a concentration of 100 (nM),B,,,,,CHEMBL617888,3805,H,BAO_0000357,1,,,,,108
2949,8,,Inhibitory activity using [3H]mesulergine as radioligand with receptor membranes isolated from a CHO-k cell line expressing the human 5-hydroxytryptamine 2C receptor at a concentration of 1 uM,B,,,,,CHEMBL617889,3857,H,BAO_0000019,1,,,,,108
2950,8,,Intrinsic efficacy against 5-hydroxytryptamine 2C receptor,B,,,,,CHEMBL617890,5635,H,BAO_0000357,1,,,,,108
2951,8,,Intrinsic efficacy against 5-hydroxytryptamine 2C receptor Intrinsic efficacy against 5-hydroxytryptamine 2C receptor; Intrinsic efficacy (%) not determined,B,,,,,CHEMBL617891,5635,H,BAO_0000357,1,,,,,108
2952,8,,Intrinsic efficacy against 5-hydroxytryptamine 2C receptor; Intrinsic efficacy (%) not determined,B,,,,,CHEMBL617892,5635,H,BAO_0000357,1,,,,,108
2953,8,,Displacement of [H]-mesulergine from CHO cells expressing human 5-hydroxytryptamine 2C receptor.,B,,,,,CHEMBL617893,4012,H,BAO_0000219,1,,,,CHO,108
2954,8,,Ability to displace [3H]- mesulergine from human cloned 5-hydroxytryptamine 2C receptor expressed in CHO cells,B,,,,,CHEMBL617894,6366,H,BAO_0000219,1,,,,CHO,108
2955,8,,Ability to displace [3H]mesulergine binding to human 5-hydroxytryptamine 2C receptor stably expressed in CHO cells,B,,,,,CHEMBL617895,15949,H,BAO_0000219,1,,,,CHO,108
2956,8,,Ability to displace [3H]mesulergine (0.5 nM) from CHO cells of human 5-hydroxytryptamine 2C receptor,B,,,,,CHEMBL617896,17211,H,BAO_0000219,1,,,,CHO,108
2957,9,Homo sapiens,Affinity towards human 5-hydroxytryptamine 2C serotonin receptor,B,9606.0,,,,CHEMBL617897,6491,D,BAO_0000357,1,,,,,108
2958,8,,Agonist activity at cloned human 5-hydroxytryptamine 2C receptor using [125I]DOI radioligand,F,,,,,CHEMBL617898,14093,H,BAO_0000019,1,,,,,108
2959,8,,Agonistic activity at cloned human 5-hydroxytryptamine 2C receptor using [125I]DOI as radioligand,F,,,,,CHEMBL617899,13481,H,BAO_0000019,1,,,,,108
2960,8,Rattus norvegicus,Agonistic binding affinity against human 5-hydroxytryptamine 2C receptor in CHO cells using [125I]- DOI ,B,10116.0,,,,CHEMBL617900,6347,H,BAO_0000219,1,,,,CHO,108
2961,8,,Antagonist activity at cloned human 5-hydroxytryptamine 2C receptor using [3H]mesulergine radioligand,F,,,,,CHEMBL617901,14093,H,BAO_0000019,1,,,,,108
2962,8,,Antagonist activity at cloned human 5-hydroxytryptamine 2C receptor using [3H]mesulergine radioligand; Not tested,F,,,,,CHEMBL617902,14093,H,BAO_0000019,1,,,,,108
2963,8,,Antagonistic activity at cloned human 5-hydroxytryptamine 2C receptor using [3H]mesulergine as radioligand,F,,,,,CHEMBL617903,13481,H,BAO_0000019,1,,,,,108
2964,8,,Binding ability of compound at cloned human 5-hydroxytryptamine 2C receptor using [125 I]DOI as radioligand,B,,,,,CHEMBL617904,14442,H,BAO_0000357,1,,,,,108
2965,8,,Binding ability of compound at cloned human 5-hydroxytryptamine 2C receptor using [3H]- mesulergine as radioligand,B,,,,,CHEMBL617905,14442,H,BAO_0000357,1,,,,,108
2966,8,,Binding ability of compound at cloned human 5-hydroxytryptamine 2C receptor using [3H]- mesulergine as radioligand;not tested,B,,,,,CHEMBL617906,14442,H,BAO_0000357,1,,,,,108
2967,8,,Binding activity against cloned human 5-hydroxytryptamine 2C receptor using [125I]DOI as the radioligand.,B,,,,,CHEMBL617907,14755,H,BAO_0000357,1,,,,,108
2968,8,,Binding affinity against the cloned human 5-hydroxytryptamine 2C receptor using [125I]DOI as the radioligand,B,,,,,CHEMBL617908,14744,H,BAO_0000357,1,,,,,108
2969,8,,Binding affinity for displacement of [3H]mesulergine to human 5-hydroxytryptamine 2C receptor stably expressed in CHO cells,B,,,,,CHEMBL620617,16659,H,BAO_0000219,1,,,,CHO,108
2970,9,Homo sapiens,Affinity for human 5-hydroxytryptamine 2C receptor expressed in mammalian cell line,B,9606.0,,,,CHEMBL620618,6857,D,BAO_0000019,1,,,,,108
2971,8,,Binding affinity against 5-hydroxytryptamine 2C receptor using [125I]DOI radioligand.,B,,,,,CHEMBL620619,5635,H,BAO_0000357,1,,,,,108
2972,9,Homo sapiens,Binding affinity to cloned human 5-hydroxytryptamine 2C receptor,B,9606.0,,,,CHEMBL620620,4234,D,BAO_0000357,1,,,,,108
2973,8,,Binding affinity towards human 5-HT2C receptor was determined using [125I]- DOI as radioligand,B,,,,,CHEMBL620621,16209,H,BAO_0000357,1,,,,,108
2974,7,Rattus norvegicus,Binding affinity for 5-HT3 receptor by displacement of [3H]-LY 278584 in rat cerebral cortex membranes,B,10116.0,,Membranes,,CHEMBL872920,5778,D,BAO_0000249,1,,,,,104698
2975,6,,Binding affinity towards rat 5-hydroxytryptamine 3 receptor was evaluated,B,,,,,CHEMBL620622,5094,H,BAO_0000223,1,,,,,104698
2976,7,Rattus norvegicus,Binding affinity against 5-hydroxytryptamine 3 receptor using [3H]BRL-43694 in rat posterior cortex,B,10116.0,,,,CHEMBL620623,809,D,BAO_0000019,1,,,,,104698
2977,6,,Binding affinity against 5-hydroxytryptamine 3 receptor using [3H]BRL-43694 as radioligand in rat posterior cortex,B,,,,,CHEMBL620624,1578,H,BAO_0000019,1,,,,,104698
2978,6,,Binding affinity against 5-hydroxytryptamine 3 receptor using [3H]BRL-43694 as radioligand in rat posterior cortex; Not tested,B,,,,,CHEMBL620625,809,H,BAO_0000019,1,,,,,104698
2979,6,,Binding affinity was measured on 5-hydroxytryptamine 3 receptor in NG-108 cells labeled with [3H]GR-65630,B,,,,,CHEMBL620626,12469,H,BAO_0000219,1,,,,,104698
2980,6,,Binding affinity was measured on 5-hydroxytryptamine 3 receptor using [3H]-BRL 43694 as radioligand in rat posterior cortex,B,,,,,CHEMBL621307,14290,H,BAO_0000019,1,,,,,104698
2981,6,,Binding affinity was measured on 5-hydroxytryptamine 3 receptor using [3H]-BRL 43694 as radioligand in rat posterior cortex.,B,,,,,CHEMBL621308,14290,H,BAO_0000019,1,,,,,104698
2982,6,,Binding affinity for central 5-hydroxytryptamine 3 receptor was determined by displacement of [3H]-5-HT,B,,,,,CHEMBL621309,10609,H,BAO_0000223,1,,,,,104698
2983,6,,Binding affinity for central 5-hydroxytryptamine 3 receptor was determined by displacement of [3H]GR-65630,B,,,,,CHEMBL621310,10609,H,BAO_0000223,1,,,,,104698
2984,6,,Binding affinity for central 5-hydroxytryptamine 3 receptor was determined by displacement of [3H]-ketanserin,B,,,,,CHEMBL621311,10609,H,BAO_0000223,1,,,,,104698
2985,6,,"Compound was evaluated for its in vitro affinity at serotonergic 5-hydroxytryptamine 3 receptor by radioligand binding assay, using [3H]-LY 278584 in rat cerebral cortex membranes.",B,,,,,CHEMBL621502,15253,H,BAO_0000249,1,,,,,104698
2986,6,,"In vitro affinity at serotonergic 5-hydroxytryptamine 3 receptor by radioligand binding assay, using [3H]-LY 278584 in rat cerebral cortex membranes.",B,,,,,CHEMBL621503,15253,H,BAO_0000249,1,,,,,104698
2987,6,,Displacement of the 5-hydroxytryptamine 3 receptor ligand [3H]GR-65630 from rat brain cortical membranes.,B,,,Membranes,,CHEMBL621504,11683,H,BAO_0000249,1,,,,,104698
2988,6,,Compound was evaluated for binding affinity against 5-hydroxytryptamine 3 receptor,B,,,,,CHEMBL621505,12092,H,BAO_0000223,1,,,,,104698
2989,6,,Binding affinity at 5-hydroxytryptamine 3 receptor in rat entorhinal cortex by [3H]BRL-43694 displacement.,B,,,,,CHEMBL621506,1946,H,BAO_0000019,1,,,,,104698
2990,6,,Ability to displace [3H]quipazine binding to 5-hydroxytryptamine 3 receptor sites in NG 108-15.,B,,,,,CHEMBL619781,11623,H,BAO_0000223,1,,,,,104698
2991,6,,Compound was evaluated for its ability to displace [3H]quipazine binding to 5-hydroxytryptamine 3 receptor sites in NG 108-15. ,B,,,,,CHEMBL619782,11623,H,BAO_0000223,1,,,,,104698
2992,6,,Compound was evaluated for its binding affinity for 5-hydroxytryptamine 3 receptor by measuring displacement [3H]GR-65630 in rat cerebral cortex,B,,,,,CHEMBL619783,14788,H,BAO_0000019,1,,,,,104698
2993,7,Rattus norvegicus,Displacement of [3H]ketanserin from rat cortex 5-HT3 receptor,B,10116.0,,,,CHEMBL619784,5432,D,BAO_0000019,1,,,,,104698
2994,6,,Ability to displace [3H]granisetron specifically bound to 5-hydroxytryptamine 3 receptor in rat cortical membrane,B,,,,,CHEMBL619785,14826,H,BAO_0000249,1,,,,,104698
2995,6,,Compound was tested for its binding affinity for the 5-hydroxytryptamine 3 receptor,B,,,,,CHEMBL619786,2222,H,BAO_0000223,1,,,,,104698
2996,6,,Displacement of binding of [3H]-BRL 43694 to 5-hydroxytryptamine 3 receptor in rat cerebral cortex,B,,,,,CHEMBL619787,11963,H,BAO_0000019,1,,,,,104698
2997,6,,In vitro affinity for 5-hydroxytryptamine 3 (5-HT3) receptor by displacement of [3H]BRL-43694 from rat entorhinal cortex,B,,,,,CHEMBL872925,14145,H,BAO_0000019,1,,,,,104698
2998,6,,In vitro binding affinity at serotonin 5-hydroxytryptamine 3 receptor in rat cortex by [3H]granisetron displacement.,B,,,,,CHEMBL619788,17819,H,BAO_0000019,1,,,,,104698
2999,6,,Inhibitory activity against 5-hydroxytryptamine 3 receptor in rat cortical membranes using [3H]- 1-Methyl-1H-indazole-3-carboxylic acid (8-methyl-8-aza-bicyclo[3.2.1]oct-3-yl)-amide as a radioligand,B,,,,,CHEMBL619789,10394,H,BAO_0000249,1,,,,,104698
3000,6,,Inhibitory activity against 5-hydroxytryptamine 3 receptor in rat cortical membranes using [3H]-1-Methyl-1H-indazole-3-carboxylic acid (8-methyl-8-aza-bicyclo[3.2.1]oct-3-yl)-amide as a radioligand,B,,,,,CHEMBL619790,10394,H,BAO_0000249,1,,,,,104698
3001,6,,Inhibitory concentration against 5-hydroxytryptamine 3 receptor in rat entorhinal cortex using [3H]-LY 278584 as radioligand,B,,,,,CHEMBL619791,15034,H,BAO_0000019,1,,,,,104698
3002,6,,Binding affinity at 5-hydroxytryptamine 3 receptor in rat entorhinal cortex by [3H]BRL-43694 displacement.,B,,,,,CHEMBL619792,691,H,BAO_0000019,1,,,,,104698
3003,6,,Displacement of [3H]GR-65630 binding to 5-hydroxytryptamine 3 receptor in rat brain cortical membranes,B,,,Membranes,,CHEMBL619793,12092,H,BAO_0000249,1,,,,,104698
3004,7,Rattus norvegicus,Inhibition of [3H]GR-65630 binding to 5-hydroxytryptamine 3 receptor,B,10116.0,,,,CHEMBL619794,11752,D,BAO_0000223,1,,,,,104698
3005,6,,The ability to inhibit [3H]GR-65630 binding to 5-hydroxytryptamine 3 receptor in rat brain cortices,B,,Brain,,,CHEMBL619795,11752,H,BAO_0000221,1,955.0,,,,104698
3006,6,,Binding affinity at 5-hydroxytryptamine 3 receptor in rat posterior cortex by [3H]-BRL 43694 displacement.,B,,,,,CHEMBL619796,301,H,BAO_0000019,1,,,,,104698
3007,6,,The binding affinity at 5-hydroxytryptamine 3 receptor was determined using [3H]LY-278584,B,,,,,CHEMBL620448,16532,H,BAO_0000223,1,,,,,104698
3008,6,,The binding affinity at 5-hydroxytryptamine 3 receptor was determined using [3H]LY-278584; Not tested,B,,,,,CHEMBL620449,16532,H,BAO_0000223,1,,,,,104698
3009,6,,The binding affinity was measured on 5-hydroxytryptamine 3 receptor using [3H]GR-65630 as radioligand.,B,,,,,CHEMBL620450,12092,H,BAO_0000223,1,,,,,104698
3010,6,,The compound was evaluated for the binding affinity towards 5-hydroxytryptamine 3 receptor by displacement of radioligand [3H]GR-65630,B,,,,,CHEMBL620451,11684,H,BAO_0000223,1,,,,,104698
3011,6,,Binding affinity towards 5-hydroxytryptamine 3 receptor by displacement of radioligand [3H]GR-65630.,B,,,,,CHEMBL620631,11684,H,BAO_0000223,1,,,,,104698
3012,6,,Binding affinity for 5-hydroxytryptamine 3 receptor from rat cortex using [3H]BRL-43694 as radioligand,B,,,,,CHEMBL620632,12953,H,BAO_0000019,1,,,,,104698
3013,6,,The compound was tested for its binding affinity towards 5-hydroxytryptamine 3 receptor from rat cortex using [3H]BRL-43694 as radioligand; NA means Not active,B,,,,,CHEMBL620633,12953,H,BAO_0000019,1,,,,,104698
3014,6,,The compound was tested for their binding affinity towards 5-hydroxytryptamine 3 receptor; Nonactive at 10 uM,B,,,,,CHEMBL620634,12953,H,BAO_0000223,1,,,,,104698
3015,6,,Binding activity against 5-hydroxytryptamine 3 receptor from rat cortex homogenate using [3H]-Q-ICS 205-930 as radioligand; NA Not Available,B,,,,,CHEMBL620635,12861,H,BAO_0000019,1,,,,,104698
3016,6,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg at 0.5 hours in urethane-anesthetized rats,F,,,,,CHEMBL620636,11454,H,BAO_0000218,1,,In vivo,,,104698
3017,6,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg at 1 hour in urethane-anesthetized rats,F,,,,,CHEMBL620637,11454,H,BAO_0000218,1,,In vivo,,,104698
3018,6,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg at 3 hours in urethane-anesthetized rats,F,,,,,CHEMBL620638,11454,H,BAO_0000218,1,,In vivo,,,104698
3019,6,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg at 6 hours in urethane-anesthetized rats,F,,,,,CHEMBL620639,11454,H,BAO_0000218,1,,In vivo,,,104698
3020,6,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.1 mg/kg at 0.5 hours in urethane-anesthetized rats,F,,,,,CHEMBL620640,11454,H,BAO_0000218,1,,In vivo,,,104698
3021,6,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.1 mg/kg at 1 hour in urethane-anesthetized rats,F,,,,,CHEMBL620641,11454,H,BAO_0000218,1,,In vivo,,,104698
3022,6,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.1 mg/kg at 16 hours in urethane-anesthetized rats,F,,,,,CHEMBL620642,11454,H,BAO_0000218,1,,In vivo,,,104698
3023,6,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.1 mg/kg at 3 hours in urethane-anesthetized rats,F,,,,,CHEMBL620643,11454,H,BAO_0000218,1,,In vivo,,,104698
3024,6,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.1 mg/kg at 6 hours in urethane-anesthetized rats,F,,,,,CHEMBL620644,11454,H,BAO_0000218,1,,In vivo,,,104698
3025,6,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.3 mg/kg at 0.5 hours in urethane-anesthetized rats,F,,,,,CHEMBL620645,11454,H,BAO_0000218,1,,In vivo,,,104698
3026,6,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.3 mg/kg at 1 hour in urethane-anesthetized rats,F,,,,,CHEMBL620646,11454,H,BAO_0000218,1,,In vivo,,,104698
3027,6,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.3 mg/kg at 3 hours in urethane-anesthetized rats,F,,,,,CHEMBL620647,11454,H,BAO_0000218,1,,In vivo,,,104698
3028,6,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.3 mg/kg at 6 hours in urethane-anesthetized rats,F,,,,,CHEMBL620648,11454,H,BAO_0000218,1,,In vivo,,,104698
3029,6,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 1 mg/kg at 0.5 hours in urethane-anesthetized rats,F,,,,,CHEMBL620649,11454,H,BAO_0000218,1,,In vivo,,,104698
3030,6,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 1 mg/kg at 3 hours in urethane-anesthetized rats,F,,,,,CHEMBL620650,11454,H,BAO_0000218,1,,In vivo,,,104698
3031,6,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 10 mg/kg at 1 hour in urethane-anesthetized rats,F,,,,,CHEMBL620651,11454,H,BAO_0000218,1,,In vivo,,,104698
3032,6,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 10 mg/kg at 3 hours in urethane-anesthetized rats,F,,,,,CHEMBL872875,11454,H,BAO_0000218,1,,In vivo,,,104698
3033,6,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 1 mg/kg at 1 hour in urethane-anesthetized rats,F,,,,,CHEMBL620652,11454,H,BAO_0000218,1,,In vivo,,,104698
3034,6,,5-hydroxytryptamine 3 receptor antagonist activity was confirmed by its ability to antagonize 5-HT evoked tachycardia of rabbit isolated heart,F,,,,,CHEMBL620653,10609,H,BAO_0000019,1,,,,,104698
3035,6,,Binding activity against 5-hydroxytryptamine 2A receptor from rat cortex homogenates using [3H]DOB as radioligand.,B,,,,,CHEMBL857076,12861,H,BAO_0000019,1,,,,,104698
3036,7,Rattus norvegicus,Inhibition of [3H]-Q-ICS 205-930 binding to rat cortex homogenate 5-hydroxytryptamine 3 receptor,B,10116.0,,,,CHEMBL620654,12861,D,BAO_0000019,1,,,,,104698
3037,6,,Binding activity radioligand.,B,,,,,CHEMBL620655,12861,H,BAO_0000223,1,,,,,104698
3038,6,,Compound was evaluated for the displacement of [3H]-Q-ICS 205-930 binding to 5-hydroxytryptamine 3 receptor in rat brain membranes,B,,,Brain membranes,,CHEMBL620656,10728,H,BAO_0000249,1,,,,,104698
3039,6,,Displacement of [3H]-Q-ICS 205-930 binding to 5-hydroxytryptamine 3 receptor recognition sites in rat brain membranes.,B,,,Brain membranes,,CHEMBL620657,10728,H,BAO_0000249,1,,,,,104698
3040,8,,Binding affinity towards 5-hydroxytryptamine 2C receptor was determined at a concentration of 0.000001 mol/L,B,,,,,CHEMBL620658,5163,H,BAO_0000357,1,,,,,108
3041,8,,Binding affinity towards 5-hydroxytryptamine 2C receptor was determined at a concentration of 0.00001 mol/L,B,,,,,CHEMBL620659,5163,H,BAO_0000357,1,,,,,108
3042,8,,Inhibition of binding towards 5-hydroxytryptamine 2C receptor at 100 nM concentration,B,,,,,CHEMBL620660,6011,H,BAO_0000357,1,,,,,108
3043,8,,Percent inhibition (at 1 uM) against 5-hydroxytryptamine 2C receptor,B,,,,,CHEMBL620661,5014,H,BAO_0000357,1,,,,,108
3044,8,,Binding affinity of compound towards 5-hydroxytryptamine 2C receptor,B,,,,,CHEMBL620662,5635,H,BAO_0000357,1,,,,,108
3045,8,,Affinity for 5-hydroxytryptamine 2C receptor,B,,,,,CHEMBL620663,5163,H,BAO_0000357,1,,,,,108
3046,8,,Binding affinity towards 5-hydroxytryptamine 2C receptor using [3H]mesulergine as radioligand,B,,,,,CHEMBL620664,6841,H,BAO_0000357,1,,,,,108
3047,8,,Binding affinity towards 5-hydroxytryptamine 2C receptor using [125I]DOI as radioligand.,B,,,,,CHEMBL620665,6119,H,BAO_0000357,1,,,,,108
3048,8,,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 2C receptor was determined,B,,,,,CHEMBL620666,4373,H,BAO_0000357,1,,,,,108
3049,8,,Compound was evaluated for the binding affinity towards 5-hydroxytryptamine 2C receptor by displacement of [3H]-Ketanserin,B,,,,,CHEMBL620667,1633,H,BAO_0000357,1,,,,,108
3050,8,,Binding affinity towards 5-hydroxytryptamine 2C receptor by displacement of [3H]N-methyl-mesulergine,B,,,,,CHEMBL620668,1633,H,BAO_0000357,1,,,,,108
3051,8,,Binding affinity for 5-hydroxytryptamine 2C receptor was determined,B,,,,,CHEMBL620669,4373,H,BAO_0000357,1,,,,,108
3052,8,,Binding affinity towards serotonin 5-hydroxytryptamine 2C receptor,B,,,,,CHEMBL620670,6576,H,BAO_0000357,1,,,,,108
3053,8,,Evaluated for the binding affinity to 5-hydroxytryptamine 2C receptor,B,,,,,CHEMBL620671,4687,H,BAO_0000357,1,,,,,108
3054,8,,Tested agains t5-hydroxytryptamine 2C receptor in experiment 1,B,,,,,CHEMBL620672,12146,H,BAO_0000357,1,,,,,108
3055,8,,Tested against 5-hydroxytryptamine 2C receptor in experiment 2,B,,,,,CHEMBL620673,12146,H,BAO_0000357,1,,,,,108
3056,8,,Ability to displace [3H]mesulergine from 5-hydroxytryptamine 2C receptor,B,,,,,CHEMBL620674,16946,H,BAO_0000357,1,,,,,108
3057,8,,Compound was evaluated for the affinity at 5-hydroxytryptamine 2C receptor,B,,,,,CHEMBL620675,14159,H,BAO_0000357,1,,,,,108
3058,8,,The binding affinity towards 5-hydroxytryptamine 2C receptor; No affinity,B,,,,,CHEMBL620676,16700,H,BAO_0000357,1,,,,,108
3059,8,,Affinity against 5-hydroxytryptamine 2C receptor,B,,,,,CHEMBL621382,3269,H,BAO_0000357,1,,,,,108
3060,9,Homo sapiens,Binding affinity against 5-hydroxytryptamine 2C receptor,B,9606.0,,,,CHEMBL621383,1274,D,BAO_0000357,1,,,,,108
3061,8,,Compound was evaluated for binding affinity against 5-hydroxytryptamine 2C receptor using radioligand binding assay,B,,,,,CHEMBL621384,1317,H,BAO_0000357,1,,,,,108
3062,8,Bos taurus,Inhibitory concentration required against 5-HT3 receptor in bovine area postrema using [3H]GR-65630,B,9913.0,,,,CHEMBL621385,5834,H,BAO_0000357,1,,,,,144
3063,8,Bos taurus,Binding affinity towards 5-hydroxytryptamine 3 receptor using [3H]GR-65630 as radioligand,B,9913.0,,,,CHEMBL617989,11147,H,BAO_0000357,1,,,,,144
3064,4,Cavia porcellus,Antagonistic potency against serotonin 5-hydroxytryptamine 3 receptor in GPI assay,F,10141.0,,,,CHEMBL617990,14145,H,BAO_0000019,1,,,,,104714
3065,4,Cavia porcellus,Binding affinity to 5-hydroxytryptamine 3 receptor entirely in guinea pig ileum,B,10141.0,Ileum,,,CHEMBL875085,10561,H,BAO_0000221,1,2116.0,,,,104714
3066,4,Cavia porcellus,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 3 receptor of guinea pig,F,10141.0,,,,CHEMBL617991,15847,H,BAO_0000019,1,,,,,104714
3067,4,Cavia porcellus,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 3 receptor of guinea pig; ND means not done,F,10141.0,,,,CHEMBL617992,15847,H,BAO_0000019,1,,,,,104714
3068,4,Cavia porcellus,Potency to 5-hydroxytryptamine 3 receptor entirely in guinea pig ileum,B,10141.0,Ileum,,,CHEMBL617993,10561,H,BAO_0000221,1,2116.0,,,,104714
3069,4,Cavia porcellus,In vitro binding affinity was measured for 5-hydroxytryptamine 3 receptor in the guinea pig ileum.,B,10141.0,Ileum,,,CHEMBL617994,11454,H,BAO_0000221,1,2116.0,,,,104714
3070,4,Cavia porcellus,Compound was tested for agonistic activity against 5-hydroxytryptamine 3 receptor on guinea colon at a concentration 0.01 uM,F,10141.0,,,,CHEMBL617995,4639,H,BAO_0000019,1,,,,,104714
3071,4,Cavia porcellus,Percent of control response to 5-HT3 agonistic activity on guinea colon at a concentration 0.1 uM,F,10141.0,,,,CHEMBL617996,4639,H,BAO_0000019,1,,,,,104714
3072,4,Cavia porcellus,Percent of control response to 5-HT3 agonistic activity on guinea colon at a concentration 1 uM,F,10141.0,,,,CHEMBL617997,4639,H,BAO_0000019,1,,,,,104714
3073,4,Cavia porcellus,Percent of control response to 5-HT3 agonistic activity on guinea colon at a concentration 1 uM in the presence of 30 uM MDL 72222,F,10141.0,,,,CHEMBL617998,4639,H,BAO_0000019,1,,,,,104714
3074,4,Cavia porcellus,Percent of control response to 5-HT3 antagonistic activity on guinea colon at a concentration 0.01 uM,F,10141.0,,,,CHEMBL617999,4639,H,BAO_0000019,1,,,,,104714
3075,4,Cavia porcellus,Percent of control response to 5-HT3 antagonistic activity on guinea colon at a concentration 1 uM,F,10141.0,,,,CHEMBL618000,4639,H,BAO_0000019,1,,,,,104714
3076,4,Cavia porcellus,"Concentration required to produce 50% of maximal contraction induced by 5-HT through 5-HT3 receptors in the presence of the compound, in isolated guinea pig ileum",F,10141.0,Ileum,,,CHEMBL617815,15253,H,BAO_0000221,1,2116.0,,,,104714
3077,4,Cavia porcellus,"Concentration required to produce 50% of maximal contraction induced by 5-HT through 5-HT3 receptors in the presence of the compound, in isolated guinea pig ileum.",F,10141.0,Ileum,,,CHEMBL617816,15253,H,BAO_0000221,1,2116.0,,,,104714
3078,4,Cavia porcellus,Tested for the antagonistic activity against 5-hydroxytryptamine 3 receptor from guinea pig ileum,F,10141.0,Ileum,,,CHEMBL617817,11963,H,BAO_0000221,1,2116.0,,,,104714
3079,4,Cavia porcellus,In vitro 5-hydroxytryptamine 3 receptor activity in guinea pig ileum,B,10141.0,Ileum,,,CHEMBL617818,1946,H,BAO_0000221,1,2116.0,,,,104714
3080,4,Cavia porcellus,In vitro 5-hydroxytryptamine 3 receptor activity in guinea pig ileum; Not tested,B,10141.0,Ileum,,,CHEMBL617819,1946,H,BAO_0000221,1,2116.0,,,,104714
3081,4,Cavia porcellus,Binding affinity towards [3H]quipazine labeled 5-hydroxytryptamine 3 receptor sites in HG108-15,B,10141.0,,,,CHEMBL617820,12045,H,BAO_0000223,1,,,,,104714
3082,4,Cavia porcellus,Binding affinity against 5-hydroxytryptamine 3 receptor of guinea pig ileum,B,10141.0,Ileum,,,CHEMBL617821,1559,H,BAO_0000221,1,2116.0,,,,104714
3083,4,Cavia porcellus,Evaluated for the antagonistic activity against 5-hydroxytryptamine 3 receptor in isolated guinea pig ileum (GPI),F,10141.0,Ileum,,,CHEMBL617822,273,H,BAO_0000221,1,2116.0,,,,104714
3084,4,Cavia porcellus,Antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor of isolated guinea pig ileum (GPI),F,10141.0,Ileum,,,CHEMBL617823,273,H,BAO_0000221,1,2116.0,,,,104714
3085,4,Cavia porcellus,Tested for antagonistic activity on 5-hydroxytryptamine 3 receptor mediated effects of 5-HT in guinea pig isolated ileum,F,10141.0,Ileum,,,CHEMBL617824,188,H,BAO_0000221,1,2116.0,,,,104714
3086,4,Cavia porcellus,Agonistic activity against 5-hydroxytryptamine 3 receptor in guinea pig ileum assay,F,10141.0,Ileum,,,CHEMBL617825,12919,H,BAO_0000221,1,2116.0,,,,104714
3087,4,Cavia porcellus,5-hydroxytryptamine 3 receptor agonism in the guinea pig ileum by functional 5-HT3 receptor assay,F,10141.0,Ileum,,,CHEMBL617826,12918,H,BAO_0000221,1,2116.0,,,,104714
3088,4,Cavia porcellus,Binding affinity against 5-hydroxytryptamine 3 receptor of guinea pig ileum,B,10141.0,Ileum,,,CHEMBL617827,1559,H,BAO_0000221,1,2116.0,,,,104714
3089,4,Cavia porcellus,Evaluated for the antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor in isolated guinea pig ileum (GPI),F,10141.0,Ileum,,,CHEMBL617828,273,H,BAO_0000221,1,2116.0,,,,104714
3090,4,Cavia porcellus,Binding affinity against 5-hydroxytryptamine 3 receptor of guinea pig ileum,B,10141.0,Ileum,,,CHEMBL617829,1559,H,BAO_0000221,1,2116.0,,,,104714
3091,4,Cavia porcellus,Binding affinity against 5-hydroxytryptamine 3 receptor of guinea pig ileum; Not determined,B,10141.0,Ileum,,,CHEMBL617830,1559,H,BAO_0000221,1,2116.0,,,,104714
3092,4,Cavia porcellus,Binding affinity towards 5-hydroxytryptamine 3 receptor of guinea pig ileum; not determined,B,10141.0,Ileum,,,CHEMBL617831,1559,H,BAO_0000221,1,2116.0,,,,104714
3093,4,Cavia porcellus,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor in guinea pig ileum.,B,10141.0,Ileum,,,CHEMBL617832,14424,H,BAO_0000221,1,2116.0,,,,104714
3094,0,Cavia porcellus,Binding affinity was determined against 5-hydroxytryptamine 2A receptor,B,10141.0,,,,CHEMBL617833,13181,U,BAO_0000019,1,,,,,22226
3095,8,,Binding affinity towards 5-HT1A receptor by the displacement of [3H]-8-OH-DPAT] in human recombinant receptors in mammalian cell,B,,,,,CHEMBL617834,5486,H,BAO_0000357,1,,,,,51
3096,5,Homo sapiens,Affinity towards human 5-hydroxytryptamine 3 serotonin receptor,B,9606.0,,,,CHEMBL617835,6491,D,BAO_0000223,1,,,,,104714
3097,4,,Binding affinity towards 5-HT3 receptor,B,,,,,CHEMBL617836,6013,H,BAO_0000223,1,,,,,104714
3098,4,,Binding activity radioligand.,B,,,,,CHEMBL617837,12861,H,BAO_0000223,1,,,,,104714
3099,4,,Binding activity against 5-hydroxytryptamine 1A receptor from human brain cortex using [3H]8-OH-DPAT-HT as radioligand.,B,,,,,CHEMBL620392,12861,H,BAO_0000019,1,,,,,104714
3100,4,,Binding affinity for human cloned 5-hydroxytryptamine 3 receptor,B,,,,,CHEMBL620393,5104,H,BAO_0000223,1,,,,,104714
3101,4,,Binding affinity for human cloned 5-hydroxytryptamine 3 receptor,B,,,,,CHEMBL620394,5105,H,BAO_0000223,1,,,,,104714
3102,4,,Binding affinity for human cloned 5-hydroxytryptamine 3 receptor; NT means Not tested,B,,,,,CHEMBL620395,5104,H,BAO_0000223,1,,,,,104714
3103,0,,Compound was evaluated for its binding affinity for human 5-hydroxytryptamine 3 receptor,B,,,,,CHEMBL620396,3935,U,BAO_0000019,1,,,,,22226
3104,4,,Displacement of [3H]-BRC 36694 from 5-hydroxytryptamine 3 receptor in NG108-15 cells,B,,,,,CHEMBL620582,13657,H,BAO_0000219,1,,,,NG108-15,105030
3105,4,,"Percent inhibition of [3H]5 binding to 5-hydroxytryptamine 3 receptor was evaluated by injection of compound (75 microCi/kg, 1.32 ug/kg) into the tail vein of mice (in vivo)",B,,,,,CHEMBL620583,10369,H,BAO_0000218,1,,In vivo,,,105030
3106,4,,The binding affinity was measured for 5-hydroxytryptamine 3 receptor on NG 108-15 cell line of mouse neuroblastoma-glioma cells in presence of [3H]5 radioligand (in vitro),B,,,,,CHEMBL620584,10369,H,BAO_0000019,1,,,,,105030
3107,4,,Compound was evaluated for the binding affinity at 5- HT3 receptor subtype,B,,,,,CHEMBL620585,12918,H,BAO_0000224,1,,,,,105030
3108,4,,Compound was evaluated for the binding affinity at 5- HT3 receptor,B,,,,,CHEMBL620586,12918,H,BAO_0000224,1,,,,,105030
3109,4,,The binding affinity was measured for 5-hydroxytryptamine 3 receptor on NG 108-15 cell line of mouse neuroblastoma-glioma cells in presence of [3H]5 radioligand (in vitro),B,,,,,CHEMBL620587,10369,H,BAO_0000019,1,,,,,105030
3110,4,,In Vitro Binding affinity againist 5-hydroxytryptamine 3 receptor by displacing [3H]-Q-ICS 205-930 from rat cortex homogenates,B,,,,,CHEMBL620588,773,H,BAO_0000019,1,,,,,105030
3111,4,,5-hydroxytryptamine 3 receptor agonism in mouse,F,,,,,CHEMBL620589,12918,H,BAO_0000218,1,,,,,105030
3112,4,,Binding affinity towards 5-hydroxytryptamine 3 receptor was determined by using [3H]-ICS 205-930 as radioligand in mouse N1E 115 cells,B,,,,,CHEMBL620590,10561,H,BAO_0000219,1,,,,,105030
3113,4,,Binding affinity towards 5-hydroxytryptamine 2A receptor in rat cortex preparations using [3H]ketanserin,B,,,,,CHEMBL617956,12827,H,BAO_0000019,1,,,,,105030
3114,4,,Binding affinity towards 5-hydroxytryptamine 2A receptor in rat cortex preparations using [3H]ketanserin,B,,,,,CHEMBL617957,12827,H,BAO_0000019,1,,,,,105030
3115,4,,Binding affinity was evaluated by 5-hydroxytryptamine 3 receptor agonism in the mouse NIE-115 by displacing tropisetron,B,,,,,CHEMBL617958,12918,H,BAO_0000224,1,,,,,105030
3116,4,,Compound was evaluated for binding to 5-hydroxytryptamine 3 receptor in N1E cells using [3H]- -Tropisetron as radioligand,B,,,,,CHEMBL617959,273,H,BAO_0000219,1,,,,,105030
3117,4,,Compound was evaluated for binding to Serotonin 5-hydroxytryptamine 3 receptor in N1E cells using [3H]- -Tropisetron as radioligand,B,,,,,CHEMBL617960,273,H,BAO_0000219,1,,,,,105030
3118,4,,Potency at neuronal 5-hydroxytryptamine 3 receptor in the rabbit heart,B,,,,,CHEMBL617961,10561,H,BAO_0000224,1,,,,,105030
3119,4,,Ability to displace the radioligand [3H]GR-65630 from 5-hydroxytryptamine 3 receptor expressed in NIE-115 cells,B,,,,,CHEMBL617962,5033,H,BAO_0000219,1,,In vitro,,,105030
3120,4,,In vitro binding affinity at 5-hydroxytryptamine 3 receptor in N1E-115 cells using 3[H]GR-65630 as the radioligand,B,,,,,CHEMBL617963,16429,H,BAO_0000219,1,,,,N1E-115,105030
3121,8,,In vitro binding affinity for the 5-hydroxytryptamine 3 receptor was determined with NG-108-15 mouse neuroblastoma-glioma cells,B,,,,,CHEMBL617964,10322,H,BAO_0000019,1,,,,,11765
3122,8,,Inhibition of [3H]BRL-43694 binding to 5-hydroxytryptamine 3 receptor in NG cells 108-15,B,,,,,CHEMBL617965,14331,H,BAO_0000219,1,,,,,11765
3123,9,Mus musculus,Compound was tested for the Binding affinity against N1e-115 neuroblastoma 5-hydroxytryptamine 3 receptor by Radio ligand [3H]GR-65630 binding assay.,B,10090.0,,,,CHEMBL617966,13462,D,BAO_0000357,1,,,,,10630
3124,8,,Binding activity against 5-hydroxytryptamine 3 receptor from rat cortex homogenate using [3H]-Q-ICS 205-930 as radioligand.,B,,,,,CHEMBL857074,12861,H,BAO_0000019,1,,,,,17106
3125,8,Sus scrofa,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor,B,9823.0,,,,CHEMBL617967,15086,H,BAO_0000357,1,,,,,144
3126,8,Sus scrofa,Binding activity radioligand.,B,9823.0,,,,CHEMBL617968,12861,H,BAO_0000357,1,,,,,144
3127,4,Oryctolagus cuniculus,Binding affinity to 5-hydroxytryptamine 3 receptor of neuronal in the afferent rabbit vagus,B,9986.0,,,,CHEMBL617969,10561,H,BAO_0000223,1,,,,,104714
3128,4,Oryctolagus cuniculus,Potency at neuronal 5-hydroxytryptamine 3 receptor in the rabbit heart,B,9986.0,,,,CHEMBL617970,10561,H,BAO_0000223,1,,,,,104714
3129,4,Oryctolagus cuniculus,Potency at neuronal 5-hydroxytryptamine 3 receptors in the rabbit heart,B,9986.0,,,,CHEMBL617971,10561,H,BAO_0000223,1,,,,,104714
3130,4,Oryctolagus cuniculus,Potency to 5-hydroxytryptamine 3 receptor using [3H]GR-65630 as radioligand in rat cortex,B,9986.0,,,,CHEMBL617972,10561,H,BAO_0000019,1,,,,,104714
3131,4,Oryctolagus cuniculus,Evaluated for the antagonistic activity against 5-hydroxytryptamine 3 receptor in isolated perfused rabbit heart (RH),F,9986.0,,,,CHEMBL617973,273,H,BAO_0000019,1,,,,,104714
3132,4,Oryctolagus cuniculus,Evaluated for the antagonistic activity against 5-hydroxytryptamine 3 receptor in isolated rabbit vagus nerve (RVN),F,9986.0,,,,CHEMBL617974,273,H,BAO_0000019,1,,,,,104714
3133,4,Oryctolagus cuniculus,Evaluated for the antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor in isolated guinea pig ileum (GPI),F,9986.0,Ileum,,,CHEMBL617975,273,H,BAO_0000221,1,2116.0,,,,104714
3134,4,Oryctolagus cuniculus,Evaluated for the antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor in isolated perfused rabbit heart (RH),F,9986.0,,,,CHEMBL617976,273,H,BAO_0000019,1,,,,,104714
3135,4,Oryctolagus cuniculus,Antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor in isolated rabbit vagus nerve (RVN),F,9986.0,,,,CHEMBL617977,273,H,BAO_0000019,1,,,,,104714
3136,4,Oryctolagus cuniculus,Evaluated for the antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor in isolated perfused rabbit heart (RH),F,9986.0,,,,CHEMBL617978,273,H,BAO_0000019,1,,,,,104714
3137,4,Oryctolagus cuniculus,Evaluated for the antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor in isolated rabbit vagus nerve (RVN),F,9986.0,,,,CHEMBL617979,273,H,BAO_0000019,1,,,,,104714
3138,4,Oryctolagus cuniculus,Binding affinity against 5-hydroxytryptamine 3 receptor in CHO cells using [3H]5-HT as radioligand,B,9986.0,,,,CHEMBL617980,13047,H,BAO_0000219,1,,,,CHO,104714
3139,7,Rattus norvegicus,In vitro displacement of [3H]-LY 278584 from rat cerebral cortex 5-hydroxytryptamine 3 receptor,B,10116.0,,,,CHEMBL617981,1650,D,BAO_0000019,1,,,,,104698
3140,8,,Affinity at 5-hydroxytryptamine 3 receptor from rat frontal cortex using [3H]granisetron as radioligand (For granisetron = Ki(nM)=0.3+/-0.01),B,,,,,CHEMBL617982,16288,H,BAO_0000019,1,,,,,12020
3141,8,,Affinity at 5-hydroxytryptamine 3 receptor (For granisetron = Ki (nM)=0.3+/-0.01),B,,,,,CHEMBL617983,16288,H,BAO_0000357,1,,,,,12020
3142,7,Rattus norvegicus,In vitro displacement of [3H]ICS-205-930 from 5-hydroxytryptamine 3 receptor in cultured NG-108-15 rat glioma cells,B,10116.0,,,,CHEMBL617984,10254,D,BAO_0000019,1,,,,,104698
3143,6,,"Binding affinity for 5-hydroxytryptamine 3 receptor in rat cerebral cortex, determined by displacement of [3H]GR-65630",B,,,,,CHEMBL617985,14532,H,BAO_0000019,1,,,,,104698
3144,6,,"5-Hydroxy tryptamine 3 receptor showing agonist activity (in vivo) in Von Bezold-Jarisch Reflex in rats at 120 (ug/kg), evaluated as change in heart rate",F,,Heart,,,CHEMBL617986,13392,H,BAO_0000218,1,948.0,In vivo,,,104698
3145,6,,"Agonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch Reflex in rats at 100 (ug/kg), evaluated as change in heart rate",F,,Heart,,,CHEMBL617987,13392,H,BAO_0000019,1,948.0,,,,104698
3146,6,,"Agonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch Reflex in rats at 120 (ug/kg), evaluated as change in heart rate",F,,Heart,,,CHEMBL617988,13392,H,BAO_0000019,1,948.0,,,,104698
3147,6,,"Agonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch Reflex in rats at 60 (ug/kg), evaluated as change in heart rate",F,,Heart,,,CHEMBL617792,13392,H,BAO_0000019,1,948.0,,,,104698
3148,6,,"Agonistic activity of compound towards 5-hydroxytryptamine 3 receptorr in Von Bezold-Jarisch Reflex in rats at 100 (ug/kg), evaluated as change in heart rate",F,,Heart,,,CHEMBL617793,13392,H,BAO_0000019,1,948.0,,,,104698
3149,6,,"Antagonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch Reflex in rats at 100(ug/kg), evaluated as percent inhibition of bradycardia",F,,,,,CHEMBL617794,13392,H,BAO_0000019,1,,,,,104698
3150,6,,"Antagonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch Reflex in rats at 60 (ug/kg), evaluated as percent inhibition of bradycardia",F,,,,,CHEMBL617795,13392,H,BAO_0000019,1,,,,,104698
3151,6,,"Antagonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch reflex in rats at 60 (ug/kg), evaluated as percent inhibition of bradycardia",F,,,,,CHEMBL617796,13392,H,BAO_0000019,1,,,,,104698
3152,6,,"Antagonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch reflex in rats at 60(ug/kg), evaluated as percent inhibition of bradycardia",F,,,,,CHEMBL617797,13392,H,BAO_0000019,1,,,,,104698
3153,7,Rattus norvegicus,Antagonism of 5-HT-induced Von Bezold-Jarisch reflex in rat after intravenous administration of 30 ug/kg of HT (5-hydroxytryptamine 3 receptor antagonism),F,10116.0,,,,CHEMBL617798,1089,D,BAO_0000218,1,,In vivo,,,104698
3154,6,,Ability to antagonise the 5-HT- induced Von Bezold-Jarisch reflex in the rat after intravenous administration of 30 ug/kg of HT (5-hydroxytryptamine 3 receptor),F,,,,,CHEMBL617799,1089,H,BAO_0000218,1,,In vivo,,,104698
3155,7,Rattus norvegicus,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 1000 ug/kg dose in urethane-anesthetized rats,F,10116.0,,,,CHEMBL617800,11454,D,BAO_0000218,1,,In vivo,,,104698
3156,7,Rattus norvegicus,Inhibition of 5-HT-induced bradycardia by 5-hydroxytryptamine 3+,F,10116.0,,,,CHEMBL617801,11454,D,BAO_0000019,1,,,,,104698
3157,7,Rattus norvegicus,In vivo inhibitory concentration after 5 minutes against 5-hydroxytryptamine 3 receptor induced bradycardia [bezold-jarisch (B-J) reflex test] in rat by intravenous administration,F,10116.0,,,,CHEMBL617802,12205,D,BAO_0000218,1,,In vivo,,,104698
3158,7,Rattus norvegicus,Inhibition of 5-HT (1 ug/mL) induced depolarization in rat vagus nerve (5-hydroxytryptamine 3 receptor antagonism),F,10116.0,,,,CHEMBL617803,1089,D,BAO_0000019,1,,,,,104698
3159,6,,Binding affinity towards 5-HT3 receptor in rat was evaluated,B,,,,,CHEMBL617804,5094,H,BAO_0000019,1,,,,,104698
3160,7,Rattus norvegicus,Inhibition of [3H]GR-65630 binding to rat cortical membrane 5-hydroxytryptamine 3 receptor,B,10116.0,,,,CHEMBL617805,2622,D,BAO_0000019,1,,,,,104698
3161,6,,Binding affinity was evaluated in vitro by displacement of [3H]zacopride radioligand from 5-hydroxytryptamine 3 receptor,B,,,,,CHEMBL617806,245,H,BAO_0000223,1,,,,,104698
3162,6,,Compound was evaluated for its binding affinity for 5-hydroxytryptamine 3 receptor by measuring displacement [3H]GR-65630 in rat cerebral cortex.,B,,,,,CHEMBL617807,14788,H,BAO_0000019,1,,,,,104698
3163,6,,Compound was evaluated for its binding affinity for 5-hydroxytryptamine 3 receptor by measuring displacement of [3H]granisetron from rat cerebral cortex,B,,,,,CHEMBL617808,14788,H,BAO_0000019,1,,,,,104698
3164,6,,Binding affinity against 5-hydroxytryptamine 3 receptor in rat cortical membrane using [3H]GR-65630 as radioligand,B,,,,,CHEMBL617809,3020,H,BAO_0000249,1,,,,,104698
3165,6,,Compound was tested for its ability to displace [3H]-Q-ICS 205-930 from 5-hydroxytryptamine 3 receptor in rat cortex homogenates,B,,,,,CHEMBL617810,1742,H,BAO_0000019,1,,,,,104698
3166,6,,Concentration of compound required to inhibit the binding of radioligand [3H]GR-65630 to 5-hydroxytryptamine 3 receptor in rat brain cortical membrane,B,,Brain,,,CHEMBL617811,17394,H,BAO_0000249,1,955.0,,,,104698
3167,6,,Concentration required to inhibit the binding of radioligand [3H]GR-65630 to serotonin 5-hydroxytryptamine-3 receptor (5-HT 3 receptor)in rat brain cortical membrane,B,,Brain,,,CHEMBL617812,17394,H,BAO_0000221,1,955.0,,,,104698
3168,6,,Concentration of compound required to inhibit the binding of radioligand [3H]GR-65630 to serotonin 5-hydroxytryptamine 3 receptor in rat cortical membrane,B,,,,,CHEMBL617813,17394,H,BAO_0000249,1,,,,,104698
3169,6,,In vitro inhibitory concentration against radioligand [3H]BRL-43694 binding to 5-hydroxytryptamine 3 receptor in rat cortical membrane,B,,,,,CHEMBL617814,14286,H,BAO_0000249,1,,,,,104698
3170,6,,Inhibition of [3H]BRL-43694 binding to 5-hydroxytryptamine 3 receptor of rat cortical homogenate.,B,,,,,CHEMBL617698,14178,H,BAO_0000019,1,,,,,104698
3171,7,Rattus norvegicus,Inhibition of [3H]BRL-43694 binding to 5-hydroxytryptamine 3 receptor of rat cortical homogenate; Not active at 10000 nm,B,10116.0,,,,CHEMBL617699,14178,D,BAO_0000019,1,,,,,104698
3172,7,Rattus norvegicus,Inhibition of [3H]BRL-43694 binding to 5-hydroxytryptamine 3 receptor of rat cortical homogenate; not active at 10000 nM,B,10116.0,,,,CHEMBL617700,14178,D,BAO_0000019,1,,,,,104698
3173,7,Rattus norvegicus,Inhibition of radiolabeled [3H]-Zacopride ligand binding to 5-hydroxytryptamine 3 receptor,B,10116.0,,,,CHEMBL617701,14178,D,BAO_0000223,1,,,,,104698
3174,6,,Inhibitory concentration against 5-hydroxytryptamine 3 receptor in rat entorhinal cortex using [3H]-LY 278584 as radioligand,B,,,,,CHEMBL617702,15034,H,BAO_0000019,1,,,,,104698
3175,6,,"Tested for inhibition of binding of [3H]GR-65630 to rat cortical membranes, expressed as IC50",B,,,Membranes,,CHEMBL617703,1089,H,BAO_0000249,1,,,,,104698
3176,7,Rattus norvegicus,Inhibition of [3H]GR-65630 binding to rat cortical membrane serotonin 3 receptor,B,10116.0,,,,CHEMBL617704,1089,D,BAO_0000019,1,,,,,104698
3177,6,,The binding affinity at 5-hydroxytryptamine 3 receptor was determined using [3H]LY-278584; Not tested,B,,,,,CHEMBL617705,16532,H,BAO_0000223,1,,,,,104698
3178,7,Rattus norvegicus,Inhibition of [3H]BRL-43694 binding to rat 5-hydroxytryptamine 3 receptor,B,10116.0,,,,CHEMBL617706,12801,D,BAO_0000223,1,,,,,104698
3179,6,,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor from NG108-15 cells (using [3H]zacopride as radioligand),B,,,,,CHEMBL617707,15194,H,BAO_0000219,1,,,,NG108-15,104698
3180,6,,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor from NG108-15 cells using [3H]zacopride as radioligand,B,,,,,CHEMBL617708,15194,H,BAO_0000219,1,,,,NG108-15,104698
3181,6,,Binding affinity against 5-hydroxytryptamine 3 (5-HT3) receptor from rat cortical homogenate using [3H]zacopride as radioligand,B,,,,,CHEMBL617709,15194,H,BAO_0000019,1,,,,,104698
3182,6,,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor from rat cortical homogenate using [3H]zacopride as radioligand; NA= Not active,B,,,,,CHEMBL617710,15194,H,BAO_0000019,1,,,,,104698
3183,6,,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor from rat cortical homogenate using [3H]zacopride as radioligand; NA=Not active,B,,,,,CHEMBL882925,15194,H,BAO_0000019,1,,,,,104698
3184,6,,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor from rat cortical homogenate using [3H]zacopride as radioligand; not active,B,,,,,CHEMBL617711,15194,H,BAO_0000019,1,,,,,104698
3185,6,,Antagonist potency to 5-hydroxytryptamine 3 receptor was assayed by antagonism of the 5-HT-evoked reflex bradycardia [Bezold-Jarisch(BJ) reflex] in rats,F,,,,,CHEMBL617712,10610,H,BAO_0000019,1,,,,,104698
3186,7,Rattus norvegicus,Antagonistic activity against 5-hydroxytryptamine 3 receptor as inhibition of 5-HT-induced bradycardia (von Bezold-jarisch reflex) in anesthetized rat,F,10116.0,,,,CHEMBL617713,10355,D,BAO_0000019,1,,,,,104698
3187,6,,"Compound was tested as a 5-hydroxytryptamine 3 receptor antagonist in the rat by assessment of the inhibition of the Bezold-Jarisch effect, when administered intravenously",F,,,,,CHEMBL617714,691,H,BAO_0000019,1,,,,,104698
3188,6,,In vivo 5-hydroxytryptamine 3 receptor (5-HT 3 receptor) antagonistic activity expressed as ability to inhibit Bezold-Jarich reflex evoked by 5-HT in rats,F,,,,,CHEMBL617715,10611,H,BAO_0000218,1,,,,,104698
3189,6,,Inhibition dose for 50 percent antagonism for 5-hydroxytryptamine 3 receptor in vivo in rats,F,,,,,CHEMBL617716,12801,H,BAO_0000218,1,,In vivo,,,104698
3190,6,,Inhibition of 5-HT evoked reflex bradycardia in rat.,F,,,,,CHEMBL617717,10609,H,BAO_0000218,1,,,,,104698
3191,6,,5-HT3 receptor antagonistic activity was measured by the inhibition of 5-HT-induced bradycardia after iv administration of 1000 ug/kg dose in urethane-anesthetized rats,F,,,,,CHEMBL617718,11454,H,BAO_0000218,1,,In vivo,,,104698
3192,6,,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after iv administration of 1 ug/kg dose in urethane-anesthetized rats,F,,,,,CHEMBL617719,11454,H,BAO_0000218,1,,In vivo,,,104698
3193,6,,5-hydroxytryptamine 3 receptor antagonistic activity measured by inhibition of 5-HT-induced bradycardia (iv administration 10 ug/kg dose in urethane-anesthetized rats),F,,,,,CHEMBL617720,11454,H,BAO_0000218,1,,In vivo,,,104698
3194,7,Rattus norvegicus,5-hydroxytryptamine 3 receptor antagonistic activity as inhibition of 5-HT-induced bradycardia after iv administration of 100 ug/kg dose in urethane-anesthetized rats,F,10116.0,,,,CHEMBL617721,11454,D,BAO_0000218,1,,In vivo,,,104698
3195,6,,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after iv administration of 1000 ug/kg dose in urethane-anesthetized rats,F,,,,,CHEMBL617722,11454,H,BAO_0000218,1,,In vivo,,,104698
3196,6,,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after iv administration of 1000 ug/kgetized rats,F,,,,,CHEMBL617723,11454,H,BAO_0000218,1,,In vivo,,,104698
3197,6,,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after iv administration of 3 ug/kg dose in urethane-anesthetized rats,F,,,,,CHEMBL617724,11454,H,BAO_0000218,1,,In vivo,,,104698
3198,6,,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after po administration of 10 ug/kg dose in urethane-anesthetized rats,F,,,,,CHEMBL617725,11454,H,BAO_0000218,1,,In vivo,,,104698
3199,6,,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after po administration of 100 ug/kg dose in urethane-anesthetized rats,F,,,,,CHEMBL617726,11454,H,BAO_0000218,1,,In vivo,,,104698
3200,6,,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after po administration of 1000 ug/kg dose in urethane-anesthetized rats,F,,,,,CHEMBL617727,11454,H,BAO_0000218,1,,In vivo,,,104698
3201,6,,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after po administration of 30 ug/kg dose in urethane-anesthetized rats,F,,,,,CHEMBL617728,11454,H,BAO_0000218,1,,In vivo,,,104698
3202,6,,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after po administration of 300 ug/kg dose in urethane-anesthetized rats,F,,,,,CHEMBL617729,11454,H,BAO_0000218,1,,In vivo,,,104698
3203,6,,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after po administration of 3ug/kg dose in urethane-anesthetized rats,F,,,,,CHEMBL617730,11454,H,BAO_0000218,1,,In vivo,,,104698
3204,6,,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5-HT-induced bradycardia after iv administration of 1000 ug/kg dose in urethane-anesthetized rats,F,,,,,CHEMBL617731,11454,H,BAO_0000218,1,,In vivo,,,104698
3205,6,,Compound was tested for the inhibition of 5-HT-induced bradycardia after intravenous administration of 0.3 ug/kg dose in urethane-anesthetized rats,F,,,,,CHEMBL617732,11454,H,BAO_0000218,1,,In vivo,,,104698
3206,6,,Compound was tested for the inhibition of 5-HT-induced bradycardia after intravenous administration of 1 ug/kg dose in urethane-anesthetized rats,F,,,,,CHEMBL617733,11454,H,BAO_0000218,1,,In vivo,,,104698
3207,6,,Compound was tested for the inhibition of 5-HT-induced bradycardia after intravenous administration of 30 ug/kg dose in urethane-anesthetized rats,F,,,,,CHEMBL617734,11454,H,BAO_0000218,1,,In vivo,,,104698
3208,6,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg dose in urethane-anesthetized rats at 0.05 hour,F,,,,,CHEMBL872874,11454,H,BAO_0000218,1,,In vivo,,,104698
3209,6,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg dose in urethane-anesthetized rats at 1 hour,F,,,,,CHEMBL617735,11454,H,BAO_0000218,1,,In vivo,,,104698
3210,6,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg dose in urethane-anesthetized rats at 16 hour,F,,,,,CHEMBL617736,11454,H,BAO_0000218,1,,In vivo,,,104698
3211,6,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg dose in urethane-anesthetized rats at 3 hour,F,,,,,CHEMBL617737,11454,H,BAO_0000218,1,,In vivo,,,104698
3212,6,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg dose in urethane-anesthetized rats at 6 hour,F,,,,,CHEMBL617738,11454,H,BAO_0000218,1,,In vivo,,,104698
3213,6,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 10 ug/kg dose in urethane-anesthetized rats,F,,,,,CHEMBL617739,11454,H,BAO_0000218,1,,In vivo,,,104698
3214,6,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 100 ug/kg dose in urethane-anesthetized rats,F,,,,,CHEMBL617740,11454,H,BAO_0000218,1,,In vivo,,,104698
3215,6,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 1000 ug/kg dose in urethane-anesthetized rats,F,,,,,CHEMBL617741,11454,H,BAO_0000218,1,,In vivo,,,104698
3216,6,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 10 ug/kg dose in urethane-anesthetized rats,F,,,,,CHEMBL617742,11454,H,BAO_0000218,1,,In vivo,,,104698
3217,6,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 3 ug/kg dose in urethane-anesthetized rats,F,,,,,CHEMBL617743,11454,H,BAO_0000218,1,,In vivo,,,104698
3218,6,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 30 ug/kg dose in urethane-anesthetized rats,F,,,,,CHEMBL617744,11454,H,BAO_0000218,1,,In vivo,,,104698
3219,6,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 300 ug/kg dose in urethane-anesthetized rats,F,,,,,CHEMBL617745,11454,H,BAO_0000218,1,,In vivo,,,104698
3220,6,,"In vivo 5-hydroxytryptamine 3 receptor antagonist activity by antagonism of the von Bezold-Jarisch (B-J) reflex in anesthetized rats, (i.v.)",F,,,,,CHEMBL617746,670,H,BAO_0000218,1,,,,,104698
3221,6,,"In vivo 5-hydroxytryptamine 3 receptor antagonist activity by antagonism of the von Bezold-Jarisch (B-J) reflex in anesthetized rats, (i.v.); Not tested",F,,,,,CHEMBL617747,670,H,BAO_0000218,1,,,,,104698
3222,6,,Serotonin receptor antagonist activity was measured as ability to block the serotonin-induced Bezold-Jarisch reflex in rats after iv administration of 10 ug/Kg,F,,,,,CHEMBL617748,10321,H,BAO_0000218,1,,In vivo,,,104698
3223,6,,Serotonin receptor antagonist activity was measured as ability to block the serotonin-induced Bezold-Jarisch reflex in rats after iv administration of 100 ug/Kg,F,,,,,CHEMBL618909,10321,H,BAO_0000218,1,,In vivo,,,104698
3224,6,,Serotonin receptor antagonist activity was measured as ability to block the serotonin-induced Bezold-Jarisch reflex in rats after iv administration of 2 ug/Kg,F,,,,,CHEMBL618910,10321,H,BAO_0000218,1,,In vivo,,,104698
3225,6,,Serotonin receptor antagonist activity was measured as ability to block the serotonin-induced Bezold-Jarisch reflex in rats after iv administration of 20 ug/Kg,F,,,,,CHEMBL618911,10321,H,BAO_0000218,1,,In vivo,,,104698
3226,6,,Serotonin receptor antagonist activity was measured as ability to block the serotonin-induced Bezold-Jarisch reflex in rats after iv administration of 5 ug/Kg,F,,,,,CHEMBL618912,10321,H,BAO_0000218,1,,In vivo,,,104698
3227,6,,Tested for inhibition of Bezold-Jarisch (B-J) reflex mediated by 5-hydroxytryptamine 3 receptor in rats after intravenous administration (2.0 ug/kg),F,,,,,CHEMBL618913,10322,H,BAO_0000218,1,,In vivo,,,104698
3228,6,,Intrinsic efficacy against 5-hydroxytryptamine 3 receptor; A means pure agonist,F,,,,,CHEMBL618914,15412,H,BAO_0000019,1,,,,,104698
3229,6,,Intrinsic efficacy against 5-hydroxytryptamine 3 receptor; A means pure agonist,F,,,,,CHEMBL618915,15412,H,BAO_0000019,1,,,,,104698
3230,7,Rattus norvegicus,Intrinsic efficacy for rat 5-hydroxytryptamine 3 receptor,B,10116.0,,,,CHEMBL618916,15412,D,BAO_0000223,1,,,,,104698
3231,6,,Intrinsic efficacy against 5-hydroxytryptamine 3 receptor; PA means partial agonist,F,,,,,CHEMBL618917,15412,H,BAO_0000019,1,,,,,104698
3232,7,,Inhibition of [3H]granisetron binding to 5-hydroxytryptamine 3 receptor (5-HT 3 receptor) of rat cortex and hippocampus tissue,B,,Hippocampus,,,CHEMBL618918,15412,D,BAO_0000221,1,10000000.0,,,,104698
3233,7,Rattus norvegicus,Inhibition of [3H]granisetron binding to 5-hydroxytryptamine 3 receptor of rat cortical membrane,B,10116.0,,,,CHEMBL618919,15412,D,BAO_0000019,1,,,,,104698
3234,7,Rattus norvegicus,Inhibition of [3H]GR-65630 binding to rat cortical membrane serotonin 5-hydroxytryptamine 3 receptor,B,10116.0,,,,CHEMBL618920,17394,D,BAO_0000019,1,,,,,104698
3235,6,,Affinity was evaluated as inhibition constant for serotonin 5-hydroxytryptamine 3 receptor,B,,,,,CHEMBL618921,12457,H,BAO_0000223,1,,,,,104698
3236,6,,Affinity was evaluated by inhibition of [3H]GR-65630 binding to NG108-15 cell transfected with cloned rat 5-hydroxytryptamine 3 receptor,B,,,,,CHEMBL618922,12457,H,BAO_0000019,1,,,,,104698
3237,6,,Binding affinity against radioligand [3H]quipazine labeled 5-hydroxytryptamine 3 receptor sites in neuroblastoma-glioma (NG108-15) cells.,B,,,,,CHEMBL618923,12205,H,BAO_0000019,1,,,,,104698
3238,6,,Binding affinity for 5-hydroxytryptamine 3 receptor was determined by measuring displacement of [3H]GR-65630 from rat brain cortices,B,,,,,CHEMBL618924,14532,H,BAO_0000019,1,,,,,104698
3239,6,,Binding affinity to 5-hydroxytryptamine 3 receptor in rat entorhinal cortex using [3H]-BRL 43694 as radioligand,B,,,,,CHEMBL618925,1122,H,BAO_0000019,1,,,,,104698
3240,6,,Binding affinity towards 5-HT3 receptor in rat was evaluated,B,,,,,CHEMBL618926,5094,H,BAO_0000019,1,,,,,104698
3241,9,Cavia porcellus,5-hydroxytryptamine 4 receptor agonist activity as increased response to electrical stimulation in guinea pig ileum,F,10141.0,Ileum,,,CHEMBL618927,809,D,BAO_0000221,1,2116.0,,,,20033
3242,9,Cavia porcellus,5-hydroxytryptamine 4 receptor agonist activity expressed as the concentration which gave a 50% increase in the response to the electrical stimulation in male guinea pig ileum; Not tested,F,10141.0,Ileum,,,CHEMBL618928,809,D,BAO_0000221,1,2116.0,,,,20033
3243,9,Cavia porcellus,"5-hydroxytryptamine 4 receptor agonist activity, concentration which gave 50% increase in the response to electrically-stimulated myenteric plexus and longitudinal muscle of the guinea pig ileum",F,10141.0,Ileum,,,CHEMBL618929,14290,D,BAO_0000221,1,2116.0,,,,20033
3244,9,Cavia porcellus,"5-hydroxytryptamine 4 receptor agonist activity, concentration which gave 50% increase in the response to electrically-stimulated myenteric plexus and longitudinal muscle of the guinea pig ileum; Inactive up to 10E-5 M",F,10141.0,Ileum,,,CHEMBL618930,14290,D,BAO_0000221,1,2116.0,,,,20033
3245,9,Cavia porcellus,"5-hydroxytryptamine 4 receptor agonist activity, concentration which gave 50% increase in the response to electrically-stimulated myenteric plexus and longitudinal muscle of the guinea pig ileum; Not tested",F,10141.0,Ileum,,,CHEMBL618931,14290,D,BAO_0000221,1,2116.0,,,,20033
3246,9,Cavia porcellus,"5-hydroxytryptamine 4 receptor agonist activity, concentration which gave 50% increase in the response to electrically-stimulated myenteric plexus and longitudinal muscle of the guinea pig ileum; Not tested",F,10141.0,Ileum,,,CHEMBL619594,14290,D,BAO_0000221,1,2116.0,,,,20033
3247,9,Cavia porcellus,"5-hydroxytryptamine 4 receptor antagonist activity, concentration which gave 50% reduction of the 5-HT-induced contractions in the guinea pig ileum; Not capable of evaluation",F,10141.0,Ileum,,,CHEMBL619595,14290,D,BAO_0000221,1,2116.0,,,,20033
3248,9,Cavia porcellus,concentration which gave a 50% increase in the response to electrical stimulation against 5-hydroxytryptamine 4 receptor in the guinea pig ileum.,F,10141.0,Ileum,,,CHEMBL619596,13961,D,BAO_0000221,1,2116.0,,,,20033
3249,9,Cavia porcellus,concentration which gave a 50% increase in the response to electrical stimulation against 5-hydroxytryptamine 4 receptor in the guinea pig ileum. Activity expressed as percent of the maximum 5-HT response given in brackets.,F,10141.0,Ileum,,,CHEMBL619755,13961,D,BAO_0000221,1,2116.0,,,,20033
3250,9,Cavia porcellus,5-hydroxytryptamine 4 receptor antagonist activity expressed as the concentration which produced a 50% reduction of 5-HT induced contraction in guinea pig ileum,F,10141.0,Ileum,,,CHEMBL619756,809,D,BAO_0000221,1,2116.0,,,,20033
3251,9,Cavia porcellus,5-hydroxytryptamine 4 receptor antagonist activity expressed as the concentration which produced a 50% reduction of 5-HT induced contraction in guinea pig ileum; Not evaluable,F,10141.0,Ileum,,,CHEMBL619757,809,D,BAO_0000221,1,2116.0,,,,20033
3252,9,Cavia porcellus,5-hydroxytryptamine 4 receptor antagonist activity expressed as the concentration which produced a 50% reduction of 5-HT induced contraction in guinea pig ileum; Not tested,F,10141.0,Ileum,,,CHEMBL619758,809,D,BAO_0000221,1,2116.0,,,,20033
3253,9,Cavia porcellus,"5-hydroxytryptamine 4 receptor antagonist activity, concentration which gave 50% reduction of the 5-HT-induced contractions in the guinea pig ileum",F,10141.0,Ileum,,,CHEMBL619759,14290,D,BAO_0000221,1,2116.0,,,,20033
3254,9,Cavia porcellus,"5-hydroxytryptamine 4 receptor antagonist activity, concentration which gave 50% reduction of the 5-HT-induced contractions in the guinea pig ileum; Inactive up to 10-5 M",F,10141.0,Ileum,,,CHEMBL619760,14290,D,BAO_0000221,1,2116.0,,,,20033
3255,9,Cavia porcellus,"5-hydroxytryptamine 4 receptor antagonist activity, concentration which gave 50% reduction of the 5-HT-induced contractions in the guinea pig ileum; Inactive up to 10E-5 M",F,10141.0,Ileum,,,CHEMBL619761,14290,D,BAO_0000221,1,2116.0,,,,20033
3256,9,Cavia porcellus,5-hydroxytryptamine 4 receptor antagonist activity as inhibition of 5-HT-induced contractions in guinea pig ileum; Not capable of evaluation.,F,10141.0,Ileum,,,CHEMBL619762,14290,D,BAO_0000221,1,2116.0,,,,20033
3257,9,Cavia porcellus,"5-hydroxytryptamine 4 receptor antagonist activity, concentration which gave 50% reduction of the 5-HT-induced contractions in the guinea pig ileum; Not tested",F,10141.0,Ileum,,,CHEMBL619763,14290,D,BAO_0000221,1,2116.0,,,,20033
3258,9,Cavia porcellus,"5-hydroxytryptamine 4 receptor antagonist activity, concentration which gave 50% reduction of the 5-HT-induced contractions in the guinea pig ileum; Not tested",F,10141.0,Ileum,,,CHEMBL617868,14290,D,BAO_0000221,1,2116.0,,,,20033
3259,9,Cavia porcellus,Displacement of [3H]GR-113808 from 5-hydroxytryptamine 4 receptor in guinea pig striatum,B,10141.0,,,,CHEMBL617869,15034,D,BAO_0000357,1,,,,,20033
3260,9,Cavia porcellus,Binding affinity towards 5-HT4 receptor in striatum membranes of guinea-pig brain was evaluated,B,10141.0,Striatum,,,CHEMBL882926,5094,D,BAO_0000249,1,2435.0,,,,20033
3261,9,Cavia porcellus,Binding affinity towards 5-hydroxytryptamine 4 receptor in striatum membranes of guinea-pig brain was evaluated,B,10141.0,Striatum,,,CHEMBL617870,5094,D,BAO_0000249,1,2435.0,,,,20033
3262,9,Cavia porcellus,Inhibitory activity against 5-hydroxytryptamine 4 receptor of guinea pig striatum using [3H]GR-113808 as radioligand,B,10141.0,Striatum,,,CHEMBL617871,5399,D,BAO_0000357,1,2435.0,,,,20033
3263,9,Cavia porcellus,Concentration of compound required to inhibit the binding of radioligand [3H]GR-113808 to 5-hydroxytryptamine 4 receptor in guinea pig striatum,B,10141.0,Striatum,,,CHEMBL617872,17394,D,BAO_0000357,1,2435.0,,,,20033
3264,9,Cavia porcellus,Concentration of compound required to inhibit the binding of radioligand [3H]GR-113808 to 5-hydroxytryptamine 4 receptor in guinea-pig striatum,B,10141.0,Striatum,,,CHEMBL617873,17394,D,BAO_0000357,1,2435.0,,,,20033
3265,9,Cavia porcellus,Concentration of compound required to inhibit the binding of radioligand [3H]GR-113808 to serotonin 5-hydroxytryptamine 4 receptor in guinea-pig striatum,B,10141.0,Striatum,,,CHEMBL617874,17394,D,BAO_0000357,1,2435.0,,,,20033
3266,9,Cavia porcellus,The antagonist activity was calculated as the concentration which produced a 50% reduction against 5-hydroxytryptamine 4 receptor in guinea pig ileum.,F,10141.0,Ileum,,,CHEMBL619067,13961,D,BAO_0000221,1,2116.0,,,,20033
3267,9,Cavia porcellus,The antagonist activity was calculated as the concentration which produced a 50% reduction against 5-hydroxytryptamine 4 receptor in guinea pig ileum. 95% confidence limits are in brackets.,F,10141.0,Ileum,,,CHEMBL619068,13961,D,BAO_0000221,1,2116.0,,,,20033
3268,9,Cavia porcellus,The antagonist activity was calculated as the concentration which produced a 50% reduction against 5-hydroxytryptamine 4 receptor in guinea pig ileum;ne=not capable of evaluation.,F,10141.0,Ileum,,,CHEMBL619069,13961,D,BAO_0000221,1,2116.0,,,,20033
3269,9,Cavia porcellus,Ability to displace [3H]GR-113808 from 5-hydroxytryptamine 4 receptor at concentration of 10e-6 M in guinea pig,B,10141.0,,,,CHEMBL619070,16946,D,BAO_0000357,1,,,,,20033
3270,9,Cavia porcellus,Ability to displace [3H]GR-113808 from 5-hydroxytryptamine 4 receptor at concentration of 10e-8 M in guinea pig,B,10141.0,,,,CHEMBL619071,16946,D,BAO_0000357,1,,,,,20033
3271,9,Cavia porcellus,Agonistic activity against 5-hydroxytryptamine 4 receptor,F,10141.0,,,,CHEMBL619072,15034,D,BAO_0000019,1,,,,,20033
3272,9,Cavia porcellus,Agonistic activity against 5-hydroxytryptamine 4 receptor; not tested,F,10141.0,,,,CHEMBL619073,15034,D,BAO_0000019,1,,,,,20033
3273,9,Cavia porcellus,Compound was evaluated for the relative potency with respect to serotonin against 5-hydroxytryptamine 4 receptor,F,10141.0,,,,CHEMBL619074,12918,D,BAO_0000019,1,,,,,20033
3274,9,Cavia porcellus,Ability to displace [3H]GR-113808 from 5-hydroxytryptamine 4 receptor,B,10141.0,,,,CHEMBL619075,16946,D,BAO_0000357,1,,,,,20033
3275,9,Cavia porcellus,Inhibition of [3H]GR-113808 binding to guinea pig striatum 5-hydroxytryptamine 4 receptor,B,10141.0,Striatum,,,CHEMBL619076,17394,D,BAO_0000357,1,2435.0,,,,20033
3276,9,Cavia porcellus,Binding affinity against 5-hydroxytryptamine 4 receptor in guinea pig striatum using [3H]GR-113808 as radioligand,B,10141.0,Striatum,,,CHEMBL619077,15034,D,BAO_0000357,1,2435.0,,,,20033
3277,9,Cavia porcellus,Binding affinity towards 5-HT4 receptor in striatum membranes of guinea-pig brain was evaluated,B,10141.0,Striatum,,,CHEMBL619078,5094,D,BAO_0000249,1,2435.0,,,,20033
3278,9,Cavia porcellus,Binding affinity towards 5-hydroxytryptamine 4 receptor in striatum membranes of guinea-pig brain was evaluated,B,10141.0,Striatum,,,CHEMBL619079,5094,D,BAO_0000249,1,2435.0,,,,20033
3279,9,Cavia porcellus,Tested for affinity against 5-hydroxytryptamine 4 receptor in the myenteric plexus of the guinea pig ileum.,B,10141.0,Ileum,,,CHEMBL619080,17358,D,BAO_0000221,1,2116.0,,,,20033
3280,9,Cavia porcellus,Displacement of [3H]-GR113808 from 5-HT4 receptor of guinea pig striatum,B,10141.0,,,,CHEMBL619081,12953,D,BAO_0000357,1,,,,,20033
3281,9,Cavia porcellus,The compound was tested for their binding affinity towards 5-HT4 receptor from guinea pig striatum using [3H]GR-113808 as radioligand; Nonactive at 10 uM,B,10141.0,,,,CHEMBL619082,12953,D,BAO_0000357,1,,,,,20033
3282,9,Cavia porcellus,The compound was tested for their binding affinity towards 5-hydroxytryptamine 4 receptor from guinea pig striatum using [3H]GR-113808 as radioligand.,B,10141.0,,,,CHEMBL619083,12953,D,BAO_0000357,1,,,,,20033
3283,9,Cavia porcellus,The compound was tested for their binding affinity towards 5-hydroxytryptamine 4 receptor from guinea pig striatum using [3H]GR-113808 as radioligand; Nonactive at 10 uM,B,10141.0,,,,CHEMBL619084,12953,D,BAO_0000357,1,,,,,20033
3284,9,Cavia porcellus,Evaluated for the antagonistic activity against Serotonin 5-hydroxytryptamine 4 receptor in non-electrically stimulated guinea-pig ileum.,F,10141.0,Ileum,,,CHEMBL859397,273,D,BAO_0000221,1,2116.0,,,,20033
3285,9,Cavia porcellus,5-hydroxytryptamine 4 receptor agonist activity in the guinea pig ileum assay,F,10141.0,Ileum,,,CHEMBL619085,12918,D,BAO_0000221,1,2116.0,,,,20033
3286,9,Cavia porcellus,5-hydroxytryptamine 4 receptor agonistic activity was measured by twitch response enhancing activity in electrically stimulated guinea pig ileum preparation,F,10141.0,Ileum,,,CHEMBL619086,12919,D,BAO_0000221,1,2116.0,,,,20033
3287,9,Cavia porcellus,Agonistic activity against Serotonin 5-hydroxytryptamine 4 receptor in low frequency field stimulation of guinea-pig ileum (FSGPI).,F,10141.0,Ileum,,,CHEMBL619087,273,D,BAO_0000221,1,2116.0,,,,20033
3288,9,Cavia porcellus,Agonistic activity against Serotonin 5-hydroxytryptamine 4 receptor in non-electrically stimulated guinea-pig ileum.,F,10141.0,Ileum,,,CHEMBL619088,273,D,BAO_0000221,1,2116.0,,,,20033
3289,9,Cavia porcellus,Ability to antagonize 5-HT-evoked contractions mediated through 5-hydroxytryptamine 4 receptor activation in the guinea pig distal colon LMMP,B,10141.0,,,,CHEMBL619089,13181,D,BAO_0000357,1,,,,,20033
3290,8,Cavia porcellus,Binding affinity was determined against 5-hydroxytryptamine 3 receptor,B,10141.0,,,,CHEMBL619090,13181,H,BAO_0000357,1,,,,,168
3291,9,Cavia porcellus,Antagonistic activity against 5-hydroxytryptamine 4 receptor,F,10141.0,,,,CHEMBL619091,15034,D,BAO_0000019,1,,,,,20033
3292,9,Cavia porcellus,Ability to displace the radioligand [3H]GR-113808 from guinea pig striatum 5-hydroxytryptamine 4 receptor,B,10141.0,,,,CHEMBL619092,5033,D,BAO_0000357,1,,,,,20033
3293,9,Cavia porcellus,Binding affinity for 5-hydroxytryptamine 4 receptor by displacement of [3H]GR-113808 from guinea pig brain striatum.,B,10141.0,,,,CHEMBL619093,1980,D,BAO_0000019,1,,,,,20033
3294,8,Cavia porcellus,Binding affinity was determined against 5-hydroxytryptamine 2C receptor using cloned rat receptors expressed in 293 cells radiolabeled with [3H]mesulergine,B,10141.0,,,,CHEMBL619094,13181,H,BAO_0000219,1,,,,HEK293,168
3295,9,Cavia porcellus,In vitro by displacement of [3H]GR-113808 from 5-hydroxytryptamine 4 receptor on guinea pig striatal membrane,B,10141.0,,,,CHEMBL619095,14287,D,BAO_0000019,1,,,,,20033
3296,9,Cavia porcellus,Compound was evaluated for binding affinity against 5-hydroxytryptamine 4 receptor using radioligand binding assay using [3H]GR as radioligand,B,10141.0,,,,CHEMBL857988,1317,D,BAO_0000357,1,,,,,20033
3297,9,Cavia porcellus,Compound was evaluated for its ability to displace [3H]GR-113808 binding from 5-hydroxytryptamine 4 receptor in guinea pig striatum.,B,10141.0,,,,CHEMBL619096,15316,D,BAO_0000357,1,,,,,20033
3298,9,Cavia porcellus,In vitro binding affinity at 5-hydroxytryptamine 4 receptor in guinea pig striatum using 3[H]GR-113808 as the radioligand,B,10141.0,Striatum,,,CHEMBL619097,16429,D,BAO_0000357,1,2435.0,,,,20033
3299,9,Cavia porcellus,The compound was tested for its binding affinity towards 5-hydroxytryptamine 4 receptor in guinea pig hippocampus using [125I]SB-207710.,B,10141.0,Hippocampus,,,CHEMBL619098,14818,D,BAO_0000221,1,10000000.0,,,,20033
3300,9,Cavia porcellus,The compound was tested for the binding affinity against 5-hydroxytryptamine 4 receptor using [3H]GR-113808 as radioligand,B,10141.0,,,,CHEMBL619751,15194,D,BAO_0000357,1,,,,,20033
3301,9,Cavia porcellus,The compound was tested for the binding affinity against 5-hydroxytryptamine 4 receptor using [3H]GR-113808 as radioligand.,B,10141.0,,,,CHEMBL619752,15194,D,BAO_0000357,1,,,,,20033
3302,9,Cavia porcellus,The antagonist activity was calculated as the concentration which produced a 50% reduction against 5-hydroxytryptamine 4 receptor in guinea pig ileum;ne=not capable of evaluation.,F,10141.0,Ileum,,,CHEMBL875096,13961,D,BAO_0000221,1,2116.0,,,,20033
3303,8,,Binding affinity towards 5-HT2C receptor by the displacement of [3H]mesulergine] in human recombinant receptors in mammalian cell,B,,,,,CHEMBL619004,5486,H,BAO_0000357,1,,,,,108
3304,8,,Binding affinity towards human 5-hydroxytryptamine 4 receptor using [3H]5-HT as radioligand,B,,,,,CHEMBL619005,16209,H,BAO_0000357,1,,,,,168
3305,8,,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 4 receptor,B,,,,,CHEMBL619006,17085,H,BAO_0000019,1,,,,,168
3306,8,,Compound was evaluated for the binding affinity against human cloned 5-hydroxytryptamine 4 receptor in HeLa cells using [3H]-LSD as the radioligand,B,,,,,CHEMBL619007,4199,H,BAO_0000219,1,,,,HeLa,168
3307,8,,Compound was tested for its binding affinity against 5-hydroxytryptamine 4 receptor,B,,,,,CHEMBL619008,15146,H,BAO_0000357,1,,,,,168
3308,8,,Compound was tested for its binding affinity for 5-hydroxytryptamine 4 receptor,B,,,,,CHEMBL619009,5213,H,BAO_0000357,1,,,,,168
3309,8,,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 4 receptor in HeLa cells, using [3H]LSD as radioligand",B,,,,,CHEMBL619010,4829,H,BAO_0000219,1,,,,HeLa,168
3310,8,,Tested for ability to stimulate production of cAMP mediated by 5-hydroxytryptamine 4 receptor in mouse Coliculi neurons,B,,,,,CHEMBL619011,17358,H,BAO_0000357,1,,,,,10622
3311,8,,Tested for ability to stimulate production of cAMP mediated by 5-hydroxytryptamine 4 receptor in mouse Coliculi neurons; IA means inactive,B,,,,,CHEMBL619012,17358,H,BAO_0000357,1,,,,,10622
3312,8,,Ability to displace [3H]GR-113808 from mouse 5-hydroxytryptamine 4 receptor in COS7 cells,B,,,,,CHEMBL619013,16946,H,BAO_0000219,1,,,,,10622
3313,8,,Tested for ability to stimulate 5-hydroxytryptamine 4 receptors in mouse Coliculi neurons,B,,,,,CHEMBL619014,17358,H,BAO_0000357,1,,,,,10622
3314,8,,Evaluated for the 5-hydroxytryptamine 4 receptor antagonistic activity in piglet atrium model,F,,Cardiac atrium,,,CHEMBL857503,268,H,BAO_0000019,1,2081.0,,,,11249
3315,8,,Evaluated for the 5-hydroxytryptamine 4 receptor antagonistic activity in piglet atrium model; compound found inactive at 1 uM,F,,Cardiac atrium,,,CHEMBL619015,268,H,BAO_0000019,1,2081.0,,,,11249
3316,8,,The compound was tested for binding affinity against 5-hydroxytryptamine 4 receptor,B,,,,,CHEMBL619016,15086,H,BAO_0000357,1,,,,,11249
3317,8,,Compound was tested for binding affinity against piglet hippocampus 5-hydroxytryptamine 4 receptor,B,,Hippocampus,,,CHEMBL619017,14875,H,BAO_0000221,1,10000000.0,,,,11249
3318,8,Sus scrofa,The binding affinity (pKi) was measured against 5-hydroxytryptamine 4 receptor of piglet hippocampus using [125I]SB 207710 as radioligand,B,9823.0,Hippocampus,,,CHEMBL619018,13267,H,BAO_0000221,1,10000000.0,,,,168
3319,8,Oryctolagus cuniculus,Binding affinity against 5-hydroxytryptamine 2A receptor using rabbit saphenous vein assay.,B,9986.0,,,,CHEMBL619019,13047,H,BAO_0000019,1,,,,,168
3320,9,Rattus norvegicus,Displacement of [3H]GR-113808 from rat striatum 5-hydroxytryptamine 4 receptor,B,10116.0,,,,CHEMBL619020,1650,D,BAO_0000357,1,,,,,10623
3321,8,,Tested for its agonist potency against the 5-hydroxytryptamine 4 receptor located in the rat esophageal tunica muscularis mucosae,F,,,,,CHEMBL619021,567,H,BAO_0000019,1,,,,,10623
3322,8,,Tested for affinity towards 5-hydroxytryptamine 4 receptor in relaxation of rat oesophagus,B,,,,,CHEMBL619022,17358,H,BAO_0000357,1,,,,,10623
3323,8,,Tested for the effect on binding at 5-hydroxytryptamine 4 receptor; No activity,B,,,,,CHEMBL619023,188,H,BAO_0000357,1,,,,,10623
3324,8,,lntrinsic activity relative to 5-HT receptor,F,,,,,CHEMBL619024,670,H,BAO_0000019,1,,,,,10623
3325,8,,Compound was evaluated for the agonistic activity towards 5-hydroxytryptamine 4 receptor using the rat tunica muscularis mucosae (TMM) esophagus strip assay,F,,,,,CHEMBL619025,204,H,BAO_0000019,1,,,,,10623
3326,8,,In vitro relaxation of carbachol pre-contracted rat oesophageal TMM.,F,,,,,CHEMBL619026,1946,H,BAO_0000019,1,,,,,10623
3327,8,,Compound was tested for agonist activity at the 5-hydroxytryptamine 4 receptor in the rat tunica muscularis mucosae (TMM) assay,F,,,,,CHEMBL619027,6398,H,BAO_0000019,1,,,,,10623
3328,8,,Compound was tested for agonist activity at the 5-hydroxytryptamine 4 receptor in the rat tunica muscularis mucosae (TMM) assay; IN = Inactive,F,,,,,CHEMBL619028,6398,H,BAO_0000019,1,,,,,10623
3329,8,,Efficient 5-hydroxytryptamine 4 agonist in the rat tunica muscularis mucosae,F,,,,,CHEMBL619029,17358,H,BAO_0000019,1,,,,,10623
3330,8,,Tested for agonist activity at the 5-hydroxytryptamine 4 receptor in the rat tunica muscularis mucosae (TMM) assay of racemate mixture,F,,,,,CHEMBL619030,6398,H,BAO_0000019,1,,,,,10623
3331,8,,Relaxation of carbachol induced contractions of rat tunica muscularis mucosae,B,,,,,CHEMBL619031,11752,H,BAO_0000357,1,,,,,10623
3332,8,,5-hydroxytryptamine 4 receptor agonist activity was determined by the relaxation of the carbachol-contracted rat esophageal tunica muscularis mucosae,F,,,,,CHEMBL619032,809,H,BAO_0000019,1,,,,,10623
3333,9,Rattus norvegicus,Inhibition of radiolabeled [3H]GR-113808 ligand binding to 5-hydroxytryptamine 4 receptor,B,10116.0,,,,CHEMBL619033,14178,D,BAO_0000357,1,,,,,10623
3334,8,,Tested for its efficacy against the 5-hydroxytryptamine 4 receptor located in the rat esophageal tunica muscularis mucosae,B,,,,,CHEMBL619034,567,H,BAO_0000357,1,,,,,10623
3335,8,,In vitro 5-hydroxytryptamine 4 receptor activity by using carbachol-precontracted esophageal tunica muscularis mucosae.,B,,,,,CHEMBL619035,1946,H,BAO_0000357,1,,,,,10623
3336,8,,In vitro 5-hydroxytryptamine 4 receptor activity by using carbachol-precontracted esophageal tunica muscularis mucosae; No activity up to 104M concentration,B,,,,,CHEMBL619036,1946,H,BAO_0000357,1,,,,,10623
3337,9,Rattus norvegicus,Binding affinity (Ki+/-SEM) against 5-hydroxytryptamine 4 receptor from cheng Prusoff equation by using [3H]GR-113808 in rat striatum,B,10116.0,,,,CHEMBL619037,13961,D,BAO_0000019,1,,,,,10623
3338,8,,Binding affinity towards 5-HT 4 receptor in rat striatum membranes using [3H]GR-113808 as radioligand,B,,Striatum,,,CHEMBL619038,6238,H,BAO_0000249,1,2435.0,,,,10623
3339,8,,Binding affinity towards 5-HT4 receptor was determined in rat striatal membranes using [3H]GR-113808 as radioligand; Not tested,B,,,,,CHEMBL619039,14290,H,BAO_0000249,1,,,,,10623
3340,8,,Binding affinity towards 5-hydroxytryptamine 4 receptor was determined in rat striatal membranes using [3H]GR-113808 as radioligand,B,,,,,CHEMBL619040,14290,H,BAO_0000249,1,,,,,10623
3341,9,Rattus norvegicus,Binding affinity against 5-hydroxytryptamine 4 receptor using [3H]GR-113808 as radioligand in rat striatum,B,10116.0,Striatum,,,CHEMBL619041,809,D,BAO_0000019,1,2435.0,,,,10623
3342,8,,Binding affinity against 5-hydroxytryptamine 4 receptor using [3H]GR-113808 as radioligand in rat striatum,B,,Striatum,,,CHEMBL619042,1578,H,BAO_0000019,1,2435.0,,,,10623
3343,8,,Binding affinity to 5-hydroxytryptamine 4 receptor using [3H]GR-113808 as radioligand in rat striatum membrane,B,,Striatum,,,CHEMBL619043,16709,H,BAO_0000249,1,2435.0,,,,10623
3344,8,,Binding affinity at 5-hydroxytryptamine 4 receptor in rat striatum by [3H]GR-113808 displacement.,B,,Striatum,,,CHEMBL619044,1946,H,BAO_0000019,1,2435.0,,,,10623
3345,8,,In vitro affinity at serotonergic 5-hydroxytryptamine 4 receptor by radioligand binding assay using [3H]GR-113808 in rat striatum membranes.,B,,Striatum,,,CHEMBL619045,15253,H,BAO_0000249,1,2435.0,,,,10623
3346,8,,In vitro binding affinity to 5-hydroxytryptamine 4 receptor in rat striatum membrane,B,,Striatum,,,CHEMBL619046,4535,H,BAO_0000249,1,2435.0,,,,10623
3347,8,,Binding affinity at 5-hydroxytryptamine 4 receptor in rat striatal membranes by [3H]GR-113808 displacement.,B,,,,,CHEMBL619047,13961,H,BAO_0000249,1,,,,,10623
3348,8,,Tested for potency against 5-hydroxytryptamine 4 receptor agonist in rat brain,F,,Brain,,,CHEMBL619048,17358,H,BAO_0000221,1,955.0,,,,10623
3349,8,,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 4 receptor of rat,F,,,,,CHEMBL859398,15847,H,BAO_0000019,1,,,,,10623
3350,8,,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 4 receptor of rat; ND means not done,F,,,,,CHEMBL619049,15847,H,BAO_0000019,1,,,,,10623
3351,8,,5-hydroxytryptamine 4 receptor agonist activity in the rat esophageal muscularis mucosae,F,,,,,CHEMBL857886,670,H,BAO_0000019,1,,,,,10623
3352,8,,5-hydroxytryptamine 4 receptor agonist activity in the rat esophageal muscularis mucosae; Not tested,F,,,,,CHEMBL619050,670,H,BAO_0000019,1,,,,,10623
3353,8,,Antagonist activity against 5-hydroxytryptamine 4 receptor mediated relaxation of rat carbachol contracted esophageal muscularis mucosae,F,,,,,CHEMBL620591,1317,H,BAO_0000019,1,,,,,10623
3354,9,Rattus norvegicus,Binding affinity against rat 5-hydroxytryptamine 4 receptor,B,10116.0,,,,CHEMBL620592,12936,D,BAO_0000357,1,,,,,10623
3355,8,,pKi against 5-hydroxytryptamine 4 receptor in rat striatum membrane,B,,Striatum,,,CHEMBL620593,4535,H,BAO_0000249,1,2435.0,,,,10623
3356,9,Rattus norvegicus,Antagonistic activity evaluated by ability to block serotonin induced relaxation (mediated by activation of 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 10e-5 M.,F,10116.0,,,,CHEMBL620594,14424,D,BAO_0000019,1,,,,,10623
3357,8,,Antagonistic activity by ability to block serotonin induced relaxation (mediated by activation of 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 10e-6 M.,F,,,,,CHEMBL875079,14424,H,BAO_0000019,1,,,,,10623
3358,8,,Antagonistic activity by ability to block serotonin induced relaxation (mediated by activation of 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 10e-7 M.,F,,,,,CHEMBL620595,14424,H,BAO_0000019,1,,,,,10623
3359,9,Rattus norvegicus,Antagonistic activity evaluated by ability to block serotonin induced relaxation (mediated by activation of 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 10e-8 M.,F,10116.0,,,,CHEMBL620596,14424,D,BAO_0000019,1,,,,,10623
3360,8,,Antagonistic activity of compound was evaluated by ability to block serotonin induced relaxation (mediated by activation of 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 3*10e-7 M.,F,,,,,CHEMBL620597,14424,H,BAO_0000019,1,,,,,10623
3361,8,,Antagonistic activity evaluated by ability to block serotonin induced relaxation (via 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 3*10e-8 M.,F,,,,,CHEMBL620598,14424,H,BAO_0000019,1,,,,,10623
3362,8,,Antagonistic activity evaluated by ability to block serotonin induced relaxation via 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 0.1 mg/kg (p.o.),F,,,,,CHEMBL620599,14424,H,BAO_0000218,1,,,,,10623
3363,8,,Antagonistic activity of compound was evaluated by ability to block serotonin induced relaxation (mediated by activation of 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 10e-7 M.,F,,,,,CHEMBL620600,14424,H,BAO_0000019,1,,,,,10623
3364,8,Rattus norvegicus,Estimate from relaxation of carbachol-contracted rat esophageal muscularis mucosae,F,10116.0,,,,CHEMBL620601,1980,H,BAO_0000019,1,,,,,168
3365,8,,Compound was tested for agonistic activity against 5-hydroxytryptamine 4 receptor on guinea colon at a concentration 0.1 uM,F,,,,,CHEMBL620602,4639,H,BAO_0000019,1,,,,,168
3366,8,,Tested for affinity towards 5-hydroxytryptamine 4 receptor,B,,,,,CHEMBL620603,17358,H,BAO_0000357,1,,,,,168
3367,8,,Tested for affinity towards 5-hydroxytryptamine 4 receptor.,B,,,,,CHEMBL620604,17358,H,BAO_0000357,1,,,,,168
3368,8,,Compound was tested for 5-hydroxytryptamine 4 binding affinity,B,,,,,CHEMBL620605,17358,H,BAO_0000357,1,,,,,168
3369,8,,Compound was tested for its affinity towards 5-hydroxytryptamine 4 receptor,B,,,,,CHEMBL620606,1558,H,BAO_0000357,1,,,,,168
3370,8,,Tested for 5-hydroxytryptamine 4 receptor antagonist activity,F,,,,,CHEMBL620607,17358,H,BAO_0000019,1,,,,,168
3371,8,,In vitro binding affinity towards 5-HT4 receptor was determined,B,,,,,CHEMBL620608,16117,H,BAO_0000357,1,,,,,168
3372,8,,Tested for 5-hydroxytryptamine 4 receptor antagonist activity,F,,,,,CHEMBL620609,17358,H,BAO_0000019,1,,,,,168
3373,8,,Tested for agonist activity against 5-hydroxytryptamine 4 receptor,F,,,,,CHEMBL620610,17358,H,BAO_0000019,1,,,,,168
3374,8,,Tested for selectivity for 5-hydroxytryptamine 4 receptor,B,,,,,CHEMBL620611,17358,H,BAO_0000357,1,,,,,168
3375,8,,Tested for 5-hydroxytryptamine 4 binding affinity against cisapride,B,,,,,CHEMBL620612,17358,H,BAO_0000357,1,,,,,168
3376,8,,Tested for 5-hydroxytryptamine 4 binding affinity against renzapride,B,,,,,CHEMBL620613,17358,H,BAO_0000357,1,,,,,168
3377,8,,Tested for 5-hydroxytryptamine 4 binding affinity against zacopride,B,,,,,CHEMBL620614,17358,H,BAO_0000357,1,,,,,168
3378,8,,Binding affinity against 5-Hydroxytryptamine 4 receptor,B,,,,,CHEMBL620615,1274,H,BAO_0000357,1,,,,,168
3379,6,,Compound was evaluated for the displacement of [3H]-Q-ICS 205-930 binding to 5-hydroxytryptamine 3 recognition sites in rat brain membranes,B,,,Brain membranes,,CHEMBL857075,10728,H,BAO_0000249,1,,,,,104698
3380,6,,Compound was evaluated for the displacement of [3H]Q-ICS-205-930 from 5-HT3 recognition sites in rat brain membranes,B,,,Brain membranes,,CHEMBL620616,11695,H,BAO_0000249,1,,,,,104698
3381,6,,Displacement of [3H]Q-ICS-205-930 from 5-hydroxytryptamine 3 receptor recognition sites in rat brain membranes,B,,,Brain membranes,,CHEMBL619411,11695,H,BAO_0000249,1,,,,,104698
3382,6,,Displacement of [3H]-Q-ICS 205-930 binding to 5-hydroxytryptamine 3 receptor from rat cortex homogenate,B,,,,,CHEMBL619412,12490,H,BAO_0000019,1,,,,,104698
3383,7,Rattus norvegicus,Displacement of [3H]-Q-ICS 205-930 from rat cortex homogenate 5-hydroxytryptamine 3 receptor,B,10116.0,,,,CHEMBL619413,11828,D,BAO_0000019,1,,,,,104698
3384,6,,Binding affinity of 5-hydroxytryptamine 3 receptor using [3H]granisetron in rat hippocampus and entorhinal cortex,B,,Hippocampus,,,CHEMBL619414,12253,H,BAO_0000221,1,10000000.0,,,,104698
3385,6,,Binding affinity to 5-hydroxytryptamine 3 receptor using [3H]GR-65630 as radioligand in rat cortex,B,,,,,CHEMBL619415,10561,H,BAO_0000019,1,,,,,104698
3386,6,,Binding affinity to 5-hydroxytryptamine 3 receptor using [3H]quipazine as radioligand in rat cortex,B,,,,,CHEMBL619416,10561,H,BAO_0000019,1,,,,,104698
3387,6,,Rat 5-hydroxytryptamine 3 receptor (5-HT3) antagonist,F,,,,,CHEMBL619417,14432,H,BAO_0000019,1,,,,,104698
3388,7,Rattus norvegicus,Binding affinity against rat 5-hydroxytryptamine 3 receptor,B,10116.0,,,,CHEMBL619418,12936,D,BAO_0000223,1,,,,,104698
3389,7,Rattus norvegicus,Binding affinity against 5-Hydroxytryptamine 3 receptor,B,10116.0,,,,CHEMBL619419,1274,D,BAO_0000223,1,,,,,104698
3390,6,,Binding affinity for 5-hydroxytryptamine 3 receptor by displacement of racemic [3H]zacopride from rat cortex,B,,,,,CHEMBL619420,1980,H,BAO_0000019,1,,,,,104698
3391,6,,Binding affinity to 5-hydroxytryptamine 3 receptor was determined in rat cerebro cortical membranes using [3H]quipazine.,B,,,,,CHEMBL619421,670,H,BAO_0000249,1,,,,,104698
3392,7,Rattus norvegicus,Displacement of [3H]granisetron from 5-hydroxytryptamine 3 receptor of rat cortex,B,10116.0,,,,CHEMBL619422,968,D,BAO_0000019,1,,,,,104698
3393,6,,In vitro by displacement of [3H]LY-278584 from 5-hydroxytryptamine 3 receptor on rat entorhinal cortex,B,,,,,CHEMBL619423,14287,H,BAO_0000019,1,,,,,104698
3394,6,,Tested for its binding affinity by measuring its ability to displace [3H]granisetron from 5-hydroxytryptamine 3 receptor in rat cortex,B,,,,,CHEMBL875080,567,H,BAO_0000019,1,,,,,104698
3395,6,,The binding affinity (pKi) measured against 5-hydroxytryptamine 1A receptor of rat cortex using [3H]8-OH-DPAT as radioligand,B,,,,,CHEMBL619424,13267,H,BAO_0000019,1,,,,,104698
3396,6,,Binding affinity at 5-hydroxytryptamine 3 receptor in rat cortical membrane by [3H]graniestron displacement.,B,,,,,CHEMBL619425,14826,H,BAO_0000249,1,,,,,104698
3397,6,,The compound was tested for the binding affinity against 5-hydroxytryptamine 3 receptor using [3H]zacopride as radioligand,B,,,,,CHEMBL619426,15194,H,BAO_0000223,1,,,,,104698
3398,6,,The compound was tested for the binding affinity against 5-hydroxytryptamine 3 receptor using [3H]zacopride as radioligand.,B,,,,,CHEMBL619427,15194,H,BAO_0000223,1,,,,,104698
3399,7,Rattus norvegicus,pKi value for inhibition of [3H]LY-278584 binding to 5-hydroxytryptamine 3 receptor,B,10116.0,,,,CHEMBL619645,10394,D,BAO_0000223,1,,,,,104698
3400,9,,"Compound was evaluated for binding affinity on 5-hydroxytryptamine 1A receptor in rat hippocampus membranes,3H-8-OH-DPAT and buspirone for nonspecific binding",B,,,,,CHEMBL619646,13657,D,BAO_0000249,1,,,,,10576
3401,8,,Compound was tested for its antagonistic activity against 5-hydroxytryptamine 3 receptor in rat brain using [3H]zacopride as the radioligand.,F,,Brain,,,CHEMBL619647,1879,H,BAO_0000221,1,955.0,,,,12020
3402,8,,Compound was tested in vitro for its antagonistic activity against 5-hydroxytryptamine 3 receptor,F,,,,,CHEMBL619648,1879,H,BAO_0000019,1,,,,,12020
3403,8,,Compound was tested in vitro for its antagonistic activity against 5-hydroxytryptamine 3 receptor in rat CNS.,F,,,,,CHEMBL619165,1879,H,BAO_0000019,1,,,,,12020
3404,8,,Compound was evaluated in vivo for the antagonistic activity towards 5-hydroxytryptamine 3 receptor,F,,,,,CHEMBL620719,204,H,BAO_0000218,1,,In vivo,,,12020
3405,8,,Compound was tested for its binding affinity towards 5-HT-3 receptor in whole rat brain using (S)-[125I]-zacopride as the radioligand.,B,,,,,CHEMBL872924,1879,H,BAO_0000019,1,,,,,12020
3406,8,,Compound was tested for its binding affinity towards 5-hydroxytryptamine 3 receptor,B,,,,,CHEMBL620720,1879,H,BAO_0000357,1,,,,,12020
3407,8,,Compound was tested for its binding affinity towards 5-hydroxytryptamine 3 receptor in whole rat brain using (S)-[125I]-zacopride as the radioligand.,B,,,,,CHEMBL620721,1879,H,BAO_0000019,1,,,,,12020
3408,8,,Compound was tested for its binding affinity towards 5-hydroxytryptamine 3 receptor in whole rat brain using [125I]DAIZAC as the radioligand.,B,,,,,CHEMBL620722,1879,H,BAO_0000019,1,,,,,12020
3409,6,,"Concentration that inhibits the binding of radioligand, [3H]-ICS 205930, to 5-hydroxytryptamine 3 receptor from rat cortex",B,,,,,CHEMBL620723,10641,H,BAO_0000019,1,,,,,104698
3410,8,,In Vitro Binding affinity againist 5-hydroxytryptamine 3 receptor by displacing [3H]-Q-ICS 205-930 from rat cortex homogenates,B,,,,,CHEMBL620724,773,H,BAO_0000019,1,,,,,12020
3411,6,,Binding affinity against 5-hydroxytryptamine 3 (5-HT3) receptor in rat brain cortical membranes using radioligand [3H]quipazine,B,,,,,CHEMBL620725,11952,H,BAO_0000249,1,,,,,104698
3412,9,Rattus norvegicus,Antagonist activity (100 ug/kg) for the Bezold Jarisch reflex evoked by 30 (ug/Kg) of 5-hydroxytryptamine 3 receptor in ethylurethane anesthetized rats i.v.,F,10116.0,,,,CHEMBL620726,14145,D,BAO_0000019,1,,,,,12020
3413,8,,Binding affinity towards 5-hydroxytryptamine 3 receptor,B,,,,,CHEMBL620727,17066,H,BAO_0000357,1,,,,,144
3414,4,,Compound was evaluated for 5-hydroxytryptamine 3 receptor binding,B,,,,,CHEMBL620728,6398,H,BAO_0000223,1,,,,,104714
3415,0,,Binding affinity towards 5-hydroxytryptamine 3 receptor by displacement of [3H]2 in Neuroblastoma-Glioma NG-108-15 cells,B,,,,,CHEMBL620729,10321,U,BAO_0000019,1,,,,,22226
3416,4,,Tested for 5-hydroxytryptamine 3 receptor antagonist activity by inhibiting the 5-HT evoked Bezold-Jarisch reflex,F,,,,,CHEMBL858288,511,H,BAO_0000019,1,,,,,104714
3417,4,,Compound was tested for binding affinity towards 5-hydroxytryptamine 3 receptor,B,,,,,CHEMBL620730,4639,H,BAO_0000223,1,,,,,104714
3418,4,,Binding affinity towards 5-hydroxytryptamine 3 receptor,B,,,,,CHEMBL620731,4639,H,BAO_0000223,1,,,,,104714
3419,4,Cavia porcellus,Compound was tested for antagonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 0.3 uM,F,10141.0,,,,CHEMBL620732,4639,H,BAO_0000019,1,,,,,104714
3420,4,Cavia porcellus,Compound was tested for antagonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 3 uM,F,10141.0,,,,CHEMBL618042,4639,H,BAO_0000019,1,,,,,104714
3421,4,Cavia porcellus,Compound was tested for antagonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 30 uM,F,10141.0,,,,CHEMBL618043,4639,H,BAO_0000019,1,,,,,104714
3422,4,,Compound was tested for its affinity towards 5-hydroxytryptamine 3 receptor,B,,,,,CHEMBL618044,1558,H,BAO_0000223,1,,,,,104714
3423,4,,Evaluated for the 5-hydroxytryptamine 3 receptor antagonistic activity in Bezold-Jarisch model expressed as inhibition of the reflex bradycardia induced by an intravenous injection,F,,,,,CHEMBL618045,268,H,BAO_0000019,1,,,,,104714
3424,4,,Compound was measured for its binding affinity at 5-hydroxytryptamine 3 receptor at a concentration of 10 uM using [3H]BRL-43694 as radioligand,B,,,,,CHEMBL618046,2474,H,BAO_0000223,1,,,,,104714
3425,4,,Intrinsic activity towards 5-hydroxytryptamine 3 receptor was determined by Benzold-Jarisch reflex (peripheral assay); A: agonist,F,,,,,CHEMBL618047,5067,H,BAO_0000019,1,,,,,104714
3426,4,,Intrinsic activity towards 5-hydroxytryptamine 3 receptor was determined by Benzold-Jarisch reflex (peripheral assay); ANT: agonist,F,,,,,CHEMBL875084,5067,H,BAO_0000019,1,,,,,104714
3427,4,,Intrinsic activity towards 5-hydroxytryptamine 3 receptor was determined by Benzold-Jarisch reflex (peripheral assay); ANT: antagonist,F,,,,,CHEMBL618048,5067,H,BAO_0000019,1,,,,,104714
3428,4,,Intrinsic activity towards 5-hydroxytryptamine 3 receptor was determined by Benzold-Jarisch reflex (peripheral assay); NA means data not available,B,,,,,CHEMBL618049,5067,H,BAO_0000223,1,,,,,104714
3429,4,,Intrinsic activity towards 5-hydroxytryptamine 3 receptor was determined by Benzold-Jarisch reflex (peripheral assay); PA: Partial agonist,F,,,,,CHEMBL619764,5067,H,BAO_0000019,1,,,,,104714
3430,4,,Intrinsic activity towards CNS 5-hydroxytryptamine 3 receptor was determined; A: agonist,F,,,,,CHEMBL619765,5067,H,BAO_0000019,1,,,,,104714
3431,4,,Intrinsic activity towards CNS 5-hydroxytryptamine 3 receptor was determined; ANT: Antagonist,F,,,,,CHEMBL619766,5067,H,BAO_0000019,1,,,,,104714
3432,4,,Intrinsic activity towards CNS 5-hydroxytryptamine 3 receptor was determined; NA: not active,B,,,,,CHEMBL619767,5067,H,BAO_0000223,1,,,,,104714
3433,4,,Intrinsic activity towards CNS 5-hydroxytryptamine 3 receptor was determined; NA means data not available,B,,,,,CHEMBL619768,5067,H,BAO_0000223,1,,,,,104714
3434,4,,Intrinsic activity towards CNS 5-hydroxytryptamine 3 receptor was determined; PA: Partial agonist,F,,,,,CHEMBL619769,5067,H,BAO_0000019,1,,,,,104714
3435,4,,Intrinsic activity towards CNS 5-hydroxytryptamine 3 receptor was determined; na means data not available,B,,,,,CHEMBL619770,5067,H,BAO_0000223,1,,,,,104714
3436,4,,Binding affinity towards 5-hydroxytryptamine 3 receptor,B,,,,,CHEMBL619771,5067,H,BAO_0000223,1,,,,,104714
3437,4,,Binding affinity of compound towards 5-hydroxytryptamine 3 receptor using [3H]-BRL-43694 (1 nM) ligand in NG cells 108-15 was determined,B,,,,,CHEMBL619772,14331,H,BAO_0000219,1,,,,,104714
3438,4,,Binding affinity of compound towards 5-hydroxytryptamine 3 receptor; NA: not active,B,,,,,CHEMBL619773,5067,H,BAO_0000223,1,,,,,104714
3439,4,,Binding affinity for 5-HT3 receptor of NG108-15 cells using [3H]GR-65630,B,,,,,CHEMBL619774,6179,H,BAO_0000219,1,,,,NG108-15,104714
3440,4,,Binding affinity to 5-HT3 serotonin receptor in NG 108-15 neuroblastoma glioma cells using [3H]GR-65630 radioligand.,B,,,,,CHEMBL875083,4265,H,BAO_0000019,1,,,,,104714
3441,4,,Binding affinity to 5-HT3 serotonin receptor in NG108-15 neuroblastoma glioma cells using [3H]GR-65630 radioligand,B,,,,,CHEMBL620718,4265,H,BAO_0000219,1,,,,NG108-15,104714
3442,4,,Compound was tested for 5-hydroxytryptamine 3 receptor binding affinity,B,,,,,CHEMBL618127,17358,H,BAO_0000223,1,,,,,104714
3443,4,,Compound was tested for selectivity against 5-hydroxytryptamine 3 receptor binding affinity,B,,,,,CHEMBL618128,17358,H,BAO_0000223,1,,,,,104714
3444,4,,Compound was tested for the inhibition of [3H]GR-65630 binding to 5-hydroxytryptamine 3 receptor expressed in NG 108-15 cells,B,,,,,CHEMBL618129,13628,H,BAO_0000219,1,,In vitro,,,104714
3445,4,,In vitro Binding affinity towards 5-hydroxytryptamine 3 receptor was determined,B,,,,,CHEMBL618130,4612,H,BAO_0000223,1,,,,,104714
3446,4,,Tested for 5-hydroxytryptamine 3 receptor antagonist activity,F,,,,,CHEMBL618131,17358,H,BAO_0000019,1,,,,,104714
3447,4,Cavia porcellus,Compound was tested for agonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 1 uM,F,10141.0,,,,CHEMBL618132,4639,H,BAO_0000019,1,,,,,104714
3448,4,Cavia porcellus,Compound was tested for agonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 10 uM,F,10141.0,,,,CHEMBL618133,4639,H,BAO_0000019,1,,,,,104714
3449,4,Cavia porcellus,Compound was tested for agonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 10 uM in the presence of 30 uM MDL 72222,F,10141.0,,,,CHEMBL618134,4639,H,BAO_0000019,1,,,,,104714
3450,4,Cavia porcellus,Compound was tested for agonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 3 uM,F,10141.0,,,,CHEMBL618135,4639,H,BAO_0000019,1,,,,,104714
3451,4,,Binding affinity for the 5-hydroxytryptamine 3 receptor was evaluated in vitro by examining its ability to displace [3H]-BRL 43694.,B,,,,,CHEMBL618136,511,H,BAO_0000223,1,,,,,104714
3452,4,,Binding affinity towards 5-hydroxytryptamine 3 receptor,B,,,,,CHEMBL618137,1479,H,BAO_0000223,1,,,,,104714
3453,4,,Compound was evaluated for binding affinity against 5-hydroxytryptamine 3 receptor using radioligand binding assay,B,,,,,CHEMBL618138,1317,H,BAO_0000223,1,,,,,104714
3454,4,,Tested against 5-hydroxytryptamine 3 receptor in experiment 1,B,,,,,CHEMBL618139,12146,H,BAO_0000223,1,,,,,104714
3455,4,,Tested against 5-hydroxytryptamine 3 receptor in experiment 2,B,,,,,CHEMBL618140,12146,H,BAO_0000223,1,,,,,104714
3456,4,,Binding affinity against 5-hydroxytryptamine 3 receptor was measured using [3H]granisetron as radioligand,B,,,,,CHEMBL618141,13969,H,BAO_0000223,1,,,,,104714
3457,8,,Binding affinity for 5-hydroxytryptamine 2C receptor,B,,,,,CHEMBL873478,13392,H,BAO_0000357,1,,,,,108
3458,6,,Binding affinity towards 5-hydroxytryptamine 3 receptor,B,,,,,CHEMBL618142,13392,H,BAO_0000223,1,,,,,104698
3459,8,,Compound was evaluated for the affinity at 5-hydroxytryptamine 3 receptor,B,,,,,CHEMBL618143,14159,H,BAO_0000357,1,,,,,144
3460,8,,Compound was tested for its affinity towards 5-hydroxytryptamine 3 receptor,B,,,,,CHEMBL618144,1558,H,BAO_0000357,1,,,,,144
3461,8,,Inhibition of GR-65630 binding to 5-hydroxytryptamine 3 receptor,B,,,,,CHEMBL618145,16655,H,BAO_0000357,1,,,,,144
3462,4,,Inhibition of [3H]- BRL 43 694 binding to 5-hydroxytryptamine 3 receptor at 10e-5 M,B,,,,,CHEMBL618146,13020,H,BAO_0000223,1,,,,,104714
3463,4,,Inhibition of [3H]-BRL 43 694 binding to 5-hydroxytryptamine 3 receptor of central nervous system,B,,,,,CHEMBL618147,13021,H,BAO_0000223,1,,,,,104714
3464,4,,Inhibition of [3H]- BRL 43 694 binding to 5-hydroxytryptamine 3 receptor at 10e-5 M,B,,,,,CHEMBL618148,13020,H,BAO_0000223,1,,,,,104714
3465,8,,Binding affinity towards 5-hydroxytryptamine 3 receptor by displacement of [3H]2 in Neuroblastoma-Glioma NG-108-15 cells,B,,,,,CHEMBL618149,10321,H,BAO_0000019,1,,,,,144
3466,8,,Compound was evaluated for its binding affinity towards 5-hydroxytryptamine 3 receptor,B,,,,,CHEMBL872927,15818,H,BAO_0000357,1,,,,,144
3467,8,,Compound was evaluated for its binding affinity towards 5-hydroxytryptamine 3 receptor,B,,,,,CHEMBL618150,15818,H,BAO_0000357,1,,,,,144
3468,8,,Compound was tested for 5-hydroxytryptamine 3 receptor binding affinity,B,,,,,CHEMBL618151,17358,H,BAO_0000357,1,,,,,144
3469,8,,Compound was tested for its binding affinity for the 5-hydroxytryptamine 3 receptor,B,,,,,CHEMBL875094,2222,H,BAO_0000357,1,,,,,144
3470,8,,In vitro binding affinity for the 5-hydroxytryptamine 3 receptor was determined with NG-108-15 mouse neuroblastoma-glioma cells,B,,,,,CHEMBL618152,10322,H,BAO_0000019,1,,,,,144
3471,8,,In vitro binding affinity towards 5-hydroxytryptamine 3 receptor was determined,B,,,,,CHEMBL618153,16117,H,BAO_0000357,1,,,,,144
3472,8,,Inhibitory constant against 5-hydroxytryptamine 3 receptor using [3H]GR-65630 radioligand,B,,,,,CHEMBL618888,17200,H,BAO_0000357,1,,,,,144
3473,8,,Tested for 5-hydroxytryptamine 3 receptor agonist activity,F,,,,,CHEMBL618889,17358,H,BAO_0000019,1,,,,,144
3474,8,,The binding affinity towards 5-hydroxytryptamine 3 receptor; No affinity,B,,,,,CHEMBL618890,16700,H,BAO_0000357,1,,,,,144
3475,8,,Binding affinity for 5-hydroxytryptamine 3 receptor by displacement of [3H](R)-zacopride from ondansetron-treated NG-108-15 cell membranes,B,,,,,CHEMBL618891,1980,H,BAO_0000019,1,,,,,144
3476,8,,Binding affinity for 5-hydroxytryptamine 3 receptor by displacement of [3H]-BRL 43694 from NG-108-15 cell membranes,B,,,,,CHEMBL619054,1980,H,BAO_0000019,1,,,,,144
3477,4,,Binding affinity against the 5-hydroxytryptamine 3 receptor,B,,,,,CHEMBL619055,12409,H,BAO_0000223,1,,,,,104714
3478,8,,Binding affinity against human 5-hydroxytryptamine 3A receptor,B,,,,,CHEMBL619056,4365,H,BAO_0000357,1,,,,,144
3479,8,,Percent efficacy against 5-hydroxytryptamine 3A receptor,F,,,,,CHEMBL619057,4365,H,BAO_0000019,1,,,,,144
3480,8,,Binding affinity against human 5-hydroxytryptamine 3A receptor,B,,,,,CHEMBL619058,4365,H,BAO_0000357,1,,,,,144
3481,9,Rattus norvegicus,Response at rat 5-hydroxytryptamine 3a receptor expressed in xenopus oocytes,F,10116.0,,,,CHEMBL619059,6769,D,BAO_0000219,1,,,,Oocytes,12020
3482,9,Rattus norvegicus,Ability to block serotonin (30 uM)-evoked responses at rat 5HT3-alpha receptor expressed in xenopus oocytes,F,10116.0,,,,CHEMBL619060,6769,D,BAO_0000219,1,,,,Oocytes,12020
3483,9,Rattus norvegicus,Effect on rat 5-hydroxytryptamine 3a receptor expressed in xenopus oocytes at concentration up to 100 uM,F,10116.0,,,,CHEMBL875095,6769,D,BAO_0000219,1,,,,Oocytes,12020
3484,9,Cavia porcellus,5-hydroxytryptamine 4 receptor agonist activity as percent maximum 5-HT effect in response to electrical stimulation in male guinea pig ileum,F,10141.0,Ileum,,,CHEMBL619061,809,D,BAO_0000221,1,2116.0,,,,20033
3485,9,Cavia porcellus,5-hydroxytryptamine 4 receptor agonist activity expressed as the concentration which gave a 50% increase in the response to the electrical stimulation in male guinea pig ileum,F,10141.0,Ileum,,,CHEMBL619062,809,D,BAO_0000221,1,2116.0,,,,20033
3486,9,Cavia porcellus,5-hydroxytryptamine 4 receptor agonist activity is expressed as percent of the maximum 5-HT response,F,10141.0,,,,CHEMBL619063,14290,D,BAO_0000019,1,,,,,20033
3487,9,Cavia porcellus,Tested for affinity towards 5-hydroxytryptamine 4 receptor in electrically stimulated longitudinal muscle preparation of guinea pig ileum,B,10141.0,Ileum,,,CHEMBL619064,17358,D,BAO_0000221,1,2116.0,,,,20033
3488,9,Cavia porcellus,Tested for affinity towards 5-hydroxytryptamine 4 receptor in guinea pig distal colon preparation,B,10141.0,,,,CHEMBL619065,17358,D,BAO_0000357,1,,,,,20033
3489,9,Cavia porcellus,Tested for affinity towards 5-hydroxytryptamine 4 receptor in isolated guinea pig ileum longitudinal muscle preparation,B,10141.0,Ileum,,,CHEMBL619066,17358,D,BAO_0000221,1,2116.0,,,,20033
3490,8,,Maximal relaxation effect induced by 3 uM compound on substance P stimulated guinea pig ileum with 5-hydroxytryptamine 7 receptor nondesensitization,B,,Ileum,,,CHEMBL619775,17386,H,BAO_0000221,1,2116.0,,,,10209
3491,8,,Affinity against 5-hydroxytryptamine 7 receptor,B,,,,,CHEMBL619776,3269,H,BAO_0000357,1,,,,,10209
3492,4,Cavia porcellus,Ability to displace [3H]5-HT binding from 5-hydroxytryptamine receptor site using 1 uM LSD as masking ligand,B,10141.0,,,,CHEMBL619777,7721,H,BAO_0000224,1,,,,,104841
3493,4,Cavia porcellus,Ability to displace [3H]5-HT binding to 5-hydroxytryptamine receptor site using 1 uM LSD as masking ligand,B,10141.0,,,,CHEMBL619778,7721,H,BAO_0000224,1,,,,,104841
3494,4,Cavia porcellus,Evaluated for inhibition of 5-hydroxytryptamine receptor on guinea pig ileum at 10 uM; No effect,B,10141.0,Ileum,,,CHEMBL619779,9117,H,BAO_0000221,1,2116.0,,,,104841
3495,4,Cavia porcellus,"Ability to displace [3H]5-HT binding to 5-hydroxytryptamine receptor site using 1 uM LSD as masking ligand, activity is expressed as Kd.",B,10141.0,,,,CHEMBL619780,7721,H,BAO_0000224,1,,,,,104841
3496,4,Cavia porcellus,"Ability to displace [3H]5-HT binding to 5-hydroxytryptamine receptor using 1 uM LSD as masking ligand, activity is expressed as Kd.",B,10141.0,,,,CHEMBL619166,7721,H,BAO_0000224,1,,,,,104841
3497,4,Cavia porcellus,5-HT level in K+ induced 5-hydroxytryptamine release in guinea pig cortex.,F,10141.0,,,,CHEMBL619167,15796,H,BAO_0000019,1,,,,,104841
3498,4,Cavia porcellus,5-hydroxytryptamine level in K+ induced 5-hydroxytryptamine release in guinea pig cortex.,F,10141.0,,,,CHEMBL619168,15796,H,BAO_0000019,1,,,,,104841
3499,9,Homo sapiens,Concentration required to produce half-maximal response against 5-hydroxytryptamine receptor in the presence of 10 nM compound in isolated human atrial myocytes,B,9606.0,Cardiac atrium,,,CHEMBL619169,15650,D,BAO_0000219,1,2081.0,,,,168
3500,9,Homo sapiens,Concentration required to produce half-maximal response against 5-hydroxytryptamine receptor on the L-type calcium current (I Ca) in isolated human atrial myocytes,B,9606.0,Cardiac atrium,,,CHEMBL619170,15650,D,BAO_0000219,1,2081.0,,,,168
3501,5,Homo sapiens,"Maximum stimulation of [35S]GTP-gamma-S, binding expressed relative to the maximal effect of 5-hydroxytryptamine",F,9606.0,,,,CHEMBL619171,6866,D,BAO_0000019,1,,,,,104841
3502,9,Homo sapiens,",Antagonism of stimulation of 5-hydroxytryptamine receptor on the L-type calcium current (I Ca) in isolated human atrial myocytes",F,9606.0,Cardiac atrium,,,CHEMBL619172,15650,D,BAO_0000219,1,2081.0,,,,168
3503,0,Mus musculus,Ability (10 ug/kg) to inhibit binding of [125I]iododexetimide to 5-hydroxytryptamine receptor in mice,B,10090.0,,,,CHEMBL619173,10063,U,BAO_0000019,1,,,,,22226
3504,0,Mus musculus,Percent inhibition of radioligand [3H]-LSD binding to 5-HT receptor at 10 uM concentration,B,10090.0,,,,CHEMBL619174,12665,U,BAO_0000019,1,,,,,22226
3505,4,,5-hydroxytryptamine receptor binding affinity was determined in rats,B,,,,,CHEMBL619175,7504,H,BAO_0000019,1,,,,,104705
3506,4,,Binding affinity at rat 5-hydroxytryptamine receptor.,B,,,,,CHEMBL619176,7504,H,BAO_0000224,1,,,,,104705
3507,4,,Affinity against 5-hydroxytryptamine receptors in rat fundus model,B,,,,,CHEMBL619177,7038,H,BAO_0000019,1,,,,,104705
3508,4,,Affinity for 5-hydroxytryptamine receptor was determined using male Dawley rat fundus preparation,B,,,,,CHEMBL619178,7626,H,BAO_0000224,1,,,,,104705
3509,4,,Affinity for 5-hydroxytryptamine receptor was determined using male Dawley rat fundus preparation; Not determined,B,,,,,CHEMBL619179,7626,H,BAO_0000224,1,,,,,104705
3510,4,,Antagonistic activity against serotonin 5-HT receptor obtained from rat stomach fundus preparation,F,,Stomach,,,CHEMBL619180,7185,H,BAO_0000019,1,945.0,,,,104705
3511,4,,Antagonistic activity against serotonin 5-HT receptor obtained from rat stomach fundus preparation (resulted in discoloration in the oxygenated muscle bath to give varying results).,F,,Stomach,,,CHEMBL619181,7185,H,BAO_0000019,1,945.0,,,,104705
3512,4,,Antagonistic activity of corresponding methoxy compound against serotonin 5-HT receptor,F,,,,,CHEMBL619182,7185,H,BAO_0000019,1,,,,,104705
3513,4,,Compound was evaluated for binding affinity towards 5-hydroxytryptamine receptor in isolated rat fundus preparation measured as pA2,B,,,,,CHEMBL619183,6960,H,BAO_0000224,1,,,,,104705
3514,4,,"Compound was evaluated for binding affinity towards 5-hydroxytryptamine receptor in isolated rat fundus preparation measured as pA2; Valid pA2, can not be determined because of slope of Schild plot.",B,,,,,CHEMBL619184,6960,H,BAO_0000224,1,,,,,104705
3515,8,,In vitro affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand in hippocampus,B,,Hippocampus,,,CHEMBL619185,12416,H,BAO_0000221,1,10000000.0,,,,10576
3516,8,,Binding affinity for rat 5-hydroxytryptamine transporter.,B,,,,,CHEMBL619186,15753,H,BAO_0000357,1,,,,,12198
3517,4,,Evaluated for inhibition of specific [3H]5-HT receptor binding in rat cortex.,B,,,,,CHEMBL619187,8062,H,BAO_0000019,1,,,,,104705
3518,5,Rattus norvegicus,Binding affinity at serotonin 5-HT1-type site receptor in rat cortex by displacing [3H]5-HT,B,10116.0,,,,CHEMBL619188,9036,D,BAO_0000019,1,,,,,104705
3519,5,Rattus norvegicus,Compound was tested for its inhibitory activity against 5-hydroxytryptamine receptor,B,10116.0,,,,CHEMBL619189,15067,D,BAO_0000224,1,,,,,104705
3520,9,Rattus norvegicus,Inhibitory activity against [3H]- 5-hydroxytryptamine reuptake in whole rat brain minus cerebellum,F,10116.0,Brain,,,CHEMBL619190,15753,D,BAO_0000019,1,955.0,,,,12198
3521,9,Rattus norvegicus,Inhibition of [3H]5-HT reuptake in whole rat brain (minus cerebellum) homogenate.,F,10116.0,Cerebellum,,,CHEMBL619191,15753,D,BAO_0000221,1,2037.0,,,,12198
3522,5,Rattus norvegicus,Displacement of [3H]-citalopram from rat forebrain membrane 5-hydroxytryptamine receptor at 10e-7 M,B,10116.0,,,,CHEMBL619192,15295,D,BAO_0000019,1,,,,,104705
3523,5,Rattus norvegicus,Percent binding affinity against 5-hydroxytryptamine receptor,B,10116.0,,,,CHEMBL619193,6347,D,BAO_0000224,1,,,,,104705
3524,0,,Ability to displace 0.4 nM [3H]paroxetine binding to 5-hydroxytryptamine receptor in rat frontal cortex,B,,,,,CHEMBL619194,6763,U,BAO_0000019,1,,,,,22226
3525,5,Rattus norvegicus,The binding affinity was measured on 5-hydroxytryptamine receptor uptake receptor using [3H]- paroxetine as radioligand.,B,10116.0,,,,CHEMBL619195,12092,D,BAO_0000224,1,,,,,104705
3526,5,Rattus norvegicus,Affinity against 5-hydroxytryptamine receptor was determined,B,10116.0,,,,CHEMBL619196,1579,D,BAO_0000224,1,,,,,104705
3527,5,Rattus norvegicus,Affinity against 5-hydroxytryptamine receptor was determined in rat stomach fundus strip,B,10116.0,Stomach,,,CHEMBL619197,1579,D,BAO_0000019,1,945.0,,,,104705
3528,9,Homo sapiens,Inhibition of [3H]5-HT uptake in HEK cells expressing human SERT,B,9606.0,,,,CHEMBL619198,5963,D,BAO_0000219,1,,In vitro,,,121
3529,9,Homo sapiens,Inhibition of [3H]5-HT uptake in HEK cells expressing human SERT,B,9606.0,,,,CHEMBL875081,5963,D,BAO_0000219,1,,In vitro,,,121
3530,8,,Ability to compete with radioactive ligands specific to the Serotonergic 5-HT receptor at 10 uM; NA means compound failed to compete,B,,,,,CHEMBL884712,5030,H,BAO_0000357,1,,,,,18065
3531,8,,Inhibition of 5-hydroxytryptamine reuptake,B,,,,,CHEMBL884710,15796,H,BAO_0000357,1,,,,,121
3532,8,,"Receptor-linked G protein activation at 5-hydroxytryptamine receptor was determined by measuring the stimulation of [35S]GTP-gamma-S, binding",F,,,,,CHEMBL619199,15413,H,BAO_0000019,1,,,,,18065
3533,8,,"Receptor-linked G protein activation at 5-hydroxytryptamine receptor was determined by measuring the stimulation of [35S]GTP-gamma-S, binding (Experiment 1)",F,,,,,CHEMBL619200,15413,H,BAO_0000019,1,,,,,18065
3534,8,,"Receptor-linked G protein activation at 5-hydroxytryptamine receptor was determined by measuring the stimulation of [35S]GTP-gamma-S, binding (Experiment 2)",F,,,,,CHEMBL619201,15413,H,BAO_0000019,1,,,,,18065
3535,8,,Tested for 5-hydroxytryptamine receptor uptake,F,,,,,CHEMBL619202,12409,H,BAO_0000019,1,,,,,18065
3536,9,Homo sapiens,Affinity constant on CHO cells expressing Human recombinant 5-hydroxytryptamine receptor 1A,B,9606.0,,,,CHEMBL619203,16909,D,BAO_0000219,1,,,,CHO,51
3537,9,Homo sapiens,Antagonistic affinity tested against isolated human cloned alpha-1d adrenoceptor subtype,F,9606.0,,,,CHEMBL619204,16909,D,BAO_0000019,1,,,,,51
3538,8,Homo sapiens,In vitro binding affinity towards 5-hydroxytryptamine receptor 1A receptor by using [3H]8-OH-DPAT in rat hippocampal membranes.,B,9606.0,,,,CHEMBL619205,15629,H,BAO_0000249,1,,,,,10576
3539,8,,Tested in vitro for % inhibition against 5-hydroxytryptamine receptor 1A,B,,,,,CHEMBL619206,15629,H,BAO_0000357,1,,,,,10576
3540,8,,In vitro binding affinity at 5-hydroxytryptamine receptor 1A receptor in rat hippocampal membranes by [3H]8-OH-DPAT displacement.,B,,,,,CHEMBL619207,15629,H,BAO_0000249,1,,,,,10576
3541,8,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP in rats corpus striatum at a dosage of 0.10 umol/kg,F,,Striatum,,,CHEMBL619208,10034,H,BAO_0000019,1,2435.0,,,,10825
3542,8,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP in rats corpus striatum at a dosage of 10 umol/kg,F,,Striatum,,,CHEMBL619209,10034,H,BAO_0000019,1,2435.0,,,,10825
3543,8,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP in rats in corpus striatum at a dosage of 0.32 umol/kg,F,,Striatum,,,CHEMBL619210,10034,H,BAO_0000019,1,2435.0,,,,10825
3544,8,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP in rats in corpus striatum at a dosage of 3.2 umol/kg,F,,Striatum,,,CHEMBL619211,10034,H,BAO_0000019,1,2435.0,,,,10825
3545,8,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP in rats in corpus striatum at a dosage of 32 umol/kg,F,,Striatum,,,CHEMBL619212,10034,H,BAO_0000019,1,2435.0,,,,10825
3546,8,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in corpus striatum at a dosage of 0.032 umol/kg,F,,Striatum,,,CHEMBL620681,10034,H,BAO_0000019,1,2435.0,,,,10825
3547,8,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in corpus striatum at a dosage of 1.0 umol/kg,F,,Striatum,,,CHEMBL620682,10034,H,BAO_0000019,1,2435.0,,,,10825
3548,8,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in corpus striatum at a dosage of 10 umol/kg,F,,Striatum,,,CHEMBL620683,10034,H,BAO_0000019,1,2435.0,,,,10825
3549,8,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in corpus striatum at a dosage of 100 umol/kg,F,,Striatum,,,CHEMBL620684,10034,H,BAO_0000019,1,2435.0,,,,10825
3550,8,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in corpus striatum at a dosage of 3.2 umol/kg,F,,Striatum,,,CHEMBL620685,10034,H,BAO_0000019,1,2435.0,,,,10825
3551,8,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in corpus striatum at a dosage of 32 umol/kg,F,,Striatum,,,CHEMBL620686,10034,H,BAO_0000019,1,2435.0,,,,10825
3552,8,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 0.032 umol/kg,F,,Limbic system,,,CHEMBL620687,10034,H,BAO_0000019,1,349.0,,,,10825
3553,8,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 0.10 umol/kg,F,,Limbic system,,,CHEMBL620688,10034,H,BAO_0000019,1,349.0,,,,10825
3554,8,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 0.32 umol/kg,F,,Limbic system,,,CHEMBL620689,10034,H,BAO_0000019,1,349.0,,,,10825
3555,8,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 1.0 umol/kg,F,,Limbic system,,,CHEMBL620690,10034,H,BAO_0000019,1,349.0,,,,10825
3556,8,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 10 umol/kg,F,,Limbic system,,,CHEMBL620691,10034,H,BAO_0000019,1,349.0,,,,10825
3557,8,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 100 umol/kg,F,,Limbic system,,,CHEMBL620692,10034,H,BAO_0000019,1,349.0,,,,10825
3558,8,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 3.2 umol/kg,F,,Limbic system,,,CHEMBL620693,10034,H,BAO_0000019,1,349.0,,,,10825
3559,8,,Binding affinity against 5-hydroxytryptamine 4 receptor,B,,,,,CHEMBL620694,1274,H,BAO_0000357,1,,,,,168
3560,8,,Tested for 5-hydroxytryptamine 4 receptor antagonist activity,F,,,,,CHEMBL857986,17358,H,BAO_0000019,1,,,,,168
3561,8,,Inhibitory activity against 5-hydroxytryptamine 4 receptor using [3H]GR-113808 as radioligand at 10e-5 M concentration,B,,,,,CHEMBL620695,14532,H,BAO_0000357,1,,,,,168
3562,8,,Binding affinity towards Serotonin 5-hydroxytryptamine 4 receptor,B,,,,,CHEMBL620696,16989,H,BAO_0000357,1,,,,,168
3563,8,,Inhibitory constant against 5-hydroxytryptamine 4 receptor using [3H]GR-113808 radioligand,B,,,,,CHEMBL620697,17200,H,BAO_0000357,1,,,,,168
3564,8,,Binding affinity towards 5-hydroxytryptamine 4 receptor,B,,,,,CHEMBL620698,15779,H,BAO_0000357,1,,,,,168
3565,8,,Binding affinity towards 5-hydroxytryptamine 4 receptor; ND means no data.,B,,,,,CHEMBL620699,15779,H,BAO_0000357,1,,,,,168
3566,8,,Binding affinity towards 5-hydroxytryptamine 4 receptor; ND means no data.,B,,,,,CHEMBL620700,15779,H,BAO_0000357,1,,,,,168
3567,8,,Binding affinity was determined against cloned 5-hydroxytryptamine 4A receptor isoform expressed in COS-7 cells,B,,,,,CHEMBL620701,15650,H,BAO_0000219,1,,,,COS-7,168
3568,8,,Binding affinity was determined against cloned 5-hydroxytryptamine 4B receptor isoform expressed in COS-7 cells,B,,,,,CHEMBL875082,15650,H,BAO_0000219,1,,,,COS-7,168
3569,8,,Binding affinity was determined against cloned 5-hydroxytryptamine 4C receptor isoform expressed in COS-7 cells,B,,,,,CHEMBL620702,15650,H,BAO_0000219,1,,,,COS-7,168
3570,8,,Binding affinity was determined against cloned 5-hydroxytryptamine 4D receptor isoform expressed in COS-7 cells,B,,,,,CHEMBL620703,15650,H,BAO_0000219,1,,,,COS-7,168
3571,8,,Binding affinity of compound towards cloned human 5-hydroxytryptamine 4E receptor expressed in C6 glial cells using [3H]GR-113808 as radioligand,B,,,,,CHEMBL620704,17046,H,BAO_0000219,1,,,,C6,168
3572,8,,Binding affinity towards cloned human 5-hydroxytryptamine 4E receptor expressed in C6 glial cells using [3H]GR-113808 as radioligand,B,,,,,CHEMBL620705,17046,H,BAO_0000219,1,,,,C6,168
3573,8,,Binding affinity was determined against cloned 5-hydroxytryptamine 4E receptor isoform expressed in C6 glial cells incubated with 0.2 nM [3H]GR-113808,B,,,,,CHEMBL620706,15650,H,BAO_0000219,1,,,,C6,168
3574,8,,Binding affinity towards cloned human 5-hydroxytryptamine 4E receptor expressed in C6 glial cells using [3H]GR-113808 as radioligand; Not determined,B,,,,,CHEMBL620707,17046,H,BAO_0000219,1,,,,C6,168
3575,8,,Binding affinity towards 5-hydroxytryptamine 5 receptor,B,,,,,CHEMBL620708,17066,H,BAO_0000357,1,,,,,10624
3576,8,,Inhibitory constant against human 5-hydroxytryptamine 5A receptor using [3H]LSD radioligand,B,,,,,CHEMBL620709,17200,H,BAO_0000357,1,,,,,105
3577,9,Homo sapiens,Binding affinity against 5-hydroxytryptamine 5A receptor,B,9606.0,,,,CHEMBL620710,16146,D,BAO_0000357,1,,,,,10624
3578,8,,Compound was tested for the displacement of [3H]5-HT binding to cloned human 5-hydroxytryptamine 5A receptor stably expressed in CHO cells,B,,,,,CHEMBL620711,15250,H,BAO_0000219,1,,,,CHO,10624
3579,9,Homo sapiens,Affinity towards human 5-hydroxytryptamine 5A serotonin receptor,B,9606.0,,,,CHEMBL620712,6491,D,BAO_0000357,1,,,,,10624
3580,9,Homo sapiens,Binding affinity towards human 5-hydroxytryptamine 5A receptor,B,9606.0,,,,CHEMBL620713,17066,D,BAO_0000357,1,,,,,10624
3581,9,Homo sapiens,Binding affinity towards human 5-hydroxytryptamine 5A receptor was evaluated using [3H]-5-CT as radioligand,B,9606.0,,,,CHEMBL620714,17066,D,BAO_0000357,1,,,,,10624
3582,9,Homo sapiens,Binding affinity to cloned human 5-hydroxytryptamine 5A receptor,B,9606.0,,,,CHEMBL620715,4234,D,BAO_0000357,1,,,,,10624
3583,8,,Binding affinity towards 5-HT5A receptor,B,,,,,CHEMBL620716,6013,H,BAO_0000357,1,,,,,10624
3584,8,,Binding affinity towards human 5-hydroxytryptamine 5A receptor using LSD as radioligand,B,,,,,CHEMBL620717,17175,H,BAO_0000357,1,,,,,10624
3585,8,,Compound was evaluated for its binding affinity towards human 5-hydroxytryptamine 5A receptor,B,,,,,CHEMBL618072,15818,H,BAO_0000357,1,,,,,10624
3586,8,,Binding affinity towards cloned human 5-HT5A receptor was determined,B,,,,,CHEMBL857987,6166,H,BAO_0000357,1,,,,,10624
3587,8,,Binding affinity towards 5-hydroxytryptamine 5A receptor (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand.,B,,,,,CHEMBL618073,15779,H,BAO_0000219,1,,,,HEK293,10624
3588,8,,Binding affinity towards 5-hydroxytryptamine 5A receptor (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand;ND means no data.,B,,,,,CHEMBL618074,15779,H,BAO_0000219,1,,,,HEK293,10624
3589,8,,Compound was tested for its binding affinity in 5-hydroxytryptamine 5A receptor (using human cloned receptors in HEK 293 and [3H]5-CTas a radioligand ),B,,,,,CHEMBL618075,5213,H,BAO_0000219,1,,,,HEK293,10624
3590,9,Mus musculus,Binding affinity towards mouse 5-hydroxytryptamine 5A receptor,B,10090.0,,,,CHEMBL618076,17066,D,BAO_0000357,1,,,,,10625
3591,9,Mus musculus,Binding affinity towards mouse 5-hydroxytryptamine 5A receptor was evaluated using [125I]-2-iodo LSD as radioligand,B,10090.0,,,,CHEMBL618077,17066,D,BAO_0000357,1,,,,,10625
3592,9,Mus musculus,Binding affinity towards mouse 5-hydroxytryptamine 5A receptor was evaluated using [3H]- LSD as radioligand,B,10090.0,,,,CHEMBL618078,17066,D,BAO_0000357,1,,,,,10625
3593,9,Mus musculus,Binding affinity towards mouse 5-hydroxytryptamine 5A receptor was evaluated using [3H]LSD as radioligand,B,10090.0,,,,CHEMBL881821,17066,D,BAO_0000357,1,,,,,10625
3594,9,Mus musculus,Binding affinity towards murine 5-hydroxytryptamine 5A receptor,B,10090.0,,,,CHEMBL618079,17066,D,BAO_0000357,1,,,,,10625
3595,8,,Binding affinity towards mouse 5-hydroxytryptamine 5A receptor using LSD as radioligand,B,,,,,CHEMBL618080,17175,H,BAO_0000357,1,,,,,10625
3596,8,,Binding affinity against 5-hydroxytryptamine 5A receptor in HEK 293 cells was determined using [3H]LSD as radioligand,B,,,,,CHEMBL618081,16190,H,BAO_0000219,1,,,,HEK293,10576
3597,8,,Binding affinity against 5-hydroxytryptamine 5A receptor in HEK 293 cells was determined using [3H]LSD as radioligand,B,,,,,CHEMBL618082,16190,H,BAO_0000219,1,,,,HEK293,10626
3598,8,,Binding affinity towards 5-HT5a receptor,B,,,,,CHEMBL618083,4820,H,BAO_0000357,1,,,,,10624
3599,9,Homo sapiens,Binding affinity towards 5-hydroxytryptamine 5A receptor,B,9606.0,,,,CHEMBL618084,17066,D,BAO_0000357,1,,,,,10624
3600,8,,Binding affinity for rodent 5-hydroxytryptamine 5A receptor,B,,,,,CHEMBL618085,17066,H,BAO_0000357,1,,,,,10624
3601,8,,Binding affinity towards 5-hydroxytryptamine 5A receptor using lysergic acid diethylamide (LSD) as radioligand,B,,,,,CHEMBL618086,17175,H,BAO_0000357,1,,,,,10624
3602,8,,Binding affinities against 5-hydroxytryptamine 5A receptor,B,,,,,CHEMBL875092,16633,H,BAO_0000357,1,,,,,10624
3603,8,,Binding affinities towards 5-hydroxytryptamine 5A receptor,B,,,,,CHEMBL618087,16633,H,BAO_0000357,1,,,,,10624
3604,8,,The binding affinity towards 5-hydroxytryptamine 5A receptor; No affinity,B,,,,,CHEMBL872926,16700,H,BAO_0000357,1,,,,,10624
3605,4,Cavia porcellus,Percent of control response to 5-HT3 agonistic activity on guinea colon at a concentration 0.01 uM,F,10141.0,,,,CHEMBL618088,4639,H,BAO_0000019,1,,,,,104714
3606,4,,Binding affinity towards 5-HT3 receptor by the displacement of [3H]GR-65630] in human recombinant receptors in mammalian cell,B,,,,,CHEMBL618089,5486,H,BAO_0000223,1,,,,,104714
3607,9,Homo sapiens,Inhibition of human 5-hydroxytryptamine 6 receptor,B,9606.0,,,,CHEMBL618090,16146,D,BAO_0000357,1,,,,,10627
3608,9,Homo sapiens,Binding affinity towards 5-hydroxytryptamine 6 receptor using [3H]- LSD as radioligand,B,9606.0,,,,CHEMBL618091,17273,D,BAO_0000357,1,,,,,10627
3609,8,,Inhibition against human 5-hydroxytryptamine 6 receptor,B,,,,,CHEMBL618092,17687,H,BAO_0000357,1,,,,,10627
3610,9,Homo sapiens,Affinity towards human 5-hydroxytryptamine 6 serotonin receptor,B,9606.0,,,,CHEMBL618093,6491,D,BAO_0000357,1,,,,,10627
3611,8,,Binding affinity as displacement of [3H]5-HT binding to 5-hydroxytryptamine 6 receptor in HeLa cells.,B,,,,,CHEMBL618094,16190,H,BAO_0000219,1,,,,HeLa,10627
3612,9,Homo sapiens,Binding affinity towards [3H]LSD-labeled human 5-hydroxytryptamine 6 receptor,B,9606.0,,,,CHEMBL618095,17066,D,BAO_0000357,1,,,,,10627
3613,9,Homo sapiens,Binding affinity towards human 5-hydroxytryptamine 6 receptor,B,9606.0,,,,CHEMBL875093,17066,D,BAO_0000357,1,,,,,10627
3614,9,Homo sapiens,Binding affinity towards human 5-hydroxytryptamine 6 receptor was evaluated using [125I]-2-iodo LSD as radioligand,B,9606.0,,,,CHEMBL618096,17066,D,BAO_0000357,1,,,,,10627
3615,9,Homo sapiens,Binding affinity towards human 5-hydroxytryptamine 6 receptor was evaluated using [3H]-LSD as radioligand,B,9606.0,,,,CHEMBL618118,17066,D,BAO_0000357,1,,,,,10627
3616,9,Homo sapiens,Binding affinity against 5-hydroxytryptamine 6 receptor,B,9606.0,,,,CHEMBL618119,3555,D,BAO_0000357,1,,,,,10627
3617,8,,Binding affinity towards human 5-hydroxytryptamine 6 receptor,B,,,,,CHEMBL618120,5808,H,BAO_0000357,1,,,,,10627
3618,8,,Binding affinity towards human 5-hydroxytryptamine 6 receptor,B,,,,,CHEMBL618121,6013,H,BAO_0000357,1,,,,,10627
3619,8,,"Binding affinity for human 5-hydroxytryptamine 6 receptor expressed in HEK 293 human embryonic kidney cells, [3H]-lysergic acid diethylamide as radioligand",B,,,,,CHEMBL618122,15818,H,BAO_0000219,1,,,,HEK293,10627
3620,8,,Binding affinity towards human 5-hydroxytryptamine 6 receptor using [3H]LSD as radioligand,B,,,,,CHEMBL618123,16209,H,BAO_0000357,1,,,,,10627
3621,8,,Binding affinity against human 5-hydroxytryptamine 6 receptor stably transfected to HEK 293 human embryonic kidney cells using [3H]-lysergic acid diethylamide as radioligand,B,,,,,CHEMBL618124,3935,H,BAO_0000219,1,,,,HEK293,10627
3622,8,,Compound was evaluated for its binding affinity towards human 5-hydroxytryptamine 6 receptor,B,,,,,CHEMBL618125,15818,H,BAO_0000357,1,,,,,10627
3623,9,Homo sapiens,Displacement of [3H]LSD from human 5-hydroxytryptamine 6 receptor expressed in HEK 293 cells,B,9606.0,,,,CHEMBL618126,3805,D,BAO_0000219,1,,,,HEK293,10627
3624,8,,Tested on cell membranes from transfected cells selectively expressing human 5-hydroxytryptamine 6 receptor incubated with 1 nM [3H]LSD,B,,,,,CHEMBL618236,16441,H,BAO_0000019,1,,,,,10627
3625,8,,Tested on cell membranes from transfected cells selectively expressing human 5-hydroxytryptamine 6 receptor incubated with 1 nM [3H]LSD; ND is No Data.,B,,,,,CHEMBL618237,16441,H,BAO_0000019,1,,,,,10627
3626,8,,Ability to displace [3H]LSD from human 5-hydroxytryptamine 6 receptor transiently expressed in COS-7 cells,B,,,,,CHEMBL618238,6786,H,BAO_0000219,1,,,,COS-7,10627
3627,9,Homo sapiens,In vitro binding affinity to human 5-hydroxytryptamine 6 receptor,B,9606.0,,,,CHEMBL618239,4234,D,BAO_0000357,1,,,,,10627
3628,8,,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 6 receptor,B,,,,,CHEMBL618240,17085,H,BAO_0000019,1,,,,,10627
3629,8,,Inhibitory constant against human 5-hydroxytryptamine 6 receptor using [3H]LSD radioligand,B,,,,,CHEMBL618241,17200,H,BAO_0000357,1,,,,,10627
3630,8,,Antagonism assessed in a functional cAMP binding assay using 5-CT to stimulate human 5-hydroxytryptamine 6 receptor expressed in HEK 293 cells,B,,,,,CHEMBL859399,17451,H,BAO_0000219,1,,,,HEK293,10627
3631,8,,The compound was tested for antagonist activity by inhibition of human 5-HT6 stimulated adenylate cyclase,F,,,,,CHEMBL618242,3935,H,BAO_0000019,1,,,,,10627
3632,8,,Ability to displace the radioligand [3H]LSD from human 5-hydroxytryptamine 6 receptor,B,,,,,CHEMBL857991,5033,H,BAO_0000357,1,,,,,10627
3633,8,,Binding affinity against human 5-hydroxytryptamine 6 receptor,B,,,,,CHEMBL619951,4540,H,BAO_0000357,1,,,,,10627
3634,9,Homo sapiens,Binding affinity to human cloned 5-HT6 receptor in HeLa cells using [3H]- LSD as radioligand,B,9606.0,,,,CHEMBL619952,4540,D,BAO_0000219,1,,,,HeLa,10627
3635,9,Homo sapiens,Binding affinity to human cloned 5-hydroxytryptamine 6 receptor in HeLa cells using [3H]- LSD as radioligand,B,9606.0,,,,CHEMBL619953,4540,D,BAO_0000219,1,,,,HeLa,10627
3636,8,,Binding affinity against 5-hydroxytryptamine 6 human cloned receptors in HeLa cells,B,,,,,CHEMBL619954,17296,H,BAO_0000219,1,,,,HeLa,10627
3637,8,,Binding affinity against 5-hydroxytryptamine 6 human cloned receptors in HeLa cells using [3H]LSD as radioligand,B,,,,,CHEMBL619955,17296,H,BAO_0000219,1,,,,HeLa,10627
3638,8,,Binding affinity against 5-hydroxytryptamine 6 human cloned receptors in HeLa cells using [3H]LSD as radioligand,B,,,,,CHEMBL619956,17296,H,BAO_0000219,1,,,,HeLa,10627
3639,8,,Binding affinity towards 5-hydroxytryptamine 6 receptor (human cloned receptor) in CHO cells using [3H]5-HT as radioligand,B,,,,,CHEMBL619957,15779,H,BAO_0000219,1,,,,CHO,10627
3640,8,,Binding affinity towards 5-hydroxytryptamine 6 receptor (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand.,B,,,,,CHEMBL619958,15779,H,BAO_0000219,1,,,,HEK293,10627
3641,8,,Binding affinity towards 5-hydroxytryptamine 6 receptor (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand; ND means no data.,B,,,,,CHEMBL620627,15779,H,BAO_0000219,1,,,,HEK293,10627
3642,8,,Binding affinity towards 5-hydroxytryptamine 6 receptor (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand;ND means no data.,B,,,,,CHEMBL620628,15779,H,BAO_0000219,1,,,,HEK293,10627
3643,8,,Binding affinity towards 5-hydroxytryptamine 6 receptor (human cloned receptor) in HeLa cells using [3H]LSD as radioligand;ND means no data.,B,,,,,CHEMBL620629,15779,H,BAO_0000219,1,,,,HeLa,10627
3644,8,,Binding affinity towards human 5-hydroxytryptamine 6 receptor,B,,,,,CHEMBL620630,6166,H,BAO_0000357,1,,,,,10627
3645,8,,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 6 receptor expressed in HeLa cells using [3H]LSD as radioligand,B,,,,,CHEMBL620782,17451,H,BAO_0000219,1,,,,HeLa,10627
3646,8,,Compound was evaluated for its ability to displace [3H]LSD binding from human recombinant 5-hydroxytryptamine 6 receptor,B,,,,,CHEMBL620783,15316,H,BAO_0000357,1,,,,,10627
3647,8,,Binding affinity against human 5-hydroxytryptamine 6 receptor,B,,,,,CHEMBL620784,4199,H,BAO_0000357,1,,,,,10627
3648,8,,Binding affinity against human cloned 5-hydroxytryptamine 6 receptor in HeLa cells using [3H]LSD,B,,,,,CHEMBL620785,15146,H,BAO_0000219,1,,,,HeLa,10627
3649,8,,Compound was tested for its binding affinity in 5-hydroxytryptamine 6 receptor (using human cloned receptors in HeLa and [3H]LSD as a radioligand ),B,,,,,CHEMBL857992,5213,H,BAO_0000357,1,,,,,10627
3650,8,,In vitro binding affinity at human recombinant 5-hydroxytryptamine 6 receptor in mammalian cells using 3[H]LSD as the radioligand,B,,,,,CHEMBL620786,16429,H,BAO_0000219,1,,,,,10627
3651,8,,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 6 receptor in HeLa cells using [3H]5-LSD.,B,,,,,CHEMBL620787,14818,H,BAO_0000219,1,,,,HeLa,10627
3652,8,,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 6 receptor in HeLa cells, using [3H]5-LSD as radioligand; n=3",B,,,,,CHEMBL620788,4829,H,BAO_0000219,1,,,,HeLa,10627
3653,8,,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 6 receptor in HeLa cells, using [3H]5-LSD as radioligand; n=9",B,,,,,CHEMBL620789,4829,H,BAO_0000219,1,,,,HeLa,10627
3654,8,,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 6 receptor in HeLa cells, using [3H]LSD as radioligand; n=3",B,,,,,CHEMBL620790,4829,H,BAO_0000219,1,,,,HeLa,10627
3655,8,,Compound was tested for the displacement of [3H]5-HT binding to cloned rat 5-hydroxytryptamine 6 receptor stably expressed in CHO cells,B,,,,,CHEMBL620791,15250,H,BAO_0000219,1,,,,CHO,10628
3656,8,,Binding affinity against 5-hydroxytryptamine 6 receptor from CHO cell membranes using [3H]5-HT as the radioligand.,B,,,,,CHEMBL620792,14423,H,BAO_0000019,1,,,,,10628
3657,8,,The compound was tested for binding affinity against 5-hydroxytryptamine 6 receptor,B,,,,,CHEMBL620793,15086,H,BAO_0000357,1,,,,,10628
3658,8,,Binding affinity of compound towards serotonin 5-hydroxytryptamine 6 receptor was determined,B,,,,,CHEMBL620794,4342,H,BAO_0000357,1,,,,,10628
3659,9,Homo sapiens,Binding affinity as displacement of [3H]5-HT binding to 5-hydroxytryptamine 6 receptor in HeLa cells,B,9606.0,,,,CHEMBL620795,16190,D,BAO_0000219,1,,,,HeLa,10627
3660,8,,Binding affinity towards human 5-hydroxytryptamine 6 receptor,B,,,,,CHEMBL620796,4820,H,BAO_0000357,1,,,,,10627
3661,8,,Percentage of displacement at 5-hydroxytryptamine 6 receptor at 10e-8 M,B,,,,,CHEMBL620797,4639,H,BAO_0000357,1,,,,,10627
3662,9,Homo sapiens,Antagonistic activity towards 5-hydroxytryptamine 6 receptor was evaluated in cAMP assay,F,9606.0,,,,CHEMBL620798,17066,D,BAO_0000019,1,,,,,10627
3663,8,,Inhibition of binding towards 5-hydroxytryptamine 6 receptor at 100 nM concentration,B,,,,,CHEMBL620799,6011,H,BAO_0000357,1,,,,,10627
3664,8,,Binding affinity towards human 5-hydroxytryptamine 6 receptor,B,,,,,CHEMBL620800,17066,H,BAO_0000357,1,,,,,10627
3665,8,,Binding affinity of compound towards serotonin 5-hydroxytryptamine 6 receptor; inactive at 10 uM,B,,,,,CHEMBL620801,17515,H,BAO_0000357,1,,,,,10627
3666,8,,Compound was tested for its binding affinity towards 5-hydroxytryptamine 6 receptor,B,,,,,CHEMBL875100,5014,H,BAO_0000357,1,,,,,10627
3667,8,,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 6 receptor was determined,B,,,,,CHEMBL620802,4373,H,BAO_0000357,1,,,,,10627
3668,8,,Antagonistic activity towards 5-hydroxytryptamine 6 receptor,F,,,,,CHEMBL620803,17066,H,BAO_0000019,1,,,,,10627
3669,8,,Antagonistic activity towards 5-hydroxytryptamine 6 receptor was evaluated in cAMP assay,F,,,,,CHEMBL620804,17066,H,BAO_0000019,1,,,,,10627
3670,8,,Binding affinity for 5-hydroxytryptamine 6 receptor was determined,B,,,,,CHEMBL620805,4373,H,BAO_0000357,1,,,,,10627
3671,8,,Evaluated for the binding affinity towards 5-hydroxytryptamine 6 receptor,B,,,,,CHEMBL620806,4687,H,BAO_0000357,1,,,,,10627
3672,8,,Ability to displace [125I]LSD 113808 from 5-hydroxytryptamine 6 receptor at concentration of 10e-6 M,B,,,,,CHEMBL620807,16946,H,BAO_0000357,1,,,,,10627
3673,8,,Ability to displace [125I]LSD 113808 from 5-hydroxytryptamine 6 receptor at concentration of 10e-8 M,B,,,,,CHEMBL620808,16946,H,BAO_0000357,1,,,,,10627
3674,8,,Binding affinities against 5-hydroxytryptamine 6 receptor,B,,,,,CHEMBL620809,16633,H,BAO_0000357,1,,,,,10627
3675,8,,Binding affinities towards 5-hydroxytryptamine 6 receptor,B,,,,,CHEMBL620810,16633,H,BAO_0000357,1,,,,,10627
3676,9,Homo sapiens,Binding affinity towards 5-hydroxytryptamine 6 receptor,B,9606.0,,,,CHEMBL620811,17066,D,BAO_0000357,1,,,,,10627
3677,8,,The binding affinity towards 5-hydroxytryptamine 6 receptor; No affinity,B,,,,,CHEMBL620812,16700,H,BAO_0000357,1,,,,,10627
3678,8,,Affinity against 5-hydroxytryptamine 6 receptor,B,,,,,CHEMBL620813,3269,H,BAO_0000357,1,,,,,10627
3679,8,,Binding affinity towards human recombinant 5-hydroxytryptamine 7 receptor by the displacement of [3H]-5-CT],B,,,,,CHEMBL620814,5486,H,BAO_0000357,1,,,,,10627
3680,9,Homo sapiens,Inhibition of human 5-hydroxytryptamine 7 receptor,B,9606.0,,,,CHEMBL620815,16146,D,BAO_0000357,1,,,,,10209
3681,8,,Compound was tested for its binding affinity towards human 5-hydroxytryptamine 7 receptor from HEK293 cells using radioligand [3H]LSD,B,,,,,CHEMBL620816,5014,H,BAO_0000219,1,,,,HEK293,10209
3682,8,,Compound at 1 uM was tested for the inhibition of radioligand [3H]LSD binding to recombinant human 5-hydroxytryptamine 7 receptor,B,,,,,CHEMBL620817,15463,H,BAO_0000357,1,,,,,10209
3683,8,,In vitro binding affinity against human 5-hydroxytryptamine 7 receptor at a concentration of 100 (nM),B,,,,,CHEMBL620818,3805,H,BAO_0000357,1,,,,,10209
3684,8,,Inhibition (at 1 uM) of radioligand [3H]LSD binding to human 5-hydroxytryptamine 7 receptor on HEK293 cells,B,,,,,CHEMBL620819,5014,H,BAO_0000219,1,,,,HEK293,10209
3685,9,Homo sapiens,Affinity towards human 5-hydroxytryptamine 7 serotonin receptor,B,9606.0,,,,CHEMBL620820,6491,D,BAO_0000357,1,,,,,10209
3686,8,,Binding affinity for 5-hydroxytryptamine 7 receptor human cloned receptors in CHO cells using [3H]5-HT,B,,,,,CHEMBL620821,16190,H,BAO_0000219,1,,,,CHO,10209
3687,9,Homo sapiens,Binding affinity towards human 5-hydroxytryptamine 7 receptor,B,9606.0,,,,CHEMBL620822,17066,D,BAO_0000357,1,,,,,10209
3688,9,Homo sapiens,Displacement of [3H]5-HT from human 5-hydroxytryptamine 7 receptor,B,9606.0,,,,CHEMBL620823,17066,D,BAO_0000357,1,,,,,10209
3689,9,Homo sapiens,Binding affinity against 5-hydroxytryptamine 7 receptor,B,9606.0,,,,CHEMBL620824,3555,D,BAO_0000357,1,,,,,10209
3690,8,,Binding affinity towards human 5-hydroxytryptamine 7 receptor by the displacement of [3H]-5-HT radioligand from the cloned receptor expressed in CHO cells,B,,,,,CHEMBL620825,6588,H,BAO_0000219,1,,,,CHO,10209
3691,8,,Binding affinity towards recombinant human 5-hydroxytryptamine 7 receptor was determined using [3H]LSD as radioligand,B,,,,,CHEMBL872930,15463,H,BAO_0000357,1,,,,,10209
3692,8,,Binding affinity towards 5-hydroxytryptamine 7 receptor,B,,,,,CHEMBL620826,6013,H,BAO_0000357,1,,,,,10209
3693,8,,Binding affinity towards human 5-hydroxytryptamine 7 receptor using [3H]5-HT as radioligand,B,,,,,CHEMBL620827,16209,H,BAO_0000357,1,,,,,10209
3694,8,,Compound was evaluated for its binding affinity for human 5-hydroxytryptamine 7 receptor,B,,,,,CHEMBL620828,3935,H,BAO_0000357,1,,,,,10209
3695,8,,Compound was evaluated for its binding affinity towards human 5-hydroxytryptamine 7 receptor,B,,,,,CHEMBL620829,15818,H,BAO_0000357,1,,,,,10209
3696,8,,Binding affinity towards human 5-hydroxytryptamine 7 receptor on HEK293 cells using radioligand [3H]LSD,B,,,,,CHEMBL620830,5014,H,BAO_0000219,1,,,,HEK293,10209
3697,8,,Tested on cell membranes from transfected cells selectively expressing human 5-hydroxytryptamine 7 receptor incubated with 1 nM [3H]LSD,B,,,,,CHEMBL620831,16441,H,BAO_0000019,1,,,,,10209
3698,8,,Tested on cell membranes from transfected cells selectively expressing human 5-hydroxytryptamine 7 receptor incubated with 1 nM [3H]LSD; ND is No Data.,B,,,,,CHEMBL620832,16441,H,BAO_0000019,1,,,,,10209
3699,9,Homo sapiens,In vitro binding affinity to human 5-hydroxytryptamine 7 receptor,B,9606.0,,,,CHEMBL621548,4234,D,BAO_0000357,1,,,,,10209
3700,8,,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 7 receptor,B,,,,,CHEMBL621549,17085,H,BAO_0000019,1,,,,,10209
3701,8,,Inhibitory constant against human 5-hydroxytryptamine 7 receptor using [3H]LSD radioligand,B,,,,,CHEMBL621550,17200,H,BAO_0000357,1,,,,,10209
3702,8,,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 7 receptor expressed in CHO cells using [3H]-LSD as radioligand; Not determined,B,,,,,CHEMBL621551,17451,H,BAO_0000219,1,,,,CHO,10209
3703,8,,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 7 receptor; ND means not determined,B,,,,,CHEMBL621552,17085,H,BAO_0000019,1,,,,,10209
3704,8,,Binding affinity for human cloned 5-hydroxytryptamine 7 receptor,B,,,,,CHEMBL857077,5104,H,BAO_0000357,1,,,,,10209
3705,8,,Binding affinity for human cloned 5-hydroxytryptamine 7 receptor; Not tested,B,,,,,CHEMBL618158,5104,H,BAO_0000357,1,,,,,10209
3706,9,Homo sapiens,Ability to displace the radioligand [3H]5-carboxyamidotryptamine ([3H]5-CT) from human 5-hydroxytryptamine 7 receptor expressed in COS-7 cells,B,9606.0,,,,CHEMBL618159,5033,D,BAO_0000219,1,,,,COS-7,10209
3707,8,,Ability to displace the radioligand [3H]5-carboximidotryptamine ([3H]-5-CT) from cloned human 5-hydroxytryptamine 7 receptor expressed in COS-7 cells,B,,,,,CHEMBL875101,5486,H,BAO_0000219,1,,,,COS-7,10209
3708,9,Homo sapiens,Binding affinity to human cloned 5-hydroxytryptamine 7 receptor in HEK 293 cells using [3H]-5-CT as radioligand,B,9606.0,,,,CHEMBL618160,4540,D,BAO_0000219,1,,,,HEK293,10209
3709,8,,Binding affinity at human cloned 5-hydroxytryptamine 7 receptor.,B,,,,,CHEMBL618161,6166,H,BAO_0000357,1,,,,,10209
3710,8,,Binding affinity towards cloned human 5-hydroxytryptamine 7 receptor was determined in HEK293 cells using [3H]5-CT as radioligand,B,,,,,CHEMBL618162,17342,H,BAO_0000219,1,,,,HEK293,10209
3711,8,,Binding affinity towards human recombinant 5-hydroxytryptamine 7 receptor was determined using [3H]5-CT as radioligand,B,,,,,CHEMBL618163,17342,H,BAO_0000357,1,,,,,10209
3712,8,,Binding affinity against 5-hydroxytryptamine 7 human receptors,B,,,,,CHEMBL618164,17296,H,BAO_0000357,1,,,,,10209
3713,8,,Binding affinity to human recombinant 5-hydroxytryptamine 7 receptor in mammalian cells using [3H]5-CT as radioligand,B,,,,,CHEMBL618165,16429,H,BAO_0000219,1,,,,,10209
3714,8,,Binding affinity toward 5-hydroxytryptamine 7 receptor (human cloned receptor) in HEK 293 cells using [3H]-5-CT as radioligand.,B,,,,,CHEMBL618166,15779,H,BAO_0000219,1,,,,HEK293,10209
3715,8,,Binding affinity towards 5-hydroxytryptamine 7 receptor (a) (human cloned receptor) in HEK 293 cells using [3H]5-CT as radioligand.,B,,,,,CHEMBL857989,15779,H,BAO_0000219,1,,,,HEK293,10209
3716,8,,Binding affinity towards 5-hydroxytryptamine 7 receptor (human cloned receptor) in HEK 293 cells using [3H]5-CT as radioligand.,B,,,,,CHEMBL619888,15779,H,BAO_0000219,1,,,,HEK293,10209
3717,8,,Binding affinity towards 5-hydroxytryptamine 7 receptor (human cloned receptor) in HEK 293 cells using [3H]5-CT as radioligand.,B,,,,,CHEMBL619889,15779,H,BAO_0000219,1,,,,HEK293,10209
3718,8,,Binding affinity towards 5-hydroxytryptamine 7 receptor 7(a) (human cloned receptor in HEK 293 cells using [3H]5-CT as radioligand.,B,,,,,CHEMBL619890,15779,H,BAO_0000219,1,,,,HEK293,10209
3719,8,,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 7 receptor expressed in CHO cells using [3H]LSD as radioligand,B,,,,,CHEMBL619891,17451,H,BAO_0000219,1,,,,CHO,10209
3720,8,,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 7 receptor in HEK 293 cells using [3H]5-CT as the radioligand (n=3),B,,,,,CHEMBL619892,4199,H,BAO_0000219,1,,,,HEK293,10209
3721,9,,Displacement of [3H]-5-CT from human 5-hydroxytryptamine 7 receptor expressed in HEK-293 cells,B,,,,,CHEMBL619893,4199,D,BAO_0000219,1,,,,HEK293,10209
3722,8,,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 7 receptor in HEK 293 cells using [3H]5-CT as the radioligand(n=6),B,,,,,CHEMBL619894,4199,H,BAO_0000219,1,,,,HEK293,10209
3723,9,,Binding affinity towards cloned human 5-hydroxytryptamine 7 receptor in HEK 293 cells,B,,,,,CHEMBL619895,3680,D,BAO_0000219,1,,,,HEK293,10209
3724,9,,Binding affinity towards human recombinant 5-hydroxytryptamine 7 receptor using [3H]5-CT as radioligand,B,,,,,CHEMBL619896,3680,D,BAO_0000357,1,,,,,10209
3725,8,,Compound was evaluated for its ability to displace [3H]5-CT binding from cloned human 5-hydroxytryptamine 7 receptor expressed in COS-7 cells.,B,,,,,CHEMBL619897,15316,H,BAO_0000219,1,,,,COS-7,10209
3726,8,,Compound was tested for its binding affinity against human cloned 5-hydroxytryptamine 7 receptor in HEK 293 cells using [3H]5-CT,B,,,,,CHEMBL619898,15146,H,BAO_0000219,1,,,,HEK293,10209
3727,8,,Binding affinity for human cloned 5-hydroxytryptamine 7 receptor in HEK 293 using [3H]5-CT as a radioligand,B,,,,,CHEMBL619899,5213,H,BAO_0000219,1,,,,HEK293,10209
3728,8,,Compound was tested for its binding affinity in 5-hydroxytryptamine 7 receptor (using human cloned receptors in HEK 293 and [3H]5-CT as a radioligand ),B,,,,,CHEMBL619900,5213,H,BAO_0000219,1,,,,HEK293,10209
3729,9,Homo sapiens,Binding affinity towards cloned human 5-hydroxytryptamine 7 receptor expressed in HEK 293 cells using [3H]5-CT,B,9606.0,,,,CHEMBL619901,14818,D,BAO_0000219,1,,,,HEK293,10209
3730,8,,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 7 receptor expressed in HEK 293 cells using [3H]5-CT. ,B,,,,,CHEMBL620580,14818,H,BAO_0000219,1,,,,HEK293,10209
3731,8,,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 7 receptor in HEK 293 cells using [3H]5-CT.,B,,,,,CHEMBL620581,14818,H,BAO_0000219,1,,,,HEK293,10209
3732,8,,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 7 receptor in HEK293 cells, using [3H]5-CT as radioligand",B,,,,,CHEMBL620733,4829,H,BAO_0000219,1,,,,HEK293,10209
3733,9,Homo sapiens,Inhibitory constant against human 5-hydroxytryptamine 7 receptor using [3H]-LSD radioligand; Not determined,B,9606.0,,,,CHEMBL620734,17200,D,BAO_0000357,1,,,,,10209
3734,9,Mus musculus,Binding affinity towards mouse 5-hydroxytryptamine 7 receptor was evaluated using [3H]5-HT as radioligand,B,10090.0,,,,CHEMBL620735,17066,D,BAO_0000357,1,,,,,10022
3735,8,Oryctolagus cuniculus,The dissociation equilibrium constant (pKB=-log KB) of compound was determined against the vascular 5-hydroxytryptamine 7 receptor in the endothelium denuded rabbit jugular vein.,B,9986.0,,,,CHEMBL620736,14025,H,BAO_0000019,1,,,,,10209
3736,8,,Compound was tested for the displacement of [3H]5-HT binding to cloned rat 5-hydroxytryptamine 7 receptor stably expressed in CHO cells,B,,,,,CHEMBL620737,15250,H,BAO_0000219,1,,,,CHO,11923
3737,8,,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT 7 receptors at a concentration of 10000 nM,B,,,,,CHEMBL620738,16372,H,BAO_0000219,1,,,,CHO,11923
3738,8,,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT 7 receptors at a concentration of 100 nM,B,,,,,CHEMBL620739,16372,H,BAO_0000219,1,,,,CHO,11923
3739,8,,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT 7 receptors at a concentration of 1 nM,B,,,,,CHEMBL620740,16372,H,BAO_0000219,1,,,,CHO,11923
3740,8,,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT 7 receptors by 10000 nM 5-HT.,B,,,,,CHEMBL620741,16372,H,BAO_0000219,1,,,,CHO,11923
3741,8,,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT 7 receptors by 100 nM 5-HT.,B,,,,,CHEMBL620742,16372,H,BAO_0000219,1,,,,CHO,11923
3742,8,,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT 7 receptors by 1 nM 5-HT,B,,,,,CHEMBL620743,16372,H,BAO_0000219,1,,,,CHO,11923
3743,8,,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors at a concentration of 10000 nM,B,,,,,CHEMBL620744,16372,H,BAO_0000219,1,,,,CHO,11923
3744,8,,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors at a concentration of 100 nM,B,,,,,CHEMBL620745,16372,H,BAO_0000219,1,,,,CHO,11923
3745,8,,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors at a concentration of 1 nM,B,,,,,CHEMBL620746,16372,H,BAO_0000219,1,,,,CHO,11923
3746,8,,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors by 10000 nM 5-HT.,B,,,,,CHEMBL620747,16372,H,BAO_0000219,1,,,,CHO,11923
3747,8,,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors by 100 nM 5-HT.,B,,,,,CHEMBL620748,16372,H,BAO_0000219,1,,,,CHO,11923
3748,8,,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors by 1 nM 5-HT.,B,,,,,CHEMBL620749,16372,H,BAO_0000219,1,,,,CHO,11923
3749,8,,Binding affinity towards rat 5-hydroxytryptamine 7 receptor,B,,,,,CHEMBL620750,17066,H,BAO_0000357,1,,,,,11923
3750,9,Rattus norvegicus,Binding affinity towards rat 5-hydroxytryptamine 7 receptor was evaluated using [3H]5-HT as radioligand,B,10116.0,,,,CHEMBL620751,17066,D,BAO_0000357,1,,,,,11923
3751,8,,Binding affinity to the rat 5-hydroxytryptamine 7 receptor,B,,,,,CHEMBL620752,17386,H,BAO_0000357,1,,,,,11923
3752,8,,Binding affinity against 5-hydroxytryptamine 7 receptor using from CHO cell membranes [3H]5-HT as the radioligand.,B,,,,,CHEMBL872929,14423,H,BAO_0000019,1,,,,,11923
3753,9,Rattus norvegicus,Binding affinity against Rat 5-hydroxytryptamine 7 receptor using [3H]5-HT,B,10116.0,,,,CHEMBL620753,15874,D,BAO_0000357,1,,,,,11923
3754,9,Rattus norvegicus,Displacement of [3H]5-HT from over-expressed rat 5-hydroxytryptamine 7 receptor,B,10116.0,,,,CHEMBL620754,15874,D,BAO_0000357,1,,,,,11923
3755,9,Rattus norvegicus,Displacement of [3H]5-HT from rat 5-hydroxytryptamine 7 receptor expressed in CHO cells,B,10116.0,,,,CHEMBL620755,16372,D,BAO_0000219,1,,,,CHO,11923
3756,8,,In vitro binding affinity towards cloned rat 5-hydroxytryptamine 7 receptor using [3H]5-HT as radioligand,B,,,,,CHEMBL620756,4622,H,BAO_0000357,1,,,,,11923
3757,8,,The compound was tested for binding affinity against 5-hydroxytryptamine 7 receptor,B,,,,,CHEMBL620757,15086,H,BAO_0000357,1,,,,,11923
3758,8,,"Effect of compound on stimulation of cAMP production in CHO cells expressing rat 5-HT7 receptors at 1, 10, 100 1000 and 10000 nM conc; Not tested",B,,,,,CHEMBL620758,16372,H,BAO_0000219,1,,,,CHO,11923
3759,8,,"Effect of compound on stimulation of cAMP production in CHO cells expressing rat 5-HT7 receptors at 1, 10, 100 1000 and 10000 nM conc; not tested",B,,,,,CHEMBL620759,16372,H,BAO_0000219,1,,,,CHO,11923
3760,8,,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors at a concentration of 1 nM; not tested,B,,,,,CHEMBL620760,16372,H,BAO_0000219,1,,,,CHO,11923
3761,8,,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors by 1 nM 5-HT; Not tested,B,,,,,CHEMBL620761,16372,H,BAO_0000219,1,,,,CHO,11923
3762,8,,Maximal relaxation effect induced by 3 uM compound on substance P stimulated guinea pig ileum with 5-hydroxytryptamine 7 receptor desensitization,F,,Ileum,,,CHEMBL620762,17386,H,BAO_0000221,1,2116.0,,,,11923
3763,8,,Maximal relaxation effect induced by 3 uM compound on substance P stimulated guinea pig ileum with 5-hydroxytryptamine 7 receptor nondesensitization,F,,Ileum,,,CHEMBL620763,17386,H,BAO_0000221,1,2116.0,,,,11923
3764,8,,Maximal relaxation effect induced by 3 uM compound on substance P stimulated guinea pig ileum with 5-hydroxytryptamine receptor desensitization,F,,Ileum,,,CHEMBL620764,17386,H,BAO_0000221,1,2116.0,,,,11923
3765,9,Rattus norvegicus,Inhibition of [3H]-5-CT binding to 5-hydroxytryptamine 7 receptor of rat cortical membranes,B,10116.0,,Membranes,,CHEMBL857990,5831,D,BAO_0000249,1,,,,,11923
3766,8,,Binding affinity of compound towards serotonin 5-hydroxytryptamine 7 receptor was determined,B,,,,,CHEMBL620765,4342,H,BAO_0000357,1,,,,,11923
3767,8,,Binding affinity at rat 5-hydroxytryptamine 7 receptor.,B,,,,,CHEMBL620766,17319,H,BAO_0000357,1,,,,,11923
3768,8,,Binding affinity towards 5-hydroxytryptamine receptor 7 on rat hypothalamus membranes using [3H]5-CT as radioligand.,B,,Hypothalamus,,,CHEMBL620767,17342,H,BAO_0000019,1,1898.0,,,,11923
3769,8,,Binding affinity towards cloned rat 5-hydroxytryptamine 7 receptor was determined using [3H]5-HT as radioligand,B,,,,,CHEMBL620768,17342,H,BAO_0000357,1,,,,,11923
3770,8,,Binding affinity against 5-hydroxytryptamine 7 receptor using [3H]-5-CT in rat hypothalamus membranes,B,,Hypothalamus,,,CHEMBL619051,3680,H,BAO_0000249,1,1898.0,,,,11923
3771,8,,Binding affinity towards 5-hydroxytryptamine 7 receptor,B,,,,,CHEMBL619052,3680,H,BAO_0000357,1,,,,,11923
3772,9,Rattus norvegicus,Agonistic activity against rat 5-HT7 adenyl cyclase expressed by HEK293 cells,F,10116.0,,,,CHEMBL619053,17319,D,BAO_0000219,1,,,,HEK293,11923
3773,9,Rattus norvegicus,Agonistic activity against rat 5-HT7 adenyl cyclase expressed in HEK293 cells; Active,F,10116.0,,,,CHEMBL619703,17319,D,BAO_0000219,1,,,,HEK293,11923
3774,9,Rattus norvegicus,Agonistic activity against rat 5-HT7-adenyl cyclase expressed by HEK293 cells; Active,F,10116.0,,,,CHEMBL619704,17319,D,BAO_0000219,1,,,,HEK293,11923
3775,8,,Binding affinity towards 5-hydroxytryptamine 7 receptor,B,,,,,CHEMBL619851,4820,H,BAO_0000357,1,,,,,10209
3776,8,,Percentage of displacement at 5-hydroxytryptamine 7 receptor at 10e-8 M,B,,,,,CHEMBL619852,4639,H,BAO_0000357,1,,,,,10209
3777,8,,Inhibition of binding towards 5-hydroxytryptamine 7 receptor at 100 nM concentration,B,,,,,CHEMBL619853,6011,H,BAO_0000357,1,,,,,10209
3778,9,Homo sapiens,Binding affinity towards human 5-hydroxytryptamine 7 receptor,B,9606.0,,,,CHEMBL619854,17066,D,BAO_0000357,1,,,,,10209
3779,8,,Binding affinity of compound towards rodent 5-hydroxytryptamine 7 receptor,B,,,,,CHEMBL619855,17066,H,BAO_0000357,1,,,,,10209
3780,8,,Binding affinity of compound towards serotonin 5-hydroxytryptamine 7 receptor; inactive at 10 uM,B,,,,,CHEMBL619856,17515,H,BAO_0000357,1,,,,,10209
3781,8,,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 7 receptor was determined,B,,,,,CHEMBL619857,4373,H,BAO_0000357,1,,,,,10209
3782,8,,Antagonistic activity towards 5-hydroxytryptamine 7 receptor was evaluated by cAMP assay,F,,,,,CHEMBL619858,17066,H,BAO_0000019,1,,,,,10209
3783,8,,Binding affinity for 5-hydroxytryptamine 7 receptor was determined,B,,,,,CHEMBL619859,4373,H,BAO_0000357,1,,,,,10209
3784,8,,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 7 receptor was determined,B,,,,,CHEMBL619860,4373,H,BAO_0000357,1,,,,,10209
3785,8,,Evaluated for the binding affinity to 5-hydroxytryptamine 7 receptor,B,,,,,CHEMBL619861,4687,H,BAO_0000357,1,,,,,10209
3786,8,,Non-selective inhibitory activity was determined against 5-hydroxytryptamine 7 receptor,B,,,,,CHEMBL619862,17342,H,BAO_0000357,1,,,,,10209
3787,8,,Ability to displace [125I]LSD 113808 from 5-hydroxytryptamine 7 receptor at concentration of 10e-6 M,B,,,,,CHEMBL619863,16946,H,BAO_0000357,1,,,,,10209
3788,8,,Ability to displace [125I]LSD 113808 from 5-hydroxytryptamine 7 receptor at concentration of 10e-8 M,B,,,,,CHEMBL619864,16946,H,BAO_0000357,1,,,,,10209
3789,8,,Binding affinities against 5-hydroxytryptamine 7 receptor,B,,,,,CHEMBL872928,16633,H,BAO_0000357,1,,,,,10209
3790,8,,Binding affinities towards 5-hydroxytryptamine 7 receptor,B,,,,,CHEMBL619865,16633,H,BAO_0000357,1,,,,,10209
3791,8,,Binding affinity towards rodent 5-hydroxytryptamine 7 receptor,B,,,,,CHEMBL619866,17066,H,BAO_0000357,1,,,,,10209
3792,8,,The binding affinity towards 5-hydroxytryptamine 7 receptor; No affinity,B,,,,,CHEMBL619867,16700,H,BAO_0000357,1,,,,,10209
3793,8,,Maximal relaxation effect induced by 3 uM compound on substance P stimulated guinea pig ileum with 5-hydroxytryptamine 7 receptor desensitization,B,,Ileum,,,CHEMBL619868,17386,H,BAO_0000221,1,2116.0,,,,10209
3794,8,,Compound was evaluated for the potency to inhibit oxidation of arachidonic acid by human recombinant 5-Lipoxygenase using a spectrophotometric assay,F,,,,,CHEMBL619869,14080,H,BAO_0000019,1,,,,,55
3795,9,Homo sapiens,Inhibition of oxidation of arachidonic acid by human 5-Lipoxygenase using spectrophotometric assay,F,9606.0,,,,CHEMBL619870,14080,D,BAO_0000019,1,,,,,55
3796,8,,In vitro inhibition of human recombinant 5-lipoxygenase enzyme,B,,,,,CHEMBL619871,409,H,BAO_0000357,1,,,,,55
3797,8,,In vitro inhibition of human recombinant lipoxygenase enzyme,B,,,,,CHEMBL619872,409,H,BAO_0000357,1,,,,,55
3798,8,,In vitro inhibition of human recombinant lipoxygenase enzyme; No inhibition,B,,,,,CHEMBL619873,409,H,BAO_0000357,1,,,,,55
3799,8,,Inhibition of 5-lipoxygenase in human whole blood.,B,,Blood,,,CHEMBL619874,11090,H,BAO_0000357,1,178.0,,,,55
3800,8,,Inhibition of 5-lipoxygenase in human whole blood.,B,,Blood,,,CHEMBL619875,11090,H,BAO_0000357,1,178.0,,,,55
3801,8,,Compound was tested for the inhibition of 5-lipoxygenase of human PMN stimulated by calcium ionophore A-23187 for the formation of 5-HETE,B,,,,,CHEMBL619876,948,H,BAO_0000357,1,,,,,55
3802,8,,Compound was tested for the inhibition of 5-lipoxygenase of human PMN stimulated by calcium ionophore A-23187 for the formation of leukotriene B4 (LTB4),B,,,,,CHEMBL619877,948,H,BAO_0000357,1,,,,,55
3803,8,,In vitro 5-lipoxygenase inhibitory activity against calcium ionophore (A23187) induced LTB4 formation in human polymorphonuclear leukocytes.,F,,,,,CHEMBL619878,13622,H,BAO_0000219,1,,,,,55
3804,8,,In vitro 5-lipoxygenase inhibitory activity against calcium ionophore (A23187) induced LTB4 formation in human whole blood,F,,Blood,,,CHEMBL619879,13622,H,BAO_0000019,1,178.0,,,,55
3805,8,,In vitro inhibition of 5-lipoxygenase from human polymorphs,B,,,,,CHEMBL619880,9637,H,BAO_0000357,1,,,,,55
3806,8,,In vitro inhibition of leukotriene B4 synthesis in human whole blood by inhibiting 5-LPO (5-lipoxygenase),B,,,,,CHEMBL619881,11320,H,BAO_0000357,1,,,,,55
3807,8,,In vitro inhibition of leukotriene B4 synthesis in human whole blood by inhibiting 5-lipoxygenase,B,,,,,CHEMBL619882,11320,H,BAO_0000357,1,,,,,55
3808,8,,In vitro inhibitory activity against 5-lipoxygenase in a human whole blood assay,B,,,,,CHEMBL619883,6838,H,BAO_0000357,1,,,,,55
3809,9,Homo sapiens,Inhibition of 5-Lipoxygenase (5-LO) of human whole blood (HWB),B,9606.0,Blood,,,CHEMBL619884,17667,D,BAO_0000357,1,178.0,,,,55
3810,8,,In vitro potency against human 5-Lipoxygenase,B,,,,,CHEMBL619885,12703,H,BAO_0000357,1,,,,,55
3811,9,Homo sapiens,Inhibitory activity against 5-lipoxygenase in Human whole blood (HWBL) stimulated with calcium ionophore (A23187) and LTB4 measured by enzyme immunoassay,F,9606.0,,,,CHEMBL619886,14312,D,BAO_0000019,1,,,,,55
3812,8,,Inhibition activity against 5-lipoxygenase in Human whole blood (HWBL) stimulated with calcium ionophore (A23187) and LTB4 measured by enzyme immunoassay; No data,F,,Blood,,,CHEMBL619887,14312,H,BAO_0000019,1,178.0,,,,55
3813,8,,Inhibition of 5-lipoxygenase activity of compound evaluated as determined by the inhibition of calcium ionophore-induced leukotriene B4 production in human blood.,F,,,,,CHEMBL875097,5364,H,BAO_0000019,1,,,,,55
3814,8,,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of 5-HETE,B,,,,,CHEMBL618001,951,H,BAO_0000219,1,,,,,55
3815,8,,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of 5-HETE; NA means Not active,B,,,,,CHEMBL618002,951,H,BAO_0000219,1,,,,,55
3816,8,,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of LTB4,B,,,,,CHEMBL618003,951,H,BAO_0000219,1,,,,,55
3817,8,,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of LTB4; NA means Not active,B,,,,,CHEMBL618004,951,H,BAO_0000219,1,,,,,55
3818,8,,Inhibition of human 5-lipoxygenase in human cells,B,,,,,CHEMBL618005,12365,H,BAO_0000219,1,,,,,55
3819,8,,Inhibition of human neutrophil 5-lipoxygenase,B,,,,,CHEMBL618006,10603,H,BAO_0000357,1,,,,,55
3820,8,,Inhibitory activity against 5-lipoxygenase expressed from human polymorphonuclear cells,B,,,,,CHEMBL875086,10501,H,BAO_0000019,1,,,,,55
3821,8,,Inhibition of 5-lipoxygenase from human whole blood,B,,Blood,,,CHEMBL618007,12281,H,BAO_0000357,1,178.0,,,,55
3822,8,,Inhibitory concentration required against 5-lipoxygenase activity in cytosolic fractions of human neutrophils,B,,,,,CHEMBL618008,2567,H,BAO_0000357,1,,,,,55
3823,8,,Inhibitory concentration required against 5-lipoxygenase activity in intact cells of human neutrophils,B,,,,,CHEMBL618009,2567,H,BAO_0000219,1,,,,,55
3824,8,,In vitro inhibition of polymorphonuclear leukocyte derived human 5-lipoxygenase,B,,,,,CHEMBL618010,10193,H,BAO_0000357,1,,,,,55
3825,8,,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in human cell at 10 uM,B,,,,,CHEMBL618011,10193,H,BAO_0000357,1,,,,,55
3826,8,,Potency to inhibit oxidation of arachidonic acid by recombinant human 5-lipoxygenase,B,,,,,CHEMBL618012,13623,H,BAO_0000357,1,,,,,55
3827,8,,Tested against 5-lipoxygenase,B,,,,,CHEMBL882927,12780,H,BAO_0000357,1,,,,,55
3828,8,,Tested for activity against 5-Lipoxygenase (5-LO),B,,,,,CHEMBL618013,12780,H,BAO_0000357,1,,,,,55
3829,8,,Tested for activity against 5-lipoxygenase,B,,,,,CHEMBL618014,12780,H,BAO_0000357,1,,,,,55
3830,8,,Tested for inhibition of 5-HPETE production by human 5-LO,B,,,,,CHEMBL618015,11966,H,BAO_0000357,1,,,,,55
3831,8,,The 5-lipoxygenase activity by the inhibition of calcium ionophore-induced leukotriene B4 production in human blood.,F,,,,,CHEMBL618016,5364,H,BAO_0000019,1,,,,,55
3832,8,,Inhibition of Human 5-lipoxygenase,B,,,,,CHEMBL618017,13165,H,BAO_0000357,1,,,,,55
3833,8,,The compound was evaluated for its inhibitory activity against 5-lipoxygenase using granulocytes-type cells,B,,,,,CHEMBL618018,5364,H,BAO_0000019,1,,,,,55
3834,8,,The compound was tested for inhibitory activity against 5-lipoxygenase in human polymorphonuclear leukocytes[PMNS],B,,,,,CHEMBL875087,11311,H,BAO_0000219,1,,,,,55
3835,8,,The compound was tested for inhibitory activity against LT synthesis in human polymorphonuclear leukocytes[PMNS],B,,,,,CHEMBL618019,11311,H,BAO_0000219,1,,,,,55
3836,8,,The compound was tested for the concentration (in uM) to inhibit 50% of 5-Lipoxygenase (5-LOX) and is expressed in IC50.,B,,,,,CHEMBL618020,14863,H,BAO_0000019,1,,,,,55
3837,8,,The compound was tested for the concentration (in uM) to inhibit 50% of 5-Lipoxygenase (5-LOX) and is expressed in IC50; Not tested,B,,,,,CHEMBL618021,14863,H,BAO_0000019,1,,,,,55
3838,8,,The compound was tested for the inhibition of 5-lipoxygenase (5-lo) in human whole blood (HWBL),B,,Blood,,,CHEMBL618022,11087,H,BAO_0000357,1,178.0,,,,55
3839,8,,The compound was tested in vitro for inhibition against 5-lipoxygenase in intact human neutrophils,B,,,,,CHEMBL618023,455,H,BAO_0000357,1,,,,,55
3840,8,,5-lipoxygenase Inhibitory activity was measured by enzyme immunoassay using human whole blood stimulated with calcium ionophore (A23187) and LTB4 (leukotriene B4),B,,,,,CHEMBL618024,13183,H,BAO_0000357,1,,,,,55
3841,8,,In vitro inhibitory activity against 5-lipoxygenase in human polymorphonuclear (PMN) cells,B,,,,,CHEMBL873950,10319,H,BAO_0000019,1,,,,,55
3842,8,,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in human cell at 10 uM,B,,,,,CHEMBL618025,10193,H,BAO_0000357,1,,,,,55
3843,8,,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of 5-HETE at 10 uM,B,,,,,CHEMBL618026,951,H,BAO_0000219,1,,,,,55
3844,8,,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of 5-HETE at 10 uM; NA means Inactive,B,,,,,CHEMBL618027,951,H,BAO_0000219,1,,,,,55
3845,8,,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of LTB4 at 10 uM,B,,,,,CHEMBL618028,951,H,BAO_0000219,1,,,,,55
3846,8,,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of LTB4 at 10 uM; NA means Inactive,B,,,,,CHEMBL618029,951,H,BAO_0000219,1,,,,,55
3847,8,,Inhibitory activity against 5-lipoxygenase at 10 uM concentration,B,,,,,CHEMBL618030,9859,H,BAO_0000357,1,,,,,55
3848,8,,Inhibitory activity against 5-lipoxygenase at 1 uM concentration,B,,,,,CHEMBL618031,9859,H,BAO_0000357,1,,,,,55
3849,8,,Inhibitory activity against lipoxygenase (LO) at 10 uM concentration,B,,,,,CHEMBL618032,9859,H,BAO_0000357,1,,,,,55
3850,8,,Inhibitory concentration required against 5-lipoxygenase activity in cytosolic fractions of human neutrophils,B,,,,,CHEMBL618033,2567,H,BAO_0000357,1,,,,,55
3851,8,,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in human cell at 1 uM,B,,,,,CHEMBL618034,10193,H,BAO_0000357,1,,,,,55
3852,8,,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in human cell at 10 uM,B,,,,,CHEMBL875088,10193,H,BAO_0000357,1,,,,,55
3853,8,,Tested for the inhibition of 5-lipoxygenase from human polymorphonuclear leukocytes(PMN) at 10 uM concentration of the compound; IA= Inactive,B,,,,,CHEMBL618035,949,H,BAO_0000019,1,,,,,55
3854,8,,Tested for the inhibition of 5-lipoxygenase from human polymorphonuclear leukocytes(PMN) at 10 uM concentration of the compound; value ranges from 70-90,B,,,,,CHEMBL618036,949,H,BAO_0000019,1,,,,,55
3855,8,,Inhibition of human neutrophil 5-lipoxygenase at the concentration of 0.1 uM,B,,,,,CHEMBL618037,10603,H,BAO_0000357,1,,,,,55
3856,8,,Inhibition of human neutrophil 5-lipoxygenase at the concentration of 1 uM,B,,,,,CHEMBL618038,10603,H,BAO_0000357,1,,,,,55
3857,8,,Inhibition of human neutrophil 5-lipoxygenase at the concentration of 1 uM,F,,,,,CHEMBL618761,10603,H,BAO_0000019,1,,,,,55
3858,8,,Inhibition of lipoxygenase at the concentration of 0.1 uM,B,,,,,CHEMBL618762,10603,H,BAO_0000357,1,,,,,55
3859,8,,Inhibition of lipoxygenase at the concentration of 1 uM,B,,,,,CHEMBL618763,10603,H,BAO_0000357,1,,,,,55
3860,8,,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in human cell,B,,,,,CHEMBL618764,10193,H,BAO_0000357,1,,,,,55
3861,9,Homo sapiens,Inhibition of 5-Lipoxygenase (5-LOX),B,9606.0,,,,CHEMBL618765,14580,D,BAO_0000357,1,,,,,55
3862,8,,Inhibition of 5-lipoxygenase in mouse macrophages.,B,,,,,CHEMBL618766,11090,H,BAO_0000357,1,,,,,17087
3863,8,,Inhibition of 5-lipoxygenase in mouse macrophages.,B,,,,,CHEMBL618767,11090,H,BAO_0000357,1,,,,,17087
3864,8,,Inhibitory activity against lipoxygenase-2 in mice,B,,,,,CHEMBL619380,6339,H,BAO_0000357,1,,,,,17087
3865,8,,Inhibitory activity against murine lipoxygenase-2.,B,,,,,CHEMBL619381,6339,H,BAO_0000357,1,,,,,17087
3866,9,Mus musculus,Inhibition of 5-lipoxygenase from mouse macrophage,B,10090.0,,,,CHEMBL619382,12281,D,BAO_0000357,1,,,,,17087
3867,8,,The compound was tested for inhibitory activity against 5-lipoxygenase in mouse macrophages,B,,,,,CHEMBL619383,11311,H,BAO_0000357,1,,,,,17087
3868,8,Sus scrofa,The compound was tested for the inhibition of Arachidonate 5-lipoxygenase purified from porcine leukocytes.,B,9823.0,,,,CHEMBL619384,11089,H,BAO_0000019,1,,,,,55
3869,8,Sus scrofa,Inhibition of 5-lipoxygenase reaction catalyzed by purified enzyme from porcine leukocytes,B,9823.0,,,,CHEMBL619385,10091,H,BAO_0000019,1,,,,,55
3870,8,Oryctolagus cuniculus,Inhibitory concentration against 5-lipoxygenase from isolated rabbit granulocytes,B,9986.0,,,,CHEMBL882928,14352,H,BAO_0000019,1,,,,,55
3871,9,Rattus norvegicus,5-lipoxygenase Inhibitory activity against rat polymorphonuclear leucocytes using 5-HETE,B,10116.0,,,,CHEMBL619386,13329,D,BAO_0000019,1,,,,,12166
3872,8,,"5-lipoxygenase inhibitory activity against rat polymorphonuclear leucocytes from female wistar rat, by using 5-HETE. ",B,,,,,CHEMBL619387,13329,H,BAO_0000019,1,,,,,12166
3873,8,,"5-lipoxygenase inhibitory activity against rat polymorphonuclear leucocytes from female wistar rat, by using 5-HETE.",B,,,,,CHEMBL619388,13329,H,BAO_0000019,1,,,,,12166
3874,8,,"5-lipoxygenase inhibitory activity against rat polymorphonuclear leucocytes from female wistar rat, by using LTB4.",B,,,,,CHEMBL619389,13329,H,BAO_0000019,1,,,,,12166
3875,8,,Inhibition of 5-lipoxygenase pathway in rat polymorphonuclear assay (inhibition of 5-HETE formation),B,,,,,CHEMBL619390,13329,H,BAO_0000019,1,,,,,12166
3876,8,,"Inhibition of 5-lipoxygenase pathway in rat polymorphonuclear assay, by ability to inhibit formation of LTB4 AT 10 uM",B,,,,,CHEMBL619391,13329,H,BAO_0000019,1,,,,,12166
3877,8,,Inhibition of 5-lipoxygenase pathway was evaluated in rat polymorphonuclear assay by compound (50 uM) ability to inhibit formation of 5-HETE,B,,,,,CHEMBL619392,13329,H,BAO_0000019,1,,,,,12166
3878,8,,The effective dose for inhibition of 5-lipoxygenase in rat blood leukocyte (ex vivo),B,,,,,CHEMBL619393,11311,H,BAO_0000019,1,,,,,12166
3879,8,,The effective dose for inhibition of 5-lipoxygenase in rat passive Arthus model after oral administration,B,,,,,CHEMBL619394,11311,H,BAO_0000019,1,,,,,12166
3880,8,,"In vitro inhibition of 5-lipoxygenase HETE (5-hydroperoxyeicosatetraenoic acid) in RBL-1 macrophage, a cell-free enzyme assay",B,,,,,CHEMBL619395,105,H,BAO_0000219,1,,,,RBL-1,12166
3881,8,,"In vitro inhibition of 5-lipoxygenase HETE (5-hydroperoxyeicosatetraenoic acid) in RBL-1 macrophage, a cell-free enzyme assay",B,,,,,CHEMBL619396,105,H,BAO_0000219,1,,,,RBL-1,12166
3882,8,,Inhibition of rat neutrophil 5- Lipoxygenase (5-LO),B,,,,,CHEMBL619397,9138,H,BAO_0000357,1,,,,,12166
3883,8,,"Inhibition of rat neutrophil 5- Lipoxygenase (5-LO),",B,,,,,CHEMBL619398,9138,H,BAO_0000357,1,,,,,12166
3884,8,,"Inhibition of rat neutrophil 5- Lipoxygenase (5-LO), (at a concentration of 0.2 nM ),",B,,,,,CHEMBL619399,9138,H,BAO_0000357,1,,,,,12166
3885,8,,5-LO inhibitory activity determined by measuring the conversion of [14C]arachidonic acid to leukotrienes in RBL-2H3 cell using thin-layer chromatography; Not determined,B,,,,,CHEMBL619400,14427,H,BAO_0000357,1,,,,,12166
3886,8,,"5-lipoxygenase inhibitory activity against rat polymorphonuclear leucocytes from female wistar rat, by using 5-HETE.",B,,,,,CHEMBL619401,13329,H,BAO_0000019,1,,,,,12166
3887,8,,"5-lipoxygenase inhibitory activity against rat polymorphonuclear leucocytes from female wistar rat, by using LTB4. ",B,,,,,CHEMBL619402,13329,H,BAO_0000019,1,,,,,12166
3888,9,Rattus norvegicus,Inhibition of 5-lipoxygenase mediated conversion of [14C]arachidonic acid to leukotrienes in RBL-2H3 cells,B,10116.0,,,,CHEMBL619403,14427,D,BAO_0000219,1,,,,RBL-2H3,12166
3889,8,,5-lipoxygenase inhibitory activity determined by measuring the conversion of [14C]arachidonic acid to leukotrienes in RBL-2H3 cell using thin-layer chromatography; Not determined,B,,,,,CHEMBL619404,14427,H,BAO_0000357,1,,,,,12166
3890,8,,5-lipoxygenase inhibitory activity determined by measuring the conversion of [14C]arachidonic acid to leukotrienes in RBL-2H3 cell using thin-layer chromatography.,B,,,,,CHEMBL619405,14427,H,BAO_0000357,1,,,,,12166
3891,8,,Ability to inhibit 5-lipoxygenase by using a crude preparation of the cytosolic enzyme from the rat basophilic leukemia (RBL-1) cell line,B,,,,,CHEMBL619406,10293,H,BAO_0000219,1,,,,RBL-1,12166
3892,9,Rattus norvegicus,Inhibition of 5-Lipoxygenase of rat basophilic leukemia cells,B,10116.0,,,,CHEMBL619407,338,D,BAO_0000219,1,,,,RBL-1,12166
3893,8,,Compound was evaluated for its inhibitory activity against 5-LO (5-lipoxygenase),B,,,,,CHEMBL619408,303,H,BAO_0000357,1,,,,,12166
3894,8,,Compound was evaluated for its inhibitory activity against 5-LO (5-lipoxygenase) in intact RBL-1 cell line assay,B,,,,,CHEMBL619409,303,H,BAO_0000219,1,,,,RBL-1,12166
3895,8,,Inhibition of rat basophilic leukemia-1 (RBL-1) 5-lipoxygenase,B,,,,,CHEMBL619410,9247,H,BAO_0000219,1,,,,RBL-1,12166
3896,8,,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 100 uM; NS = no significant activity,B,,,,,CHEMBL619753,9247,H,BAO_0000219,1,,,,RBL-1,12166
3897,8,,Compound was evaluated in an intact RBL-1 cell line for inhibition of 5-lipoxygenase,B,,,,,CHEMBL619754,137,H,BAO_0000219,1,,,,RBL-1,12166
3898,8,,Evaluated in vitro for its inhibitory activity against 5-lipoxygenase,B,,,,,CHEMBL619903,11481,H,BAO_0000357,1,,,,,12166
3899,8,,"Evaluated in vitro for its inhibitory activity against 5-lipoxygenase; N=Inactive, <50% inhibition at 10 uM concentration",B,,,,,CHEMBL619904,11481,H,BAO_0000357,1,,,,,12166
3900,8,,Inhibition of rat polymorphonuclear leukocyte (PMN) 5-Lipoxygenase in vitro,B,,,,,CHEMBL619905,9029,H,BAO_0000357,1,,,,,12166
3901,8,,Compound was tested for inhibition of 5-lipoxygenase activity in a broken cell supernatant rat basophilic leukemia cells,B,,,,,CHEMBL619906,1701,H,BAO_0000019,1,,,,,12166
3902,8,,Compound was tested for inhibition of 5-lipoxygenase activity in a broken cell supernatant rat basophilic leukemia cells at concentration of 32 uM; Not active,B,,,,,CHEMBL619907,1701,H,BAO_0000019,1,,,,,12166
3903,8,,Compound was tested for inhibition of 5-lipoxygenase activity in a broken cell supernatant rat basophilic leukemia cells at concentration of 50 uM; Not active,B,,,,,CHEMBL619908,1701,H,BAO_0000019,1,,,,,12166
3904,8,,Compound was tested for inhibition of 5-lipoxygenase activity in a broken cell supernatant rat basophilic leukemia cells; No data,B,,,,,CHEMBL619909,1701,H,BAO_0000019,1,,,,,12166
3905,8,,Inhibition of 5-lipoxygenase by measuring 5-HETE levels in RBL-1 cell-free supernatant,F,,,,,CHEMBL619910,13358,H,BAO_0000219,1,,,,RBL-1,12166
3906,8,,Inhibitory activity against 5-lipoxygenase enzyme from RBL-1 cells,B,,,,,CHEMBL882929,1175,H,BAO_0000219,1,,,,RBL-1,12166
3907,8,,Ability to inhibit 5-lipoxygenase in rat basophilic leukemia cells.,B,,,,,CHEMBL619911,8797,H,BAO_0000219,1,,,,RBL-1,12166
3908,8,,Compound was tested for its ability to inhibit 5-lipoxygenase in rat basophilic leukemia cells; No data,B,,,,,CHEMBL619912,8797,H,BAO_0000019,1,,,,,12166
3909,9,Rattus norvegicus,Inhibition of rat basophilic leukemia cell 5-lipoxygenase,B,10116.0,,,,CHEMBL619913,577,D,BAO_0000357,1,,,,,12166
3910,8,,In vitro inhibitory activity against RBL-1 5-LO,B,,,,,CHEMBL619914,9295,H,BAO_0000219,1,,,,RBL-1,12166
3911,8,,Compound was tested for its in vitro inhibitory activity against RBL-1 5-LO (insoluble above 45 uM),B,,,,,CHEMBL619915,9295,H,BAO_0000219,1,,,,RBL-1,12166
3912,8,,Compound was tested for its in vitro inhibitory activity against RBL-1 5-LO (time dependent),B,,,,,CHEMBL619916,9295,H,BAO_0000219,1,,,,RBL-1,12166
3913,8,,Compound was tested for its inhibition activity against 5-LO of the whole cell in vitro in rat.,B,,,,,CHEMBL619917,9295,H,BAO_0000218,1,,,,,12166
3914,8,,Compound was tested for its inhibition activity against the 5-LO in isolated enzyme,B,,,,,CHEMBL619918,9295,H,BAO_0000357,1,,,,,12166
3915,8,,Compound was tested for its inhibitory activity against 5-lipoxygenase in rat.,B,,,,,CHEMBL619919,216,H,BAO_0000218,1,,,,,12166
3916,8,,Compound was tested for the inhibition of 5-lipoxygenase (5-LPO) in rat basophilic leukemia (RBL) cells.,B,,,,,CHEMBL883710,11090,H,BAO_0000219,1,,,,RBL-1,12166
3917,8,,Compound was tested for the inhibition of 5-lipoxygenase (5-Lpo) in rat whole blood.,B,,Blood,,,CHEMBL619920,11090,H,BAO_0000019,1,178.0,,,,12166
3918,8,,Concentration required for 50 % inhibition of arachidonic acid oxidation by rat 5-lipoxygenase,B,,,,,CHEMBL619921,10091,H,BAO_0000357,1,,,,,12166
3919,8,,Concentration that produces 50% inhibition of A-23187-stimulated radiolabeled 5-HETE and TXB2 synthesis by PMN 5-lipoxygenase.,F,,,,,CHEMBL619922,10274,H,BAO_0000019,1,,,,,12166
3920,8,,In vitro 5-lipoxygenase inhibitory activity against calcium ionophore (A23187) induced LTB4 formation in rat polymorphonuclear leukocytes,F,,,,,CHEMBL619923,13622,H,BAO_0000219,1,,,,,12166
3921,8,,In vitro inhibition against 5-lipoxygenase in RBL-1 cells was determined,B,,,,,CHEMBL619924,12118,H,BAO_0000219,1,,,,RBL-1,12166
3922,8,,In vitro inhibition of 5-lipoxygenase (5-HETE) derived from the 9000xg supernatant of RBL broken cell assay,B,,,,,CHEMBL619925,12576,H,BAO_0000357,1,,,,,12166
3923,8,,In vitro inhibition of 5-lipoxygenase from RBL-1 cells,B,,,,,CHEMBL619926,9546,H,BAO_0000219,1,,,,RBL-1,12166
3924,8,,In vitro inhibition of 5-lipoxygenase in RBL-1 cells,B,,,,,CHEMBL619927,9521,H,BAO_0000219,1,,,,RBL-1,12166
3925,8,,In vitro inhibition of 5-lipoxygenase pathway in rat basophilic leukemia (RBL-1) cells,B,,,,,CHEMBL619928,10626,H,BAO_0000219,1,,,,RBL-1,12166
3926,8,,In vitro inhibition of RBL-1 5-lipoxygenase,B,,,,,CHEMBL619929,9225,H,BAO_0000219,1,,,,RBL-1,12166
3927,8,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 0.18-0.31,B,,,,,CHEMBL875089,9225,H,BAO_0000219,1,,,,RBL-1,12166
3928,8,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 0.3-1.6,B,,,,,CHEMBL619930,9225,H,BAO_0000219,1,,,,RBL-1,12166
3929,8,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 0.4-2.2,B,,,,,CHEMBL619931,9225,H,BAO_0000219,1,,,,RBL-1,12166
3930,8,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 0.72-1.07,B,,,,,CHEMBL619932,9225,H,BAO_0000219,1,,,,RBL-1,12166
3931,8,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 0.9-4.0,B,,,,,CHEMBL619933,9225,H,BAO_0000219,1,,,,RBL-1,12166
3932,8,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.0-1.5,B,,,,,CHEMBL619934,9225,H,BAO_0000219,1,,,,RBL-1,12166
3933,8,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.0-1.7,B,,,,,CHEMBL619935,9225,H,BAO_0000219,1,,,,RBL-1,12166
3934,8,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.0-2.4,B,,,,,CHEMBL619936,9225,H,BAO_0000219,1,,,,RBL-1,12166
3935,8,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.07-5.54,B,,,,,CHEMBL619937,9225,H,BAO_0000219,1,,,,RBL-1,12166
3936,8,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.1-1.6,B,,,,,CHEMBL619938,9225,H,BAO_0000219,1,,,,RBL-1,12166
3937,8,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.3-2.8,B,,,,,CHEMBL619939,9225,H,BAO_0000219,1,,,,RBL-1,12166
3938,8,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.4-3.2,B,,,,,CHEMBL619940,9225,H,BAO_0000219,1,,,,RBL-1,12166
3939,8,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.7-2.6,B,,,,,CHEMBL875090,9225,H,BAO_0000219,1,,,,RBL-1,12166
3940,8,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.8-2.8,B,,,,,CHEMBL619941,9225,H,BAO_0000219,1,,,,RBL-1,12166
3941,8,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.8-5.7,B,,,,,CHEMBL619942,9225,H,BAO_0000219,1,,,,RBL-1,12166
3942,8,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.9-2.4,B,,,,,CHEMBL883711,9225,H,BAO_0000219,1,,,,RBL-1,12166
3943,8,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 2.3-.8,B,,,,,CHEMBL619943,9225,H,BAO_0000219,1,,,,RBL-1,12166
3944,8,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 2.46-2.63,B,,,,,CHEMBL619944,9225,H,BAO_0000219,1,,,,RBL-1,12166
3945,8,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 3.3-3.5,B,,,,,CHEMBL619945,9225,H,BAO_0000219,1,,,,RBL-1,12166
3946,8,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 3.8-7.1,B,,,,,CHEMBL619946,9225,H,BAO_0000219,1,,,,RBL-1,12166
3947,8,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 4.0-6.4,B,,,,,CHEMBL619947,9225,H,BAO_0000219,1,,,,RBL-1,12166
3948,8,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 4.9-11.6,B,,,,,CHEMBL619948,9225,H,BAO_0000219,1,,,,RBL-1,12166
3949,8,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 7.5-11.8,B,,,,,CHEMBL619949,9225,H,BAO_0000219,1,,,,RBL-1,12166
3950,8,,In vitro inhibitory activity against 5-lipoxygenase from rat basophilic leukemia cells.,B,,,,,CHEMBL619950,9401,H,BAO_0000019,1,,,,,12166
3951,8,,In vitro inhibitory activity against 5-Lipoxygenase in rat by Peritoneal 5-lipoxygenase assay,B,,,,,CHEMBL618050,10325,H,BAO_0000019,1,,,,,12166
3952,8,,In vitro inhibition of 5-lipoxygenase in RBL-2H3 (Rat basophilic leukemia) cells.,F,,,,,CHEMBL875091,1556,H,BAO_0000219,1,,,,RBL-2H3,12166
3953,8,,In vitro inhibition of 5-lipoxygenase in RBL-2H3 (Rat basophilic leukemia) cells; Not tested,F,,,,,CHEMBL618051,1556,H,BAO_0000219,1,,,,RBL-2H3,12166
3954,9,Rattus norvegicus,Inhibition of 5-lipoxygenase from rat basophilic leukemia(RBL-1) cells,B,10116.0,,,,CHEMBL618052,961,D,BAO_0000219,1,,,,RBL-1,12166
3955,8,,In vitro inhibitory activity against 5-lipoxygenase in an RBL-2H3 cell lysate,B,,,,,CHEMBL618053,6838,H,BAO_0000019,1,,,,,12166
3956,8,,In vitro inhibition of 5-lipoxygenase in rat (peritoneal assay),B,,,,,CHEMBL618054,10325,H,BAO_0000019,1,,,,,12166
3957,9,Rattus norvegicus,In vitro inhibitory activity against 5-lipoxygenase in rat RBL-1 cells,B,10116.0,,,,CHEMBL618055,9209,D,BAO_0000219,1,,,,RBL-1,12166
3958,8,,inhibitory activity against 5-lipoxygenase in rat basophilic leukemia cell line.,B,,,,,CHEMBL618056,11520,H,BAO_0000219,1,,,,RBL-1,12166
3959,8,,In vitro inhibitory activity against 5-lipoxygenase was determined,B,,,,,CHEMBL618057,137,H,BAO_0000357,1,,,,,12166
3960,8,,In vitro inhibitory concentration against 5-lipoxygenase in RBL-1 cells,B,,,,,CHEMBL618058,4717,H,BAO_0000219,1,,,,RBL-1,12166
3961,8,,Inhibition of 5-lipoxygenase in intact RBL-1 cell line,B,,,,,CHEMBL618059,10636,H,BAO_0000219,1,,,,RBL-1,12166
3962,9,Rattus norvegicus,Inhibitory activity against 5-lipoxygenase catalysis (5-LO) in sonicated rat basophilic leukemia cell lysate,F,10116.0,,,,CHEMBL618060,14312,D,BAO_0000019,1,,,,,12166
3963,8,,Inhibition of 5-Lipoxygenase (5-LO) in rat basophilic leukemia cells,B,,,,,CHEMBL618061,1203,H,BAO_0000219,1,,,,RBL-1,12166
3964,8,,Inhibition of 5-Lipoxygenase (5-LO) in rat basophilic leukemic cells,B,,,,,CHEMBL618062,1203,H,BAO_0000019,1,,,,,12166
3965,8,,Inhibition of 5-lipoxygenase catalysis in rat basophilic leukemia (RBL) cells by measuring 5-HETE product formation,B,,,,,CHEMBL618063,13622,H,BAO_0000219,1,,,,RBL-1,12166
3966,8,,Inhibition of 5-lipoxygenase from rat peritoneal neutrophils after oral administration,B,,,,,CHEMBL618064,9793,H,BAO_0000357,1,,,,,12166
3967,9,Rattus norvegicus,Inhibition of 5-lipoxygenase of rat basophilic leukemia (RBL) cell cytosolic enzymes,B,10116.0,,,,CHEMBL618065,1143,D,BAO_0000219,1,,,,RBL-1,12166
3968,9,Rattus norvegicus,Inhibition 5-lipoxygenase mediated LTB4 formation in rat basophilic leukemia (RBL-1) cells,B,10116.0,,,,CHEMBL618066,11854,D,BAO_0000219,1,,,,RBL-1,12166
3969,8,,Inhibitory activity against 5-lipoxygenase (5-LO) in intact rat barophilic leukemia cells (RBL-1),B,,,,,CHEMBL618067,3595,H,BAO_0000219,1,,,,RBL-1,12166
3970,8,,Inhibitory activity against 5-lipoxygenase (5-LO) using broken rat barophilic leukemia cells (RBL-1),B,,,,,CHEMBL618068,3595,H,BAO_0000219,1,,,,RBL-1,12166
3971,9,Rattus norvegicus,Inhibition of 5-lipoxygenase in rat RBL-1 cells,B,10116.0,,,,CHEMBL618069,10501,D,BAO_0000219,1,,,,RBL-1,12166
3972,8,,Inhibition of 5-lipoxygenase in intact rat basophilic leukemia cells stimulated with the calcium ionophore A-23187,B,,,,,CHEMBL618070,12526,H,BAO_0000219,1,,,,RBL-1,12166
3973,8,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 32 umol/kg,F,,Limbic system,,,CHEMBL618071,10034,H,BAO_0000019,1,349.0,,,,10825
3974,8,,Compound was tested for its effects on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 0.10 umol/kg,F,,Limbic system,,,CHEMBL619247,10034,H,BAO_0000019,1,349.0,,,,10825
3975,8,,Approximate dose levels for a half maximal reduction of 5-HTP levels,F,,,,,CHEMBL619248,10034,H,BAO_0000019,1,,,,,10825
3976,8,,Inhibitory activity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue using [3H]OH-DPAT as radioligand.,B,,Hippocampus,,,CHEMBL619249,10046,H,BAO_0000221,1,10000000.0,,,,10576
3977,8,,Inhibitory activity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue using [3H]OH-DPAT as radioligand.,B,,Hippocampus,,,CHEMBL619250,10046,H,BAO_0000221,1,10000000.0,,,,10576
3978,8,,Inhibitory activity against 5-hydroxytryptamine 1B receptor of rat striatal membrane homogenate using [3H]5-HT as the radioligand.,B,,,,,CHEMBL619251,10046,H,BAO_0000019,1,,,,,10577
3979,8,Canis lupus familiaris,Inhibitory concentration against human platelet 5-lipoxygenase in dog whole blood,F,9615.0,Blood,,,CHEMBL619252,12079,H,BAO_0000019,1,178.0,,,,55
3980,8,,Inhibitory concentration against human platelet 5-lipoxygenase in human whole blood,F,,Blood,,,CHEMBL619253,12079,H,BAO_0000019,1,178.0,,,,55
3981,8,,The compound was tested for inhibitory activity against 5-Lipoxygenase in rat polymorphonuclear leukocytes[PMNS],B,,,,,CHEMBL619254,11311,H,BAO_0000219,1,,,,,12166
3982,8,,Inhibition of 5-lipoxygenase in bovine polymorphonuclear leukocytes,B,,,,,CHEMBL619255,12338,H,BAO_0000219,1,,,,,17140
3983,8,,Inhibitory activity against 5-lipoxygenase (inhibition of 5-HETE and LTB4 biosynthesis) in bovine polymorphonuclear leukocytes (PMNL).,B,,,,,CHEMBL619256,12143,H,BAO_0000219,1,,,,,17140
3984,8,,Inhibitory activity against 5-lipoxygenase (inhibition of 5-HETE and LTB4 biosynthesis) in bovine polymorphonuclear leukocytes (PMNL),B,,,,,CHEMBL875418,12143,H,BAO_0000219,1,,,,,17140
3985,8,,Inhibitory activity against 5-lipoxygenase (inhibition of 5-HETE and LTB4 biosynthesis) in bovine polymorphonuclear leukocytes (PMNL) at 30 uM,B,,,,,CHEMBL619257,12143,H,BAO_0000219,1,,,,,17140
3986,8,,Inhibitory activity against 5-lipoxygenase (inhibition of 5-HETE and LTB4 biosynthesis) in bovine polymorphonuclear leukocytes (PMNL) at 30 uM,B,,,,,CHEMBL619258,12143,H,BAO_0000219,1,,,,,17140
3987,8,,Inhibition of 5-lipoxygenase in bovine PMNL cell assay.,B,,,,,CHEMBL619259,12365,H,BAO_0000357,1,,,,,17140
3988,8,,Tested for inhibition of 5-lipoxygenase as inhibition of 5-HETE and LTB4 biosynthesis in bovine PMNL,B,,,,,CHEMBL619260,13500,H,BAO_0000357,1,,,,,17140
3989,8,Canis lupus familiaris,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.08h, following intravenous administration at the dose of 1.0 mg/kg",F,9615.0,Blood,,,CHEMBL619261,12832,H,BAO_0000218,1,178.0,In vivo,,,55
3990,8,Canis lupus familiaris,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.25h, following intravenous administration at the dose of 1.0 mg/kg",F,9615.0,Blood,,,CHEMBL619263,12832,H,BAO_0000218,1,178.0,In vivo,,,55
3991,8,Canis lupus familiaris,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.5h, following intravenous administration at the dose of 1.0 mg/kg",F,9615.0,Blood,,,CHEMBL619264,12832,H,BAO_0000218,1,178.0,In vivo,,,55
3992,8,Canis lupus familiaris,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 1.0h, following intravenous administration at the dose of 1.0 mg/kg",F,9615.0,Blood,,,CHEMBL619265,12832,H,BAO_0000218,1,178.0,In vivo,,,55
3993,8,Canis lupus familiaris,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 24h, following intravenous administration at the dose of 1.0 mg/kg",F,9615.0,Blood,,,CHEMBL619266,12832,H,BAO_0000218,1,178.0,In vivo,,,55
3994,8,Canis lupus familiaris,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 3.0h, following intravenous administration at the dose of 1.0 mg/kg",F,9615.0,Blood,,,CHEMBL619902,12832,H,BAO_0000218,1,178.0,In vivo,,,55
3995,8,Canis lupus familiaris,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 6.0h, following intravenous administration at the dose of 1.0 mg/kg",F,9615.0,Blood,,,CHEMBL620058,12832,H,BAO_0000218,1,178.0,In vivo,,,55
3996,8,Canis lupus familiaris,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 9.0h, following intravenous administration at the dose of 1.0 mg/kg",F,9615.0,Blood,,,CHEMBL620059,12832,H,BAO_0000218,1,178.0,In vivo,,,55
3997,8,Canis lupus familiaris,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.08h, following intravenous administration at the dose of 1.0 mg/kg",F,9615.0,Blood,,,CHEMBL620060,12832,H,BAO_0000218,1,178.0,In vivo,,,55
3998,8,Canis lupus familiaris,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.25h, following intravenous administration at the dose of 1.0 mg/kg",F,9615.0,Blood,,,CHEMBL620061,12832,H,BAO_0000218,1,178.0,In vivo,,,55
3999,8,Canis lupus familiaris,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.25h, following peroral administration at the dose of 0.3 mg/kg",F,9615.0,Blood,,,CHEMBL620062,12832,H,BAO_0000218,1,178.0,In vivo,,,55
4000,8,Canis lupus familiaris,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.25h, following peroral administration at the dose of 1.0 mg/kg",F,9615.0,Blood,,,CHEMBL620063,12832,H,BAO_0000218,1,178.0,In vivo,,,55
4001,8,Canis lupus familiaris,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.25h, following peroral administration at the dose of 3.0 mg/kg",F,9615.0,Blood,,,CHEMBL620064,12832,H,BAO_0000218,1,178.0,In vivo,,,55
4002,8,Canis lupus familiaris,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.5h, following intravenous administration at the dose of 1.0 mg/kg",F,9615.0,Blood,,,CHEMBL620065,12832,H,BAO_0000218,1,178.0,In vivo,,,55
4003,8,Canis lupus familiaris,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.5h, following peroral administration at the dose of 0.3 mg/kg",F,9615.0,Blood,,,CHEMBL620066,12832,H,BAO_0000218,1,178.0,In vivo,,,55
4004,8,Canis lupus familiaris,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.5h, following peroral administration at the dose of 1.0 mg/kg",F,9615.0,Blood,,,CHEMBL620067,12832,H,BAO_0000218,1,178.0,In vivo,,,55
4005,8,Canis lupus familiaris,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.5h, following peroral administration at the dose of 3.0 mg/kg",F,9615.0,Blood,,,CHEMBL620068,12832,H,BAO_0000218,1,178.0,In vivo,,,55
4006,8,Canis lupus familiaris,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 1.0h, following intravenous administration at the dose of 1.0 mg/kg",F,9615.0,Blood,,,CHEMBL620069,12832,H,BAO_0000218,1,178.0,In vivo,,,55
4007,8,Canis lupus familiaris,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 1.0h, following peroral administration at the dose of 0.3 mg/kg",F,9615.0,Blood,,,CHEMBL620070,12832,H,BAO_0000218,1,178.0,In vivo,,,55
4008,8,Canis lupus familiaris,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 1.0h, following peroral administration at the dose of 1.0 mg/kg",F,9615.0,Blood,,,CHEMBL620071,12832,H,BAO_0000218,1,178.0,In vivo,,,55
4009,8,Canis lupus familiaris,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 1.0h, following peroral administration at the dose of 3.0 mg/kg",F,9615.0,Blood,,,CHEMBL620072,12832,H,BAO_0000218,1,178.0,In vivo,,,55
4010,8,Canis lupus familiaris,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 24h, following intravenous administration at the dose of 1.0 mg/kg",F,9615.0,Blood,,,CHEMBL620036,12832,H,BAO_0000218,1,178.0,In vivo,,,55
4011,8,Canis lupus familiaris,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 24h, following peroral administration at the dose of 0.3 mg/kg",F,9615.0,Blood,,,CHEMBL857702,12832,H,BAO_0000218,1,178.0,In vivo,,,55
4012,8,Canis lupus familiaris,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 24h, following peroral administration at the dose of 1.0 mg/kg",F,9615.0,Blood,,,CHEMBL620037,12832,H,BAO_0000218,1,178.0,In vivo,,,55
4013,8,Canis lupus familiaris,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 24h, following peroral administration at the dose of 3.0 mg/kg",F,9615.0,Blood,,,CHEMBL620038,12832,H,BAO_0000218,1,178.0,In vivo,,,55
4014,8,Canis lupus familiaris,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 3.0h, following intravenous administration at the dose of 1.0 mg/kg",F,9615.0,Blood,,,CHEMBL620039,12832,H,BAO_0000218,1,178.0,In vivo,,,55
4015,8,Canis lupus familiaris,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 3.0h, following peroral administration at the dose of 0.3 mg/kg",F,9615.0,Blood,,,CHEMBL620040,12832,H,BAO_0000218,1,178.0,In vivo,,,55
4016,8,Canis lupus familiaris,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 3.0h, following peroral administration at the dose of 1.0 mg/kg",F,9615.0,Blood,,,CHEMBL620041,12832,H,BAO_0000218,1,178.0,In vivo,,,55
4017,8,Canis lupus familiaris,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 3.0h, following peroral administration at the dose of 3.0 mg/kg",F,9615.0,Blood,,,CHEMBL620042,12832,H,BAO_0000218,1,178.0,In vivo,,,55
4018,8,Canis lupus familiaris,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 6.0h, following intravenous administration at the dose of 1.0 mg/kg",F,9615.0,Blood,,,CHEMBL620043,12832,H,BAO_0000218,1,178.0,In vivo,,,55
4019,8,Canis lupus familiaris,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 6.0h, following peroral administration at the dose of 0.3 mg/kg",F,9615.0,Blood,,,CHEMBL620044,12832,H,BAO_0000218,1,178.0,In vivo,,,55
4020,8,Canis lupus familiaris,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 6.0h, following peroral administration at the dose of 1.0 mg/kg",F,9615.0,Blood,,,CHEMBL620045,12832,H,BAO_0000218,1,178.0,In vivo,,,55
4021,8,Canis lupus familiaris,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 6.0h, following peroral administration at the dose of 3.0 mg/kg",F,9615.0,Blood,,,CHEMBL620046,12832,H,BAO_0000218,1,178.0,In vivo,,,55
4022,8,Canis lupus familiaris,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 9.0h, following intravenous administration at the dose of 1.0 mg/kg",F,9615.0,Blood,,,CHEMBL620047,12832,H,BAO_0000218,1,178.0,In vivo,,,55
4023,8,Canis lupus familiaris,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 9.0h, following peroral administration at the dose of 0.3 mg/kg",F,9615.0,Blood,,,CHEMBL620048,12832,H,BAO_0000218,1,178.0,In vivo,,,55
4024,8,Canis lupus familiaris,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 9.0h, following peroral administration at the dose of 1.0 mg/kg",F,9615.0,Blood,,,CHEMBL857703,12832,H,BAO_0000218,1,178.0,In vivo,,,55
4025,8,Canis lupus familiaris,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 9.0h, following peroral administration at the dose of 3.0 mg/kg",F,9615.0,Blood,,,CHEMBL620049,12832,H,BAO_0000218,1,178.0,In vivo,,,55
4026,8,Canis lupus familiaris,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.08h, following intravenous administration at the dose of 1.0 mg/kg",F,9615.0,Blood,,,CHEMBL620050,12832,H,BAO_0000218,1,178.0,In vivo,,,55
4027,8,Canis lupus familiaris,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.25h, following intravenous administration at the dose of 1.0 mg/kg",F,9615.0,Blood,,,CHEMBL620051,12832,H,BAO_0000218,1,178.0,In vivo,,,55
4028,8,Canis lupus familiaris,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.5h, following intravenous administration at the dose of 1.0 mg/kg",F,9615.0,Blood,,,CHEMBL619213,12832,H,BAO_0000218,1,178.0,In vivo,,,55
4029,8,Canis lupus familiaris,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 1.0h, following intravenous administration at the dose of 1.0 mg/kg",F,9615.0,Blood,,,CHEMBL619214,12832,H,BAO_0000218,1,178.0,In vivo,,,55
4030,8,Canis lupus familiaris,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 3.0h, following intravenous administration at the dose of 1.0 mg/kg",F,9615.0,Blood,,,CHEMBL619804,12832,H,BAO_0000218,1,178.0,In vivo,,,55
4031,8,Canis lupus familiaris,"Ex vivo inhibition was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.25h, following peroral administration at the dose of 1.0 mg/kg",F,9615.0,Blood,,,CHEMBL619805,12832,H,BAO_0000218,1,178.0,In vivo,,,55
4032,8,Canis lupus familiaris,"Ex vivo inhibition was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 24h, following intravenous administration at the dose of 1.0 mg/kg",F,9615.0,Blood,,,CHEMBL619806,12832,H,BAO_0000218,1,178.0,In vivo,,,55
4033,8,Canis lupus familiaris,"Ex vivo inhibition was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 6.0h, following intravenous administration at the dose of 1.0 mg/kg",F,9615.0,Blood,,,CHEMBL619807,12832,H,BAO_0000218,1,178.0,In vivo,,,55
4034,8,Canis lupus familiaris,"Ex vivo inhibition was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 9.0h, following intravenous administration at the dose of 1.0 mg/kg",F,9615.0,Blood,,,CHEMBL619808,12832,H,BAO_0000218,1,178.0,In vivo,,,55
4035,8,Canis lupus familiaris,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 24 hr r,B,9615.0,,,,CHEMBL619809,3595,H,BAO_0000218,1,,,,,55
4036,8,Canis lupus familiaris,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 24 hr r to canine,B,9615.0,,,,CHEMBL619810,3595,H,BAO_0000218,1,,,,,55
4037,8,Canis lupus familiaris,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 2 hr,B,9615.0,,,,CHEMBL619811,3595,H,BAO_0000218,1,,,,,55
4038,8,Canis lupus familiaris,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 2 hr to canine,B,9615.0,,,,CHEMBL620769,3595,H,BAO_0000218,1,,,,,55
4039,8,Canis lupus familiaris,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 4 hr,B,9615.0,,,,CHEMBL620770,3595,H,BAO_0000218,1,,,,,55
4040,8,Canis lupus familiaris,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 4 hr to canine,B,9615.0,,,,CHEMBL620771,3595,H,BAO_0000218,1,,,,,55
4041,8,Canis lupus familiaris,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 8 hr,B,9615.0,,,,CHEMBL620772,3595,H,BAO_0000218,1,,,,,55
4042,8,Canis lupus familiaris,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 8 hr to canine,B,9615.0,,,,CHEMBL620773,3595,H,BAO_0000218,1,,,,,55
4043,8,Cavia porcellus,Ability to inhibit 5-lipoxygenase in guinea pig,B,10141.0,,,,CHEMBL620774,9203,H,BAO_0000357,1,,,,,55
4044,8,Cavia porcellus,Inhibition of [14C]arachidonic acid conversion to 5-HETE by broken cell 5-lipoxygenase in vitro (guinea pig PMN),B,10141.0,,,,CHEMBL620775,82,H,BAO_0000357,1,,,,,55
4045,8,Cavia porcellus,Compound was tested for the inhibition of 5-lipoxygenase (5-Lpo) in guinea pig.,B,10141.0,,,,CHEMBL620776,11090,H,BAO_0000357,1,,,,,55
4046,8,Cavia porcellus,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 12 h, following intravenous administration at the dose of 1.0 mg/kg",B,10141.0,Blood,,,CHEMBL620777,12832,H,BAO_0000218,1,178.0,,,,55
4047,8,Cavia porcellus,In vitro 5-lipoxygenase inhibition in guinea pig PMNs was determined based on 5-hydroxyeicosapentaenoic acid (5-HETE) production,B,10141.0,,,,CHEMBL620778,1065,H,BAO_0000357,1,,,,,55
4048,8,Cavia porcellus,In vitro 5-lipoxygenase inhibition in guinea pig PMNs was determined based on LTB4 production,B,10141.0,,,,CHEMBL620779,1065,H,BAO_0000357,1,,,,,55
4049,8,Cavia porcellus,In vitro 5-lipoxygenase inhibitory activity against A-23187-stimulated conversion of [14C]-AA to 5-HETE in guinea pig peritoneal polymorphonuclear leukocytes,B,10141.0,,,,CHEMBL621500,12832,H,BAO_0000019,1,,,,,55
4050,8,Cavia porcellus,In vitro 5-lipoxygenase inhibitory activity against A-23187-stimulated conversion of [14C]AA to LTB4 in guinea pig peritoneal polymorphonuclear leukocytes,B,10141.0,,,,CHEMBL621501,12832,H,BAO_0000019,1,,,,,55
4051,8,Cavia porcellus,In vitro 5-lipoxygenase inhibitory activity against A-23187-stimulated conversion of [14C]AA to LTB4 in guinea pig peritoneal polymorphonuclear leukocytes,B,10141.0,,,,CHEMBL618098,12832,H,BAO_0000019,1,,,,,55
4052,8,Cavia porcellus,Inhibition against 5-lipoxygenase from guinea pig polymorphonuclear lymphocytes,B,10141.0,,,,CHEMBL618099,10504,H,BAO_0000019,1,,,,,55
4053,8,Cavia porcellus,Inhibitory activity against 5-lipoxygenase,B,10141.0,,,,CHEMBL618100,7788,H,BAO_0000357,1,,,,,55
4054,8,Cavia porcellus,Inhibitory activity against 5-lipoxygenase in guinea pig leukocyte,B,10141.0,,,,CHEMBL618101,10001,H,BAO_0000357,1,,,,,55
4055,8,Cavia porcellus,Inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase using guinea pig supernatant,B,10141.0,,,,CHEMBL618102,10193,H,BAO_0000357,1,,,,,55
4056,8,Cavia porcellus,Inhibitory activity against partially-purified Guinea pig PMN 5-lipoxygenase,B,10141.0,,,,CHEMBL618103,13243,H,BAO_0000357,1,,,,,55
4057,8,Cavia porcellus,Inhibitory activity uM,B,10141.0,,,,CHEMBL618104,13243,H,BAO_0000357,1,,,,,55
4058,8,Cavia porcellus,Inhibitory activity against 5-lipoxygenase in guinea pig leukocytes was determined,B,10141.0,,,,CHEMBL883712,969,H,BAO_0000219,1,,,,,55
4059,8,Cavia porcellus,Inhibitory activity against 5-lipoxygenase at 10 uM,B,10141.0,,,,CHEMBL618105,10001,H,BAO_0000357,1,,,,,55
4060,8,Cavia porcellus,Inhibitory activity against 5-lipoxygenase at a dose of 0.1 mM,B,10141.0,,,,CHEMBL618106,7788,H,BAO_0000357,1,,,,,55
4061,8,Cavia porcellus,Inhibitory activity against 5-lipoxygenase in guinea pig leukocyte at 30 uM,B,10141.0,,,,CHEMBL618107,10001,H,BAO_0000357,1,,,,,55
4062,8,Cavia porcellus,Inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase using guinea pig supernatant at 10 uM,B,10141.0,,,,CHEMBL618108,10193,H,BAO_0000357,1,,,,,55
4063,8,Cavia porcellus,Inhibitory activity uM,B,10141.0,,,,CHEMBL618109,13243,H,BAO_0000357,1,,,,,55
4064,8,Cavia porcellus,Inhibitory activity against partially-purified Guinea pig PMN 5-lipoxygenase at 10 uM,B,10141.0,,,,CHEMBL618110,13243,H,BAO_0000357,1,,,,,55
4065,8,Cavia porcellus,Inhibitory activity uM,B,10141.0,,,,CHEMBL618111,13243,H,BAO_0000357,1,,,,,55
4066,8,Cavia porcellus,Inhibitory activity uM,F,10141.0,,,,CHEMBL618112,13243,H,BAO_0000019,1,,,,,55
4067,8,Cavia porcellus,Percent inhibition against 5-lipoxygenase from guinea pig polymorphonuclear lymphocytes,B,10141.0,,,,CHEMBL618113,10504,H,BAO_0000019,1,,,,,55
4068,8,Cavia porcellus,Inhibitory activity against 5-lipoxygenase at a dose of 0.1 mM,B,10141.0,,,,CHEMBL618114,7788,H,BAO_0000357,1,,,,,55
4069,8,Cavia porcellus,Evaluated for inhibition of the formation and release of 5-lipoxygenase in isolated guinea pig ileum,F,10141.0,Ileum,,,CHEMBL620871,10546,H,BAO_0000221,1,2116.0,,,,55
4070,8,,5-lipoxygenase Inhibitory activity was measured by enzyme immunoassay using human whole blood stimulated with calcium ionophore (A23187) and LTB4 (leukotriene B4),B,,,,,CHEMBL620872,13183,H,BAO_0000357,1,,,,,55
4071,8,,5-lipoxygenase Inhibitory activity was measured by enzyme immunoassay using human whole blood stimulated with calcium ionophore (A23187) and LTB4 (leukotriene B4),B,,,,,CHEMBL620873,13183,H,BAO_0000357,1,,,,,55
4072,8,,Compound was evaluated for in vitro inhibition of recombinant human 5-lipoxygenase (5-LO),B,,,,,CHEMBL620874,2578,H,BAO_0000357,1,,,,,55
4073,8,,In vitro inhibition of human 5-Lipoxygenase.,B,,,,,CHEMBL620875,12780,H,BAO_0000357,1,,,,,55
4074,0,Rattus norvegicus,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 75 uM,B,10116.0,Liver,Microsomes,,CHEMBL620876,7411,U,BAO_0000251,1,2107.0,,,,22226
4075,0,Rattus norvegicus,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 1 uM,B,10116.0,Liver,Microsomes,,CHEMBL620877,7411,U,BAO_0000251,1,2107.0,,,,22226
4076,0,Rattus norvegicus,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 10 uM,B,10116.0,Liver,Microsomes,,CHEMBL857854,7411,U,BAO_0000251,1,2107.0,,,,22226
4077,0,Rattus norvegicus,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 10 uM exposed 100 uM,B,10116.0,Liver,Microsomes,,CHEMBL620878,7411,U,BAO_0000251,1,2107.0,,,,22226
4078,0,Rattus norvegicus,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 100 uM,B,10116.0,Liver,Microsomes,,CHEMBL620879,7411,U,BAO_0000251,1,2107.0,,,,22226
4079,0,Rattus norvegicus,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 1000 uM,B,10116.0,Liver,Microsomes,,CHEMBL620880,7411,U,BAO_0000251,1,2107.0,,,,22226
4080,0,Rattus norvegicus,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 1000 uM,B,10116.0,Liver,Microsomes,,CHEMBL620881,7411,U,BAO_0000251,1,2107.0,,,,22226
4081,0,Rattus norvegicus,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 150 uM,B,10116.0,Liver,Microsomes,,CHEMBL620882,7411,U,BAO_0000251,1,2107.0,,,,22226
4082,0,Rattus norvegicus,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 1500 uM,B,10116.0,Liver,Microsomes,,CHEMBL620883,7411,U,BAO_0000251,1,2107.0,,,,22226
4083,0,Rattus norvegicus,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 2.5 uM,B,10116.0,Liver,Microsomes,,CHEMBL620884,7411,U,BAO_0000251,1,2107.0,,,,22226
4084,0,Rattus norvegicus,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 200 uM,B,10116.0,Liver,Microsomes,,CHEMBL620885,7411,U,BAO_0000251,1,2107.0,,,,22226
4085,0,Rattus norvegicus,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 27.5 uM,B,10116.0,Liver,Microsomes,,CHEMBL620886,7411,U,BAO_0000251,1,2107.0,,,,22226
4086,0,Rattus norvegicus,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 5 uM,B,10116.0,Liver,Microsomes,,CHEMBL620887,7411,U,BAO_0000251,1,2107.0,,,,22226
4087,0,Rattus norvegicus,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 50 uM,B,10116.0,Liver,Microsomes,,CHEMBL618039,7411,U,BAO_0000251,1,2107.0,,,,22226
4088,0,Rattus norvegicus,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 500 uM,B,10116.0,Liver,Microsomes,,CHEMBL618040,7411,U,BAO_0000251,1,2107.0,,,,22226
4089,0,Rattus norvegicus,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to exposed to 3-methylcholanthrene at concentration of 200 uM,B,10116.0,Liver,Microsomes,,CHEMBL618041,7411,U,BAO_0000251,1,2107.0,,,,22226
4090,0,Rattus norvegicus,"Compound was evaluated for inhibition constant, in liver microsomes from 3-methylcholanthrene-exposed rats",B,10116.0,Liver,Microsomes,,CHEMBL618216,7411,U,BAO_0000251,1,2107.0,,,,22226
4091,0,Rattus norvegicus,"Compound was evaluated for inhibition constant, in liver microsomes from beta-naphthoflavone-exposed rats",B,10116.0,Liver,Microsomes,,CHEMBL618217,7411,U,BAO_0000251,1,2107.0,,,,22226
4092,0,Rattus norvegicus,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes 3-methylcholanthrene at concentration of 100 uM,B,10116.0,Liver,Microsomes,,CHEMBL618218,7411,U,BAO_0000251,1,2107.0,,,,22226
4093,0,Rattus norvegicus,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes 3-methylcholanthrene at concentration of 200 uM,B,10116.0,Liver,Microsomes,,CHEMBL618219,7411,U,BAO_0000251,1,2107.0,,,,22226
4094,0,Rattus norvegicus,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes 3-methylcholanthrene at concentration of 50 uM,B,10116.0,Liver,Microsomes,,CHEMBL618220,7411,U,BAO_0000251,1,2107.0,,,,22226
4095,0,Rattus norvegicus,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at 5 uM,B,10116.0,Liver,Microsomes,,CHEMBL618221,7411,U,BAO_0000251,1,2107.0,,,,22226
4096,0,Rattus norvegicus,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at 50 uM,B,10116.0,Liver,Microsomes,,CHEMBL618222,7411,U,BAO_0000251,1,2107.0,,,,22226
4097,0,Rattus norvegicus,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at a concentration of 10 uM,B,10116.0,Liver,Microsomes,,CHEMBL618223,7411,U,BAO_0000251,1,2107.0,,,,22226
4098,0,Rattus norvegicus,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 100 uM,B,10116.0,Liver,Microsomes,,CHEMBL618224,7411,U,BAO_0000251,1,2107.0,,,,22226
4099,0,Rattus norvegicus,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 1 uM,B,10116.0,Liver,Microsomes,,CHEMBL618225,7411,U,BAO_0000251,1,2107.0,,,,22226
4100,0,Rattus norvegicus,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 20 uM,B,10116.0,Liver,Microsomes,,CHEMBL618226,7411,U,BAO_0000251,1,2107.0,,,,22226
4101,0,Rattus norvegicus,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 200 uM,B,10116.0,Liver,Microsomes,,CHEMBL618227,7411,U,BAO_0000251,1,2107.0,,,,22226
4102,0,Rattus norvegicus,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 25 uM,B,10116.0,Liver,Microsomes,,CHEMBL618228,7411,U,BAO_0000251,1,2107.0,,,,22226
4103,0,Rattus norvegicus,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 50 uM,B,10116.0,Liver,Microsomes,,CHEMBL618229,7411,U,BAO_0000251,1,2107.0,,,,22226
4104,0,Rattus norvegicus,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 75 uM,B,10116.0,Liver,Microsomes,,CHEMBL618230,7411,U,BAO_0000251,1,2107.0,,,,22226
4105,0,Rattus norvegicus,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 1 uM,B,10116.0,Liver,Microsomes,,CHEMBL618231,7411,U,BAO_0000251,1,2107.0,,,,22226
4106,0,Rattus norvegicus,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 10 uM,B,10116.0,Liver,Microsomes,,CHEMBL618232,7411,U,BAO_0000251,1,2107.0,,,,22226
4107,0,Rattus norvegicus,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 100 uM,B,10116.0,Liver,Microsomes,,CHEMBL618233,7411,U,BAO_0000251,1,2107.0,,,,22226
4108,0,Rattus norvegicus,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 1000 uM,B,10116.0,Liver,Microsomes,,CHEMBL618234,7411,U,BAO_0000251,1,2107.0,,,,22226
4109,0,Rattus norvegicus,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 150 uM,B,10116.0,Liver,Microsomes,,CHEMBL618235,7411,U,BAO_0000251,1,2107.0,,,,22226
4110,0,Rattus norvegicus,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 1500 uM,B,10116.0,Liver,Microsomes,,CHEMBL618115,7411,U,BAO_0000251,1,2107.0,,,,22226
4111,0,Rattus norvegicus,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 2.5 uM,B,10116.0,Liver,Microsomes,,CHEMBL618116,7411,U,BAO_0000251,1,2107.0,,,,22226
4112,0,Rattus norvegicus,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 200 uM,B,10116.0,Liver,Microsomes,,CHEMBL618117,7411,U,BAO_0000251,1,2107.0,,,,22226
4113,0,Rattus norvegicus,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 5 uM,B,10116.0,Liver,Microsomes,,CHEMBL619968,7411,U,BAO_0000251,1,2107.0,,,,22226
4114,0,Rattus norvegicus,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 50 uM,B,10116.0,Liver,Microsomes,,CHEMBL619969,7411,U,BAO_0000251,1,2107.0,,,,22226
4115,0,Rattus norvegicus,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 500 uM,B,10116.0,Liver,Microsomes,,CHEMBL619970,7411,U,BAO_0000251,1,2107.0,,,,22226
4116,0,Rattus norvegicus,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at concentration of 1000 uM,B,10116.0,Liver,Microsomes,,CHEMBL619971,7411,U,BAO_0000251,1,2107.0,,,,22226
4117,0,Rattus norvegicus,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at concentration of 1500 uM,B,10116.0,Liver,Microsomes,,CHEMBL619972,7411,U,BAO_0000251,1,2107.0,,,,22226
4118,0,Rattus norvegicus,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at concentration of 27.5 uM,B,10116.0,Liver,Microsomes,,CHEMBL619973,7411,U,BAO_0000251,1,2107.0,,,,22226
4119,0,Rattus norvegicus,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at concentration of 500 uM,B,10116.0,Liver,Microsomes,,CHEMBL619974,7411,U,BAO_0000251,1,2107.0,,,,22226
4120,0,Rattus norvegicus,Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 50 uM,B,10116.0,Liver,Microsomes,,CHEMBL619975,7411,U,BAO_0000251,1,2107.0,,,,22226
4121,0,Rattus norvegicus,Vmax determined by 7-ethoxycoumarin deethylation in the presence by liver microsomes from rats exposed to 3-methylcholanthrene at concentration of 10 uM,B,10116.0,,Microsomes,,CHEMBL619976,7411,U,BAO_0000251,1,,,,,22226
4122,0,Rattus norvegicus,"Compound was evaluated for alpha -rate constant, in liver microsomes from 3-methylcholanthrene-exposed rats",B,10116.0,Liver,Microsomes,,CHEMBL619977,7411,U,BAO_0000251,1,2107.0,,,,22226
4123,0,Rattus norvegicus,"Compound was evaluated for alpha -rate constant, in liver microsomes from beta-naphthoflavone-exposed rats",B,10116.0,Liver,Microsomes,,CHEMBL619978,7411,U,BAO_0000251,1,2107.0,,,,22226
4124,0,Rattus norvegicus,"Compound was evaluated for alpha -rate constant, in liver microsomes from beta-naphthoflavone-exposed rats; competitive inhibition",B,10116.0,Liver,Microsomes,,CHEMBL619979,7411,U,BAO_0000251,1,2107.0,,,,22226
4125,0,Rattus norvegicus,"Compound was evaluated for alpha inhibition constant, in liver microsomes from 3-methylcholanthrene-exposed rats",B,10116.0,Liver,Microsomes,,CHEMBL619980,7411,U,BAO_0000251,1,2107.0,,,,22226
4126,0,Rattus norvegicus,"Compound was evaluated for alpha inhibition constant, in liver microsomes from beta-naphthoflavone-exposed rats",B,10116.0,Liver,Microsomes,,CHEMBL619981,7411,U,BAO_0000251,1,2107.0,,,,22226
4127,1,Homo sapiens,In vitro inhibition of 7226/S myeloma cancer cell line,F,9606.0,,,,CHEMBL619982,10797,N,BAO_0000219,1,,,,RPMI-8226,80433
4128,1,Homo sapiens,In vitro antitumor activity of compound against 7404 cell line (human liver carcinoma cells),F,9606.0,,,,CHEMBL619983,6881,N,BAO_0000219,1,,,,BEL-7404 tumor cell line,80698
4129,1,Homo sapiens,In vitro growth inhibition of compound was determined against 768-0 cell lines of Renal cancer,F,9606.0,,,,CHEMBL620031,3838,N,BAO_0000219,1,,,,786-0,80640
4130,1,Homo sapiens,In vitro growth inhibition of compound was determined against 768-0 cell lines of Renal cancer,F,9606.0,,,,CHEMBL620032,3838,N,BAO_0000219,1,,,,786-0,80640
4131,1,Cricetulus griseus,Net accumulation of the [99mTc]Isonitrile complex was measured in 77A cell lines in the presence of Verapamil.,F,10029.0,,,,CHEMBL620033,12981,N,BAO_0000219,1,,,,V79,81264
4132,1,Cricetulus griseus,Verapamil index represents the ratio of net uptake in the presense of verapamil over control in 77A cell lines.,F,10029.0,,,,CHEMBL620034,12981,N,BAO_0000219,1,,,,V79,81264
4133,1,Rattus norvegicus,Tested for its cytotoxic effect on the growth of the cell strain 7800C1 (1 x 10e 4 (MEM)) at 10 ug/mL dose,F,10116.0,,,,CHEMBL620035,7653,N,BAO_0000219,1,,,,7800C1 cell line,80635
4134,1,Rattus norvegicus,Tested for its cytotoxic effect on the growth of the cell strain 7800C1 (1 x 10e 4 (MEM)) at 2 ug/mL dose,F,10116.0,,,,CHEMBL618318,7653,N,BAO_0000219,1,,,,7800C1 cell line,80635
4135,1,Rattus norvegicus,Tested for its cytotoxic effect on the growth of the cell strain 7800C1 (1 x 10e 4 (MEM)) at 20 ug/mL dose,F,10116.0,,,,CHEMBL618319,7653,N,BAO_0000219,1,,,,7800C1 cell line,80635
4136,1,Rattus norvegicus,Tested for its cytotoxic effect on the growth of the cell strain 7800C1 (1 x 10e 4 (MEM)) at 5 ug/mL dose,F,10116.0,,,,CHEMBL618320,7653,N,BAO_0000219,1,,,,7800C1 cell line,80635
4137,1,Rattus norvegicus,Tested for its cytotoxic effect on the growth of the cell strain 7800C1 (1 x 10e 4 (MEM)) at 50 ug/mL dose,F,10116.0,,,,CHEMBL618321,7653,N,BAO_0000219,1,,,,7800C1 cell line,80635
4138,1,Rattus norvegicus,Tested for its cytotoxic effect on the growth of the cell strain 7800C1 (1 x 10e 4 (MEM)) at 75 ug/mL dose,F,10116.0,,,,CHEMBL883118,7653,N,BAO_0000219,1,,,,7800C1 cell line,80635
4139,1,Homo sapiens,In vitro antitumor activity against renal 786-0 tumor cell lines,F,9606.0,,,,CHEMBL883795,17229,N,BAO_0000219,1,,,,786-0,80640
4140,1,Homo sapiens,Cytotoxic activity against 786-0 Renal cancer cell line,F,9606.0,,,,CHEMBL618322,12858,N,BAO_0000219,1,,,,786-0,80640
4141,1,Homo sapiens,Growth inhibitory activity was determined against 786-0 cancer cell line of Renal cancer,F,9606.0,,,,CHEMBL618323,16325,N,BAO_0000219,1,,,,786-0,80640
4142,1,Homo sapiens,Growth inhibitory activity was determined against 786-0 cancer cell line of renal cancer,F,9606.0,,,,CHEMBL618324,16325,N,BAO_0000219,1,,,,786-0,80640
4143,1,Homo sapiens,In vitro antitumor activity against human renal 786-0 cell line,F,9606.0,,,,CHEMBL618325,5858,N,BAO_0000219,1,,,,786-0,80640
4144,1,Homo sapiens,Inhibition of Renal cancer in 786-0 cancer cell lines,F,9606.0,,,,CHEMBL875416,16325,N,BAO_0000219,1,,,,786-0,80640
4145,1,Homo sapiens,Inhibition of the growth of renal cancer(786-0) cell line. value in parentheses is percent inhibition at 0.01 uM,F,9606.0,,,,CHEMBL618326,14696,N,BAO_0000219,1,,,,786-0,80640
4146,1,Homo sapiens,The compound was tested for its cytotoxic activity against the following renal cancer cell lines 786-0,F,9606.0,,,,CHEMBL618327,3786,N,BAO_0000219,1,,,,786-0,80640
4147,1,Homo sapiens,inhibition of the growth of renal cancer(786-0) cell line,F,9606.0,,,,CHEMBL619215,14696,N,BAO_0000219,1,,,,786-0,80640
4148,1,Homo sapiens,Compound was evaluated for in vitro activity against 786-0 kidney cell lines (Human tumor cells ),F,9606.0,,,,CHEMBL619216,14769,N,BAO_0000219,1,,,,786-0,80640
4149,1,Homo sapiens,Compound was tested for the growth inhibition of 786-0 renal tumor cell line,F,9606.0,,,,CHEMBL619217,15354,N,BAO_0000219,1,,,,786-0,80640
4150,1,Homo sapiens,The IC50 value was measured on 786-0 cell line in ovarian tumor,F,9606.0,,,,CHEMBL619218,14255,N,BAO_0000219,1,,,,786-0,80640
4151,1,Homo sapiens,The IC50 value was measured on 786-0 cell line in ovarian tumor t,F,9606.0,,,,CHEMBL619219,14255,N,BAO_0000219,1,,,,786-0,80640
4152,1,Homo sapiens,The IC50 value was measured on 786-0 cell line in renal tumor type.,F,9606.0,,,,CHEMBL619220,14255,N,BAO_0000219,1,,,,786-0,80640
4153,1,Homo sapiens,Inhibition of the growth of renal cancer(786-0) cell line at 0.01 uM,F,9606.0,,,,CHEMBL619221,14696,N,BAO_0000219,1,,,,786-0,80640
4154,1,Homo sapiens,Tested for cytotoxic activity against renal cancer 786-0 cell line,F,9606.0,,,,CHEMBL619222,12016,N,BAO_0000219,1,,,,786-0,80640
4155,1,Homo sapiens,Compound was tested for growth inhibitory activity against 786-0 cell line,F,9606.0,,,,CHEMBL857454,2597,N,BAO_0000219,1,,,,786-0,80640
4156,8,,Inhibitory activity against 5-lipoxygenase in intact rat basophilic leukemia cells stimulated with the calcium ionophore A-23187; Inactive(N)= <50% inhibition at 10 uM,B,,,,,CHEMBL619223,12526,H,BAO_0000219,1,,,,RBL-1,12166
4157,8,,Inhibitory activity against 5-lipoxygenase in intact rat basophilic leukemia cells stimulated with the calcium ionophore A-23187; N=Inactive,B,,,,,CHEMBL619224,12526,H,BAO_0000219,1,,,,RBL-1,12166
4158,8,,Inhibitory activity against 5-lipoxygenase obtained from rat basophilic leukemia cells,B,,,,,CHEMBL619225,14799,H,BAO_0000019,1,,,,,12166
4159,8,,Inhibitory activity against 5-lipoxygenase (5-LO) in intact rat barophilic leukemia cells (RBL-1),B,,,,,CHEMBL619226,3595,H,BAO_0000219,1,,,,RBL-1,12166
4160,8,,Inhibitory activity against 5-lipoxygenase (5-LO) using broken rat barophilic leukemia cells (RBL-1),B,,,,,CHEMBL619227,3595,H,BAO_0000219,1,,,,RBL-1,12166
4161,8,,Inhibitory activity against rat basophilic leukemia 5-lipoxygenase,B,,,,,CHEMBL619228,12767,H,BAO_0000357,1,,,,,12166
4162,8,,Inhibitory activity against 5-lipoxygenase in rat polymorphonuclear leukocytes,B,,,,,CHEMBL619229,10997,H,BAO_0000219,1,,,,,12166
4163,8,,Inhibitory activity against 5-lipoxygenase of RBL-1 cell line,B,,,,,CHEMBL619230,11388,H,BAO_0000219,1,,,,RBL-1,12166
4164,8,,Inhibitory activity against RBL broken cell-supematant 5-lipoxygenase was evaluated,B,,,,,CHEMBL619231,167,H,BAO_0000357,1,,,,,12166
4165,8,,"Inhibitory activity against intact rat PMNL, LTB4 5-lipoxygenase was evaluated",B,,,,,CHEMBL619232,167,H,BAO_0000357,1,,,,,12166
4166,8,,Inhibitory activity against rat 5-lipoxygenase by using continuous oxygen consumption assay.,B,,,,,CHEMBL619233,13744,H,BAO_0000357,1,,,,,12166
4167,8,,Inhibitory activity against rat basophilic leukemia cell 5-lipoxygenase,B,,,,,CHEMBL619234,1630,H,BAO_0000357,1,,,,,12166
4168,8,,Inhibitory activity against rat basophilic leukemia cell 5-lipoxygenase (5-LO),B,,,,,CHEMBL619235,1630,H,BAO_0000357,1,,,,,12166
4169,9,Rattus norvegicus,"Inhibitory activity against 5-lipoxygenase in rat neutrophils as inhibition of A 23,187-induced LTB4 production",B,10116.0,,,,CHEMBL619236,969,D,BAO_0000019,1,,,,,12166
4170,8,,Inhibitory concentration against 5-lipoxygenase in rat RBL-1 cells,B,,,,,CHEMBL619237,13621,H,BAO_0000219,1,,,,RBL-1,12166
4171,8,,Inhibitory concentration to inhibit 5-lipoxygenase in the rat,B,,,,,CHEMBL619238,10089,H,BAO_0000357,1,,,,,12166
4172,8,,In vitro inhibition of rat polymorphonuclear leukocyte 5-lipoxygenase,B,,,,,CHEMBL619239,10193,H,BAO_0000357,1,,,,,12166
4173,8,,Tested for inhibition of 5-HPETE production by rat 5-LO; value ranges from 16-36 nM,B,,,,,CHEMBL619240,11966,H,BAO_0000357,1,,,,,12166
4174,8,,Tested for inhibition of 5-LO by measuring the reduction of leukotriene B4 (LTB4) in intact basophilic rat leukemia cells,B,,,,,CHEMBL875417,12251,H,BAO_0000019,1,,,,,12166
4175,8,,Tested for inhibition of 5-Lipoxygenase (ARBL) in calcium-stimulated rat basophilic leukemia cells(RBL-1),B,,,,,CHEMBL619241,211,H,BAO_0000219,1,,,,RBL-1,12166
4176,8,,Inhibition of 5-lipoxygenase measured by the reduction of leukotriene B4 (LTB4) in intact basophilic rat leukemia cells,F,,,,,CHEMBL619242,12251,H,BAO_0000019,1,,,,,12166
4177,8,,Tested for inhibitory activity against 5-lipoxygenase in microsome of RBL-1 cells,B,,,,,CHEMBL883796,12495,H,BAO_0000219,1,,,,RBL-1,12166
4178,8,,Tested for its inhibitory activity against 5-lipoxygenase,B,,,,,CHEMBL619243,414,H,BAO_0000357,1,,,,,12166
4179,8,,Tested for its inhibitory activity against 5-lipoxygenase; Not determined,B,,,,,CHEMBL619244,414,H,BAO_0000357,1,,,,,12166
4180,8,,"Iin vitro inhibition of 5-lipoxygenase activity in rat basophil leukemia type 1(RBL1) cell homogenates, (reduction of [14C]-5-HETE formation)",B,,,,,CHEMBL619245,10325,H,BAO_0000019,1,,,,,12166
4181,8,,In vitro test for inhibition of 5-lipoxygenase in cell-free preparations from rat PMN leukocytes,B,,,,,CHEMBL619246,11966,H,BAO_0000019,1,,,,,12166
4182,8,,In vitro inhibition of 5-lipoxygenase activity in RBL-1 cells.,B,,,,,CHEMBL619984,165,H,BAO_0000219,1,,,,RBL-1,12166
4183,8,,The compound was evaluated in vitro for inhibition of 5-lipoxygenase activity in RBL-1 cells; No significant inhibitory activity up to 30 uM,B,,,,,CHEMBL619985,165,H,BAO_0000219,1,,,,RBL-1,12166
4184,8,,The compound was evaluated in vitro for inhibition of 5-lipoxygenase activity in RBL-1 cells.,B,,,,,CHEMBL619986,165,H,BAO_0000219,1,,,,RBL-1,12166
4185,8,,In vitro for inhibition of 5-lipoxygenase activity in RBL-1 cells.,B,,,,,CHEMBL619987,165,H,BAO_0000219,1,,,,RBL-1,12166
4186,8,,The compound was tested for inhibitory activity against 5-lipoxygenase in mouse,B,,,,,CHEMBL619988,11311,H,BAO_0000218,1,,,,,12166
4187,8,,The compound was tested for inhibitory activity against 5-lipoxygenase in rat RBL-1,B,,,,,CHEMBL619989,11311,H,BAO_0000219,1,,,,RBL-1,12166
4188,8,,The compound was tested for inhibitory activity against 5-lipoxygenase in rat RBL-1 cells,B,,,,,CHEMBL619990,11311,H,BAO_0000219,1,,,,RBL-1,12166
4189,8,,The compound was tested for inhibitory activity against 5-lipoxygenase in rat polymorphonuclear leukocytes[PMNS],B,,,,,CHEMBL619991,11311,H,BAO_0000219,1,,,,,12166
4190,8,,The compound was tested for inhibitory activity against 5-lipoxygenase in rat polymorphonuclear leukocytes[PMNS] (in vitro),B,,,,,CHEMBL619992,11311,H,BAO_0000219,1,,,,,12166
4191,8,,The compound was tested for inhibitory activity against 5-lipoxygenase in rat polymorphonuclear leukocytes[PMNS] (in vivo),B,,,,,CHEMBL619993,11311,H,BAO_0000218,1,,In vivo,,,12166
4192,8,,The compound was tested for inhibitory activity against 5-lipoxygenase translocation inhibitor in RBL-2H3 cells,F,,,,,CHEMBL619994,11311,H,BAO_0000219,1,,,,RBL-2H3,12166
4193,8,,The compound was tested for inhibitory activity against 5-lipoxygenase translocation inhibitor in rat RBL-2H3 cells,F,,,,,CHEMBL619995,11311,H,BAO_0000219,1,,,,RBL-2H3,12166
4194,8,,The compound was tested for inhibitory activity against 5-lipoxygenase using rat polymorphonuclear leukocytes[PMNS],B,,,,,CHEMBL619996,11311,H,BAO_0000019,1,,,,,12166
4195,8,,The compound was tested for its inhibitory activity against arachidonic acid in rat 5-lipoxygenase,B,,,,,CHEMBL619997,11732,H,BAO_0000019,1,,,,,12166
4196,8,,Tested for its inhibitory activity against arachidonic acid in rat 5-lipoxygenase.,B,,,,,CHEMBL619998,11732,H,BAO_0000019,1,,,,,12166
4197,8,,In vitro inhibition of 5-lipoxygenase (5-lo) from the 20000 g supernatant of RBI-1 cells,B,,,,,CHEMBL619999,11087,H,BAO_0000019,1,,,,,12166
4198,8,,The compound was tested for the in vitro inhibition of 5-lipoxygenase from the 20000 g supernatant of RBI-1 cells,B,,,,,CHEMBL620000,11087,H,BAO_0000019,1,,,,,12166
4199,8,,The compound was tested for the inhibition of 5-lipoxygenase (5-lo) in homogenized rat basophilic leukemia (RBL-1) cells,B,,,,,CHEMBL620001,11087,H,BAO_0000219,1,,,,RBL-1,12166
4200,9,Rattus norvegicus,Inhibition of 5-lipoxygenase (5-lo) in intact rat polymorphonuclear leukocyte RPMNL,B,10116.0,,,,CHEMBL620002,11087,D,BAO_0000357,1,,,,,12166
4201,8,,The compound was tested for the inhibition of 5-lipoxygenase in intact basophilic rat leukemia cells,B,,,,,CHEMBL620003,496,H,BAO_0000219,1,,,,RBL-1,12166
4202,8,,Inhibition of 5-lipoxygenase on rat basophil leukemia cell line lysate (RBL-1 2H3 subline) by measuring 5-HETE production,F,,,,,CHEMBL620004,13986,H,BAO_0000219,1,,,,RBL-1,12166
4203,8,,Compound was evaluated for the inhibition of 5-lipoxygenase,B,,,,,CHEMBL874063,11520,H,BAO_0000357,1,,,,,12166
4204,8,,Ability to inhibit 5-lipoxygenase by using a crude preparation of the cytosolic enzyme from the rat basophilic leukemia (RBL-1) cell line at a concentration of 25 uM,B,,,,,CHEMBL620005,10293,H,BAO_0000219,1,,,,RBL-1,12166
4205,8,,Compound was evaluated for its inhibitory activity against 5-LO (5-lipoxygenase) at 10 uM concentration in intact RBL-1 cell line assay,B,,,,,CHEMBL620006,303,H,BAO_0000219,1,,,,RBL-1,12166
4206,8,,Compound was evaluated for its inhibitory activity against 5-LO (5-lipoxygenase) at 10 uM concentration in intact RBL-1 cell line assay; Less than 5% inhibition at 10 uM reported as not active,B,,,,,CHEMBL620007,303,H,BAO_0000219,1,,,,RBL-1,12166
4207,8,,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 10 uM,B,,,,,CHEMBL620008,9247,H,BAO_0000219,1,,,,RBL-1,12166
4208,9,Rattus norvegicus,Inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 100 uM,B,10116.0,,,,CHEMBL620009,9247,D,BAO_0000219,1,,,,RBL-1,12166
4209,8,,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 100 uM; NS = no significant activity,B,,,,,CHEMBL620010,9247,H,BAO_0000219,1,,,,RBL-1,12166
4210,8,,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 30 uM,B,,,,,CHEMBL620011,9247,H,BAO_0000219,1,,,,RBL-1,12166
4211,8,,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 300 uM,B,,,,,CHEMBL620677,9247,H,BAO_0000219,1,,,,RBL-1,12166
4212,8,,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 33 uM,B,,,,,CHEMBL620678,9247,H,BAO_0000219,1,,,,RBL-1,12166
4213,8,,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 40 uM,B,,,,,CHEMBL620679,9247,H,BAO_0000219,1,,,,RBL-1,12166
4214,8,,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 75 uM,B,,,,,CHEMBL620680,9247,H,BAO_0000219,1,,,,RBL-1,12166
4215,9,Rattus norvegicus,Inhibitory activity against 5-lipoxygenase at 10 uM,B,10116.0,,,,CHEMBL620838,11481,D,BAO_0000357,1,,,,,12166
4216,8,,In vitro inhibition of 5-lipoxygenase; NS means no significant inhibition,B,,,,,CHEMBL620839,105,H,BAO_0000357,1,,,,,12166
4217,8,,In vitro inhibition of rat polymorphonuclear leukocyte (PMN) 5-Lipoxygenase at 10 uM,B,,,,,CHEMBL620840,9029,H,BAO_0000357,1,,,,,12166
4218,8,,Inhibitory activity against 5-lipoxygenase enzyme from RBL-1 cells at 20 uM,B,,,,,CHEMBL620841,1175,H,BAO_0000219,1,,,,RBL-1,12166
4219,8,,In vitro inhibition against 5-lipoxygenase in RBL-1 cells was determined at 100 uM,B,,,,,CHEMBL620842,12118,H,BAO_0000219,1,,,,RBL-1,12166
4220,8,,In vitro inhibition against 5-lipoxygenase in RBL-1 cells was determined at 10e-4 M,B,,,,,CHEMBL620843,12118,H,BAO_0000219,1,,,,RBL-1,12166
4221,8,,In vitro inhibition against 5-lipoxygenase in RBL-1 cells was determinedb at 100 uM,B,,,,,CHEMBL620844,12118,H,BAO_0000219,1,,,,RBL-1,12166
4222,8,,In vitro inhibition of RBL-1 5-lipoxygenase at 20 uM,B,,,,,CHEMBL620845,9225,H,BAO_0000219,1,,,,RBL-1,12166
4223,8,,In vitro inhibitory activity against 5-Lipoxygenase from rat basophilic leukemia cells at 30 uM concentration,B,,,,,CHEMBL620846,9401,H,BAO_0000019,1,,,,,12166
4224,8,,In vitro inhibitory activity against 5-lipoxygenase was determined at 16 uM,B,,,,,CHEMBL873951,137,H,BAO_0000357,1,,,,,12166
4225,8,,In vitro inhibitory activity against 5-lipoxygenase was determined at 16 uM,B,,,,,CHEMBL620847,137,H,BAO_0000357,1,,,,,12166
4226,8,,In vitro percent inhibition against 5-lipoxygenase in RBL-1 cells at 10 uM concentration,B,,,,,CHEMBL620848,4717,H,BAO_0000219,1,,,,RBL-1,12166
4227,8,,Inhibitory activity against 5-lipoxygenase (5-LO) using broken rat barophilic leukemia cells (RBL-1) at 10 uM,B,,,,,CHEMBL620849,3595,H,BAO_0000219,1,,,,RBL-1,12166
4228,8,,Inhibitory activity against 5-lipoxygenase in RBL-1 cells at 40 uM concentration,B,,,,,CHEMBL620850,10501,H,BAO_0000219,1,,,,RBL-1,12166
4229,8,,Inhibitory activity against 5-lipoxygenase in RBL-1 cells at a concentration 40 uM,B,,,,,CHEMBL620851,10501,H,BAO_0000219,1,,,,RBL-1,12166
4230,8,,Inhibitory activity against 5-lipoxygenase in RBL-1 cells at a concentration 40 uM.,B,,,,,CHEMBL620852,10501,H,BAO_0000219,1,,,,RBL-1,12166
4231,8,,Inhibitory activity against 5-lipoxygenase in intact rat basophilic leukemia cells stimulated with the calcium ionophore A-23187,B,,,,,CHEMBL875098,12526,H,BAO_0000219,1,,,,RBL-1,12166
4232,9,Rattus norvegicus,Inhibition of 5-lipoxygenase of rat basophilic leukemia cells at 30 uM,B,10116.0,,,,CHEMBL620853,14799,D,BAO_0000219,1,,,,RBL-1,12166
4233,8,,Inhibitory activity against 5-lipoxygenase obtained from rat basophilic leukemia cells at 30 uM concentration; NT=Not tested,B,,,,,CHEMBL620854,14799,H,BAO_0000019,1,,,,,12166
4234,8,,Inhibitory activity against 5-lipoxygenase (5-LO) using broken rat barophilic leukemia cells (RBL-1) at 10 uM,B,,,,,CHEMBL620855,3595,H,BAO_0000219,1,,,,RBL-1,12166
4235,8,,Inhibitory activity against 5-lipoxygenase (5-LO) using broken rat barophilic leukemia cells (RBL-1)at 10 uM,B,,,,,CHEMBL839884,3595,H,BAO_0000219,1,,,,RBL-1,12166
4236,8,,Inhibitory activity at 10 uM against 5-lipoxygenase in intact rat basophilic leukemia cells stimulated with the calcium ionophore A-23187,B,,,,,CHEMBL620856,12526,H,BAO_0000219,1,,,,RBL-1,12166
4237,8,,Inhibitory activity at 1 uM against 5-lipoxygenase in intact rat basophilic leukemia cells stimulated with the calcium ionophore A-23187,B,,,,,CHEMBL620857,12526,H,BAO_0000219,1,,,,RBL-1,12166
4238,8,,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in rat cell at 1 uM,B,,,,,CHEMBL620858,10193,H,BAO_0000019,1,,,,,12166
4239,8,,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in rat cell at 10 uM,B,,,,,CHEMBL620859,10193,H,BAO_0000019,1,,,,,12166
4240,8,,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in rat cell at 1 uM,B,,,,,CHEMBL620860,10193,H,BAO_0000019,1,,,,,12166
4241,8,,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in rat cell at 3 uM,B,,,,,CHEMBL620861,10193,H,BAO_0000019,1,,,,,12166
4242,8,,Percent inhibition of rat neutrophil 5-lipoxygenase (5-LO),B,,,,,CHEMBL620862,9138,H,BAO_0000357,1,,,,,12166
4243,8,,Percent inhibition of rat neutrophil 5- Lipoxygenase (5-LO) at 100 uM,B,,,,,CHEMBL620863,9138,H,BAO_0000357,1,,,,,12166
4244,8,,Tested in vitro for the inhibition of 5-lipoxygenase in cell-free preparations from rat PMN leukocytes,B,,,,,CHEMBL620864,11966,H,BAO_0000019,1,,,,,12166
4245,8,,The compound was evaluated in vitro for inhibition of 5-lipoxygenase activity in RBL-1 cells at 100 uM,B,,,,,CHEMBL620865,165,H,BAO_0000219,1,,,,RBL-1,12166
4246,8,,The compound was evaluated in vitro for inhibition of 5-lipoxygenase activity in RBL-1 cells at 30 uM,B,,,,,CHEMBL620866,165,H,BAO_0000219,1,,,,RBL-1,12166
4247,8,,The compound was tested for inhibition of 5-lipoxygenase in rat RBL-2H3 cells,B,,,,,CHEMBL620867,11311,H,BAO_0000219,1,,,,RBL-2H3,12166
4248,8,,The compound was tested for inhibition of 5-lipoxygenase translocation in SAR in rat RBL-2H3 cells,B,,,,,CHEMBL620868,11311,H,BAO_0000219,1,,,,RBL-2H3,12166
4249,8,,The compound was tested for inhibition of 5-lipoxygenase translocation in SAR in rat RBL-2H3 cells,F,,,,,CHEMBL620869,11311,H,BAO_0000219,1,,,,RBL-2H3,12166
4250,8,,The compound was tested for inhibition of LTB4 synthesis on isolated 5-lipoxygenase,F,,,,,CHEMBL873952,11311,H,BAO_0000019,1,,,,,12166
4251,8,,The compound was tested for inhibition of isolated 5-lipoxygenase,B,,,,,CHEMBL875099,11311,H,BAO_0000357,1,,,,,12166
4252,8,,The compound was tested for inhibition of isolated 5-lipoxygenase translocation into rat RBL-2H3 cells,F,,,,,CHEMBL620870,11311,H,BAO_0000219,1,,,,RBL-2H3,12166
4253,8,,The compound was tested for the in vitro inhibition of 5-lipoxygenase (5-lo) from the 20000 g supernatant of RBI-1 cells at a concentration of 30 uM,B,,,,,CHEMBL618261,11087,H,BAO_0000019,1,,,,,12166
4254,8,,The compound was tested for the in vitro inhibition of 5-lipoxygenase (5-lo) from the 20000 g supernatant of RBI-1 cells at a concentration of 32 uM,B,,,,,CHEMBL618262,11087,H,BAO_0000019,1,,,,,12166
4255,8,,The compound was tested for the in vitro inhibition of 5-lipoxygenase (5-lo) from the 20000 g supernatant of RBI-1 cells measured at a concentration of 30 uM,B,,,,,CHEMBL619428,11087,H,BAO_0000019,1,,,,,12166
4256,8,,The compound was tested for the in vitro inhibition of 5-lipoxygenase (5-lo) from the 20000 g supernatant of RBI-1 cells; NS indicates nonsignificant inhibition at 32 uM concentration,B,,,,,CHEMBL619429,11087,H,BAO_0000019,1,,,,,12166
4257,8,,The compound was tested for the in vitro inhibition of 5-lipoxygenase from the 20000 g supernatant of RBI-1 cells; NS indicates nonsignificant inhibition at 32 uM concentration,B,,,,,CHEMBL619430,11087,H,BAO_0000019,1,,,,,12166
4258,8,,The compound was tested for the inhibition of 5-lipoxygenase in intact basophilic rat leukemia cells at 1.0 uM,B,,,,,CHEMBL620017,496,H,BAO_0000219,1,,,,RBL-1,12166
4259,8,,The compound was tested for the inhibition of 5-lipoxygenase in intact basophilic rat leukemia cells at 10 uM,B,,,,,CHEMBL620018,496,H,BAO_0000219,1,,,,RBL-1,12166
4260,8,,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by 5-HETE production at 0.1 uM,F,,,,,CHEMBL620019,13986,H,BAO_0000219,1,,,,RBL-1,12166
4261,8,,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by 5-HETE production at 0.195 uM,F,,,,,CHEMBL620020,13986,H,BAO_0000219,1,,,,RBL-1,12166
4262,8,,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by 5-HETE production at 0.2 at uM,F,,,,,CHEMBL620021,13986,H,BAO_0000219,1,,,,RBL-1,12166
4263,8,,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by 5-HETE production at 0.25 uM,F,,,,,CHEMBL620022,13986,H,BAO_0000219,1,,,,RBL-1,12166
4264,8,,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by 5-HETE production at 0.39,F,,,,,CHEMBL620023,13986,H,BAO_0000219,1,,,,RBL-1,12166
4265,8,,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by 5-HETE production at 0.39 uM,F,,,,,CHEMBL620024,13986,H,BAO_0000219,1,,,,RBL-1,12166
4266,8,,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by measuring 5-HETE production at 0.195 uM,F,,,,,CHEMBL620025,13986,H,BAO_0000219,1,,,,RBL-1,12166
4267,8,,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by measuring 5-HETE production at 0.2 uM,F,,,,,CHEMBL620026,13986,H,BAO_0000219,1,,,,RBL-1,12166
4268,8,,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by measuring 5-HETE production at 0.39 uM,F,,,,,CHEMBL620027,13986,H,BAO_0000219,1,,,,RBL-1,12166
4269,9,Rattus norvegicus,Inhibition of 5-lipoxygenase on rat basophil leukemia cell (RBL-2H3) lysate as 5-HETE production at 32 uM,F,10116.0,,,,CHEMBL620028,13986,D,BAO_0000019,1,,,,,12166
4270,8,,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase,B,,,,,CHEMBL620029,10193,H,BAO_0000357,1,,,,,12166
4271,8,,Compound was tested for the percent of inhibition against 5-LO at 10 uM,B,,,,,CHEMBL620030,9295,H,BAO_0000357,1,,,,,12166
4272,8,,In vitro percent inhibition against 5-lipoxygenase in RBL-1 cells at 1 uM concentration,B,,,,,CHEMBL875415,4717,H,BAO_0000219,1,,,,RBL-1,12166
4273,8,,In vitro percent inhibition against 5-lipoxygenase in RBL-1 cells at 10 uM concentration,B,,,,,CHEMBL618256,4717,H,BAO_0000219,1,,,,RBL-1,12166
4274,8,,Inhibition of LTB4 in whole cell 5-lipoxygenase assay in an intact rat basophilic leukemia (RBL-1) cell line,B,,,,,CHEMBL618257,11854,H,BAO_0000219,1,,,,RBL-1,12166
4275,8,,Inhibition of LTB4 in whole cell 5-lipoxygenase assay in an intact rat basophilic leukemia (RBL-1) cell line at 10 uM,B,,,,,CHEMBL618258,11854,H,BAO_0000219,1,,,,RBL-1,12166
4276,8,,Inhibition of LTB4 in whole cell 5-lipoxygenase assay in an intact rat basophilic leukemia (RBL-1) cell line at 16 uM,B,,,,,CHEMBL618259,11854,H,BAO_0000219,1,,,,RBL-1,12166
4277,8,,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in rat cell at 10 uM,B,,,,,CHEMBL618260,10193,H,BAO_0000019,1,,,,,12166
4278,8,,Percent inhibition against RBL-1 5-LO in vitro at 10 uM,B,,,,,CHEMBL618215,9295,H,BAO_0000219,1,,,,RBL-1,12166
4279,8,,Percent inhibition against RBL-1 5-LO in vitro at 100 uM,B,,,,,CHEMBL618390,9295,H,BAO_0000219,1,,,,RBL-1,12166
4280,8,,Percent inhibition against RBL-1 5-LO in vitro at 30 uM,B,,,,,CHEMBL618391,9295,H,BAO_0000219,1,,,,RBL-1,12166
4281,8,,Percent inhibition against RBL-1 5-LO in vitro at 300 uM,B,,,,,CHEMBL618392,9295,H,BAO_0000219,1,,,,RBL-1,12166
4282,8,,The compound was evaluated in vitro for inhibition of 5-lipoxygenase activity in RBL-1 cells at 20 uM,B,,,,,CHEMBL618393,165,H,BAO_0000219,1,,,,RBL-1,12166
4283,8,,The compound was tested for inhibition against 5-lipoxygenase in rat polymorphonuclear leukocytes[PMNS] at 10 uM concentration,B,,,,,CHEMBL618394,11311,H,BAO_0000219,1,,,,,12166
4284,8,Homo sapiens,In vitro inhibitory activity against 5-lipoxygenase in rat basophilic leukemia cells(RBL-1),B,9606.0,,,,CHEMBL618395,10489,H,BAO_0000219,1,,,,RBL-1,12166
4285,9,Rattus norvegicus,In vitro inhibitory activity against 5-lipoxygenase in rat basophilic leukemia cells(RBL-1),B,10116.0,,,,CHEMBL618396,10489,D,BAO_0000219,1,,,,RBL-1,12166
4286,9,Rattus norvegicus,Logarithmic value of inhibitory concentration against 5-lipoxygenase in rat basophilic leukemia cells (RBL-1),B,10116.0,,,,CHEMBL858253,10489,D,BAO_0000219,1,,,,RBL-1,12166
4287,9,Rattus norvegicus,Inhibitory activity against 5-lipoxygenase obtained from rat basophilic leukemia cells,B,10116.0,,,,CHEMBL618397,14799,D,BAO_0000019,1,,,,,12166
4288,8,Glycine max,Compound was tested for the percent of inhibition against soybean 15-LO (at 100 uM),B,3847.0,,,,CHEMBL618398,9295,H,BAO_0000357,1,,,,,12054
4289,0,,"Inhibitory activity against 5-lipoxygenase, by using soybean lipoxygenase spectrophotometric assay",B,,,,,CHEMBL618399,16811,U,BAO_0000019,1,,,,,22226
4290,8,,In vitro inhibition of 5-Lipoxygenase; Inactive.,B,,,,,CHEMBL618400,168,H,BAO_0000357,1,,,,,55
4291,8,,Inhibitory concentration against 5-lipoxygenase was determined; No inhibition,B,,,,,CHEMBL618401,6309,H,BAO_0000357,1,,,,,55
4292,8,,Inhibitory concentration against 5-lipoxygenase; No inhibition,B,,,,,CHEMBL618402,6309,H,BAO_0000357,1,,,,,55
4293,8,,Evaluated for inhibitory activity against RBL-1 cell 5-lipoxygenase in guinea pig,B,,,,,CHEMBL876400,3092,H,BAO_0000219,1,,,,RBL-1,55
4294,8,,Inhibitory activity against 5-lipoxygenase.,B,,,,,CHEMBL618403,168,H,BAO_0000357,1,,,,,55
4295,8,,Inhibitory Activity against 5-Lipoxygenase was determined; IA=Inactive,B,,,,,CHEMBL618404,168,H,BAO_0000357,1,,,,,55
4296,8,,Inhibitory Activity against 5-Lipoxygenase was determined; IA=Inactive at concentrations less than 32 uM,B,,,,,CHEMBL618405,168,H,BAO_0000357,1,,,,,55
4297,8,,Inhibitory Activity against 5-Lipoxygenase was determined; NA=No significant inhibitory activity up to 300 uM,B,,,,,CHEMBL618406,168,H,BAO_0000357,1,,,,,55
4298,8,,Inhibitory concentration against arachidonic acid 5-lipoxygenation,F,,,,,CHEMBL618407,12338,H,BAO_0000019,1,,,,,55
4299,8,,Tested for the inhibitory activity against 5-lipoxygenase,B,,,,,CHEMBL618408,4501,H,BAO_0000357,1,,,,,55
4300,8,,Compound was tested for its inhibitory activity against 5-lipoxygenase,B,,,,,CHEMBL618409,1132,H,BAO_0000357,1,,,,,55
4301,8,,Compound was tested for inhibition of 5-lipoxygenase at 50 uM; NI means no inhibition was observed,B,,,,,CHEMBL618410,2117,H,BAO_0000357,1,,,,,55
4302,8,,Inhibitory Activity against 5-Lipoxygenase at 30 uM was determined; Weakly active,B,,,,,CHEMBL618411,168,H,BAO_0000357,1,,,,,55
4303,8,,Inhibitory Activity against 5-Lipoxygenase at concentration 32 uM was determined,B,,,,,CHEMBL618412,168,H,BAO_0000357,1,,,,,55
4304,8,,Concentration required to inhibit RBL-1 supernatant 5-lipoxygenase,B,,,,,CHEMBL618413,13575,H,BAO_0000219,1,,,,RBL-1,12166
4305,8,,,B,,,,,CHEMBL618414,11089,H,BAO_0000357,1,,,,,12166
4306,8,,Compound was tested for its binding activity towards 5-lipoxygenase activating protein (FLAP),B,,,,,CHEMBL618415,216,H,BAO_0000357,1,,,,,10102
4307,8,,Inhibition of 5-lipoxygenase activating protein using human leukocyte membrane preparations,B,,,,,CHEMBL618416,13165,H,BAO_0000019,1,,,,,10102
4308,8,,Measuring the affinity of leukotriene synthesis inhibitor for 5-Lipoxygenase activating protein (FLAP) by using [125I]L-691831 as radioligand.,B,,,,,CHEMBL876401,3278,H,BAO_0000357,1,,,,,10102
4309,8,,Measuring the affinity of leukotriene synthesis inhibitor for 5-lipoxygenase activating protein by using [125I]L-691831 as radioligand.,B,,,,,CHEMBL618417,3278,H,BAO_0000357,1,,,,,10102
4310,8,,Tested for inhibition of leukotriene biosynthesis by binding to 5-lipoxygenase activating protein,B,,,,,CHEMBL618418,11966,H,BAO_0000357,1,,,,,10102
4311,8,,"The compound was tested for the inhibition of binding of [125I]- L- 691,831 binding to 5-lipoxygenase activating protein",B,,,,,CHEMBL618419,175,H,BAO_0000357,1,,,,,10102
4312,8,,"The compound was tested for the inhibition of binding of [125I]- L- 691,831 binding to 5-lipoxygenase activating protein (FLAP)",B,,,,,CHEMBL618420,175,H,BAO_0000357,1,,,,,10102
4313,8,,Binding affinity of compound for 5-lipoxygenase activating protein protein by FLAP binding assay,B,,,,,CHEMBL618421,13449,H,BAO_0000357,1,,,,,10102
4314,8,,Tested for inhibition of 5-phosphatase isolated from human erythrocyte membrane,B,,,,,CHEMBL618422,12014,H,BAO_0000019,1,,,,,11238
4315,8,,Tested for inhibition of 5-phosphatase isolated from human erythrocyte membrane (R metabolically resistant),B,,,,,CHEMBL618423,12014,H,BAO_0000019,1,,,,,11238
4316,8,,Tested for inhibition of 5-phosphatase isolated from human erythrocyte membrane (S substrate),B,,,,,CHEMBL618424,12014,H,BAO_0000019,1,,,,,11238
4317,2,,Inhibition of protein biosynthesis at the level of the peptidyl transferase center of the 50 s ribosomal subunit,B,,,,,CHEMBL618425,99,S,BAO_0000220,1,,,,,100284
4318,0,Homo sapiens,The dark toxicity against 543 human galactophore carcinoma cells,F,9606.0,,,,CHEMBL618426,4349,U,BAO_0000019,1,,,,,22226
4319,1,Homo sapiens,Tested in vitro for cytotoxicity against 56 human tumor cell lines,F,9606.0,,,,CHEMBL618427,4071,N,BAO_0000219,1,,,,Panel (56 tumour cell lines),80623
4320,1,Homo sapiens,Cytotoxic activity against human 5637 cell line at 20 uM expressed as percent growth value,F,9606.0,,,,CHEMBL618428,17589,N,BAO_0000219,1,,,,5637,80008
4321,1,Homo sapiens,Antitumor activity was evaluated against human bladder carcinoma cell line 5637.,F,9606.0,,,,CHEMBL618429,15002,N,BAO_0000219,1,,,,5637,80008
4322,1,Homo sapiens,"Compound was tested for antiproliferative activity against 5637, human bladder carcinoma cell line",F,9606.0,,,,CHEMBL618430,13958,N,BAO_0000219,1,,,,5637,80008
4323,1,Homo sapiens,Growth inhibition against human 5637 cell lines,F,9606.0,,,,CHEMBL618431,17589,N,BAO_0000219,1,,,,5637,80008
4324,1,Homo sapiens,Antitumor activity against human bladder carcinoma 5637 cells.,F,9606.0,,,,CHEMBL883799,16748,N,BAO_0000219,1,,,,5637,80008
4325,1,Homo sapiens,Antitumor activity against human bladder carcinoma 5637 cells,F,9606.0,,,,CHEMBL618432,16747,N,BAO_0000219,1,,,,5637,80008
4326,1,Homo sapiens,Antitumor activity against human bladder carcinoma 5637 cells,F,9606.0,,,,CHEMBL618433,16747,N,BAO_0000219,1,,,,5637,80008
4327,9,Bos taurus,In vitro inhibition of bovine trypsin(Trp).,B,9913.0,,,,CHEMBL618434,15285,D,BAO_0000357,1,,,,,10443
4328,8,Cercopithecidae,Transcriptional activation in CV-1 cells expressing retinoic acid gamma receptor,B,9527.0,,,,CHEMBL618435,3726,H,BAO_0000219,1,,,,CV-1,240
4329,8,,Ability to displace the radioligand [125I](-)-iodocyanopindolol from rat striatal 5-HT1B receptor,B,,,,,CHEMBL876402,5033,H,BAO_0000357,1,,,,,10577
4330,6,,In vitro antagonism of the 5-HT-3 receptor determined by inhibition of 5-HT-induced depolarization of the isolated rat vagus nerve.,F,,,,,CHEMBL618436,11756,H,BAO_0000019,1,,,,,104698
4331,0,,Concentration required to inhibit pressor response to serotonin after 15 min i.v. administration of compound mediated via activation of vascular 5-HT2 receptors in rat,F,,,,,CHEMBL618437,11953,U,BAO_0000218,1,,In vivo,,,22226
4332,9,Cavia porcellus,Ability to displace the radioligand [3H]GR-113808 from guinea pig striatum 5-HT4 receptor,B,10141.0,,,,CHEMBL618438,5033,D,BAO_0000357,1,,,,,20033
4333,8,Rattus norvegicus,Inhibition of progesterone 6-beta-hydroxylase in rat hepatic microsomes,A,10116.0,,Microsomes,,CHEMBL883800,11347,H,BAO_0000251,1,,,,,17045
4334,8,Rattus norvegicus,Inhibition of progesterone 6-beta-hydroxylase in rat hepatic microsomes,A,10116.0,,Microsomes,,CHEMBL618439,11347,H,BAO_0000251,1,,,,,17045
4335,0,,In vitro anticancer activity against 6 NCI ovarian cancer cell lines; inactive,F,,,,,CHEMBL618440,1229,U,BAO_0000019,1,,,,,22226
4336,0,,In vitro anticancer activity against 6 NCI ovarian cancer cell lines; inactive,F,,,,,CHEMBL618441,1229,U,BAO_0000019,1,,,,,22226
4337,8,Trypanosoma brucei,Inhibition constant against 6-phosphogluconate dehydrogenase of Trypanosoma brucei expressed in Escherichia coli,B,5691.0,,,,CHEMBL618442,17588,H,BAO_0000019,1,,,,,11938
4338,8,Trypanosoma brucei,Inhibition constant against 6-phosphogluconate dehydrogenase of Trypanosoma brucei expressed in Escherichia coli; NI denotes no inhibition,B,5691.0,,,,CHEMBL618443,17588,H,BAO_0000019,1,,,,,11938
4339,8,Ovis aries,Inhibition constant against 6-phosphogluconate dehydrogenase of sheep liver,B,9940.0,,,,CHEMBL619158,17588,H,BAO_0000019,1,,,,,11938
4340,8,Ovis aries,Inhibition constant against 6-phosphogluconate dehydrogenase of sheep liver; NI denotes no inhibition,B,9940.0,,,,CHEMBL620974,17588,H,BAO_0000019,1,,,,,11938
4341,8,,log Kd which is the binding affinity against 6-phosphogluconate dehydrogenase,B,,,,,CHEMBL620975,16485,H,BAO_0000357,1,,,,,11938
4342,0,Homo sapiens,Average inhibitory concentration against 60 human cell lines was reported,F,9606.0,,,,CHEMBL620976,4337,U,BAO_0000019,1,,,,,22226
4343,0,Homo sapiens,Inhibition of proliferation in NCI panel of 60 human tumor cell lines,F,9606.0,,,,CHEMBL620977,4112,U,BAO_0000019,1,,,,,22226
4344,1,Homo sapiens,Cancer specificity was measured from the +/- value under average log LC50 60-cell line,F,9606.0,,,,CHEMBL620978,16160,N,BAO_0000219,1,,,,Panel NCI-60 (60 carcinoma cell lines),80315
4345,1,Homo sapiens,Cancer specificity was measured from the +/- value under average log LC50 60-cell line. ,F,9606.0,,,,CHEMBL620979,16160,N,BAO_0000219,1,,,,Panel NCI-60 (60 carcinoma cell lines),80315
4346,1,,In vitro mean growth inhibitory activity against 60-cell panel,F,,,,,CHEMBL620980,17376,N,BAO_0000219,1,,,,Panel NCI-60 (60 carcinoma cell lines),80315
4347,1,,In vitro mean growth lethal concentration against 60-cell panel,F,,,,,CHEMBL620981,17376,N,BAO_0000219,1,,,,Panel NCI-60 (60 carcinoma cell lines),80315
4348,1,,In vitro mean growth lethal concentration in colon subpanel against 60-cell panel,F,,,,,CHEMBL620982,17376,N,BAO_0000219,1,,,,Panel NCI-60 (60 carcinoma cell lines),80315
4349,1,,In vitro mean growth lethal concentration in renal subpanel against 60-cell panel,F,,,,,CHEMBL620983,17376,N,BAO_0000219,1,,,,Panel NCI-60 (60 carcinoma cell lines),80315
4350,4,,Inhibition of CK-II-mediated 60S acidic ribosomal P protein activity at 10 uM,F,,,,,CHEMBL620984,3241,H,BAO_0000019,1,,,,,104775
4351,4,,Inhibition of CK-II-mediated 60S acidic ribosomal P protein activity at 10 uM,F,,,,,CHEMBL620985,3241,H,BAO_0000019,1,,,,,104775
4352,8,,Transcriptional activation in CV-1 expressing retinoid X receptor RXR alpha,B,,,,,CHEMBL620986,3725,H,BAO_0000357,1,,,,,275
4353,1,Plasmodium falciparum,Inhibitory activity against Plasmodium falciparum 68 neutral proteinase,F,5833.0,,,,CHEMBL620987,10805,N,BAO_0000218,1,,,,,50425
4354,1,Plasmodium falciparum,In vitro inhibition of Plasmodium falciparum 68 neutral proteinase activity by reinvasion of red blood cells,F,5833.0,,,,CHEMBL620988,10805,N,BAO_0000218,1,,,,,50425
4355,1,Plasmodium falciparum,Inhibitory activity against Plasmodium falciparum 68 neutral proteinase.,F,5833.0,,,,CHEMBL620989,10805,N,BAO_0000218,1,,,,,50425
4356,1,Plasmodium falciparum,Substrate affinity for Plasmodium falciparum 68 neutral proteinase.,F,5833.0,,,,CHEMBL620990,10805,N,BAO_0000218,1,,,,,50425
4357,1,Plasmodium falciparum,Reaction velocity for Plasmodium falciparum 68 neutral proteinase.,F,5833.0,,,,CHEMBL620991,10805,N,BAO_0000218,1,,,,,50425
4358,1,Mus musculus,Percent inhibition against 6C3HED lymphosarcoma at dose 100 mg/kg in C3H mice,F,10090.0,,,,CHEMBL620992,10144,N,BAO_0000218,1,,,,6C3HED,80628
4359,1,Mus musculus,Percent inhibition against 6C3HED lymphosarcoma at dose 12.5 mg/kg in C3H mice,F,10090.0,,,,CHEMBL620993,10144,N,BAO_0000218,1,,,,6C3HED,80628
4360,1,Mus musculus,Percent inhibition against 6C3HED lymphosarcoma at dose 200 mg/kg in C3H mice,F,10090.0,,,,CHEMBL620994,10144,N,BAO_0000218,1,,,,6C3HED,80628
4361,1,Mus musculus,Percent inhibition against 6C3HED lymphosarcoma at dose 25 mg/kg in C3H mice,F,10090.0,,,,CHEMBL620995,10144,N,BAO_0000218,1,,,,6C3HED,80628
4362,1,Mus musculus,Percent inhibition against 6C3HED lymphosarcoma at dose 50 mg/kg in C3H mice,F,10090.0,,,,CHEMBL620996,10144,N,BAO_0000218,1,,,,6C3HED,80628
4363,1,Mus musculus,Percent inhibition against 6C3HED lymphosarcoma at dose 6 mg/kg in C3H mice,F,10090.0,,,,CHEMBL875581,10144,N,BAO_0000218,1,,,,6C3HED,80628
4364,0,Mus musculus,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 100 mg/kg,F,10090.0,,,,CHEMBL620997,10685,U,BAO_0000218,1,,In vivo,,,22224
4365,0,Mus musculus,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 150 mg/kg,F,10090.0,,,,CHEMBL620998,10685,U,BAO_0000218,1,,In vivo,,,22224
4366,0,Mus musculus,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 1600 mg/kg (intraperitoneal dosing for 8 days),F,10090.0,,,,CHEMBL620999,10685,U,BAO_0000218,1,,In vivo,,,22224
4367,0,Mus musculus,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 200 mg/kg,F,10090.0,,,,CHEMBL621000,10685,U,BAO_0000218,1,,In vivo,,,22224
4368,0,Mus musculus,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 225 mg/kg,F,10090.0,,,,CHEMBL621001,10685,U,BAO_0000218,1,,In vivo,,,22224
4369,0,Mus musculus,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 270 mg/kg,F,10090.0,,,,CHEMBL621002,10685,U,BAO_0000218,1,,In vivo,,,22224
4370,0,Mus musculus,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 275 mg/kg,F,10090.0,,,,CHEMBL621003,10685,U,BAO_0000218,1,,In vivo,,,22224
4371,0,Mus musculus,"Antitumor activity in vivo against the 6C3HED lymphosarcoma, dosed for 10 days at 300 mg/kg",F,10090.0,,,,CHEMBL621004,10685,U,BAO_0000218,1,,In vivo,,,22224
4372,0,Mus musculus,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 300 mg/kg (intraperitoneal dosing for 8 days),F,10090.0,,,,CHEMBL621005,10685,U,BAO_0000218,1,,In vivo,,,22224
4373,0,Mus musculus,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 300 mg/kg (ip dosing daily for 8 days),F,10090.0,,,,CHEMBL621006,10685,U,BAO_0000218,1,,In vivo,,,22224
4374,0,Mus musculus,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 600 mg/kg,F,10090.0,,,,CHEMBL621007,10685,U,BAO_0000218,1,,In vivo,,,22224
4375,0,Mus musculus,Percent inhibition against 6C3HED lymphosarcoma at dose 100 mg/kg in C3H mice,F,10090.0,,,,CHEMBL621008,10144,U,BAO_0000218,1,,,,,22224
4376,0,Mus musculus,Percent inhibition against 6C3HED lymphosarcoma at dose 12.5 mg/kg in C3H mice,F,10090.0,,,,CHEMBL621009,10144,U,BAO_0000218,1,,,,,22224
4377,0,Mus musculus,Percent inhibition against 6C3HED lymphosarcoma at dose 25 mg/kg in C3H mice,F,10090.0,,,,CHEMBL857705,10144,U,BAO_0000218,1,,,,,22224
4378,0,Mus musculus,Percent inhibition against 6C3HED lymphosarcoma at dose 50 mg/kg in C3H mice,F,10090.0,,,,CHEMBL619828,10144,U,BAO_0000218,1,,,,,22224
4379,0,Mus musculus,Tested on 6C3HED lymphosarcoma and percent inhibition was determined at 100 mg/kg dosage administered for 8 days intraperitoneally,F,10090.0,,,,CHEMBL619829,10685,U,BAO_0000218,1,,,,,22224
4380,0,Mus musculus,Tested on 6C3HED lymphosarcoma and percent inhibition was determined at 200 mg/kg dosage administered for 10 days intraperitoneally,F,10090.0,,,,CHEMBL619830,10685,U,BAO_0000218,1,,,,,22224
4381,0,Mus musculus,Tested on 6C3HED lymphosarcoma and percent inhibition was determined at 200 mg/kg dosage administered for 8 days intraperitoneally,F,10090.0,,,,CHEMBL619831,10685,U,BAO_0000218,1,,,,,22224
4382,0,Mus musculus,Tested on 6C3HED lymphosarcoma and percent inhibition was determined at 50 mg/kg dosage administered for 8 days intraperitoneally,F,10090.0,,,,CHEMBL619832,10685,U,BAO_0000218,1,,,,,22224
4383,0,Mus musculus,Tested on 6 C3 HED lymphosarcoma and number of drug related deaths/total animals in treatment group was determined at 100 mg/kg dosage administered for 8 days intraperitoneally; 0/10,A,10090.0,,,,CHEMBL619833,10685,U,BAO_0000218,1,,,,,22224
4384,0,Mus musculus,Tested on 6 C3 HED lymphosarcoma and number of drug related deaths/total animals in treatment group was determined at 200 mg/kg dosage administered for 8 days perorally; 1/10,A,10090.0,,,,CHEMBL619834,10685,U,BAO_0000218,1,,,,,22224
4385,0,Mus musculus,Tested on 6 C3 HED lymphosarcoma and number of drug related deaths/total animals in treatment group was determined at 200 mg/kg dosage administered for 10 days intraperitoneally; 1/10,A,10090.0,,,,CHEMBL619835,10685,U,BAO_0000218,1,,,,,22224
4386,0,Mus musculus,Tested on 6 C3 HED lymphosarcoma and number of drug related deaths/total animals in treatment group was determined at 50 mg/kg dosage administered for 8 days perorally; 3/10,A,10090.0,,,,CHEMBL619836,10685,U,BAO_0000218,1,,,,,22224
4387,1,Mus musculus,"Compound was evaluated for the antitumor activity against 6C3HED lymphosarcoma for ip administration and daily x 8 schedule; Number of toxic deaths over total number of mice per group (T/C), 0/10 at dose of 35 mg/kg",F,10090.0,,,,CHEMBL619837,8831,N,BAO_0000218,1,,,,6C3HED,80628
4388,0,,In vivo antitumor activity against 6C3HED tumor type after intraperitoneal administration of 400 mg/kg,F,,,,,CHEMBL619838,11704,U,BAO_0000218,1,,In vivo,,,22224
4389,1,Mus musculus,In vivo antitumor activity against 6C3HED tumor type was expressed as toxic deaths/total treated mice at 400 mg/kg dose; 2/10,A,10090.0,,,,CHEMBL619839,11704,N,BAO_0000218,1,,,,,50594
4390,1,Mus musculus,Antitumor activity in vivo expressed as percent of inhibition in 6C3HED-lymphosarcoma tumor cell line,F,10090.0,,,,CHEMBL619840,10685,N,BAO_0000218,1,,In vivo,,6C3HED,80628
4391,1,Mus musculus,Antitumor activity in vivo expressed as percent of inhibition in 6C3HED-lymphosarcoma tumor cell line; 95-100% inhibition,F,10090.0,,,,CHEMBL619841,10685,N,BAO_0000218,1,,In vivo,,6C3HED,80628
4392,1,Mus musculus,Inhibition of tumor growth of 6C3HED lymphosarcoma tumor cell line in mice at a dose of 150 mg/kg given orally(daily x 8),F,10090.0,,,,CHEMBL857704,11368,N,BAO_0000218,1,,,,6C3HED,80628
4393,1,Mus musculus,Inhibition of tumor growth of 6C3HED lymphosarcoma tumor cell line in mice at a dose of 200 mg/kg given orally(daily x 8),F,10090.0,,,,CHEMBL619842,11368,N,BAO_0000218,1,,,,6C3HED,80628
4394,1,Mus musculus,Inhibition of tumor growth of 6C3HED lymphosarcoma tumor cell line in mice at a dose of 300 mg/kg given orally (daily x 8),F,10090.0,,,,CHEMBL619843,11368,N,BAO_0000218,1,,,,6C3HED,80628
4395,0,Staphylococcus aureus,"Inhibition of Staphylococcus aureus 7,8-dihydroneopterin aldolase",B,1280.0,,,,CHEMBL619844,17763,U,BAO_0000019,1,,,,,22226
4396,0,Rattus norvegicus,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes 3-methylcholanthrene at a concentration of 5 uM,B,10116.0,Liver,Microsomes,,CHEMBL857855,7411,U,BAO_0000251,1,2107.0,,,,22226
4397,0,Rattus norvegicus,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at a concentration of 10 uM,B,10116.0,Liver,Microsomes,,CHEMBL619845,7411,U,BAO_0000251,1,2107.0,,,,22226
4398,0,Rattus norvegicus,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at a concentration of 1 uM,B,10116.0,Liver,Microsomes,,CHEMBL619846,7411,U,BAO_0000251,1,2107.0,,,,22226
4399,0,Rattus norvegicus,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at a concentration of 20 uM,B,10116.0,Liver,Microsomes,,CHEMBL619847,7411,U,BAO_0000251,1,2107.0,,,,22226
4400,0,Rattus norvegicus,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at a concentration of 25 uM,B,10116.0,Liver,Microsomes,,CHEMBL619848,7411,U,BAO_0000251,1,2107.0,,,,22226
4401,0,Rattus norvegicus,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at a concentration of 50 uM,B,10116.0,Liver,Microsomes,,CHEMBL620893,7411,U,BAO_0000251,1,2107.0,,,,22226
4402,0,Rattus norvegicus,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at a concentration of 5 uM,B,10116.0,Liver,Microsomes,,CHEMBL620894,7411,U,BAO_0000251,1,2107.0,,,,22226
4403,0,Rattus norvegicus,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 10 uM,B,10116.0,Liver,Microsomes,,CHEMBL620895,7411,U,BAO_0000251,1,2107.0,,,,22226
4404,0,Rattus norvegicus,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 100 uM,B,10116.0,Liver,Microsomes,,CHEMBL620896,7411,U,BAO_0000251,1,2107.0,,,,22226
4405,0,Rattus norvegicus,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 200 uM,B,10116.0,Liver,Microsomes,,CHEMBL620897,7411,U,BAO_0000251,1,2107.0,,,,22226
4406,0,Rattus norvegicus,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 25 uM,B,10116.0,Liver,Microsomes,,CHEMBL620898,7411,U,BAO_0000251,1,2107.0,,,,22226
4407,0,Rattus norvegicus,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 50 uM,B,10116.0,Liver,Microsomes,,CHEMBL620899,7411,U,BAO_0000251,1,2107.0,,,,22226
4408,0,Cercopithecidae,The apparent total plasma clearance in monkey,A,9527.0,Plasma,,,CHEMBL620900,347,U,BAO_0000218,1,1969.0,In vivo,,,22224
4409,0,Cercopithecidae,Compound was evaluated for Hepatic clearance in monkey,A,9527.0,,,,CHEMBL620901,3341,U,BAO_0000218,1,,In vivo,,,22224
4410,0,Cercopithecidae,Lower clearance in monkey (i.v.) at 0.5 mpk,A,9527.0,,,,CHEMBL620902,17853,U,BAO_0000218,1,,In vivo,,,22224
4411,0,Cercopithecidae,Plasma clearance in rhesus monkey,A,9527.0,,,,CHEMBL620903,4514,U,BAO_0000218,1,,In vivo,,,22224
4412,0,Cercopithecidae,Plasma clearance for the compound was measured in monkey after an iv dose of 1 mg/kg,A,9527.0,,,,CHEMBL620904,6062,U,BAO_0000218,1,,In vivo,,,22224
4413,0,Cercopithecidae,Plasma clearance of compound was determined in monkey,A,9527.0,,,,CHEMBL620905,6821,U,BAO_0000218,1,,In vivo,,,22224
4414,0,Cercopithecidae,Plasma clearance was calculated in rhesus monkey,A,9527.0,,,,CHEMBL620906,6057,U,BAO_0000218,1,,In vivo,,,22224
4415,0,Cercopithecidae,Plasma clearance in rhesus monkey,A,9527.0,,,,CHEMBL875420,5145,U,BAO_0000218,1,,In vivo,,,22224
4416,0,Cercopithecidae,Plasma clearance in monkey (dosed at 0.5 mpk iv and 2.0 mpk orally),A,9527.0,,,,CHEMBL620907,6641,U,BAO_0000218,1,,In vivo,,,22224
4417,0,Cercopithecidae,Plasma clearance was evaluated in rhesus,A,9527.0,,,,CHEMBL620908,5472,U,BAO_0000218,1,,In vivo,,,22224
4418,0,Cercopithecidae,Plasma clearance value was determined in monkey after a 3 mg/kg of iv dose,A,9527.0,,,,CHEMBL620909,4257,U,BAO_0000218,1,,In vivo,,,22224
4419,0,Cercopithecidae,Plasma clearance was determined in rhesus monkey at a dose of 1 mg/kg by iv administration,A,9527.0,,,,CHEMBL620910,5546,U,BAO_0000218,1,,In vivo,,,22224
4420,0,Cercopithecidae,Plasma clearance was reported after intravenous administration at a dose of 1 mg/kg in Rhesus monkey (male),A,9527.0,,,,CHEMBL620911,5334,U,BAO_0000218,1,,In vivo,,,22224
4421,0,Cercopithecidae,Plasma clearance was reported after oral administration at a dose of 2 mg/kg in Rhesus monkey (male),A,9527.0,,,,CHEMBL620912,5334,U,BAO_0000218,1,,In vivo,,,22224
4422,0,Cercopithecidae,Cmax 24 hr after 2 mg/kg oral administration in monkeys,A,9527.0,,,,CHEMBL620913,17509,U,BAO_0000218,1,,In vivo,,,22224
4423,0,Cercopithecidae,Cmax in monkey after administration of 1 mg/kg iv,A,9527.0,,,,CHEMBL620914,6535,U,BAO_0000218,1,,In vivo,,,22224
4424,0,Cercopithecidae,Cmax was determine after peroral administration at 10 mpk in Rhesus,A,9527.0,,,,CHEMBL620915,5668,U,BAO_0000218,1,,In vivo,,,22224
4425,0,Cercopithecidae,Cmax in cynomolgus monkey by iv administration,A,9527.0,,,,CHEMBL620916,5922,U,BAO_0000218,1,,In vivo,,,22224
4426,0,Cercopithecidae,Cmax in cynomolgus monkey by po administration,A,9527.0,,,,CHEMBL620917,5922,U,BAO_0000218,1,,In vivo,,,22224
4427,0,Cercopithecidae,Cmax value evaluated in monkey,A,9527.0,,,,CHEMBL620918,6078,U,BAO_0000218,1,,In vivo,,,22224
4428,0,Cercopithecidae,Compound was evaluated for maximum concentration after treatment with oral dose of 2 mgkg to female cynomolgus monkey,A,9527.0,,,,CHEMBL620919,2661,U,BAO_0000218,1,,In vivo,,,22224
4429,0,Cercopithecidae,Maximal concentration (Cmax) in rhesus monkey plasma at a dose of 5 mg/kg,A,9527.0,Plasma,,,CHEMBL620920,3249,U,BAO_0000218,1,1969.0,In vivo,,,22224
4430,0,Cercopithecidae,Maximal concentration (Cmax) in squirrel monkey plasma at a dose of 5 mg/kg,A,9527.0,Plasma,,,CHEMBL620921,3249,U,BAO_0000218,1,1969.0,In vivo,,,22224
4431,0,Cercopithecidae,Maximal plasma concentration in squirrel monkeys,A,9527.0,Plasma,,,CHEMBL620922,5553,U,BAO_0000218,1,1969.0,In vivo,,,22224
4432,0,Cercopithecidae,Maximum concentration was evaluated against Cynomolgus monkey at a dose of 15 mg/kg after po administration,A,9527.0,,,,CHEMBL620923,1916,U,BAO_0000218,1,,In vivo,,,22224
4433,0,Cercopithecidae,Maximum plasma concentration (Cmax) in rhesus monkey(in vivo) at a dose of 5 mg/kg,A,9527.0,Plasma,,,CHEMBL620924,6227,U,BAO_0000218,1,1969.0,In vivo,,,22224
4434,0,Cercopithecidae,Pharmacokinetic parameter Cmax was determined in monkey after (po) administration of a dose of 50 (uM/kg),A,9527.0,,,,CHEMBL620925,4809,U,BAO_0000218,1,,In vivo,,,22224
4435,0,Cercopithecidae,The peak concentration (Cmax) value after intravenous administration in cynomolgus monkeys; NA means Not applicable,A,9527.0,,,,CHEMBL620926,5355,U,BAO_0000218,1,,In vivo,,,22224
4436,0,Cercopithecidae,The peak concentration (Cmax) value after intravenous administration in cynomolgus monkeys; NA means not applicable,A,9527.0,,,,CHEMBL620927,5355,U,BAO_0000218,1,,In vivo,,,22224
4437,0,Cercopithecidae,The peak concentration (Cmax) value after intravenous administration in cynomolgus monkeys;NA means not applicable,A,9527.0,,,,CHEMBL620928,5355,U,BAO_0000218,1,,In vivo,,,22224
4438,0,Cercopithecidae,The peak concentration (Cmax) value after oral administration in cynomolgus monkeys,A,9527.0,,,,CHEMBL620929,5355,U,BAO_0000218,1,,In vivo,,,22224
4439,0,Cercopithecidae,The peak plasma concentration after 5 hr administration (2.5 mg/kg) in monkey was determined,A,9527.0,Plasma,,,CHEMBL620930,6221,U,BAO_0000218,1,1969.0,In vivo,,,22224
4440,0,Cercopithecidae,Compound was evaluated for Plasma levels upon oral administration at 30 mg/kg in Monkey at maximum of 0.4 hours,A,9527.0,,,,CHEMBL620931,167,U,BAO_0000218,1,,,,,22224
4441,0,Cercopithecidae,Compound was evaluated for Plasma levels upon oral administration at 30 mg/kg in Monkey at maximum of 1.0 hours,A,9527.0,,,,CHEMBL620932,167,U,BAO_0000218,1,,,,,22224
4442,0,monkey,Absolute bioavailability was evaluated in monkey,A,9443.0,,,,CHEMBL620933,4257,U,BAO_0000218,1,,In vivo,,,22224
4443,0,monkey,Bioavailability after oral administration (2.5 mg/kg) in monkey was determined,A,9443.0,,,,CHEMBL620934,6221,U,BAO_0000218,1,,In vivo,,,22224
4444,0,monkey,Bioavailability of compound at 3 mg/kg in monkey after i.v. administration,A,9443.0,,,,CHEMBL620935,17667,U,BAO_0000218,1,,In vivo,,,22224
4445,0,Macaca mulatta,Bioavailability of compound was determined in rhesus monkey,A,9544.0,,,,CHEMBL620936,17267,U,BAO_0000218,1,,In vivo,,,22224
4446,0,marmosets,Bioavailability determined after oral administration in marmoset,A,38020.0,,,,CHEMBL620937,4256,U,BAO_0000218,1,,In vivo,,,22224
4447,0,Macaca fascicularis,Oral bioavailability in cynomolgus monkey,A,9541.0,,,,CHEMBL620938,4256,U,BAO_0000218,1,,In vivo,,,22224
4448,0,monkey,Bioavailability in monkey (p.o.) at 2.0 mpk,A,9443.0,,,,CHEMBL620939,17853,U,BAO_0000218,1,,In vivo,,,22224
4449,0,monkey,Bioavailability was evaluated after oral administration in monkey,A,9443.0,,,,CHEMBL620940,16365,U,BAO_0000218,1,,In vivo,,,22224
4450,0,Macaca fascicularis,Bioavailability was evaluated against Cynomolgus monkey at a dose of 15 mg/kg after po administration,A,9541.0,,,,CHEMBL620941,1916,U,BAO_0000218,1,,In vivo,,,22224
4451,0,Macaca mulatta,Bioavailability was reported after intravenous administration at a dose of 1 mg/kg in Rhesus monkey (male),A,9544.0,,,,CHEMBL620942,5334,U,BAO_0000218,1,,In vivo,,,22224
4452,0,Macaca mulatta,Bioavailability was reported after oral administration at a dose of 2 mg/kg in Rhesus monkey (male),A,9544.0,,,,CHEMBL620943,5334,U,BAO_0000218,1,,In vivo,,,22224
4453,0,monkey,Bioavailability of the compound was determined in monkey,A,9443.0,,,,CHEMBL620944,17592,U,BAO_0000218,1,,In vivo,,,22224
4454,0,Saimiri sciureus,Bioavailability in squirrel monkey (dose 5 mg/kg),A,9521.0,,,,CHEMBL620945,1399,U,BAO_0000218,1,,In vivo,,,22224
4455,0,monkey,Bioavailability was determined in monkey after (po) administration of a dose of 50 (uM/kg),A,9443.0,,,,CHEMBL620946,4809,U,BAO_0000218,1,,In vivo,,,22224
4456,0,monkey,Oral bioavailability in monkey,A,9443.0,,,,CHEMBL620947,3341,U,BAO_0000218,1,,In vivo,,,22224
4457,0,Saimiri sciureus,Compound was tested for bioavailability in squirrel monkey,A,9521.0,,,,CHEMBL620948,64,U,BAO_0000218,1,,In vivo,,,22224
4458,0,Macaca mulatta,Oral bioavailability in Rhesus monkey,A,9544.0,,,,CHEMBL620949,5005,U,BAO_0000218,1,,In vivo,,,22224
4459,0,Macaca mulatta,Oral bioavailability in Rhesus monkey (dose of 0.75 mg/kg i.v. and 1.5 mg/kg p.o.),A,9544.0,,,,CHEMBL620950,5005,U,BAO_0000218,1,,In vivo,,,22224
4460,0,Macaca fascicularis,Oral bioavailability in cynomolgus monkeys for the compound was determined; Acceptable,A,9541.0,,,,CHEMBL620951,5237,U,BAO_0000218,1,,In vivo,,,22224
4461,0,Macaca fascicularis,Oral bioavailability in cynomolgus monkeys was determined; Acceptable,A,9541.0,,,,CHEMBL620952,5237,U,BAO_0000218,1,,In vivo,,,22224
4462,0,monkey,Oral bioavailability in monkey (dose 5 mg/kg),A,9443.0,,,,CHEMBL875421,5302,U,BAO_0000218,1,,In vivo,,,22224
4463,0,monkey,Oral bioavailability of compound at 5 mg/kg in monkey,A,9443.0,,,,CHEMBL620953,17667,U,BAO_0000218,1,,In vivo,,,22224
4464,1,Canis lupus familiaris,Pharmacokinetic profile in terms of half life was determined at a dose of 0.5 mg/kg administered intravenously in dog,A,9615.0,,,,CHEMBL873491,6161,N,BAO_0000218,1,,In vivo,,,50588
4465,1,Canis lupus familiaris,Pharmacokinetic profile in terms of half life was determined at a dose of 5 mg/kg administered intravenously in dog,A,9615.0,,,,CHEMBL620954,6161,N,BAO_0000218,1,,In vivo,,,50588
4466,1,Canis lupus familiaris,Plasma half life determined,A,9615.0,Plasma,,,CHEMBL620955,3854,N,BAO_0000218,1,1969.0,,,,50588
4467,1,Canis lupus familiaris,Plasma half life in dog,A,9615.0,Plasma,,,CHEMBL618097,993,N,BAO_0000218,1,1969.0,,,,50588
4468,1,Canis lupus familiaris,Plasma half-life in Beagle dogs,A,9615.0,Plasma,,,CHEMBL618268,4514,N,BAO_0000218,1,1969.0,,,,50588
4469,1,Canis lupus familiaris,Plasma half-life period (0-8 h) was reported after intravenous administration at a dose of 1 mg/kg in Beagle dog (male),A,9615.0,Plasma,,,CHEMBL618269,5334,N,BAO_0000218,1,1969.0,In vivo,,,50588
4470,1,Canis lupus familiaris,Plasma half-life period (0-8 h) was reported after oral administration at a dose of 2 mg/kg respectively in Beagle dog (male),A,9615.0,Plasma,,,CHEMBL618270,5334,N,BAO_0000218,1,1969.0,In vivo,,,50588
4471,1,Canis lupus familiaris,Tested for t1/2 upon intravenous administration of 5.0 mg/Kg dose in dog,A,9615.0,,,,CHEMBL618271,1466,N,BAO_0000218,1,,In vivo,,,50588
4472,1,Canis lupus familiaris,Tested for t1/2 upon peroral administration of 10.0 mg/Kg dose in dog,A,9615.0,,,,CHEMBL873493,1466,N,BAO_0000218,1,,In vivo,,,50588
4473,1,Canis lupus familiaris,Tested for the half life period in dog,A,9615.0,,,,CHEMBL621031,5313,N,BAO_0000218,1,,,,,50588
4474,1,Canis lupus familiaris,Tested for the half life period in dog at dosage of 10 mpk,A,9615.0,,,,CHEMBL621032,5313,N,BAO_0000218,1,,In vivo,,,50588
4475,1,Canis lupus familiaris,The compound was tested for half life in dog,A,9615.0,,,,CHEMBL621033,3880,N,BAO_0000218,1,,,,,50588
4476,1,Canis lupus familiaris,"The compound was tested for time taken to decrease, half of its initial concentration in dog plasma.",A,9615.0,Plasma,,,CHEMBL621034,3639,N,BAO_0000218,1,1969.0,,,,50588
4477,1,Canis lupus familiaris,The half life was determined,A,9615.0,,,,CHEMBL621035,3880,N,BAO_0000218,1,,,,,50588
4478,1,Canis lupus familiaris,The plasma half-life in dogs,A,9615.0,Plasma,,,CHEMBL621036,3918,N,BAO_0000218,1,1969.0,,,,50588
4479,1,Canis lupus familiaris,suboptimal plasma half-life caused a10% prolongation of QTc interval in dogs at a plasma level of 2.5 M,A,9615.0,Plasma,,,CHEMBL621037,16452,N,BAO_0000218,1,1969.0,,,,50588
4480,1,Canis lupus familiaris,Half life in dog,A,9615.0,,,,CHEMBL619812,17796,N,BAO_0000218,1,,,,,50588
4481,1,Canis lupus familiaris,Pharmacokinetic property (t1/2beta) was measured in dog at the dose of 0.032 mg/kg i.v.,A,9615.0,,,,CHEMBL619813,5983,N,BAO_0000218,1,,In vivo,,,50588
4482,1,Canis lupus familiaris,tmax upon peroral administration of 10.0 mg/Kg dose in dog,A,9615.0,,,,CHEMBL873335,1466,N,BAO_0000218,1,,In vivo,,,50588
4483,1,Canis lupus familiaris,Volume of distribution in Beagle dogs after intravenous administration at a dose of 10 mg/kg,A,9615.0,,,,CHEMBL619814,16456,N,BAO_0000218,1,,In vivo,,,50588
4484,1,Mustela putorius furo,Cmax in ferrets after 30 mg/kg oral dose,A,9669.0,,,,CHEMBL619815,6113,N,BAO_0000218,1,,In vivo,,,50506
4485,1,Mustela putorius furo,Emesis in ferrets at 30 mg/kg oral dose,F,9669.0,,,,CHEMBL619816,6113,N,BAO_0000218,1,,In vivo,,,50506
4486,0,Macaca fascicularis,Bioavailability in cynomolgus monkey,A,9541.0,,,,CHEMBL619817,17796,U,BAO_0000218,1,,In vivo,,,22224
4487,1,Macaca fascicularis,Volume of distribution in cynomolgus,A,9541.0,,,,CHEMBL619818,17796,N,BAO_0000218,1,,In vivo,,,100710
4488,0,Cavia porcellus,AUC tested in guinea pig when 3 mg/kg dose was given perorally,A,10141.0,Plasma,,,CHEMBL619819,5308,U,BAO_0000218,1,1969.0,,,,22224
4489,0,Cavia porcellus,Tested for concentration as Area Under Curve against PDE4 in guinea pig lung eosinophilia orally at 5 mg/kg,A,10141.0,,,,CHEMBL619820,4877,U,BAO_0000218,1,,,,,22224
4490,0,Cavia porcellus,"Tested for the pharmacokinetic parameter in guinea pig, administered orally at 5 mg/kg",A,10141.0,,,,CHEMBL875419,4876,U,BAO_0000218,1,,,,,22224
4491,0,Cavia porcellus,AUC in guinea pig after 3mg/kg oral dose,A,10141.0,Plasma,,,CHEMBL619821,4878,U,BAO_0000218,1,1969.0,In vivo,,,22224
4492,0,Cavia porcellus,Bioavailability in guinea pig was tested,A,10141.0,,,,CHEMBL619822,5308,U,BAO_0000218,1,,In vivo,,,22224
4493,0,Cavia porcellus,Tested for oral bioavailability in guinea pig at 5 mg/kg,A,10141.0,,,,CHEMBL619823,4877,U,BAO_0000218,1,,In vivo,,,22224
4494,0,Cavia porcellus,Tested for the oral bioavailability of the compound,A,10141.0,,,,CHEMBL619824,4876,U,BAO_0000218,1,,In vivo,,,22224
4495,0,Cavia porcellus,Compound at a dose 5 mg/kg was administered orally to guinea pig and the pharmacokinetic parameter (Cmax) was reported,A,10141.0,,,,CHEMBL619825,4876,U,BAO_0000218,1,,In vivo,,,22224
4496,0,Cavia porcellus,Maximum plsma drug concentration in guinea pig when 3 mg/kg dose was given perorally,A,10141.0,,,,CHEMBL619826,5308,U,BAO_0000218,1,,In vivo,,,22224
4497,0,Cavia porcellus,Tested for maximum concentration against PDE4 in guinea pig lung eosinophilia orally at 5 mg/kg,A,10141.0,Lung,,,CHEMBL619827,4877,U,BAO_0000218,1,2048.0,In vivo,,,22224
4498,0,Cavia porcellus,Cmax in guinea pig after 3mg/kg oral dose,A,10141.0,,,,CHEMBL618167,4878,U,BAO_0000218,1,,In vivo,,,22224
4499,0,Cavia porcellus,Distribution in blood expressed as [18F]- organ uptake in % of injected activity/gram,A,10141.0,Blood,,,CHEMBL618168,5689,U,BAO_0000019,1,178.0,,,,22224
4500,0,Cavia porcellus,Distribution in brain expressed as [18F]- organ uptake in % of injected activity/gram,A,10141.0,Brain,,,CHEMBL618169,5689,U,BAO_0000019,1,955.0,,,,22224
4501,0,Cavia porcellus,Distribution in heart expressed as [18F]- organ uptake in % of injected activity/gram,A,10141.0,,,,CHEMBL618170,5689,U,BAO_0000019,1,,,,,22224
4502,0,Cavia porcellus,Distribution in intestine expressed as [18F]- organ uptake in % of injected activity/gram,A,10141.0,Intestine,,,CHEMBL618171,5689,U,BAO_0000019,1,160.0,,,,22224
4503,0,Cavia porcellus,Distribution in kidney expressed as [18F]- organ uptake in % of injected activity/gram,A,10141.0,Kidney,,,CHEMBL618172,5689,U,BAO_0000019,1,2113.0,,,,22224
4504,0,Cavia porcellus,Distribution in liver expressed as [18F]- organ uptake in % of injected activity/gram,A,10141.0,Liver,,,CHEMBL618173,5689,U,BAO_0000019,1,2107.0,,,,22224
4505,0,Cavia porcellus,Distribution in lung expressed as [18F]- organ uptake in % of injected activity/gram,A,10141.0,,,,CHEMBL618174,5689,U,BAO_0000019,1,,,,,22224
4506,0,Cavia porcellus,Distribution in spleen expressed as [18F]- organ uptake in % of injected activity/gram,A,10141.0,Spleen,,,CHEMBL875408,5689,U,BAO_0000019,1,2106.0,,,,22224
4507,0,Cavia porcellus,Elimination T1/2 in Guinea pig (PO dose),A,10141.0,,,,CHEMBL839827,14465,U,BAO_0000218,1,,In vivo,,,22224
4508,0,Cavia porcellus,Partition coefficient was measured as -log (counts per min ),A,10141.0,,,,CHEMBL618175,5689,U,BAO_0000019,1,,,,,22224
4509,0,Cavia porcellus,Biological half life when administered at 0.1 umol/kg intravenously to guinea pig in GR-64349 antagonism,A,10141.0,,,,CHEMBL618176,611,U,BAO_0000218,1,,In vivo,,,22224
4510,0,Cavia porcellus,Biological half life when administered at 5 umol/kg intravenously to guinea pig in GR-64349 antagonism,A,10141.0,,,,CHEMBL618177,611,U,BAO_0000218,1,,In vivo,,,22224
4511,0,Cavia porcellus,Elimination T1/2 in Guinea pig (PO dose),A,10141.0,,,,CHEMBL618178,14465,U,BAO_0000218,1,,In vivo,,,22224
4512,0,Cavia porcellus,"Tested for the half life period of the compound, intravenously",A,10141.0,,,,CHEMBL618179,4876,U,BAO_0000218,1,,In vivo,,,22224
4513,0,Cavia porcellus,Half-life was measured,A,10141.0,,,,CHEMBL873489,5689,U,BAO_0000019,1,,,,,22224
4514,0,Cavia porcellus,The time required for onset of inotropy after addition of a single dose of delta F75,A,10141.0,,,,CHEMBL618180,7515,U,BAO_0000019,1,,,,,22224
4515,0,Cavia porcellus,Bioavailability of compound at 10 mg/kg in guinea pig after i.v. administration,A,10141.0,,,,CHEMBL618181,17667,U,BAO_0000218,1,,In vivo,,,22224
4516,0,Cavia porcellus,Bioavailability of compound at 3 mg/kg in guinea pig after i.v. administration,A,10141.0,,,,CHEMBL618182,17667,U,BAO_0000218,1,,In vivo,,,22224
4517,0,Cricetulus griseus,Plasma clearance was measured in hamster at the dose of 10 mg/kg by peroral administration,A,10029.0,,,,CHEMBL618183,4727,U,BAO_0000218,1,,In vivo,,,22224
4518,1,Mus musculus,Biodistribution of intravenously injected [82Br]-labeled compound in tumor of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,A,10090.0,,,,CHEMBL618184,10107,N,BAO_0000218,1,,In vivo,,,50594
4519,1,Mus musculus,Biodistribution of intravenously injected [82Br]-labeled compound in tumor of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,A,10090.0,,,,CHEMBL618185,10107,N,BAO_0000218,1,,In vivo,,,50594
4520,1,Mus musculus,Biodistribution of intravenously injected [82Br]-labeled compound in tumor of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,A,10090.0,,,,CHEMBL618186,10107,N,BAO_0000218,1,,In vivo,,,50594
4521,1,Mus musculus,Biodistribution of intravenously injected [82Br]-labeled compound in tumor of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,A,10090.0,,,,CHEMBL618187,10107,N,BAO_0000218,1,,In vivo,,,50594
4522,1,Mus musculus,Biodistribution of intravenously injected [82Br]-labeled compound in tumor of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hr,A,10090.0,,,,CHEMBL618188,10107,N,BAO_0000218,1,,In vivo,,,50594
4523,1,Mus musculus,Biodistribution of intravenously injected [82Br]-labeled compound in tumor of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,A,10090.0,,,,CHEMBL875409,10107,N,BAO_0000218,1,,In vivo,,,50594
4524,1,Mus musculus,Biodistribution of intravenously injected [82Br]-labeled compound in tumor of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,A,10090.0,,,,CHEMBL618189,10107,N,BAO_0000218,1,,In vivo,,,50594
4525,1,Mus musculus,Biodistribution of the injected compound in blood of female BALB/C mice for 0.5 hours,A,10090.0,Blood,,,CHEMBL618190,3655,N,BAO_0000218,1,178.0,In vivo,,,50594
4526,1,Mus musculus,Biodistribution of the injected compound in blood of female BALB/C mice for 2.5 hours,A,10090.0,Blood,,,CHEMBL618191,3655,N,BAO_0000218,1,178.0,In vivo,,,50594
4527,1,Mus musculus,Biodistribution of the injected compound in blood of female BALB/C mice for 5 hours,A,10090.0,Blood,,,CHEMBL618192,3655,N,BAO_0000218,1,178.0,In vivo,,,50594
4528,1,Mus musculus,Biodistribution of the injected compound in bone of female BALB/C mice for 0.5 hours,A,10090.0,Bone,,,CHEMBL618193,3655,N,BAO_0000218,1,10000001.0,In vivo,,,50594
4529,1,Mus musculus,Biodistribution of the injected compound in bone of female BALB/C mice for 2.5 hours,A,10090.0,Bone,,,CHEMBL618194,3655,N,BAO_0000218,1,10000001.0,In vivo,,,50594
4530,1,Mus musculus,Biodistribution of the injected compound in bone of female BALB/C mice for 5 hours,A,10090.0,Bone,,,CHEMBL618195,3655,N,BAO_0000218,1,10000001.0,In vivo,,,50594
4531,1,Mus musculus,Biodistribution of the injected compound in brain of female BALB/C mice for 0.5 hours,A,10090.0,Brain,,,CHEMBL618196,3655,N,BAO_0000218,1,955.0,In vivo,,,50594
4532,1,Mus musculus,Biodistribution of the injected compound in brain of female BALB/C mice for 2.5 hours,A,10090.0,Brain,,,CHEMBL618197,3655,N,BAO_0000218,1,955.0,In vivo,,,50594
4533,1,Mus musculus,Biodistribution of the injected compound in brain of female BALB/C mice for 5 hours,A,10090.0,Brain,,,CHEMBL618198,3655,N,BAO_0000218,1,955.0,In vivo,,,50594
4534,1,Mus musculus,Biodistribution of the injected compound in heart of female BALB/C mice for 0.5 hours,A,10090.0,Heart,,,CHEMBL618199,3655,N,BAO_0000218,1,948.0,In vivo,,,50594
4535,1,Mus musculus,Biodistribution of the injected compound in heart of female BALB/C mice for 2.5 hours,A,10090.0,Heart,,,CHEMBL618200,3655,N,BAO_0000218,1,948.0,In vivo,,,50594
4536,1,Mus musculus,Biodistribution of the injected compound in heart of female BALB/C mice for 5 hours,A,10090.0,Heart,,,CHEMBL618201,3655,N,BAO_0000218,1,948.0,In vivo,,,50594
4537,1,Mus musculus,Biodistribution of the injected compound in intestines of female BALB/C mice for 0.5 hours,A,10090.0,Intestine,,,CHEMBL618202,3655,N,BAO_0000218,1,160.0,In vivo,,,50594
4538,1,Mus musculus,Biodistribution of the injected compound in intestines of female BALB/C mice for 2.5 hours,A,10090.0,Intestine,,,CHEMBL618203,3655,N,BAO_0000218,1,160.0,In vivo,,,50594
4539,1,Mus musculus,Biodistribution of the injected compound in intestines of female BALB/C mice for 5 hours,A,10090.0,Intestine,,,CHEMBL618204,3655,N,BAO_0000218,1,160.0,In vivo,,,50594
4540,1,Mus musculus,Biodistribution of the injected compound in kidneys of female BALB/C mice for 0.5 hours,A,10090.0,Kidney,,,CHEMBL618205,3655,N,BAO_0000218,1,2113.0,In vivo,,,50594
4541,1,Mus musculus,Biodistribution of the injected compound in kidneys of female BALB/C mice for 2.5 hours,A,10090.0,Kidney,,,CHEMBL618206,3655,N,BAO_0000218,1,2113.0,In vivo,,,50594
4542,1,Mus musculus,Biodistribution of the injected compound in kidneys of female BALB/C mice for 5 hours,A,10090.0,Kidney,,,CHEMBL618207,3655,N,BAO_0000218,1,2113.0,In vivo,,,50594
4543,1,Mus musculus,Biodistribution of the injected compound in liver of female BALB/C mice for 0.5 hours,A,10090.0,Liver,,,CHEMBL618208,3655,N,BAO_0000218,1,2107.0,In vivo,,,50594
4544,1,Mus musculus,Biodistribution of the injected compound in liver of female BALB/C mice for 2.5 hours,A,10090.0,Liver,,,CHEMBL618932,3655,N,BAO_0000218,1,2107.0,In vivo,,,50594
4545,1,Mus musculus,Biodistribution of the injected compound in liver of female BALB/C mice for 5 hours,A,10090.0,Liver,,,CHEMBL618933,3655,N,BAO_0000218,1,2107.0,In vivo,,,50594
4546,1,Mus musculus,Biodistribution of the injected compound in lung of female BALB/C mice for 0.5 hours,A,10090.0,Lung,,,CHEMBL618934,3655,N,BAO_0000218,1,2048.0,In vivo,,,50594
4547,1,Mus musculus,Biodistribution of the injected compound in lung of female BALB/C mice for 2.5 hours,A,10090.0,Lung,,,CHEMBL618935,3655,N,BAO_0000218,1,2048.0,In vivo,,,50594
4548,1,Mus musculus,Biodistribution of the injected compound in lung of female BALB/C mice for 5 hours,A,10090.0,Lung,,,CHEMBL618936,3655,N,BAO_0000218,1,2048.0,In vivo,,,50594
4549,1,Mus musculus,Biodistribution of the injected compound in muscle of female BALB/C mice for 0.5 hours,A,10090.0,Muscle tissue,,,CHEMBL618937,3655,N,BAO_0000218,1,2385.0,In vivo,,,50594
4550,1,Mus musculus,Biodistribution of the injected compound in muscle of female BALB/C mice for 2.5 hours,A,10090.0,Muscle tissue,,,CHEMBL618938,3655,N,BAO_0000218,1,2385.0,In vivo,,,50594
4551,1,Mus musculus,Biodistribution of the injected compound in muscle of female BALB/C mice for 5 hours,A,10090.0,Muscle tissue,,,CHEMBL619104,3655,N,BAO_0000218,1,2385.0,In vivo,,,50594
4552,1,Mus musculus,Biodistribution of the injected compound in spleen of female BALB/C mice for 0.5 hours,A,10090.0,Spleen,,,CHEMBL619105,3655,N,BAO_0000218,1,2106.0,In vivo,,,50594
4553,1,Mus musculus,Biodistribution of the injected compound in spleen of female BALB/C mice for 2.5 hours,A,10090.0,Spleen,,,CHEMBL619106,3655,N,BAO_0000218,1,2106.0,In vivo,,,50594
4554,1,Mus musculus,Biodistribution of the injected compound in spleen of female BALB/C mice for 5 hours,A,10090.0,Spleen,,,CHEMBL619107,3655,N,BAO_0000218,1,2106.0,In vivo,,,50594
4555,1,Mus musculus,Biodistribution of the injected compound in stomach of female BALB/C mice for 0.5 hours,A,10090.0,Stomach,,,CHEMBL875410,3655,N,BAO_0000218,1,945.0,In vivo,,,50594
4556,1,Mus musculus,Biodistribution of the injected compound in stomach of female BALB/C mice for 2.5 hours,A,10090.0,Stomach,,,CHEMBL619108,3655,N,BAO_0000218,1,945.0,In vivo,,,50594
4557,1,Mus musculus,Biodistribution of the injected compound in stomach of female BALB/C mice for 5 hours,A,10090.0,Stomach,,,CHEMBL619109,3655,N,BAO_0000218,1,945.0,In vivo,,,50594
4558,1,Mus musculus,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for MRT,A,10090.0,,,,CHEMBL619110,16597,N,BAO_0000218,1,,In vivo,,,50594
4559,1,Mus musculus,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for MRT,F,10090.0,,,,CHEMBL619111,16597,N,BAO_0000218,1,,In vivo,,,50594
4560,1,Mus musculus,MRT value at a dose of 10 mg/kg intravenous administration in mice.,A,10090.0,,,,CHEMBL619112,16597,N,BAO_0000218,1,,In vivo,,,50594
4561,1,Mus musculus,MRT value at a dose of 10 mg/kg peroral administration in mice.,A,10090.0,,,,CHEMBL619113,16597,N,BAO_0000218,1,,In vivo,,,50594
4562,1,Mus musculus,Mean-residence time of compound after intravenous administration in mice at 24 uM/kg,A,10090.0,,,,CHEMBL619114,17764,N,BAO_0000218,1,,In vivo,,,50594
4563,1,Mus musculus,Mean-residence time was determined for compound after intraperitoneal administration in mice at 18 uM/kg,F,10090.0,,,,CHEMBL619115,17764,N,BAO_0000218,1,,In vivo,,,50594
4564,1,Homo sapiens,In vitro cytotoxicity of compound was determined against A2780 cell lines (cisplatin resistant) at 37 degree C after 96 hr,F,9606.0,,,,CHEMBL619116,3830,N,BAO_0000219,1,,,,A2780,81034
4565,1,Homo sapiens,In vitro cytotoxicity of compound was determined against A2780 cell lines (cisplatin resistant) at 37 degree C for 96 hr,F,9606.0,,,,CHEMBL619117,3829,N,BAO_0000219,1,,,,A2780,81034
4566,1,Homo sapiens,Compound was evaluated for cytotoxicity against A2780 cell lines.,F,9606.0,,,,CHEMBL619118,2040,N,BAO_0000219,1,,,,A2780,81034
4567,1,Homo sapiens,Potentiation of growth inhibition of A2780 by compound alone in experiment 1,F,9606.0,,,,CHEMBL619119,15684,N,BAO_0000219,1,,,,A2780,81034
4568,1,Homo sapiens,Potentiation of growth inhibition of A2780 cells by compound alone in experiment 2,F,9606.0,,,,CHEMBL619120,15684,N,BAO_0000219,1,,,,A2780,81034
4569,1,Homo sapiens,Potentiation of growth inhibition of A2780 cells along with 10 uM NU1085 in experiment 1,F,9606.0,,,,CHEMBL619121,15684,N,BAO_0000219,1,,,,A2780,81034
4570,1,Homo sapiens,Potentiation of growth inhibition of A2780 cells along with 10 uM NU1085 in experiment 2,F,9606.0,,,,CHEMBL619122,15684,N,BAO_0000219,1,,,,A2780,81034
4571,1,Homo sapiens,Potentiation factor at 50% growth inhibition (IC50 of compound to that of compound along with PARP inhibitor) in experiment 1,F,9606.0,,,,CHEMBL619123,15684,N,BAO_0000219,1,,,,A2780,81034
4572,1,Homo sapiens,Potentiation factor at 50% growth inhibition (IC50 of compound to that of compound along with PARP inhibitor) in experiment 2,F,9606.0,,,,CHEMBL619124,15684,N,BAO_0000219,1,,,,A2780,81034
4573,1,Homo sapiens,Compound was evaluated for cytotoxicity against A2780 cell line,F,9606.0,,,,CHEMBL619125,2859,N,BAO_0000219,1,,,,A2780,81034
4574,1,Homo sapiens,In vitro inhibitory activity against human tumor cell line A2780,F,9606.0,,,,CHEMBL875411,5618,N,BAO_0000219,1,,,,A2780,81034
4575,1,Homo sapiens,Potentiation of growth inhibition of A2780 cells by compound alone in experiment 1,F,9606.0,,,,CHEMBL619126,15684,N,BAO_0000219,1,,,,A2780,81034
4576,1,Homo sapiens,Potentiation of growth inhibition of A2780 cells by compound alone in experiment 2,F,9606.0,,,,CHEMBL619127,15684,N,BAO_0000219,1,,,,A2780,81034
4577,1,Homo sapiens,Potentiation of growth inhibition of A2780 cells along with 10 uM NU1085 in experiment 1,F,9606.0,,,,CHEMBL619128,15684,N,BAO_0000219,1,,,,A2780,81034
4578,1,Homo sapiens,Potentiation of growth inhibition of A2780 cells along with 10 uM NU1085 in experiment 2,F,9606.0,,,,CHEMBL619129,15684,N,BAO_0000219,1,,,,A2780,81034
4579,1,Homo sapiens,The compound was tested for cytotoxic potency against A2780 human tumor cell lines,F,9606.0,,,,CHEMBL619130,2113,N,BAO_0000219,1,,,,A2780,81034
4580,1,Homo sapiens,The compound was tested for cytotoxic potency against A2780 human tumor cell lines.,F,9606.0,,,,CHEMBL619131,2113,N,BAO_0000219,1,,,,A2780,81034
4581,1,Homo sapiens,cytotoxicity against A2780 cells incubated for 24 hr in MTT assay.,F,9606.0,,,,CHEMBL619132,16745,N,BAO_0000219,1,,,,A2780,81034
4582,1,Homo sapiens,In vitro antitumor activity against A2780 human ovarian carcinoma at 7.5 mg/kg i.p. /qd x7,F,9606.0,,,,CHEMBL619133,16597,N,BAO_0000218,1,,,,A2780,81034
4583,1,Homo sapiens,Potentiation factor at 50% growth inhibition (IC50 of compound to that of compound along with PARP inhibitor) in experiment 1,F,9606.0,,,,CHEMBL619134,15684,N,BAO_0000219,1,,,,A2780,81034
4584,1,Homo sapiens,Potentiation factor at 50% growth inhibition (IC50 of compound to that of compound along with PARP inhibitor) in experiment 2,F,9606.0,,,,CHEMBL619135,15684,N,BAO_0000219,1,,,,A2780,81034
4585,1,Homo sapiens,Compound was evaluated for cytotoxicity against A2780 cis cell lines.,F,9606.0,,,,CHEMBL619136,2040,N,BAO_0000219,1,,,,A2780,81034
4586,1,Homo sapiens,Relative resistance factor in A2780 cisplatin-resistant line,F,9606.0,,,,CHEMBL619137,2040,N,BAO_0000219,1,,,,A2780,81034
4587,1,Homo sapiens,Concentration required to inhibit 50% growth of A2780 human ovarian cancer cells,F,9606.0,,,,CHEMBL883713,16165,N,BAO_0000219,1,,,,A2780,81034
4588,1,Homo sapiens,Concentration required to inhibit 50% growth of A2780 human ovarian cancer cells.,F,9606.0,,,,CHEMBL875412,16165,N,BAO_0000219,1,,,,A2780,81034
4589,1,Homo sapiens,In vitro antitumor activity against A2780 human ovarian carcinoma at 7.5 mg/kg i.p. /qd x7,F,9606.0,,,,CHEMBL619138,16597,N,BAO_0000218,1,,,,A2780,81034
4590,1,Homo sapiens,In vitro antitumor activity against A2780 human ovarian carcinoma at 7.5 mg/kg i.p. /qd x7,F,9606.0,,,,CHEMBL619262,16597,N,BAO_0000218,1,,,,A2780,81034
4591,1,Homo sapiens,Cytotoxicity against A2780 ovarian carcinoma cells was evaluated using standard sulforhodamine 96h assay test,F,9606.0,,,,CHEMBL619139,3992,N,BAO_0000219,1,,,,A2780,81034
4592,1,Homo sapiens,In vitro cytotoxicity was determined against A2780 human ovarian cell line using NCI screen,F,9606.0,,,,CHEMBL619140,10553,N,BAO_0000219,1,,,,A2780,81034
4593,1,Homo sapiens,cytotoxic activity toward A2780 ovarian human cell line sensitive (S) to cisplatin,F,9606.0,,,,CHEMBL619141,15608,N,BAO_0000219,1,,,,A2780,81034
4594,1,Homo sapiens,cytotoxic activity toward A2780 ovarian human cell line sensitive (S) to cisplatin in experiment 1,F,9606.0,,,,CHEMBL619142,15608,N,BAO_0000219,1,,,,A2780,81034
4595,1,Homo sapiens,cytotoxic activity toward A2780 ovarian human cell line sensitive (S) to cisplatin in experiment 2,F,9606.0,,,,CHEMBL619143,15608,N,BAO_0000219,1,,,,A2780,81034
4596,1,Homo sapiens,cytotoxic activity toward A2780 ovarian human cell line sensitive (S) to cisplatin in experiment 3,F,9606.0,,,,CHEMBL619144,15608,N,BAO_0000219,1,,,,A2780,81034
4597,1,Homo sapiens,cytotoxic activity toward A2780 ovarian human cell line sensitive (S) to cisplatin in experiment 5,F,9606.0,,,,CHEMBL619145,15608,N,BAO_0000219,1,,,,A2780,81034
4598,1,Homo sapiens,cytotoxic activity toward A2780 ovarian human cell line sensitive (S) to cisplatin in experiment 8,F,9606.0,,,,CHEMBL619146,15608,N,BAO_0000219,1,,,,A2780,81034
4599,1,Homo sapiens,Cytotoxic activity in a panel of Human ovarian tumor A2780/CDDP cell line after 96h of drug exposure,F,9606.0,,,,CHEMBL619147,15569,N,BAO_0000219,1,,,,A2780,81034
4600,1,Homo sapiens,Antiproliferative effect of compound on A2780/DX cell line,F,9606.0,,,,CHEMBL619148,17420,N,BAO_0000219,1,,,,A2780,81034
4601,1,Homo sapiens,Antiproliferative effect of compound on A2780/DX cell line; n.d. indicates not determined,F,9606.0,,,,CHEMBL619149,17420,N,BAO_0000219,1,,,,A2780,81034
4602,1,Homo sapiens,In vitro Cytotoxic activity of compound in comparison with reference compounds in human cell line A2780/DX(RI),F,9606.0,,,,CHEMBL619150,15099,N,BAO_0000219,1,,,,A2780,81034
4603,1,Homo sapiens,In vitro Cytotoxic activity of compound in comparison with reference compounds in human cell line A2780/Dx(RI),F,9606.0,,,,CHEMBL619151,15099,N,BAO_0000219,1,,,,A2780,81034
4604,1,Homo sapiens,Cytotoxicity against ovarian carcinoma A2780/cis tumor cell lines,F,9606.0,,,,CHEMBL883794,17672,N,BAO_0000219,1,,,,A2780,81034
4605,1,Homo sapiens,Cytotoxicity against ovarian carcinoma A2780/cis90 tumor cell lines,F,9606.0,,,,CHEMBL619152,17672,N,BAO_0000219,1,,,,A2780,81034
4606,1,Homo sapiens,In vitro cytotoxicity against A2780ADR cell line,F,9606.0,,,,CHEMBL619153,17270,N,BAO_0000219,1,,,,A2780,81034
4607,1,Homo sapiens,In vitro cytotoxicity against A2780CIS cell line,F,9606.0,,,,CHEMBL619154,17270,N,BAO_0000219,1,,,,A2780,81034
4608,1,Homo sapiens,In vitro cytotoxic activity against human tumor cell line A2780CisR after incubation for 96 hours,F,9606.0,,,,CHEMBL619155,5574,N,BAO_0000219,1,,,,A2780,81034
4609,1,Homo sapiens,The compound was tested for cytotoxic potency against A2780R human tumor cell lines.,F,9606.0,,,,CHEMBL619156,2113,N,BAO_0000219,1,,,,A2780,81034
4610,1,Homo sapiens,"Inhibitory effect of Gold(III) complex, 2,2' bipy on growth of cisplatin-resistant A2780/R human tumor cell lines",F,9606.0,,,,CHEMBL619157,16913,N,BAO_0000219,1,,,,A2780,81034
4611,1,Homo sapiens,"Inhibitory effect of Gold(III) complex, CDDP on growth of cisplatin-resistant A2780/R human tumor cell lines",F,9606.0,,,,CHEMBL619797,16913,N,BAO_0000219,1,,,,A2780,81034
4612,0,Macaca mulatta,Oral bioavailability of compound in rhesus macaques,A,9544.0,,,,CHEMBL619798,17839,U,BAO_0000218,1,,In vivo,,,22224
4613,0,monkey,Oral bioavailability in monkey,A,9443.0,,,,CHEMBL619799,6821,U,BAO_0000218,1,,In vivo,,,22224
4614,0,monkey,Oral bioavailability evaluated in monkey,A,9443.0,,,,CHEMBL619800,6078,U,BAO_0000218,1,,In vivo,,,22224
4615,0,monkey,Oral bioavailability in monkey (dose 1 mg/kg p.o.),A,9443.0,,,,CHEMBL619801,6535,U,BAO_0000218,1,,In vivo,,,22224
4616,0,Macaca mulatta,Oral bioavailability in Rhesus monkey,A,9544.0,,,,CHEMBL619802,4449,U,BAO_0000218,1,,In vivo,,,22224
4617,0,Macaca mulatta,Oral bioavailability was calculated in rhesus monkey,A,9544.0,,,,CHEMBL619803,6057,U,BAO_0000218,1,,In vivo,,,22224
4618,0,Macaca fascicularis,Oral bioavailability in cynomolgus monkey,A,9541.0,,,,CHEMBL619965,5922,U,BAO_0000218,1,,In vivo,,,22224
4619,0,monkey,Oral bioavailability in monkey,A,9443.0,,,,CHEMBL619966,5940,U,BAO_0000218,1,,In vivo,,,22224
4620,0,monkey,Oral bioavailability in monkey,A,9443.0,,,,CHEMBL619967,6265,U,BAO_0000218,1,,In vivo,,,22224
4621,0,monkey,Oral bioavailability in monkey (dose 1 mg/kg),A,9443.0,,,,CHEMBL620073,6265,U,BAO_0000218,1,,In vivo,,,22224
4622,0,monkey,Oral bioavailability in monkey (dose 5 mg/kg),A,9443.0,,,,CHEMBL620074,6265,U,BAO_0000218,1,,In vivo,,,22224
4623,0,monkey,Oral bioavailability in monkey,A,9443.0,,,,CHEMBL620075,5940,U,BAO_0000218,1,,In vivo,,,22224
4624,0,monkey,Oral bioavailability in monkey,A,9443.0,,,,CHEMBL620076,5940,U,BAO_0000218,1,,In vivo,,,22224
4625,0,Macaca mulatta,Oral bioavailability in rhesus monkey,A,9544.0,,,,CHEMBL620077,4514,U,BAO_0000218,1,,In vivo,,,22224
4626,0,Macaca mulatta,Oral bioavailability in rhesus monkey at a dose of 2 mg/kg by po administration,A,9544.0,,,,CHEMBL620078,5546,U,BAO_0000218,1,,In vivo,,,22224
4627,0,Saimiri sciureus,Oral bioavailability in squirrel monkey at a dose of 10 mg/kg,A,9521.0,,,,CHEMBL620079,5553,U,BAO_0000218,1,,In vivo,,,22224
4628,0,monkey,Oral bioavailability in monkey (dosed at 0.5 mpk iv and 2.0 mpk orally),A,9443.0,,,,CHEMBL620080,6641,U,BAO_0000218,1,,In vivo,,,22224
4629,0,Macaca mulatta,Oral bioavailability in Rhesus monkey,A,9544.0,,,,CHEMBL620081,5472,U,BAO_0000218,1,,In vivo,,,22224
4630,0,Macaca mulatta,Oral bioavailability in Rhesus monkey (dose 10 mg/kg p.o.),A,9544.0,,,,CHEMBL620082,5668,U,BAO_0000218,1,,In vivo,,,22224
4631,0,monkey,Oral bioavailability in monkey at 10 mg/kg of the compound,A,9443.0,,,,CHEMBL620083,5711,U,BAO_0000218,1,,In vivo,,,22224
4632,0,Macaca mulatta,Bioavailability in Rhesus monkey,A,9544.0,,,,CHEMBL620084,5145,U,BAO_0000218,1,,In vivo,,,22224
4633,0,Cercopithecidae,Glomerular Filtration Rate(GFR) evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,A,9527.0,,,,CHEMBL620085,3443,U,BAO_0000218,1,,,,,22224
4634,0,Cercopithecidae,Glomerular Filtration Rate(GFR)of the compound compared to Cilastatin evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,A,9527.0,,,,CHEMBL874595,3443,U,BAO_0000218,1,,,,,22224
4635,0,Cercopithecidae,Half life by ''Cr'' assay in rhesus monkey at a dose of 5 mg/kg,A,9527.0,,,,CHEMBL873352,3249,U,BAO_0000218,1,,In vivo,,,22224
4636,0,Cercopithecidae,Half life the of compound was determined by ''Cr'' assay in squirrel monkey at a dose of 5 mg/kg,A,9527.0,,,,CHEMBL620086,3249,U,BAO_0000218,1,,In vivo,,,22224
4637,0,Cercopithecidae,Mean residence time was determined after intravenous administration in cynomolgus monkeys,A,9527.0,,,,CHEMBL620087,5355,U,BAO_0000218,1,,In vivo,,,22224
4638,0,Cercopithecidae,Mean residence time was determined after oral administration in cynomolgus monkeys; NA means Not applicable,A,9527.0,,,,CHEMBL620088,5355,U,BAO_0000218,1,,In vivo,,,22224
4639,0,Cercopithecidae,Mean residence time was determined after oral administration in cynomolgus monkeys; NA means not applicable,A,9527.0,,,,CHEMBL620089,5355,U,BAO_0000218,1,,In vivo,,,22224
4640,0,Cercopithecidae,Pharmacokinetic parameter MRT was determined in monkey after (iv) administration of a dose of 13 (uM/kg),A,9527.0,,,,CHEMBL620090,4809,U,BAO_0000218,1,,In vivo,,,22224
4641,0,Cercopithecidae,Pharmacokinetic parameter MRT was determined in monkey after (po) administration of a dose of 50 (uM/kg),A,9527.0,,,,CHEMBL620091,4809,U,BAO_0000218,1,,In vivo,,,22224
4642,0,Cercopithecidae,Metabolism of compound in monkey S9 microsomes ('+''indicates <20% largest observed peak),A,9527.0,,Microsomes,,CHEMBL620092,14294,U,BAO_0000251,1,,,,,22224
4643,0,Cercopithecidae,Metabolism of compound in monkey S9 microsomes ('++''indicates 20-50% largest observed peak),A,9527.0,,Microsomes,,CHEMBL620093,14294,U,BAO_0000251,1,,,,,22224
4644,0,Cercopithecidae,Metabolism of compound in monkey S9 microsomes ('+++'indicates 50-80% largest observed peak),A,9527.0,,Microsomes,,CHEMBL620094,14294,U,BAO_0000251,1,,,,,22224
4645,0,Cercopithecidae,Metabolism of compound in monkey S9 microsomes ('++++' indicates largest observed peak),A,9527.0,,Microsomes,,CHEMBL620095,14294,U,BAO_0000251,1,,,,,22224
4646,0,Cercopithecidae,Plasma clearance evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,A,9527.0,,,,CHEMBL620096,3443,U,BAO_0000218,1,,In vivo,,,22224
4647,0,Cercopithecidae,Plasma clearance compared to Cilastatin evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,A,9527.0,,,,CHEMBL620097,3443,U,BAO_0000218,1,,In vivo,,,22224
4648,0,Cercopithecidae,Clearance from plasma(with matabolite-corrected plasma radioactivity-time integral) at 30 min after administration.,A,9527.0,,,,CHEMBL620098,11271,U,BAO_0000019,1,,,,,22224
4649,0,Cercopithecidae,Renal clearance evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,A,9527.0,,,,CHEMBL620099,3443,U,BAO_0000218,1,,,,,22224
4650,0,Cercopithecidae,Renal clearance compared to Cilastatin evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,A,9527.0,,,,CHEMBL620100,3443,U,BAO_0000218,1,,,,,22224
4651,0,Cercopithecidae,Elimination Half-life of compound was determined in monkey,A,9527.0,,,,CHEMBL620101,6821,U,BAO_0000019,1,,,,,22224
4652,0,Cercopithecidae,Half life of compound was determined in rhesus monkey,A,9527.0,,,,CHEMBL620102,17267,U,BAO_0000019,1,,,,,22224
4653,0,Cercopithecidae,Half life in monkey plasma,A,9527.0,Plasma,,,CHEMBL620103,5819,U,BAO_0000366,1,1969.0,,,,22224
4654,0,Cercopithecidae,Half life in monkey plasma; Not detected,A,9527.0,Plasma,,,CHEMBL620104,5819,U,BAO_0000366,1,1969.0,,,,22224
4655,0,Cercopithecidae,Half life period was evaluated against Cynomolgus monkey at a dose of 15 mg/kg after po administration,A,9527.0,,,,CHEMBL874596,1916,U,BAO_0000218,1,,In vivo,,,22224
4656,0,Cercopithecidae,Half-life 24 hr after 2 mg/kg iv administration in monkeys,A,9527.0,,,,CHEMBL873490,17509,U,BAO_0000218,1,,In vivo,,,22224
4657,0,Cercopithecidae,Terminal half life of the compound.,A,9527.0,,,,CHEMBL620105,1399,U,BAO_0000019,1,,,,,22224
4658,0,Cercopithecidae,Maximum time was evaluated against Cynomolgus monkey at a dose of 15 mg/kg after po administration,A,9527.0,,,,CHEMBL620780,1916,U,BAO_0000218,1,,In vivo,,,22224
4659,0,Cercopithecidae,Pharmacokinetic parameter Tmax was determined in monkey after (po) administration of a dose of 50 (uM/kg),A,9527.0,,,,CHEMBL620781,4809,U,BAO_0000218,1,,In vivo,,,22224
4660,0,Cercopithecidae,Unbound plasma was determined in rhesus monkey at a dose of 1 mg/kg by iv administration,A,9527.0,,,,CHEMBL620956,5546,U,BAO_0000218,1,,,,,22224
4661,0,Cercopithecidae,Urinary recovery evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,A,9527.0,Urine,,,CHEMBL620957,3443,U,BAO_0000218,1,1088.0,,,,22224
4662,0,Cercopithecidae,Urinary recovery compared to Cilastatin evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,A,9527.0,Urine,,,CHEMBL620958,3443,U,BAO_0000218,1,1088.0,,,,22224
4663,0,Cercopithecidae,Volume of distribution was determined in monkey after a 3 mg/kg of iv dose,A,9527.0,,,,CHEMBL620959,4257,U,BAO_0000218,1,,In vivo,,,22224
4664,0,Cercopithecidae,Volume distribution after oral administration (2.5 mg/kg) in monkey was determined,A,9527.0,,,,CHEMBL620960,6221,U,BAO_0000218,1,,In vivo,,,22224
4665,0,Cercopithecidae,Volume of distribution was evaluated in rhesus,A,9527.0,,,,CHEMBL620961,5472,U,BAO_0000218,1,,In vivo,,,22224
4666,0,Cricetulus griseus,Plasma clearance was measured in hamster at the dose of 10 mg/kg by peroral administration,A,10029.0,,,,CHEMBL620962,4727,U,BAO_0000218,1,,In vivo,,,22224
4667,0,Cricetulus griseus,Plasma clearance was measured in hamster at the dose of 3 mg/kg by intravenous administration,A,10029.0,,,,CHEMBL620963,4727,U,BAO_0000218,1,,In vivo,,,22224
4668,0,Cricetulus griseus,Bioavailability in hamster was determined,A,10029.0,,,,CHEMBL620964,4727,U,BAO_0000218,1,,In vivo,,,22224
4669,0,Cricetulus griseus,Bioavailability in hamster at a dose of 3 mg/kg by intravenous administration,A,10029.0,,,,CHEMBL620965,4727,U,BAO_0000218,1,,In vivo,,,22224
4670,0,Cricetulus griseus,Bioavailability in hamster at a dose of 3 mg/kg by oral administration,A,10029.0,,,,CHEMBL620966,4727,U,BAO_0000218,1,,In vivo,,,22224
4671,0,Cricetulus griseus,Half life of compound was determined in hamster blood,A,10029.0,Blood,,,CHEMBL620967,4727,U,BAO_0000221,1,178.0,,,,22224
4672,0,Sus scrofa,Michaelis-Menten constant of the compound.,A,9823.0,,,,CHEMBL620968,1452,U,BAO_0000019,1,,,,,22224
4673,0,Sus scrofa,Vmax value was measured at 0 uM concentration of silyl ether.,A,9823.0,,,,CHEMBL874597,1452,U,BAO_0000019,1,,,,,22224
4674,0,Sus scrofa,Vmax value was measured at 10 uM concentration of silyl ether.,A,9823.0,,,,CHEMBL620969,1452,U,BAO_0000019,1,,,,,22224
4675,0,Sus scrofa,Vmax value was measured at 5 uM concentration of silyl ether.,A,9823.0,,,,CHEMBL620970,1452,U,BAO_0000019,1,,,,,22224
4676,9,Homo sapiens,Inactivation of human leukocyte (neutrophil) elastase(HLE)(HNE) as rate constant,B,9606.0,,,,CHEMBL620971,11706,D,BAO_0000357,1,,,,,235
4677,0,Homo sapiens,Area under curve was evaluated against man at a dose of 10 mg/kg after po administration,A,9606.0,,,,CHEMBL620972,1916,U,BAO_0000218,1,,,,,22224
4678,0,Homo sapiens,Compound was evaluated for area under the curve expressed as (h*ug/ml),A,9606.0,,,,CHEMBL620973,17791,U,BAO_0000019,1,,,,,22224
4679,0,Homo sapiens,Active metabolite of ifosfamide determined in humans; A-Active,A,9606.0,,,,CHEMBL618243,7766,U,BAO_0000019,1,,,,,22224
4680,0,Homo sapiens,Amount of tecadenoson present after 30 min in the liver S-9 assay as determined by mass specanalysis,A,9606.0,,,,CHEMBL618244,6567,U,BAO_0000019,1,,,,,22224
4681,0,Homo sapiens,Amount of tecadenoson present after 30 min in the liver S-9 assay as determined by mass specanalysis; -0.5 to 1,A,9606.0,,,,CHEMBL618245,6567,U,BAO_0000019,1,,,,,22224
4682,0,Homo sapiens,Amount of tecadenoson present after 30 min in the liver S-9 assay as determined by mass specanalysis; 1-2,A,9606.0,,,,CHEMBL618246,6567,U,BAO_0000019,1,,,,,22224
4683,0,Homo sapiens,Amount of tecadenoson present after 30 min in the liver S-9 assay as determined by mass specanalysis; trace,A,9606.0,,,,CHEMBL618247,6567,U,BAO_0000019,1,,,,,22224
4684,0,Homo sapiens,Compound was evaluated for oral bioavailability in human,A,9606.0,,,,CHEMBL618248,17791,U,BAO_0000218,1,,,,,22224
4685,0,Homo sapiens,Metabolite of ifosfamide determined in urine; NF-Not found,A,9606.0,Urine,,,CHEMBL618249,7766,U,BAO_0000019,1,1088.0,,,,22224
4686,0,Homo sapiens,Percent of compound in cirrhotic patients of spontaneous ascitic fluid infection (Group A and B),A,9606.0,,,,CHEMBL618250,6852,U,BAO_0000019,1,,,,,22224
4687,0,Homo sapiens,Percent of compound in cirrhotic patients of spontaneous ascitic fluid infection after dosing with normal antibiotics,A,9606.0,,,,CHEMBL874598,6852,U,BAO_0000019,1,,,,,22224
4688,0,Homo sapiens,Percent of compound in cirrhotic patients of spontaneous ascitic fluid infection after dosing with normal antibiotics and lactose,A,9606.0,,,,CHEMBL618251,6852,U,BAO_0000019,1,,,,,22224
4689,0,Homo sapiens,Percent of compound in cirrhotic patients of spontaneous ascitic fluid infection before dosing with normal antibiotics,A,9606.0,,,,CHEMBL618252,6852,U,BAO_0000019,1,,,,,22224
4690,0,Homo sapiens,Percent of compound in cirrhotic patients of spontaneous ascitic fluid infection before dosing with normal antibiotics and lactose,A,9606.0,,,,CHEMBL618253,6852,U,BAO_0000019,1,,,,,22224
4691,0,Homo sapiens,Percent of compound in cirrhotic patients of sterile ascitic fluid (Group C),A,9606.0,,,,CHEMBL618254,6852,U,BAO_0000019,1,,,,,22224
4692,0,Homo sapiens,Percent of compound in healthy individuals (Group D),A,9606.0,,,,CHEMBL618255,6852,U,BAO_0000019,1,,,,,22224
4693,0,Homo sapiens,Percent of the parent compound remaining after 20 mins incubation with human liver microsomes,A,9606.0,Liver,Microsomes,,CHEMBL618983,4397,U,BAO_0000251,1,2107.0,,,,22224
4694,0,Homo sapiens,Binding towards human plasma protein at 10 uM,A,9606.0,,,,CHEMBL618984,17409,U,BAO_0000019,1,,,,,22224
4695,0,Homo sapiens,Binding towards human plasma protein at 100 uM,A,9606.0,,,,CHEMBL618985,17409,U,BAO_0000019,1,,,,,22224
4696,0,Homo sapiens,Human plasma protein binding activity was determined,A,9606.0,,,,CHEMBL618986,17176,U,BAO_0000019,1,,,,,22224
4697,0,Homo sapiens,The ability binding to plasma (Binding classified based on injection of compound at 80 concentration.),A,9606.0,,,,CHEMBL618987,15444,U,BAO_0000019,1,,,,,22224
4698,0,Homo sapiens,Percent binding of compound towards human plasma protein was determined,A,9606.0,,,,CHEMBL618988,17267,U,BAO_0000019,1,,,,,22224
4699,0,Homo sapiens,Plasma clearance in human liver microsomes,A,9606.0,Liver,Microsomes,,CHEMBL618989,5944,U,BAO_0000251,1,2107.0,In vitro,,,22224
4700,0,Homo sapiens,In vitro intrinsic clearance in human liver microsome,A,9606.0,Liver,Microsomes,,CHEMBL618990,5668,U,BAO_0000251,1,2107.0,In vitro,,,22224
4701,0,Homo sapiens,In vitro intrinsic clearance in human liver microsome,A,9606.0,Liver,Microsomes,,CHEMBL618991,5669,U,BAO_0000251,1,2107.0,In vitro,,,22224
4702,0,Homo sapiens,In vitro microsome metabolism clearance in human was determined,A,9606.0,,Microsomes,,CHEMBL876725,5041,U,BAO_0000251,1,,In vitro,,,22224
4703,0,Homo sapiens,In vitro microsome metabolism clearance in human was determined; High,A,9606.0,,Microsomes,,CHEMBL618992,5041,U,BAO_0000251,1,,In vitro,,,22224
4704,0,Homo sapiens,In vitro microsome metabolism clearance in human was determined; ND denotes no data,A,9606.0,,Microsomes,,CHEMBL618993,5041,U,BAO_0000251,1,,In vitro,,,22224
4705,0,Homo sapiens,Pharmacokinetic property (clearance) in human liver microsome,A,9606.0,Liver,Microsomes,,CHEMBL618994,5676,U,BAO_0000251,1,2107.0,In vitro,,,22224
4706,0,Homo sapiens,Plasma clearance in human liver microsomes,A,9606.0,Liver,Microsomes,,CHEMBL618995,5944,U,BAO_0000251,1,2107.0,In vitro,,,22224
4707,0,Homo sapiens,In vitro clearance in human liver microsomes,A,9606.0,Liver,Microsomes,,CHEMBL618996,17538,U,BAO_0000251,1,2107.0,In vitro,,,22224
4708,0,Homo sapiens,Intrinsic clearance in human liver microsomes was determined,A,9606.0,Liver,Microsomes,,CHEMBL618997,6331,U,BAO_0000251,1,2107.0,In vitro,,,22224
4709,0,Homo sapiens,Intrinsic clearance in human liver microsomes was determined,A,9606.0,Liver,Microsomes,,CHEMBL618998,5948,U,BAO_0000251,1,2107.0,In vitro,,,22224
4710,0,Homo sapiens,Cmax (Tissue distribution) of compound was determined at a dose of 5 mg/kg in human,A,9606.0,,,,CHEMBL618999,5965,U,BAO_0000218,1,,In vivo,,,22224
4711,0,Homo sapiens,Maximum concentration was evaluated against man at a dose of 10 mg/kg after po administration,A,9606.0,,,,CHEMBL620223,1916,U,BAO_0000218,1,,In vivo,,,22224
4712,0,Homo sapiens,Cmin (Clearance) of compound was determined at a dose of 5 mg/kg in human,A,9606.0,,,,CHEMBL620224,5965,U,BAO_0000218,1,,,,,22224
4713,0,Homo sapiens,Stability in human plasma 2 hr after incubation expressed as percent concentration,A,9606.0,,,,CHEMBL620225,1299,U,BAO_0000019,1,,,,,22224
4714,0,Homo sapiens,Stability in human plasma 4 hr after incubation expressed as percent concentration,A,9606.0,,,,CHEMBL620226,1299,U,BAO_0000019,1,,,,,22224
4715,0,Homo sapiens,Portion of holoxan excreted in the form of the metabolite from 1200 mL of urine on day 3 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,A,9606.0,Urine,,,CHEMBL620227,7766,U,BAO_0000019,1,1088.0,,,,22224
4716,0,Homo sapiens,Portion of holoxan excreted in the form of the metabolite from 1200 mL of urine on day 7 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,A,9606.0,Urine,,,CHEMBL876726,7766,U,BAO_0000019,1,1088.0,,,,22224
4717,0,Homo sapiens,Portion of holoxan excreted in the form of the metabolite from 1300 mL of urine on day 6 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,A,9606.0,Urine,,,CHEMBL620228,7766,U,BAO_0000019,1,1088.0,,,,22224
4718,0,Homo sapiens,Portion of holoxan excreted in the form of the metabolite from 1300 mL of urine on day 8 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,A,9606.0,Urine,,,CHEMBL620229,7766,U,BAO_0000019,1,1088.0,,,,22224
4719,1,Mus musculus,Mean-residence time was determined for compound after intraperitoneal administration in mice at 23 uM/kg,F,10090.0,,,,CHEMBL620230,17764,N,BAO_0000218,1,,In vivo,,,50594
4720,1,Mus musculus,Mean-residence time was determined for compound after intraperitoneal administration in mice at 25 uM/kg,F,10090.0,,,,CHEMBL620231,17764,N,BAO_0000218,1,,In vivo,,,50594
4721,1,Mus musculus,Mean-residence time was determined for compound after intraperitoneal administration in mice at 26 uM/kg,F,10090.0,,,,CHEMBL620232,17764,N,BAO_0000218,1,,In vivo,,,50594
4722,1,Mus musculus,Mean-residence time was determined for compound intravenous administration in mice at 23 uM/kg,F,10090.0,,,,CHEMBL620233,17764,N,BAO_0000218,1,,In vivo,,,50594
4723,1,Mus musculus,Metabolism of compound in Mouse S9 microsomes ('++++'indicates largest observed peak),A,10090.0,,,,CHEMBL620234,14294,N,BAO_0000218,1,,,,,50594
4724,1,Mus musculus,Metabolism of compound in mouse S9 microsomes ('+''indicates <20% largest observed peak),A,10090.0,,,,CHEMBL620235,14294,N,BAO_0000218,1,,,,,50594
4725,1,Mus musculus,Metabolism of compound in mouse S9 microsomes ('++++' indicates largest observed peak),A,10090.0,,,,CHEMBL620236,14294,N,BAO_0000218,1,,,,,50594
4726,1,Mus musculus,In vitro metabolic potential in mouse liver microsomes,A,10090.0,Liver,,,CHEMBL620237,6251,N,BAO_0000218,1,2107.0,,,,50594
4727,1,Mus musculus,Ability of compound to bind to plasma protein was evaluated in HSA cells,A,10090.0,,,,CHEMBL620238,17582,N,BAO_0000218,1,,,,,50594
4728,1,Mus musculus,Compound was tested for radioactivity level in mice adrenal glands (Compound is radiolabeled),A,10090.0,Adrenal gland,,,CHEMBL620239,17811,N,BAO_0000218,1,2369.0,,,,50594
4729,1,Mus musculus,Compound was tested for radioactivity level in mice brain (Compound is radiolabeled); 2.2-4.9% ID/g,A,10090.0,Brain,,,CHEMBL620240,17811,N,BAO_0000218,1,955.0,,,,50594
4730,1,Mus musculus,Compound was tested for radioactivity level in mice brain (Compound is radiolabeled); 2.6-4.4% ID/g,A,10090.0,Brain,,,CHEMBL620241,17811,N,BAO_0000218,1,955.0,,,,50594
4731,1,Mus musculus,Compound was tested for radioactivity level in mice heart (Compound is radiolabeled),A,10090.0,,,,CHEMBL876727,17811,N,BAO_0000218,1,,,,,50594
4732,1,Mus musculus,Compound was tested for radioactivity level in mice kidney (Compound is radiolabeled),A,10090.0,Kidney,,,CHEMBL620242,17811,N,BAO_0000218,1,2113.0,,,,50594
4733,1,Mus musculus,Compound was tested for radioactivity level in mice lungs (Compound is radiolabeled),A,10090.0,,,,CHEMBL620243,17811,N,BAO_0000218,1,,,,,50594
4734,1,Mus musculus,Tested for urinary recovery in mice after subcutaneous administration of 20 mg/Kg,A,10090.0,,,,CHEMBL620244,5288,N,BAO_0000218,1,,,,,50594
4735,1,Mus musculus,Compound was evaluated for its potency in CDF1 mice and the serum cholesterol levels were determined,A,10090.0,Serum,,,CHEMBL620245,2717,N,BAO_0000218,1,1977.0,,,,50594
4736,1,Mus musculus,Compound was evaluated for its potency in CDF1 mice and the serum metabolite levels were determined,A,10090.0,Serum,,,CHEMBL620246,2717,N,BAO_0000218,1,1977.0,,,,50594
4737,1,Mus musculus,Compound was evaluated for its potency in CDF1 mice and the serum triglyceride levels were determined,A,10090.0,Serum,,,CHEMBL620247,2717,N,BAO_0000218,1,1977.0,,,,50594
4738,1,Mus musculus,Half life of compound was determined in plasma of mice at 24 mg/Kg,A,10090.0,Plasma,,,CHEMBL620248,17753,N,BAO_0000218,1,1969.0,In vivo,,,50594
4739,1,Mus musculus,Half life of compound was determined in plasma of mice at 40 mg/Kg,A,10090.0,Plasma,,,CHEMBL873497,17753,N,BAO_0000218,1,1969.0,In vivo,,,50594
4740,1,Mus musculus,Half life of compound was determined in plasma of mice at 5 mg/Kg,A,10090.0,Plasma,,,CHEMBL620249,17753,N,BAO_0000218,1,1969.0,In vivo,,,50594
4741,1,Mus musculus,Half life after intraperitoneal administration in mice at 18 uM/kg,F,10090.0,,,,CHEMBL620250,17764,N,BAO_0000218,1,,In vivo,,,50594
4742,1,Mus musculus,Half life after intraperitoneal administration in mice at 23 uM/kg,F,10090.0,,,,CHEMBL620251,17764,N,BAO_0000218,1,,In vivo,,,50594
4743,1,Mus musculus,Half life after intraperitoneal administration in mice at 25 uM/kg,F,10090.0,,,,CHEMBL620252,17764,N,BAO_0000218,1,,In vivo,,,50594
4744,1,Mus musculus,Half life after intraperitoneal administration in mice at 26 uM/kg,F,10090.0,,,,CHEMBL620253,17764,N,BAO_0000218,1,,In vivo,,,50594
4745,1,Mus musculus,Half life after intravenous administration in mice at 23 uM/kg,F,10090.0,,,,CHEMBL620254,17764,N,BAO_0000218,1,,In vivo,,,50594
4746,1,Mus musculus,Half life after intravenous administration in mice at 24 uM/kg,A,10090.0,,,,CHEMBL620255,17764,N,BAO_0000218,1,,In vivo,,,50594
4747,1,Mus musculus,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for T max,A,10090.0,,,,CHEMBL620256,16597,N,BAO_0000218,1,,In vivo,,,50594
4748,1,Mus musculus,Maximum time required to reach Cp max was evaluated in mice after intravenous administration; T max Not determined,A,10090.0,,,,CHEMBL876728,2675,N,BAO_0000218,1,,In vivo,,,50594
4749,1,Mus musculus,Maximum time required to reach Cp max was evaluated in mice after oral administration,A,10090.0,,,,CHEMBL620257,2675,N,BAO_0000218,1,,In vivo,,,50594
4750,1,Mus musculus,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for half life (T1/2),A,10090.0,,,,CHEMBL620258,16597,N,BAO_0000218,1,,In vivo,,,50594
4751,1,Mus musculus,"Compound was evaluated for the pharmacokinetic parameter, Terminal half life period",A,10090.0,,,,CHEMBL620259,4890,N,BAO_0000218,1,,In vivo,,,50594
4752,1,Mus musculus,Evaluated for pharmacokinetic parameter half-life in mouse at the dose 20 mg/kg,A,10090.0,,,,CHEMBL620260,429,N,BAO_0000218,1,,In vivo,,,50594
4753,1,Mus musculus,Half life of compound in mouse blood following i.v. administration of 10 mg/kg,A,10090.0,Blood,,,CHEMBL620261,17837,N,BAO_0000218,1,178.0,In vivo,,,50594
4754,1,Mus musculus,Half life at a dose of 10 mg/kg intravenous administration in mice.,A,10090.0,,,,CHEMBL620262,16597,N,BAO_0000218,1,,In vivo,,,50594
4755,1,Mus musculus,Half life at a dose of 10 mg/kg peroral administration in mice.,A,10090.0,,,,CHEMBL620263,16597,N,BAO_0000218,1,,In vivo,,,50594
4756,1,Mus musculus,Half life in ob/ob mice,A,10090.0,,,,CHEMBL620264,6619,N,BAO_0000218,1,,,,,50594
4757,1,Mus musculus,Half-life at a single subcutaneous administration of 40 mg/kg in mice,A,10090.0,,,,CHEMBL620265,4066,N,BAO_0000218,1,,In vivo,,,50594
4758,1,Mus musculus,Half-life was measured in mouse,A,10090.0,,,,CHEMBL620266,4239,N,BAO_0000218,1,,,,,50594
4759,1,Mus musculus,In vivo half life period was determined in murine septicemia at dose of 50 mg/kg,A,10090.0,,,,CHEMBL620267,5969,N,BAO_0000218,1,,In vivo,,,50594
4760,1,Mus musculus,Time for esterases in unfractionated mouse serum to reduce the concentration due to thio ester deacylation,A,10090.0,,,,CHEMBL619364,8999,N,BAO_0000218,1,,,,,50594
4761,1,Mus musculus,Time for esterases in unfractionated mouse serum to reduce the concentration due to thio ester deacylation; 10 % hydrolysis at 60 mins,A,10090.0,,,,CHEMBL619365,8999,N,BAO_0000218,1,,,,,50594
4762,1,Mus musculus,T2 in brain of mice at the oral dose of 50 mg/kg,A,10090.0,Brain,,,CHEMBL619366,17641,N,BAO_0000218,1,955.0,,,,50594
4763,1,Mus musculus,T2 in kidney of mice at the oral dose of 50 mg/kg,A,10090.0,Kidney,,,CHEMBL619367,17641,N,BAO_0000218,1,2113.0,,,,50594
4764,1,Mus musculus,T2 in liver of mice at the oral dose of 50 mg/kg,A,10090.0,Liver,,,CHEMBL619368,17641,N,BAO_0000218,1,2107.0,,,,50594
4765,1,Mus musculus,T2 in lungs of mice at the oral dose of 50 mg/kg,A,10090.0,Lung,,,CHEMBL619369,17641,N,BAO_0000218,1,2048.0,,,,50594
4766,1,Mus musculus,T2 in spleen of mice at the oral dose of 50 mg/kg,A,10090.0,Spleen,,,CHEMBL876729,17641,N,BAO_0000218,1,2106.0,,,,50594
4767,1,Mus musculus,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for T max,A,10090.0,,,,CHEMBL619370,16597,N,BAO_0000218,1,,In vivo,,,50594
4768,1,Mus musculus,"Compound was evaluated for the pharmacokinetic parameter, maximum time constant",A,10090.0,,,,CHEMBL619371,4890,N,BAO_0000218,1,,In vivo,,,50594
4769,1,Mus musculus,Evaluated for pharmacokinetic parameter tmax in mouse at the dose 20 mg/kg,A,10090.0,,,,CHEMBL619372,429,N,BAO_0000218,1,,In vivo,,,50594
4770,1,Mus musculus,Evaluated for pharmacokinetic parameter tmax in mouse at the dose 20 mg/kg was determined,A,10090.0,,,,CHEMBL620012,429,N,BAO_0000218,1,,In vivo,,,50594
4771,1,Mus musculus,In vivo Tmax was determined in murine septicemia at dose of 100 mg/kg,A,10090.0,,,,CHEMBL620013,5969,N,BAO_0000218,1,,In vivo,,,50594
4772,1,Homo sapiens,"Inhibitory effect of Gold(III) complex, [Au(bipy)-(OH)2]-[PF6] on growth of cisplatin-resistant A2780/R human tumor cell lines",F,9606.0,,,,CHEMBL620014,16913,N,BAO_0000219,1,,,,A2780,81034
4773,1,Homo sapiens,"Inhibitory effect of Gold(III) complex, [Au(bipy-H)(OH)]-[PF6] on growth of cisplatin-resistant A2780/R human tumor cell lines",F,9606.0,,,,CHEMBL620015,16913,N,BAO_0000219,1,,,,A2780,81034
4774,1,Homo sapiens,"Inhibitory effect of Gold(III) complex, 2,2' bipy on growth of cisplatin-sensitive A2780/S human tumor cell lines",F,9606.0,,,,CHEMBL621010,16913,N,BAO_0000219,1,,,,A2780,81034
4775,1,Homo sapiens,"Inhibitory effect of Gold(III) complex, CDDP on growth of cisplatin-sensitive A2780/S human tumor cell lines",F,9606.0,,,,CHEMBL621011,16913,N,BAO_0000219,1,,,,A2780,81034
4776,1,Homo sapiens,"Inhibitory effect of Gold(III) complex, [Au(bipy)-(OH)2]-[PF6] on growth of cisplatin-sensitive A2780/S human tumor cell lines",F,9606.0,,,,CHEMBL621012,16913,N,BAO_0000219,1,,,,A2780,81034
4777,1,Homo sapiens,"Inhibitory effect of Gold(III) complex, [Au(bipy-H)(OH)]-[PF6] on growth of cisplatin-sensitive A2780/S human tumor cell lines",F,9606.0,,,,CHEMBL621013,16913,N,BAO_0000219,1,,,,A2780,81034
4778,1,Homo sapiens,In vitro cytotoxicity against A2780TAX cell line,F,9606.0,,,,CHEMBL621014,17270,N,BAO_0000219,1,,,,A2780,81034
4779,1,Homo sapiens,In vitro inhibitory activity against human tumor cell line A2780cis,F,9606.0,,,,CHEMBL618154,5618,N,BAO_0000219,1,,,,A2780cisR,80017
4780,1,Homo sapiens,Growth inhibition against A2780 cisplatin resistant wild-type ovarian cell lines,F,9606.0,,,,CHEMBL618155,17777,N,BAO_0000219,1,,,,A2780,81034
4781,1,Homo sapiens,Antitumor activity of compound for 96-h exposure in A2780cisR (acquired resistance to cisplatin) human ovarian cell line,F,9606.0,,,,CHEMBL618156,16112,N,BAO_0000219,1,,,,A2780cisR,80017
4782,1,Homo sapiens,The compound was tested for cytotoxic activity against A2780cisR cell line(human ovarian carcinoma ),F,9606.0,,,,CHEMBL618157,15748,N,BAO_0000219,1,,,,A2780cisR,80017
4783,1,Homo sapiens,Concentration required to inhibit A2780cisR cell growth when compared with control after incubation for 96 h at 37 C,F,9606.0,,,,CHEMBL618328,6633,N,BAO_0000219,1,,,,A2780,81034
4784,1,Homo sapiens,Compound was evaluated against human Ovarian carcinoma cell line A2780cisR,F,9606.0,,,,CHEMBL618329,16930,N,BAO_0000219,1,,,,A2780,81034
4785,1,Homo sapiens,Cytotoxicity against human ovarian carcinoma A2780cisR cell line,F,9606.0,,,,CHEMBL618330,17496,N,BAO_0000219,1,,,,A2780,81034
4786,1,Homo sapiens,In vitro antitumor activity against A2780cisR cell line.,F,9606.0,,,,CHEMBL618331,12989,N,BAO_0000219,1,,,,A2780,81034
4787,1,Homo sapiens,Tested for the cytotoxicity in A2780cisR ovarian cell line (cisR denotes resistance to cisplatin),F,9606.0,,,,CHEMBL618332,4840,N,BAO_0000219,1,,,,A2780,81034
4788,1,Homo sapiens,Resistant factor determined between IC50 of resistant line to that of A2780cisR cell line,F,9606.0,,,,CHEMBL618333,12989,N,BAO_0000219,1,,,,A2780,81034
4789,1,Homo sapiens,cytotoxicity against A2780cisR cells incubated for 24 hr in MTT assay,F,9606.0,,,,CHEMBL618334,16745,N,BAO_0000219,1,,,,A2780cisR,80017
4790,1,Homo sapiens,Inhibition of A2780 / DDP-S human ovarian carcinoma cell proliferation,F,9606.0,,,,CHEMBL618335,16597,N,BAO_0000219,1,,,,A2780,81034
4791,9,Rattus norvegicus,Inhibition against A2A-Adenosine Receptor of rat PC12 cell membranes,B,10116.0,,,,CHEMBL618336,16547,D,BAO_0000019,1,,,,,11736
4792,8,,Inhibition against A2A-Adenosine Receptor of rat PC12 cell membranes (functional antagonist activity),F,,,,,CHEMBL618337,16547,H,BAO_0000019,1,,,,,11736
4793,9,Rattus norvegicus,Inhibition against A2A-Adenosine Receptor of rat PC12 cell membranes (functional antagonist activity),F,10116.0,,,,CHEMBL618338,16547,D,BAO_0000019,1,,,,,11736
4794,9,Homo sapiens,Antagonist activity against human A2B adenosine receptor expressed in HEK293 cells uisng [3H]ZM-241385 or [125I]-IABOPX,F,9606.0,,,,CHEMBL618339,15856,D,BAO_0000219,1,,,,HEK293,278
4795,9,Homo sapiens,Antagonist activity against human A2B adenosine receptor expressed in HEK293 cells using [3H]ZM-241385 (or) [125 I]IABOPX at 10e-5 M,F,9606.0,,,,CHEMBL618340,15856,D,BAO_0000219,1,,,,HEK293,278
4796,9,Mus musculus,Inhibition against A2B-Adenosine Receptor in mouse NIH 3T3 fibroblast cell membranes,B,10090.0,,,,CHEMBL618341,16547,D,BAO_0000019,1,,,,,11831
4797,8,,Inhibition against A2B-Adenosine Receptor in mouse NIH 3T3 fibroblast cell membranes (functional antagonist activity),F,,,,,CHEMBL618342,16547,H,BAO_0000019,1,,,,,11831
4798,9,Mus musculus,Inhibition against A2B-Adenosine Receptor in mouse NIH 3T3 fibroblast cell membranes (functional antagonist activity),F,10090.0,,,,CHEMBL618343,16547,D,BAO_0000019,1,,,,,11831
4799,8,,Ability to displace the binding of [3H]-MRE 3008-F20 to the ligand binding site of CHO:hA3 (human Adenosine receptor) at concentration of 10 uM,B,,,,,CHEMBL621038,17402,H,BAO_0000357,1,,,,,280
4800,0,Homo sapiens,Compound was tested in vitro for inhibition of cytopathogenicity of LAV(IIIB) in CD4+ T-cells (A3.01),F,9606.0,,,,CHEMBL621039,11746,U,BAO_0000219,1,,,,T-cells,22226
4801,0,Homo sapiens,Compound was tested in vitro for inhibition of cytopathogenicity of LAV(IIIB) in CD4+ T-cells (A3.01); Not active,F,9606.0,,,,CHEMBL621040,11746,U,BAO_0000219,1,,,,T-cells,22226
4802,1,Homo sapiens,Compound was evaluated for cytotoxic activity against human melanoma cell line A375,F,9606.0,,,,CHEMBL621041,5455,N,BAO_0000219,1,,,,A-375,80018
4803,1,Homo sapiens,In vitro antitumor activity against A375 (melanoma) human tumor cell lines.,F,9606.0,,,,CHEMBL621042,2068,N,BAO_0000219,1,,,,A-375,80018
4804,1,Homo sapiens,In vitro antitumor activity against A375cell line extracted form melanoma,F,9606.0,,,,CHEMBL621043,2683,N,BAO_0000219,1,,,,A-375,80018
4805,1,Homo sapiens,Inhibition of cell growth in (A375) melan cell line,F,9606.0,,,,CHEMBL621044,15313,N,BAO_0000219,1,,,,A-375,80018
4806,1,Homo sapiens,In vitro tumor cell growth inhibitory activity against Human melanoma cell lines A375,F,9606.0,,,,CHEMBL621045,13739,N,BAO_0000219,1,,,,A-375,80018
4807,1,Homo sapiens,In vitro tumor cell growth inhibitory activity against Human melanoma cell lines. A375,F,9606.0,,,,CHEMBL621046,13739,N,BAO_0000219,1,,,,A-375,80018
4808,1,Homo sapiens,Compound was tested in vitro for cytotoxicity against A375 cell lines from melanoma.,F,9606.0,,,,CHEMBL621047,14750,N,BAO_0000219,1,,,,A-375,80018
4809,1,Homo sapiens,Antiproliferative activity measured against A427 human lung carcinoma,F,9606.0,,,,CHEMBL621048,14777,N,BAO_0000219,1,,,,A-427,80019
4810,1,Homo sapiens,Antiproliferative activity measured against A427 human lung carcinoma,F,9606.0,,,,CHEMBL883798,14777,N,BAO_0000219,1,,,,A-427,80019
4811,1,Homo sapiens,Cytotoxicity against lung carcinoma A427 tumor cell lines,F,9606.0,,,,CHEMBL621049,17672,N,BAO_0000219,1,,,,A-427,80019
4812,1,Homo sapiens,Inhibition of large cell lung carcinoma (A427),F,9606.0,,,,CHEMBL621050,14368,N,BAO_0000219,1,,,,A-427,80019
4813,1,Homo sapiens,Inhibition of large cell lung carcinoma (A427) after 48-h treatment,F,9606.0,,,,CHEMBL621051,14368,N,BAO_0000219,1,,,,A-427,80019
4814,1,Homo sapiens,Inhibitory activity against A427 epithelial Cancer cell line at the concentration 0-30 uM for 48 hr,F,9606.0,,,,CHEMBL621052,13866,N,BAO_0000219,1,,,,A-427,80019
4815,1,Homo sapiens,Inhibitory concentration in human lung carcinoma A427 cell line,F,9606.0,,,,CHEMBL621053,2545,N,BAO_0000219,1,,,,A-427,80019
4816,1,Homo sapiens,Inhibitory concentration in human lung carcinoma A427/VCR cell line,F,9606.0,,,,CHEMBL621054,2545,N,BAO_0000219,1,,,,A-427,80019
4817,0,Cercopithecidae,Terminal phase volume of distribution was measured in monkey after an iv dose of 1 mg/kg,A,9527.0,,,,CHEMBL621055,6062,U,BAO_0000218,1,,In vivo,,,22224
4818,0,Cercopithecidae,Tested for volume of distribution upon iv administration to african green monkey,A,9527.0,,,,CHEMBL876398,4578,U,BAO_0000218,1,,In vivo,,,22224
4819,0,Cercopithecidae,Volume of distribution in monkey,A,9527.0,,,,CHEMBL621056,17592,U,BAO_0000218,1,,In vivo,,,22224
4820,0,Macaca mulatta,Compound was tested for its plasma volume distribution in rhesus monkey at a dose of 0.75 mg/kg iv/ 1.5 mg/kg po,A,9544.0,,,,CHEMBL621057,5005,U,BAO_0000218,1,,In vivo,,,22224
4821,0,Macaca mulatta,Compound was tested for its plasma volume distribution in rhesus monkey at a dose of 0.75 mg/kg iv/ 1.5 mg/kg po; ND is not determined.,A,9544.0,,,,CHEMBL621058,5005,U,BAO_0000218,1,,In vivo,,,22224
4822,0,Cercopithecidae,Pharmacokinetic property(Vdss) in cynomolgus monkey,A,9527.0,,,,CHEMBL621059,5922,U,BAO_0000218,1,,In vivo,,,22224
4823,0,Cercopithecidae,The distribution volume after intravenous administration in cynomolgus monkeys,A,9527.0,,,,CHEMBL621060,5355,U,BAO_0000218,1,,In vivo,,,22224
4824,0,Cercopithecidae,The distribution volume after oral administration in cynomolgus monkeys; NA means Not applicable,A,9527.0,,,,CHEMBL621061,5355,U,BAO_0000218,1,,In vivo,,,22224
4825,0,Cercopithecidae,The distribution volume after oral administration in cynomolgus monkeys; NA means not applicable,A,9527.0,,,,CHEMBL621062,5355,U,BAO_0000218,1,,In vivo,,,22224
4826,0,Cercopithecidae,Volume displacement was calculated in rhesus monkey,A,9527.0,,,,CHEMBL621063,6057,U,BAO_0000218,1,,In vivo,,,22224
4827,0,Cercopithecidae,Volume of distribution in steady state was determined in rhesus monkey,A,9527.0,,,,CHEMBL621064,5145,U,BAO_0000218,1,,In vivo,,,22224
4828,0,Cercopithecidae,Volume of distribution of compound was determined in monkey,A,9527.0,,,,CHEMBL621065,6821,U,BAO_0000218,1,,In vivo,,,22224
4829,0,Cercopithecidae,Volume of distribution was reported after intravenous administration at a dose of 1 mg/kg in Rhesus monkey (male),A,9527.0,,,,CHEMBL621066,5334,U,BAO_0000218,1,,In vivo,,,22224
4830,0,Cercopithecidae,Volume of distribution was reported after oral administration at a dose of 2 mg/kg in Rhesus monkey (male),A,9527.0,,,,CHEMBL621067,5334,U,BAO_0000218,1,,In vivo,,,22224
4831,0,Cercopithecidae,Volumes of distribution in monkey (dosed at 0.5 mpk iv and 2.0 mpk orally),A,9527.0,,,,CHEMBL621068,6641,U,BAO_0000218,1,,In vivo,,,22224
4832,0,Cercopithecidae,Compound was evaluated for volume of distribution (steady state) after treatment with iv dose of 1 mgkg to female cynomolgus monkey,A,9527.0,,,,CHEMBL876399,2661,U,BAO_0000218,1,,In vivo,,,22224
4833,0,Cercopithecidae,Volume distribution in monkey after administration of 1 mg/kg iv,A,9527.0,,,,CHEMBL621069,6535,U,BAO_0000218,1,,In vivo,,,22224
4834,0,Cercopithecidae,Volume distribution was determined in monkey after (iv) administration of a dose of 13 (uM/kg),A,9527.0,,,,CHEMBL621070,4809,U,BAO_0000218,1,,In vivo,,,22224
4835,0,Cercopithecidae,Volume of distribution was measured in monkey after an iv dose of 1 mg/kg,A,9527.0,,,,CHEMBL621071,6062,U,BAO_0000218,1,,In vivo,,,22224
4836,0,Cercopithecidae,Half life evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,A,9527.0,,,,CHEMBL621072,3443,U,BAO_0000218,1,,In vivo,,,22224
4837,0,Cercopithecidae,Oral systemic bioavailability upon iv administration to african green monkey,A,9527.0,,,,CHEMBL618209,4578,U,BAO_0000218,1,,In vivo,,,22224
4838,0,Cercopithecidae,Plasma clearance was determined in monkey after (iv) administration of a dose of 13 (uM/kg),A,9527.0,,,,CHEMBL618210,4809,U,BAO_0000218,1,,In vivo,,,22224
4839,0,Cercopithecidae,Baboon plasma free fraction. ,A,9527.0,,,,CHEMBL618211,11271,U,BAO_0000019,1,,,,,22224
4840,0,Cercopithecidae,Area under the curve was calculated in rhesus monkey after iv administration,A,9527.0,,,,CHEMBL618212,6057,U,BAO_0000218,1,,,,,22224
4841,0,Cercopithecidae,Area under the curve was calculated in rhesus monkey after peroral administration,A,9527.0,,,,CHEMBL618213,6057,U,BAO_0000019,1,,,,,22224
4842,0,Cercopithecidae,Dose-normalized area under curve in monkey (p.o.) at 2.0 mpk,A,9527.0,,,,CHEMBL618214,17853,U,BAO_0000019,1,,,,,22224
4843,0,Cercopithecidae,Half life period in monkey after 5 mg/kg dose,A,9527.0,,,,CHEMBL873492,5302,U,BAO_0000218,1,,In vivo,,,22224
4844,0,Cercopithecidae,Half-life was determined in monkey after 3 mg/kg of i.v. dose,A,9527.0,,,,CHEMBL618272,4257,U,BAO_0000218,1,,In vivo,,,22224
4845,0,Cercopithecidae,Half-life was determined in monkey after 3 mg/kg of i.v. dose; Not determined,A,9527.0,,,,CHEMBL618273,4257,U,BAO_0000218,1,,In vivo,,,22224
4846,0,Cercopithecidae,Apparent Half life was determined from the linear portion of the log plasma concentration-time profile after oral administration of compound 18 at a dose of 1 mg/kg to rhesus monkey,A,9527.0,Plasma,,,CHEMBL618274,13501,U,BAO_0000218,1,1969.0,In vivo,,,22224
4847,0,Cercopithecidae,Compound at a dose 3 mg/kg was administered to monkey and was evaluated for half life after administration into monkey at 3 mg/kg,A,9527.0,,,,CHEMBL618275,5394,U,BAO_0000218,1,,In vivo,,,22224
4848,0,Cercopithecidae,Compound was evaluated for half-life after treatment with iv dose of 1 mgkg to female cynomolgus monkey,A,9527.0,,,,CHEMBL618276,2661,U,BAO_0000218,1,,In vivo,,,22224
4849,0,Cercopithecidae,Compound was evaluated for terminal half life in monkey,A,9527.0,,,,CHEMBL618277,3341,U,BAO_0000019,1,,,,,22224
4850,0,Cercopithecidae,Compound was evaluated for the half life period after iv administration in cynomolgus monkey,A,9527.0,,,,CHEMBL618278,3045,U,BAO_0000218,1,,In vivo,,,22224
4851,0,Macaca mulatta,Compound was tested for its plasma half life in rhesus monkey at a dose of 0.75 mg/kg iv/ 1.5 mg/kg po,A,9544.0,Plasma,,,CHEMBL618279,5005,U,BAO_0000218,1,1969.0,In vivo,,,22224
4852,0,Cercopithecidae,Half life of compound was determined in squirrel monkey,A,9527.0,,,,CHEMBL618280,4847,U,BAO_0000019,1,,,,,22224
4853,0,Macaca fascicularis,Half life after iv administration in cynomolgus monkey,A,9541.0,,,,CHEMBL618281,4256,U,BAO_0000218,1,,In vivo,,,22224
4854,0,Cercopithecidae,Half life in monkey plasma after administration of 1 mg/kg iv,A,9527.0,Plasma,,,CHEMBL618282,6535,U,BAO_0000218,1,1969.0,In vivo,,,22224
4855,0,Cercopithecidae,Half life was calculated in rhesus monkey,A,9527.0,,,,CHEMBL618283,6057,U,BAO_0000019,1,,,,,22224
4856,0,Cercopithecidae,Half life in monkey,A,9527.0,,,,CHEMBL618284,17592,U,BAO_0000019,1,,,,,22224
4857,0,Cercopithecidae,Half life in monkey (dosed at 0.5 mpk iv and 2.0 mpk orally),A,9527.0,,,,CHEMBL618285,6641,U,BAO_0000218,1,,In vivo,,,22224
4858,0,Cercopithecidae,Half life was evaluated in rhesus,A,9527.0,,,,CHEMBL618286,5472,U,BAO_0000019,1,,,,,22224
4859,0,Cercopithecidae,Half life period after oral administration (2.5 mg/kg) in monkey was determined,A,9527.0,,,,CHEMBL618287,6221,U,BAO_0000218,1,,In vivo,,,22224
4860,0,Cercopithecidae,Half life period was determine after peroral administration at 10 mpk in Rhesus,A,9527.0,,,,CHEMBL618288,5668,U,BAO_0000218,1,,In vivo,,,22224
4861,0,Cercopithecidae,Half life period was determined in monkey after (iv) administration of a dose of 13 (uM/kg),A,9527.0,,,,CHEMBL876393,4809,U,BAO_0000218,1,,In vivo,,,22224
4862,0,Cercopithecidae,Half life period was determined in rhesus monkey at a dose of 1 mg/kg by iv administration,A,9527.0,,,,CHEMBL618289,5546,U,BAO_0000218,1,,In vivo,,,22224
4863,0,Cercopithecidae,Half life period was determined in squirrel monkey after iv administration at a dose of 5 mg/kg,A,9527.0,,,,CHEMBL618290,5553,U,BAO_0000218,1,,In vivo,,,22224
4864,0,Cercopithecidae,Half-life was calculated in monkey,A,9527.0,,,,CHEMBL618291,6078,U,BAO_0000019,1,,,,,22224
4865,0,Cercopithecidae,Half-life in Squirrel monkey,A,9527.0,,,,CHEMBL618292,5147,U,BAO_0000019,1,,,,,22224
4866,0,Cercopithecidae,Half-life in rhesus monkey,A,9527.0,,,,CHEMBL618293,5145,U,BAO_0000019,1,,,,,22224
4867,0,Cercopithecidae,Half-life was measured in monkey after an iv dose of 1 mg/kg,A,9527.0,,,,CHEMBL618294,6062,U,BAO_0000218,1,,In vivo,,,22224
4868,0,Cercopithecidae,Half-life period after intravenous administration in cynomolgus monkeys,A,9527.0,,,,CHEMBL618295,5355,U,BAO_0000218,1,,In vivo,,,22224
4869,0,Cercopithecidae,Half-life period after oral administration in cynomolgus monkeys,A,9527.0,,,,CHEMBL618296,5355,U,BAO_0000218,1,,In vivo,,,22224
4870,0,Cercopithecidae,Half-life period after oral administration in cynomolgus monkeys; ND meansn Not determined,A,9527.0,,,,CHEMBL618297,5355,U,BAO_0000218,1,,In vivo,,,22224
4871,0,Homo sapiens,Portion of holoxan excreted in the form of the metabolite from 1500 mL of urine on day 9 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,A,9606.0,Urine,,,CHEMBL618298,7766,U,BAO_0000019,1,1088.0,,,,22224
4872,0,Homo sapiens,Portion of holoxan excreted in the form of the metabolite from 1600 mL of urine on day 10 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,A,9606.0,Urine,,,CHEMBL618299,7766,U,BAO_0000019,1,1088.0,,,,22224
4873,0,Homo sapiens,Portion of holoxan excreted in the form of the metabolite from 1700 mL of urine on day 5 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,A,9606.0,Urine,,,CHEMBL618300,7766,U,BAO_0000019,1,1088.0,,,,22224
4874,0,Homo sapiens,Portion of holoxan excreted in the form of the metabolite from 2310 mL of urine on day 4 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,A,9606.0,Urine,,,CHEMBL618301,7766,U,BAO_0000019,1,1088.0,,,,22224
4875,0,Homo sapiens,Percent ratio of the enantiomeric form (+)R extracted from the urine of alveolar rhabdomyosarcoma patients was determined,A,9606.0,Urine,,,CHEMBL618302,7766,U,BAO_0000019,1,1088.0,,,,22224
4876,0,Homo sapiens,Percent ratio of the enantiomeric form (+)R extracted from the urine of embryonal rhabdomyosarcoma patients was determined,A,9606.0,Urine,,,CHEMBL876394,7766,U,BAO_0000019,1,1088.0,,,,22224
4877,0,Homo sapiens,Percent ratio of the enantiomeric form (-)S extracted from the urine of alveolar rhabdomyosarcoma patients was determined,A,9606.0,Urine,,,CHEMBL618303,7766,U,BAO_0000019,1,1088.0,,,,22224
4878,0,Homo sapiens,Percent ratio of the enantiomeric form (-)S extracted from the urine of embryonal rhabdomyosarcoma patients was determined,A,9606.0,Urine,,,CHEMBL618304,7766,U,BAO_0000019,1,1088.0,,,,22224
4879,0,Homo sapiens,Bioavailability was evaluated in man at a dose of 10 mg/kg after po administration; not determined,A,9606.0,,,,CHEMBL618305,1916,U,BAO_0000218,1,,In vivo,,,22224
4880,0,Homo sapiens,Oral bioavailability in human,A,9606.0,,,,CHEMBL618306,16643,U,BAO_0000218,1,,In vivo,,,22224
4881,0,Homo sapiens,Compound was tested for human plasma protein binding,A,9606.0,,,,CHEMBL618307,17248,U,BAO_0000019,1,,,,,22224
4882,0,Homo sapiens,Compound was tested for human plasma protein binding; Not determined,A,9606.0,,,,CHEMBL618308,17248,U,BAO_0000019,1,,,,,22224
4883,0,Homo sapiens,Protein binding activity of compound in human plasma; % Free,A,9606.0,,,,CHEMBL618309,6241,U,BAO_0000019,1,,,,,22224
4884,0,Homo sapiens,Unbound fraction (plasma),A,9606.0,,,,CHEMBL618310,17716,U,BAO_0000019,1,,,,,22224
4885,0,Homo sapiens,Half life for the hydrolysis of compound in human blood serum,A,9606.0,Plasma,,,CHEMBL873353,17605,U,BAO_0000366,1,1969.0,,,,22224
4886,0,Homo sapiens,Half life period in human plasma using phosphate buffer (0.08 M),A,9606.0,Plasma,,,CHEMBL618311,17625,U,BAO_0000366,1,1969.0,,,,22224
4887,0,Homo sapiens,Half life period in human plasma using phosphate buffer (0.1 M),A,9606.0,Plasma,,,CHEMBL618312,17625,U,BAO_0000366,1,1969.0,,,,22224
4888,0,Homo sapiens,Half-life in human plasma was determined,A,9606.0,Plasma,,,CHEMBL618313,17747,U,BAO_0000366,1,1969.0,,,,22224
4889,0,Homo sapiens,Concentration required for 50% toxicity in metastatic lung carcinoma (MV522) cells.,A,9606.0,,,,CHEMBL618314,15613,U,BAO_0000019,1,,,,,22224
4890,0,Homo sapiens,Effect of compound on gelation time of human serum induced by dithiothreitol (DTT),A,9606.0,,,,CHEMBL618315,354,U,BAO_0000019,1,,,,,22224
4891,0,Homo sapiens,"Rate constant in chemical and enzymatic hydrolysis to form L-DOPA, in 80% human plasma",A,9606.0,,,,CHEMBL618316,3741,U,BAO_0000019,1,,,,,22224
4892,0,Homo sapiens,"Rate constant in chemical and enzymatic hydrolysis to form another compound (8)*, in 80% human plasma (experiment 1)",A,9606.0,,,,CHEMBL618317,3741,U,BAO_0000019,1,,,,,22224
4893,0,Homo sapiens,"Rate constant in chemical and enzymatic hydrolysis to form another compound (8)*, in 80% human plasma (experiment 2)",A,9606.0,,,,CHEMBL620138,3741,U,BAO_0000019,1,,,,,22224
4894,0,Homo sapiens,Partition coefficient (logP),A,9606.0,,,,CHEMBL858280,17599,U,BAO_0000019,1,,,,,22224
4895,0,Homo sapiens,In vitro metabolic stability in human was measured as pmol/min/mg/protein,A,9606.0,,,,CHEMBL620139,5486,U,BAO_0000019,1,,,,,22224
4896,0,Homo sapiens,In vitro metabolic stability determined after 30 min of incubation in human hepatic microsomes,A,9606.0,,Microsomes,,CHEMBL620140,5600,U,BAO_0000251,1,,,,,22224
4897,0,Homo sapiens,Metabolism of compound in human liver slices (male) ('+''indicates <20% largest observed peak),A,9606.0,,,,CHEMBL620141,14294,U,BAO_0000019,1,,,,,22224
4898,0,Homo sapiens,Metabolism of compound in human liver slices (male) ('++''indicates 20-50% largest observed peak),A,9606.0,,,,CHEMBL620142,14294,U,BAO_0000019,1,,,,,22224
4899,0,Homo sapiens,Metabolism of compound in human liver slices (male) ('++++' indicates largest observed peak),A,9606.0,,,,CHEMBL620143,14294,U,BAO_0000019,1,,,,,22224
4900,0,Homo sapiens,Metabolism of compound in human microsomes ('+''indicates <20% largest observed peak),A,9606.0,,Microsomes,,CHEMBL620144,14294,U,BAO_0000251,1,,,,,22224
4901,0,Homo sapiens,Metabolism of compound in human microsomes ('++++' indicates largest observed peak),A,9606.0,,Microsomes,,CHEMBL620145,14294,U,BAO_0000251,1,,,,,22224
4902,0,Homo sapiens,Metabolism of compound in human microsomes; Trace,A,9606.0,,Microsomes,,CHEMBL620146,14294,U,BAO_0000251,1,,,,,22224
4903,0,Homo sapiens,Percent of compound remaining after 120 min of Metabolization upon incubation with human liver microsomes,A,9606.0,Liver,Microsomes,,CHEMBL620147,6260,U,BAO_0000251,1,2107.0,,,,22224
4904,0,Homo sapiens,Percent metabolized in an in vitro human liver microsomal incubation assay after 60 min,A,9606.0,,Microsomes,,CHEMBL620148,6187,U,BAO_0000251,1,,,,,22224
4905,0,Homo sapiens,In vitro metabolic potential in human liver microsomes,A,9606.0,Liver,Microsomes,,CHEMBL620149,6251,U,BAO_0000251,1,2107.0,,,,22224
4906,0,Homo sapiens,Metabolism by recombinant human NAD(P)H:quinone oxidoreductase (NQO1) was evaluated,A,9606.0,,,,CHEMBL876412,3246,U,BAO_0000019,1,,,,,22224
4907,0,Homo sapiens,Tested for human plasma protein binding of the compound; Not tested,A,9606.0,,,,CHEMBL619352,17313,U,BAO_0000019,1,,,,,22224
4908,0,Homo sapiens,Compound was tested for percent protein binding (PB) in human,A,9606.0,,,,CHEMBL619353,6227,U,BAO_0000019,1,,,,,22224
4909,0,Homo sapiens,Protein binding in human plasma,A,9606.0,Plasma,,,CHEMBL619354,5530,U,BAO_0000019,1,1969.0,,,,22224
4910,0,Homo sapiens,Permeability coefficient (B to A) in Caco-2 cell,A,9606.0,,,,CHEMBL619355,6108,U,BAO_0000019,1,,,,,22224
4911,0,Homo sapiens,Permeability directional ratio (PB-A/PA-B) in Caco-2 cell,A,9606.0,,,,CHEMBL619356,6108,U,BAO_0000019,1,,,,,22224
4912,0,Homo sapiens,Apparent permeability coefficient (Papp) was determined in human Caco-2 cell monolayer (n = 3),A,9606.0,,,,CHEMBL619357,2774,U,BAO_0000019,1,,,,,22224
4913,0,Homo sapiens,In vitro rate of absorption observed as Caco-2 permeability in humans,A,9606.0,,,,CHEMBL619358,16643,U,BAO_0000019,1,,,,,22224
4914,0,Homo sapiens,Cellular permeability of compound was determined in Caco-2 cells; High,A,9606.0,,,,CHEMBL619359,17582,U,BAO_0000219,1,,,,Caco-2,22224
4915,0,Homo sapiens,Permeability in Caco-2 cells of compound,A,9606.0,,,,CHEMBL619360,6838,U,BAO_0000219,1,,,,Caco-2,22224
4916,0,Homo sapiens,Permeability coefficient (A to B) in Caco-2 cell,A,9606.0,,,,CHEMBL619361,6108,U,BAO_0000019,1,,,,,22224
4917,0,Homo sapiens,Permeability coefficient (B to A) in Caco-2 cell,A,9606.0,,,,CHEMBL619362,6108,U,BAO_0000019,1,,,,,22224
4918,0,Homo sapiens,Permeability coefficient (Papp) (Caco-2 cell monolayer),A,9606.0,,,,CHEMBL619363,6108,U,BAO_0000019,1,,,,,22224
4919,0,Homo sapiens,Compound was measured for binding rate for human serum at a carbapenem concentration of 10 ug/mL,A,9606.0,,,,CHEMBL618942,2146,U,BAO_0000019,1,,,,,22224
4920,0,Homo sapiens,Compound was tested for protein binding in human plasma,A,9606.0,,,,CHEMBL618943,4514,U,BAO_0000019,1,,,,,22224
4921,0,Homo sapiens,Transcellular permeability of the [(PA-B+PB-A)/2)] compound was determined in Caco-2 cell,A,9606.0,,,,CHEMBL618944,6108,U,BAO_0000019,1,,,,,22224
4922,0,Homo sapiens,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 1200 mL of urine tested on day 3,A,9606.0,Urine,,,CHEMBL618945,7766,U,BAO_0000019,1,1088.0,,,,22224
4923,1,Mus musculus,In vivo Tmax was determined in murine septicemia at dose of 50 mg/kg,A,10090.0,,,,CHEMBL618946,5969,N,BAO_0000218,1,,In vivo,,,50594
4924,1,Mus musculus,Maximum time was determined in mice at a single subcutaneous administration of 40 mg/kg (n=4),A,10090.0,,,,CHEMBL876413,3277,N,BAO_0000218,1,,In vivo,,,50594
4925,1,Mus musculus,Tested for Tmax value at the dose of 10 mg/kg when administered perorally in mouse,A,10090.0,,,,CHEMBL618947,3802,N,BAO_0000218,1,,In vivo,,,50594
4926,1,Mus musculus,Time taken to reach maximum concentration in plasma upon oral administration in mouse,A,10090.0,Plasma,,,CHEMBL618948,2862,N,BAO_0000218,1,1969.0,In vivo,,,50594
4927,1,Mus musculus,Time to reach maximum plasma concentration was determined in mouse after 5 mg/kg (i.v.) and 6 mg/kg (p.o.) administration,A,10090.0,Plasma,,,CHEMBL618949,6348,N,BAO_0000218,1,1969.0,In vivo,,,50594
4928,1,Mus musculus,Tmax after intraperitoneal administration in mice at 23 uM/kg,F,10090.0,,,,CHEMBL618950,17764,N,BAO_0000218,1,,In vivo,,,50594
4929,1,Mus musculus,Tmax after oral administration at 30 mg/kg in ICR mouse,A,10090.0,,,,CHEMBL618951,5781,N,BAO_0000218,1,,In vivo,,,50594
4930,1,Mus musculus,Tmax after peroral administration in mice at 2.4 uM/kg,A,10090.0,,,,CHEMBL618952,17764,N,BAO_0000218,1,,In vivo,,,50594
4931,1,Mus musculus,Tmax at a single subcutaneous administration of 40 mg/kg in mice,A,10090.0,,,,CHEMBL618953,4066,N,BAO_0000218,1,,In vivo,,,50594
4932,1,Mus musculus,Tmax in brain of mice at the oral dose of 50 mg/kg,A,10090.0,Brain,,,CHEMBL618954,17641,N,BAO_0000218,1,955.0,In vivo,,,50594
4933,1,Mus musculus,Tmax in kidney of mice at the oral dose of 50 mg/kg,A,10090.0,Kidney,,,CHEMBL618955,17641,N,BAO_0000218,1,2113.0,In vivo,,,50594
4934,1,Mus musculus,Tmax in liver of mice at the oral dose of 50 mg/kg,A,10090.0,Liver,,,CHEMBL618956,17641,N,BAO_0000218,1,2107.0,In vivo,,,50594
4935,1,Mus musculus,Tmax in lungs of mice at the oral dose of 50 mg/kg,A,10090.0,Lung,,,CHEMBL618957,17641,N,BAO_0000218,1,2048.0,In vivo,,,50594
4936,1,Mus musculus,Tmax in mice at 18 uM/kg i.p. administration,F,10090.0,,,,CHEMBL618958,17764,N,BAO_0000218,1,,In vivo,,,50594
4937,1,Mus musculus,Tmax in mice at 23 uM/kg i.v. administration,F,10090.0,,,,CHEMBL618959,17764,N,BAO_0000218,1,,In vivo,,,50594
4938,1,Mus musculus,Tmax in mice at 25 uM/kg i.p. administration,F,10090.0,,,,CHEMBL618960,17764,N,BAO_0000218,1,,In vivo,,,50594
4939,1,Mus musculus,Tmax in mice at 26 uM/kg i.p. administration,F,10090.0,,,,CHEMBL876723,17764,N,BAO_0000218,1,,In vivo,,,50594
4940,1,Mus musculus,Tmax in spleen of mice at the oral dose of 50 mg/kg,A,10090.0,Spleen,,,CHEMBL618961,17641,N,BAO_0000218,1,2106.0,In vivo,,,50594
4941,1,Mus musculus,Tmax value at a dose of 10 mg/kg intravenous administration in mice.,A,10090.0,,,,CHEMBL618962,16597,N,BAO_0000218,1,,In vivo,,,50594
4942,1,Mus musculus,Tmax value at a dose of 10 mg/kg peroral administration in mice.,A,10090.0,,,,CHEMBL618963,16597,N,BAO_0000218,1,,In vivo,,,50594
4943,1,Mus musculus,Tmax value in IRC mice,A,10090.0,,,,CHEMBL618964,5951,N,BAO_0000218,1,,,,,50594
4944,1,Mus musculus,Tmax value was determined at a dose of 100 mg/kg (i.p.) in Mice,A,10090.0,,,,CHEMBL618965,5506,N,BAO_0000218,1,,In vivo,,,50594
4945,1,Mus musculus,Tmax value was determined at a dose of 200 mg/kg (i.p.) in Mice,A,10090.0,,,,CHEMBL618966,5506,N,BAO_0000218,1,,In vivo,,,50594
4946,1,Mus musculus,Evaluated for pharmacokinetic parameter urine recovery in mouse at the dose 20 mg/kg ( 0-24 hr ),A,10090.0,Urine,,,CHEMBL618967,429,N,BAO_0000218,1,1088.0,,,,50594
4947,1,Mus musculus,Evaluated for pharmacokinetic parameter urine recovery in mouse at the dose 20 mg/kg (0-24 hr),A,10090.0,Urine,,,CHEMBL618968,429,N,BAO_0000218,1,1088.0,,,,50594
4948,1,Mus musculus,Urinary recovery by disk method using Streptococcus pyogenes (0-24 h),A,10090.0,Urine,,,CHEMBL618969,4066,N,BAO_0000218,1,1088.0,,,,50594
4949,1,Mus musculus,The first compartment constitutes the majority of the volume of distribution after intraperitoneal administration of 100 mg/kg in mice,A,10090.0,,,,CHEMBL618970,17734,N,BAO_0000218,1,,,,,50594
4950,1,Mus musculus,The second majority of the volume of distribution after intraperitoneal administration of 100 mg/kg in mice,A,10090.0,,,,CHEMBL618971,17734,N,BAO_0000218,1,,,,,50594
4951,1,Mus musculus,Terminal phase volume of distribution was measured in mouse after an iv dose of 1 mg/kg,A,10090.0,,,,CHEMBL618972,6062,N,BAO_0000218,1,,In vivo,,,50594
4952,1,Mus musculus,In vivo volume distribution (Vd) was determined in murine septicemia at dose of 100 mg/kg,A,10090.0,,,,CHEMBL618973,5969,N,BAO_0000218,1,,In vivo,,,50594
4953,1,Mus musculus,In vivo volume distribution (Vd) was determined in murine septicemia at dose of 50 mg/kg,A,10090.0,,,,CHEMBL618974,5969,N,BAO_0000218,1,,In vivo,,,50594
4954,1,Mus musculus,In vivo volume distribution (Vd) was determined in murine septicemia at dose of 50 mg/kg;ND=not determined,A,10090.0,,,,CHEMBL618975,5969,N,BAO_0000218,1,,In vivo,,,50594
4955,1,Mus musculus,Vd in mice,A,10090.0,,,,CHEMBL618976,5980,N,BAO_0000218,1,,In vivo,,,50594
4956,1,Mus musculus,Volume of distribution in mouse,A,10090.0,,,,CHEMBL618977,17592,N,BAO_0000218,1,,In vivo,,,50594
4957,1,Mus musculus,Volume of distribution was determined in mouse after 5 mg/kg (i.v.) and 6 mg/kg (p.o.) administration,A,10090.0,,,,CHEMBL876724,6348,N,BAO_0000218,1,,In vivo,,,50594
4958,1,Mus musculus,Volume of distribution of compound in plasma was determined at 24 mg/Kg,A,10090.0,,,,CHEMBL618978,17753,N,BAO_0000218,1,,In vivo,,,50594
4959,1,Mus musculus,Volume of distribution of compound in plasma was determined at 40 mg/Kg,A,10090.0,,,,CHEMBL618979,17753,N,BAO_0000218,1,,In vivo,,,50594
4960,1,Mus musculus,Volume of distribution of compound in plasma was determined at 5 mg/Kg,A,10090.0,,,,CHEMBL618980,17753,N,BAO_0000218,1,,In vivo,,,50594
4961,1,Mus musculus,Pharmacokinetic property (vdss) was measured in mouse,A,10090.0,,,,CHEMBL618981,4239,N,BAO_0000218,1,,In vivo,,,50594
4962,1,Mus musculus,Value distribution upon iv administration in mouse,A,10090.0,,,,CHEMBL618982,2862,N,BAO_0000218,1,,In vivo,,,50594
4963,1,Mus musculus,Volume of distribution after intraperitoneal administration of 100 mg/kg in mice,A,10090.0,,,,CHEMBL620150,17734,N,BAO_0000218,1,,In vivo,,,50594
4964,1,Mus musculus,Volume of distribution was evaluated in mice after intravenous administration,A,10090.0,,,,CHEMBL620151,2675,N,BAO_0000218,1,,In vivo,,,50594
4965,1,Mus musculus,Volume of distribution was evaluated in mice after oral administration,A,10090.0,,,,CHEMBL620152,2675,N,BAO_0000218,1,,In vivo,,,50594
4966,1,Mus musculus,Steady state volume of distribution of compound in mouse blood following i.v. administration of 10 mg/kg,A,10090.0,,,,CHEMBL620153,17837,N,BAO_0000218,1,,In vivo,,,50594
4967,1,Mus musculus,Steady state volume of distribution was determined in mice,A,10090.0,,,,CHEMBL876395,5727,N,BAO_0000218,1,,In vivo,,,50594
4968,1,Mus musculus,Volume distribution (steady state) of compound was determined in mouse,A,10090.0,,,,CHEMBL620154,17852,N,BAO_0000218,1,,In vivo,,,50594
4969,1,Mus musculus,Volume of solubility in solution after intravenous administration in mice at 24 uM/kg,A,10090.0,,,,CHEMBL620155,17764,N,BAO_0000218,1,,In vivo,,,50594
4970,1,Mus musculus,Vss value at a dose of 10 mg/kg intravenous administration in mice.,A,10090.0,,,,CHEMBL620156,16597,N,BAO_0000218,1,,In vivo,,,50594
4971,1,Mus musculus,Volume of distribution was measured in mouse after an iv dose of 1 mg/kg,A,10090.0,,,,CHEMBL620157,6062,N,BAO_0000218,1,,In vivo,,,50594
4972,1,Mus musculus,Biodistribution of compound (oxidized form) in in kidney tissue,A,10090.0,Kidney,,,CHEMBL620158,16438,N,BAO_0000218,1,2113.0,In vivo,,,50594
4973,1,Mus musculus,Biodistribution in mice as total concentration of both oxidized and reduced forms in blood and animals were sacrificed 10 minutes after ip administration in DMSO solution,A,10090.0,Blood,,,CHEMBL620159,16438,N,BAO_0000218,1,178.0,In vivo,,,50594
4974,1,Mus musculus,"Biodistribution in mice as total concentration of both oxidized and reduced forms in blood and animals were sacrificed 10 minutes after ip dosing, in DMSO solution",A,10090.0,Blood,,,CHEMBL620160,16438,N,BAO_0000218,1,178.0,In vivo,,,50594
4975,1,Mus musculus,"Biodistribution in mice as total concentration of both oxidized and reduced forms in blood tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",A,10090.0,Blood,,,CHEMBL620161,16438,N,BAO_0000218,1,178.0,In vivo,,,50594
4976,1,Homo sapiens,Evaluated for the inhibitory concentration required to cause growth inhibition of A427Mer- cell line of lung using the MTT Cytotoxicity Assay,F,9606.0,,,,CHEMBL620162,10708,N,BAO_0000219,1,,,,A-427,80019
4977,1,Homo sapiens,Inhibition of A431 human squamous cell carcinoma cell proliferation,F,9606.0,,,,CHEMBL620163,16597,N,BAO_0000219,1,,,,A-431,80852
4978,1,Homo sapiens,Inhibition of cell growth of human epidermoid carcinoma xenograft (A431) model using cell based assay,F,9606.0,,,,CHEMBL620833,16062,N,BAO_0000219,1,,,,A-431,80852
4979,1,Homo sapiens,Inhibition of human epidermoid carcinoma xenograft (A431) tumor growth,F,9606.0,,,,CHEMBL876396,16062,N,BAO_0000219,1,,,,A-431,80852
4980,1,Homo sapiens,Concentration required to inhibit growth of human carcinoma epidermoid (A431) cell line,F,9606.0,,,,CHEMBL620834,16958,N,BAO_0000219,1,,,,A-431,80852
4981,1,Homo sapiens,Inhibition of A431 human carcinoma cell proliferation,F,9606.0,,,,CHEMBL620835,6700,N,BAO_0000219,1,,,,A-431,80852
4982,1,Homo sapiens,In vitro inhibition of A431 (human carcinoma) cell basal growth.,F,9606.0,,,,CHEMBL620836,17226,N,BAO_0000219,1,,,,A-431,80852
4983,1,Homo sapiens,Inhibitory concentration of compound against growth of human A431 cell line; Resistant,F,9606.0,,,,CHEMBL620837,6828,N,BAO_0000219,1,,,,A-431,80852
4984,1,Homo sapiens,In vitro cytotoxicity against epidermoid carcinoma cell line,F,9606.0,,,,CHEMBL621017,12314,N,BAO_0000219,1,,,,A-431,80852
4985,9,Homo sapiens,"In vivo efficacy following oral administration in nude mouse tumor model, xenograft A431 cells expressing EGF-R",F,9606.0,,,,CHEMBL621018,13412,D,BAO_0000218,1,,,,A-431,9
4986,1,Homo sapiens,Antiproliferative activity of compound was measured on human tumor cell line A431.,F,9606.0,,,,CHEMBL621019,13299,N,BAO_0000219,1,,,,A-431,80852
4987,1,Homo sapiens,Antiproliferative effect of compound on A431 cell line expressing mutant p53,F,9606.0,,,,CHEMBL621020,17420,N,BAO_0000219,1,,,,A-431,80852
4988,1,Homo sapiens,Compound was evaluated for cell growth inhibition against A 431 cell line by irradiation in the presence of examined compound,F,9606.0,,,,CHEMBL621021,13678,N,BAO_0000219,1,,,,A-431,80852
4989,8,,Inhibition of EGF-stimulated tyrosine phosphorylation in A431 cells.,F,,,,,CHEMBL621022,14171,H,BAO_0000219,1,,,,A-431,9
4990,1,Homo sapiens,Tested for antiproliferative activity against human A431 cells,F,9606.0,,,,CHEMBL621023,6333,N,BAO_0000219,1,,,,A-431,80852
4991,9,Homo sapiens,Inhibition of epidermal growth factor receptor (EGF-R) autophosphorylation in A431 cells,F,9606.0,,,,CHEMBL621024,2356,D,BAO_0000219,1,,,,A-431,9
4992,1,Homo sapiens,Concentration needed to inhibit 50% growth of the human A431 (epidermoid carcinoma) cell lines,F,9606.0,,,,CHEMBL621025,15578,N,BAO_0000219,1,,,,A-431,80852
4993,1,Homo sapiens,Inhibition of A431 cell proliferation,F,9606.0,,,,CHEMBL621026,5126,N,BAO_0000219,1,,,,A-431,80852
4994,1,Homo sapiens,Cytotoxic effect on A431 human epidermoid carcinoma cells,F,9606.0,,,,CHEMBL621027,6844,N,BAO_0000219,1,,,,A-431,80852
4995,1,Homo sapiens,Cytotoxic effect on A431 human epidermoid carcinoma cells (No response to 1 mM),F,9606.0,,,,CHEMBL876397,6844,N,BAO_0000219,1,,,,A-431,80852
4996,1,Homo sapiens,Cytotoxicity expressed as inhibitory concentration required to reduce the cell growth of A431 human epidermal carcinoma cell line,F,9606.0,,,,CHEMBL883797,4925,N,BAO_0000219,1,,,,A-431,80852
4997,1,Homo sapiens,Cytotoxicity expressed as inhibitory concentration required to reduce the cell growth of A431 human epidermal carcinoma cell line; NT=Not tested,F,9606.0,,,,CHEMBL621028,4925,N,BAO_0000219,1,,,,A-431,80852
4998,1,Homo sapiens,In vitro Growth Inhibitory activity against A431 Human vulva cancer cell line,F,9606.0,,,,CHEMBL621029,13978,N,BAO_0000219,1,,,,A-431,80852
4999,1,Homo sapiens,In vitro cytotoxicity of compound against human A431 (epidermoid) cancer cell line after 72 hr of drug exposure,F,9606.0,,,,CHEMBL621030,16786,N,BAO_0000219,1,,,,A-431,80852
5000,8,,Inhibition of EGF-stimulated tyrosine phosphorylation in A431 cells expressing EGF-R,F,,,,,CHEMBL621147,13412,H,BAO_0000219,1,,,,A-431,9
5001,1,Homo sapiens,In vivo antiproliferative activity against A431 cell line,F,9606.0,,,,CHEMBL621148,17824,N,BAO_0000218,1,,,,A-431,80852
5002,9,Homo sapiens,Inhibition of EGF-dependent autophosphorylation of EGF-R in human A431 cells,F,9606.0,,,,CHEMBL621149,12751,D,BAO_0000219,1,,,,A-431,9
5003,1,Homo sapiens,Inhibition of A431 human epidermoid carcinoma cell proliferation,F,9606.0,,,,CHEMBL621150,12380,N,BAO_0000219,1,,,,A-431,80852
5004,9,Homo sapiens,Inhibition of autophosphorylation of human epidermal growth factor-receptor (EGF-R) expressed in A431 cells,F,9606.0,,,,CHEMBL621151,4959,D,BAO_0000219,1,,,,A-431,9
5005,1,Homo sapiens,Inhibitory effect on nonphospho-Src after EGF (100 uM) stimulation of A431 cells (control=178),F,9606.0,,,,CHEMBL621152,6333,N,BAO_0000219,1,,,,A-431,80852
5006,1,Homo sapiens,Inhibitory effect on phospho-Src (Tyr416) after EGF (100 uM) stimulation of A431 cells (38),F,9606.0,,,,CHEMBL621153,6333,N,BAO_0000219,1,,,,A-431,80852
5007,1,Homo sapiens,Inhibitory effect on phospho-Src/nonphospho after EGF (100 uM) stimulation of A431 cells (21),F,9606.0,,,,CHEMBL884000,6333,N,BAO_0000219,1,,,,A-431,80852
5008,9,Homo sapiens,Inhibition of EGFR overexpressing A431 cell proliferation,F,9606.0,,,,CHEMBL621154,5296,D,BAO_0000019,1,,,,,9
5009,1,Homo sapiens,Inhibition of A431 cell proliferation,F,9606.0,,,,CHEMBL621155,12624,N,BAO_0000219,1,,,,A-431,80852
5010,9,Homo sapiens,No inhibition of EGFR phosphorylation in A431 cells 8 hour after washing cells free of the inhibitor,F,9606.0,,,,CHEMBL621156,14926,D,BAO_0000219,1,,,,A-431,9
5011,9,Homo sapiens,"Partial inhibition of EGFR phosphorylation in A431 cells, 8 hour after washing cells free of the inhibitor",F,9606.0,,,,CHEMBL621157,14926,D,BAO_0000219,1,,,,A-431,9
5012,8,,Irreversible inhibition of ATP binding site of EGFR (lack of phosphorylated EGFR) in A431 cells 8 hour after washing cells free of the inhibitor),F,,,,,CHEMBL621158,14926,H,BAO_0000219,1,,,,A-431,9
5013,1,Homo sapiens,The compound was tested in vitro for antiproliferative activity against A431 tumor cell lines,F,9606.0,,,,CHEMBL621159,15144,N,BAO_0000219,1,,,,A-431,80852
5014,1,Homo sapiens,The compound was tested in vitro for antiproliferative activity against A431 tumor cell lines,F,9606.0,,,,CHEMBL621160,15144,N,BAO_0000219,1,,,,A-431,80852
5015,1,Homo sapiens,Cell viability in A431 cells unstimulated with EGF was tested when incubated with concentration at 2 uM after 48 h; Did not affect the viability,F,9606.0,,,,CHEMBL621161,5245,N,BAO_0000219,1,,,,A-431,80852
5016,1,Homo sapiens,Cell viability in A431 cells unstimulated with EGF was tested when incubated with concentration in the range of 1-10 uM after 48 h; Did not affect the viability,F,9606.0,,,,CHEMBL621162,5245,N,BAO_0000219,1,,,,A-431,80852
5017,1,Homo sapiens,Cell viability in A431 cells unstimulated with EGF was tested when incubated with concentration up to 10 uM after 48 h; Did not affect the viability,F,9606.0,,,,CHEMBL621163,5245,N,BAO_0000219,1,,,,A-431,80852
5018,1,Homo sapiens,Cell viability in A431 cells when stimulated with EGF was tested when incubated with concentration 0.01 uM after 48 h; Cell death,F,9606.0,,,,CHEMBL621164,5245,N,BAO_0000219,1,,,,A-431,80852
5019,1,Homo sapiens,Cell viability in A431 cells when stimulated with EGF was tested when incubated with concentration 2 uM after 48 h; Cell death,F,9606.0,,,,CHEMBL621165,5245,N,BAO_0000219,1,,,,A-431,80852
5020,0,Cercopithecidae,Half-life period in cynomolgus monkey,A,9527.0,,,,CHEMBL619159,5922,U,BAO_0000019,1,,,,,22224
5021,0,Cercopithecidae,"In vitro half life at 1.5 -5.6ug/mL, 37 degree C in monkey plasma",A,9527.0,Plasma,,,CHEMBL619160,1116,U,BAO_0000366,1,1969.0,In vitro,,,22224
5022,0,Cercopithecidae,Longer half-life in monkey (i.v.) at 0.5 mpk,A,9527.0,,,,CHEMBL619161,17853,U,BAO_0000218,1,,In vivo,,,22224
5023,0,Cercopithecidae,Plasma half life in monkey,A,9527.0,Plasma,,,CHEMBL619162,993,U,BAO_0000366,1,1969.0,,,,22224
5024,0,Cercopithecidae,Plasma half-life in rhesus monkey,A,9527.0,Plasma,,,CHEMBL619163,4514,U,BAO_0000366,1,1969.0,,,,22224
5025,0,Cercopithecidae,Plasma half-life period (0-8 h) was reported after intravenous administration at a dose of 1 mg/kg in Rhesus monkey (male),A,9527.0,Plasma,,,CHEMBL619164,5334,U,BAO_0000218,1,1969.0,In vivo,,,22224
5026,0,Cercopithecidae,Plasma half-life period (0-8 h) was reported after oral administration at a dose of 2 mg/kg in Rhesus monkey (male),A,9527.0,Plasma,,,CHEMBL619320,5334,U,BAO_0000218,1,1969.0,In vivo,,,22224
5027,0,Cercopithecidae,Tested for half life upon iv administration to african green monkey,A,9527.0,,,,CHEMBL619321,4578,U,BAO_0000218,1,,In vivo,,,22224
5028,0,Cercopithecidae,Compound was evaluated for maximum time to reach Cmax after treatment with oral dose of 2 mgkg to female cynomolgus monkey,A,9527.0,,,,CHEMBL873336,2661,U,BAO_0000218,1,,In vivo,,,22224
5029,0,Cercopithecidae,The time for peak concentration value after intravenous administration in cynomolgus monkeys; NA means Not applicable,A,9527.0,,,,CHEMBL619322,5355,U,BAO_0000218,1,,In vivo,,,22224
5030,0,Cercopithecidae,The time for peak concentration value after intravenous administration in cynomolgus monkeys; NA means not applicable,A,9527.0,,,,CHEMBL619323,5355,U,BAO_0000218,1,,In vivo,,,22224
5031,0,Cercopithecidae,The time for peak concentration value after oral administration in cynomolgus monkeys,A,9527.0,,,,CHEMBL619324,5355,U,BAO_0000218,1,,In vivo,,,22224
5032,0,Cercopithecidae,Percentage of tracer or metabolite (CO2) in baboon plasma at 10 min after injection of the compound,A,9527.0,,,,CHEMBL619325,11271,U,BAO_0000019,1,,,,,22224
5033,0,Cercopithecidae,Percentage of tracer or metabolite (CO2) in baboon plasma at 1 min after injection of the compound,A,9527.0,,,,CHEMBL876411,11271,U,BAO_0000019,1,,,,,22224
5034,0,Cercopithecidae,Percentage of tracer or metabolite (CO2) in baboon plasma at 30 min after injection of the compound,A,9527.0,,,,CHEMBL619326,11271,U,BAO_0000019,1,,,,,22224
5035,0,Cercopithecidae,Percentage of tracer or metabolite (CO2) in baboon plasma at 5 min after injection of the compound,A,9527.0,,,,CHEMBL619327,11271,U,BAO_0000019,1,,,,,22224
5036,0,Cercopithecidae,Percentage of tracer or metabolite(EME) in baboon plasma at 10 min after injection of the compound,A,9527.0,,,,CHEMBL619328,11271,U,BAO_0000019,1,,,,,22224
5037,0,Cercopithecidae,Percentage of tracer or metabolite(EME) in baboon plasma at 1 min after injection of the compound,A,9527.0,,,,CHEMBL619329,11271,U,BAO_0000019,1,,,,,22224
5038,0,Cercopithecidae,Percentage of tracer or metabolite(EME) in baboon plasma at 30 min after injection of the compound,A,9527.0,,,,CHEMBL619330,11271,U,BAO_0000019,1,,,,,22224
5039,0,Cercopithecidae,Percentage of tracer or metabolite(EME) in baboon plasma at 5 min after injection of the compound,A,9527.0,,,,CHEMBL619331,11271,U,BAO_0000019,1,,,,,22224
5040,0,Cercopithecidae,Percentage of tracer or metabolite (acid metabolites) in baboon plasma at 10 min after injection of the compound,A,9527.0,,,,CHEMBL619332,11271,U,BAO_0000019,1,,,,,22224
5041,0,Cercopithecidae,Percentage of tracer or metabolite (acid metabolites) in baboon plasma at 1 min after injection of the compound,A,9527.0,,,,CHEMBL619333,11271,U,BAO_0000019,1,,,,,22224
5042,0,Cercopithecidae,Percentage of tracer or metabolite (acid metabolites) in baboon plasma at 30 min after injection of the compound,A,9527.0,,,,CHEMBL619334,11271,U,BAO_0000019,1,,,,,22224
5043,0,Cercopithecidae,Percentage of tracer or metabolite (acid metabolites) in baboon plasma at 5 min after injection of the compound,A,9527.0,,,,CHEMBL619335,11271,U,BAO_0000019,1,,,,,22224
5044,0,Cercopithecidae,Percentage of tracer or metabolite (unchanged) in baboon plasma at 10 min after injection of the compound,A,9527.0,,,,CHEMBL619336,11271,U,BAO_0000019,1,,,,,22224
5045,0,Cercopithecidae,Percentage of tracer or metabolite (unchanged) in baboon plasma at 1 min after injection of the compound,A,9527.0,,,,CHEMBL619337,11271,U,BAO_0000019,1,,,,,22224
5046,0,Cercopithecidae,Percentage of tracer or metabolite (unchanged) in baboon plasma at 30 min after injection of the compound,A,9527.0,,,,CHEMBL619338,11271,U,BAO_0000019,1,,,,,22224
5047,0,Cercopithecidae,Percentage of tracer or metabolite (unchanged) in baboon plasma at 5 min after injection of the compound,A,9527.0,,,,CHEMBL619339,11271,U,BAO_0000019,1,,,,,22224
5048,1,Rattus norvegicus,Bioavailability in rat (cannulated) (dose 2 mg/kg),A,10116.0,,,,CHEMBL619340,5809,N,BAO_0000218,1,,In vivo,,,50597
5049,1,Rattus norvegicus,Half life at a dose of 4 mg/kg in Rat Plasma after iv administration,A,10116.0,Plasma,,,CHEMBL873496,17720,N,BAO_0000218,1,1969.0,In vivo,,,50597
5050,1,Rattus norvegicus,AUC value in rat after IV administration at a dose of 10 mg/kg,A,10116.0,Plasma,,,CHEMBL619341,3546,N,BAO_0000218,1,1969.0,,,,50597
5051,1,Rattus norvegicus,AUC value in rat after oral administration at a dose of 10 mg/kg,A,10116.0,Plasma,,,CHEMBL619342,3546,N,BAO_0000218,1,1969.0,,,,50597
5052,1,Rattus norvegicus,Cmax value in rat after oral administration at a dose of 10 mg/kg,A,10116.0,,,,CHEMBL619343,3546,N,BAO_0000218,1,,In vivo,,,50597
5053,1,Rattus norvegicus,Bioavailability in rat after oral administration at a dose of 10 mg/kg,A,10116.0,,,,CHEMBL619344,3546,N,BAO_0000218,1,,In vivo,,,50597
5054,1,Rattus norvegicus,Tmax value in rat after oral administration at a dose of 10 mg/kg,A,10116.0,,,,CHEMBL619345,3546,N,BAO_0000218,1,,In vivo,,,50597
5055,1,Rattus norvegicus,Vc value in rat after IV administration at a dose of 10 mg/kg,A,10116.0,,,,CHEMBL619346,3546,N,BAO_0000218,1,,,,,50597
5056,1,Rattus norvegicus,Half life period in rat after IV administration at a dose of 10 mg/kg,A,10116.0,,,,CHEMBL619347,3546,N,BAO_0000218,1,,In vivo,,,50597
5057,0,Papio hamadryas,The absolute striatal uptake of the carbon-11 labeled compound at 60 min was determined in baboon,A,9557.0,,,,CHEMBL619348,10625,U,BAO_0000019,1,,,,,22224
5058,0,Papio hamadryas,Peak plasma radioactivity for the carbon-11 labeled compound was determined at 0.5 min after injection in baboon; (Range = 0.08-0.11),A,9557.0,,,,CHEMBL619349,10625,U,BAO_0000019,1,,,,,22224
5059,0,Papio hamadryas,Peak plasma radioactivity for the carbon-11 labeled compound was determined at 1.5 min after injection in baboon; (Range = 0.08-0.11),A,9557.0,,,,CHEMBL619350,10625,U,BAO_0000019,1,,,,,22224
5060,0,Papio hamadryas,The amount of unchanged tracer in baboon plasma was determined 1 min after injection of the carbon-11 labeled compound,A,9557.0,,,,CHEMBL619351,10625,U,BAO_0000019,1,,,,,22224
5061,0,Papio hamadryas,The amount of unchanged tracer in baboon plasma was determined 10 min after injection of the carbon-11 labeled compound,A,9557.0,,,,CHEMBL875953,10625,U,BAO_0000019,1,,,,,22224
5062,0,Papio hamadryas,The amount of unchanged tracer in baboon plasma was determined 30 min after injection of the carbon-11 labeled compound,A,9557.0,,,,CHEMBL621716,10625,U,BAO_0000019,1,,,,,22224
5063,0,Papio hamadryas,The amount of unchanged tracer in baboon plasma was determined 60 min after injection of the carbon-11 labeled compound,A,9557.0,,,,CHEMBL621717,10625,U,BAO_0000019,1,,,,,22224
5064,0,Papio hamadryas,The absolute striatal uptake of the carbon-11 labeled compound at 60 min was determined in baboon,A,9557.0,,,,CHEMBL621718,10625,U,BAO_0000019,1,,,,,22224
5065,0,beagle,Area under curve after 1 mpk peroral administration to beagles,A,9615.0,,,,CHEMBL621719,3510,U,BAO_0000019,1,,,,,22224
5066,0,beagle,Area under curve after 2 mpk peroral administration to beagles,A,9615.0,,,,CHEMBL621720,3510,U,BAO_0000019,1,,,,,22224
5067,0,beagle,Cmax value after 1 mpk peroral administration to beagles,A,9615.0,,,,CHEMBL621721,3510,U,BAO_0000218,1,,In vivo,,,22224
5068,0,Homo sapiens,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 1200 mL of urine tested on day 7,A,9606.0,Urine,,,CHEMBL621722,7766,U,BAO_0000019,1,1088.0,,,,22224
5069,0,Homo sapiens,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 1300 mL of urine tested on day 6,A,9606.0,Urine,,,CHEMBL621723,7766,U,BAO_0000019,1,1088.0,,,,22224
5070,0,Homo sapiens,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 1300 mL of urine tested on day 8,A,9606.0,Urine,,,CHEMBL621724,7766,U,BAO_0000019,1,1088.0,,,,22224
5071,0,Homo sapiens,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 1500 mL of urine tested on day 9,A,9606.0,Urine,,,CHEMBL623443,7766,U,BAO_0000019,1,1088.0,,,,22224
5072,0,Homo sapiens,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 1600 mL of urine tested on day 10,A,9606.0,Urine,,,CHEMBL623444,7766,U,BAO_0000019,1,1088.0,,,,22224
5073,0,Homo sapiens,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 1700 mL of urine tested on day 5,A,9606.0,Urine,,,CHEMBL623445,7766,U,BAO_0000019,1,1088.0,,,,22224
5074,0,Homo sapiens,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 2310 mL of urine tested on day 4,A,9606.0,Urine,,,CHEMBL623446,7766,U,BAO_0000019,1,1088.0,,,,22224
5075,0,Homo sapiens,Metabolic stability observed at 30 min after administration in human liver microsomes,A,9606.0,Liver,Microsomes,,CHEMBL623447,16643,U,BAO_0000251,1,2107.0,,,,22224
5076,0,Homo sapiens,Percent recovery of 100 ug/mL compound after administration in cirrhotic patients,A,9606.0,,,,CHEMBL623448,6852,U,BAO_0000019,1,,,,,22224
5077,0,Homo sapiens,Percent recovery of 10 ug/mL compound after administration in cirrhotic patients,A,9606.0,,,,CHEMBL623449,6852,U,BAO_0000019,1,,,,,22224
5078,0,Homo sapiens,Percent recovery of 500 ug/mL compound after administration in cirrhotic patients,A,9606.0,,,,CHEMBL623450,6852,U,BAO_0000019,1,,,,,22224
5079,0,Homo sapiens,"Compound remaining after incubation with 2 mg/mL of human liver microsomes at 37 degrees C for 30 min in a pH 7.4, 0.05 M phosphate buffer",A,9606.0,Liver,Microsomes,,CHEMBL623451,6567,U,BAO_0000251,1,2107.0,,,,22224
5080,0,Homo sapiens,Metabolic stability (% remaining at 30 mins) in human S9.,A,9606.0,,,,CHEMBL623452,6570,U,BAO_0000019,1,,,,,22224
5081,0,Homo sapiens,Metabolic stability determined as remaining percent after 30 min of incubation in human isolated liver S9 preparations; N/D= Not determined,A,9606.0,,,,CHEMBL623453,6570,U,BAO_0000019,1,,,,,22224
5082,0,Homo sapiens,Percent parent compound remaining after 20 min incubation with human liver microsomes,A,9606.0,Liver,Microsomes,,CHEMBL623454,5237,U,BAO_0000251,1,2107.0,,,,22224
5083,0,Homo sapiens,Percent parent compound remaining after 20 min incubation with human liver microsomes; ND=No data,A,9606.0,Liver,Microsomes,,CHEMBL623455,5237,U,BAO_0000251,1,2107.0,,,,22224
5084,0,Homo sapiens,Percent parent compound remaining after 20 min incubation with human liver microsomes; No data,A,9606.0,Liver,Microsomes,,CHEMBL624371,5237,U,BAO_0000251,1,2107.0,,,,22224
5085,0,Homo sapiens,First pass metabolism and metabolic bioavailability using human hepatic microsomes,A,9606.0,,,,CHEMBL624372,5202,U,BAO_0000218,1,,,,,22224
5086,0,Homo sapiens,Percent compound remaining in human plasma after incubation for 60 min at 37 C.,A,9606.0,,,,CHEMBL624373,5481,U,BAO_0000019,1,,,,,22224
5087,0,Homo sapiens,Percent remaining in human plasma after incubation for 60 min at 37 C.,A,9606.0,,,,CHEMBL624374,5481,U,BAO_0000019,1,,,,,22224
5088,0,Homo sapiens,The percent remaining in human plasma after 30 min was determined,A,9606.0,,,,CHEMBL624556,3956,U,BAO_0000019,1,,,,,22224
5089,0,Homo sapiens,Conversion rate of the prodrug in human plasma,A,9606.0,Plasma,,,CHEMBL624557,5074,U,BAO_0000366,1,1969.0,,,,22224
5090,0,Homo sapiens,Conversion rate of the prodrug in human plasma; ND means no data,A,9606.0,Plasma,,,CHEMBL624558,5074,U,BAO_0000366,1,1969.0,,,,22224
5091,0,Homo sapiens,Half life of compound was determined in human blood,A,9606.0,Blood,,,CHEMBL624559,4727,U,BAO_0000221,1,178.0,,,,22224
5092,0,Homo sapiens,Half life of compound was determined in man with once daily dosing,A,9606.0,,,,CHEMBL624560,5965,U,BAO_0000019,1,,,,,22224
5093,0,Homo sapiens,Half life in human microsomes,A,9606.0,,Microsomes,,CHEMBL624561,5732,U,BAO_0000251,1,,In vitro,,,22224
5094,0,Homo sapiens,Half life in human plasma,A,9606.0,Plasma,,,CHEMBL624562,5819,U,BAO_0000366,1,1969.0,,,,22224
5095,0,Homo sapiens,Half life in human plasma; Not detected,A,9606.0,Plasma,,,CHEMBL624563,5819,U,BAO_0000366,1,1969.0,,,,22224
5096,0,Homo sapiens,Half life period was evaluated against man at a dose of 10 mg/kg after po administration,A,9606.0,,,,CHEMBL624564,1916,U,BAO_0000218,1,,In vivo,,,22224
5097,0,Homo sapiens,Half-life for oxidative metabolic stability was determined using rat liver microsomes,A,9606.0,Liver,Microsomes,,CHEMBL624565,6597,U,BAO_0000251,1,2107.0,In vitro,,,22224
5098,0,Homo sapiens,Half-life in human plasma,A,9606.0,Plasma,,,CHEMBL875152,5229,U,BAO_0000366,1,1969.0,,,,22224
5099,0,Homo sapiens,Half-life of the parent prodrug in plasma,A,9606.0,Plasma,,,CHEMBL624566,5229,U,BAO_0000366,1,1969.0,,,,22224
5100,0,Homo sapiens,In vitro half life in human plasma was determined,A,9606.0,Plasma,,,CHEMBL873805,2192,U,BAO_0000366,1,1969.0,In vitro,,,22224
5101,0,Homo sapiens,The compound was tested In Vitro for half life in human liver microsomes.,A,9606.0,Liver,Microsomes,,CHEMBL624567,3032,U,BAO_0000251,1,2107.0,In vitro,,,22224
5102,0,Homo sapiens,Maximum time was evaluated against man at a dose of 10 mg/kg after po administration,A,9606.0,,,,CHEMBL624568,1916,U,BAO_0000218,1,,In vivo,,,22224
5103,0,Homo sapiens,Observed volume of distribution,A,9606.0,,,,CHEMBL624569,17716,U,BAO_0000218,1,,In vivo,,,22224
5104,0,Homo sapiens,Oral bioavailability in human,A,9606.0,,,,CHEMBL624570,15778,U,BAO_0000218,1,,In vivo,,,22224
5105,0,Homo sapiens,Tested for human plasma protein binding of the compound,A,9606.0,,,,CHEMBL624571,17313,U,BAO_0000019,1,,,,,22224
5106,0,Homo sapiens,"First order rate constant, k was determined in human plasma",A,9606.0,,,,CHEMBL624572,4231,U,BAO_0000019,1,,,,,22224
5107,0,Homo sapiens,Observed rate constant in 80% human plasma at 37 degree Centigrade,A,9606.0,,,,CHEMBL624573,4755,U,BAO_0000019,1,,,,,22224
5108,0,Homo sapiens,Observed rate constant in 80% human plasma at 37 degree Centigrade,A,9606.0,,,,CHEMBL875153,4755,U,BAO_0000019,1,,,,,22224
5109,0,Homo sapiens,Loss of compound (%metabolized) after 30 min exposure to human liver microsomes,A,9606.0,Liver,Microsomes,,CHEMBL624574,16907,U,BAO_0000251,1,2107.0,,,,22224
5110,0,Homo sapiens,The compound was tested for the plasma binding in human,A,9606.0,,,,CHEMBL624575,10839,U,BAO_0000019,1,,,,,22224
5111,0,Homo sapiens,Plasma protein binding (human),A,9606.0,,,,CHEMBL624576,10839,U,BAO_0000019,1,,,,,22224
5112,0,Homo sapiens,Compound was evaluated for half-life in human liver microsomes,A,9606.0,Liver,Microsomes,,CHEMBL624577,3199,U,BAO_0000251,1,2107.0,In vitro,,,22224
5113,0,Homo sapiens,Half life measured in vitro for its stability in human blood,A,9606.0,Blood,,,CHEMBL624578,1345,U,BAO_0000221,1,178.0,In vitro,,,22224
5114,0,Homo sapiens,Half life in human serum,A,9606.0,Serum,,,CHEMBL622796,4297,U,BAO_0000019,1,1977.0,,,,22224
5115,0,Homo sapiens,Half life in human serum; ND=not determined,A,9606.0,Serum,,,CHEMBL622797,4297,U,BAO_0000019,1,1977.0,,,,22224
5116,0,Homo sapiens,Half life were determined in CEM-SS cell extract in decomposition step 1,A,9606.0,,,,CHEMBL622798,4297,U,BAO_0000019,1,,,,,22224
5117,0,Homo sapiens,Half life were determined in CEM-SS cell extract in decomposition step 2,A,9606.0,,,,CHEMBL622799,4297,U,BAO_0000019,1,,,,,22224
5118,0,Homo sapiens,Half life of the in human plasma,A,9606.0,Plasma,,,CHEMBL622800,4231,U,BAO_0000366,1,1969.0,,,,22224
5119,0,Homo sapiens,Half life period in human hepatic S9 fraction was determined,A,9606.0,,S9,,CHEMBL622801,5633,U,BAO_0000220,1,,In vitro,,,22224
5120,0,Homo sapiens,Half life period in human liver microsome was determined,A,9606.0,Liver,Microsomes,,CHEMBL622802,5633,U,BAO_0000251,1,2107.0,In vitro,,,22224
5121,0,Homo sapiens,Half life period was determined; 6-7,A,9606.0,,,,CHEMBL622803,17791,U,BAO_0000019,1,,,,,22224
5122,0,Homo sapiens,Half life period was evaluated in human,A,9606.0,,,,CHEMBL875154,17791,U,BAO_0000019,1,,,,,22224
5123,0,Homo sapiens,Half life time in human plasma,A,9606.0,Plasma,,,CHEMBL622804,3160,U,BAO_0000366,1,1969.0,,,,22224
5124,1,Mus musculus,"Biodistribution in mice as total concentration of both oxidized and reduced forms in brain tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",A,10090.0,Brain,,,CHEMBL622805,16438,N,BAO_0000218,1,955.0,In vivo,,,50594
5125,1,Mus musculus,"Biodistribution in mice as total concentration of both oxidized and reduced forms in heart tissues, animals were sacrificed 10 minutes after dosing, in DMSO sol.",A,10090.0,Heart,,,CHEMBL622611,16438,N,BAO_0000218,1,948.0,In vivo,,,50594
5126,1,Mus musculus,"Biodistribution in mice as total concentration of both oxidized and reduced forms in heart tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",A,10090.0,Heart,,,CHEMBL622612,16438,N,BAO_0000218,1,948.0,In vivo,,,50594
5127,1,Mus musculus,"Biodistribution in mice as total concentration of both oxidized and reduced forms in kidney and animals were sacrificed 10 minutes after dosing, in DMSO sol.",A,10090.0,Kidney,,,CHEMBL875160,16438,N,BAO_0000218,1,2113.0,In vivo,,,50594
5128,1,Mus musculus,"Biodistribution in mice as total concentration of both oxidized and reduced forms in kidney and animals were sacrificed 10 minutes after ip dosing, in DMSO solution",A,10090.0,Kidney,,,CHEMBL622613,16438,N,BAO_0000218,1,2113.0,In vivo,,,50594
5129,1,Mus musculus,"Biodistribution in mice as total concentration of both oxidized and reduced forms in kidney tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",A,10090.0,Kidney,,,CHEMBL622614,16438,N,BAO_0000218,1,2113.0,In vivo,,,50594
5130,1,Mus musculus,"Biodistribution in mice as total concentration of both oxidized and reduced forms in liver and animals were sacrificed 10 minutes after dosing, in DMSO sol.",A,10090.0,Liver,,,CHEMBL622615,16438,N,BAO_0000218,1,2107.0,In vivo,,,50594
5131,1,Mus musculus,Biodistribution in mice as total concentration of both oxidized and reduced forms in liver and animals were sacrificed 10 minutes after ip administration in DMSO solution,A,10090.0,Liver,,,CHEMBL622616,16438,N,BAO_0000218,1,2107.0,In vivo,,,50594
5132,1,Mus musculus,"Biodistribution in mice as total concentration of both oxidized and reduced forms in liver tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",A,10090.0,Liver,,,CHEMBL622617,16438,N,BAO_0000218,1,2107.0,In vivo,,,50594
5133,1,Mus musculus,Biodistribution in mice as total concentration of both oxidized and reduced forms in spleen and animals were sacrificed 10 minutes after ip administration in DMSO solution,A,10090.0,Spleen,,,CHEMBL622618,16438,N,BAO_0000218,1,2106.0,In vivo,,,50594
5134,1,Mus musculus,"Biodistribution in mice as total concentration of both oxidized and reduced forms in spleen and animals were sacrificed 10 minutes after ip dosing, in DMSO solution",A,10090.0,Spleen,,,CHEMBL622619,16438,N,BAO_0000218,1,2106.0,In vivo,,,50594
5135,1,Mus musculus,"Biodistribution in mice as total concentration of both oxidized and reduced forms in spleen tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",A,10090.0,Spleen,,,CHEMBL622620,16438,N,BAO_0000218,1,2106.0,In vivo,,,50594
5136,1,Mus musculus,"Biodistribution in mice, total concentration of both oxidized and reduced forms in brain tissues, animals were sacrificed 60 minutes after dosing, in DMSO",A,10090.0,Brain,,,CHEMBL622621,16438,N,BAO_0000218,1,955.0,In vivo,,,50594
5137,1,Mus musculus,Biodistribution of compound (oxidized form) in blood tissue,A,10090.0,Blood,,,CHEMBL622622,16438,N,BAO_0000218,1,178.0,In vivo,,,50594
5138,1,Mus musculus,"Biodistribution of compound (oxidized form) in blood tissue, animals were sacrificed 10 minutes after dosing, in DMSO sol.",A,10090.0,Blood,,,CHEMBL622623,16438,N,BAO_0000218,1,178.0,In vivo,,,50594
5139,1,Mus musculus,"Biodistribution of compound (oxidized form) in blood tissue, animals were sacrificed 10 minutes after dosing, in DMSO solution",A,10090.0,Blood,,,CHEMBL622624,16438,N,BAO_0000218,1,178.0,In vivo,,,50594
5140,1,Mus musculus,"Biodistribution of compound (oxidized form) in blood tissues, animals were sacrificed 60 minutes after dosing, in DMSO",A,10090.0,Blood,,,CHEMBL622625,16438,N,BAO_0000218,1,178.0,In vivo,,,50594
5141,1,Mus musculus,"Biodistribution of compound (oxidized form) in blood tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",A,10090.0,Blood,,,CHEMBL622626,16438,N,BAO_0000218,1,178.0,In vivo,,,50594
5142,1,Mus musculus,"Biodistribution of compound (oxidized form) in blood tissues, animals were sacrificed 60 minutes after dosing, in DMSO solution",A,10090.0,Blood,,,CHEMBL622627,16438,N,BAO_0000218,1,178.0,In vivo,,,50594
5143,1,Mus musculus,Biodistribution of compound (oxidized form) in brain tissue of mice,A,10090.0,Brain,,,CHEMBL622628,16438,N,BAO_0000218,1,955.0,In vivo,,,50594
5144,1,Mus musculus,"Biodistribution of compound (oxidized form) in brain tissue, animals were sacrificed 10 minutes after dosing, in DMSO sol.",A,10090.0,Brain,,,CHEMBL622629,16438,N,BAO_0000218,1,955.0,In vivo,,,50594
5145,1,Mus musculus,"Biodistribution of compound (oxidized form) in brain tissue, animals were sacrificed 60 minutes after dosing, in DMSO",A,10090.0,Brain,,,CHEMBL622630,16438,N,BAO_0000218,1,955.0,In vivo,,,50594
5146,1,Mus musculus,"Biodistribution of compound (oxidized form) in brain tissue, animals were sacrificed 60 minutes after dosing, in DMSO sol.",A,10090.0,Brain,,,CHEMBL622631,16438,N,BAO_0000218,1,955.0,In vivo,,,50594
5147,1,Mus musculus,"Biodistribution of compound (oxidized form) in brain tissue, animals were sacrificed 60 minutes after dosing, in DMSO solution",A,10090.0,Brain,,,CHEMBL622632,16438,N,BAO_0000218,1,955.0,In vivo,,,50594
5148,1,Mus musculus,"Biodistribution of compound (oxidized form) in brain tissues, animals were sacrificed 10 minutes after dosing, in DMSO solution",A,10090.0,Brain,,,CHEMBL622633,16438,N,BAO_0000218,1,955.0,In vivo,,,50594
5149,1,Mus musculus,Biodistribution of compound (oxidized form) in heart tissue of mice,A,10090.0,Heart,,,CHEMBL622634,16438,N,BAO_0000218,1,948.0,In vivo,,,50594
5150,1,Mus musculus,"Biodistribution of compound (oxidized form) in heart tissue, animals were sacrificed 10 minutes after dosing, in DMSO sol.",A,10090.0,Heart,,,CHEMBL622635,16438,N,BAO_0000218,1,948.0,In vivo,,,50594
5151,1,Mus musculus,"Biodistribution of compound (oxidized form) in heart tissue, animals were sacrificed 10 minutes after dosing, in DMSO sol.",A,10090.0,Heart,,,CHEMBL875161,16438,N,BAO_0000218,1,948.0,In vivo,,,50594
5152,1,Mus musculus,"Biodistribution of compound (oxidized form) in heart tissue, animals were sacrificed 60 minutes after dosing, in DMSO",A,10090.0,Heart,,,CHEMBL622636,16438,N,BAO_0000218,1,948.0,In vivo,,,50594
5153,1,Mus musculus,"Biodistribution of compound (oxidized form) in heart tissue, animals were sacrificed 60 minutes after dosing, in DMSO sol.",A,10090.0,Heart,,,CHEMBL623335,16438,N,BAO_0000218,1,948.0,In vivo,,,50594
5154,1,Mus musculus,"Biodistribution of compound (oxidized form) in heart tissue, animals were sacrificed 60 minutes after dosing, in DMSO solution",A,10090.0,Heart,,,CHEMBL623336,16438,N,BAO_0000218,1,948.0,In vivo,,,50594
5155,1,Mus musculus,"Biodistribution of compound (oxidized form) in kidney tissue, animals were sacrificed 10 minutes after dosing, in DMSO sol.",A,10090.0,Kidney,,,CHEMBL623337,16438,N,BAO_0000218,1,2113.0,In vivo,,,50594
5156,1,Mus musculus,"Biodistribution of compound (oxidized form) in kidney tissue, animals were sacrificed 10 minutes after dosing, in DMSO solution",A,10090.0,Kidney,,,CHEMBL623338,16438,N,BAO_0000218,1,2113.0,In vivo,,,50594
5157,1,Mus musculus,"Biodistribution of compound (oxidized form) in kidney tissue, animals were sacrificed 60 minutes after dosing, in DMSO",A,10090.0,Kidney,,,CHEMBL623339,16438,N,BAO_0000218,1,2113.0,In vivo,,,50594
5158,1,Mus musculus,"Biodistribution of compound (oxidized form) in kidney tissue, animals were sacrificed 60 minutes after dosing, in DMSO sol.",A,10090.0,Kidney,,,CHEMBL623524,16438,N,BAO_0000218,1,2113.0,In vivo,,,50594
5159,1,Mus musculus,"Biodistribution of compound (oxidized form) in kidney tissue, animals were sacrificed 60 minutes after dosing, in DMSO solution",A,10090.0,Kidney,,,CHEMBL623525,16438,N,BAO_0000218,1,2113.0,In vivo,,,50594
5160,1,Mus musculus,Biodistribution of compound (oxidized form) in liver tissue,A,10090.0,Liver,,,CHEMBL623526,16438,N,BAO_0000218,1,2107.0,In vivo,,,50594
5161,1,Mus musculus,"Biodistribution of compound (oxidized form) in liver tissue, animals were sacrificed 10 minutes after dosing, in DMSO sol.",A,10090.0,Liver,,,CHEMBL623527,16438,N,BAO_0000218,1,2107.0,In vivo,,,50594
5162,1,Mus musculus,"Biodistribution of compound (oxidized form) in liver tissues, animals were sacrificed 60 minutes after dosing, in DMSO",A,10090.0,Liver,,,CHEMBL623528,16438,N,BAO_0000218,1,2107.0,In vivo,,,50594
5163,1,Homo sapiens,Cell viability in A431 cells when stimulated with EGF was tested when incubated with concentration in the range of 1-10 uM of the compound after 48 h; Cell death,F,9606.0,,,,CHEMBL624615,5245,N,BAO_0000219,1,,,,A-431,80852
5164,1,Homo sapiens,Cell viability in A431 cells when stimulated with EGF was tested when incubated with concentration up to 10 uM after 48 h; Did not affect the viability,F,9606.0,,,,CHEMBL621672,5245,N,BAO_0000219,1,,,,A-431,80852
5165,1,,"In vivo activity in A431 tumor bearing mice, maximum dose (schedule 10-24 days)",F,,,,,CHEMBL621673,16289,N,BAO_0000218,1,,,,A-431,80852
5166,1,,"In vivo activity in A431 tumor bearing mice, maximum dose (schedule 12-26 days)",F,,,,,CHEMBL621674,16289,N,BAO_0000218,1,,,,A-431,80852
5167,9,Homo sapiens,Inhibition of EGF-induced Tyrosine phosphorylation in A431 cells expressing EGF-R,F,9606.0,,,,CHEMBL884002,16093,D,BAO_0000219,1,,,,A-431,9
5168,1,Homo sapiens,"Concentration required to inhibit the epidermoid A431 cell growth by 50%, P53 status of cell line used was wild-type. ",F,9606.0,,,,CHEMBL621850,16825,N,BAO_0000219,1,,,,A-431,80852
5169,1,Homo sapiens,Inhibitory activity against proliferation of human epidermoid carcinoma (A431) cells,F,9606.0,,,,CHEMBL621851,4848,N,BAO_0000219,1,,,,A-431,80852
5170,9,Homo sapiens,Inhibition of EGF-dependent autophosphorylation of EGF-R in A431 cells,F,9606.0,,,,CHEMBL621852,14827,D,BAO_0000219,1,,,,A-431,9
5171,9,Homo sapiens,Inhibition of autophosphorylation of epidermal growth factor receptor in A431 cells in culture,F,9606.0,,,,CHEMBL621853,14827,D,BAO_0000219,1,,,,A-431,9
5172,1,,"In vivo activity in A431 tumor bearing mice, relative time required for treated and control tumors to reach 750 mg (schedule 10-24 days)",F,,,,,CHEMBL621854,16289,N,BAO_0000218,1,,,,A-431,80852
5173,1,,"In vivo activity in A431 tumor bearing mice, relative time required for treated and control tumors to reach 750 mg (schedule 12-26 days)",F,,,,,CHEMBL621855,16289,N,BAO_0000218,1,,,,A-431,80852
5174,1,,"In vivo activity in A431 tumor bearing mice, relative time required for treated and control tumors to reach 750 mg (schedule 12-26 days)",F,,,,,CHEMBL623724,16289,N,BAO_0000218,1,,,,A-431,80852
5175,1,,"In vivo activity in A431 tumor bearing mice, ratio of treated and control tumor mass day 24",F,,,,,CHEMBL623725,16289,N,BAO_0000218,1,,,,A-431,80852
5176,1,,"In vivo activity in A431 tumor bearing mice, ratio of treated and control tumor mass day 26",F,,,,,CHEMBL623726,16289,N,BAO_0000218,1,,,,A-431,80852
5177,9,Homo sapiens,"Irreversible inhibition of EGF-R phosphorylation in A431 cells, 8 hr after washing cells free of compound",F,9606.0,,,,CHEMBL623727,16289,D,BAO_0000219,1,,,,A-431,9
5178,8,,Irreversible inhibition of formation of phosphorylated EGFR in A431 cells 8 hr after washing cells free of compound,F,,,,,CHEMBL623728,16289,H,BAO_0000219,1,,,,A-431,9
5179,1,,"In vivo activity in A431 tumor bearing mice, maximum weight loss days 10-24",F,,,,,CHEMBL623729,16289,N,BAO_0000218,1,,,,A-431,80852
5180,1,,"In vivo activity in A431 tumor bearing mice, maximum weight loss days 12-26",F,,,,,CHEMBL623730,16289,N,BAO_0000218,1,,,,A-431,80852
5181,1,,"In vivo activity in A431 tumor bearing mice, maximum weight loss days 12-26",F,,,,,CHEMBL623731,16289,N,BAO_0000218,1,,,,A-431,80852
5182,1,Mus musculus,"Ratio of treated and control A431 cell tumor mass in mice at 5 mg/kg peroral dose, days 7-21 administration",F,10090.0,,,,CHEMBL623732,14555,N,BAO_0000218,1,,,,A-431,80852
5183,1,Mus musculus,"Difference in days for treated (T) and control (C) A431 cell tumors to reach 750 mg in mice at 5 mg/kg peroral dose, days 7-21 administration",F,10090.0,,,,CHEMBL623733,14555,N,BAO_0000218,1,,,,A-431,80852
5184,1,Mus musculus,"Net reduction in tumor burden between first and last treatments of A431 cell tumors in mice at 5 mg/kg peroral dose, days 7-21 administration",F,10090.0,,,,CHEMBL623734,14555,N,BAO_0000218,1,,,,A-431,80852
5185,1,Mus musculus,"Weight change of A431 cell tumors in mice at 5 mg/kg peroral dose, days 7-21 administration",F,10090.0,,,,CHEMBL623735,14555,N,BAO_0000218,1,,,,A-431,80852
5186,1,Homo sapiens,In vitro antiproliferative effect against A431 human epidermoid carcinoma cells,F,9606.0,,,,CHEMBL623736,1937,N,BAO_0000219,1,,,,A-431,80852
5187,1,Homo sapiens,In vitro tumor cell growth inhibitory activity against Human leiomyosarcoma A431 cell lines,F,9606.0,,,,CHEMBL623737,13739,N,BAO_0000219,1,,,,A-431,80852
5188,1,Homo sapiens,Cytotoxicity against A437 cells is the dose giving 50% decrease in the formation of formazan dye,F,9606.0,,,,CHEMBL623738,3558,N,BAO_0000219,1,,,,A-431,80852
5189,1,Homo sapiens,Dose giving a 50% decrease in the living cell number (A437 cells),F,9606.0,,,,CHEMBL875168,3558,N,BAO_0000219,1,,,,A-431,80852
5190,1,Homo sapiens,In vitro inhibitory concentration against proliferation of A459 cell line.,F,9606.0,,,,CHEMBL623739,17686,N,BAO_0000219,1,,,,A549,80682
5191,1,Homo sapiens,Inhibitory concentration of compound for cytotoxicity against A459 human lung cells was determined,F,9606.0,,,,CHEMBL623740,5305,N,BAO_0000219,1,,,,A549,80682
5192,1,Homo sapiens,Inhibition of growth of human NSCL non small cell lung carcinoma cell line (A459) after 72 hr of drug exposure,F,9606.0,,,,CHEMBL624424,3614,N,BAO_0000219,1,,,,A549,80682
5193,1,Homo sapiens,In vitro antitumor activity against renal A498 tumor cell lines,F,9606.0,,,,CHEMBL624425,17229,N,BAO_0000219,1,,,,A498,80021
5194,1,Homo sapiens,"In vitro growth inhibition of human kidney carcinoma cell line, A498 with low levels of folate receptors",F,9606.0,,,,CHEMBL624426,15935,N,BAO_0000219,1,,,,A498,80021
5195,1,Homo sapiens,"In vitro growth inhibition of human kidney carcinoma cell line, A498 with low levels of folate receptors in folate deficient medium",F,9606.0,,,,CHEMBL624427,15935,N,BAO_0000219,1,,,,A498,80021
5196,1,Homo sapiens,Cytotoxicity against A498 Tumor cell line in SRB Cell viability test,F,9606.0,,,,CHEMBL624428,15560,N,BAO_0000219,1,,,,A498,80021
5197,1,Homo sapiens,Cytotoxicity concentration against human kidney carcinoma A-498 cell line,F,9606.0,,,,CHEMBL624429,13891,N,BAO_0000219,1,,,,A498,80021
5198,1,Homo sapiens,Cytotoxicity concentration against human kidney carcinoma A-498 cell line; NT =Not tested,F,9606.0,,,,CHEMBL624620,13891,N,BAO_0000219,1,,,,A498,80021
5199,1,Homo sapiens,Cytotoxicity on kidney carcinoma (A-498) cell line,F,9606.0,,,,CHEMBL624621,13788,N,BAO_0000219,1,,,,A498,80021
5200,1,Homo sapiens,Compound was evaluated against Human cell line renal A498,F,9606.0,,,,CHEMBL624622,15403,N,BAO_0000219,1,,,,A498,80021
5201,1,Homo sapiens,Compound was tested for inhibition of A498 human renal cancer cell line,F,9606.0,,,,CHEMBL624623,1009,N,BAO_0000219,1,,,,A498,80021
5202,1,Homo sapiens,Growth inhibitory activity against A498 human cancer cell line,F,9606.0,,,,CHEMBL874365,1043,N,BAO_0000219,1,,,,A498,80021
5203,1,Homo sapiens,In vitro antitumor activity against human renal A498 cell line,F,9606.0,,,,CHEMBL624624,5858,N,BAO_0000219,1,,,,A498,80021
5204,1,Homo sapiens,In vitro cytotoxic activity against renal (A498) cell line,F,9606.0,,,,CHEMBL624625,5958,N,BAO_0000219,1,,,,A498,80021
5205,1,Homo sapiens,In vitro cytotoxic activity against human renal cancer (A498) cell line,F,9606.0,,,,CHEMBL624626,5506,N,BAO_0000219,1,,,,A498,80021
5206,1,Homo sapiens,Tested for cytostatic activity against renal A498 cell line,F,9606.0,,,,CHEMBL624627,12781,N,BAO_0000219,1,,,,A498,80021
5207,1,Homo sapiens,The compound was tested for the concentration to inhibit 50% of renal A498 cell lines.,F,9606.0,,,,CHEMBL883157,14399,N,BAO_0000219,1,,,,A498,80021
5208,1,Homo sapiens,In vitro cytotoxic activity against renal (A498) cell line at a concentration of 10e-5 M,F,9606.0,,,,CHEMBL624628,5958,N,BAO_0000219,1,,,,A498,80021
5209,0,beagle,Cmax value after 2 mpk peroral administration to beagles,A,9615.0,,,,CHEMBL624629,3510,U,BAO_0000218,1,,In vivo,,,22224
5210,0,Canis lupus familiaris,Bioavailability,A,9615.0,,,,CHEMBL623551,3510,U,BAO_0000218,1,,In vivo,beagle,,22224
5211,0,Canis lupus familiaris,Bioavailability after 1 mpk peroral administration to beagles,A,9615.0,,,,CHEMBL623552,3510,U,BAO_0000218,1,,In vivo,beagle,,22224
5212,0,Canis lupus familiaris,Bioavailability after 2 mpk peroral administration to beagles,A,9615.0,,,,CHEMBL623553,3510,U,BAO_0000218,1,,In vivo,beagle,,22224
5213,0,Bos taurus,Specificity constant of the BSA-catalyzed deprotonation of compound at pH 9,A,9913.0,,,,CHEMBL623554,3085,U,BAO_0000019,1,,,,,22224
5214,0,Bos taurus,Specificity constant of the bovine serum albumin catalyzed reaction expressed as (kcat/KM)/kuncat,A,9913.0,,,,CHEMBL623555,3085,U,BAO_0000019,1,,,,,22224
5215,0,Bos taurus,Michaelis-Menten kinetics of the bovine serum albumin catalyzed reaction of the compound,A,9913.0,,,,CHEMBL623556,3085,U,BAO_0000019,1,,,,,22224
5216,0,Bos taurus,Solubility against bovine alpha-chymotrypsin,A,9913.0,,,,CHEMBL623557,9372,U,BAO_0000019,1,,,,,22224
5217,0,Bos taurus,Rate constant of the bovine serum albumin catalyzed reaction of the compound,A,9913.0,,,,CHEMBL623558,3085,U,BAO_0000019,1,,,,,22224
5218,0,Bos taurus,Rate constant of the bovine serum albumin catalyzed reaction of the compound,A,9913.0,,,,CHEMBL623559,3085,U,BAO_0000019,1,,,,,22224
5219,0,Bos taurus,Half life (t) of enzymatic phosphodiester hydrolysis of compound towards calf spleen (CS-PDE) at a concentration of 20 microg,A,9913.0,Spleen,,,CHEMBL623560,1469,U,BAO_0000221,1,2106.0,,,,22224
5220,0,Bos taurus,Half life in culture medium containing 10% of heat inactivated foetal calf serum,A,9913.0,,,,CHEMBL623561,4297,U,BAO_0000019,1,,,,,22224
5221,0,Bos taurus,Half life in culture medium containing 10% of heat inactivated foetal calf serum; ND=not determined,A,9913.0,,,,CHEMBL623562,4297,U,BAO_0000019,1,,,,,22224
5222,0,Bos taurus,Ability to get deaminated by adenosine deaminase (ADA); Expressed as t1/2,A,9913.0,,,,CHEMBL623563,17585,U,BAO_0000019,1,,,,,22224
5223,0,Bos taurus,Enzymatic stability was assessed with bovine spleen phosphodiesterase (BS PDE) exonuclase,A,9913.0,Spleen,,,CHEMBL623564,1336,U,BAO_0000221,1,2106.0,,,,22224
5224,0,Bos taurus,Half life in presence of 2 mg/mL BSA at pH 8.8,A,9913.0,,,,CHEMBL873806,3085,U,BAO_0000019,1,,,,,22224
5225,0,Bos taurus,Half-life in RPMI 1640 containing 10% heat inactivated fetal calf serum culture medium at step 1,A,9913.0,,,,CHEMBL623565,2857,U,BAO_0000019,1,,,,,22224
5226,0,Bos taurus,Half-life in RPMI 1640 containing 10% heat inactivated fetal calf serum culture medium at step 2,A,9913.0,,,,CHEMBL623566,2857,U,BAO_0000019,1,,,,,22224
5227,0,Bos taurus,Half-life in RPMI 1640 containing 10% heat inactivated fetal calf serum culture medium at step 2; Not determined,A,9913.0,,,,CHEMBL623567,2857,U,BAO_0000019,1,,,,,22224
5228,0,Bos taurus,Half-life in the culture medium (RPMI 1640+10% fetal calf serum FCS),A,9913.0,,,,CHEMBL623568,1540,U,BAO_0000019,1,,,,,22224
5229,1,Canis lupus familiaris,AUC (Area Under Plasma concentration-time curve) was after oral administration at 5 mg/kg,A,9615.0,Plasma,,,CHEMBL623569,6316,N,BAO_0000218,1,1969.0,,,,50588
5230,1,Canis lupus familiaris,AUC after administration at 100 mg/kg/day in dogs,A,9615.0,Plasma,,,CHEMBL623570,17594,N,BAO_0000218,1,1969.0,,,,50588
5231,1,Canis lupus familiaris,AUC in dog at 0-24 hr by peroral administration at 3 mpk,A,9615.0,Plasma,,,CHEMBL624254,4953,N,BAO_0000218,1,1969.0,,,,50588
5232,1,Canis lupus familiaris,AUC value after 15 mg/kg iv dose in Dogs,A,9615.0,Plasma,,,CHEMBL624255,16907,N,BAO_0000218,1,1969.0,,,,50588
5233,1,Canis lupus familiaris,AUC value after 30 mg/kg po dose in Dogs,A,9615.0,Plasma,,,CHEMBL624256,16907,N,BAO_0000218,1,1969.0,,,,50588
5234,1,Canis lupus familiaris,AUC value after administration of 4 mg/Kg oral dose in dog,A,9615.0,Plasma,,,CHEMBL624257,2959,N,BAO_0000218,1,1969.0,,,,50588
5235,1,Canis lupus familiaris,AUC0-infinity after single intravenous bolus of 1 mg/kg in dogs,A,9615.0,Plasma,,,CHEMBL624258,17594,N,BAO_0000218,1,1969.0,,,,50588
5236,1,Canis lupus familiaris,Area Under Curve for the compound was determined in dogs at 1 mg/kg oral dosing; 25-50 ug min/mL,A,9615.0,,,,CHEMBL875277,5356,N,BAO_0000218,1,,,,,50588
5237,1,Canis lupus familiaris,Area under curve (AUC) value in dogs after an intravenous dose of 0.2 mg/Kg in 0.025 M aqueous methanesulfonic acid solution with 5% mannitol at a concentration of 0.2,A,9615.0,,,,CHEMBL622667,16807,N,BAO_0000218,1,,,,,50588
5238,1,Canis lupus familiaris,Area under curve by intravenous administration at a dose of 1 uM/kg in dog was determined,A,9615.0,,,,CHEMBL622668,4527,N,BAO_0000218,1,,,,,50588
5239,1,Canis lupus familiaris,Area under curve by oral administration at a dose of 10 uM/kg in dog was determined,A,9615.0,,,,CHEMBL622669,4527,N,BAO_0000218,1,,,,,50588
5240,1,Canis lupus familiaris,Area under curve determined in dogs after intravenous administration of 3 mg/kg,A,9615.0,,,,CHEMBL622670,15660,N,BAO_0000218,1,,,,,50588
5241,1,Canis lupus familiaris,Area under curve determined in dogs after oral administration of 10 mg/kg,A,9615.0,,,,CHEMBL622671,15660,N,BAO_0000218,1,,,,,50588
5242,1,Canis lupus familiaris,Area under curve of compound after both po and iv administration at a dose of 5 mg/kg and 2 mg/kg resp in dog,A,9615.0,,,,CHEMBL622672,5802,N,BAO_0000218,1,,,,,50588
5243,1,Canis lupus familiaris,Area under curve of compound determined in dog after iv administration at a dose of 10 mg/kg,A,9615.0,,,,CHEMBL622673,3598,N,BAO_0000218,1,,,,,50588
5244,1,Canis lupus familiaris,Area under curve of compound from zero time to infinity determined in dog after iv administration at a dose of 10 mg/kg,A,9615.0,,,,CHEMBL622674,3598,N,BAO_0000218,1,,,,,50588
5245,1,Canis lupus familiaris,Area under curve determined in dog at a dose of 0 mg/kg by oral administration along with indavir (10 mg/kg),A,9615.0,,,,CHEMBL622675,5944,N,BAO_0000218,1,,,,,50588
5246,1,Canis lupus familiaris,Area under curve determined in dog at a dose of 10 mg/kg by oral administration,A,9615.0,,,,CHEMBL622676,5944,N,BAO_0000218,1,,,,,50588
5247,1,Canis lupus familiaris,Area under curve determined in dog at a dose of 10 mg/kg by oral administration along with indavir (10 mg/kg),A,9615.0,,,,CHEMBL622677,5944,N,BAO_0000218,1,,,,,50588
5248,1,Canis lupus familiaris,Area under curve determined in dog at a dose of 5 mg/kg by oral administration,A,9615.0,,,,CHEMBL622678,5944,N,BAO_0000218,1,,,,,50588
5249,1,Canis lupus familiaris,Area under curve in dog after administration of 20 mg/kg dose through peroral route,A,9615.0,,,,CHEMBL622679,4186,N,BAO_0000218,1,,,,,50588
5250,1,Canis lupus familiaris,Area under curve in dogs administered perorally (5 mg/kg) and intravenously (2 mg/kg),A,9615.0,,,,CHEMBL622680,5007,N,BAO_0000218,1,,,,,50588
5251,1,Canis lupus familiaris,Area under curve was determine after peroral administration at 10 mpk in dog,A,9615.0,,,,CHEMBL622681,5668,N,BAO_0000218,1,,,,,50588
5252,1,Canis lupus familiaris,Area under curve was determine after peroral administration at 5 mpk in dog,A,9615.0,,,,CHEMBL875278,5668,N,BAO_0000218,1,,,,,50588
5253,1,Canis lupus familiaris,Area under curve was determined,A,9615.0,,,,CHEMBL622682,5006,N,BAO_0000218,1,,,,,50588
5254,1,Canis lupus familiaris,Area under curve in dogs,A,9615.0,,,,CHEMBL622683,5006,N,BAO_0000218,1,,,,,50588
5255,1,Canis lupus familiaris,Area under curve in dogs at 10 mg/kg dose fo oral administration,A,9615.0,,,,CHEMBL622684,3771,N,BAO_0000218,1,,,,,50588
5256,1,Canis lupus familiaris,Area under curve in dogs at 10 mg/kg dose fo oral administration (Evokes hyperglycerolemia),A,9615.0,,,,CHEMBL622685,3771,N,BAO_0000218,1,,,,,50588
5257,1,Canis lupus familiaris,Area under curve in dogs at 3 mg/kg dose fo intravenous administration,A,9615.0,,,,CHEMBL622686,3771,N,BAO_0000218,1,,,,,50588
5258,1,Canis lupus familiaris,Area under curve was evaluated against Beagle dog at a dose of 15 mg/kg after po administration,A,9615.0,,,,CHEMBL618344,1916,N,BAO_0000218,1,,,,,50588
5259,1,Canis lupus familiaris,Area under curve value in dog at a dose of 5 mg/kg,A,9615.0,,,,CHEMBL875582,5302,N,BAO_0000218,1,,,,,50588
5260,1,Canis lupus familiaris,Area under curve was determined after 0.1 mg/kg iv administration in dog,A,9615.0,,,,CHEMBL618345,5600,N,BAO_0000218,1,,,,,50588
5261,1,Canis lupus familiaris,Area under curve was determined after 0.3 mg/kg po administration in dog,A,9615.0,,,,CHEMBL618346,5600,N,BAO_0000218,1,,,,,50588
5262,1,Canis lupus familiaris,Area under curve was determined for compound after intravenous administration in dogs at 1.2 uM/kg,A,9615.0,,,,CHEMBL618347,17764,N,BAO_0000218,1,,,,,50588
5263,1,Canis lupus familiaris,Area under curve was determined for the compound by intravenous administration of 1.2 mg/kg in dog,A,9615.0,,,,CHEMBL618348,4368,N,BAO_0000218,1,,,,,50588
5264,0,Homo sapiens,Tested for half life period at 37 degree Celsius in PBS buffer at 10.5 pH containing human serum esterase,A,9606.0,,,,CHEMBL618349,5318,U,BAO_0000019,1,,,,,22224
5265,0,Homo sapiens,Tested for half life period at 37 degree Centigrade in PBS buffer at 7.3 pH containing human serum esterase,A,9606.0,,,,CHEMBL618350,5318,U,BAO_0000019,1,,,,,22224
5266,0,Homo sapiens,Tested for half life period at 37 degree Celsius in PBS buffer at 8.0 pH containing human serum esterase,A,9606.0,,,,CHEMBL618351,5318,U,BAO_0000019,1,,,,,22224
5267,0,Homo sapiens,Tested for half life period at 37 degree Celsius in PBS buffer at 8.8 pH containing human serum esterase,A,9606.0,,,,CHEMBL618352,5318,U,BAO_0000019,1,,,,,22224
5268,0,Homo sapiens,Time taken to reduce 50% of the concentration of compound in blood plasma,A,9606.0,Blood,,,CHEMBL873494,14518,U,BAO_0000221,1,178.0,,,,22224
5269,0,Homo sapiens,"Biological half life in human plasma (stability to human renal dehydropeptidase I,DHP-I).",A,9606.0,Plasma,,,CHEMBL618353,2209,U,BAO_0000366,1,1969.0,,,,22224
5270,0,Homo sapiens,Half life in human plasma,A,9606.0,Plasma,,,CHEMBL618354,6787,U,BAO_0000366,1,1969.0,,,,22224
5271,0,Homo sapiens,Half life in human plasma was reported,A,9606.0,Plasma,,,CHEMBL875583,4898,U,BAO_0000366,1,1969.0,,,,22224
5272,0,Homo sapiens,Half life in human serum,A,9606.0,Serum,,,CHEMBL618355,6072,U,BAO_0000019,1,1977.0,,,,22224
5273,0,Homo sapiens,Half life upon exposure to human plasma,A,9606.0,Plasma,,,CHEMBL618356,16907,U,BAO_0000366,1,1969.0,,,,22224
5274,0,Homo sapiens,t1/2 in human microsomes,A,9606.0,,Microsomes,,CHEMBL618357,5656,U,BAO_0000251,1,,In vitro,,,22224
5275,0,Homo sapiens,Half life period in 80% human plasma at 37 degree Centigrade,A,9606.0,Plasma,,,CHEMBL618358,4755,U,BAO_0000366,1,1969.0,,,,22224
5276,0,Homo sapiens,Half-life for rate of hydrolysis was determined in in human skin homogenate (pH 7.4),A,9606.0,Zone of skin,,,CHEMBL618359,17503,U,BAO_0000221,1,14.0,,,,22224
5277,0,Homo sapiens,Half-life measured in in vitro Cathepsin B assay in human plasma,A,9606.0,Plasma,,,CHEMBL618360,12357,U,BAO_0000366,1,1969.0,In vitro,,,22224
5278,0,Homo sapiens,Half-life at initial concentration of 5*10e-5 M in CEM cell extract,A,9606.0,,,,CHEMBL618361,3076,U,BAO_0000019,1,,,,,22224
5279,0,Homo sapiens,Half-life determined by human liver microsome stability assay at a concentration of 5 uM,A,9606.0,Liver,Microsomes,,CHEMBL618362,6410,U,BAO_0000251,1,2107.0,In vitro,,,22224
5280,0,Homo sapiens,"Half-life in chemical and enzymatic hydrolysis to form L-DOPA, in 80% human plasma",A,9606.0,Plasma,,,CHEMBL618363,3741,U,BAO_0000366,1,1969.0,,,,22224
5281,0,Homo sapiens,"Half-life in chemical and enzymatic hydrolysis to form another compound (8)*, in 80% human plasma (experiment 1)",A,9606.0,Plasma,,,CHEMBL618364,3741,U,BAO_0000366,1,1969.0,,,,22224
5282,0,Homo sapiens,"Half-life in chemical and enzymatic hydrolysis to form another compound (8)*, in 80% human plasma (experiment 2)",A,9606.0,Plasma,,,CHEMBL875584,3741,U,BAO_0000366,1,1969.0,,,,22224
5283,0,Homo sapiens,Half-life in the CEM cell extracts,A,9606.0,,,,CHEMBL618365,1540,U,BAO_0000019,1,,,,,22224
5284,0,Homo sapiens,Half-life was calculated by Human plasma stability assay at 37 degree Centigrade,A,9606.0,Plasma,,,CHEMBL873495,2905,U,BAO_0000366,1,1969.0,,,,22224
5285,0,Homo sapiens,Half-life was calculated by Human plasma stability assay at 37 degree centigrade; Not hydrolyzed,A,9606.0,Plasma,,,CHEMBL618366,2905,U,BAO_0000366,1,1969.0,,,,22224
5286,0,Homo sapiens,Half-life was determined,A,9606.0,,,,CHEMBL618367,5523,U,BAO_0000019,1,,,,,22224
5287,0,Homo sapiens,Half-life (human blood stability),A,9606.0,Blood,,,CHEMBL618368,1499,U,BAO_0000221,1,178.0,,,,22224
5288,0,Homo sapiens,Half-life (human blood stability); no data,A,9606.0,Blood,,,CHEMBL618369,1499,U,BAO_0000221,1,178.0,,,,22224
5289,0,Homo sapiens,Half-life in human plasma,A,9606.0,Plasma,,,CHEMBL618370,17065,U,BAO_0000366,1,1969.0,,,,22224
5290,0,Homo sapiens,CYP3A4 metabolism half-life (t1/2),A,9606.0,,,,CHEMBL618371,6861,U,BAO_0000019,1,,,,,22224
5291,0,Homo sapiens,Half-life was determined; 88% of parent remained after incubation for 120 min (human blood stability),A,9606.0,Blood,,,CHEMBL618372,1499,U,BAO_0000221,1,178.0,,,,22224
5292,0,Homo sapiens,In vitro half life in human plasma,A,9606.0,Plasma,,,CHEMBL618373,530,U,BAO_0000366,1,1969.0,In vitro,,,22224
5293,0,Homo sapiens,"In vitro half life at 1.5 -5.6ug/mL, 37 degree C in human plasma",A,9606.0,Plasma,,,CHEMBL618374,1116,U,BAO_0000366,1,1969.0,In vitro,,,22224
5294,0,Homo sapiens,In vitro hydrolysis in human plasma,A,9606.0,Plasma,,,CHEMBL618375,6695,U,BAO_0000366,1,1969.0,In vitro,,,22224
5295,0,Homo sapiens,In vitro hydrolysis in human plasma; no data,A,9606.0,Plasma,,,CHEMBL618376,6695,U,BAO_0000366,1,1969.0,In vitro,,,22224
5296,0,Homo sapiens,In vitro metabolic stability at 5 uM was determined by incubating with human liver microsomes at 37 degree C,A,9606.0,Liver,Microsomes,,CHEMBL618377,10,U,BAO_0000251,1,2107.0,In vitro,,,22224
5297,0,Homo sapiens,Plasma half life in human,A,9606.0,Plasma,,,CHEMBL618378,993,U,BAO_0000366,1,1969.0,,,,22224
5298,0,Homo sapiens,Stability after incubation with human plasma (at 37 degree C),A,9606.0,Plasma,,,CHEMBL618379,15429,U,BAO_0000366,1,1969.0,,,,22224
5299,0,Homo sapiens,T1/2 was evaluated in human plasma,A,9606.0,Plasma,,,CHEMBL618380,1675,U,BAO_0000366,1,1969.0,,,,22224
5300,0,Homo sapiens,"Tested for Biological half life in human plasma (stability to human renal dehydropeptidase I,DHP-I).",A,9606.0,Plasma,,,CHEMBL618381,2209,U,BAO_0000366,1,1969.0,,,,22224
5301,0,Homo sapiens,"Tested for Biological half life in human plasma (stability to human renal dehydropeptidase I,DHP-I); Not determined",A,9606.0,Plasma,,,CHEMBL618382,2209,U,BAO_0000366,1,1969.0,,,,22224
5302,0,Homo sapiens,Tested for half life period at 37 degree Centigrade in PBS buffer at 7.3 pH containing human serum esterase,A,9606.0,,,,CHEMBL618383,5318,U,BAO_0000019,1,,,,,22224
5303,0,Homo sapiens,Tested in vitro for the time for half reactivation against human lysosomal alpha-glucosidase,A,9606.0,,,,CHEMBL618384,2412,U,BAO_0000019,1,,In vitro,,,22224
5304,0,Homo sapiens,Tested in vitro for the time for half reactivation against human lysosomal alpha-glucosidase; ND=Not determined,A,9606.0,,,,CHEMBL618385,2412,U,BAO_0000019,1,,In vitro,,,22224
5305,0,Homo sapiens,The release rate of the free drug from the substrate in human plasma by human plasma stability assay,A,9606.0,Plasma,,,CHEMBL619099,2906,U,BAO_0000366,1,1969.0,,,,22224
5306,0,Homo sapiens,The release rate of the free drug from the substrate in human plasma by human plasma stability assay; Not hydrolyzed,A,9606.0,Plasma,,,CHEMBL619100,2906,U,BAO_0000366,1,1969.0,,,,22224
5307,0,Homo sapiens,Time taken for 50% to be consumed by serum PON1 was determined,A,9606.0,,,,CHEMBL619101,5495,U,BAO_0000019,1,,,,,22224
5308,0,Homo sapiens,Time taken for 50% to be consumed by serum PON1; NH is Not hydrolysed,A,9606.0,,,,CHEMBL619102,5495,U,BAO_0000019,1,,,,,22224
5309,0,Homo sapiens,Percent of the parent compound remaining after 20 mins incubation with human liver microsomes,A,9606.0,Liver,Microsomes,,CHEMBL619103,4397,U,BAO_0000251,1,2107.0,,,,22224
5310,0,Mus sp.,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice blood upon intraveneous administration at 2.6 gmol/mice after 1 hour,A,10095.0,,,,CHEMBL619268,2413,U,BAO_0000218,1,,,,,22224
5311,0,Mus sp.,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice blood upon intraveneous administration at 2.6 gmol/mice after 3 hour,A,10095.0,,,,CHEMBL619269,2413,U,BAO_0000218,1,,,,,22224
5312,0,Mus sp.,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice brain upon intraveneous administration at 2.6 gmol/mice after 1 hour,A,10095.0,,,,CHEMBL619270,2413,U,BAO_0000218,1,,,,,22224
5313,0,Mus sp.,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice brain upon intraveneous administration at 2.6 gmol/mice after 3 hour,A,10095.0,,,,CHEMBL619271,2413,U,BAO_0000218,1,,,,,22224
5314,0,Mus sp.,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice kidney upon intraveneous administration at 2.6 gmol/mice after 1 hour,A,10095.0,,,,CHEMBL875585,2413,U,BAO_0000218,1,,,,,22224
5315,0,Mus sp.,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice kidney upon intraveneous administration at 2.6 gmol/mice after 24 hour,A,10095.0,,,,CHEMBL619272,2413,U,BAO_0000218,1,,,,,22224
5316,1,Homo sapiens,Compound tested for growth inhibition of renal cancer cell line 786-0,F,9606.0,,,,CHEMBL619273,6058,N,BAO_0000219,1,,,,786-0,80640
5317,1,Homo sapiens,Compound was tested for 50% growth inhibition against human renal cancer 786-0 cell line,F,9606.0,,,,CHEMBL619274,17708,N,BAO_0000219,1,,,,786-0,80640
5318,1,Homo sapiens,Concentration which reduced cell growth to 50 % of level against 786-0 renal cancer line,F,9606.0,,,,CHEMBL619275,14017,N,BAO_0000219,1,,,,786-0,80640
5319,1,Homo sapiens,"Percent growth of NCI cell line, renal: 786-0 exposed for 48 hr at 10e-4 concentration",F,9606.0,,,,CHEMBL619276,16818,N,BAO_0000219,1,,,,786-0,80640
5320,1,Homo sapiens,"Percent growth of NCI cell line, renal: 786-0 exposed for 48 hr at 10e-6 concentration",F,9606.0,,,,CHEMBL619277,16818,N,BAO_0000219,1,,,,786-0,80640
5321,1,Homo sapiens,"Percent growth of NCI cell line, renal: 786-0 exposed for 48 hr at 10e-8 concentration",F,9606.0,,,,CHEMBL619278,16818,N,BAO_0000219,1,,,,786-0,80640
5322,1,Homo sapiens,Tested for cytotoxicity against 786-0 cell lines in renal cancer,F,9606.0,,,,CHEMBL619279,11970,N,BAO_0000219,1,,,,786-0,80640
5323,1,Homo sapiens,Tested in vitro for cytotoxicity in 786-0 cell line of Renal cancer,F,9606.0,,,,CHEMBL858458,12400,N,BAO_0000219,1,,,,786-0,80640
5324,1,Homo sapiens,Cytotoxic effect on renal cancer line 786-0,F,9606.0,,,,CHEMBL619280,12888,N,BAO_0000219,1,,,,786-0,80640
5325,1,Homo sapiens,In vitro antitumor activity against Renal cancer 786-0 cell lines by 6-day assay,F,9606.0,,,,CHEMBL619281,15300,N,BAO_0000219,1,,,,786-0,80640
5326,1,Homo sapiens,Compound was evaluated for in vitro activity against 786-0 kidney cell lines (Human tumor cells ),F,9606.0,,,,CHEMBL619282,14769,N,BAO_0000219,1,,,,786-0,80640
5327,1,Homo sapiens,"Cytotoxicity against NCI tumor panel, 786-0 renal cancer cell line",F,9606.0,,,,CHEMBL619283,15895,N,BAO_0000219,1,,,,786-0,80640
5328,1,Homo sapiens,Concentration of compound that cause 50% cytotoxicity of 786-0 renal cancer cell line,F,9606.0,,,,CHEMBL619284,17376,N,BAO_0000219,1,,,,786-0,80640
5329,1,Homo sapiens,Compound was tested for antitumor activity against 786-0 renal cancer cell line(molar concentration that inhibits 50% net cell growth).,F,9606.0,,,,CHEMBL619285,14882,N,BAO_0000219,1,,,,786-0,80640
5330,1,Homo sapiens,Compound was tested for antitumor activity against 786-0 renal cancer cell line(molar concentration leading to 50% net cell death),F,9606.0,,,,CHEMBL619286,14882,N,BAO_0000219,1,,,,786-0,80640
5331,1,Homo sapiens,Growth inhibition of the 786-O Renal cancer cell line for 2-day in vitro assay.,F,9606.0,,,,CHEMBL619287,15176,N,BAO_0000219,1,,,,786-0,80640
5332,1,Homo sapiens,In vitro anti tumor activity against human tumor Renal cancer cell lines was determined,F,9606.0,,,,CHEMBL857455,12696,N,BAO_0000219,1,,,,786-0,80640
5333,1,Homo sapiens,The compound was tested in vitro for cytotoxic activity against 786-O cell line (human perirenal carcinoma),F,9606.0,,,,CHEMBL883801,2496,N,BAO_0000219,1,,,,786-0,80640
5334,1,Homo sapiens,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells having only 3-5% antigen expression,F,9606.0,,,,CHEMBL619288,11831,N,BAO_0000219,1,,,,791T cell line,80641
5335,1,Homo sapiens,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells having only 3-5% antigen expression (49% inhibition achieved at 100 micro g/mL),F,9606.0,,,,CHEMBL619289,11831,N,BAO_0000219,1,,,,791T cell line,80641
5336,1,Homo sapiens,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells having only 3-5% antigen expression; <20% inhibition achieved,F,9606.0,,,,CHEMBL619290,11831,N,BAO_0000219,1,,,,791T cell line,80641
5337,1,Homo sapiens,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells of conjugate AH1.11 (Type H1: MSR-33),F,9606.0,,,,CHEMBL619291,11831,N,BAO_0000219,1,,,,791T cell line,80641
5338,1,Homo sapiens,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells of conjugate AH1.11 (Type H2: MSR-26),F,9606.0,,,,CHEMBL619292,11831,N,BAO_0000219,1,,,,791T cell line,80641
5339,1,Homo sapiens,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells of conjugate AH1.11 (Type H3: MSR-28); <20% inhibition achieved,F,9606.0,,,,CHEMBL619293,11831,N,BAO_0000219,1,,,,791T cell line,80641
5340,1,Homo sapiens,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells of conjugate H1.11 (Type H1: MSR-33),F,9606.0,,,,CHEMBL619294,11831,N,BAO_0000219,1,,,,791T cell line,80641
5341,1,Homo sapiens,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells of conjugate H1.11 (Type H2: MSR-26),F,9606.0,,,,CHEMBL619295,11831,N,BAO_0000219,1,,,,791T cell line,80641
5342,1,Homo sapiens,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells of conjugate H1.11 (Type H2: MSR-26) (less than 20% inhibition achieved),F,9606.0,,,,CHEMBL619296,11831,N,BAO_0000219,1,,,,791T cell line,80641
5343,1,Homo sapiens,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells of conjugate H1.11 (Type H3: MSR-28); <20% inhibition achieved,F,9606.0,,,,CHEMBL619297,11831,N,BAO_0000219,1,,,,791T cell line,80641
5344,1,Homo sapiens,Growth inhibitory concentration against tumor cells in culture renal cancer 796-0 cell line,F,9606.0,,,,CHEMBL619298,12782,N,BAO_0000219,1,,,,786-0,80640
5345,0,,In vitro anticancer activity against 8 NCI CNS cancer cell lines; inactive,F,,,,,CHEMBL619299,1229,U,BAO_0000019,1,,,,,22226
5346,1,Homo sapiens,Inhibition of cell growth in drug resistant 8226 myeloma cell line,F,9606.0,,,,CHEMBL619300,15313,N,BAO_0000219,1,,,,RPMI-8226,80433
5347,1,Homo sapiens,Inhibition of cell growth in drug sensitive 8226 myeloma cell line,F,9606.0,,,,CHEMBL619301,15313,N,BAO_0000219,1,,,,RPMI-8226,80433
5348,1,Homo sapiens,In vitro inhibition of tumor cell growth in the human myeloma 8226 system.,F,9606.0,,,,CHEMBL619302,11544,N,BAO_0000219,1,,,,RPMI-8226,80433
5349,1,Homo sapiens,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.01 ug/mL,F,9606.0,,,,CHEMBL619303,9424,N,BAO_0000219,1,,,,RPMI-8226,80433
5350,1,Homo sapiens,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.1 ug/mL,F,9606.0,,,,CHEMBL619304,9424,N,BAO_0000219,1,,,,RPMI-8226,80433
5351,1,Homo sapiens,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.1 ug/mL (*: >50% cell kill),F,9606.0,,,,CHEMBL857706,9424,N,BAO_0000219,1,,,,RPMI-8226,80433
5352,1,Homo sapiens,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.3 ug/mL (*: >50% cell kill),F,9606.0,,,,CHEMBL619305,9424,N,BAO_0000219,1,,,,RPMI-8226,80433
5353,1,Homo sapiens,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.5 ug/mL. (*: >1 log cell kill),F,9606.0,,,,CHEMBL619306,9424,N,BAO_0000219,1,,,,RPMI-8226,80433
5354,1,Homo sapiens,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 10 ug/mL (*: >1 log cell kill),F,9606.0,,,,CHEMBL619307,9424,N,BAO_0000219,1,,,,RPMI-8226,80433
5355,1,Homo sapiens,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 10 ug/mL (*: >1 log cell kill),F,9606.0,,,,CHEMBL619308,9424,N,BAO_0000219,1,,,,RPMI-8226,80433
5356,1,Homo sapiens,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 1 ug/mL. (*: >50% cell kill),F,9606.0,,,,CHEMBL619309,9424,N,BAO_0000219,1,,,,RPMI-8226,80433
5357,1,Homo sapiens,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 1 ug/mL. (*: >1 log cell kill),F,9606.0,,,,CHEMBL619310,9424,N,BAO_0000219,1,,,,RPMI-8226,80433
5358,1,Homo sapiens,Compound was evaluated for in vitro activity against A498 kidney cell lines (Human tumor cells ),F,9606.0,,,,CHEMBL619311,14769,N,BAO_0000219,1,,,,A498,80021
5359,1,Homo sapiens,Compound was tested for the growth inhibition of A498 renal tumor cell line,F,9606.0,,,,CHEMBL619312,15354,N,BAO_0000219,1,,,,A498,80021
5360,1,Homo sapiens,In vitro cytotoxicity against human tumor A498 cell line (renal cancer),F,9606.0,,,,CHEMBL619313,17445,N,BAO_0000219,1,,,,A498,80021
5361,1,Homo sapiens,In vitro inhibitory concentration against renal cancer cell line A498,F,9606.0,,,,CHEMBL619314,4337,N,BAO_0000219,1,,,,A498,80021
5362,1,Homo sapiens,Cytotoxicity against A 498 tumor cell line,F,9606.0,,,,CHEMBL619959,15277,N,BAO_0000219,1,,,,A498,80021
5363,1,Homo sapiens,In vitro antitumor activity against A498 human cancer cell line,F,9606.0,,,,CHEMBL619960,4812,N,BAO_0000219,1,,,,A498,80021
5364,1,Homo sapiens,In vitro antitumor activity against A498 human cancer cell line (Data from NCI-screening),F,9606.0,,,,CHEMBL619961,4812,N,BAO_0000219,1,,,,A498,80021
5365,1,Homo sapiens,Inhibitory dose required against A498 human tumor cell lines,F,9606.0,,,,CHEMBL619962,4995,N,BAO_0000219,1,,,,A498,80021
5366,1,Homo sapiens,Anticancer activity against one renal cancer (A498 cell line),F,9606.0,,,,CHEMBL875586,5847,N,BAO_0000219,1,,,,A498,80021
5367,1,Homo sapiens,In vitro cytotoxicity against melanoma A498 cell line,F,9606.0,,,,CHEMBL619963,6557,N,BAO_0000219,1,,,,A498,80021
5368,1,Homo sapiens,Compound was tested for growth inhibitory activity against A498 cell line,F,9606.0,,,,CHEMBL619964,2597,N,BAO_0000219,1,,,,A498,80021
5369,1,Homo sapiens,Compound tested for growth inhibition of renal cancer cell line A498,F,9606.0,,,,CHEMBL620108,6058,N,BAO_0000219,1,,,,A498,80021
5370,1,Homo sapiens,Compound was tested for 50% growth inhibition against human renal cancer A498 cell line,F,9606.0,,,,CHEMBL620109,17708,N,BAO_0000219,1,,,,A498,80021
5371,1,Homo sapiens,Growth inhibition of the A498 Renal cancer cell line for 2-day in vitro assay.,F,9606.0,,,,CHEMBL620110,15176,N,BAO_0000219,1,,,,A498,80021
5372,1,Homo sapiens,In vitro antitumor activity against Renal cancer A498 cell lines by 6-day assay,F,9606.0,,,,CHEMBL620111,15300,N,BAO_0000219,1,,,,A498,80021
5373,1,Homo sapiens,Tested for cytotoxicity against A498 cell lines in renal cancer,F,9606.0,,,,CHEMBL620112,11970,N,BAO_0000219,1,,,,A498,80021
5374,1,Homo sapiens,Tested in vitro for cytotoxicity in A498 cell line of Renal cancer,F,9606.0,,,,CHEMBL620113,12400,N,BAO_0000219,1,,,,A498,80021
5375,1,Homo sapiens,Cytotoxic effect on renal cancer lines A498,F,9606.0,,,,CHEMBL620114,12888,N,BAO_0000219,1,,,,A498,80021
5376,1,Homo sapiens,Antitumor activity was evaluated for reduction of growth of renal cancer (A498) cells at a concentration of 100 uM,F,9606.0,,,,CHEMBL620115,3030,N,BAO_0000219,1,,,,A498,80021
5377,1,Homo sapiens,Compound was evaluated for in vitro activity against A498 kidney cell lines (Human tumor cells ),F,9606.0,,,,CHEMBL620116,14769,N,BAO_0000219,1,,,,A498,80021
5378,1,Homo sapiens,Concentration of compound that cause 50% cytotoxicity of A498 renal cancer cell line,F,9606.0,,,,CHEMBL620117,17376,N,BAO_0000219,1,,,,A498,80021
5379,1,Homo sapiens,Growth inhibitory activity against A498-2LM human solid tumor cell line using MTT assay,F,9606.0,,,,CHEMBL620118,16558,N,BAO_0000219,1,,,,A498,80021
5380,1,Homo sapiens,Cytotoxicity against human kidney carcinoma cell lines A4982LM,F,9606.0,,,,CHEMBL620119,5194,N,BAO_0000219,1,,,,A498,80021
5381,1,Homo sapiens,Evaluated for the inhibitory concentration required to cause growth inhibition of A498Rem- renal cell line using the MTT Cytotoxicity Assay,F,9606.0,,,,CHEMBL620120,10708,N,BAO_0000219,1,,,,A498,80021
5382,1,Homo sapiens,Antiproliferative activity in vitro against A549 (human non-small lung carcinoma) cell line.,F,9606.0,,,,CHEMBL620121,16880,N,BAO_0000219,1,,,,A549,80682
5383,1,Homo sapiens,Antitumor activity against A549 human lung carcinoma cell line,F,9606.0,,,,CHEMBL620122,10196,N,BAO_0000219,1,,,,A549,80682
5384,1,Homo sapiens,Antitumor activity against A549 human lung carcinoma cell line in experiment 1,F,9606.0,,,,CHEMBL620123,10196,N,BAO_0000219,1,,,,A549,80682
5385,1,Homo sapiens,Antitumor activity against A549 human lung carcinoma cell line in experiment 2,F,9606.0,,,,CHEMBL620124,10196,N,BAO_0000219,1,,,,A549,80682
5386,1,Homo sapiens,"Concentration required to inhibit tumor growth in A549, human lung carcinoma (NSCLC) cell line",F,9606.0,,,,CHEMBL620125,12083,N,BAO_0000219,1,,,,A549,80682
5387,1,Homo sapiens,Cytotoxicity against A549 nonsmall lung cell line using MTT colorimetric assay,F,9606.0,,,,CHEMBL620126,16464,N,BAO_0000219,1,,,,A549,80682
5388,1,Homo sapiens,Cytotoxicity against A549 nonsmall lung cell line using MTT colorimetric assay; NE is no effect at 1x 10 E-5,F,9606.0,,,,CHEMBL883027,16464,N,BAO_0000219,1,,,,A549,80682
5389,1,Homo sapiens,In vitro cytotoxic activity against human lung A549 cell line,F,9606.0,,,,CHEMBL620127,16470,N,BAO_0000219,1,,,,A549,80682
5390,1,Homo sapiens,In vitro cytotoxic activity against human lung A549 cell line ( standard deviation in parenthesis),F,9606.0,,,,CHEMBL620128,16470,N,BAO_0000219,1,,,,A549,80682
5391,1,Homo sapiens,In vitro cytotoxic activity against human lung A549 cell line),F,9606.0,,,,CHEMBL620129,16470,N,BAO_0000219,1,,,,A549,80682
5392,1,Homo sapiens,In vitro cytotoxic activity against human lung A549 cell line;NT is not tested,F,9606.0,,,,CHEMBL620130,16470,N,BAO_0000219,1,,,,A549,80682
5393,1,Homo sapiens,In vitro cytotoxicity against human non small-cell-lung cell line A549.,F,9606.0,,,,CHEMBL620131,16582,N,BAO_0000219,1,,,,A549,80682
5394,1,Homo sapiens,"In vitro growth inhibition of human lung carcinoma cell line, A549 with low levels of folate receptors",F,9606.0,,,,CHEMBL620132,15935,N,BAO_0000219,1,,,,A549,80682
5395,1,Homo sapiens,"In vitro growth inhibition of human lung carcinoma cell line, A549 with low levels of folate receptors in folate deficient medium",F,9606.0,,,,CHEMBL620133,15935,N,BAO_0000219,1,,,,A549,80682
5396,1,Homo sapiens,Inhibition of A549 human lung carcinoma cell proliferation,F,9606.0,,,,CHEMBL620134,16597,N,BAO_0000219,1,,,,A549,80682
5397,1,Homo sapiens,Inhibitory activity against A549 lung adenocarcinoma cell line,F,9606.0,,,,CHEMBL620135,17376,N,BAO_0000219,1,,,,A549,80682
5398,1,Homo sapiens,Inhibitory concentration required to reduce A549 tumor cell growth by 50% in MTT assay,F,9606.0,,,,CHEMBL620136,16496,N,BAO_0000219,1,,,,A549,80682
5399,1,Homo sapiens,in vitro anticancer activity against cultured A549 human tumor(lung) cell line,F,9606.0,,,,CHEMBL620137,16152,N,BAO_0000219,1,,,,A549,80682
5400,1,Homo sapiens,in vitro inhibition of tumor cell growth in cultured A549 human tumor cell line,F,9606.0,,,,CHEMBL620268,16152,N,BAO_0000219,1,,,,A549,80682
5401,1,Homo sapiens,Cytotoxicity against A549 nonsmall lung cell line using MTT colorimetric assay; NE is no effect at 1x 10 E-5,F,9606.0,,,,CHEMBL620269,16464,N,BAO_0000219,1,,,,A549,80682
5402,1,Homo sapiens,Cytotoxicity was evaluated against A549 non-small cell lung carcinoma human cancer cell line,F,9606.0,,,,CHEMBL620270,2288,N,BAO_0000219,1,,,,A549,80682
5403,1,Homo sapiens,Compound was tested for antiproliferative activity against human A549 cancer cell lines using MTT assay,F,9606.0,,,,CHEMBL620271,17350,N,BAO_0000219,1,,,,A549,80682
5404,1,Homo sapiens,Inhibition of A549 cancer cell proliferation,F,9606.0,,,,CHEMBL620272,4090,N,BAO_0000219,1,,,,A549,80682
5405,1,Homo sapiens,Inhibition of A549 cancer cell proliferation (Not tested),F,9606.0,,,,CHEMBL620273,4090,N,BAO_0000219,1,,,,A549,80682
5406,1,Homo sapiens,Compound was tested for antiproliferative activity against human A549 cancer cell lines using MTT assay,F,9606.0,,,,CHEMBL620274,17350,N,BAO_0000219,1,,,,A549,80682
5407,1,Homo sapiens,In vitro inhibitory concentration required against human lung A549 carcinoma cells proliferation,F,9606.0,,,,CHEMBL620275,4197,N,BAO_0000219,1,,,,A549,80682
5408,1,Homo sapiens,Antiproliferative potency determined as inhibitory concentration against A549 cells,F,9606.0,,,,CHEMBL620276,17072,N,BAO_0000219,1,,,,A549,80682
5409,1,Homo sapiens,Percent assembly of bovine brain tubulin induced by compound at 10 uM versus that caused by 10 uM paclitaxel,F,9606.0,,,,CHEMBL620277,17072,N,BAO_0000219,1,,,,A549,80682
5410,1,Homo sapiens,Cytotoxicity against Renal cell lines A549 was determined,F,9606.0,,,,CHEMBL620278,5194,N,BAO_0000219,1,,,,A549,80682
5411,1,Canis lupus familiaris,Area under curve was determined in dog after a 3 mg/kg of oral dose,A,9615.0,,,,CHEMBL620279,4257,N,BAO_0000218,1,,,,,50588
5412,1,Canis lupus familiaris,Area under curve was determined in dog after oral administration at 1 mg/kg,A,9615.0,,,,CHEMBL620280,6123,N,BAO_0000218,1,,,,,50588
5413,1,Canis lupus familiaris,Area under curve was determined in dogs after oral administration (10 mg/kg) as a 0.05 M citric acid solution.,A,9615.0,,,,CHEMBL620281,1337,N,BAO_0000218,1,,,,,50588
5414,1,Canis lupus familiaris,Area under curve was determined in dogs after oral administration (8 mg/kg) as a 0.05 M citric acid solution.,A,9615.0,,,,CHEMBL620282,1337,N,BAO_0000218,1,,,,,50588
5415,1,Canis lupus familiaris,Area under increased blood flow curve (AUC) at 1 microg ia at a duration of ( 0-2 mins),A,9615.0,,,,CHEMBL621134,8833,N,BAO_0000218,1,,,,,50588
5416,1,Canis lupus familiaris,Area under increased blood flow curve (AUC) at 1 microg ia at a duration of ( 0-5 mins),A,9615.0,,,,CHEMBL621135,8833,N,BAO_0000218,1,,,,,50588
5417,1,Canis lupus familiaris,Area under increased blood flow curve (AUC) at 1 microg ia at a duration of (0-15 mins),A,9615.0,,,,CHEMBL621136,8833,N,BAO_0000218,1,,,,,50588
5418,1,Canis lupus familiaris,Area under increased blood flow curve (AUC) at 1 microg ia at a duration of( 0-120 mins),A,9615.0,,,,CHEMBL621137,8833,N,BAO_0000218,1,,,,,50588
5419,1,Canis lupus familiaris,Area under plasma concentration time curve in dog upon oral administration,A,9615.0,Plasma,,,CHEMBL621138,17657,N,BAO_0000218,1,1969.0,,,,50588
5420,1,Canis lupus familiaris,Area under plasma concentration time curve was measured in dogs after an oral dose of 10 uM/kg,A,9615.0,Plasma,,,CHEMBL875587,17650,N,BAO_0000218,1,1969.0,,,,50588
5421,1,Canis lupus familiaris,Area under the curve for compound was evaluated in dog at a dose of 10 mg/kg.,A,9615.0,,,,CHEMBL621139,1977,N,BAO_0000218,1,,,,,50588
5422,1,Canis lupus familiaris,Area under the curve for compound was evaluated in dog at a dose of 20 mg/kg.,A,9615.0,,,,CHEMBL621140,1977,N,BAO_0000218,1,,,,,50588
5423,1,Canis lupus familiaris,Area under the curve for the compound was obtained when tested in dog,A,9615.0,,,,CHEMBL621141,3132,N,BAO_0000218,1,,,,,50588
5424,1,Canis lupus familiaris,Area under the curve at a dose of 1 mg/kg,A,9615.0,,,,CHEMBL621142,5473,N,BAO_0000218,1,,,,,50588
5425,1,Canis lupus familiaris,Area under the curve at a dose of 1 mg/kg (oral),A,9615.0,,,,CHEMBL621143,5474,N,BAO_0000218,1,,,,,50588
5426,1,Canis lupus familiaris,Area under the curve at i.v. dose of 0.2 mg/kg,A,9615.0,,,,CHEMBL621144,5474,N,BAO_0000218,1,,,,,50588
5427,1,Canis lupus familiaris,Area under the curve was measured in dog after an iv dose of 1 mg/kg,A,9615.0,,,,CHEMBL621145,6062,N,BAO_0000218,1,,,,,50588
5428,1,Canis lupus familiaris,Bioavailability from area under the curve at time 0 to infinity after intravenous administration of 1 mg/kg in dog,A,9615.0,,,,CHEMBL621146,4709,N,BAO_0000218,1,,,,,50588
5429,1,Canis lupus familiaris,Compound was evaluated for area under curve (total concentration) in dogs at a dose of 1 mpk perorally,A,9615.0,,,,CHEMBL622567,2652,N,BAO_0000218,1,,,,,50588
5430,1,Canis lupus familiaris,Compound was evaluated for area under curve (total concentration) in dogs at a dose of 5 mpk perorally,A,9615.0,,,,CHEMBL622568,2652,N,BAO_0000218,1,,,,,50588
5431,1,Canis lupus familiaris,Compound was evaluated for area under the curve in dog blood.,A,9615.0,,,,CHEMBL622569,2877,N,BAO_0000218,1,,,,,50588
5432,1,Canis lupus familiaris,In vivo area under curve was calculated by peroral administration at 1 mg/kg in fasted dog,A,9615.0,,,,CHEMBL622570,5444,N,BAO_0000218,1,,,,,50588
5433,1,Canis lupus familiaris,AUC in dog after oral dose (1 mg/kg),A,9615.0,Plasma,,,CHEMBL622571,5130,N,BAO_0000218,1,1969.0,,,,50588
5434,1,Canis lupus familiaris,Pharmacokinetic (PK) property (AUC) was determined in dog at the single oral dose of 1 mg/kg,A,9615.0,,,,CHEMBL622572,6265,N,BAO_0000218,1,,,,,50588
5435,1,Canis lupus familiaris,"Pharmacokinetic data in dogs at dose of 1 mg/kg perorally, and the area under curve (AUC) was reported.",A,9615.0,,,,CHEMBL622573,4657,N,BAO_0000218,1,,,,,50588
5436,1,Canis lupus familiaris,Pharmacokinetic parameter AUC after intravenous administration to dogs,A,9615.0,,,,CHEMBL622574,16367,N,BAO_0000218,1,,,,,50588
5437,1,Canis lupus familiaris,Pharmacokinetic parameter AUC after oral administration to dogs,A,9615.0,,,,CHEMBL622575,16367,N,BAO_0000218,1,,,,,50588
5438,1,Canis lupus familiaris,Pharmacokinetic parameter AUC was determined in dog after oral administration of 17b,A,9615.0,,,,CHEMBL622576,9579,N,BAO_0000218,1,,,,,50588
5439,1,Canis lupus familiaris,Pharmacokinetic parameter AUC was determined in dog after oral administration of 2b,A,9615.0,,,,CHEMBL622577,9579,N,BAO_0000218,1,,,,,50588
5440,1,Canis lupus familiaris,Pharmacokinetic property (AUC) was measured in dog at the dose of 0.032 mg/kg p.o.,A,9615.0,,,,CHEMBL622578,5983,N,BAO_0000218,1,,,,,50588
5441,1,Canis lupus familiaris,Pharmacokinetic property in dogs after oral administration at 1 mg/kg,A,9615.0,,,,CHEMBL622579,6241,N,BAO_0000218,1,,,,,50588
5442,1,Canis lupus familiaris,"Tested for the pharmacokinetic data, area under the curve of concentration versus time in dog",A,9615.0,,,,CHEMBL622580,5313,N,BAO_0000218,1,,,,,50588
5443,1,Canis lupus familiaris,"Tested for the pharmacokinetic data, area under the curve of concentration versus time in dog at dosage of 10 mpk",A,9615.0,,,,CHEMBL622581,5313,N,BAO_0000218,1,,,,,50588
5444,1,Canis lupus familiaris,Oral AUCN in dog ( (dosed as a mixture of five compounds at 0.5 mpk each via iv only),A,9615.0,,,,CHEMBL622582,6642,N,BAO_0000218,1,,,,,50588
5445,1,Canis lupus familiaris,Oral AUCN in dog (dosed as a mixture of five compounds at 0.5 mpk each via iv only),A,9615.0,,,,CHEMBL622583,6642,N,BAO_0000218,1,,,,,50588
5446,1,Canis lupus familiaris,Oral AUCN in dog (dosed at 0.5 mpk iv ),A,9615.0,,,,CHEMBL622584,6641,N,BAO_0000218,1,,,,,50588
5447,1,Canis lupus familiaris,Oral AUCN in dog (dosed at 0.5 mpk iv ),A,9615.0,,,,CHEMBL622585,6642,N,BAO_0000218,1,,,,,50588
5448,1,Canis lupus familiaris,Compound was evaluated for oral bioavailability in dog; 90-100,A,9615.0,,,,CHEMBL622586,17791,N,BAO_0000218,1,,,,,50588
5449,1,Canis lupus familiaris,Compound was tested for its cell permeability in the Madin-Darby canine kidney cell monolayer transport assay,A,9615.0,,,,CHEMBL623281,17655,N,BAO_0000218,1,,,,,50588
5450,1,Canis lupus familiaris,Compound was tested for its cell permeability in the Madin-Darby canine kidney cell monolayer transport assay; Not determined,A,9615.0,,,,CHEMBL623282,17655,N,BAO_0000218,1,,,,,50588
5451,1,Canis lupus familiaris,PAPP (membrane permeability) in dog kidney cell monolayer assay,A,9615.0,,,,CHEMBL623283,6596,N,BAO_0000218,1,,,,,50588
5452,1,Canis lupus familiaris,Oral bioavailability in dog,A,9615.0,,,,CHEMBL623284,3880,N,BAO_0000218,1,,,,,50588
5453,1,Canis lupus familiaris,Bioavailability administered orally at a dose of 10 mg/kg to dogs,A,9615.0,,,,CHEMBL623285,16367,N,BAO_0000218,1,,,,,50588
5454,1,Canis lupus familiaris,Plasma protein binding towards dog plasma at 10 uM,A,9615.0,Plasma,,,CHEMBL623463,17409,N,BAO_0000218,1,1969.0,,,,50588
5455,1,Canis lupus familiaris,Plasma protein binding towards dog plasma at 100 uM,A,9615.0,Plasma,,,CHEMBL875952,17409,N,BAO_0000218,1,1969.0,,,,50588
5456,1,Canis lupus familiaris,Bioavailability in dog (dose 4 mg/kg p.o.),A,9615.0,,,,CHEMBL621705,2959,N,BAO_0000218,1,,In vivo,,,50588
5457,1,Canis lupus familiaris,Bioavailability was determined after oral administration of compound 18 at a dose of 2 mg/kg to dog,A,9615.0,,,,CHEMBL621706,13501,N,BAO_0000218,1,,In vivo,,,50588
5458,1,Canis lupus familiaris,Bioavailability by oral administration at a dose of 10 uM/kg in dog was determined,A,9615.0,,,,CHEMBL621707,4527,N,BAO_0000218,1,,In vivo,,,50588
5459,1,Canis lupus familiaris,Bioavailability in dogs,A,9615.0,,,,CHEMBL621708,15145,N,BAO_0000218,1,,In vivo,,,50588
5460,1,Canis lupus familiaris,Bioavailability,A,9615.0,,,,CHEMBL621709,4219,N,BAO_0000218,1,,In vivo,,,50588
5461,1,Canis lupus familiaris,Oral bioavailability in dog (dose 10 mg/kg),A,9615.0,,,,CHEMBL621710,17538,N,BAO_0000218,1,,In vivo,,,50588
5462,1,Canis lupus familiaris,Bioavailability in dog after po administration at a dose of 10 mg/kg; nd is not determined,A,9615.0,,,,CHEMBL621711,17538,N,BAO_0000218,1,,In vivo,,,50588
5463,1,Canis lupus familiaris,Bioavailability in dog (dose 10.0 mg/kg p.o.),A,9615.0,,,,CHEMBL621712,1466,N,BAO_0000218,1,,In vivo,,,50588
5464,1,Canis lupus familiaris,Bioavailability was measured in dogs after an oral dose of 10 uM/kg,A,9615.0,,,,CHEMBL621713,17650,N,BAO_0000218,1,,In vivo,,,50588
5465,1,Canis lupus familiaris,Bioavailability was obtained by the comparison of AUC of intravenous dosing and AUC of oral dosing in dog,A,9615.0,,,,CHEMBL621714,3132,N,BAO_0000218,1,,In vivo,,,50588
5466,0,Mus sp.,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice kidney upon intraveneous administration at 2.6 gmol/mice after 3 hour,A,10095.0,,,,CHEMBL621715,2413,U,BAO_0000218,1,,,,,22224
5467,0,Mus sp.,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice liver upon intraveneous administration at 2.6 gmol/mice after 1 hour,A,10095.0,Liver,,,CHEMBL623717,2413,U,BAO_0000218,1,2107.0,,,,22224
5468,0,Mus sp.,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice liver upon intraveneous administration at 2.6 gmol/mice after 24 hour,A,10095.0,Liver,,,CHEMBL623718,2413,U,BAO_0000218,1,2107.0,,,,22224
5469,0,Mus sp.,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice liver upon intraveneous administration at 2.6 gmol/mice after 3 hour,A,10095.0,Liver,,,CHEMBL623719,2413,U,BAO_0000218,1,2107.0,,,,22224
5470,0,Mus sp.,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice lungs upon intraveneous administration at 2.6 gmol/mice after 1 hour,A,10095.0,,,,CHEMBL623720,2413,U,BAO_0000218,1,,,,,22224
5471,0,Mus sp.,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice lungs upon intraveneous administration at 2.6 gmol/mice after 3 hour,A,10095.0,,,,CHEMBL623721,2413,U,BAO_0000218,1,,,,,22224
5472,0,Mus sp.,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice muscle upon intraveneous administration at 2.6 gmol/mice after 1 hour,A,10095.0,Muscle tissue,,,CHEMBL623722,2413,U,BAO_0000218,1,2385.0,,,,22224
5473,0,Mus sp.,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice muscle upon intraveneous administration at 2.6 gmol/mice after 24 hour,A,10095.0,Muscle tissue,,,CHEMBL623723,2413,U,BAO_0000218,1,2385.0,,,,22224
5474,0,Mus sp.,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice muscle upon intraveneous administration at 2.6 gmol/mice after 3 hour,A,10095.0,Muscle tissue,,,CHEMBL618543,2413,U,BAO_0000218,1,2385.0,,,,22224
5475,0,Mus sp.,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice spleen upon intraveneous administration at 2.6 gmol/mice after 1 hour,A,10095.0,Spleen,,,CHEMBL618544,2413,U,BAO_0000218,1,2106.0,,,,22224
5476,0,Mus sp.,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice spleen upon intraveneous administration at 2.6 gmol/mice after 3 hour,A,10095.0,Spleen,,,CHEMBL875155,2413,U,BAO_0000218,1,2106.0,,,,22224
5477,0,Mus sp.,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice upon intraveneous administration at 2.6 gmol/mice after 1 hour,A,10095.0,,,,CHEMBL618545,2413,U,BAO_0000218,1,,,,,22224
5478,0,Mus sp.,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice upon intraveneous administration at 2.6 gmol/mice after 24 hour,A,10095.0,,,,CHEMBL618546,2413,U,BAO_0000218,1,,,,,22224
5479,0,Mus sp.,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice upon intraveneous administration at 2.6 gmol/mice after 3 hour,A,10095.0,,,,CHEMBL623529,2413,U,BAO_0000218,1,,,,,22224
5480,0,Mus sp.,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice uvea upon intraveneous administration at 2.6 gmol/mice after 24 hour,A,10095.0,,,,CHEMBL623530,2413,U,BAO_0000218,1,,,,,22224
5481,0,Mus sp.,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice uvea upon intraveneous administration at 2.6 gmol/mice after 3 hour,A,10095.0,,,,CHEMBL621764,2413,U,BAO_0000218,1,,,,,22224
5482,0,Cercopithecidae,Compound (i.v.) was evaluated for elimination rate constants in brainstem of rhesus monkeys (Radiolabeled compound),A,9527.0,,,,CHEMBL621765,17827,U,BAO_0000019,1,,,,,22224
5483,0,Cercopithecidae,Compound (i.v.) was evaluated for elimination rate constants in cerebellum of rhesus monkeys (Radiolabeled compound),A,9527.0,Cerebellum,,,CHEMBL621766,17827,U,BAO_0000019,1,2037.0,,,,22224
5484,0,Cercopithecidae,Compound (i.v.) was evaluated for elimination rate constants in frontal cortex of rhesus monkey (Radiolabeled compound),A,9527.0,Frontal cortex,,,CHEMBL621767,17827,U,BAO_0000019,1,1870.0,,,,22224
5485,0,Cercopithecidae,Compound (i.v.) was evaluated for elimination rate constants in jaw bone of rhesus monkeys; NA = not active (Radiolabeled compound),A,9527.0,,,,CHEMBL621768,17827,U,BAO_0000019,1,,,,,22224
5486,0,Cercopithecidae,Compound (i.v.) was evaluated for elimination rate constants in striatum of rhesus monkey (Radiolabeled compound),A,9527.0,Striatum,,,CHEMBL621769,17827,U,BAO_0000019,1,2435.0,,,,22224
5487,0,Cercopithecidae,Compound (i.v.) was evaluated for uptake rate constants in brainstem of rhesus monkeys (Radiolabeled compound),A,9527.0,,,,CHEMBL621770,17827,U,BAO_0000019,1,,,,,22224
5488,0,Cercopithecidae,Compound (i.v.) was evaluated for uptake rate constants in cerebellum of rhesus monkeys (Radiolabeled compound),A,9527.0,Cerebellum,,,CHEMBL621771,17827,U,BAO_0000019,1,2037.0,,,,22224
5489,0,Cercopithecidae,Compound (i.v.) was evaluated for uptake rate constants in frontal cortex of rhesus monkey (Radiolabeled compound),A,9527.0,Frontal cortex,,,CHEMBL621772,17827,U,BAO_0000019,1,1870.0,,,,22224
5490,0,Cercopithecidae,Compound (i.v.) was evaluated for uptake rate constants in jaw bone of rhesus monkey (Radiolabeled compound),A,9527.0,,,,CHEMBL621773,17827,U,BAO_0000019,1,,,,,22224
5491,0,Cercopithecidae,Compound (i.v.) was evaluated for uptake rate constants in striatum of rhesus monkeys (Radiolabeled compound),A,9527.0,Striatum,,,CHEMBL621774,17827,U,BAO_0000019,1,2435.0,,,,22224
5492,0,Cercopithecidae,Compound was evaluated for oral bioavailability in rats,A,9527.0,,,,CHEMBL621775,17791,U,BAO_0000218,1,,,,,22224
5493,0,Cercopithecidae,Maximum concentration of compound found in plasma at 5 mg/kg after oral administration,A,9527.0,Plasma,,,CHEMBL621776,17667,U,BAO_0000218,1,1969.0,In vivo,,,22224
5494,0,Cercopithecidae,Half life period was evaluated in monkey,A,9527.0,,,,CHEMBL621777,17791,U,BAO_0000019,1,,,,,22224
5495,0,Cercopithecidae,Half-life in rhesus monkeys by intravenous administration of dose,A,9527.0,,,,CHEMBL875162,110,U,BAO_0000218,1,,In vivo,,,22224
5496,1,Mus musculus,AUC (0-6 hr) after oral administration at 30 mg/kg in ICR mouse,A,10090.0,Plasma,,,CHEMBL621778,5781,N,BAO_0000218,1,1969.0,,,,50594
5497,1,Mus musculus,AUC after intraperitoneal administration of 100 mg/kg in mice,A,10090.0,Plasma,,,CHEMBL621779,17734,N,BAO_0000218,1,1969.0,,,,50594
5498,1,Mus musculus,AUC value was determined after oral administration,A,10090.0,Plasma,,,CHEMBL622479,17718,N,BAO_0000218,1,1969.0,,,,50594
5499,1,Mus musculus,Area under curve (AUC) determined at a dose 10 mg/kg administered intraperitoneally to mice,A,10090.0,,,,CHEMBL622480,4573,N,BAO_0000218,1,,,,,50594
5500,1,Mus musculus,Area under curve (AUC) was determined in mice at a single subcutaneous administration of 40 mg/kg (n=4),A,10090.0,,,,CHEMBL622481,3277,N,BAO_0000218,1,,,,,50594
5501,1,Mus musculus,Area under curve by ioral administration in mouse,A,10090.0,,,,CHEMBL622482,2862,N,BAO_0000218,1,,,,,50594
5502,1,Mus musculus,Area under curve by iv administration in mouse,A,10090.0,,,,CHEMBL622483,2862,N,BAO_0000218,1,,,,,50594
5503,1,Mus musculus,Area under curve at 0-8 hr in IRC mice after peroral administration,A,10090.0,,,,CHEMBL622484,5951,N,BAO_0000218,1,,,,,50594
5504,1,Mus musculus,Area under curve when injected i.p. in mice at a dose of 50 mg/kg,A,10090.0,,,,CHEMBL622641,17729,N,BAO_0000218,1,,,,,50594
5505,1,Mus musculus,Area under curve when injected intraperitoneally in BALB/C mice at a dose of 20 mg/kg,A,10090.0,,,,CHEMBL622642,17728,N,BAO_0000218,1,,,,,50594
5506,1,Mus musculus,Area under curve when injected intravenously in BALB/C mice at a dose of 20 mg/kg,A,10090.0,,,,CHEMBL622643,17728,N,BAO_0000218,1,,,,,50594
5507,1,Mus musculus,Area under curve when injected intravenously in mice at a dose of 20 mg/kg,A,10090.0,,,,CHEMBL622644,17729,N,BAO_0000218,1,,,,,50594
5508,1,Homo sapiens,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.01 ug/mL,F,9606.0,,,,CHEMBL622645,9424,N,BAO_0000219,1,,,,RPMI-8226,80433
5509,1,Homo sapiens,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.1 ug/mL,F,9606.0,,,,CHEMBL622646,9424,N,BAO_0000219,1,,,,RPMI-8226,80433
5510,1,Homo sapiens,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.1 ug/mL (*: >50% cell kill),F,9606.0,,,,CHEMBL621238,9424,N,BAO_0000219,1,,,,RPMI-8226,80433
5511,1,Homo sapiens,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.3 ug/mL (*: >50% cell kill),F,9606.0,,,,CHEMBL621239,9424,N,BAO_0000219,1,,,,RPMI-8226,80433
5512,1,Homo sapiens,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.5 ug/mL. (*: >1 log cell kill),F,9606.0,,,,CHEMBL621240,9424,N,BAO_0000219,1,,,,RPMI-8226,80433
5513,1,Homo sapiens,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 10 ug/mL (*: >1 log cell kill),F,9606.0,,,,CHEMBL621241,9424,N,BAO_0000219,1,,,,RPMI-8226,80433
5514,1,Homo sapiens,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 1 ug/mL. (*: >50% cell kill),F,9606.0,,,,CHEMBL621242,9424,N,BAO_0000219,1,,,,RPMI-8226,80433
5515,1,Homo sapiens,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 1 ug/mL. (*: >1 log cell kill),F,9606.0,,,,CHEMBL620350,9424,N,BAO_0000219,1,,,,RPMI-8226,80433
5516,1,Homo sapiens,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.01 ug/mL,F,9606.0,,,,CHEMBL620351,9424,N,BAO_0000219,1,,,,RPMI-8226,80433
5517,1,Homo sapiens,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.1 ug/mL,F,9606.0,,,,CHEMBL620352,9424,N,BAO_0000219,1,,,,RPMI-8226,80433
5518,1,Homo sapiens,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.1 ug/mL (*: >50% cell kill),F,9606.0,,,,CHEMBL620353,9424,N,BAO_0000219,1,,,,RPMI-8226,80433
5519,1,Homo sapiens,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.3 ug/mL (*: >50% cell kill),F,9606.0,,,,CHEMBL620354,9424,N,BAO_0000219,1,,,,RPMI-8226,80433
5520,1,Homo sapiens,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.5 ug/mL. (*: >1 log cell kill),F,9606.0,,,,CHEMBL620355,9424,N,BAO_0000219,1,,,,RPMI-8226,80433
5521,1,Homo sapiens,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 10 ug/mL (*: >1 log cell kill),F,9606.0,,,,CHEMBL620356,9424,N,BAO_0000219,1,,,,RPMI-8226,80433
5522,1,Homo sapiens,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 1 ug/mL. (*: >50% cell kill),F,9606.0,,,,CHEMBL620357,9424,N,BAO_0000219,1,,,,RPMI-8226,80433
5523,1,Homo sapiens,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 1 ug/mL. (*: >1 log cell kill),F,9606.0,,,,CHEMBL620358,9424,N,BAO_0000219,1,,,,RPMI-8226,80433
5524,1,Homo sapiens,In vitro inhibition of human 8226 myeloma tumor cell line growth.,F,9606.0,,,,CHEMBL620359,9424,N,BAO_0000219,1,,,,RPMI-8226,80433
5525,1,Homo sapiens,In vitro inhibition of tumor cell growth in the human myeloma 8226/ADR system.,F,9606.0,,,,CHEMBL620360,11544,N,BAO_0000219,1,,,,RPMI-8226,80433
5526,1,Homo sapiens,Cytotoxicity of compound against 8226/DOX1V cells,F,9606.0,,,,CHEMBL620361,17378,N,BAO_0000219,1,,,,RPMI-8226,80433
5527,1,Homo sapiens,Cytotoxicity of compound against 8226/S cells,F,9606.0,,,,CHEMBL620362,17378,N,BAO_0000219,1,,,,RPMI-8226,80433
5528,1,Homo sapiens,Inhibitory concentration against 8226 myeloma cancer cell line,F,9606.0,,,,CHEMBL620363,17079,N,BAO_0000219,1,,,,RPMI-8226,80433
5529,1,Homo sapiens,Inhibitory concentration against 8226/Dox40 (Dox-Re) cancer cell line,F,9606.0,,,,CHEMBL620364,17079,N,BAO_0000219,1,,,,RPMI-8226,80433
5530,1,Homo sapiens,Inhibition of cell growth was studied in human teratocarcinoma (833K).,F,9606.0,,,,CHEMBL620365,13466,N,BAO_0000219,1,,,,833K,80647
5531,1,Homo sapiens,Inhibition of cell growth was studied in human teratocarcinoma (833K); ND ='not determined',F,9606.0,,,,CHEMBL620366,13466,N,BAO_0000219,1,,,,833K,80647
5532,1,Homo sapiens,Tested in vitro for growth inhibitory activity against 833K (human teratorcarcinoma) cells,F,9606.0,,,,CHEMBL620367,2392,N,BAO_0000219,1,,,,833K,80647
5533,1,Homo sapiens,The compound was tested in vitro for growth inhibitory activity against 833K (human teratorcarcinoma) cells; No data,F,9606.0,,,,CHEMBL620368,2392,N,BAO_0000219,1,,,,833K,80647
5534,0,,Inhibitory activity against caspase-1,B,,,,,CHEMBL620369,6608,U,BAO_0000019,1,,,,,22226
5535,8,Enterococcus faecalis,Percent inhibition of DAla-DAla Ligase at 10e -3 M of the compound,B,1351.0,,,,CHEMBL620370,10199,H,BAO_0000357,1,,,,,45
5536,1,Homo sapiens,In vitro antiproliferative activity against 8701-BC human breast cancer cells at a concentration of (0-100 uM) for 72 hr using MTT assay,F,9606.0,,,,CHEMBL620371,17749,N,BAO_0000219,1,,,,8701-BC,80648
5537,1,Homo sapiens,In vitro antiproliferative activity against 8701-BC human breast cancer cells at a concentration of (0-100 uM,F,9606.0,,,,CHEMBL620372,17749,N,BAO_0000219,1,,,,8701-BC,80648
5538,0,,In vitro anticancer activity against 9 NCI colon cancer cell lines; inactive,F,,,,,CHEMBL876492,1229,U,BAO_0000019,1,,,,,22226
5539,0,,In vitro anticancer activity against 9 NCI melanoma cell lines; inactive,F,,,,,CHEMBL620373,1229,U,BAO_0000019,1,,,,,22226
5540,0,,In vitro anticancer activity against 9 NCI renal cancer cell lines; inactive,F,,,,,CHEMBL620374,1229,U,BAO_0000019,1,,,,,22226
5541,0,,Inhibitory activity was determined against 9-cis-epoxycarotenoid dioxygenase (NCED) expressed in Escherichia coli in presence of 9''-cis-neo-xanthin,B,,,,,CHEMBL620375,6390,U,BAO_0000019,1,,,,,22226
5542,0,Streptococcus pyogenes,Minimum inhibitory concentration against Streptococcus pyogenes 930MLSB,F,1314.0,,,,CHEMBL857902,16219,U,BAO_0000019,1,,,,,22226
5543,0,Streptococcus pyogenes,Minimum inhibitory concentration against Streptococcus pyogenes 930MLSB,F,1314.0,,,,CHEMBL620376,16219,U,BAO_0000019,1,,,,,22226
5544,8,,Percent inhibition against Cdc25C phosphatase at 50 uM of compound,B,,,,,CHEMBL620377,17043,H,BAO_0000357,1,,,,,11922
5545,1,Homo sapiens,Tested for in vitro cytotoxic potency of compound in 9KB assay,F,9606.0,,,,CHEMBL620378,6929,N,BAO_0000219,1,,,,KB ,81115
5546,1,Homo sapiens,Tested for in vitro cytotoxic potency of compound in 9KB assay,A,9606.0,,,,CHEMBL620379,6929,N,BAO_0000219,1,,,,KB ,81115
5547,0,Homo sapiens,In vitro cytotoxicity of compound was tested against 9KB cells.,F,9606.0,,,,CHEMBL620380,7083,U,BAO_0000219,1,,,,,22226
5548,1,Rattus norvegicus,Cytotoxic concentration against 9L cells was determined on day 3,F,10116.0,,,,CHEMBL884006,12446,N,BAO_0000219,1,,,,9L,80653
5549,1,Rattus norvegicus,Tested in vitro for anticancer activity against 9L cells,F,10116.0,,,,CHEMBL620381,15345,N,BAO_0000219,1,,,,9L,80653
5550,1,Rattus norvegicus,Tested in vitro for anticancer activity against 9L cells; Not determined,F,10116.0,,,,CHEMBL620382,15345,N,BAO_0000219,1,,,,9L,80653
5551,1,Homo sapiens,In vitro inhibitory activity against human A549 non-small cell lung tumor; Active,F,9606.0,,,,CHEMBL620383,6301,N,BAO_0000219,1,,,,A549,80682
5552,1,Homo sapiens,The compound was tested in vitro for its cytotoxicity against human A-549 cancer cell line by MTT method at 1 uM concentration; No inhibition,F,9606.0,,,,CHEMBL876493,4833,N,BAO_0000219,1,,,,A549,80682
5553,1,Homo sapiens,The compound was tested in vitro for its cytotoxicity against human A-549 cancer cell line by MTT method at 1 uM concentration; Significant inhibition,F,9606.0,,,,CHEMBL620384,4833,N,BAO_0000219,1,,,,A549,80682
5554,1,Homo sapiens,The compound was tested in vitro for its cytotoxicity against human A-549 cancer cell line by MTT method at 1 uM concentration; Slight inhibition,F,9606.0,,,,CHEMBL620385,4833,N,BAO_0000219,1,,,,A549,80682
5555,1,Homo sapiens,Cytotoxicity against human lung carcinoma A549 cell line,F,9606.0,,,,CHEMBL620386,13330,N,BAO_0000219,1,,,,A549,80682
5556,9,Homo sapiens,Ability to induce human IL-6 assay in A549 lung carcinoma cell line.,F,9606.0,,,,CHEMBL620387,17517,D,BAO_0000219,1,,,,A549,25
5557,9,Homo sapiens,"Ability to induce human IL-6 assay in A549 lung carcinoma cell line; n.r.: not reported, EC50 values not reported in cases were %dex e 35%.",F,9606.0,,,,CHEMBL621404,17517,D,BAO_0000219,1,,,,A549,25
5558,1,Homo sapiens,"In vitro growth inhibition of A549, lung carcinoma",F,9606.0,,,,CHEMBL621405,14425,N,BAO_0000219,1,,,,A549,80682
5559,1,Homo sapiens,"In vitro growth inhibition of A549, lung carcinoma.",F,9606.0,,,,CHEMBL621406,14425,N,BAO_0000219,1,,,,A549,80682
5560,1,Homo sapiens,In vitro cytotoxicity against A549 (human lung carcinoma) cell line.,F,9606.0,,,,CHEMBL621407,5228,N,BAO_0000219,1,,,,A549,80682
5561,1,Homo sapiens,Cytotoxic activity against human lung cancer A549 cell line was determined,F,9606.0,,,,CHEMBL621408,5351,N,BAO_0000219,1,,,,A549,80682
5562,1,Homo sapiens,Cytotoxicity against human solid tumor lung carcinoma A549 cell line,F,9606.0,,,,CHEMBL885345,12198,N,BAO_0000219,1,,,,A549,80682
5563,1,Homo sapiens,Cytotoxicity concentration against human lung carcinoma A-549 cell line,F,9606.0,,,,CHEMBL621409,13891,N,BAO_0000219,1,,,,A549,80682
5564,1,Homo sapiens,Cytotoxicity in A549 (human carcinoma) cell line.,F,9606.0,,,,CHEMBL876034,5677,N,BAO_0000219,1,,,,A549,80682
5565,1,Homo sapiens,Cytotoxicity on lung carcinoma (A-549) cell line,F,9606.0,,,,CHEMBL621410,13788,N,BAO_0000219,1,,,,A549,80682
5566,1,Homo sapiens,Effective dose against 50% reduction in Human lung carcinoma (A-549) cell number after 3-day incubation.,F,9606.0,,,,CHEMBL621411,13384,N,BAO_0000219,1,,,,A549,80682
5567,1,Homo sapiens,Effective dose of compound against replication of A549 cell line was evaluated,F,9606.0,,,,CHEMBL621412,6726,N,BAO_0000219,1,,,,A549,80682
5568,1,Homo sapiens,In vitro cytotoxic activity was determined against lung carcinoma (A549) cell line,F,9606.0,,,,CHEMBL621413,3455,N,BAO_0000219,1,,,,A549,80682
5569,1,Homo sapiens,In vitro cytotoxicity evaluated against human lung cancer (A549 cell line),F,9606.0,,,,CHEMBL621414,5726,N,BAO_0000219,1,,,,A549,80682
5570,1,Homo sapiens,In vitro cytotoxicity evaluated against human lung cancer (A549 cell line); NA is not active,F,9606.0,,,,CHEMBL621415,5726,N,BAO_0000219,1,,,,A549,80682
5571,1,Homo sapiens,The compound was evaluated for antiproliferative activity against A549 cell line,F,9606.0,,,,CHEMBL621416,3936,N,BAO_0000219,1,,,,A549,80682
5572,1,Homo sapiens,The compound was tested for tumor cell growth inhibitory activity against human lung carcinoma (A549) cell line.,F,9606.0,,,,CHEMBL621417,14991,N,BAO_0000219,1,,,,A549,80682
5573,1,Homo sapiens,Concentration required for growth inhibition of human lung carcinoma cell line A549,F,9606.0,,,,CHEMBL621418,5243,N,BAO_0000219,1,,,,A549,80682
5574,1,Homo sapiens,Cytotoxic activity against A549/ATCC non-small cell-lung cancer cell line,F,9606.0,,,,CHEMBL621419,12858,N,BAO_0000219,1,,,,A549,80682
5575,1,Homo sapiens,Growth inhibition against A549 cell line was evaluated,F,9606.0,,,,CHEMBL621420,6776,N,BAO_0000219,1,,,,A549,80682
5576,1,Homo sapiens,Growth inhibitory activity against A549 human solid tumor cell line using MTT assay,F,9606.0,,,,CHEMBL875823,16558,N,BAO_0000219,1,,,,A549,80682
5577,1,Homo sapiens,Inhibition of anchorage independent growth of human tumor cell line A549 K-ras-transformed in soft agar,F,9606.0,,,,CHEMBL621421,4583,N,BAO_0000219,1,,,,A549,80682
5578,1,Homo sapiens,Inhibitor activity against A549 (Human lung carcinoma)cell line with varying concentration of the drug for 72 hrs,F,9606.0,,,,CHEMBL621422,13514,N,BAO_0000219,1,,,,A549,80682
5579,1,Homo sapiens,Chemosensitivity against DT-diaphorase rich A549 cell lines,F,9606.0,,,,CHEMBL884014,15166,N,BAO_0000219,1,,,,A549,80682
5580,1,Homo sapiens,Compound tested against A549 lung carcinoma in the sulforhodamine B assay.,F,9606.0,,,,CHEMBL621423,13873,N,BAO_0000219,1,,,,A549,80682
5581,1,Homo sapiens,In vitro cytotoxicity against human A549 (lung cancer) cell line.,F,9606.0,,,,CHEMBL621424,6447,N,BAO_0000219,1,,,,A549,80682
5582,1,Homo sapiens,In vitro antitumor activity against A549 (lung) human tumor cell lines.,F,9606.0,,,,CHEMBL621425,2068,N,BAO_0000219,1,,,,A549,80682
5583,1,Homo sapiens,In vitro cytotoxic activity against human lung carcinoma A549 cell line,F,9606.0,,,,CHEMBL621426,1863,N,BAO_0000219,1,,,,A549,80682
5584,1,Homo sapiens,Compound was tested against A549 lung cancer cell line in the sulforhodamine B assay.,F,9606.0,,,,CHEMBL621427,13873,N,BAO_0000219,1,,,,A549,80682
5585,1,Homo sapiens,Compound was tested against A549 lung carcinoma cell line in the sulforhodamine B assay.,F,9606.0,,,,CHEMBL621428,13873,N,BAO_0000219,1,,,,A549,80682
5586,1,Homo sapiens,Tested against A549 lung carcinoma in the sulforhodamine B assay.,F,9606.0,,,,CHEMBL621429,13873,N,BAO_0000219,1,,,,A549,80682
5587,1,Homo sapiens,Compound was tested for cytotoxicity on A549 lung adenocarcinoma cell line using a proliferation assay (MTT reduction),F,9606.0,,,,CHEMBL621430,579,N,BAO_0000219,1,,,,A549,80682
5588,1,Homo sapiens,Compound was tested for cytotoxicity on A549 lung adenocarcinoma cell line using a proliferation assay (MTT reduction).,F,9606.0,,,,CHEMBL621431,579,N,BAO_0000219,1,,,,A549,80682
5589,1,Homo sapiens,Compound was tested for inhibition of growth of human lung carcinoma cell line A549 up to a conc of 10 uM; NI means no inhibition,F,9606.0,,,,CHEMBL621432,4584,N,BAO_0000219,1,,,,A549,80682
5590,1,Homo sapiens,Inhibition of NFkB (transcription factor) activation in A549 human lung carcinoma cell line,F,9606.0,,,,CHEMBL621433,5421,N,BAO_0000219,1,,,,A549,80682
5591,1,Homo sapiens,Compound was tested for its ability to inhibit tumor necrosis factor alpha (TNF alpha) induced apoptosis in A549 human lung carcinoma cell line,F,9606.0,,,,CHEMBL875824,5421,N,BAO_0000219,1,,,,A549,80682
5592,1,Homo sapiens,Compound was tested for its ability to inhibit tumor necrosis factor alpha (TNF alpha) induced apoptosis in A549 human lung carcinoma cell line at 20 uM concentration,F,9606.0,,,,CHEMBL621434,5421,N,BAO_0000219,1,,,,A549,80682
5593,1,Homo sapiens,Compound was tested for its ability to inhibit tumor necrosis factor alpha (TNF alpha) induced apoptosis in A549 human lung carcinoma cell line; NA=Not assayed,F,9606.0,,,,CHEMBL621435,5421,N,BAO_0000219,1,,,,A549,80682
5594,1,Homo sapiens,Compound was tested for potency against human lung A549 cells using sulforhodamine B assay.,F,9606.0,,,,CHEMBL621436,14188,N,BAO_0000219,1,,,,A549,80682
5595,1,Homo sapiens,Compound was tested for potency against human lung A549 cells using sulforhodamine B assay; UA=Potency was so low that the IC50 was unachievable.,F,9606.0,,,,CHEMBL621437,14188,N,BAO_0000219,1,,,,A549,80682
5596,1,Homo sapiens,Compound was tested for the growth inhibition of A549 lung tumor cell line,F,9606.0,,,,CHEMBL621438,15354,N,BAO_0000219,1,,,,A549,80682
5597,1,Homo sapiens,Growth inhibition of human non-small-lung carcinoma (A549) cell line,F,9606.0,,,,CHEMBL621439,14253,N,BAO_0000219,1,,,,A549,80682
5598,1,Homo sapiens,Compound was tested against A549 lung carcinoma cell line in the sulforhodamine B assay.,F,9606.0,,,,CHEMBL621440,13873,N,BAO_0000219,1,,,,A549,80682
5599,1,Canis lupus familiaris,Oral bioavailability in dog (conscious),A,9615.0,,,,CHEMBL621441,3043,N,BAO_0000218,1,,In vivo,,,50588
5600,1,Canis lupus familiaris,Compound was evaluated for the oral bioavailability after oral administration in dog.,A,9615.0,,,,CHEMBL621442,3045,N,BAO_0000218,1,,In vivo,,,50588
5601,1,Canis lupus familiaris,Compound was tested for percent of oral bioavailability at 10 mg/ml dose in dogs,A,9615.0,,,,CHEMBL621443,3022,N,BAO_0000218,1,,In vivo,,,50588
5602,1,Canis lupus familiaris,Oral bioavailability in dog,A,9615.0,,,,CHEMBL621444,4453,N,BAO_0000218,1,,In vivo,,,50588
5603,1,Canis lupus familiaris,Oral bioavailability in dog,A,9615.0,,,,CHEMBL625133,1696,N,BAO_0000218,1,,In vivo,,,50588
5604,1,Canis lupus familiaris,Oral bioavailability in dog,A,9615.0,,,,CHEMBL625134,5045,N,BAO_0000218,1,,In vivo,,,50588
5605,1,Canis lupus familiaris,Oral bioavailability in dog (fasted),A,9615.0,,,,CHEMBL625135,5356,N,BAO_0000218,1,,In vivo,,,50588
5606,1,Canis lupus familiaris,Oral bioavailability after intravenous administration in dogs at 1.2 uM/kg,A,9615.0,,,,CHEMBL625136,17764,N,BAO_0000218,1,,In vivo,,,50588
5607,1,Canis lupus familiaris,Oral bioavailability in dog,A,9615.0,,,,CHEMBL625137,6448,N,BAO_0000218,1,,In vivo,,,50588
5608,1,Canis lupus familiaris,Oral bioavailability in dog,A,9615.0,,,,CHEMBL625138,1475,N,BAO_0000218,1,,In vivo,,,50588
5609,1,Canis lupus familiaris,Percent bioavailability in dog,A,9615.0,,,,CHEMBL625139,3788,N,BAO_0000218,1,,In vivo,,,50588
5610,1,Canis lupus familiaris,Percent oral bioavailability of intravenously administered compound (6 mg/kg) was tested in dog,A,9615.0,,,,CHEMBL872264,3639,N,BAO_0000218,1,,In vivo,,,50588
5611,1,Canis lupus familiaris,Oral bioavailability in dog,A,9615.0,,,,CHEMBL625140,13397,N,BAO_0000218,1,,In vivo,,,50588
5612,1,Canis lupus familiaris,The compound was evaluated for bioavailability in dogs; 34-44,A,9615.0,,,,CHEMBL624436,2137,N,BAO_0000218,1,,In vivo,,,50588
5613,1,Canis lupus familiaris,Bioavailability in dog (dose 4 mg/kg p.o.),A,9615.0,,,,CHEMBL624437,2959,N,BAO_0000218,1,,In vivo,,,50588
5614,1,Canis lupus familiaris,Oral bioavailability in dog,A,9615.0,,,,CHEMBL872261,6448,N,BAO_0000218,1,,In vivo,,,50588
5615,1,Canis lupus familiaris,8 hour trough Blood level in dog was measured after administration of compound,A,9615.0,,,,CHEMBL624438,6084,N,BAO_0000218,1,,,,,50588
5616,1,Canis lupus familiaris,The compound was tested for maximum concentration ( Cmax ) in dog plasma.,A,9615.0,Plasma,,,CHEMBL624439,3639,N,BAO_0000218,1,1969.0,In vivo,,,50588
5617,1,Canis lupus familiaris,C24 after oral administration at 5 mg/kg,A,9615.0,,,,CHEMBL624440,6316,N,BAO_0000218,1,,,,,50588
5618,1,Canis lupus familiaris,Clearance after oral and iv dosing in dogs,A,9615.0,,,,CHEMBL624441,5238,N,BAO_0000218,1,,,,,50588
5619,1,Canis lupus familiaris,Clearance of the drug was measured in the plasma of dog,A,9615.0,Plasma,,,CHEMBL624442,17796,N,BAO_0000218,1,1969.0,,,,50588
5620,1,Canis lupus familiaris,Compound was evaluated for Clearance in dogs at a dose of 1 mpk intravenously,A,9615.0,,,,CHEMBL624443,2652,N,BAO_0000218,1,,,,,50588
5621,1,Canis lupus familiaris,CL (clearance) of compound was determined after intravenous administration in average of two dogs at a dose of 1 mg/kg,A,9615.0,,,,CHEMBL624444,5654,N,BAO_0000218,1,,In vivo,,,50588
5622,1,Canis lupus familiaris,Clearance of compound was determined in dogs,A,9615.0,,,,CHEMBL624445,6621,N,BAO_0000218,1,,In vivo,,,50588
5623,1,Canis lupus familiaris,Clearance on i.v. administration of 2 mg/kg was measured in dog,A,9615.0,,,,CHEMBL624446,6505,N,BAO_0000218,1,,In vivo,,,50588
5624,1,Canis lupus familiaris,Clearance of compound after both po and iv administration at a dose of 5 mg/kg and 2 mg/kg resp in dog,A,9615.0,,,,CHEMBL624447,5802,N,BAO_0000218,1,,In vivo,,,50588
5625,1,Canis lupus familiaris,Plasma clearance in dog was determined,A,9615.0,,,,CHEMBL624448,17267,N,BAO_0000218,1,,In vivo,,,50588
5626,1,Canis lupus familiaris,Plasma clearance in dog after 2 mg/kg by oral and 0.5 mg/kg by intravenous administration; ND is not determined,A,9615.0,,,,CHEMBL624449,4521,N,BAO_0000218,1,,In vivo,,,50588
5627,1,Canis lupus familiaris,Plasma clearance in dog after administration of 0.25 mg/kg iv,A,9615.0,,,,CHEMBL624450,6535,N,BAO_0000218,1,,In vivo,,,50588
5628,1,Canis lupus familiaris,Plasma clearance in dog after administration of 1 mg/kg iv,A,9615.0,,,,CHEMBL875942,6535,N,BAO_0000218,1,,In vivo,,,50588
5629,1,Canis lupus familiaris,Plasma clearance in dogs,A,9615.0,,,,CHEMBL624451,6535,N,BAO_0000218,1,,In vivo,,,50588
5630,1,Canis lupus familiaris,Plasma clearance by iv administration in dog at a dose of 0.3 mg/kg,A,9615.0,,,,CHEMBL624452,5542,N,BAO_0000218,1,,In vivo,,,50588
5631,1,Canis lupus familiaris,Plasma clearance was determined in canine following intravenous (iv) administration of drug (1 mg/kg).,A,9615.0,,,,CHEMBL624453,5199,N,BAO_0000218,1,,In vivo,,,50588
5632,1,Canis lupus familiaris,Plasma clearance after 15 mg/kg iv dose in Dogs,A,9615.0,,,,CHEMBL624454,16907,N,BAO_0000218,1,,In vivo,,,50588
5633,1,Canis lupus familiaris,Plasma clearance after 30 mg/kg po dose in Dogs,A,9615.0,,,,CHEMBL624455,16907,N,BAO_0000218,1,,In vivo,,,50588
5634,1,Canis lupus familiaris,Plasma administration to dogs,A,9615.0,,,,CHEMBL624456,16367,N,BAO_0000218,1,,In vivo,,,50588
5635,1,Canis lupus familiaris,Plasma clearance was determined,A,9615.0,,,,CHEMBL624457,5505,N,BAO_0000218,1,,In vivo,,,50588
5636,1,Canis lupus familiaris,Systemic clearance after intravenous administration (0.5 mg/kg) was determined in dog,A,9615.0,,,,CHEMBL624458,6215,N,BAO_0000218,1,,In vivo,,,50588
5637,1,Canis lupus familiaris,Tested for systemic clearance upon intravenous administration of 5.0 mg/Kg dose in dog,A,9615.0,,,,CHEMBL624459,1466,N,BAO_0000218,1,,In vivo,,,50588
5638,2,Homo sapiens,Intrinsic clearance in human liver microsomes,A,9606.0,Liver,Microsomes,,CHEMBL624460,5007,S,BAO_0000251,1,2107.0,In vitro,,,102164
5639,2,Homo sapiens,Intrinsic clearance in human liver microsomes,A,9606.0,Liver,Microsomes,,CHEMBL624461,5007,S,BAO_0000251,1,2107.0,In vitro,,,102164
5640,1,Canis lupus familiaris,Pharmacokinetic data at 0.5 mg/kg dose given to dogs intravenously.,A,9615.0,,,,CHEMBL875943,16452,N,BAO_0000218,1,,In vivo,,,50588
5641,1,Canis lupus familiaris,Pharmacokinetic data at 1 mg/kg dose given to dogs intravenously,A,9615.0,,,,CHEMBL624462,16452,N,BAO_0000218,1,,In vivo,,,50588
5642,1,Canis lupus familiaris,Clearance in dog (dose 1 mg/kg i.v.),A,9615.0,,,,CHEMBL624463,16452,N,BAO_0000218,1,,In vivo,,,50588
5643,1,Canis lupus familiaris,Plasma clearance after oral administration (2.5 mg/kg) in dog was determined,A,9615.0,,,,CHEMBL624464,6221,N,BAO_0000218,1,,In vivo,,,50588
5644,1,Canis lupus familiaris,Plasma clearance in dogs administered perorally (5 mg/kg) and intravenously (2 mg/kg),A,9615.0,,,,CHEMBL624465,5007,N,BAO_0000218,1,,In vivo,,,50588
5645,1,Canis lupus familiaris,Plasma clearance after peroral administration at 10 mpk in dog,A,9615.0,,,,CHEMBL624466,5668,N,BAO_0000218,1,,In vivo,,,50588
5646,1,Canis lupus familiaris,Plasma clearance after peroral administration at 5 mpk in dog,A,9615.0,,,,CHEMBL624467,5668,N,BAO_0000218,1,,In vivo,,,50588
5647,1,Canis lupus familiaris,Plasma clearance after peroral administration at 5 mg/kg in dog,A,9615.0,,,,CHEMBL624468,5668,N,BAO_0000218,1,,In vivo,,,50588
5648,1,Canis lupus familiaris,Plasma clearance was measured in dog,A,9615.0,,,,CHEMBL624469,15660,N,BAO_0000218,1,,In vivo,,,50588
5649,1,Canis lupus familiaris,Plasma clearance was measured in dog,A,9615.0,,,,CHEMBL624470,15660,N,BAO_0000218,1,,In vivo,,,50588
5650,1,Canis lupus familiaris,Pharmacokinetic property (CLtot) was measured in dog at the dose of 0.032 mg/kg i.v.,A,9615.0,,,,CHEMBL624471,5983,N,BAO_0000218,1,,In vivo,,,50588
5651,1,Canis lupus familiaris,Total clearance was determined after 0.1 mg/kg iv administration in dog,A,9615.0,,,,CHEMBL624472,5600,N,BAO_0000218,1,,In vivo,,,50588
5652,1,Canis lupus familiaris,Clearance of compound after intravenous administration in dogs at 1.2 uM/kg,A,9615.0,,,,CHEMBL622775,17764,N,BAO_0000218,1,,In vivo,,,50588
5653,1,Canis lupus familiaris,Clearance after intravenous administration of 0.5 mg/kg in dog was determined,A,9615.0,,,,CHEMBL622776,6039,N,BAO_0000218,1,,In vivo,,,50588
5654,1,Canis lupus familiaris,Clearance after intravenous administration of 1.0 mg/kg in dog was determined,A,9615.0,,,,CHEMBL622777,6039,N,BAO_0000218,1,,In vivo,,,50588
5655,1,Canis lupus familiaris,Clearance after peroral administration of 0.2 mg/kg in dog was determined,A,9615.0,,,,CHEMBL622778,6039,N,BAO_0000218,1,,In vivo,,,50588
5656,1,Canis lupus familiaris,Clearance by intravenous administration of 1.2 mg/kg in dog,A,9615.0,,,,CHEMBL622779,4368,N,BAO_0000218,1,,In vivo,,,50588
5657,1,Canis lupus familiaris,Clearance by iv administration in dogs at a dose of 1 mg/kg,A,9615.0,,,,CHEMBL622780,4305,N,BAO_0000218,1,,In vivo,,,50588
5658,1,Canis lupus familiaris,Clearance value was evaluated in dog plasma,A,9615.0,Plasma,,,CHEMBL622781,1918,N,BAO_0000218,1,1969.0,In vivo,,,50588
5659,1,Canis lupus familiaris,Clearance was evaluated after i.v. administration in dog at a dose of 1 mg/kg,A,9615.0,,,,CHEMBL622782,6005,N,BAO_0000218,1,,In vivo,,,50588
5660,1,Canis lupus familiaris,Compound was tested for plasma clearance in dog,A,9615.0,Plasma,,,CHEMBL622783,4839,N,BAO_0000218,1,1969.0,In vivo,,,50588
5661,1,Canis lupus familiaris,Pharmacokinetic property (Plasma clearance) was measured in dog,A,9615.0,,,,CHEMBL622784,4239,N,BAO_0000218,1,,In vivo,,,50588
5662,1,Mus musculus,Area under curve when injected perorally in mice at a dose of 50 mg/kg,A,10090.0,,,,CHEMBL622785,17729,N,BAO_0000218,1,,,,,50594
5663,1,Mus musculus,Area under curve when injected perorally in BALB/C mice at a dose of 50 mg/kg,A,10090.0,,,,CHEMBL622786,17728,N,BAO_0000218,1,,,,,50594
5664,1,Mus musculus,Area under curve value in mouse at a dose of 10 mg/kg,A,10090.0,,,,CHEMBL622787,5302,N,BAO_0000218,1,,,,,50594
5665,1,Mus musculus,Area under curve was determined at a dose of 100 mg/kg (i.p.) in Mice,A,10090.0,,,,CHEMBL875949,5506,N,BAO_0000218,1,,,,,50594
5666,1,Mus musculus,Area under curve was determined at a dose of 200 mg/kg (i.p.) in Mice,A,10090.0,,,,CHEMBL622788,5506,N,BAO_0000218,1,,,,,50594
5667,1,Mus musculus,Area under curve was determined for compound after intraperitoneal administration in mice at 18 uM/kg,F,10090.0,,,,CHEMBL622789,17764,N,BAO_0000218,1,,,,,50594
5668,1,Mus musculus,Area under curve was determined for compound after intraperitoneal administration in mice at 23 uM/kg,F,10090.0,,,,CHEMBL622790,17764,N,BAO_0000218,1,,,,,50594
5669,1,Mus musculus,Area under curve was determined for compound after intraperitoneal administration in mice at 25 uM/kg,F,10090.0,,,,CHEMBL622791,17764,N,BAO_0000218,1,,,,,50594
5670,1,Mus musculus,Area under curve was determined for compound after intraperitoneal administration in mice at 26 uM/kg,F,10090.0,,,,CHEMBL622792,17764,N,BAO_0000218,1,,,,,50594
5671,1,Mus musculus,Area under curve was determined for compound after intravenous administration in mice at 24 uM/kg,A,10090.0,,,,CHEMBL622793,17764,N,BAO_0000218,1,,,,,50594
5672,1,Mus musculus,Area under curve was determined for the compound at 24 mg/Kg,A,10090.0,,,,CHEMBL622794,17753,N,BAO_0000218,1,,,,,50594
5673,1,Mus musculus,Area under curve was determined for the compound at 40 mg/Kg,A,10090.0,,,,CHEMBL622795,17753,N,BAO_0000218,1,,,,,50594
5674,1,Mus musculus,Area under curve was determined for the compound at 5 mg/Kg,A,10090.0,,,,CHEMBL621803,17753,N,BAO_0000218,1,,,,,50594
5675,1,Mus musculus,Area under the curve for the compound is obtained at dose 25 mg/kg,A,10090.0,,,,CHEMBL621804,3132,N,BAO_0000218,1,,,,,50594
5676,1,Mus musculus,Area under the curve for the compound was obtained when tested in mouse,A,10090.0,,,,CHEMBL621805,3132,N,BAO_0000218,1,,,,,50594
5677,1,Mus musculus,Area under the curve of compound in mouse blood following i.v. administration of 10 mg/kg,A,10090.0,,,,CHEMBL621806,17837,N,BAO_0000218,1,,,,,50594
5678,1,Mus musculus,Area under the curve of compound in mouse blood following p.o. administration of 30 mg/kg,A,10090.0,,,,CHEMBL621807,17837,N,BAO_0000218,1,,,,,50594
5679,1,Mus musculus,Area under the curve was measured in mouse after an iv dose of 1 mg/kg,A,10090.0,,,,CHEMBL621808,6062,N,BAO_0000218,1,,,,,50594
5680,1,Mus musculus,Area under the curve was determined for the compound at a single subcutaneous administration of 40 mg/kg in mice,A,10090.0,,,,CHEMBL621809,4066,N,BAO_0000218,1,,,,,50594
5681,1,Mus musculus,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for area under curve (AUCtot),A,10090.0,,,,CHEMBL621810,16597,N,BAO_0000218,1,,,,,50594
5682,1,Mus musculus,Compound was evaluated for the area under the concentration - time curve by administering intravenously at 25 mg/kg in mice,A,10090.0,,,,CHEMBL875164,14239,N,BAO_0000218,1,,,,,50594
5683,1,Mus musculus,Compound was evaluated for the area under the concentration - time curve by administering orally at 25 mg/kg in mice,A,10090.0,,,,CHEMBL621811,14239,N,BAO_0000218,1,,,,,50594
5684,1,Mus musculus,"Compound was evaluated for the pharmacokinetic parameter, area under curve",A,10090.0,,,,CHEMBL621812,4890,N,BAO_0000218,1,,,,,50594
5685,1,Mus musculus,Evaluated for pharmacokinetic parameter area under curve in mouse at the dose 20 mg/kg (0-4 hr ),A,10090.0,,,,CHEMBL621813,429,N,BAO_0000218,1,,,,,50594
5686,1,Mus musculus,Evaluated for pharmacokinetic parameter area under curve in mouse at the dose 20 mg/kg (0-4 hr),A,10090.0,,,,CHEMBL621814,429,N,BAO_0000218,1,,,,,50594
5687,1,Mus musculus,In vivo area under curve (AUC) was determined in murine septicemia at dose of 100 mg/kg,A,10090.0,,,,CHEMBL621815,5969,N,BAO_0000218,1,,,,,50594
5688,1,Mus musculus,In vivo area under curve (AUC) was determined in murine septicemia at dose of 50 mg/kg,A,10090.0,,,,CHEMBL621816,5969,N,BAO_0000218,1,,,,,50594
5689,1,Mus musculus,In vivo area under curve (AUC) was determined in murine septicemia at dose of 50 mg/kg;ND=not determined,A,10090.0,,,,CHEMBL621817,5969,N,BAO_0000218,1,,,,,50594
5690,1,Mus musculus,Pharmacokinetic activity (AUC) in vivo after intravenous administration of 10 mg/kg in mouse,A,10090.0,,,,CHEMBL621818,6091,N,BAO_0000218,1,,,,,50594
5691,1,Mus musculus,Pharmacokinetic activity (AUC) in vivo after intravenous administration of 10 mg/kg in mouse;ND=Not determined,A,10090.0,,,,CHEMBL621819,6091,N,BAO_0000218,1,,,,,50594
5692,1,Mus musculus,Pharmacokinetic activity (AUC) in vivo after peroral administration of 10 mg/kg in mice,A,10090.0,,,,CHEMBL621820,6091,N,BAO_0000218,1,,,,,50594
5693,1,Mus musculus,Pharmacokinetic activity (AUC) in vivo after peroral administration of 10 mg/kg in mice;ND=Not determined,A,10090.0,,,,CHEMBL621821,6091,N,BAO_0000218,1,,,,,50594
5694,1,Mus musculus,Pharmacokinetic property (AUC) was determined after ip administration of 32 mg/kg in mice,A,10090.0,,,,CHEMBL621822,6178,N,BAO_0000218,1,,,,,50594
5695,1,Mus musculus,Pharmacokinetic property (AUC) was determined after po administration of 32 mg/kg in mice,A,10090.0,,,,CHEMBL619474,6178,N,BAO_0000218,1,,,,,50594
5696,1,Mus musculus,"Reduction in area under curve was determined in DIO mice by oral glucose tolerance test following a single i.p. dose (10 mg/kg, 30 min pre-treatment)",A,10090.0,,,,CHEMBL619475,6619,N,BAO_0000218,1,,,,,50594
5697,1,Mus musculus,"Reduction in area under curve was determined in ob/ob mice by oral glucose tolerance test following a single i.p. dose (10 mg/kg, 30 min pre-treatment)",A,10090.0,,,,CHEMBL619476,6619,N,BAO_0000218,1,,,,,50594
5698,1,Mus musculus,"The area under concentration-time curve(AUC) was determined at 5 mg/kg of compound dose, administered intravenously in mice",A,10090.0,,,,CHEMBL619477,3760,N,BAO_0000218,1,,,,,50594
5699,1,Mus musculus,"The area under concentration-time curve(AUC) was determined at 5 mg/kg of compound dose, administered perorally in mice",A,10090.0,,,,CHEMBL619478,3760,N,BAO_0000218,1,,,,,50594
5700,1,Mus musculus,"The area under concentration-time curve(AUC) was determined at 50 mg/kg of compound dose, administered intravenously in mice",A,10090.0,,,,CHEMBL619479,3760,N,BAO_0000218,1,,,,,50594
5701,1,Mus musculus,"The area under concentration-time curve(AUC) was determined at 50 mg/kg of compound dose, administered perorally in mice",A,10090.0,,,,CHEMBL619480,3760,N,BAO_0000218,1,,,,,50594
5702,1,Mus musculus,The area under curve in vivo in mouse blood level after oral administration at dose 50 mk/kg e-1,A,10090.0,,,,CHEMBL619481,3192,N,BAO_0000218,1,,,,,50594
5703,1,Mus musculus,The area under curve in vivo in mouse blood level after subcutaneous administration at dose 50 mk/kg e-1,A,10090.0,,,,CHEMBL619482,3192,N,BAO_0000218,1,,,,,50594
5704,1,Mus musculus,Area under the curve was evaluated in mice after intravenous administration,A,10090.0,,,,CHEMBL619483,2675,N,BAO_0000218,1,,,,,50594
5705,1,Mus musculus,Area under the curve was evaluated in mice after oral administration,A,10090.0,,,,CHEMBL619484,2675,N,BAO_0000218,1,,,,,50594
5706,1,Mus musculus,AUC total value at a dose of 10 mg/kg intravenous administration in mice.,A,10090.0,Plasma,,,CHEMBL619485,16597,N,BAO_0000218,1,1969.0,,,,50594
5707,1,Mus musculus,AUC total value at a dose of 10 mg/kg peroral administration in mice.,A,10090.0,Plasma,,,CHEMBL619486,16597,N,BAO_0000218,1,1969.0,,,,50594
5708,1,Mus musculus,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for area under curve (AUCtot),A,10090.0,,,,CHEMBL619487,16597,N,BAO_0000218,1,,,,,50594
5709,1,Mus musculus,AUMC after intraperitoneal administration of 100 mg/kg in mice,A,10090.0,,,,CHEMBL619488,17734,N,BAO_0000218,1,,,,,50594
5710,1,Mus musculus,Biodistribution in blood was determined in mice after iv administration at 15 min Value expressed as percent injected dose per gram,A,10090.0,Blood,,,CHEMBL620106,7767,N,BAO_0000218,1,178.0,In vivo,,,50594
5711,1,,The compound was tested in vitro for anticancer activity against 9L cells,F,,,,,CHEMBL620107,15345,N,BAO_0000219,1,,,,9L,80653
5712,0,Rattus norvegicus,Anti proliferation activity determined; Weak effect,F,10116.0,,,,CHEMBL620283,2181,U,BAO_0000019,1,,,,,22226
5713,0,Rattus norvegicus,Inhibition of cell growth by compound at a concentration of 100 uM in 9Ltk+ cells; Completely stopped the process,F,10116.0,,,,CHEMBL875176,2181,U,BAO_0000219,1,,,,,22226
5714,0,Rattus norvegicus,Inhibition of cell growth by compound at a concentration of 10 uM in 9Ltk+ cells,F,10116.0,,,,CHEMBL620284,2181,U,BAO_0000219,1,,,,,22226
5715,0,Rattus norvegicus,Inhibition of cell growth by compound at a concentration of 10 uM in 9Ltk+ cells; Completely stopped the process,F,10116.0,,,,CHEMBL623515,2181,U,BAO_0000219,1,,,,,22226
5716,0,Mus musculus,The cytotoxic activity was in vitro tested by 9PS assay method,F,10090.0,,,,CHEMBL623516,10486,U,BAO_0000019,1,,,,,22226
5717,0,Mus musculus,The cytotoxic activity was in vitro tested by 9PS assay method.,F,10090.0,,,,CHEMBL623517,10486,U,BAO_0000019,1,,,,,22226
5718,0,,Partition coefficient (logD6.5),A,,,,,CHEMBL857878,15508,U,BAO_0000019,1,,,,,22224
5719,1,Homo sapiens,Inhibitory concentration in vitro for cytotoxic activity against A 2780 human ovarian carcinoma cells,F,9606.0,,,,CHEMBL623518,5242,N,BAO_0000219,1,,,,A2780,81034
5720,1,Homo sapiens,Effective concentration against A 375 cell line growth (DFMO concentration is 5.0 mM),F,9606.0,,,,CHEMBL624195,16167,N,BAO_0000219,1,,,,A-375,80018
5721,1,Homo sapiens,Inhibitory concentration required against A 431 human epidermoid carcinoma cell line,F,9606.0,,,,CHEMBL624196,4782,N,BAO_0000219,1,,,,A-431,80852
5722,9,Homo sapiens,Inhibition of EGF-induced Tyrosine phosphorylation in A431 cells expressing EGF-R,F,9606.0,,,,CHEMBL624197,16093,D,BAO_0000219,1,,,,A-431,9
5723,1,Homo sapiens,Compound was evaluated for in vitro cytotoxicity against A 498 cancer cell line,F,9606.0,,,,CHEMBL624198,2596,N,BAO_0000219,1,,,,A498,80021
5724,1,Homo sapiens,in vitro cytotoxicity against A 498 cancer cell line,F,9606.0,,,,CHEMBL621287,2596,N,BAO_0000219,1,,,,A498,80021
5725,1,Homo sapiens,In vitro cytotoxic activity against renal (A 498) cancer cell line.,F,9606.0,,,,CHEMBL621288,3239,N,BAO_0000219,1,,,,A498,80021
5726,1,Homo sapiens,Cytotoxic activity against A 498 renal cancer cell lines.,F,9606.0,,,,CHEMBL876496,1847,N,BAO_0000219,1,,,,A498,80021
5727,1,Homo sapiens,In vitro cytotoxicity was determined against A 498 human renal tumor cell line using NCI screen,F,9606.0,,,,CHEMBL621289,10553,N,BAO_0000219,1,,,,A498,80021
5728,0,Staphylococcus aureus,Minimum inhibitory concentration against Staphylococcus aureus A 5177 MLSB-i,F,1280.0,,,,CHEMBL621290,16219,U,BAO_0000019,1,,,,,22226
5729,0,Staphylococcus aureus,Minimum inhibitory concentration against Staphylococcus aureus A 5177 MLSB-i,F,1280.0,,,,CHEMBL621291,16219,U,BAO_0000019,1,,,,,22226
5730,0,Staphylococcus aureus,Minimum inhibitory concentration against Staphylococcus aureus A 5278 MLSB-c,F,1280.0,,,,CHEMBL621292,16219,U,BAO_0000019,1,,,,,22226
5731,0,Staphylococcus aureus,Minimum inhibitory concentration against Staphylococcus aureus A 5278 MLSB-c,F,1280.0,,,,CHEMBL621293,16219,U,BAO_0000019,1,,,,,22226
5732,1,Homo sapiens,Inhibitory concentration required against A 549 lung cancer cell line,F,9606.0,,,,CHEMBL621294,4782,N,BAO_0000219,1,,,,A549,80682
5733,1,Homo sapiens,Growth inhibition of A 549 cell line by MTT reduction for 3 days of incubation time,F,9606.0,,,,CHEMBL621295,11805,N,BAO_0000219,1,,,,A549,80682
5734,1,Homo sapiens,Growth inhibition of A 549 cell line by MTT reduction for 7 days of incubation time,F,9606.0,,,,CHEMBL884007,11805,N,BAO_0000219,1,,,,A549,80682
5735,1,Homo sapiens,In vitro cytotoxicity against lung cancer A 549 cell lines,F,9606.0,,,,CHEMBL621296,2007,N,BAO_0000219,1,,,,A549,80682
5736,1,Homo sapiens,Compound was tested for its cytotoxicity against A 549 cell line,F,9606.0,,,,CHEMBL621297,4594,N,BAO_0000219,1,,,,A549,80682
5737,1,Homo sapiens,"Cytotoxic activity against A 549 human lung tumor cell line, using sulforhodamine B (SRB) assay.",F,9606.0,,,,CHEMBL839828,6018,N,BAO_0000219,1,,,,A549,80682
5738,1,Homo sapiens,"Cytotoxic activity against A 549 human lung tumor cell line, using sulforhodamine B (SRB) assay.; No data",F,9606.0,,,,CHEMBL620397,6018,N,BAO_0000219,1,,,,A549,80682
5739,1,Homo sapiens,In vitro cytotoxic activity against A 549 (non-small cell lung) using SRB (sulforhodamine B) assay,F,9606.0,,,,CHEMBL620398,3599,N,BAO_0000219,1,,,,A549,80682
5740,1,Homo sapiens,Tested for in vitro cytotoxicity against A 549 (human lung) tumor cell line using sulforhodamine B (SRB) assay,F,9606.0,,,,CHEMBL620399,2551,N,BAO_0000219,1,,,,A549,80682
5741,1,Homo sapiens,In vitro inhibition of A549 (human lung cancer) cell growth.,F,9606.0,,,,CHEMBL620400,16132,N,BAO_0000219,1,,,,A549,80682
5742,1,Homo sapiens,Cytotoxic related antitumor activity against human cancer cell lines A 549; No data available,F,9606.0,,,,CHEMBL620401,16132,N,BAO_0000219,1,,,,A549,80682
5743,1,Homo sapiens,Tested for in vitro cytotoxicity against A 549 (human lung) tumor cell line using sulforhodamine B (SRB) assay,F,9606.0,,,,CHEMBL620402,2551,N,BAO_0000219,1,,,,A549,80682
5744,1,Homo sapiens,Tested for in vitro cytotoxicity against A 549 (human lung) tumor cell line using sulforhodamine B (SRB) assay; not active (> 100 uM),F,9606.0,,,,CHEMBL620403,2551,N,BAO_0000219,1,,,,A549,80682
5745,0,,Tested against A II at (100 ng/kg iv) in Dawley rats (n=2). 24 h,F,,,,,CHEMBL620404,11913,U,BAO_0000218,1,,,,,22226
5746,4,,The duration of action for the % peak inhibition of A II pressor response for dose of 0.1 mg/kg intravenous administration in conscious dogs.,F,,,,,CHEMBL620405,12621,H,BAO_0000218,1,,In vivo,,,104694
5747,4,,The duration of action for the % peak inhibition of A II pressor response for dose of 1.0 mg/kg peroral administration in rhesus monkeys.,F,,,,,CHEMBL620406,12621,H,BAO_0000218,1,,In vivo,,,104694
5748,4,,The duration of action for the % peak inhibition of angiotensin II pressor response for dose of 0.1 mg/kg peroral administration in conscious rats.,F,,,,,CHEMBL620407,12621,H,BAO_0000218,1,,In vivo,,,104694
5749,4,,The compound was evaluated for the % peak inhibition of A II pressor response for dose of 0.3 mg/kg peroral administration in rhesus monkeys.,F,,,,,CHEMBL620408,12621,H,BAO_0000218,1,,In vivo,,,104694
5750,4,,The compound was evaluated for the percentage of inhibition of A II pressor response in rats for peroral administration.,F,,,,,CHEMBL620409,12621,H,BAO_0000218,1,,In vivo,,,104694
5751,1,Homo sapiens,Inhibition of A-498 human Renal cell proliferation,F,9606.0,,,,CHEMBL620410,3600,N,BAO_0000219,1,,,,A498,80021
5752,0,Rattus norvegicus,"Membrane potential change (fluorescence-based in vitro assay using DIBAC4 as indicator) in A-10 smooth muscle cell, to estimate potassium channel opening activity at 0.1 uM",F,10116.0,,,,CHEMBL620411,1796,U,BAO_0000019,1,,,,,22226
5753,0,Rattus norvegicus,"Membrane potential change (fluorescence-based in vitro assay using DIBAC4 as indicator) in A-10 smooth muscle cell, to estimate potassium channel opening activity at 1 uM",F,10116.0,,,,CHEMBL620412,1796,U,BAO_0000019,1,,,,,22226
5754,0,Rattus norvegicus,"Membrane potential change (fluorescence-based in vitro assay using DIBAC4 as indicator) in A-10 smooth muscle cell, to estimate potassium channel opening activity at 10 uM",F,10116.0,,,,CHEMBL876596,1796,U,BAO_0000019,1,,,,,22226
5755,1,Homo sapiens,Cytotoxicity against A-172 glioblastomas using MTT colorimetric assay,F,9606.0,,,,CHEMBL620413,16464,N,BAO_0000219,1,,,,A 172,80012
5756,1,Homo sapiens,Cytotoxicity against A-172 glioblastomas using MTT colorimetric assay; NE is no effect at 1x 10 E-5,F,9606.0,,,,CHEMBL620414,16464,N,BAO_0000219,1,,,,A 172,80012
5757,1,Homo sapiens,Cytotoxicity against A-172 glioblastomas using MTT colorimetric assay; NE is no effect at 1x 10 E-5,F,9606.0,,,,CHEMBL620415,16464,N,BAO_0000219,1,,,,A 172,80012
5758,1,Homo sapiens,Concentration required to inhibit growth of human tumor A549 (NSCL) cell line.,F,9606.0,,,,CHEMBL620416,13617,N,BAO_0000219,1,,,,A549,80682
5759,1,Homo sapiens,Concentration which produces 50% inhibition of growth of human lung carcinoma cell line A549,F,9606.0,,,,CHEMBL620417,4584,N,BAO_0000219,1,,,,A549,80682
5760,1,Homo sapiens,Cytotoxic activity evaluated against A549 tumor cells,F,9606.0,,,,CHEMBL620418,13799,N,BAO_0000219,1,,,,A549,80682
5761,1,Homo sapiens,Cytotoxic potentiation of Topotecan (TP) by the compound in human lung carcinoma A549 cell line,F,9606.0,,,,CHEMBL620419,16726,N,BAO_0000219,1,,,,A549,80682
5762,1,Homo sapiens,Cytotoxicity against A549 cells when the drug is exposed for a time of 1 hr,F,9606.0,,,,CHEMBL620420,16109,N,BAO_0000219,1,,,,A549,80682
5763,1,Homo sapiens,Cytotoxicity against A549 cells when the drug is exposed for a time of 96 hrs,F,9606.0,,,,CHEMBL620421,16109,N,BAO_0000219,1,,,,A549,80682
5764,1,Homo sapiens,Cytotoxicity against A549 tumor cell line determined by WST-1 assay,F,9606.0,,,,CHEMBL620422,15474,N,BAO_0000219,1,,,,A549,80682
5765,1,Homo sapiens,Cytotoxicity of compound against A549 cell line,F,9606.0,,,,CHEMBL620423,6851,N,BAO_0000219,1,,,,A549,80682
5766,1,Homo sapiens,Cytotoxicity against human lung cell carcinoma A549 cell line,F,9606.0,,,,CHEMBL620424,17534,N,BAO_0000219,1,,,,A549,80682
5767,1,Homo sapiens,Cytotoxicity against human lung carcinoma A549 cell line using MTT assay,F,9606.0,,,,CHEMBL620425,2621,N,BAO_0000219,1,,,,A549,80682
5768,1,Homo sapiens,Cytotoxicity was evaluated in vitro against A549 (non-small cell lung carcinoma) human tumor cell lines,F,9606.0,,,,CHEMBL620426,830,N,BAO_0000219,1,,,,A549,80682
5769,1,Homo sapiens,In vitro antitumor activity against A549 human non-small lung carcinoma cells containing 10% fetal bovine serum,F,9606.0,,,,CHEMBL620427,14255,N,BAO_0000219,1,,,,A549,80682
5770,1,Homo sapiens,In vitro antitumor activity against A549 human non-small lung carcinoma cells containing 10% fetal bovine serum; Not determined,F,9606.0,,,,CHEMBL620428,14255,N,BAO_0000219,1,,,,A549,80682
5771,1,Homo sapiens,In vitro antitumor activity against A549 human NSCLC lung carcinoma cells,F,9606.0,,,,CHEMBL620429,1590,N,BAO_0000219,1,,,,A549,80682
5772,1,Homo sapiens,In vitro concentration required to inhibit the TNF-alpha-induced RANTES production in A549 human lung epithelium cell line,F,9606.0,,,,CHEMBL620430,6146,N,BAO_0000219,1,,,,A549,80682
5773,1,Homo sapiens,In vitro cytotoxicity against A549 (human lung carcinoma) cell line.,F,9606.0,,,,CHEMBL839887,17427,N,BAO_0000219,1,,,,A549,80682
5774,1,Homo sapiens,In vitro cytotoxicity against parental and drug resistant lung human tumor cell line A549,F,9606.0,,,,CHEMBL620431,5280,N,BAO_0000219,1,,,,A549,80682
5775,1,Homo sapiens,In vitro cytotoxicity of compound against human A549 (non small cell lung) cancer cell line after 72 hr of drug exposure,F,9606.0,,,,CHEMBL884010,16786,N,BAO_0000219,1,,,,A549,80682
5776,1,Homo sapiens,In vitro cytotoxicity against A549 (human lung cancer),F,9606.0,,,,CHEMBL620538,5895,N,BAO_0000219,1,,,,A549,80682
5777,1,Homo sapiens,In vitro cytotoxicity against A-549 (human lung carcinoma) cell line.,F,9606.0,,,,CHEMBL620539,14297,N,BAO_0000219,1,,,,A549,80682
5778,1,Homo sapiens,In vivo antiproliferative activity against A549 cell line,F,9606.0,,,,CHEMBL623373,17824,N,BAO_0000218,1,,,,A549,80682
5779,1,Homo sapiens,Inhibition of non-small-cell lung adenocarcinoma (A549),F,9606.0,,,,CHEMBL623374,14368,N,BAO_0000219,1,,,,A549,80682
5780,1,Homo sapiens,Inhibition of non-small-cell lung adenocarcinoma (A549) after 48-h treatment,F,9606.0,,,,CHEMBL623375,14368,N,BAO_0000219,1,,,,A549,80682
5781,1,Homo sapiens,Inhibition of the growth against human non-small-lung carcinoma (A549) cell line after 72 hr exposure,F,9606.0,,,,CHEMBL623376,14254,N,BAO_0000219,1,,,,A549,80682
5782,1,Homo sapiens,Inhibitory activity against A549 cell line using MTT assay(Wild type p53),F,9606.0,,,,CHEMBL623377,15897,N,BAO_0000219,1,,,,A549,80682
5783,1,Homo sapiens,Inhibitory activity against A549 epithelial Cancer cell line at the concentration 0-30 uM for 48 hr,F,9606.0,,,,CHEMBL623378,13866,N,BAO_0000219,1,,,,A549,80682
5784,1,Homo sapiens,Inhibitory activity of compound against human A549 lung carcinoma cell line.,F,9606.0,,,,CHEMBL623379,13370,N,BAO_0000219,1,,,,A549,80682
5785,1,Homo sapiens,Inhibitory activity against A549 lung cancer cell line,F,9606.0,,,,CHEMBL623380,4862,N,BAO_0000219,1,,,,A549,80682
5786,1,Homo sapiens,Inhibitory activity against Taxol-resistant A549 lung cancer cell line,F,9606.0,,,,CHEMBL623381,4862,N,BAO_0000219,1,,,,A549,80682
5787,1,Homo sapiens,Inhibitory activity against Taxol-resistant A549 lung cancer cell line; not determined,F,9606.0,,,,CHEMBL623382,4862,N,BAO_0000219,1,,,,A549,80682
5788,1,Homo sapiens,Inhibitory concentration against A549 (lung cancer) cell line,F,9606.0,,,,CHEMBL623383,15970,N,BAO_0000219,1,,,,A549,80682
5789,1,Homo sapiens,In vitro cytotoxicity against A-549 (human lung carcinoma) cell line.,F,9606.0,,,,CHEMBL623384,17713,N,BAO_0000219,1,,,,A549,80682
5790,1,Homo sapiens,Tested in vitro for inhibitory effect on the growth of human A-549 cancer cell line,F,9606.0,,,,CHEMBL623385,4833,N,BAO_0000219,1,,,,A549,80682
5791,1,Homo sapiens,Activity against A549 cancer cell line.,F,9606.0,,,,CHEMBL623386,13736,N,BAO_0000219,1,,,,A549,80682
5792,1,Homo sapiens,The compound was evaluated for cytotoxicity against A549 cell line,F,9606.0,,,,CHEMBL884105,4312,N,BAO_0000219,1,,,,A549,80682
5793,1,Homo sapiens,The compound was examined for its ability to block tumor necrosis factor alpha (TNF alpha) induced IL-8 production in A549 human lung carcinoma cell line using an ELISA,F,9606.0,,,,CHEMBL623387,5421,N,BAO_0000219,1,,,,A549,80682
5794,1,Homo sapiens,The compound was tested for its ability to inhibit tumor necrosis factor alpha (TNF alpha) induced apoptosis in A549 human lung carcinoma cell line,F,9606.0,,,,CHEMBL621568,5421,N,BAO_0000219,1,,,,A549,80682
5795,1,Homo sapiens,Growth inhibitory activity was measured for human A549 tumor cell line.,F,9606.0,,,,CHEMBL621569,14717,N,BAO_0000219,1,,,,A549,80682
5796,1,Homo sapiens,Inhibitory activity against A549 lung cancer cell line,F,9606.0,,,,CHEMBL621570,4634,N,BAO_0000219,1,,,,A549,80682
5797,1,Homo sapiens,Inhibitory activity against A549 cell line; inactive,F,9606.0,,,,CHEMBL621571,1149,N,BAO_0000219,1,,,,A549,80682
5798,1,Homo sapiens,Inhibition of NFkB (transcription factor) activation in A549 human lung carcinoma cell line at 20 uM,F,9606.0,,,,CHEMBL621572,5421,N,BAO_0000219,1,,,,A549,80682
5799,1,Homo sapiens,Inhibition of NFkB (transcription factor) activation in A549 human lung carcinoma cell line at 20 uM,F,9606.0,,,,CHEMBL621573,5421,N,BAO_0000219,1,,,,A549,80682
5800,1,Homo sapiens,Compound was tested for its ability to inhibit tumor necrosis factor alpha (TNF alpha) induced apoptosis in A549 human lung carcinoma cell line at 20 uM concentration,F,9606.0,,,,CHEMBL621574,5421,N,BAO_0000219,1,,,,A549,80682
5801,1,Homo sapiens,In vitro cytotoxic activity against A549 tumor cell line by SRB assay at 72 hour at a concentration 10E-4 (M/L),F,9606.0,,,,CHEMBL621575,3320,N,BAO_0000219,1,,,,A549,80682
5802,1,Homo sapiens,In vitro cytotoxic activity against A549 tumor cell line by SRB assay at 72 hour at a concentration 10E-5 (M/L),F,9606.0,,,,CHEMBL621576,3320,N,BAO_0000219,1,,,,A549,80682
5803,1,Homo sapiens,In vitro cytotoxic activity against A549 tumor cell line by SRB assay at 72 hour at a concentration 10E-6 (M/L),F,9606.0,,,,CHEMBL621577,3320,N,BAO_0000219,1,,,,A549,80682
5804,1,Homo sapiens,In vitro cytotoxic activity against A549 tumor cell line by SRB assay at 72 hour at a concentration 10E-7 (M/L),F,9606.0,,,,CHEMBL621578,3320,N,BAO_0000219,1,,,,A549,80682
5805,1,Homo sapiens,In vitro cytotoxic activity against A549 tumor cell line by SRB assay at 72 hour at a concentration 10E-8 (M/L),F,9606.0,,,,CHEMBL621579,3320,N,BAO_0000219,1,,,,A549,80682
5806,1,Homo sapiens,In vitro percent inhibition evaluated against human lung cancer (A549 cell line) at >20 ug/mL,F,9606.0,,,,CHEMBL621580,5726,N,BAO_0000219,1,,,,A549,80682
5807,1,Canis lupus familiaris,Plasma clearance (in vivo) in mongrel dogs was determined,A,9615.0,,,,CHEMBL621581,17800,N,BAO_0000218,1,,In vivo,,,50588
5808,1,Canis lupus familiaris,Plasma clearance was measured in dog,A,9615.0,,,,CHEMBL621582,5985,N,BAO_0000218,1,,In vivo,,,50588
5809,1,Canis lupus familiaris,Plasma clearance in vivo in dog by intravenous administration at a dose of 0.2 mg/kg,A,9615.0,,,,CHEMBL621583,5530,N,BAO_0000218,1,,In vivo,,,50588
5810,1,Canis lupus familiaris,Plasma clearance in vivo in dog by intravenous administration at a dose of 1 mg/kg,A,9615.0,,,,CHEMBL621584,5530,N,BAO_0000218,1,,In vivo,,,50588
5811,1,Canis lupus familiaris,Tested for plasma clearance in dog,A,9615.0,Plasma,,,CHEMBL621585,4839,N,BAO_0000218,1,1969.0,In vivo,,,50588
5812,1,Canis lupus familiaris,The compound was tested for clearance in dog plasma.,A,9615.0,,,,CHEMBL621586,3639,N,BAO_0000218,1,,In vivo,,,50588
5813,1,Canis lupus familiaris,"The pharmacokinetic parameter, clearance was reported in dog after intravenous administration",A,9615.0,,,,CHEMBL875835,4838,N,BAO_0000218,1,,In vivo,,,50588
5814,1,Canis lupus familiaris,Clearance value of compound was determined after intravenous administration of 1 mg/kg/h in dog,A,9615.0,,,,CHEMBL621587,4137,N,BAO_0000218,1,,In vivo,,,50588
5815,1,Canis lupus familiaris,Compound was tested for its ability of plasma clearance when administered in dog perorally (1 mg/kg) and intravenously (0.2 mg/kg),A,9615.0,Plasma,,,CHEMBL621588,5017,N,BAO_0000218,1,1969.0,In vivo,,,50588
5816,1,Canis lupus familiaris,In vitro clearance in dog liver microsomes,A,9615.0,Liver,Microsomes,,CHEMBL621589,17538,N,BAO_0000218,1,2107.0,In vitro,,,50588
5817,1,Canis lupus familiaris,Pharmacokinetic profile in terms of clearance was determined at a dose of 0.5 mg/kg administered intravenously in dog,A,9615.0,,,,CHEMBL621590,6161,N,BAO_0000218,1,,In vivo,,,50588
5818,1,Canis lupus familiaris,Pharmacokinetic profile in terms of clearance was determined at a dose of 5 mg/kg administered intravenously in dog,A,9615.0,,,,CHEMBL621591,6161,N,BAO_0000218,1,,In vivo,,,50588
5819,1,Canis lupus familiaris,Plasma clearance in dog,A,9615.0,,,,CHEMBL621592,1696,N,BAO_0000218,1,,In vivo,,,50588
5820,1,Canis lupus familiaris,Clearance rate in dog,A,9615.0,,,,CHEMBL621593,6762,N,BAO_0000218,1,,In vivo,,,50588
5821,1,Canis lupus familiaris,Plasma concentration in dogs after 2 hr at 30mg/kg oral dose,A,9615.0,Plasma,,,CHEMBL621594,5932,N,BAO_0000218,1,1969.0,In vivo,,,50588
5822,1,Canis lupus familiaris,Clearance in dogs,A,9615.0,,,,CHEMBL621595,6305,N,BAO_0000218,1,,In vivo,,,50588
5823,1,Canis lupus familiaris,Plasma clearance in dogs,A,9615.0,,,,CHEMBL621596,4942,N,BAO_0000218,1,,In vivo,,,50588
5824,1,Canis lupus familiaris,Plasma clearance was determined,A,9615.0,,,,CHEMBL621597,4219,N,BAO_0000218,1,,In vivo,,,50588
5825,1,Canis lupus familiaris,Lower clearance in dog (i.v.) at 0.5 mpk,A,9615.0,,,,CHEMBL621598,17853,N,BAO_0000218,1,,In vivo,,,50588
5826,1,Canis lupus familiaris,Plasma clearance in Beagle dogs,A,9615.0,,,,CHEMBL621599,4514,N,BAO_0000218,1,,In vivo,,,50588
5827,1,Canis lupus familiaris,Plasma clearance (Clp) in dog,A,9615.0,,,,CHEMBL875836,6448,N,BAO_0000218,1,,In vivo,,,50588
5828,1,Canis lupus familiaris,Plasma clearance (pharmacokinetic parameter) in dog (in vivo) at a dose of 1 mg/kg,A,9615.0,,,,CHEMBL621600,6227,N,BAO_0000218,1,,In vivo,,,50588
5829,1,Canis lupus familiaris,Plasma clearance (pharmacokinetic parameter) in dog was determined,A,9615.0,,,,CHEMBL621601,6227,N,BAO_0000218,1,,In vivo,,,50588
5830,1,Canis lupus familiaris,Plasma clearance for the compound was measured in dog after an iv dose of 1 mg/kg,A,9615.0,,,,CHEMBL618474,6062,N,BAO_0000218,1,,In vivo,,,50588
5831,1,Canis lupus familiaris,Plasma clearance of compound was determined in dog,A,9615.0,,,,CHEMBL618475,6821,N,BAO_0000218,1,,In vivo,,,50588
5832,1,Canis lupus familiaris,Plasma clearance after intravenous administration of 1 mg/kg in dog,A,9615.0,,,,CHEMBL624524,4709,N,BAO_0000218,1,,In vivo,,,50588
5833,1,Canis lupus familiaris,Plasma clearance in dog after 2 mg/kg by oral and 0.5 mg/kg by intravenous administration,A,9615.0,,,,CHEMBL624525,4521,N,BAO_0000218,1,,In vivo,,,50588
5834,1,Canis lupus familiaris,Plasma clearance in dog was determined,A,9615.0,,,,CHEMBL624526,5374,N,BAO_0000218,1,,In vivo,,,50588
5835,1,Canis lupus familiaris,Plasma clearance was calculated in dog,A,9615.0,,,,CHEMBL624527,6057,N,BAO_0000218,1,,In vivo,,,50588
5836,1,Canis lupus familiaris,Plasma clearance at the dose of 2 mg/kg in dog,A,9615.0,,,,CHEMBL624528,4727,N,BAO_0000218,1,,In vivo,,,50588
5837,1,Canis lupus familiaris,Plasma clearance in dog,A,9615.0,,,,CHEMBL624529,5145,N,BAO_0000218,1,,In vivo,,,50588
5838,1,Canis lupus familiaris,Plasma clearance in dog,A,9615.0,,,,CHEMBL624530,17657,N,BAO_0000218,1,,In vivo,,,50588
5839,1,Canis lupus familiaris,Plasma clearance in dog; Unable to calculate,A,9615.0,,,,CHEMBL624531,17657,N,BAO_0000218,1,,In vivo,,,50588
5840,1,Canis lupus familiaris,Plasma clearance in rhesus monkey,A,9615.0,,,,CHEMBL624532,5145,N,BAO_0000218,1,,In vivo,,,50588
5841,1,Canis lupus familiaris,Plasma clearance in dog (dosed as a mixture of five compounds at 0.5 mpk each via iv only),A,9615.0,,,,CHEMBL624533,6642,N,BAO_0000218,1,,In vivo,,,50588
5842,1,Canis lupus familiaris,Plasma clearance in dog (dosed at 0.5 mpk iv and 2.0 mpk orally),A,9615.0,,,,CHEMBL624534,6641,N,BAO_0000218,1,,In vivo,,,50588
5843,1,Canis lupus familiaris,Plasma clearance in dog (dosed at 0.5 mpk iv and 2.0 mpk orally),A,9615.0,,,,CHEMBL624535,6642,N,BAO_0000218,1,,In vivo,,,50588
5844,1,Canis lupus familiaris,Plasma clearance was evaluated in dog,A,9615.0,,,,CHEMBL624536,5472,N,BAO_0000218,1,,In vivo,,,50588
5845,1,Canis lupus familiaris,Plasma clearance was evaluated in dog; Not tested,A,9615.0,,,,CHEMBL624537,5472,N,BAO_0000218,1,,In vivo,,,50588
5846,1,Canis lupus familiaris,Plasma clearance was evaluated in rhesus,A,9615.0,,,,CHEMBL624538,5472,N,BAO_0000218,1,,In vivo,,,50588
5847,1,Canis lupus familiaris,Plasma clearance was evaluated in rhesus; Not tested,A,9615.0,,,,CHEMBL624539,5472,N,BAO_0000218,1,,In vivo,,,50588
5848,1,Canis lupus familiaris,Plasma clearance value was determined in dog after a 3 mg/kg of iv dose,A,9615.0,,,,CHEMBL624540,4257,N,BAO_0000218,1,,In vivo,,,50588
5849,1,Canis lupus familiaris,Plasma clearance was determined after 1 mg/kg (i.v.) / 2 mg/kg (p.o.) of compound administration,A,9615.0,,,,CHEMBL624541,6679,N,BAO_0000218,1,,In vivo,,,50588
5850,1,Canis lupus familiaris,Plasma clearance was determined in Beagle dog at a dose of 1 mg/kg by iv administration,A,9615.0,,,,CHEMBL624542,5546,N,BAO_0000218,1,,In vivo,,,50588
5851,1,Canis lupus familiaris,Plasma clearance was determined in dog after 1 mg/kg (i.v.) and 5 mg/kg (p.o.) administration,A,9615.0,,,,CHEMBL624543,6348,N,BAO_0000218,1,,In vivo,,,50588
5852,1,Canis lupus familiaris,Clearance value at a dose of 0.2 mg/kg i.v.,A,9615.0,,,,CHEMBL624544,5474,N,BAO_0000218,1,,In vivo,,,50588
5853,1,Canis lupus familiaris,Cmax (Maximum (Peak) plasma drug concentration) was after oral administration at 5 mg/kg,A,9615.0,Plasma,,,CHEMBL624545,6316,N,BAO_0000218,1,1969.0,In vivo,,,50588
5854,1,Canis lupus familiaris,Cmax after oral dose of compound at 3 mg/kg in dogs,A,9615.0,,,,CHEMBL624546,17594,N,BAO_0000218,1,,In vivo,,,50588
5855,1,Canis lupus familiaris,Cmax after single intravenous bolus of 1 mg/kg in dogs,A,9615.0,,,,CHEMBL875957,17594,N,BAO_0000218,1,,In vivo,,,50588
5856,1,Canis lupus familiaris,Cmax of compound after both po and iv administration at a dose of 5 mg/kg and 2 mg/kg resp in dog,A,9615.0,,,,CHEMBL624547,5802,N,BAO_0000218,1,,In vivo,,,50588
5857,1,Canis lupus familiaris,Cmax in dog after administration of 0.25 mg/kg iv; ND = not determined,A,9615.0,,,,CHEMBL624548,6535,N,BAO_0000218,1,,In vivo,,,50588
5858,1,Canis lupus familiaris,Cmax in dog after administration of 1 mg/kg iv,A,9615.0,,,,CHEMBL624549,6535,N,BAO_0000218,1,,In vivo,,,50588
5859,1,Canis lupus familiaris,Cmax in plasma was determined upon peroral administration of 10.0 mg/Kg dose in dog,A,9615.0,Plasma,,,CHEMBL624550,1466,N,BAO_0000218,1,1969.0,In vivo,,,50588
5860,1,Canis lupus familiaris,Cmax on p.o. administration of 10 mg/kg was measured in dog,A,9615.0,,,,CHEMBL621613,6505,N,BAO_0000218,1,,In vivo,,,50588
5861,1,Canis lupus familiaris,Cmax was determine after peroral administration at 10 mpk in dog,A,9615.0,,,,CHEMBL621614,5668,N,BAO_0000218,1,,In vivo,,,50588
5862,1,Canis lupus familiaris,Cmax was determine after peroral administration at 5 mpk in dog,A,9615.0,,,,CHEMBL623431,5668,N,BAO_0000218,1,,In vivo,,,50588
5863,1,Canis lupus familiaris,Cmax was determine after peroral administration at 5 mg/kg in dog,A,9615.0,,,,CHEMBL623432,5668,N,BAO_0000218,1,,In vivo,,,50588
5864,1,Canis lupus familiaris,Cmax after 0.3 mg/kg po administration in dog,A,9615.0,,,,CHEMBL623433,5600,N,BAO_0000218,1,,In vivo,,,50588
5865,1,Canis lupus familiaris,Cmax after peroral administration in dogs at 2.4 uM/kg,A,9615.0,,,,CHEMBL623434,17764,N,BAO_0000218,1,,In vivo,,,50588
5866,1,Canis lupus familiaris,Cmax in dog after oral administration at 1 mg/kg,A,9615.0,,,,CHEMBL623435,6123,N,BAO_0000218,1,,In vivo,,,50588
5867,1,Canis lupus familiaris,Cmax in dog after oral administration at 1 mg/kg; Below the level of quantitation,A,9615.0,,,,CHEMBL623436,6123,N,BAO_0000218,1,,In vivo,,,50588
5868,1,Canis lupus familiaris,Cmax upon oral administration in male Beagle dog at 10 mg/kg,A,9615.0,,,,CHEMBL875958,6757,N,BAO_0000218,1,,In vivo,,,50588
5869,1,Canis lupus familiaris,Cmax value after 15 mg/kg iv dose in Dogs,A,9615.0,,,,CHEMBL623437,16907,N,BAO_0000218,1,,In vivo,,,50588
5870,1,Mus musculus,Biodistribution in blood was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,A,10090.0,Blood,,,CHEMBL623438,7767,N,BAO_0000218,1,178.0,In vivo,,,50594
5871,1,Mus musculus,Biodistribution in blood was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,A,10090.0,Blood,,,CHEMBL623439,7767,N,BAO_0000218,1,178.0,In vivo,,,50594
5872,1,Mus musculus,Biodistribution in bone was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,A,10090.0,Bone,,,CHEMBL623440,7767,N,BAO_0000218,1,10000001.0,In vivo,,,50594
5873,1,Mus musculus,Biodistribution in bone was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,A,10090.0,Bone,,,CHEMBL623441,7767,N,BAO_0000218,1,10000001.0,In vivo,,,50594
5874,1,Mus musculus,Biodistribution in bone was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,A,10090.0,Bone,,,CHEMBL623442,7767,N,BAO_0000218,1,10000001.0,In vivo,,,50594
5875,1,Mus musculus,Biodistribution in fat and fur was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,A,10090.0,,,,CHEMBL623469,7767,N,BAO_0000218,1,,In vivo,,,50594
5876,1,Mus musculus,Biodistribution in fat and fur was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,A,10090.0,,,,CHEMBL623470,7767,N,BAO_0000218,1,,In vivo,,,50594
5877,1,Mus musculus,Biodistribution in fat and fur was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,A,10090.0,,,,CHEMBL623471,7767,N,BAO_0000218,1,,In vivo,,,50594
5878,1,Mus musculus,Biodistribution in heart was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,A,10090.0,Heart,,,CHEMBL623472,7767,N,BAO_0000218,1,948.0,In vivo,,,50594
5879,1,Mus musculus,Biodistribution in heart was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,A,10090.0,Heart,,,CHEMBL623473,7767,N,BAO_0000218,1,948.0,In vivo,,,50594
5880,1,Mus musculus,Biodistribution in heart was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,A,10090.0,Heart,,,CHEMBL623474,7767,N,BAO_0000218,1,948.0,In vivo,,,50594
5881,1,Mus musculus,Biodistribution in kidney was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,A,10090.0,Kidney,,,CHEMBL623475,7767,N,BAO_0000218,1,2113.0,In vivo,,,50594
5882,1,Mus musculus,Biodistribution in kidney was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,A,10090.0,Kidney,,,CHEMBL623476,7767,N,BAO_0000218,1,2113.0,In vivo,,,50594
5883,1,Mus musculus,Biodistribution in kidney was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,A,10090.0,Kidney,,,CHEMBL623477,7767,N,BAO_0000218,1,2113.0,In vivo,,,50594
5884,1,Mus musculus,Biodistribution in large intestine after iv administration at 1 hr; Value expressed as percent injected dose per gram,A,10090.0,Intestine,,,CHEMBL621896,7767,N,BAO_0000218,1,160.0,In vivo,,,50594
5885,1,Mus musculus,Biodistribution in large intestine was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,A,10090.0,Intestine,,,CHEMBL621897,7767,N,BAO_0000218,1,160.0,In vivo,,,50594
5886,1,Mus musculus,Biodistribution in large intestine was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,A,10090.0,Intestine,,,CHEMBL621898,7767,N,BAO_0000218,1,160.0,In vivo,,,50594
5887,1,Mus musculus,Biodistribution in liver was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,A,10090.0,Liver,,,CHEMBL621899,7767,N,BAO_0000218,1,2107.0,In vivo,,,50594
5888,1,Mus musculus,Biodistribution in liver was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,A,10090.0,Liver,,,CHEMBL621900,7767,N,BAO_0000218,1,2107.0,In vivo,,,50594
5889,1,Mus musculus,Biodistribution in liver was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,A,10090.0,Liver,,,CHEMBL621901,7767,N,BAO_0000218,1,2107.0,In vivo,,,50594
5890,1,Mus musculus,Biodistribution in lung was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,A,10090.0,Lung,,,CHEMBL621902,7767,N,BAO_0000218,1,2048.0,In vivo,,,50594
5891,1,Mus musculus,Biodistribution in lung was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,A,10090.0,Lung,,,CHEMBL621903,7767,N,BAO_0000218,1,2048.0,In vivo,,,50594
5892,1,Mus musculus,Biodistribution in lung was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,A,10090.0,Lung,,,CHEMBL622587,7767,N,BAO_0000218,1,2048.0,In vivo,,,50594
5893,1,Mus musculus,Biodistribution in muscle was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,A,10090.0,Muscle tissue,,,CHEMBL620285,7767,N,BAO_0000218,1,2385.0,In vivo,,,50594
5894,1,Mus musculus,Biodistribution in muscle was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,A,10090.0,Muscle tissue,,,CHEMBL875285,7767,N,BAO_0000218,1,2385.0,In vivo,,,50594
5895,1,Mus musculus,Biodistribution in muscle was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,A,10090.0,Muscle tissue,,,CHEMBL620286,7767,N,BAO_0000218,1,2385.0,In vivo,,,50594
5896,1,Mus musculus,Biodistribution in pancreatic tissue was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,A,10090.0,,,,CHEMBL620287,7767,N,BAO_0000218,1,,In vivo,,,50594
5897,1,Mus musculus,Biodistribution in pancreatic tissue was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,A,10090.0,,,,CHEMBL620288,7767,N,BAO_0000218,1,,In vivo,,,50594
5898,1,Mus musculus,Biodistribution in pancreatic tissue was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,A,10090.0,,,,CHEMBL620289,7767,N,BAO_0000218,1,,In vivo,,,50594
5899,1,Mus musculus,Biodistribution in small intestine was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,A,10090.0,Intestine,,,CHEMBL620290,7767,N,BAO_0000218,1,160.0,In vivo,,,50594
5900,1,Mus musculus,Biodistribution in small intestine was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,A,10090.0,Intestine,,,CHEMBL620291,7767,N,BAO_0000218,1,160.0,In vivo,,,50594
5901,1,Mus musculus,Biodistribution in small intestine was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,A,10090.0,Intestine,,,CHEMBL620292,7767,N,BAO_0000218,1,160.0,In vivo,,,50594
5902,1,Mus musculus,Biodistribution in spleen was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,A,10090.0,Spleen,,,CHEMBL620293,7767,N,BAO_0000218,1,2106.0,In vivo,,,50594
5903,1,Mus musculus,Biodistribution in spleen was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,A,10090.0,Spleen,,,CHEMBL620294,7767,N,BAO_0000218,1,2106.0,In vivo,,,50594
5904,1,Mus musculus,Biodistribution in spleen was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,A,10090.0,Spleen,,,CHEMBL618614,7767,N,BAO_0000218,1,2106.0,In vivo,,,50594
5905,1,Mus musculus,Biodistribution in stomach was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,A,10090.0,Stomach,,,CHEMBL618615,7767,N,BAO_0000218,1,945.0,In vivo,,,50594
5906,1,Mus musculus,Biodistribution in stomach was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,A,10090.0,Stomach,,,CHEMBL618616,7767,N,BAO_0000218,1,945.0,In vivo,,,50594
5907,1,Homo sapiens,Cytotoxicity against A-172 human tumor cell lines,F,9606.0,,,,CHEMBL618617,2036,N,BAO_0000219,1,,,,A 172,80012
5908,1,Homo sapiens,Compound was evaluated for the in vitro cytotoxicity against A-172 human glioblastoma cell line,F,9606.0,,,,CHEMBL618618,2357,N,BAO_0000219,1,,,,A 172,80012
5909,1,Homo sapiens,Antiproliferative activity of compound was tested against rhabdomyosarcoma (A-204) human tumor cells,F,9606.0,,,,CHEMBL618619,1457,N,BAO_0000219,1,,,,A204,80014
5910,1,Homo sapiens,Tested for antiproliferative activity against A-2780 tumoral cell line,F,9606.0,,,,CHEMBL618620,4379,N,BAO_0000219,1,,,,A2780,81034
5911,1,Homo sapiens,Inhibitory concentration against melanoma A-375 cell line for cytotoxicity was determined,F,9606.0,,,,CHEMBL618621,1093,N,BAO_0000219,1,,,,A-375,80018
5912,1,Homo sapiens,Tested in vitro against A-375 cell line human melanoma,F,9606.0,,,,CHEMBL618622,12152,N,BAO_0000219,1,,,,A-375,80018
5913,1,Homo sapiens,Cytotoxicity against A-427 nonsmall lung cell line using MTT colorimetric assay,F,9606.0,,,,CHEMBL618623,16464,N,BAO_0000219,1,,,,A-427,80019
5914,1,Homo sapiens,Cytotoxicity against A-427 nonsmall lung cell line using MTT colorimetric assay; NE is no effect at 1x 10 E-5,F,9606.0,,,,CHEMBL618624,16464,N,BAO_0000219,1,,,,A-427,80019
5915,1,Homo sapiens,In vitro cytotoxicity against human non small-cell-lung cell line A-427.,F,9606.0,,,,CHEMBL618625,16582,N,BAO_0000219,1,,,,A-427,80019
5916,1,Homo sapiens,Cytotoxicity against A-427 nonsmall lung cell line using MTT colorimetric assay; NE is no effect at 1x 10 E-5,F,9606.0,,,,CHEMBL618626,16464,N,BAO_0000219,1,,,,A-427,80019
5917,1,Homo sapiens,Antitumor activity on A-427 lung carcinoma cell lines,F,9606.0,,,,CHEMBL618627,10413,N,BAO_0000219,1,,,,A-427,80019
5918,1,Homo sapiens,Cytotoxic activity against human A-427 lung tumor cell line,F,9606.0,,,,CHEMBL618628,6418,N,BAO_0000219,1,,,,A-427,80019
5919,1,Homo sapiens,In vitro antitumor effects against human A-427 cell lines.,F,9606.0,,,,CHEMBL618629,17134,N,BAO_0000219,1,,,,A-427,80019
5920,1,Homo sapiens,In vitro inhibition of A-427 (human lung cancer) cell growth.,F,9606.0,,,,CHEMBL618630,16132,N,BAO_0000219,1,,,,A-427,80019
5921,1,Homo sapiens,Cytotoxic related antitumor activity against human cancer cell lines A-427; No data available,F,9606.0,,,,CHEMBL618631,16132,N,BAO_0000219,1,,,,A-427,80019
5922,1,Homo sapiens,Cytotoxic activity of compound against A-427 lung human tumor cell line,F,9606.0,,,,CHEMBL618632,16780,N,BAO_0000219,1,,,,A-427,80019
5923,1,Homo sapiens,Cytotoxicity measured for the growth inhibition of A-431 Human epidermoid carcinoma cell line,F,9606.0,,,,CHEMBL618633,4085,N,BAO_0000219,1,,,,A-431,80852
5924,1,Homo sapiens,Cytotoxic activity was tested against human A-498 (Kidney carcinoma) cell line,F,9606.0,,,,CHEMBL619315,1276,N,BAO_0000219,1,,,,A498,80021
5925,1,Homo sapiens,Cytotoxicity against A-498 cell line in the purdue cell culture screen was determined,F,9606.0,,,,CHEMBL619316,3498,N,BAO_0000219,1,,,,A498,80021
5926,1,Homo sapiens,Cytotoxicity against human kidney carcinoma A-498cell lines,F,9606.0,,,,CHEMBL619317,1169,N,BAO_0000219,1,,,,A498,80021
5927,1,Homo sapiens,In vitro cytotoxic activity against A-498 (human kidney carcinoma) cell line,F,9606.0,,,,CHEMBL619318,4450,N,BAO_0000219,1,,,,A498,80021
5928,1,Homo sapiens,In vitro cytotoxicity against Renal A-498 human tumors following a 6 day exposure.,F,9606.0,,,,CHEMBL619319,3311,N,BAO_0000219,1,,,,A498,80021
5929,1,Homo sapiens,Antitumor cytotoxic activity against A-498 cell line was determined,F,9606.0,,,,CHEMBL619739,4461,N,BAO_0000219,1,,,,A498,80021
5930,1,Homo sapiens,In vitro cytotoxicity against Renal A-498 human tumors following a 2 day exposure.,F,9606.0,,,,CHEMBL619740,3311,N,BAO_0000219,1,,,,A498,80021
5931,1,Homo sapiens,In vitro cytotoxicity against Renal A-498 human tumors following a 2 day exposure; ND is no data,F,9606.0,,,,CHEMBL883158,3311,N,BAO_0000219,1,,,,A498,80021
5932,1,Homo sapiens,Antiproliferative activity of compound was tested against renal cancer (A-498) human tumor cells,F,9606.0,,,,CHEMBL884012,1457,N,BAO_0000219,1,,,,A498,80021
5933,1,Homo sapiens,In vitro inhibitory activity against A-498 ovarian cancer cell lines,F,9606.0,,,,CHEMBL619741,3664,N,BAO_0000219,1,,,,A498,80021
5934,1,Homo sapiens,"Cytotoxicity against NCI tumor panel, A-498 renal cancer cell line",F,9606.0,,,,CHEMBL619742,15895,N,BAO_0000219,1,,,,A498,80021
5935,1,Homo sapiens,Inhibition of growth lung non-small cell carcinoma A-549 cell line,F,9606.0,,,,CHEMBL876610,11843,N,BAO_0000219,1,,,,A549,80682
5936,1,Homo sapiens,Inhibition of growth of lung non-small cell carcinoma A-549 cell line,F,9606.0,,,,CHEMBL619743,11843,N,BAO_0000219,1,,,,A549,80682
5937,1,Homo sapiens,In vitro antiproliferative activity against human A-549 NSCL cell line,F,9606.0,,,,CHEMBL619744,17705,N,BAO_0000219,1,,,,A549,80682
5938,1,Homo sapiens,In vitro antiproliferative activity against human A-549 NSCL cell line; NS = Not significant,F,9606.0,,,,CHEMBL619745,17705,N,BAO_0000219,1,,,,A549,80682
5939,1,Homo sapiens,Growth inhibition of A-549 human lung adenocarcinoma at 0.01 uM compound concentration in standard MTT assay,F,9606.0,,,,CHEMBL619746,4369,N,BAO_0000219,1,,,,A549,80682
5940,1,Homo sapiens,Percent growth inhibition of A-549 human lung adenocarcinoma at 10e-6 M compound concentration in standard MTT assay,F,9606.0,,,,CHEMBL619747,4369,N,BAO_0000219,1,,,,A549,80682
5941,1,Homo sapiens,Percent growth inhibition of A-549 human lung adenocarcinoma at 10e-6 M compound concentration in standard MTT assay; ND means No data,F,9606.0,,,,CHEMBL619748,4369,N,BAO_0000219,1,,,,A549,80682
5942,1,Homo sapiens,Percent growth inhibition of A-549 human lung adenocarcinoma at 10e-7 M compound concentration in standard MTT assay,F,9606.0,,,,CHEMBL619749,4369,N,BAO_0000219,1,,,,A549,80682
5943,1,Homo sapiens,Percent growth inhibition of A-549 human lung adenocarcinoma at 10e-7 M compound concentration in standard MTT assay; ND means No data,F,9606.0,,,,CHEMBL619750,4369,N,BAO_0000219,1,,,,A549,80682
5944,1,Homo sapiens,Percent growth inhibition of A-549 human lung adenocarcinoma at 10e-8 M compound concentration in standard MTT assay,F,9606.0,,,,CHEMBL624014,4369,N,BAO_0000219,1,,,,A549,80682
5945,1,Homo sapiens,Percent growth inhibition of A-549 human lung adenocarcinoma at 10e-8 M compound concentration in standard MTT assay; ND means No data,F,9606.0,,,,CHEMBL624015,4369,N,BAO_0000219,1,,,,A549,80682
5946,1,Homo sapiens,In vitro effective concentration required to reduce the number of human lung carcinoma (A-549) after 3-day incubation,F,9606.0,,,,CHEMBL885344,4787,N,BAO_0000219,1,,,,A549,80682
5947,1,Homo sapiens,In vitro effective concentration required to reduce the number of human lung carcinoma cells (A-549) after 3-day incubation,F,9606.0,,,,CHEMBL623224,4787,N,BAO_0000219,1,,,,A549,80682
5948,1,Homo sapiens,Cytotoxic activity against A-549 cell line,F,9606.0,,,,CHEMBL623225,6513,N,BAO_0000219,1,,,,A549,80682
5949,1,Homo sapiens,Antitumor cytotoxicity was determined against the A-549(human lung carcinoma) cell line; Range: 0.01 to 0.03,F,9606.0,,,,CHEMBL622698,6690,N,BAO_0000219,1,,,,A549,80682
5950,1,Homo sapiens,Antitumor cytotoxicity was determined against the A-549(human lung carcinoma) cell line; Range: 10.4 to 118.1,F,9606.0,,,,CHEMBL622699,6690,N,BAO_0000219,1,,,,A549,80682
5951,1,Homo sapiens,"Cytotoxicity in vitro expressed as 50% reduction in cell number after a 3-day incubation, in human lung carcinoma A-549 cell line",F,9606.0,,,,CHEMBL622700,12263,N,BAO_0000219,1,,,,A549,80682
5952,1,Homo sapiens,Compound was tested for cytotoxic activity against human lung carcinoma (A-549),F,9606.0,,,,CHEMBL622701,1054,N,BAO_0000219,1,,,,A549,80682
5953,1,Homo sapiens,Compound was tested for its cytotoxic activity in MTT assay against A-549 cell line (human lung carcinoma),F,9606.0,,,,CHEMBL622702,1359,N,BAO_0000219,1,,,,A549,80682
5954,1,Homo sapiens,Cytotoxic activity against human lung carcinoma (A-549) cell line,F,9606.0,,,,CHEMBL622703,3547,N,BAO_0000219,1,,,,A549,80682
5955,1,Homo sapiens,Cytotoxic activity towards A-549 cells,F,9606.0,,,,CHEMBL622704,5771,N,BAO_0000219,1,,,,A549,80682
5956,1,Homo sapiens,"In vitro percent inhibition of A549, lung carcinoma.",F,9606.0,,,,CHEMBL622705,14425,N,BAO_0000219,1,,,,A549,80682
5957,1,Homo sapiens,"In vitro percent inhibition of A549, lung carcinoma",F,9606.0,,,,CHEMBL622706,14425,N,BAO_0000219,1,,,,A549,80682
5958,1,Homo sapiens,"In vitro percent inhibition of A549, lung carcinoma.",F,9606.0,,,,CHEMBL622707,14425,N,BAO_0000219,1,,,,A549,80682
5959,1,Homo sapiens,"In vitro percent inhibition of A549, lung carcinoma.; Range 18-23",F,9606.0,,,,CHEMBL622708,14425,N,BAO_0000219,1,,,,A549,80682
5960,1,Homo sapiens,Percentage inhibition against parental and drug resistant lung human tumor cell line A549 at 10 uM,F,9606.0,,,,CHEMBL622709,5280,N,BAO_0000219,1,,,,A549,80682
5961,1,Homo sapiens,Growth inhibition of the A549/ATCC non-small cell lung cancer cell line for 2-day in vitro assay.,F,9606.0,,,,CHEMBL622710,15176,N,BAO_0000219,1,,,,A549,80682
5962,1,Homo sapiens,In vitro antitumor activity against Non-small cell lung cancer A549/ATCC cell lines by 6-day assay,F,9606.0,,,,CHEMBL622711,15300,N,BAO_0000219,1,,,,A549,80682
5963,1,Homo sapiens,"Antitumor activity against A549 non small cell carcinoma at dose range of 1.56-6.25 mg/kg on day 14, 21, 28; activity expressed as maximum tolerated dose",F,9606.0,,,,CHEMBL622712,17824,N,BAO_0000218,1,,,,A549,80682
5964,1,Homo sapiens,"Antitumor activity against A549 non small cell carcinoma at dose range of 25-100 mg/kg on day 14, 21, 28; activity expressed as maximum tolerated dose",F,9606.0,,,,CHEMBL622713,17824,N,BAO_0000218,1,,,,A549,80682
5965,1,Homo sapiens,"Antitumor activity against A549 non small cell carcinoma at dose range of 3.12-12.5 mg/kg on day 14, 21, 28; activity expressed as maximum tolerated dose",F,9606.0,,,,CHEMBL622714,17824,N,BAO_0000218,1,,,,A549,80682
5966,1,Homo sapiens,"Antitumor activity against A549 non small cell carcinoma at dose range of 6.25-25 mg/kg on day 14, 21, 28; activity expressed as maximum tolerated dose",F,9606.0,,,,CHEMBL622715,17824,N,BAO_0000218,1,,,,A549,80682
5967,1,Homo sapiens,"Antitumor activity against A549 non small cell carcinoma at dose range of 70-100 mg/kg on day 14, 21, 28; activity expressed as maximum tolerated dose",F,9606.0,,,,CHEMBL622716,17824,N,BAO_0000218,1,,,,A549,80682
5968,1,Homo sapiens,"Antitumor activity against A549 non small cell carcinoma on day 14, 21, 28; activity expressed as maximum tolerated dose; NT = Not tested",F,9606.0,,,,CHEMBL622717,17824,N,BAO_0000219,1,,,,A549,80682
5969,1,Homo sapiens,Optimal dose required to inhibit human non small cell lung A549 tumor growth after subcutaneous transplantation on athymic mice at 10 mg/kg (treatment schedule: q7dX3),F,9606.0,,,,CHEMBL622718,17528,N,BAO_0000218,1,,,,A549,80682
5970,1,Homo sapiens,Cytotoxic potentiation factor of temoxolomide in human A549 tumor cell line at 0.4 uM concentration,F,9606.0,,,,CHEMBL622719,6870,N,BAO_0000219,1,,,,A549,80682
5971,1,Homo sapiens,Compound was evaluated for cytotoxic potentiation factor of temoxolomide in human A549 tumor cell line at 0.4 uM concentration; ND - not determined,F,9606.0,,,,CHEMBL622720,6870,N,BAO_0000219,1,,,,A549,80682
5972,1,Homo sapiens,Compound was evaluated for cytotoxic potentiation factor of topotecan in human A549 tumor cell line at 0.4 uM concentration,F,9606.0,,,,CHEMBL622721,6870,N,BAO_0000219,1,,,,A549,80682
5973,1,Homo sapiens,Compound was evaluated for cytotoxic potentiation factor of topotecan in human A549 tumor cell line at 0.4 uM concentration; ND - not determined,F,9606.0,,,,CHEMBL622722,6870,N,BAO_0000219,1,,,,A549,80682
5974,1,Homo sapiens,Cytotoxicity potentiation of Topotecan in human lung carcinoma A549 cells by the compound as potentiation factor at 50% growth inhibition,F,9606.0,,,,CHEMBL876030,16726,N,BAO_0000219,1,,,,A549,80682
5975,1,Homo sapiens,"Concentration required for 50% inhibition of proliferation of lung cancer cell line, A549 with respect to paclitaxel was tested in vitro after 72 hr of incubation",F,9606.0,,,,CHEMBL620206,6170,N,BAO_0000219,1,,,,A549,80682
5976,1,Homo sapiens,Inhibition ratio against A-549 cancer cell growth at a concentration of 10e-4 mol/L,F,9606.0,,,,CHEMBL620207,6583,N,BAO_0000219,1,,,,A549,80682
5977,1,Homo sapiens,Inhibition ratio against A-549 cancer cell growth at a concentration of 10e-5 mol/L,F,9606.0,,,,CHEMBL620208,6583,N,BAO_0000219,1,,,,A549,80682
5978,1,Homo sapiens,Inhibition ratio against A-549 cancer cell growth at a concentration of 10e-6 mol/L,F,9606.0,,,,CHEMBL620209,6583,N,BAO_0000219,1,,,,A549,80682
5979,1,Homo sapiens,Inhibition ratio against A-549 cancer cell growth at a concentration of 10e-7 mol/L,F,9606.0,,,,CHEMBL620210,6583,N,BAO_0000219,1,,,,A549,80682
5980,1,Homo sapiens,Inhibition ratio against A-549 cancer cell growth at a concentration of 10e-8 mol/L,F,9606.0,,,,CHEMBL621639,6583,N,BAO_0000219,1,,,,A549,80682
5981,1,Homo sapiens,Tested for cytotoxicity against human lung adenocarcinoma A549 cell line,F,9606.0,,,,CHEMBL621640,17321,N,BAO_0000219,1,,,,A549,80682
5982,1,Homo sapiens,Percentage tumor growth inhibition was calculated in respect to controls one week after the end of the treatment,F,9606.0,,,,CHEMBL621641,17528,N,BAO_0000219,1,,,,A549,80682
5983,1,Homo sapiens,Cytotoxic effect on non-small-cell lung cancer cell line A549/ATCC,F,9606.0,,,,CHEMBL621642,12888,N,BAO_0000219,1,,,,A549,80682
5984,1,Homo sapiens,Cytotoxicity of compound in synergy in 94% BCNU (10 uM) against A549 cell line,F,9606.0,,,,CHEMBL621643,4312,N,BAO_0000219,1,,,,A549,80682
5985,1,Homo sapiens,Cytotoxicity of compound in synergy in BCNU (10 uM) against A549 cell line,F,9606.0,,,,CHEMBL621644,4312,N,BAO_0000219,1,,,,A549,80682
5986,1,Homo sapiens,Cytotoxicity of compound in synergy in BCNU (10 uM) against A549 cell line; No data,F,9606.0,,,,CHEMBL621645,4312,N,BAO_0000219,1,,,,A549,80682
5987,1,Mus musculus,In vitro antiproliferative activity against A549 cell line,F,10090.0,,,,CHEMBL621646,17737,N,BAO_0000219,1,,,,A549,80682
5988,1,,Synergism with indomethacin in A549 cells,F,,,,,CHEMBL621647,6630,N,BAO_0000219,1,,,,A549,80682
5989,1,,Synergism with tolmetin in A549 cells,F,,,,,CHEMBL621648,6630,N,BAO_0000219,1,,,,A549,80682
5990,1,,Synergism with sulindac in A549 cells,F,,,,,CHEMBL621649,6630,N,BAO_0000219,1,,,,A549,80682
5991,1,,Antagonism of indomethacin in A549 cells,F,,,,,CHEMBL621650,6630,N,BAO_0000219,1,,,,A549,80682
5992,1,,Antagonism of sulindac in A549 cells,F,,,,,CHEMBL621651,6630,N,BAO_0000219,1,,,,A549,80682
5993,1,,Antagonism of tolmetin in A549 cells,F,,,,,CHEMBL621652,6630,N,BAO_0000219,1,,,,A549,80682
5994,1,,Synergism with indomethacin in A549 cells,F,,,,,CHEMBL621653,6630,N,BAO_0000219,1,,,,A549,80682
5995,1,,Synergism with sulindac in A549 cells,F,,,,,CHEMBL621654,6630,N,BAO_0000219,1,,,,A549,80682
5996,1,,Drug interaction towards A549 cell line was determined in terms of combination index in presence of Tolmetin; Not available,F,,,,,CHEMBL621655,6630,N,BAO_0000219,1,,,,A549,80682
5997,1,Canis lupus familiaris,Cmax value after 30 mg/kg po dose in Dogs,A,9615.0,,,,CHEMBL621656,16907,N,BAO_0000218,1,,In vivo,,,50588
5998,1,Canis lupus familiaris,Cmax value determined in dog at a dose of 0 mg/kg by oral administration along with indavir (10 mg/kg),A,9615.0,,,,CHEMBL621657,5944,N,BAO_0000218,1,,In vivo,,,50588
5999,1,Canis lupus familiaris,Cmax value determined in dog at a dose of 10 mg/kg by oral administration,A,9615.0,,,,CHEMBL621658,5944,N,BAO_0000218,1,,In vivo,,,50588
6000,1,Canis lupus familiaris,Cmax value determined in dog at a dose of 10 mg/kg by oral administration along with indavir (10 mg/kg),A,9615.0,,,,CHEMBL621659,5944,N,BAO_0000218,1,,In vivo,,,50588
6001,1,Canis lupus familiaris,Cmax value determined in dog at a dose of 5 mg/kg by oral administration,A,9615.0,,,,CHEMBL621660,5944,N,BAO_0000218,1,,In vivo,,,50588
6002,1,Canis lupus familiaris,Cmax value after administration of 4 mg/Kg oral dose in dog,A,9615.0,,,,CHEMBL621661,2959,N,BAO_0000218,1,,In vivo,,,50588
6003,1,Canis lupus familiaris,Cmax value in dog,A,9615.0,,,,CHEMBL621662,6241,N,BAO_0000218,1,,In vivo,,,50588
6004,1,Canis lupus familiaris,Cmax value in dogs after oral administration at 1 mg/kg,A,9615.0,,,,CHEMBL621663,6241,N,BAO_0000218,1,,In vivo,,,50588
6005,1,Canis lupus familiaris,Bioavailability as Cmax in dogs at 5 mg/kg oral dose,A,9615.0,,,,CHEMBL621664,2652,N,BAO_0000218,1,,In vivo,,,50588
6006,1,Canis lupus familiaris,Compound was evaluated for maximum observed plasma concentration at dose 27.5 mg/kg DMP323 equiv in dogs,A,9615.0,Plasma,,,CHEMBL621665,1806,N,BAO_0000218,1,1969.0,In vivo,,,50588
6007,1,Canis lupus familiaris,Compound was evaluated for maximum observed plasma concentration at dose 7.7 mg/kg DMP323 equiv in dogs,A,9615.0,Plasma,,,CHEMBL621666,1806,N,BAO_0000218,1,1969.0,In vivo,,,50588
6008,1,Canis lupus familiaris,Concentration maxima after oral dosing in dogs,A,9615.0,,,,CHEMBL621667,1021,N,BAO_0000218,1,,In vivo,,,50588
6009,1,Canis lupus familiaris,Concentration maxima after oral dosing in dogs; not available,A,9615.0,,,,CHEMBL876738,1021,N,BAO_0000218,1,,In vivo,,,50588
6010,1,Canis lupus familiaris,Concentration maxima after oral dosing in dogs; not available,A,9615.0,,,,CHEMBL621668,1021,N,BAO_0000218,1,,In vivo,,,50588
6011,1,Canis lupus familiaris,In vivo maximal concentration was calculated at 0.4 mg/kg in dog; Not absorbed,A,9615.0,,,,CHEMBL621669,5444,N,BAO_0000218,1,,In vivo,,,50588
6012,1,Canis lupus familiaris,In vivo maximal concentration was calculated at 0.6 mg/kg in dog; Not absorbed,A,9615.0,,,,CHEMBL621670,5444,N,BAO_0000218,1,,In vivo,,,50588
6013,1,Canis lupus familiaris,In vivo maximal concentration was calculated at 1 mg/kg in dog,A,9615.0,,,,CHEMBL621671,5444,N,BAO_0000218,1,,In vivo,,,50588
6014,1,Canis lupus familiaris,In vivo maximal concentration was calculated at 1 mg/kg in dog; Not absorbed,A,9615.0,,,,CHEMBL622360,5444,N,BAO_0000218,1,,In vivo,,,50588
6015,1,Canis lupus familiaris,In vivo maximal concentration was calculated at 1 mg/kg in dog; Poor absorption,A,9615.0,,,,CHEMBL622361,5444,N,BAO_0000218,1,,In vivo,,,50588
6016,1,Canis lupus familiaris,Cmax in dog plasma after oral dose (1 mg/kg),A,9615.0,Plasma,,,CHEMBL622362,5130,N,BAO_0000218,1,1969.0,In vivo,,,50588
6017,1,Canis lupus familiaris,Maximal concentration (Cmax) in dog plasma at a dose of 5 mg/kg,A,9615.0,Plasma,,,CHEMBL622363,3249,N,BAO_0000218,1,1969.0,In vivo,,,50588
6018,1,Canis lupus familiaris,Maximal plasma concentration at a dose of 1 mg/kg,A,9615.0,Plasma,,,CHEMBL622364,5473,N,BAO_0000218,1,1969.0,In vivo,,,50588
6019,1,Canis lupus familiaris,Maximal plasma concentration at a dose of 1 mg/kg (oral),A,9615.0,Plasma,,,CHEMBL622365,5474,N,BAO_0000218,1,1969.0,In vivo,,,50588
6020,1,Canis lupus familiaris,Maximal plasma concentration required for pharmacokinetic data in dogs at dose of 1 mg/kg perorally,A,9615.0,Plasma,,,CHEMBL622533,4657,N,BAO_0000218,1,1969.0,In vivo,,,50588
6021,1,Canis lupus familiaris,Maximum concentration of compound in dog was evaluated.,A,9615.0,,,,CHEMBL622534,3031,N,BAO_0000218,1,,In vivo,,,50588
6022,1,Canis lupus familiaris,Maximum concentration by oral administration at a dose of 10 uM/kg in dog was determined,A,9615.0,,,,CHEMBL622535,4527,N,BAO_0000218,1,,In vivo,,,50588
6023,1,Canis lupus familiaris,Maximum concentration in dog after administration of 20 mg/kg dose through peroral route,A,9615.0,,,,CHEMBL876739,4186,N,BAO_0000218,1,,In vivo,,,50588
6024,1,Canis lupus familiaris,Maximum concentration in dogs administered perorally (5 mg/kg) and intravenously (2 mg/kg),A,9615.0,,,,CHEMBL622536,5007,N,BAO_0000218,1,,In vivo,,,50588
6025,1,Canis lupus familiaris,Maximum concentration obtained in dog plasma was determined,A,9615.0,Plasma,,,CHEMBL622537,3132,N,BAO_0000218,1,1969.0,In vivo,,,50588
6026,1,Canis lupus familiaris,Maximum concentration was determined,A,9615.0,,,,CHEMBL622538,5006,N,BAO_0000218,1,,In vivo,,,50588
6027,1,Canis lupus familiaris,Maximum concentration at the dose of 2 mg/kg in dog,A,9615.0,,,,CHEMBL627867,4727,N,BAO_0000218,1,,In vivo,,,50588
6028,1,Canis lupus familiaris,Maximum concentration was evaluated against Beagle dog at a dose of 15 mg/kg after po administration,A,9615.0,,,,CHEMBL627868,1916,N,BAO_0000218,1,,In vivo,,,50588
6029,1,Canis lupus familiaris,Maximum concentration was evaluated in dog plasma,A,9615.0,Plasma,,,CHEMBL627869,1918,N,BAO_0000218,1,1969.0,In vivo,,,50588
6030,1,Canis lupus familiaris,Maximum concentration was evaluated after 75 min after administration in dog,A,9615.0,,,,CHEMBL627870,3045,N,BAO_0000218,1,,In vivo,,,50588
6031,1,Canis lupus familiaris,Maximum plasma concentration determined in dog after oral administration of 17b,A,9615.0,Plasma,,,CHEMBL627871,9579,N,BAO_0000218,1,1969.0,In vivo,,,50588
6032,1,Canis lupus familiaris,Maximum plasma concentration determined in dog after oral administration of 2b,A,9615.0,Plasma,,,CHEMBL627872,9579,N,BAO_0000218,1,1969.0,In vivo,,,50588
6033,1,Canis lupus familiaris,Maximum plasma concentration in dog,A,9615.0,Plasma,,,CHEMBL627873,933,N,BAO_0000218,1,1969.0,In vivo,,,50588
6034,1,Canis lupus familiaris,Maximum plasma concentration of compound in dog following p.o. administration of 0.5 mg/kg,A,9615.0,Plasma,,,CHEMBL627874,17839,N,BAO_0000218,1,1969.0,In vivo,,,50588
6035,1,Canis lupus familiaris,Maximum plasma concentration of compound in dog following p.o. administration of 0.9 mg/kg,A,9615.0,Plasma,,,CHEMBL627875,17839,N,BAO_0000218,1,1969.0,In vivo,,,50588
6036,1,Canis lupus familiaris,Maximum plasma concentration of compound in dog following p.o. administration of 0.95 mg/kg,A,9615.0,Plasma,,,CHEMBL627876,17839,N,BAO_0000218,1,1969.0,In vivo,,,50588
6037,1,Canis lupus familiaris,Maximum plasma concentration of compound in dog following p.o. administration of 1 mg/kg,A,9615.0,Plasma,,,CHEMBL627877,17839,N,BAO_0000218,1,1969.0,In vivo,,,50588
6038,1,Canis lupus familiaris,Maximum plasma concentration of compound was determined in dog after 1 mg/kg (i.v.) and 5 mg/kg (p.o.) administration,A,9615.0,Plasma,,,CHEMBL627878,6348,N,BAO_0000218,1,1969.0,In vivo,,,50588
6039,1,Canis lupus familiaris,Maximum plasma concentration after oral administration to dogs at a dose of 10 mg/kg,A,9615.0,Plasma,,,CHEMBL627879,16367,N,BAO_0000218,1,1969.0,In vivo,,,50588
6040,1,Canis lupus familiaris,Maximum plasma concentration in dogs after oral administration (10 mg/kg) as a 0.05 M citric acid solution.,A,9615.0,Plasma,,,CHEMBL875355,1337,N,BAO_0000218,1,1969.0,In vivo,,,50588
6041,1,Canis lupus familiaris,Maximum plasma concentration in dogs after oral administration (8 mg/kg) as a 0.05 M citric acid solution.,A,9615.0,Plasma,,,CHEMBL627880,1337,N,BAO_0000218,1,1969.0,In vivo,,,50588
6042,1,Canis lupus familiaris,Maximum plasma concentration at a 1 mg/kg oral dose in male and female Beagle dogs.,A,9615.0,Plasma,,,CHEMBL627881,5199,N,BAO_0000218,1,1969.0,In vivo,,,50588
6043,1,Canis lupus familiaris,Maximum plasma concentration was measured in dogs after an oral dose of 10 uM/kg,A,9615.0,Plasma,,,CHEMBL627882,17650,N,BAO_0000218,1,1969.0,In vivo,,,50588
6044,1,Canis lupus familiaris,Maximum plasma concentration reached by compound was determined after 2 mg/kg (p.o.) administration,A,9615.0,Plasma,,,CHEMBL627883,6679,N,BAO_0000218,1,1969.0,In vivo,,,50588
6045,1,Canis lupus familiaris,Maximum plasma concentration was determined as in dogs at 1 mg/kg oral dosing Cmax; 0.05-0.2 ug/mL,A,9615.0,Plasma,,,CHEMBL628526,5356,N,BAO_0000218,1,1969.0,In vivo,,,50588
6046,1,Canis lupus familiaris,Maximum plasma concentration was determined in dogs at 1 mg/kg oral dosing; 0.05-0.2 ug/mL,A,9615.0,Plasma,,,CHEMBL628527,5356,N,BAO_0000218,1,1969.0,In vivo,,,50588
6047,1,Canis lupus familiaris,Maximum plasma concentration (Cmax) in dog (in vivo) at a dose of 1 mg/kg,A,9615.0,Plasma,,,CHEMBL628528,6227,N,BAO_0000218,1,1969.0,In vivo,,,50588
6048,1,Canis lupus familiaris,Maximum plasma concentration (Cmax) in dog at a dose of 0.5 mg/kg,A,9615.0,Plasma,,,CHEMBL628529,6227,N,BAO_0000218,1,1969.0,In vivo,,,50588
6049,1,Canis lupus familiaris,Maximum plasma concentration (Cmax) in dog at a dose of 0.7 mg/kg,A,9615.0,Plasma,,,CHEMBL628530,6227,N,BAO_0000218,1,1969.0,In vivo,,,50588
6050,1,Canis lupus familiaris,Maximum plasma concentration (Cmax) in dog at a dose of 1 mg/kg,A,9615.0,Plasma,,,CHEMBL625243,6227,N,BAO_0000218,1,1969.0,In vivo,,,50588
6051,1,Canis lupus familiaris,Maximum plasma drug concentration of compound determined in dog after iv administration at a dose of 10 mg/kg,A,9615.0,Plasma,,,CHEMBL625244,3598,N,BAO_0000218,1,1969.0,In vivo,,,50588
6052,1,Canis lupus familiaris,Maximum concentration by intravenous administration of 1.2 mg/kg in dog,A,9615.0,,,,CHEMBL625245,4368,N,BAO_0000218,1,,In vivo,,,50588
6053,1,Canis lupus familiaris,Pharmacokinetic (PK) property (Cmax) was determined in dog at the single dose of 1 mg/kg,A,9615.0,,,,CHEMBL625246,6265,N,BAO_0000218,1,,In vivo,,,50588
6054,1,Mus musculus,Biodistribution in stomach was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,A,10090.0,Stomach,,,CHEMBL625247,7767,N,BAO_0000218,1,945.0,In vivo,,,50594
6055,1,Mus musculus,Biodistribution in urine was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,A,10090.0,Urine,,,CHEMBL625248,7767,N,BAO_0000218,1,1088.0,In vivo,,,50594
6056,1,Mus musculus,Biodistribution in urine was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram; ND- No data,A,10090.0,Urine,,,CHEMBL625249,7767,N,BAO_0000218,1,1088.0,In vivo,,,50594
6057,1,Mus musculus,Biodistribution in urine was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram; ND- No data,A,10090.0,Urine,,,CHEMBL625250,7767,N,BAO_0000218,1,1088.0,In vivo,,,50594
6058,1,Mus musculus,Compound (0.09% dose/g) was tested for accumulation in mice bone (Compound is radiolabeled) after 120 min; No increase,A,10090.0,,,,CHEMBL625251,17811,N,BAO_0000218,1,,,,,50594
6059,1,Mus musculus,Compound (0.31% dose/g) was tested for accumulation in mice bone (Compound is radiolabeled) after 30 min; Low increase,A,10090.0,,,,CHEMBL875356,17811,N,BAO_0000218,1,,,,,50594
6060,1,Mus musculus,Compound (i.v.) was tested for maximum activity in mice (Radiolabeled compound),A,10090.0,,,,CHEMBL625252,17827,N,BAO_0000218,1,,,,,50594
6061,1,Mus musculus,Compound was evaluated for elimination rate constants in vivo in whole blood of normal mice (Radiolabeled compound),A,10090.0,Blood,,,CHEMBL625253,17827,N,BAO_0000218,1,178.0,,,,50594
6062,1,Mus musculus,Compound was evaluated for rate of bone uptake after administration of radiolabeled in mice (Radiolabeled compound),A,10090.0,,,,CHEMBL625254,17827,N,BAO_0000218,1,,,,,50594
6063,1,Mus musculus,Compound was evaluated for rate of bone uptake in mice (Radiolabeled compound),A,10090.0,,,,CHEMBL625255,17827,N,BAO_0000218,1,,,,,50594
6064,1,Mus musculus,Compound was evaluated for rate of bone uptake in mice; NA - not active (Radiolabeled compound),A,10090.0,,,,CHEMBL625256,17827,N,BAO_0000218,1,,,,,50594
6065,1,Mus musculus,Compound was evaluated for uptake rate constants in vivo in whole blood of normal mice (Radiolabeled compound),A,10090.0,Blood,,,CHEMBL625257,17827,N,BAO_0000218,1,178.0,,,,50594
6066,1,Mus musculus,Compound was evaluated for uptake rate constants in vivo in whole blood of normal mice; NA = not active (Radiolabeled compound),A,10090.0,Blood,,,CHEMBL625258,17827,N,BAO_0000218,1,178.0,,,,50594
6067,1,Mus musculus,Compound was evaluated for washout rate in mice (Radiolabeled compound),A,10090.0,,,,CHEMBL625259,17827,N,BAO_0000218,1,,,,,50594
6068,1,Mus musculus,Compound was evaluated for washout rate in mice after radiolabeled ligand injected,A,10090.0,,,,CHEMBL625260,17827,N,BAO_0000218,1,,,,,50594
6069,1,Mus musculus,"Maximum activity (i.v.) after in mice, expressed as [(ID%-kg)/g] (Radiolabeled compound)",A,10090.0,,,,CHEMBL625261,17827,N,BAO_0000218,1,,,,,50594
6070,1,Mus musculus,"Maximum activity in mice, expressed as [(ID%-kg)/g] (Radiolabeled compound)",A,10090.0,,,,CHEMBL625262,17827,N,BAO_0000218,1,,,,,50594
6071,1,Mus musculus,"Residual activity in mice at 120 minutes, expressed as [(ID%-kg)/g] (Radiolabeled compound)",A,10090.0,,,,CHEMBL622639,17827,N,BAO_0000218,1,,,,,50594
6072,1,Mus musculus,Tested for plasma level after 90 min of 10 mg/kg dose administered in mice,A,10090.0,,,,CHEMBL622640,17257,N,BAO_0000218,1,,,,,50594
6073,1,Mus musculus,Tested for plasma level after 90 min of 10 mg/kg dose administered in mice; Not detected.,A,10090.0,,,,CHEMBL622812,17257,N,BAO_0000218,1,,,,,50594
6074,1,Mus musculus,Tested for plasma level after 90 min of 30 mg/kg dose administered in mice,A,10090.0,,,,CHEMBL622813,17257,N,BAO_0000218,1,,,,,50594
6075,1,Mus musculus,Tested for plasma level after 90 min of 30 mg/kg dose administered in mice; Not determined,A,10090.0,,,,CHEMBL622814,17257,N,BAO_0000218,1,,,,,50594
6076,1,Mus musculus,Time at maximum activity in mice (Radiolabeled compound),A,10090.0,,,,CHEMBL622815,17827,N,BAO_0000218,1,,,,,50594
6077,1,Mus musculus,Percent oral bioavailability was determined after administration of compound at 5 mg/kg perorally in mice,A,10090.0,,,,CHEMBL625342,3760,N,BAO_0000218,1,,,,,50594
6078,1,Mus musculus,Percent oral bioavailability was determined after administration of compound at 50 mg/kg perorally in mice,A,10090.0,,,,CHEMBL625343,3760,N,BAO_0000218,1,,,,,50594
6079,1,Mus musculus,Binding towards mouse plasma protein at 10 uM,A,10090.0,,,,CHEMBL877591,17409,N,BAO_0000218,1,,,,,50594
6080,1,Mus musculus,Binding towards mouse plasma protein at 100 uM,A,10090.0,,,,CHEMBL625344,17409,N,BAO_0000218,1,,,,,50594
6081,1,Mus musculus,Bioavailability was evaluated in mice after intravenous administration,A,10090.0,,,,CHEMBL625345,2675,N,BAO_0000218,1,,In vivo,,,50594
6082,1,Mus musculus,Bioavailability was evaluated in mice after oral administration,A,10090.0,,,,CHEMBL625346,2675,N,BAO_0000218,1,,In vivo,,,50594
6083,1,Mus musculus,Bioavailability was obtained by the comparison of AUC of subcutaneous dosing and AUC of oral dosing in mouse,A,10090.0,,,,CHEMBL625347,3132,N,BAO_0000218,1,,In vivo,,,50594
6084,1,Mus musculus,Bioavailability was obtained by the comparison of AUC of subcutaneous dosing and AUC of oral dosing in mouse at dose 25 mg/kg,A,10090.0,,,,CHEMBL625348,3132,N,BAO_0000218,1,,In vivo,,,50594
6085,1,Mus musculus,Bioavailability at a dose of 10 mg/kg peroral administration in mice.,A,10090.0,,,,CHEMBL625349,16597,N,BAO_0000218,1,,In vivo,,,50594
6086,1,Mus musculus,Oral bioavailability in mouse,A,10090.0,,,,CHEMBL625350,2862,N,BAO_0000218,1,,In vivo,,,50594
6087,1,Mus musculus,Oral bioavailability after intravenous administration in mice at 24 uM/kg,A,10090.0,,,,CHEMBL882952,17764,N,BAO_0000218,1,,In vivo,,,50594
6088,1,Mus musculus,Biodistribution of [123I]- labeled compound in mice brain was determined after 1 min of administration; expressed in percent of injected dose per gram of organ,A,10090.0,Brain,,,CHEMBL625351,846,N,BAO_0000218,1,955.0,In vivo,,,50594
6089,1,Mus musculus,Biodistribution of [123I]- labeled compound in mice brain was determined after 10 min of administration; expressed in percent of injected dose per gram of organ,A,10090.0,Brain,,,CHEMBL625352,846,N,BAO_0000218,1,955.0,In vivo,,,50594
6090,1,Mus musculus,Biodistribution of [123I]- labeled compound in mice brain was determined after 15 sec of administration; expressed in percent of injected dose per gram of organ,A,10090.0,Brain,,,CHEMBL877592,846,N,BAO_0000218,1,955.0,In vivo,,,50594
6091,1,Mus musculus,Biodistribution of [123I]- labeled compound in mice brain was determined after 2 min of administration; expressed in percent of injected dose per gram of organ,A,10090.0,Brain,,,CHEMBL625353,846,N,BAO_0000218,1,955.0,In vivo,,,50594
6092,1,Mus musculus,Biodistribution of [123I]- labeled compound in mice brain was determined after 30 sec of administration; expressed in percent of injected dose per gram of organ,A,10090.0,Brain,,,CHEMBL625354,846,N,BAO_0000218,1,955.0,In vivo,,,50594
6093,1,Mus musculus,Biodistribution of [123I]- labeled compound in mice brain was determined after 5 min of administration; expressed in percent of injected dose per gram of organ,A,10090.0,Brain,,,CHEMBL626019,846,N,BAO_0000218,1,955.0,In vivo,,,50594
6094,1,Mus musculus,Biodistribution of [123I]- labeled compound in mice heart was determined after 10 min of administration; expressed in percent of injected dose per gram of organ,A,10090.0,Heart,,,CHEMBL626020,846,N,BAO_0000218,1,948.0,In vivo,,,50594
6095,1,Mus musculus,Biodistribution of [123I]- labeled compound in mice heart was determined after 15 sec of administration; expressed in percent of injected dose per gram of organ,A,10090.0,Heart,,,CHEMBL626021,846,N,BAO_0000218,1,948.0,In vivo,,,50594
6096,1,Mus musculus,Biodistribution of [123I]- labeled compound in mice heart was determined after 1 min of administration; expressed in percent of injected dose per gram of organ,A,10090.0,Heart,,,CHEMBL626022,846,N,BAO_0000218,1,948.0,In vivo,,,50594
6097,1,Mus musculus,Biodistribution of [123I]- labeled compound in mice heart was determined after 2 min of administration; expressed in percent of injected dose per gram of organ,A,10090.0,Heart,,,CHEMBL626192,846,N,BAO_0000218,1,948.0,In vivo,,,50594
6098,1,Homo sapiens,Cytotoxic activity was tested against human prostate cell line A-549 (lung carcinoma),F,9606.0,,,,CHEMBL626193,1276,N,BAO_0000219,1,,,,A549,80682
6099,1,Homo sapiens,Cytotoxicity against A-549 cell line in the purdue cell culture screen was determined,F,9606.0,,,,CHEMBL626194,3498,N,BAO_0000219,1,,,,A549,80682
6100,1,Homo sapiens,Cytotoxicity against human lung carcinoma A-549 cell lines,F,9606.0,,,,CHEMBL626195,1169,N,BAO_0000219,1,,,,A549,80682
6101,1,Homo sapiens,In vitro cytotoxic activity against A-549 (human lung carcinoma) cell line,F,9606.0,,,,CHEMBL626196,4450,N,BAO_0000219,1,,,,A549,80682
6102,1,Homo sapiens,In vitro cytotoxicity against human lung carcinoma cell line A-549,F,9606.0,,,,CHEMBL626197,358,N,BAO_0000219,1,,,,A549,80682
6103,1,Homo sapiens,In vitro cytotoxicity against human lung carcinoma cell line A-549 at 3.6*10e-5 M,F,9606.0,,,,CHEMBL626198,358,N,BAO_0000219,1,,,,A549,80682
6104,1,Homo sapiens,In vitro cytotoxicity against human lung carcinoma cell line A-549 at 4.2*10e-5M,F,9606.0,,,,CHEMBL626199,358,N,BAO_0000219,1,,,,A549,80682
6105,1,Homo sapiens,In vitro cytotoxicity against human lung carcinoma cell line A-549 at 4.3*10e-5M,F,9606.0,,,,CHEMBL626200,358,N,BAO_0000219,1,,,,A549,80682
6106,1,Homo sapiens,In vitro cytotoxicity against human lung carcinoma cell line A-549 at 5.0*10e-5M,F,9606.0,,,,CHEMBL626201,358,N,BAO_0000219,1,,,,A549,80682
6107,1,Homo sapiens,In vitro cytotoxicity against human lung carcinoma cell line A-549 at 6.1*10e-5 M,F,9606.0,,,,CHEMBL626202,358,N,BAO_0000219,1,,,,A549,80682
6108,1,Homo sapiens,In vitro cytotoxicity against human lung carcinoma cell line A-549 at 7.4*10e-5 M,F,9606.0,,,,CHEMBL626203,358,N,BAO_0000219,1,,,,A549,80682
6109,1,Homo sapiens,In vitro cytotoxicity against A-549 human lung cancer cells,F,9606.0,,,,CHEMBL626204,15167,N,BAO_0000219,1,,,,A549,80682
6110,1,Homo sapiens,In vitro cytotoxicity against human lung carcinoma (A-549) cell line,F,9606.0,,,,CHEMBL624701,4139,N,BAO_0000219,1,,,,A549,80682
6111,1,Homo sapiens,In vitro cytotoxicity in human tumor lung carcinoma A-549 cell lines,F,9606.0,,,,CHEMBL624702,833,N,BAO_0000219,1,,,,A549,80682
6112,1,Homo sapiens,Tested in vitro for cytotoxic activity against lung carcinoma (A-549) cell line,F,9606.0,,,,CHEMBL624703,15718,N,BAO_0000219,1,,,,A549,80682
6113,1,Homo sapiens,Tested in vitro for cytotoxicity against A-549 lung cancer cells,F,9606.0,,,,CHEMBL624704,12373,N,BAO_0000219,1,,,,A549,80682
6114,1,Homo sapiens,The compound was tested for cytotoxicity against A-549 cell in human lung carcinoma,F,9606.0,,,,CHEMBL624705,637,N,BAO_0000219,1,,,,A549,80682
6115,1,Homo sapiens,Cytotoxicity against human lung carcinoma cells (A-549) using SRB assay.,F,9606.0,,,,CHEMBL624706,14867,N,BAO_0000219,1,,,,A549,80682
6116,1,Homo sapiens,Antitumor cytotoxic activity against A-549 cell line was determined,F,9606.0,,,,CHEMBL624707,4461,N,BAO_0000219,1,,,,A549,80682
6117,1,Homo sapiens,"Tested for the cytotoxicity against the Non-small cell lung cancer cell line A-549, growth inhibition by 50% is reported",F,9606.0,,,,CHEMBL624708,5406,N,BAO_0000219,1,,,,A549,80682
6118,1,Homo sapiens,Compound was tested for cytotoxicity against A-549 human solid tumor cell line,F,9606.0,,,,CHEMBL624709,4457,N,BAO_0000219,1,,,,A549,80682
6119,1,Homo sapiens,Antineoplastic activity against A-549 (human lung carcinoma) cell line.,F,9606.0,,,,CHEMBL884107,1386,N,BAO_0000219,1,,,,A549,80682
6120,1,Homo sapiens,Antitumoral activity was assayed against A-549 cell line,F,9606.0,,,,CHEMBL624710,3265,N,BAO_0000219,1,,,,A549,80682
6121,1,Homo sapiens,Compound was evaluated for the cytotoxicity against A-549 tumor cell line after 3 days of incubation,F,9606.0,,,,CHEMBL624711,2359,N,BAO_0000219,1,,,,A549,80682
6122,1,Homo sapiens,Compound was tested for cytotoxicity against A-549 human solid tumor cell line,F,9606.0,,,,CHEMBL624712,4457,N,BAO_0000219,1,,,,A549,80682
6123,1,Homo sapiens,In vitro cytotoxicity against A549 (human lung carcinoma) cell line.,F,9606.0,,,,CHEMBL624713,12454,N,BAO_0000219,1,,,,A549,80682
6124,1,Homo sapiens,Compound was tested for inhibition of cell growth of A-549 cells,F,9606.0,,,,CHEMBL624714,1481,N,BAO_0000219,1,,,,A549,80682
6125,1,Homo sapiens,Compound was tested for its inhibitory effect on the growth of A-549 tumor cell line from lung.,F,9606.0,,,,CHEMBL624715,1750,N,BAO_0000219,1,,,,A549,80682
6126,1,Homo sapiens,Concentration required for 50% inhibition of growth in human lung carcinoma cell line was determined,F,9606.0,,,,CHEMBL624716,5065,N,BAO_0000219,1,,,,A549,80682
6127,1,Homo sapiens,In vitro cytotoxicity against A549-human lung carcinoma cells.,F,9606.0,,,,CHEMBL619505,808,N,BAO_0000219,1,,,,A549,80682
6128,1,Homo sapiens,Cytotoxic activity against cultured cells of A-549 human lung carcinoma.,F,9606.0,,,,CHEMBL619506,16364,N,BAO_0000219,1,,,,A549,80682
6129,1,Homo sapiens,Cytotoxic activity against A-549 cell lines.,F,9606.0,,,,CHEMBL619507,1847,N,BAO_0000219,1,,,,A549,80682
6130,1,Homo sapiens,Cytotoxicity was measured against neoplastic cultured A-549 cells of human lung carcinoma.,F,9606.0,,,,CHEMBL619508,1747,N,BAO_0000219,1,,,,A549,80682
6131,1,Homo sapiens,Cytotoxicity against human A549 non small cell lung cell lines,F,9606.0,,,,CHEMBL619509,1003,N,BAO_0000219,1,,,,A549,80682
6132,1,Homo sapiens,Inhibition of cell growth in (A-549) lung cell line,F,9606.0,,,,CHEMBL619510,15313,N,BAO_0000219,1,,,,A549,80682
6133,1,Homo sapiens,Growth inhibitory effect of compound was measured on A-549 human lung adenocarcinoma cancer cell line,F,9606.0,,,,CHEMBL619511,3122,N,BAO_0000219,1,,,,A549,80682
6134,1,Homo sapiens,In vitro antitumor activity against A-549 tumor cells.,F,9606.0,,,,CHEMBL619512,16049,N,BAO_0000219,1,,,,A549,80682
6135,1,Homo sapiens,In vitro antitumor effects against human A-549 cell lines.,F,9606.0,,,,CHEMBL619513,17134,N,BAO_0000219,1,,,,A549,80682
6136,1,Homo sapiens,In vitro cytotoxic activity of compound against A-549 cell line,F,9606.0,,,,CHEMBL619514,6406,N,BAO_0000219,1,,,,A549,80682
6137,1,Homo sapiens,In vitro cytotoxicity against human lung carcinoma A-549 cell line,F,9606.0,,,,CHEMBL619515,627,N,BAO_0000219,1,,,,A549,80682
6138,1,Homo sapiens,In vitro cytotoxicity against human non-small cell lung carcinoma A549,F,9606.0,,,,CHEMBL619516,12307,N,BAO_0000219,1,,,,A549,80682
6139,1,Homo sapiens,In vitro cytotoxicity against human A-549 cancer cell line was evaluated,F,9606.0,,,,CHEMBL884005,17861,N,BAO_0000219,1,,,,A549,80682
6140,1,Homo sapiens,In vitro cytotoxicity against the A-549 (human lung carcinoma) neoplastic cell line,F,9606.0,,,,CHEMBL619517,6682,N,BAO_0000219,1,,,,A549,80682
6141,1,Homo sapiens,Inhibitory concentration of compound against A-549 cell line,F,9606.0,,,,CHEMBL619518,6663,N,BAO_0000219,1,,,,A549,80682
6142,1,Homo sapiens,Tested for the cytostatic activity as inhibitory concentration against A-549 human pulmonary adenocarcinoma cells,F,9606.0,,,,CHEMBL619519,2454,N,BAO_0000219,1,,,,A549,80682
6143,1,Homo sapiens,cytotoxic activity against leukemia (A-549) cancer cell line,F,9606.0,,,,CHEMBL876489,14709,N,BAO_0000219,1,,,,A549,80682
6144,1,Homo sapiens,Tested in vitro for cytotoxic activity against lung carcinoma (A-549) cell line,F,9606.0,,,,CHEMBL619520,15718,N,BAO_0000219,1,,,,A549,80682
6145,1,Homo sapiens,Percent inhibition for cytotoxic activity against lung carcinoma (A-549) cell line,F,9606.0,,,,CHEMBL619521,15718,N,BAO_0000219,1,,,,A549,80682
6146,1,Homo sapiens,Cytotoxic activity of compound against A-549 cell lines at concentration of 0.1(ug/ml),F,9606.0,,,,CHEMBL619522,17130,N,BAO_0000219,1,,,,A549,80682
6147,1,Homo sapiens,Cytotoxic activity of compound against A-549 cell lines at concentration of 0.4(ug/ml),F,9606.0,,,,CHEMBL619523,17130,N,BAO_0000219,1,,,,A549,80682
6148,1,Homo sapiens,Cytotoxic activity of compound against A-549 cell lines at concentration of 1.1 (ug/ml),F,9606.0,,,,CHEMBL619524,17130,N,BAO_0000219,1,,,,A549,80682
6149,1,Homo sapiens,Cytotoxic activity of compound against A-549 cell lines at concentration of 10(ug/ml),F,9606.0,,,,CHEMBL619525,17130,N,BAO_0000219,1,,,,A549,80682
6150,1,,Drug interaction towards A549 cell line was determined in terms of combination index in presence of Tometin; Not available,F,,,,,CHEMBL619526,6630,N,BAO_0000219,1,,,,A549,80682
6151,1,Homo sapiens,Influence of PARP-1 cellular activity in human lung carcinoma A549 cells on %ADP Polymer formation at a concentration of 25 uM of the compound,F,9606.0,,,,CHEMBL619527,16726,N,BAO_0000219,1,,,,A549,80682
6152,1,Homo sapiens,Cytotoxicity against A549 cells; No cytotoxicity,F,9606.0,,,,CHEMBL619528,17846,N,BAO_0000219,1,,,,A549,80682
6153,1,Homo sapiens,Cytotoxicity against human lung carcinoma (A549) cell lines,F,9606.0,,,,CHEMBL619529,3415,N,BAO_0000219,1,,,,A549,80682
6154,1,Homo sapiens,Cytotoxicity against human lung carcinoma (A549) cell lines; Not active,F,9606.0,,,,CHEMBL619530,3415,N,BAO_0000219,1,,,,A549,80682
6155,1,Homo sapiens,In vitro anticancer activity against human lung (A549) cell line,F,9606.0,,,,CHEMBL876490,5609,N,BAO_0000219,1,,,,A549,80682
6156,1,Homo sapiens,Percent growth inhibition at 200 uM PARP inhibitor in A549 cells,F,9606.0,,,,CHEMBL619531,17206,N,BAO_0000219,1,,,,A549,80682
6157,1,Homo sapiens,Percent ADP-ribose polymer formation in presence of MNNG (25 uM) at 0..006 uM compound concentration in A549 cells,F,9606.0,,,,CHEMBL619532,17206,N,BAO_0000219,1,,,,A549,80682
6158,1,Homo sapiens,Percent ADP-ribose polymer formation in presence of MNNG (25 uM) at 0..03 uM compound concentration in A549 cells,F,9606.0,,,,CHEMBL619533,17206,N,BAO_0000219,1,,,,A549,80682
6159,1,Homo sapiens,Percent ADP-ribose polymer formation in presence of MNNG (25 uM) at 0..15 uM compound concentration in A549 cells,F,9606.0,,,,CHEMBL619534,17206,N,BAO_0000219,1,,,,A549,80682
6160,1,Homo sapiens,Percent ADP-ribose polymer formation in presence of MNNG (25 uM) at 0..4 uM compound concentration in A549 cells,F,9606.0,,,,CHEMBL620164,17206,N,BAO_0000219,1,,,,A549,80682
6161,1,Homo sapiens,Percent ADP-ribose polymer formation in presence of MNNG (25 uM) at 11 uM compound concentration in A549 cells,F,9606.0,,,,CHEMBL620165,17206,N,BAO_0000219,1,,,,A549,80682
6162,1,Homo sapiens,Inhibition of A549 human lung tumor cell proliferation,F,9606.0,,,,CHEMBL620166,16295,N,BAO_0000219,1,,,,A549,80682
6163,1,Homo sapiens,"Concentration required to inhibit the lung A549 cell growth by 50%,P53 status of cell line used was wild-type. ",F,9606.0,,,,CHEMBL620167,16825,N,BAO_0000219,1,,,,A549,80682
6164,1,Homo sapiens,In vitro cytotoxicity against human tumor cell line A549,F,9606.0,,,,CHEMBL620168,3439,N,BAO_0000219,1,,,,A549,80682
6165,1,Homo sapiens,In vitro growth inhibitory activity against A549 human nonsmall cell lung carcinoma cells. ,F,9606.0,,,,CHEMBL620338,10870,N,BAO_0000219,1,,,,A549,80682
6166,1,Homo sapiens,Inhibitory concentration of compound against proliferation of lung carcinoma A549 cell line,F,9606.0,,,,CHEMBL620339,4845,N,BAO_0000219,1,,,,A549,80682
6167,1,Homo sapiens,Inhibitory concentration (resynthesized pure material) against TNF-alpha induced apoptosis of A549 cells,F,9606.0,,,,CHEMBL620340,5822,N,BAO_0000219,1,,,,A549,80682
6168,1,Homo sapiens,Inhibitory concentration (solid phase) against TNF-alpha induced apoptosis of A549 cells,F,9606.0,,,,CHEMBL620341,5822,N,BAO_0000219,1,,,,A549,80682
6169,1,Homo sapiens,Inhibitory concentration (solid phase) against TNF-alpha induced apoptosis of A549 cells: Not tested,F,9606.0,,,,CHEMBL876491,5822,N,BAO_0000219,1,,,,A549,80682
6170,1,Homo sapiens,% inhibition against A549 cells (lung cancer) at 0.04 ug/mL,F,9606.0,,,,CHEMBL620342,16381,N,BAO_0000219,1,,,,A549,80682
6171,1,Homo sapiens,% inhibition against A549 cells (lung cancer) at 0.4 ug/mL,F,9606.0,,,,CHEMBL620343,16381,N,BAO_0000219,1,,,,A549,80682
6172,1,Homo sapiens,% inhibition against A549 cells (lung cancer) at 4 ug/mL,F,9606.0,,,,CHEMBL620344,16381,N,BAO_0000219,1,,,,A549,80682
6173,1,Homo sapiens,In vitro anticancer activity against human lung (A549) cell line,F,9606.0,,,,CHEMBL620345,5609,N,BAO_0000219,1,,,,A549,80682
6174,1,Homo sapiens,Inhibition of proliferation of A549 cells at concentration of 0.1 uM was determined,F,9606.0,,,,CHEMBL620346,4644,N,BAO_0000219,1,,,,A549,80682
6175,1,Homo sapiens,Inhibition of proliferation of A549 cells at concentration of 100 uM was determined,F,9606.0,,,,CHEMBL620347,4644,N,BAO_0000219,1,,,,A549,80682
6176,1,Homo sapiens,Inhibition of proliferation of A549 cells at concentration of 10 uM was determined,F,9606.0,,,,CHEMBL620348,4644,N,BAO_0000219,1,,,,A549,80682
6177,1,Homo sapiens,Inhibition of proliferation of A549 cells at concentration of 1 uM was determined,F,9606.0,,,,CHEMBL620349,4644,N,BAO_0000219,1,,,,A549,80682
6178,1,Homo sapiens,Inhibitory concentration (resynthesized pure material) against TNF-alpha induced apoptosis of A549 cells at 20 uM,F,9606.0,,,,CHEMBL618667,5822,N,BAO_0000219,1,,,,A549,80682
6179,1,Homo sapiens,Percentage inhibition of human lung carcinoma (A549) cell lines,F,9606.0,,,,CHEMBL618668,3415,N,BAO_0000219,1,,,,A549,80682
6180,1,Homo sapiens,Influence of PARP-1 cellular activity on NAD+ levels at a concentration of 25 uM of the compound,F,9606.0,,,,CHEMBL876031,16726,N,BAO_0000219,1,,,,A549,80682
6181,1,Homo sapiens,"Concentration that gives 50% growth inhibition in A549 cells, activity expressed as PF50 (TM); ND denotes not determined",F,9606.0,,,,CHEMBL618759,17206,N,BAO_0000219,1,,,,A549,80682
6182,1,Homo sapiens,Concentration that gives 50% growth inhibition (temozolomide alone/ (temozolomide + 0.4 uM of compound)) in A549 cells; ND denotes not determined,F,9606.0,,,,CHEMBL618760,17206,N,BAO_0000219,1,,,,A549,80682
6183,1,Homo sapiens,Concentration that gives 50% growth inhibition (topotecan alone/ (topotecan + 0.4 uM of compound)) in A549 cells; ND denotes not determined,F,9606.0,,,,CHEMBL619000,17206,N,BAO_0000219,1,,,,A549,80682
6184,1,Homo sapiens,"Concentration that gives 50% growth inhibition in A549 cells, activity expressed as PF50 (TM)",F,9606.0,,,,CHEMBL619001,17206,N,BAO_0000219,1,,,,A549,80682
6185,1,Homo sapiens,"Concentration that gives 50% growth inhibition in A549 cells, activity expressed as PF50 (TP) at 0.006 uM",F,9606.0,,,,CHEMBL619002,17206,N,BAO_0000219,1,,,,A549,80682
6186,1,Homo sapiens,"Concentration that gives 50% growth inhibition in A549 cells, activity expressed as PF50 (TP) at 0.03 uM",F,9606.0,,,,CHEMBL619003,17206,N,BAO_0000219,1,,,,A549,80682
6187,1,Homo sapiens,"Concentration that gives 50% growth inhibition in A549 cells, activity expressed as PF50 (TP) at 0.15 uM",F,9606.0,,,,CHEMBL619597,17206,N,BAO_0000219,1,,,,A549,80682
6188,1,Homo sapiens,"Concentration that gives 50% growth inhibition in A549 cells, activity expressed as PF50 (TP) at 0.4 uM",F,9606.0,,,,CHEMBL619598,17206,N,BAO_0000219,1,,,,A549,80682
6189,1,Homo sapiens,Concentration that gives 50% growth inhibition (temozolomide alone/ (temozolomide + 0.4 uM of compound)) in A549 cells,F,9606.0,,,,CHEMBL619599,17206,N,BAO_0000219,1,,,,A549,80682
6190,1,Homo sapiens,Concentration that gives 50% growth inhibition (topotecan alone/ (topotecan + 0.4 uM of compound)) in A549 cells,F,9606.0,,,,CHEMBL619600,17206,N,BAO_0000219,1,,,,A549,80682
6191,1,Homo sapiens,Cytotoxicity potentiation of Topotecan in human lung carcinoma A549 cells by the compound as potentiation factor at 50% growth inhibition,F,9606.0,,,,CHEMBL619601,16726,N,BAO_0000219,1,,,,A549,80682
6192,1,Homo sapiens,Effect on NAD+ depletion (% remaining versus vehicle control) in presence of MNNG (25 uM) at 0.006 uM compound concentration in A549 cells,F,9606.0,,,,CHEMBL619602,17206,N,BAO_0000219,1,,,,A549,80682
6193,1,Homo sapiens,Effect on NAD+ depletion (% remaining versus vehicle control) in presence of MNNG (25 uM) at 0.03 uM compound concentration in A549 cells,F,9606.0,,,,CHEMBL619603,17206,N,BAO_0000219,1,,,,A549,80682
6194,1,Homo sapiens,Effect on NAD+ depletion (% remaining versus vehicle control) in presence of MNNG (25 uM) at 0.15 uM compound concentration in A549 cells,F,9606.0,,,,CHEMBL619604,17206,N,BAO_0000219,1,,,,A549,80682
6195,1,Homo sapiens,Effect on NAD+ depletion (% remaining versus vehicle control) in presence of MNNG (25 uM) at 0.4 uM compound concentration in A549 cells,F,9606.0,,,,CHEMBL619605,17206,N,BAO_0000219,1,,,,A549,80682
6196,1,Canis lupus familiaris,Pharmacokinetic activity (Cmax) (10 mg/kg) was determined in dog,A,9615.0,,,,CHEMBL619606,6084,N,BAO_0000218,1,,In vivo,,,50588
6197,1,Canis lupus familiaris,Pharmacokinetic activity (Cmax) in dog,A,9615.0,,,,CHEMBL876032,6084,N,BAO_0000218,1,,In vivo,,,50588
6198,1,Canis lupus familiaris,Pharmacokinetic parameter Cmax was determined in Beagle dogs after (iv) administration of a dose of 28 (uM/kg),A,9615.0,,,,CHEMBL619607,4809,N,BAO_0000218,1,,In vivo,,,50588
6199,1,Canis lupus familiaris,Pharmacokinetic property (Cmax) was measured in dog at the dose of 0.032 mg/kg,A,9615.0,,,,CHEMBL619608,5983,N,BAO_0000218,1,,In vivo,,,50588
6200,1,Canis lupus familiaris,Plasma clearance rate by iv administration in dog at a dose of 6 mg/kg,A,9615.0,,,,CHEMBL619609,6251,N,BAO_0000218,1,,In vivo,,,50588
6201,1,Canis lupus familiaris,Cmax in dog plasma after 30mg/kg oral dose,A,9615.0,Plasma,,,CHEMBL619610,5932,N,BAO_0000218,1,1969.0,In vivo,,,50588
6202,1,Canis lupus familiaris,Tested for the peak blood level in dog,A,9615.0,Blood,,,CHEMBL619611,4273,N,BAO_0000218,1,178.0,In vivo,,,50588
6203,1,Canis lupus familiaris,"Tested for the pharmacokinetic data, maximum concentration (Cmax) in dog",A,9615.0,,,,CHEMBL619612,5313,N,BAO_0000218,1,,In vivo,,,50588
6204,1,Canis lupus familiaris,"Tested for the pharmacokinetic data, maximum concentration (Cmax) in dog at dosage of 10 mpk",A,9615.0,,,,CHEMBL619613,5313,N,BAO_0000218,1,,In vivo,,,50588
6205,1,Canis lupus familiaris,The peak blood concentration after 5 hr administration (2.5 mg/kg) in dog was determined,A,9615.0,Blood,,,CHEMBL619614,6221,N,BAO_0000218,1,178.0,In vivo,,,50588
6206,1,Canis lupus familiaris,Concentration in the plasma after intravenous administration of 1 mg/kg in dog,A,9615.0,,,,CHEMBL619615,4709,N,BAO_0000218,1,,,,,50588
6207,1,Canis lupus familiaris,Compound was evaluated for Plasma levels upon oral administration at 30 mg/kg in Dog at maximum of 0.3 hours,A,9615.0,,,,CHEMBL619616,167,N,BAO_0000218,1,,,,,50588
6208,1,Canis lupus familiaris,Final plasma concentration in dogs after oral administration at 1 mg/kg,A,9615.0,Plasma,,,CHEMBL619617,6241,N,BAO_0000218,1,1969.0,,,,50588
6209,1,Canis lupus familiaris,Plasma concentration in dogs when measured 1 and 5 hours following initiation of reperfusion at 300 min,A,9615.0,,,,CHEMBL619618,344,N,BAO_0000218,1,,,,,50588
6210,1,Canis lupus familiaris,Plasma concentration in dogs when measured 1 and 5 hours following initiation of reperfusion at 30 min,A,9615.0,,,,CHEMBL876033,344,N,BAO_0000218,1,,,,,50588
6211,1,Canis lupus familiaris,Plasma concentration in dogs when measured 1 and 5 hours following initiation of reperfusion at 60 min,A,9615.0,,,,CHEMBL619619,344,N,BAO_0000218,1,,,,,50588
6212,1,Canis lupus familiaris,Percent of radioactive dose in urine and faeces excreted in 0-24 hr by dogs,A,9615.0,,,,CHEMBL619620,2189,N,BAO_0000218,1,,,,,50588
6213,1,Canis lupus familiaris,Percent of radioactive dose in urine and feces excreted by 0-24 hr in dogs,A,9615.0,Urine,,,CHEMBL619621,2189,N,BAO_0000218,1,1088.0,,,,50588
6214,1,Canis lupus familiaris,Percent of radioactive dose in urine and feces excreted by 0-24 hr in dogs; NA is <10% inhibition at 1 uM for binding data,A,9615.0,Urine,,,CHEMBL619622,2189,N,BAO_0000218,1,1088.0,,,,50588
6215,1,Canis lupus familiaris,Percent of radioactive dose in urine and feces excreted in 0-24 hr by dogs; NA is <10% inhibition at 1 uM for binding data,A,9615.0,Urine,,,CHEMBL618874,2189,N,BAO_0000218,1,1088.0,,,,50588
6216,1,Canis lupus familiaris,Absolute bioavailability was evaluated in dog,A,9615.0,,,,CHEMBL618875,4257,N,BAO_0000218,1,,In vivo,,,50588
6217,1,Canis lupus familiaris,Bioavailability after oral administration (2.5 mg/kg) in dog was determined,A,9615.0,,,,CHEMBL618876,6221,N,BAO_0000218,1,,In vivo,,,50588
6218,1,Canis lupus familiaris,Bioavailability after peroral administration (1 mg/kg) was determined in dog,A,9615.0,,,,CHEMBL618877,6215,N,BAO_0000218,1,,In vivo,,,50588
6219,1,Canis lupus familiaris,Bioavailability in dog,A,9615.0,,,,CHEMBL618878,17267,N,BAO_0000218,1,,In vivo,,,50588
6220,1,Canis lupus familiaris,Bioavailability in dog,A,9615.0,,,,CHEMBL618879,6621,N,BAO_0000218,1,,In vivo,,,50588
6221,1,Canis lupus familiaris,Bioavailability after intravenous administration in dogs,A,9615.0,,,,CHEMBL618880,3854,N,BAO_0000218,1,,In vivo,,,50588
6222,1,Canis lupus familiaris,Bioavailability after peroral administration in dogs,A,9615.0,,,,CHEMBL618881,3854,N,BAO_0000218,1,,In vivo,,,50588
6223,1,Canis lupus familiaris,Bioavailability in dog (dose 5 mg/kg p.o. and 2 mg/kg i.v.),A,9615.0,,,,CHEMBL618882,5007,N,BAO_0000218,1,,In vivo,,,50588
6224,1,Canis lupus familiaris,Bioavailability in dog (Beagle) (male) (dose 3 mg/kg i.v. and 10 mg/kg p.o.) measured from 1 to 24 hr,A,9615.0,,,,CHEMBL624226,4333,N,BAO_0000218,1,,In vivo,,,50588
6225,1,Canis lupus familiaris,Bioavailability in plasma of male Beagle dogs treated with 3 mg/kg (i.v.) and 10 mg/kg (p.o.) measured from 1 to 24 hr; ND indicates not determined,A,9615.0,Plasma,,,CHEMBL624227,4333,N,BAO_0000218,1,1969.0,In vivo,,,50588
6226,1,Canis lupus familiaris,Bioavailability,A,9615.0,,,,CHEMBL624228,5006,N,BAO_0000218,1,,In vivo,,,50588
6227,1,Canis lupus familiaris,Bioavailability,A,9615.0,,,,CHEMBL624229,5199,N,BAO_0000218,1,,In vivo,,,50588
6228,1,Canis lupus familiaris,Bioavailability by intravenous administration of 1.2 mg/kg in dog,A,9615.0,,,,CHEMBL624230,4368,N,BAO_0000218,1,,In vivo,,,50588
6229,1,Canis lupus familiaris,Bioavailability in dog,A,9615.0,,,,CHEMBL624231,3771,N,BAO_0000218,1,,In vivo,,,50588
6230,1,Canis lupus familiaris,Bioavailability in dog,A,9615.0,,,,CHEMBL624232,4953,N,BAO_0000218,1,,In vivo,,,50588
6231,1,Canis lupus familiaris,Bioavailability in dog,A,9615.0,,,,CHEMBL625127,5064,N,BAO_0000218,1,,In vivo,,,50588
6232,1,Canis lupus familiaris,Bioavailability in dog,A,9615.0,,,,CHEMBL625128,17657,N,BAO_0000218,1,,In vivo,,,50588
6233,1,Canis lupus familiaris,Bioavailability in dog,A,9615.0,,,,CHEMBL621675,17796,N,BAO_0000218,1,,In vivo,,,50588
6234,1,Canis lupus familiaris,Bioavailability in dog (p.o.) at 2.0 mpk,A,9615.0,,,,CHEMBL621676,17853,N,BAO_0000218,1,,In vivo,,,50588
6235,1,Canis lupus familiaris,Bioavailability in dog (dose 2 mg/kg p.o. and 0.5 mg/kg i.v.),A,9615.0,,,,CHEMBL621677,4521,N,BAO_0000218,1,,In vivo,,,50588
6236,1,Canis lupus familiaris,Bioavailability in dog after 2 mg/kg by oral and 0.5 mg/kg by intravenous administration; ND is not determined,A,9615.0,,,,CHEMBL621678,4521,N,BAO_0000218,1,,In vivo,,,50588
6237,1,Canis lupus familiaris,Bioavailability in dog,A,9615.0,,,,CHEMBL621679,5006,N,BAO_0000218,1,,In vivo,,,50588
6238,1,Canis lupus familiaris,Bioavailability was evaluated after oral administration in dog,A,9615.0,,,,CHEMBL621680,16365,N,BAO_0000218,1,,In vivo,,,50588
6239,1,Canis lupus familiaris,Bioavailability was evaluated against Beagle dog at a dose of 15 mg/kg after po administration,A,9615.0,,,,CHEMBL621681,1916,N,BAO_0000218,1,,In vivo,,,50588
6240,1,Canis lupus familiaris,Bioavailability was evaluated in dog,A,9615.0,,,,CHEMBL876740,1918,N,BAO_0000218,1,,In vivo,,,50588
6241,1,Canis lupus familiaris,Bioavailability in dog,A,9615.0,,,,CHEMBL621682,4239,N,BAO_0000218,1,,In vivo,,,50588
6242,1,Canis lupus familiaris,Bioavailability in dog,A,9615.0,,,,CHEMBL621683,6505,N,BAO_0000218,1,,In vivo,,,50588
6243,1,Canis lupus familiaris,Bioavailability was reported after intravenous administration at a dose of 1 mg/kg in Beagle dog (male),A,9615.0,,,,CHEMBL621684,5334,N,BAO_0000218,1,,In vivo,,,50588
6244,1,Canis lupus familiaris,Bioavailability was reported after oral administration at a dose of 2 mg/kg in Beagle dog (male),A,9615.0,,,,CHEMBL621685,5334,N,BAO_0000218,1,,In vivo,,,50588
6245,1,Canis lupus familiaris,Bioavailability was determined in Beagle dogs after (iv) administration of a dose of 28 (uM/kg),A,9615.0,,,,CHEMBL621686,4809,N,BAO_0000218,1,,In vivo,,,50588
6246,1,Canis lupus familiaris,Bioavailability was determined in dog after 1 mg/kg (i.v.) and 5 mg/kg (p.o.) administration,A,9615.0,,,,CHEMBL621687,6348,N,BAO_0000218,1,,In vivo,,,50588
6247,1,Canis lupus familiaris,Bioavailability was evaluated in dog after peroral administration at a dose of 1 mg/kg,A,9615.0,,,,CHEMBL621688,6005,N,BAO_0000218,1,,In vivo,,,50588
6248,1,Canis lupus familiaris,Bioavailability of compound in dog was determined after peroral administration,A,9615.0,,,,CHEMBL621689,17804,N,BAO_0000218,1,,In vivo,,,50588
6249,1,Canis lupus familiaris,Oral bioavailability in dog,A,9615.0,,,,CHEMBL621690,3184,N,BAO_0000218,1,,In vivo,,,50588
6250,1,Canis lupus familiaris,Compound was evaluated for oral bioavailability at different dose 27.5 mg/kg DMP323 equiv in dogs,A,9615.0,,,,CHEMBL621691,1806,N,BAO_0000218,1,,In vivo,,,50588
6251,1,Canis lupus familiaris,Compound was evaluated for oral bioavailability at different dose 7.7 mg/kg DMP323 equiv in dogs,A,9615.0,,,,CHEMBL875941,1806,N,BAO_0000218,1,,In vivo,,,50588
6252,1,Canis lupus familiaris,Compound was evaluated for oral bioavailability in dogs; 37-38 %,A,9615.0,,,,CHEMBL621692,1806,N,BAO_0000218,1,,In vivo,,,50588
6253,1,Canis lupus familiaris,Bioavailability in dog,A,9615.0,,,,CHEMBL621693,4839,N,BAO_0000218,1,,In vivo,,,50588
6254,1,Canis lupus familiaris,Oral bioavailability in dog (1 mg/kg p.o. and 0.2 mg/kg i.v.),A,9615.0,,,,CHEMBL621694,5017,N,BAO_0000218,1,,In vivo,,,50588
6255,1,Mus musculus,Biodistribution of [123I]- labeled compound in mice heart was determined after 30 sec of administration; expressed in percent of injected dose per gram of organ,A,10090.0,Heart,,,CHEMBL621695,846,N,BAO_0000218,1,948.0,In vivo,,,50594
6256,1,Mus musculus,Biodistribution of [123I]- labeled compound in mice heart was determined after 5 min of administration; expressed in percent of injected dose per gram of organ,A,10090.0,Heart,,,CHEMBL621696,846,N,BAO_0000218,1,948.0,In vivo,,,50594
6257,1,Mus musculus,Biodistribution of [123I]- labeled compound in mice kidneys was determined after 1 min of administration; expressed in percent of injected dose per gram of organ,A,10090.0,Kidney,,,CHEMBL621697,846,N,BAO_0000218,1,2113.0,In vivo,,,50594
6258,1,Mus musculus,Biodistribution of [123I]- labeled compound in mice kidneys was determined after 10 min of administration; expressed in percent of injected dose per gram of organ,A,10090.0,Kidney,,,CHEMBL621698,846,N,BAO_0000218,1,2113.0,In vivo,,,50594
6259,1,Mus musculus,Biodistribution of [123I]- labeled compound in mice kidneys was determined after 15 sec of administration; expressed in percent of injected dose per gram of organ,A,10090.0,Kidney,,,CHEMBL623420,846,N,BAO_0000218,1,2113.0,In vivo,,,50594
6260,1,Mus musculus,Biodistribution of [123I]- labeled compound in mice kidneys was determined after 2 min of administration; expressed in percent of injected dose per gram of organ,A,10090.0,Kidney,,,CHEMBL623421,846,N,BAO_0000218,1,2113.0,In vivo,,,50594
6261,1,Mus musculus,Biodistribution of [123I]- labeled compound in mice kidneys was determined after 30 sec of administration; expressed in percent of injected dose per gram of organ,A,10090.0,Kidney,,,CHEMBL623422,846,N,BAO_0000218,1,2113.0,In vivo,,,50594
6262,1,Mus musculus,Biodistribution of [123I]- labeled compound in mice kidneys was determined after 5 min of administration; expressed in percent of injected dose per gram of organ,A,10090.0,Kidney,,,CHEMBL623423,846,N,BAO_0000218,1,2113.0,In vivo,,,50594
6263,1,Mus musculus,Biodistribution of [123I]- labeled compound in mice liver was determined after 1 min of administration; expressed in percent of injected dose per gram of organ,A,10090.0,Liver,,,CHEMBL623424,846,N,BAO_0000218,1,2107.0,In vivo,,,50594
6264,1,Mus musculus,Biodistribution of [123I]- labeled compound in mice liver was determined after 10 min of administration; expressed in percent of injected dose per gram of organ,A,10090.0,Liver,,,CHEMBL623425,846,N,BAO_0000218,1,2107.0,In vivo,,,50594
6265,1,Mus musculus,Biodistribution of [123I]- labeled compound in mice liver was determined after 15 sec of administration; expressed in percent of injected dose per gram of organ,A,10090.0,Liver,,,CHEMBL623426,846,N,BAO_0000218,1,2107.0,In vivo,,,50594
6266,1,Mus musculus,Biodistribution of [123I]- labeled compound in mice liver was determined after 2 min of administration; expressed in percent of injected dose per gram of organ,A,10090.0,Liver,,,CHEMBL623427,846,N,BAO_0000218,1,2107.0,In vivo,,,50594
6267,1,Mus musculus,Biodistribution of [123I]- labeled compound in mice liver was determined after 30 sec of administration; expressed in percent of injected dose per gram of organ,A,10090.0,Liver,,,CHEMBL623428,846,N,BAO_0000218,1,2107.0,In vivo,,,50594
6268,1,Mus musculus,Biodistribution of [123I]- labeled compound in mice liver was determined after 5 min of administration; expressed in percent of injected dose per gram of organ,A,10090.0,Liver,,,CHEMBL875947,846,N,BAO_0000218,1,2107.0,In vivo,,,50594
6269,1,Mus musculus,Biodistribution of [123I]- labeled compound in mice lungs was determined after 1 min of administration; expressed in percent of injected dose per gram of organ,A,10090.0,Lung,,,CHEMBL623429,846,N,BAO_0000218,1,2048.0,In vivo,,,50594
6270,1,Mus musculus,Biodistribution of [123I]- labeled compound in mice lungs was determined after 10 min of administration; expressed in percent of injected dose per gram of organ,A,10090.0,Lung,,,CHEMBL623430,846,N,BAO_0000218,1,2048.0,In vivo,,,50594
6271,1,Mus musculus,Biodistribution of [123I]- labeled compound in mice lungs was determined after 15 sec of administration; expressed in percent of injected dose per gram of organ,A,10090.0,Lung,,,CHEMBL622588,846,N,BAO_0000218,1,2048.0,In vivo,,,50594
6272,1,Mus musculus,Biodistribution of [123I]- labeled compound in mice lungs was determined after 2 min of administration; expressed in percent of injected dose per gram of organ,A,10090.0,Lung,,,CHEMBL622589,846,N,BAO_0000218,1,2048.0,In vivo,,,50594
6273,1,Mus musculus,Biodistribution of [123I]- labeled compound in mice lungs was determined after 30 sec of administration; expressed in percent of injected dose per gram of organ,A,10090.0,Lung,,,CHEMBL622751,846,N,BAO_0000218,1,2048.0,In vivo,,,50594
6274,1,Mus musculus,Biodistribution of [123I]- labeled compound in mice lungs was determined after 5 min of administration; expressed in percent of injected dose per gram of organ,A,10090.0,Lung,,,CHEMBL622752,846,N,BAO_0000218,1,2048.0,In vivo,,,50594
6275,1,Mus musculus,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice blood bearing S180 tumor cell line for 1 hour,A,10090.0,,,,CHEMBL622753,6599,N,BAO_0000218,1,,,,CCRF S-180,50594
6276,1,Mus musculus,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice blood bearing S180 tumor cell line for 2 hours,A,10090.0,,,,CHEMBL622647,6599,N,BAO_0000218,1,,,,CCRF S-180,50594
6277,1,Mus musculus,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice blood bearing S180 tumor cell line for 30 minutes,A,10090.0,,,,CHEMBL875163,6599,N,BAO_0000218,1,,,,CCRF S-180,50594
6278,1,Mus musculus,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice blood bearing S180 tumor cell line for 4 hours,A,10090.0,,,,CHEMBL622648,6599,N,BAO_0000218,1,,,,CCRF S-180,50594
6279,1,Mus musculus,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice blood bearing S180 tumor cell line for 8 hours,A,10090.0,,,,CHEMBL622649,6599,N,BAO_0000218,1,,,,CCRF S-180,50594
6280,1,Mus musculus,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice brain bearing S180 tumor cell line for 1 hour,A,10090.0,Brain,,,CHEMBL622650,6599,N,BAO_0000218,1,955.0,,,CCRF S-180,50594
6281,1,Mus musculus,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice brain bearing S180 tumor cell line for 2 hours,A,10090.0,Brain,,,CHEMBL622651,6599,N,BAO_0000218,1,955.0,,,CCRF S-180,50594
6282,1,Mus musculus,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice brain bearing S180 tumor cell line for 30 minutes,A,10090.0,Brain,,,CHEMBL622652,6599,N,BAO_0000218,1,955.0,,,CCRF S-180,50594
6283,1,Mus musculus,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice brain bearing S180 tumor cell line for 4 hours,A,10090.0,Brain,,,CHEMBL622653,6599,N,BAO_0000218,1,955.0,,,CCRF S-180,50594
6284,1,Mus musculus,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice brain bearing S180 tumor cell line for 8 hours,A,10090.0,Brain,,,CHEMBL622654,6599,N,BAO_0000218,1,955.0,,,CCRF S-180,50594
6285,1,Mus musculus,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice heart bearing S180 tumor cell line for 1 hour,A,10090.0,Heart,,,CHEMBL622655,6599,N,BAO_0000218,1,948.0,,,CCRF S-180,50594
6286,1,Mus musculus,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice heart bearing S180 tumor cell line for 2 hours,A,10090.0,Heart,,,CHEMBL622656,6599,N,BAO_0000218,1,948.0,,,CCRF S-180,50594
6287,1,Mus musculus,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice heart bearing S180 tumor cell line for 30 minutes,A,10090.0,Heart,,,CHEMBL622657,6599,N,BAO_0000218,1,948.0,,,CCRF S-180,50594
6288,1,Mus musculus,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice heart bearing S180 tumor cell line for 4 hours,A,10090.0,Heart,,,CHEMBL622658,6599,N,BAO_0000218,1,948.0,,,CCRF S-180,50594
6289,1,Mus musculus,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice heart bearing S180 tumor cell line for 8 hours,A,10090.0,Heart,,,CHEMBL622659,6599,N,BAO_0000218,1,948.0,,,CCRF S-180,50594
6290,1,Mus musculus,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice kidney bearing S180 tumor cell line for 1 hour,A,10090.0,Kidney,,,CHEMBL624630,6599,N,BAO_0000218,1,2113.0,,,CCRF S-180,50594
6291,1,Mus musculus,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice kidney bearing S180 tumor cell line for 2 hours,A,10090.0,Kidney,,,CHEMBL624631,6599,N,BAO_0000218,1,2113.0,,,CCRF S-180,50594
6292,1,Mus musculus,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice kidney bearing S180 tumor cell line for 30 minutes,A,10090.0,Kidney,,,CHEMBL624632,6599,N,BAO_0000218,1,2113.0,,,CCRF S-180,50594
6293,1,Homo sapiens,Cytotoxic activity of compound against A-549 cell lines at concentration of 10(ug/ml) on,F,9606.0,,,,CHEMBL624633,17130,N,BAO_0000219,1,,,,A549,80682
6294,1,Homo sapiens,Cytotoxic activity of compound against A-549 cell lines at concentration of 10(ug/ml)on,F,9606.0,,,,CHEMBL624634,17130,N,BAO_0000219,1,,,,A549,80682
6295,1,Homo sapiens,Cytotoxic activity of compound against A-549 cell lines at concentration of 3.3 (ug/ml),F,9606.0,,,,CHEMBL624635,17130,N,BAO_0000219,1,,,,A549,80682
6296,1,Homo sapiens,Cytotoxic activity of compound against A-549 cell lines at concentration of 3.3 (ug/ml)),F,9606.0,,,,CHEMBL624636,17130,N,BAO_0000219,1,,,,A549,80682
6297,1,Homo sapiens,Antineoplastic activity against A-549 (human lung carcinoma) cell line.,F,9606.0,,,,CHEMBL857055,3263,N,BAO_0000219,1,,,,A549,80682
6298,1,Homo sapiens,In vitro rate of inhibition of A-549 tumor cell growth at 10E-4 mol/L,F,9606.0,,,,CHEMBL624637,6663,N,BAO_0000219,1,,,,A549,80682
6299,1,Homo sapiens,In vitro rate of inhibition of A-549 tumor cell growth at 10E-5 mol/L,F,9606.0,,,,CHEMBL624638,6663,N,BAO_0000219,1,,,,A549,80682
6300,1,Homo sapiens,In vitro rate of inhibition of A-549 tumor cell growth at 10E-6 mol/L,F,9606.0,,,,CHEMBL874366,6663,N,BAO_0000219,1,,,,A549,80682
6301,1,Homo sapiens,In vitro rate of inhibition of A-549 tumor cell growth at 10E-7 mol/L,F,9606.0,,,,CHEMBL624639,6663,N,BAO_0000219,1,,,,A549,80682
6302,1,Homo sapiens,In vitro rate of inhibition of A-549 tumor cell growth at 10E-8 mol/L,F,9606.0,,,,CHEMBL624640,6663,N,BAO_0000219,1,,,,A549,80682
6303,1,Homo sapiens,Rate of inhibition of A-549 tumor cell growth at a concentration of 0.0625 uM,F,9606.0,,,,CHEMBL624641,6663,N,BAO_0000219,1,,,,A549,80682
6304,1,Homo sapiens,Rate of inhibition of A-549 tumor cell growth at a concentration of 0.125 uM,F,9606.0,,,,CHEMBL624642,6663,N,BAO_0000219,1,,,,A549,80682
6305,1,Homo sapiens,Rate of inhibition of A-549 tumor cell growth at a concentration of 0.25 uM,F,9606.0,,,,CHEMBL624643,6663,N,BAO_0000219,1,,,,A549,80682
6306,1,Homo sapiens,Rate of inhibition of A-549 tumor cell growth at a concentration of 0.5 uM,F,9606.0,,,,CHEMBL624644,6663,N,BAO_0000219,1,,,,A549,80682
6307,1,Homo sapiens,Rate of inhibition of A-549 tumor cell growth at a concentration of 1 uM,F,9606.0,,,,CHEMBL624645,6663,N,BAO_0000219,1,,,,A549,80682
6308,1,Homo sapiens,The compound was evaluated for its cytotoxic potency against A-549 cell line,F,9606.0,,,,CHEMBL619445,3983,N,BAO_0000219,1,,,,A549,80682
6309,1,Homo sapiens,Cytotoxic concentration required to inhibit 50% cell growth in A-549 lung carcinoma cell lines,F,9606.0,,,,CHEMBL839886,11141,N,BAO_0000219,1,,,,A549,80682
6310,1,Homo sapiens,Cytotoxic activity of compound against A-549 tumor cell line.,F,9606.0,,,,CHEMBL619446,5076,N,BAO_0000219,1,,,,A549,80682
6311,1,Homo sapiens,In vitro cytotoxicity against Lung A-549 human tumors following a 6 day exposure.,F,9606.0,,,,CHEMBL619447,3311,N,BAO_0000219,1,,,,A549,80682
6312,1,Homo sapiens,In vitro cytotoxicity against Lung A-549 human tumors following a 2 day exposure.,F,9606.0,,,,CHEMBL619448,3311,N,BAO_0000219,1,,,,A549,80682
6313,1,Homo sapiens,In vitro cytotoxicity against Lung A-549 human tumors following a 2 day exposure; ND is no data,F,9606.0,,,,CHEMBL619449,3311,N,BAO_0000219,1,,,,A549,80682
6314,1,Homo sapiens,Cytotoxic activity of compound against A-549 tumor cell line at conc. of 20 ug/mL,F,9606.0,,,,CHEMBL619450,5076,N,BAO_0000219,1,,,,A549,80682
6315,1,Homo sapiens,Compound was tested for cytotoxic activity against A-549 human lung carcinoma (ATCC:CCL-185),F,9606.0,,,,CHEMBL619451,4150,N,BAO_0000219,1,,,,A549,80682
6316,1,Homo sapiens,In vitro inhibitory concentration against cell culture of A-549 human lung carcinoma,F,9606.0,,,,CHEMBL619452,2150,N,BAO_0000219,1,,,,A549,80682
6317,1,Homo sapiens,Concentration for in vitro cytotoxicity against A-549 human lung tumor cells,F,9606.0,,,,CHEMBL619453,4644,N,BAO_0000219,1,,,,A549,80682
6318,1,Homo sapiens,Dose required for in vitro cytotoxic activity against A-549 lung carcinoma cells at concentration of 10 ug/ml; NA is no cytotoxicity,F,9606.0,,,,CHEMBL874367,263,N,BAO_0000219,1,,,,A549,80682
6319,1,Homo sapiens,Cytotoxic concentration against A-549 tumor cells.,F,9606.0,,,,CHEMBL619454,11333,N,BAO_0000219,1,,,,A549,80682
6320,1,Homo sapiens,Cytotoxic concentration against A-549 tumor cells; Inactive at 10 ug/mL.,F,9606.0,,,,CHEMBL619455,11333,N,BAO_0000219,1,,,,A549,80682
6321,1,Homo sapiens,"Cytotoxicity against NCI tumor panel, A-549/ATCC non small-cell lung cancer cell line",F,9606.0,,,,CHEMBL619456,15895,N,BAO_0000219,1,,,,A549,80682
6322,1,Acinetobacter baumannii,Minimum inhibitory concentration (lowest peptide concentration) required to prevent visible bacterial growth after 18 hr of incubation at 37 C in Mueller-Hinton broth against Acinetobacter baumannii 118A,F,470.0,,,,CHEMBL619457,16677,N,BAO_0000218,1,,,,,50191
6323,1,Acinetobacter calcoaceticus,Activity against Acinetobacter calcoaceticus (AC54),F,471.0,,,,CHEMBL619458,10624,N,BAO_0000218,1,,,,,50192
6324,1,Aspergillus flavus,In vitro antifungal activity against Aspergillus flavus CM74,F,5059.0,,,,CHEMBL619459,16717,N,BAO_0000218,1,,,,,50274
6325,1,Aspergillus flavus,In vitro antifungal activity against Aspergillus flavus CM74,F,5059.0,,,,CHEMBL619460,16717,N,BAO_0000218,1,,,,,50274
6326,1,Aspergillus fumigatus,Inhibitory activity tested against Aspergillus fumigatus at 256 ug/mL concentration,F,746128.0,,,,CHEMBL619461,5513,N,BAO_0000218,1,,,,,50416
6327,1,Aspergillus fumigatus,In vitro minimum fungicidal concentration required to inhibit Aspergillus fumigatus(MFC),F,746128.0,,,,CHEMBL619462,15962,N,BAO_0000218,1,,,,,50416
6328,1,Aspergillus fumigatus,Antimicrobial activity against Aspergillus fumigatus (MIC),F,746128.0,,,,CHEMBL620388,15962,N,BAO_0000218,1,,,,,50416
6329,1,Aspergillus fumigatus,Antimicrobial activity against Aspergillus fumigatus (MIC),F,746128.0,,,,CHEMBL620389,15962,N,BAO_0000218,1,,,,,50416
6330,1,Aspergillus fumigatus,In vitro antimicrobial activity against Aspergillus fumigatus (MIC),F,746128.0,,,,CHEMBL620390,15962,N,BAO_0000218,1,,,,,50416
6331,1,Aspergillus fumigatus,In vitro antifungal activity against Aspergillus fumigatus 48238E,F,746128.0,,,,CHEMBL620391,16717,N,BAO_0000218,1,,,,,50416
6332,1,Aspergillus fumigatus,In vitro antifungal activity against Aspergillus fumigatus 48238E,F,746128.0,,,,CHEMBL621073,16717,N,BAO_0000218,1,,,,,50416
6333,1,Actinomyces naeslundii,Compound is evaluated for plaque-bactericidal index (PBI) against Actinomyces naeslundii 631,F,1655.0,,,,CHEMBL621074,8117,N,BAO_0000218,1,,,,,50296
6334,1,Actinomyces viscosus,Compound is evaluated for plaque-bactericidal index (PBI) against Actinomyces viscosus M-100,F,1656.0,,,,CHEMBL621075,8117,N,BAO_0000218,1,,,,,50366
6335,1,Acanthocheilonema viteae,Tested in vivo for Acanthocheilonema viteae at 200 mg/kg X 5 days(perorally),F,6277.0,,,,CHEMBL619554,15472,N,BAO_0000218,1,,,,,50535
6336,1,Acanthocheilonema viteae,Tested in vivo for Acanthocheilonema viteae at 200 mg/kg X 5 days(perorally),F,6277.0,,,,CHEMBL619555,15472,N,BAO_0000218,1,,,,,50535
6337,1,Aggregatibacter actinomycetemcomitans,Antibacterial activity determined as minimal inhibitory concentration (MIC) against Actinobacillus actinomycetecommitans ATCC 29527,F,714.0,,,,CHEMBL619556,16443,N,BAO_0000218,1,,,,,50169
6338,1,Aggregatibacter actinomycetemcomitans,Antibacterial activity determined as minimal inhibitory concentration (MIC) against Actinobacillus actinomycetecommitans ATCC 29527; value ranges from 1-2,F,714.0,,,,CHEMBL619557,16443,N,BAO_0000218,1,,,,,50169
6339,1,Aggregatibacter actinomycetemcomitans,Antibacterial activity determined as minimal inhibitory concentration (MIC) against Actinobacillus actinomycetecommitans ATCC 29527; value ranges from 1-2; ND is Not Determined,F,714.0,,,,CHEMBL619558,16443,N,BAO_0000218,1,,,,,50169
6340,1,Homo sapiens,Effect on NAD+ depletion (% remaining versus vehicle control) in presence of MNNG (25 uM) at 11 uM compound concentration in A549 cells,F,9606.0,,,,CHEMBL619559,17206,N,BAO_0000219,1,,,,A549,80682
6341,1,Homo sapiens,Percent ADP-ribose polymer formation at 25 uM compound concentration in A549 cells,F,9606.0,,,,CHEMBL619560,17206,N,BAO_0000219,1,,,,A549,80682
6342,1,Homo sapiens,% inhibition against A549 cells (lung cancer) at 0.04 ug/mL,F,9606.0,,,,CHEMBL619561,16381,N,BAO_0000219,1,,,,A549,80682
6343,1,Homo sapiens,% inhibition against A549 cells (lung cancer) at 0.4 ug/mL,F,9606.0,,,,CHEMBL619562,16381,N,BAO_0000219,1,,,,A549,80682
6344,1,Homo sapiens,% inhibition against A549 cells (lung cancer) at 4 ug/mL,F,9606.0,,,,CHEMBL619563,16381,N,BAO_0000219,1,,,,A549,80682
6345,1,Homo sapiens,GI values against A549 cells (lung cancer),F,9606.0,,,,CHEMBL857457,16381,N,BAO_0000219,1,,,,A549,80682
6346,1,Homo sapiens,Effect on NAD+ depletion (% remaining versus vehicle control) 25 uM compound concentration in A549 cells,F,9606.0,,,,CHEMBL619564,17206,N,BAO_0000219,1,,,,A549,80682
6347,1,Homo sapiens,Inhibitory activity against A549 human adenocarcinoma,F,9606.0,,,,CHEMBL619565,16325,N,BAO_0000219,1,,,,A549,80682
6348,1,Homo sapiens,Evaluated for the antineoplastic activity against A549 lung (nonsmall cell) tumor xenograft in nude mice after administering 3 injections (intra peritoneally) at a dose of 200 mg/kg,F,9606.0,,,,CHEMBL619566,10708,N,BAO_0000218,1,,,,A549,80682
6349,1,Homo sapiens,Evaluated for the antineoplastic activity against A549 lung (nonsmall cell) tumor xenograft in nude mice after administering 3 injections (intra peritoneally) at a dose of 100 mg/kg,F,9606.0,,,,CHEMBL619567,10708,N,BAO_0000218,1,,,,A549,80682
6350,1,Homo sapiens,Inhibitory activity against A549 lung adenocarcinoma cell line,F,9606.0,,,,CHEMBL619568,17376,N,BAO_0000219,1,,,,A549,80682
6351,1,Homo sapiens,Inhibitory activity against A549 lung adenocarcinoma cell line; not determined,F,9606.0,,,,CHEMBL619569,17376,N,BAO_0000219,1,,,,A549,80682
6352,1,Homo sapiens,Cytotoxicity against human A549 lung cells,F,9606.0,,,,CHEMBL619570,17488,N,BAO_0000219,1,,,,A549,80682
6353,1,Homo sapiens,In vivo percent inhibitory activity of intraperitoneally administered compound (50 mg/kg/day) against mice infected with A549 tumor,F,9606.0,,,,CHEMBL619571,17404,N,BAO_0000218,1,,,,A549,80682
6354,1,Homo sapiens,Growth inhibition of A549 (human lung carcinoma) cell line.,F,9606.0,,,,CHEMBL619572,10958,N,BAO_0000219,1,,,,A549,80682
6355,1,Homo sapiens,Effective dose required for inhibitory activity against A549 human tumor cell line.,F,9606.0,,,,CHEMBL619573,17099,N,BAO_0000219,1,,,,A549,80682
6356,1,Homo sapiens,Effective dose required for inhibitory activity against A549 human tumor cell line; Not active,F,9606.0,,,,CHEMBL619574,17099,N,BAO_0000219,1,,,,A549,80682
6357,1,Homo sapiens,Cytotoxicity was evaluated against A549 tumor cell lines; Inactive,F,9606.0,,,,CHEMBL619575,4096,N,BAO_0000219,1,,,,A549,80682
6358,1,Homo sapiens,Cytotoxicity evaluated against A549 tumor cell lines; significant activity,F,9606.0,,,,CHEMBL619576,4096,N,BAO_0000219,1,,,,A549,80682
6359,1,Homo sapiens,Cytotoxicity was evaluated against A549 tumor cell lines; Slightly active,F,9606.0,,,,CHEMBL619577,4096,N,BAO_0000219,1,,,,A549,80682
6360,1,Homo sapiens,In vitro inhibitory activity against A549 tumor cell culture,F,9606.0,,,,CHEMBL619578,2525,N,BAO_0000219,1,,,,A549,80682
6361,1,Homo sapiens,In vitro inhibitory activity against A549 tumor cell culture; IA= Inactive,F,9606.0,,,,CHEMBL884009,2525,N,BAO_0000219,1,,,,A549,80682
6362,1,Homo sapiens,Activity against human lung cancer with mutated beta-tubulin (A549-T2415),F,9606.0,,,,CHEMBL619579,5302,N,BAO_0000219,1,,,,A549,80682
6363,1,Homo sapiens,Growth inhibitory activity was determined against A549/ATCC cancer cell line of non-small cell lung cancer,F,9606.0,,,,CHEMBL619580,16325,N,BAO_0000219,1,,,,A549,80682
6364,1,Homo sapiens,Inhibition of growth of A549/ATCC nonsmall cell lung cancer cell line,F,9606.0,,,,CHEMBL619581,16939,N,BAO_0000219,1,,,,A549,80682
6365,1,Homo sapiens,In vitro antitumor activity against NSCL A549/ATCC tumor cell lines,F,9606.0,,,,CHEMBL619582,17229,N,BAO_0000219,1,,,,A549,80682
6366,1,Homo sapiens,Cytotoxicity evaluation against A549/ATCC non-small-cell lung cancer cells,F,9606.0,,,,CHEMBL619583,17380,N,BAO_0000219,1,,,,A549,80682
6367,1,Homo sapiens,Cytotoxicity evaluation against A549/ATCC non-small-cell lung cancer cells; No data,F,9606.0,,,,CHEMBL876502,17380,N,BAO_0000219,1,,,,A549,80682
6368,1,Homo sapiens,In vitro cytotoxicity against human Non-small cell lung cancer A549/ATCC cell line.,F,9606.0,,,,CHEMBL619584,1903,N,BAO_0000219,1,,,,A549,80682
6369,1,Homo sapiens,In vitro growth inhibition of compound was determined against A549/ATCC cell lines of non-small cell lung cancer,F,9606.0,,,,CHEMBL619585,3838,N,BAO_0000219,1,,,,A549,80682
6370,1,Homo sapiens,Inhibition of the growth of non-small-cell lung cancer (A549/ATCC) cell line,F,9606.0,,,,CHEMBL619586,14696,N,BAO_0000219,1,,,,A549,80682
6371,1,Homo sapiens,In vitro growth inhibition of compound was determined against A549/ATCC cell lines of non-small cell lung cancer,F,9606.0,,,,CHEMBL619587,3838,N,BAO_0000219,1,,,,A549,80682
6372,1,Homo sapiens,Tested for in vitro cytotoxicity against non-small cell lung cancer cell line A549/ATCC,F,9606.0,,,,CHEMBL619588,1522,N,BAO_0000219,1,,,,A549,80682
6373,1,Homo sapiens,Tested in vitro for cytotoxicity in A549/ATCC cell lines,F,9606.0,,,,CHEMBL619589,12400,N,BAO_0000219,1,,,,A549,80682
6374,1,Homo sapiens,inhibition of the growth of non-small-cell lung cancer (A549/ATCC) cell line,F,9606.0,,,,CHEMBL619590,14696,N,BAO_0000219,1,,,,A549,80682
6375,1,Homo sapiens,Compound was evaluated for in vitro activity against A549/ATCC lung cancer cell lines (Human tumor cells ),F,9606.0,,,,CHEMBL619591,14769,N,BAO_0000219,1,,,,A549,80682
6376,1,Homo sapiens,Inhibition of the growth of non-small-cell lung cancer (A549/ATCC) cell line at 0.01 uM,F,9606.0,,,,CHEMBL619592,14696,N,BAO_0000219,1,,,,A549,80682
6377,1,Homo sapiens,Compound was evaluated for cytotoxic activity against non-small lung cancer A549/ATCC cell lines.,F,9606.0,,,,CHEMBL619593,1888,N,BAO_0000219,1,,,,A549,80682
6378,1,Homo sapiens,Tested for cytotoxic activity against non-small cell lung cancer A549/ATCC cell line,F,9606.0,,,,CHEMBL620217,12016,N,BAO_0000219,1,,,,A549,80682
6379,1,Homo sapiens,Compound tested for growth inhibition of non-small cell lung cancer cell line A549/ATCC,F,9606.0,,,,CHEMBL620218,6058,N,BAO_0000219,1,,,,A549,80682
6380,1,Homo sapiens,Compound was tested for 50% growth inhibition against human non-small cell lung cancer A549/ATCC cell line,F,9606.0,,,,CHEMBL620219,17708,N,BAO_0000219,1,,,,A549,80682
6381,1,Homo sapiens,Antitumor activity against A549/ATCC cell line,F,9606.0,,,,CHEMBL620220,12301,N,BAO_0000219,1,,,,A549,80682
6382,1,Homo sapiens,Tested for cytotoxicity against A549/ATCC cell lines in non-small-cell lung cancer,F,9606.0,,,,CHEMBL625141,11970,N,BAO_0000219,1,,,,A549,80682
6383,1,Homo sapiens,In vitro cytotoxicity against A549/ATCC cell line.,F,9606.0,,,,CHEMBL625142,11818,N,BAO_0000219,1,,,,A549,80682
6384,1,Homo sapiens,Tested in vitro for cytotoxicity in A549/ATCC cell line of Non-Small Cell Lung Cancer,F,9606.0,,,,CHEMBL625143,12400,N,BAO_0000219,1,,,,A549,80682
6385,1,Homo sapiens,In vitro inhibition of Non-Small Cell Lung Cancer A549/ATCC cell lines,F,9606.0,,,,CHEMBL625144,3381,N,BAO_0000219,1,,,,A549,80682
6386,1,Homo sapiens,Concentration of compound that cause 50% cytotoxicity of A549/ATCC non small cell lung cancer cell line,F,9606.0,,,,CHEMBL622474,17376,N,BAO_0000219,1,,,,A549,80682
6387,1,Homo sapiens,Evaluated for the inhibitory concentration required to cause growth inhibition of A549Rem- cell line of lung using the MTT Cytotoxicity Assay,F,9606.0,,,,CHEMBL884104,10708,N,BAO_0000219,1,,,,A549,80682
6388,0,Homo sapiens,Cytotoxicity was evaluated against A649 human mammary carcinoma cells,F,9606.0,,,,CHEMBL622475,2964,U,BAO_0000219,1,,,,,22226
6389,0,Canis lupus familiaris,Compound was tested for oral bioavailability in dogs,A,9615.0,,,,CHEMBL622476,5005,U,BAO_0000218,1,,In vivo,,,22224
6390,1,Canis lupus familiaris,Compound was tested for orally bioavailable in dogs with a half life of 0.7 hr,A,9615.0,,,,CHEMBL875831,6229,N,BAO_0000218,1,,In vivo,,,50588
6391,1,Canis lupus familiaris,Compound was tested for orally bioavailable in dogs with a half life of 1.2h,A,9615.0,,,,CHEMBL622477,6229,N,BAO_0000218,1,,In vivo,,,50588
6392,1,Canis lupus familiaris,Oral bioavailability in dog,A,9615.0,,,,CHEMBL622478,5374,N,BAO_0000218,1,,In vivo,,,50588
6393,1,Canis lupus familiaris,Compound was tested for the oral bioavailability in dog; No availability,A,9615.0,,,,CHEMBL623172,5374,N,BAO_0000218,1,,In vivo,,,50588
6394,1,Canis lupus familiaris,Oral bioavailability in dog (dose 5 mg/kg),A,9615.0,,,,CHEMBL623173,6265,N,BAO_0000218,1,,In vivo,,,50588
6395,1,Canis lupus familiaris,Oral bioavailability (F%) of compound was determined after intravenous administration in average of two dogs at a dose of 1 mg/kg; ND=not determined,A,9615.0,,,,CHEMBL623174,5654,N,BAO_0000218,1,,In vivo,,,50588
6396,1,Canis lupus familiaris,Oral bioavailability (F%) of compound was determined after intravenous administration in average of two dogs at a dose of 1 mg/kg; ND=not determined,A,9615.0,,,,CHEMBL623175,5654,N,BAO_0000218,1,,In vivo,,,50588
6397,1,Canis lupus familiaris,Oral bioavailability in Beagle dogs after Per oral administration at dose of 50(mg/kg),A,9615.0,,,,CHEMBL623340,16456,N,BAO_0000218,1,,In vivo,,,50588
6398,1,Canis lupus familiaris,Oral bioavailability in dog (dose 5 mg/kg),A,9615.0,,,,CHEMBL623341,5302,N,BAO_0000218,1,,In vivo,,,50588
6399,1,Canis lupus familiaris,Oral bioavailability in dog (p.o. dosing of 0.05 M citric acid/0.05 M hydrochloric acid solution),A,9615.0,,,,CHEMBL623342,3624,N,BAO_0000218,1,,In vivo,,,50588
6400,1,Canis lupus familiaris,Oral bioavailability of active FTIs in dogs,A,9615.0,,,,CHEMBL623343,16452,N,BAO_0000218,1,,In vivo,,,50588
6401,1,Canis lupus familiaris,Oral bioavailability in dog (dose 5 mg/kg p.o. and 2 mg/kg i.v.),A,9615.0,,,,CHEMBL623344,5802,N,BAO_0000218,1,,In vivo,,,50588
6402,1,Canis lupus familiaris,Oral bioavailability of compound determined in dog after iv administration at a dose of 10 mg/kg,A,9615.0,,,,CHEMBL623345,3598,N,BAO_0000218,1,,In vivo,,,50588
6403,1,Canis lupus familiaris,Oral bioavailability in dog,A,9615.0,,,,CHEMBL875832,17839,N,BAO_0000218,1,,In vivo,,,50588
6404,1,Canis lupus familiaris,Oral bioavailability in dog,A,9615.0,,,,CHEMBL623346,6762,N,BAO_0000218,1,,In vivo,,,50588
6405,1,Canis lupus familiaris,Oral bioavailability in dog,A,9615.0,,,,CHEMBL623347,6821,N,BAO_0000218,1,,In vivo,,,50588
6406,1,Canis lupus familiaris,Oral bioavailability of compound was determined in dog; Not tested,A,9615.0,,,,CHEMBL623348,6821,N,BAO_0000218,1,,In vivo,,,50588
6407,1,Canis lupus familiaris,Oral bioavailability in dog,A,9615.0,,,,CHEMBL623349,5210,N,BAO_0000218,1,,In vivo,,,50588
6408,1,Canis lupus familiaris,Oral bioavailability (10 mg/kg) was determined in dog,A,9615.0,,,,CHEMBL623350,6227,N,BAO_0000218,1,,In vivo,,,50588
6409,1,Canis lupus familiaris,Oral bioavailability,A,9615.0,,,,CHEMBL623351,761,N,BAO_0000218,1,,In vivo,,,50588
6410,1,Canis lupus familiaris,Oral bioavailability in dog (dosed as neat powder in hard gelatin capsule),A,9615.0,,,,CHEMBL623352,761,N,BAO_0000218,1,,In vivo,,,50588
6411,1,Canis lupus familiaris,Oral bioavailability administered in solution in rats,A,9615.0,,,,CHEMBL623353,761,N,BAO_0000218,1,,In vivo,,,50588
6412,1,Canis lupus familiaris,Oral bioavailability after 30 mg/kg po dose in Dogs,A,9615.0,,,,CHEMBL875833,16907,N,BAO_0000218,1,,In vivo,,,50588
6413,1,Canis lupus familiaris,Oral bioavailability at a dose of 1 mg/kg in dogs,A,9615.0,,,,CHEMBL623354,5474,N,BAO_0000218,1,,In vivo,,,50588
6414,1,Canis lupus familiaris,Oral bioavailability in dog (dose 1 mg/kg p.o.),A,9615.0,,,,CHEMBL623355,6535,N,BAO_0000218,1,,In vivo,,,50588
6415,1,Canis lupus familiaris,Oral bioavailability in Dog; ND = not determined,A,9615.0,,,,CHEMBL623356,6535,N,BAO_0000218,1,,In vivo,,,50588
6416,1,Canis lupus familiaris,Oral bioavailability in dog,A,9615.0,,,,CHEMBL623357,3352,N,BAO_0000218,1,,In vivo,,,50588
6417,1,Canis lupus familiaris,Oral bioavailability in dog,A,9615.0,,,,CHEMBL623358,6168,N,BAO_0000218,1,,In vivo,,,50588
6418,1,Canis lupus familiaris,Oral bioavailability in dog,A,9615.0,,,,CHEMBL623359,5988,N,BAO_0000218,1,,In vivo,,,50588
6419,1,Canis lupus familiaris,Oral bioavailability in dog,A,9615.0,,,,CHEMBL623360,4942,N,BAO_0000218,1,,In vivo,,,50588
6420,1,Canis lupus familiaris,Oral bioavailability in dogs; No data,A,9615.0,,,,CHEMBL623361,4942,N,BAO_0000218,1,,In vivo,,,50588
6421,1,Canis lupus familiaris,Oral bioavailability measured in dogs,A,9615.0,,,,CHEMBL623362,14541,N,BAO_0000218,1,,In vivo,,,50588
6422,1,Canis lupus familiaris,Oral bioavailability in dog,A,9615.0,,,,CHEMBL623363,4449,N,BAO_0000218,1,,In vivo,,,50588
6423,1,Canis lupus familiaris,Oral bioavailability was calculated in dog,A,9615.0,,,,CHEMBL623364,6057,N,BAO_0000218,1,,In vivo,,,50588
6424,1,Canis lupus familiaris,Oral bioavailability after 0.3 mg/kg po administration in dog,A,9615.0,,,,CHEMBL875834,5600,N,BAO_0000218,1,,In vivo,,,50588
6425,1,Canis lupus familiaris,Oral bioavailability in dog (i.v. dosing),A,9615.0,,,,CHEMBL623365,5542,N,BAO_0000218,1,,In vivo,,,50588
6426,1,Canis lupus familiaris,Oral bioavailability in dog,A,9615.0,,,,CHEMBL623366,5542,N,BAO_0000218,1,,In vivo,,,50588
6427,1,Canis lupus familiaris,Oral bioavailability in Beagle dog at a dose of 2 mg/kg by po administration,A,9615.0,,,,CHEMBL623367,5546,N,BAO_0000218,1,,In vivo,,,50588
6428,1,Canis lupus familiaris,Oral bioavailability in Beagle dogs,A,9615.0,,,,CHEMBL623368,4514,N,BAO_0000218,1,,In vivo,,,50588
6429,1,Canis lupus familiaris,Oral bioavailability in dog,A,9615.0,,,,CHEMBL623369,3624,N,BAO_0000218,1,,In vivo,,,50588
6430,1,Canis lupus familiaris,Oral bioavailability in dog,A,9615.0,,,,CHEMBL623370,3854,N,BAO_0000218,1,,In vivo,,,50588
6431,1,Canis lupus familiaris,Oral bioavailability in dog,A,9615.0,,,,CHEMBL623371,5836,N,BAO_0000218,1,,In vivo,,,50588
6432,1,Canis lupus familiaris,Oral bioavailability in dog,A,9615.0,,,,CHEMBL623372,5940,N,BAO_0000218,1,,In vivo,,,50588
6433,1,Canis lupus familiaris,Oral bioavailability in dog,A,9615.0,,,,CHEMBL621351,6168,N,BAO_0000218,1,,In vivo,,,50588
6434,1,Canis lupus familiaris,Oral bioavailability in dog,A,9615.0,,,,CHEMBL621352,6227,N,BAO_0000218,1,,In vivo,,,50588
6435,1,Canis lupus familiaris,Oral bioavailability in dog,A,9615.0,,,,CHEMBL621353,6251,N,BAO_0000218,1,,In vivo,,,50588
6436,1,Canis lupus familiaris,Oral bioavailability in dog,A,9615.0,,,,CHEMBL621354,6448,N,BAO_0000218,1,,In vivo,,,50588
6437,1,Canis lupus familiaris,Oral bioavailability in dog,A,9615.0,,,,CHEMBL621355,6647,N,BAO_0000218,1,,In vivo,,,50588
6438,1,Canis lupus familiaris,Oral bioavailability in dog,A,9615.0,,,,CHEMBL621356,5940,N,BAO_0000218,1,,In vivo,,,50588
6439,1,Canis lupus familiaris,Oral bioavailability in dog,A,9615.0,,,,CHEMBL621357,933,N,BAO_0000218,1,,In vivo,,,50588
6440,1,Canis lupus familiaris,Oral bioavailability in dog,A,9615.0,,,,CHEMBL621358,5210,N,BAO_0000218,1,,In vivo,,,50588
6441,1,Canis lupus familiaris,Oral bioavailability in dog (dosed as a mixture of five compounds at 0.5 mg/kg each via i.v. only),A,9615.0,,,,CHEMBL621359,6642,N,BAO_0000218,1,,In vivo,,,50588
6442,1,Canis lupus familiaris,Oral bioavailability in dog (dose 0.5 mg/kg i.v. and 2.0 mg/kg p.o.),A,9615.0,,,,CHEMBL621360,6641,N,BAO_0000218,1,,In vivo,,,50588
6443,1,Canis lupus familiaris,Oral bioavailability in dog (dose 0.5 mg/kg i.v. and 2.0 mg/kg p.o.),A,9615.0,,,,CHEMBL621361,6642,N,BAO_0000218,1,,In vivo,,,50588
6444,1,Canis lupus familiaris,Oral bioavailability in dog,A,9615.0,,,,CHEMBL621362,5472,N,BAO_0000218,1,,In vivo,,,50588
6445,1,Canis lupus familiaris,Oral bioavailability in dog,A,9615.0,,,,CHEMBL621363,5985,N,BAO_0000218,1,,In vivo,,,50588
6446,1,Canis lupus familiaris,Oral bioavailability in dog,A,9615.0,,,,CHEMBL621364,15660,N,BAO_0000218,1,,In vivo,,,50588
6447,1,Canis lupus familiaris,Oral bioavailability in dog (dose 0.2 mg/kg i.v.),A,9615.0,,,,CHEMBL621166,5530,N,BAO_0000218,1,,In vivo,,,50588
6448,1,Canis lupus familiaris,Oral bioavailability in dog (dose 1 mg/kg i.v.),A,9615.0,,,,CHEMBL621167,5530,N,BAO_0000218,1,,In vivo,,,50588
6449,1,Canis lupus familiaris,Oral bioavailability (F) in dogs,A,9615.0,,,,CHEMBL621168,6305,N,BAO_0000218,1,,In vivo,,,50588
6450,1,Canis lupus familiaris,Oral bioavailability in dog,A,9615.0,,,,CHEMBL621169,5210,N,BAO_0000218,1,,In vivo,,,50588
6451,1,Canis lupus familiaris,Bioavailability in dog,A,9615.0,,,,CHEMBL875950,5238,N,BAO_0000218,1,,In vivo,,,50588
6452,1,Canis lupus familiaris,Oral bioavailability in dog (dose 10 mg/kg),A,9615.0,,,,CHEMBL621170,5668,N,BAO_0000218,1,,In vivo,,,50588
6453,1,Canis lupus familiaris,Oral bioavailability after peroral administration at 5 mpk in Dog,A,9615.0,,,,CHEMBL621171,5668,N,BAO_0000218,1,,In vivo,,,50588
6454,1,Canis lupus familiaris,Oral bioavailability in dog (dose 5 mg/kg),A,9615.0,,,,CHEMBL621172,5668,N,BAO_0000218,1,,In vivo,,,50588
6455,1,Canis lupus familiaris,Oral bioavailability in dog (dose 10 mg/kg),A,9615.0,,,,CHEMBL621173,6084,N,BAO_0000218,1,,In vivo,,,50588
6456,1,Mus musculus,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice kidney bearing S180 tumor cell line for 4 hours,A,10090.0,Kidney,,,CHEMBL621174,6599,N,BAO_0000218,1,2113.0,,,CCRF S-180,50594
6457,1,Mus musculus,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice kidney bearing S180 tumor cell line for 8 hours,A,10090.0,Kidney,,,CHEMBL621175,6599,N,BAO_0000218,1,2113.0,,,CCRF S-180,50594
6458,1,Mus musculus,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice liver bearing S180 tumor cell line for 1 hour,A,10090.0,Liver,,,CHEMBL621176,6599,N,BAO_0000218,1,2107.0,,,CCRF S-180,50594
6459,1,Mus musculus,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice liver bearing S180 tumor cell line for 2 hours,A,10090.0,Liver,,,CHEMBL621177,6599,N,BAO_0000218,1,2107.0,,,CCRF S-180,50594
6460,1,Mus musculus,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice liver bearing S180 tumor cell line for 30 minutes,A,10090.0,Liver,,,CHEMBL621178,6599,N,BAO_0000218,1,2107.0,,,CCRF S-180,50594
6461,1,Mus musculus,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice liver bearing S180 tumor cell line for 4 hours,A,10090.0,Liver,,,CHEMBL621179,6599,N,BAO_0000218,1,2107.0,,,CCRF S-180,50594
6462,1,Mus musculus,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice liver bearing S180 tumor cell line for 8 hours,A,10090.0,Liver,,,CHEMBL621180,6599,N,BAO_0000218,1,2107.0,,,CCRF S-180,50594
6463,1,Mus musculus,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice lung bearing S180 tumor cell line for 1 hour,A,10090.0,Lung,,,CHEMBL875951,6599,N,BAO_0000218,1,2048.0,,,CCRF S-180,50594
6464,1,Mus musculus,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice lung bearing S180 tumor cell line for 2 hours,A,10090.0,Lung,,,CHEMBL621181,6599,N,BAO_0000218,1,2048.0,,,CCRF S-180,50594
6465,1,Mus musculus,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice lung bearing S180 tumor cell line for 30 minutes,A,10090.0,Lung,,,CHEMBL621182,6599,N,BAO_0000218,1,2048.0,,,CCRF S-180,50594
6466,1,Mus musculus,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice lung bearing S180 tumor cell line for 4 hours,A,10090.0,Lung,,,CHEMBL621183,6599,N,BAO_0000218,1,2048.0,,,CCRF S-180,50594
6467,1,Mus musculus,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice lung bearing S180 tumor cell line for 8 hours,A,10090.0,Lung,,,CHEMBL621184,6599,N,BAO_0000218,1,2048.0,,,CCRF S-180,50594
6468,1,Mus musculus,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice muscle bearing S180 tumor cell line for 1 hour,A,10090.0,,,,CHEMBL621185,6599,N,BAO_0000218,1,,,,CCRF S-180,50594
6469,1,Mus musculus,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice muscle bearing S180 tumor cell line for 2 hours,A,10090.0,,,,CHEMBL621186,6599,N,BAO_0000218,1,,,,CCRF S-180,50594
6470,1,Mus musculus,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice muscle bearing S180 tumor cell line for 30 minutes,A,10090.0,,,,CHEMBL621187,6599,N,BAO_0000218,1,,,,CCRF S-180,50594
6471,1,Mus musculus,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice muscle bearing S180 tumor cell line for 4 hours,A,10090.0,,,,CHEMBL621188,6599,N,BAO_0000218,1,,,,CCRF S-180,50594
6472,1,Mus musculus,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice muscle bearing S180 tumor cell line for 8 hours,A,10090.0,,,,CHEMBL621189,6599,N,BAO_0000218,1,,,,CCRF S-180,50594
6473,1,Mus musculus,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice spleen bearing S180 tumor cell line for 1 hour,A,10090.0,Spleen,,,CHEMBL621190,6599,N,BAO_0000218,1,2106.0,,,CCRF S-180,50594
6474,1,Mus musculus,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice spleen bearing S180 tumor cell line for 2 hours,A,10090.0,Spleen,,,CHEMBL618520,6599,N,BAO_0000218,1,2106.0,,,CCRF S-180,50594
6475,1,Mus musculus,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice spleen bearing S180 tumor cell line for 30 minutes,A,10090.0,Spleen,,,CHEMBL621739,6599,N,BAO_0000218,1,2106.0,,,CCRF S-180,50594
6476,1,Mus musculus,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice spleen bearing S180 tumor cell line for 4 hours,A,10090.0,Spleen,,,CHEMBL621740,6599,N,BAO_0000218,1,2106.0,,,CCRF S-180,50594
6477,1,Mus musculus,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice spleen bearing S180 tumor cell line for 8 hours,A,10090.0,Spleen,,,CHEMBL621741,6599,N,BAO_0000218,1,2106.0,,,CCRF S-180,50594
6478,1,Mus musculus,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor bearing S180 tumor cell line for 1 hour,A,10090.0,,,,CHEMBL621742,6599,N,BAO_0000218,1,,,,CCRF S-180,50594
6479,1,Mus musculus,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor bearing S180 tumor cell line for 2 hours,A,10090.0,,,,CHEMBL621743,6599,N,BAO_0000218,1,,,,CCRF S-180,50594
6480,1,Mus musculus,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor bearing S180 tumor cell line for 30 minutes,A,10090.0,,,,CHEMBL621744,6599,N,BAO_0000218,1,,,,CCRF S-180,50594
6481,1,Mus musculus,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor bearing S180 tumor cell line for 4 hours,A,10090.0,,,,CHEMBL621745,6599,N,BAO_0000218,1,,,,CCRF S-180,50594
6482,1,Mus musculus,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor bearing S180 tumor cell line for 8 hours,A,10090.0,,,,CHEMBL621746,6599,N,BAO_0000218,1,,,,CCRF S-180,50594
6483,1,Mus musculus,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/blood bearing S180 tumor cell line for 1 hour,A,10090.0,,,,CHEMBL621747,6599,N,BAO_0000218,1,,,,CCRF S-180,50594
6484,1,Mus musculus,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/blood bearing S180 tumor cell line for 2 hours,A,10090.0,,,,CHEMBL621748,6599,N,BAO_0000218,1,,,,CCRF S-180,50594
6485,1,Mus musculus,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/blood bearing S180 tumor cell line for 30 minutes,A,10090.0,,,,CHEMBL621749,6599,N,BAO_0000218,1,,,,CCRF S-180,50594
6486,1,Mus musculus,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/blood bearing S180 tumor cell line for 4 hours,A,10090.0,,,,CHEMBL621750,6599,N,BAO_0000218,1,,,,CCRF S-180,50594
6487,1,Mus musculus,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/blood bearing S180 tumor cell line for 8 hours,A,10090.0,,,,CHEMBL621751,6599,N,BAO_0000218,1,,,,CCRF S-180,50594
6488,1,Mus musculus,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/heart bearing S180 tumor cell line for 1 hour,A,10090.0,Heart,,,CHEMBL621752,6599,N,BAO_0000218,1,948.0,,,CCRF S-180,50594
6489,1,Mus musculus,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/heart bearing S180 tumor cell line for 2 hours,A,10090.0,Heart,,,CHEMBL621753,6599,N,BAO_0000218,1,948.0,,,CCRF S-180,50594
6490,1,Mus musculus,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/heart bearing S180 tumor cell line for 30 minutes,A,10090.0,Heart,,,CHEMBL875955,6599,N,BAO_0000218,1,948.0,,,CCRF S-180,50594
6491,1,Mus musculus,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/heart bearing S180 tumor cell line for 4 hours,A,10090.0,Heart,,,CHEMBL621754,6599,N,BAO_0000218,1,948.0,,,CCRF S-180,50594
6492,1,Mus musculus,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/heart bearing S180 tumor cell line for 8 hours,A,10090.0,Heart,,,CHEMBL621755,6599,N,BAO_0000218,1,948.0,,,CCRF S-180,50594
6493,1,Mus musculus,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/liver bearing S180 tumor cell line for 1 hour,A,10090.0,Liver,,,CHEMBL621756,6599,N,BAO_0000218,1,2107.0,,,CCRF S-180,50594
6494,1,Mus musculus,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/liver bearing S180 tumor cell line for 2 hours,A,10090.0,Liver,,,CHEMBL624199,6599,N,BAO_0000218,1,2107.0,,,CCRF S-180,50594
6495,1,Mus musculus,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/liver bearing S180 tumor cell line for 30 minutes,A,10090.0,Liver,,,CHEMBL624200,6599,N,BAO_0000218,1,2107.0,,,CCRF S-180,50594
6496,1,Mus musculus,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/liver bearing S180 tumor cell line for 4 hours,A,10090.0,Liver,,,CHEMBL624375,6599,N,BAO_0000218,1,2107.0,,,CCRF S-180,50594
6497,1,Mus musculus,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/liver bearing S180 tumor cell line for 8 hours,A,10090.0,Liver,,,CHEMBL624376,6599,N,BAO_0000218,1,2107.0,,,CCRF S-180,50594
6498,1,Mus musculus,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/lung bearing S180 tumor cell line for 1 hour,A,10090.0,Lung,,,CHEMBL624377,6599,N,BAO_0000218,1,2048.0,,,CCRF S-180,50594
6499,1,Mus musculus,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/lung bearing S180 tumor cell line for 2 hours,A,10090.0,Lung,,,CHEMBL624378,6599,N,BAO_0000218,1,2048.0,,,CCRF S-180,50594
6500,1,aeinetobacter anitrotap,Compound tested for the antimicrobial activity against Acinetobacter anitratus,F,107673.0,,,,CHEMBL857901,12269,N,BAO_0000218,1,,,,,50067
6501,1,Acinetobacter calcoaceticus subsp. anitratus,Compound tested for the antimicrobial activity against Acinetobacter anitratus,F,107673.0,,,,CHEMBL875274,12269,N,BAO_0000218,1,,,,,50067
6502,1,Acinetobacter calcoaceticus subsp. anitratus,Compound tested for the antimicrobial activity against Acinetobacter anitratus,F,107673.0,,,,CHEMBL624379,12269,N,BAO_0000218,1,,,,,50067
6503,1,aeinetobacter anitrotap,Compound tested for the antimicrobial activity against Acinetobacter anitratus,F,107673.0,,,,CHEMBL624380,12269,N,BAO_0000218,1,,,,,50067
6504,1,Acinetobacter calcoaceticus,Activity against Acinetobacter calcoaceticus (AC54),F,471.0,,,,CHEMBL624381,10624,N,BAO_0000218,1,,,,,50192
6505,1,Anolis carolinensis,Biological activity using the lizard skin (Anolis carolinensis) assay. The value indicates no prolonged biological activity,F,28377.0,,,,CHEMBL624382,17216,N,BAO_0000218,1,,,,,50714
6506,1,Anolis carolinensis,Biological activity using the lizard skin (Anolis carolinensis) assay. The value indicates prolonged biological activity,F,28377.0,,,,CHEMBL624383,17216,N,BAO_0000218,1,,,,,50714
6507,1,Actinomyces naeslundii,Chlorohexidine coefficient for Actinomyces naeslundii 631,F,1655.0,,,,CHEMBL624384,9560,N,BAO_0000218,1,,,,,50296
6508,1,Actinomyces naeslundii,Chlorohexidine coefficient for Actinomyces naeslundii B74,F,1655.0,,,,CHEMBL624385,9560,N,BAO_0000218,1,,,,,50296
6509,1,Actinomyces naeslundii,Chlorohexidine coefficient for Actinomyces naeslundii N/3,F,1655.0,,,,CHEMBL624386,9560,N,BAO_0000218,1,,,,,50296
6510,1,Actinomyces naeslundii,Chlorohexidine coefficient for Actinomyces naeslundii N/9,F,1655.0,,,,CHEMBL624387,9560,N,BAO_0000218,1,,,,,50296
6511,1,Actinomyces naeslundii,Plaque bactericidal index against Actinomyces naeslundii 631,F,1655.0,,,,CHEMBL624388,9560,N,BAO_0000218,1,,,,,50296
6512,1,Actinomyces naeslundii,Plaque bactericidal index against Actinomyces naeslundii N/9,F,1655.0,,,,CHEMBL624389,9560,N,BAO_0000218,1,,,,,50296
6513,1,Actinomyces naeslundii,Plaque bactericidal index against Actinomyces naeslundii B74,F,1655.0,,,,CHEMBL624390,9560,N,BAO_0000218,1,,,,,50296
6514,1,Actinomyces naeslundii,Plaque bactericidal index against Actinomyces naeslundii N/3,F,1655.0,,,,CHEMBL875275,9560,N,BAO_0000218,1,,,,,50296
6515,1,Artemia salina,Compound was tested for its inhibitory activity using brine shrimp (Artemia salina) immobilization assay,F,85549.0,,,,CHEMBL624391,114,N,BAO_0000218,1,,,,,50056
6516,1,Artemia salina,"Compound was tested for its inhibitory activity using brine shrimp (Artemia salina) immobilization assay; highest level tested, showed <100% activity",F,85549.0,,,,CHEMBL623636,114,N,BAO_0000218,1,,,,,50056
6517,1,Ascaris suum,Effect on incorporation of [32Pi] by isolated Ascaris suum mitochondria at a concentration of 0 uM,F,6253.0,,,,CHEMBL623637,10841,N,BAO_0000218,1,,,,,50532
6518,1,Ascaris suum,Effect on incorporation of [32Pi] by isolated Ascaris suum mitochondria at a concentration of 10 uM,F,6253.0,,,,CHEMBL623638,10841,N,BAO_0000218,1,,,,,50532
6519,1,Ascaris suum,Effect on incorporation of [32Pi] by isolated Ascaris suum mitochondria at a concentration of 200 uM,F,6253.0,,,,CHEMBL623639,10841,N,BAO_0000218,1,,,,,50532
6520,1,Ascaris suum,Effect on incorporation of [32Pi] by isolated Ascaris suum mitochondria at a concentration of 25 uM,F,6253.0,,,,CHEMBL623640,10841,N,BAO_0000218,1,,,,,50532
6521,1,Ascaris suum,Effect on incorporation of [32Pi] by isolated Ascaris suum mitochondria at a concentration of 3 uM,F,6253.0,,,,CHEMBL623641,10841,N,BAO_0000218,1,,,,,50532
6522,1,Ascaris suum,Effect on incorporation of [32Pi] by isolated Ascaris suum mitochondria at a concentration of 50 uM.,F,6253.0,,,,CHEMBL623642,10841,N,BAO_0000218,1,,,,,50532
6523,1,Ascaris suum,Effect on succinate formation by isolated Ascaris suum mitochondria at a concentration of 0 uM,F,6253.0,,,,CHEMBL623643,10841,N,BAO_0000218,1,,,,,50532
6524,1,Ascaris suum,Effect on succinate formation by isolated Ascaris suum mitochondria at a concentration of 10 uM,F,6253.0,,,,CHEMBL623644,10841,N,BAO_0000218,1,,,,,50532
6525,1,Ascaris suum,Effect on succinate formation by isolated Ascaris suum mitochondria at a concentration of 200 uM,F,6253.0,,,,CHEMBL623645,10841,N,BAO_0000218,1,,,,,50532
6526,1,Ascaris suum,Effect on succinate formation by isolated Ascaris suum mitochondria at a concentration of 25 uM,F,6253.0,,,,CHEMBL623646,10841,N,BAO_0000218,1,,,,,50532
6527,1,Ascaris suum,Effect on succinate formation by isolated Ascaris suum mitochondria at a concentration of 3 uM,F,6253.0,,,,CHEMBL623647,10841,N,BAO_0000218,1,,,,,50532
6528,1,Ascaris suum,Effect on succinate formation by isolated Ascaris suum mitochondria at a concentration of 50 uM,F,6253.0,,,,CHEMBL623648,10841,N,BAO_0000218,1,,,,,50532
6529,1,Actinomyces viscosus,Compound is evaluated for minimal bactericidal concentration against plaque formation for Actinomyces viscosus,F,1656.0,,,,CHEMBL623649,8117,N,BAO_0000218,1,,,,,50366
6530,1,Actinomyces viscosus,Compound is evaluated for minimal bactericidal concentration against plaque formation for Actinomyces viscosus,F,1656.0,,,,CHEMBL623650,8117,N,BAO_0000218,1,,,,,50366
6531,1,Actinomyces viscosus,Chlorohexidine coefficient for Actinomyces viscosus 8A06,F,1656.0,,,,CHEMBL623651,9560,N,BAO_0000218,1,,,,,50366
6532,1,Actinomyces viscosus,Chlorohexidine coefficient for Actinomyces viscosus M-100,F,1656.0,,,,CHEMBL623652,9560,N,BAO_0000218,1,,,,,50366
6533,1,Actinomyces viscosus,Chlorohexidine coefficient for Actinomyces viscosus M-626,F,1656.0,,,,CHEMBL623653,9560,N,BAO_0000218,1,,,,,50366
6534,1,Actinomyces viscosus,Chlorohexidine coefficient for Actinomyces viscosus T14V,F,1656.0,,,,CHEMBL623654,9560,N,BAO_0000218,1,,,,,50366
6535,1,Actinomyces viscosus,Plaque bactericidal index against Actinomyces viscosus 8A06,F,1656.0,,,,CHEMBL623655,9560,N,BAO_0000218,1,,,,,50366
6536,1,Actinomyces viscosus,Plaque bactericidal index against Actinomyces viscosus M-100,F,1656.0,,,,CHEMBL623656,9560,N,BAO_0000218,1,,,,,50366
6537,1,Actinomyces viscosus,Plaque bactericidal index against Actinomyces viscosus M-100 measured as chlorohexidine coefficient,F,1656.0,,,,CHEMBL623657,9560,N,BAO_0000218,1,,,,,50366
6538,1,Actinomyces viscosus,"Plaque bactericidal index against Actinomyces viscosus M-100 measured as chlorohexidine coefficient; d=Not bactericidal at highest concentration tested (0.2% w/v, 2min, 5 days)",F,1656.0,,,,CHEMBL623658,9560,N,BAO_0000218,1,,,,,50366
6539,1,Actinomyces viscosus,"Plaque bactericidal index against Actinomyces viscosus M-100 measured as chlorohexidine coefficient; not bactericidal at highest concentration tested (0.2% w/v, 2min, 5 days)",F,1656.0,,,,CHEMBL623659,9560,N,BAO_0000218,1,,,,,50366
6540,1,Actinomyces viscosus,Plaque bactericidal index against Actinomyces viscosus 626,F,1656.0,,,,CHEMBL623660,9560,N,BAO_0000218,1,,,,,50366
6541,1,Actinomyces viscosus,Plaque bactericidal index against Actinomyces viscosus T14V,F,1656.0,,,,CHEMBL623661,9560,N,BAO_0000218,1,,,,,50366
6542,1,Acanthocheilonema viteae,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 1.56 mg/kg/day(5 days) dose,F,6277.0,,,,CHEMBL875281,10986,N,BAO_0000218,1,,,,,50535
6543,1,Acanthocheilonema viteae,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 100 mg/kg/day(5 days) dose,F,6277.0,,,,CHEMBL623662,10986,N,BAO_0000218,1,,,,,50535
6544,1,Acanthocheilonema viteae,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 12.5 mg/kg/day(5 days) dose,F,6277.0,,,,CHEMBL623663,10986,N,BAO_0000218,1,,,,,50535
6545,1,Acanthocheilonema viteae,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 200 mg/kg/day(5 days) dose,F,6277.0,,,,CHEMBL623664,10986,N,BAO_0000218,1,,,,,50535
6546,1,Acanthocheilonema viteae,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 25 mg/kg/day(5 days) dose,F,6277.0,,,,CHEMBL623665,10986,N,BAO_0000218,1,,,,,50535
6547,1,Homo sapiens,Evaluated for the inhibitory concentration required to cause growth inhibition of A673Mer+ sarcoma cell line using the MTT Cytotoxicity Assay,F,9606.0,,,,CHEMBL621856,10708,N,BAO_0000219,1,,,,A673,80023
6548,1,Homo sapiens,Evaluated for the inhibitory concentration required to cause growth inhibition of A704Rem- renal cell line using the MTT Cytotoxicity Assay,F,9606.0,,,,CHEMBL620432,10708,N,BAO_0000219,1,,,,A704,80661
6549,0,Rattus norvegicus,Tested for inhibition of ET-1 induced phosphoinositide (PI) turnover in A7r5 smooth muscle cells,F,10116.0,,,,CHEMBL620433,416,U,BAO_0000219,1,,,,,22226
6550,1,Mus musculus,Inhibition of Forskolin-Induced cAMP production in A9 L cells expressing m2 receptors,F,10090.0,,,,CHEMBL620434,14354,N,BAO_0000219,1,,,,A9,80024
6551,1,Mus musculus,Percent inhibition of Forskolin-Induced cAMP production in A9 L cells expressing m2 receptors,F,10090.0,,,,CHEMBL620435,14354,N,BAO_0000219,1,,,,A9,80024
6552,1,Homo sapiens,Cytotoxicity against Beta- tubulin mutant expressing A9-PTX10 cell line of humans was tested,F,9606.0,,,,CHEMBL620436,5116,N,BAO_0000219,1,,,,A9,80024
6553,1,Homo sapiens,Percentage inhibition at higher concentration (100 nM) against Beta- tubulin mutant expressing A9-PTX10 cell line,F,9606.0,,,,CHEMBL876597,5116,N,BAO_0000219,1,,,,A9,80024
6554,1,Homo sapiens,Inhibition of human ovarian carcinoma (A90) FGF-R overexpressing cell proliferation,F,9606.0,,,,CHEMBL620437,15694,N,BAO_0000219,1,,,,Human ovarian carcinoma cell line,81037
6555,1,Mus musculus,"Tested for stimulating PI (phosphoinositol) hydrolysis in A9L-m1 cells, activity expressed as EC50 mM.",F,10090.0,,,,CHEMBL620438,13038,N,BAO_0000219,1,,,,A9,80024
6556,1,Mus musculus,Stimulating PI (phosphoinositol) hydrolysis in A9L-m1 cells.,F,10090.0,,,,CHEMBL620439,13038,N,BAO_0000219,1,,,,A9,80024
6557,1,Mus musculus,Increase in phosphoinositide (PI) metabolism in A9L-m1 cells at 100 uM.,F,10090.0,,,,CHEMBL619657,10923,N,BAO_0000219,1,,,,A9,80024
6558,1,Mus musculus,The increase in phosphoinositide (PI) metabolism in A9L-m1 cells was measured at 100 uM; - = Not determined,F,10090.0,,,,CHEMBL619658,10923,N,BAO_0000219,1,,,,A9,80024
6559,1,Mus musculus,The increase in phosphoinositide (PI) metabolism in A9L-m1 cells was measured at 100 uM; i = inactive,F,10090.0,,,,CHEMBL619659,10923,N,BAO_0000219,1,,,,A9,80024
6560,8,,"Increase in phosphoinositide (PI) metabolism in A9L-cholinergic receptor, muscarinic 3 expressing cells was measured at 100 uMolar",F,,,,,CHEMBL619660,10923,H,BAO_0000019,1,,,,,10649
6561,1,Mus musculus,The increase in phosphoinositide (PI) metabolism in A9L-m3 cells was measured at 100 uM; - = Not determined,F,10090.0,,,,CHEMBL619661,10923,N,BAO_0000219,1,,,,A9,80024
6562,1,Mus musculus,The increase in phosphoinositide (PI) metabolism in A9L-m3 cells was measured at 100 uM; i = inactive,F,10090.0,,,,CHEMBL619662,10923,N,BAO_0000219,1,,,,A9,80024
6563,1,Cricetulus griseus,Ability to inhibit growth of AA-6 cells (a mutant cell line resistant to 8-azaadenine and lacks adenine phosphoryltransferase) was determined,F,10029.0,,,,CHEMBL619663,8158,N,BAO_0000219,1,,,,AA6,80663
6564,0,Homo sapiens,Intracellular phosphorylation (100 uM) in uninfected AA2 cells was studied after 5 hrs of Incubation.,F,9606.0,,,,CHEMBL619664,15494,U,BAO_0000219,1,,,,,22226
6565,0,Homo sapiens,"Intracellular phosphorylation (100 uM) in uninfected AA2 cells was studied, after 5 hrs of Incubation.",F,9606.0,,,,CHEMBL619665,15494,U,BAO_0000219,1,,,,,22226
6566,1,Homo sapiens,Anti -HIV activity was measured against AA5/HIV-1(IIIB),F,9606.0,,,,CHEMBL883244,12348,N,BAO_0000219,1,,,,AA5,80662
6567,1,Homo sapiens,Cytotoxicity was measured against AA5/HIV-1(IIIB),F,9606.0,,,,CHEMBL884011,12348,N,BAO_0000219,1,,,,AA5,80662
6568,1,Homo sapiens,Compound was evaluated for the anti-HIV activity against HIV strain IIIB in AA5 EBV-infected B-cell,F,9606.0,,,,CHEMBL619666,2726,N,BAO_0000219,1,,,,AA5,80662
6569,1,Homo sapiens,Compound was evaluated for the anti-HIV activity against HIV strain IIIB in U937 monocytic cell,F,9606.0,,,,CHEMBL619667,2726,N,BAO_0000219,1,,,,U-937,80566
6570,1,Cricetulus griseus,Hypersensitivity factor obtained from in vitro cytotoxicities against Chinese hamster ovary derived AA8 / UV4 cell lines,F,10029.0,,,,CHEMBL619668,10747,N,BAO_0000219,1,,,,UV4,80578
6571,1,Cricetulus griseus,"Inhibition of cell growth in culture against Chinese hamster ovary derived cell line, AA8",F,10029.0,,,,CHEMBL619669,11005,N,BAO_0000219,1,,,,CHO-AA8,80089
6572,1,Cricetulus griseus,Average intracellular compound concentration when the hypoxic SER=1.6,F,10029.0,,,,CHEMBL876608,12687,N,BAO_0000219,1,,,,CHO-AA8,80089
6573,1,Cricetulus griseus,Average intracellular compound concentration when the hypoxic SER=1.6.,F,10029.0,,,,CHEMBL619670,12687,N,BAO_0000219,1,,,,CHO-AA8,80089
6574,1,Cricetulus griseus,Average intracellular compound concentration where the hypoxia sensitizer enhancement ratio (SER)=1.6,F,10029.0,,,,CHEMBL619671,12687,N,BAO_0000219,1,,,,CHO-AA8,80089
6575,1,Cricetulus griseus,Average intracellular compound concentration where the sensitizer enhancement ratio (SER)=1.6 under hypoxia,F,10029.0,,,,CHEMBL619672,12687,N,BAO_0000219,1,,,,CHO-AA8,80089
6576,1,Cricetulus griseus,Compound concentration at which sensitizer enhancement ratio =1.6 under hypoxia.,F,10029.0,,,,CHEMBL619673,12687,N,BAO_0000219,1,,,,CHO-AA8,80089
6577,1,Cricetulus griseus,"Compound was tested for the concentration required to reduce cell survival under hypoxic conditions, using the cell line AA8 in the clonogenic assay.",F,10029.0,,,,CHEMBL619674,13436,N,BAO_0000219,1,,,,CHO-AA8,80089
6578,1,Cricetulus griseus,"Concentration needed to reduce cell survival to 10% of control values, using 1 hour exposure of plateau phase AA8 cells at 10e6 cells/ml",F,10029.0,,,,CHEMBL619675,13435,N,BAO_0000219,1,,,,CHO-AA8,80089
6579,1,Cricetulus griseus,Activity to reduce the surviving fraction to 10% (CT10) was used as an inverse measure of cytotoxic potency in aerobic conditions,F,10029.0,,,,CHEMBL619676,13302,N,BAO_0000219,1,,,,CHO-AA8,80089
6580,1,Cricetulus griseus,Compound concentration required to reduce cell survival to 10% of control values under hypoxic condition,F,10029.0,,,,CHEMBL619677,12687,N,BAO_0000219,1,,,,CHO-AA8,80089
6581,1,Cricetulus griseus,Compound concentration required to reduce cell survival to 10% of control values under hypoxic condition,A,10029.0,,,,CHEMBL619678,12687,N,BAO_0000219,1,,,,CHO-AA8,80089
6582,1,Cricetulus griseus,Compound concentration required to reduce cell survival to 10% of control values under hypoxic condition.,A,10029.0,,,,CHEMBL619679,12687,N,BAO_0000219,1,,,,CHO-AA8,80089
6583,1,Cricetulus griseus,Concentration x time (uM h) to reduce cell survival to 10% of control values under hypoxic conditions by clonogenic assay,A,10029.0,,,,CHEMBL619680,12878,N,BAO_0000219,1,,,,CHO-AA8,80089
6584,1,Cricetulus griseus,Concentration x time (uM h) to reduce cell survival to 10% of control values under hypoxic conditions by clonogenic assay. Inactive at the solubility limit,A,10029.0,,,,CHEMBL621457,12878,N,BAO_0000219,1,,,,CHO-AA8,80089
6585,1,Cricetulus griseus,Cytotoxicity under aerobic conditions determined to reduce the AA8 cell survival to 10% controls in clonogenic assay,F,10029.0,,,,CHEMBL876609,14367,N,BAO_0000219,1,,,,CHO-AA8,80089
6586,1,Cricetulus griseus,Cytotoxicity under aerobic conditions determined to reduce the AA8 cell survival to 10% of controls in clonogenic assay,F,10029.0,,,,CHEMBL621458,14367,N,BAO_0000219,1,,,,CHO-AA8,80089
6587,1,hampster,Aerobic cytotoxicity was assessed in a growth inhibition assay using log phase cultures of the chinese hamster ovary fibroblast line AA8,F,36483.0,,,,CHEMBL621459,12398,N,BAO_0000219,1,,,,CHO-AA8,80089
6588,1,Cricetulus griseus,Aerobic growth inhibition in Chinese hamster cell line AA8,F,10029.0,,,,CHEMBL621460,12878,N,BAO_0000219,1,,,,CHO-AA8,80089
6589,1,Cricetulus griseus,Cytotoxicity against AA8 cell and IC50 values were determined as drug concentration required to inhibit cell protein to 50%.,F,10029.0,,,,CHEMBL621461,13820,N,BAO_0000219,1,,,,CHO-AA8,80089
6590,1,Cricetulus griseus,Inhibition of growth under aerobic conditions in AA8 cells,F,10029.0,,,,CHEMBL621462,13436,N,BAO_0000219,1,,,,CHO-AA8,80089
6591,1,Canis lupus familiaris,Oral bioavailability in dog (dose 10 mg/kg),A,9615.0,,,,CHEMBL621463,6084,N,BAO_0000218,1,,In vivo,,,50588
6592,1,Canis lupus familiaris,Oral bioavailability in dog at 10 mg/kg of the compound,A,9615.0,,,,CHEMBL621464,5711,N,BAO_0000218,1,,In vivo,,,50588
6593,1,Canis lupus familiaris,Oral bioavailability in dog (dose 5 uM/kg),A,9615.0,,,,CHEMBL621465,4353,N,BAO_0000218,1,,In vivo,,,50588
6594,1,Canis lupus familiaris,Oral bioavailability in dog (dose 5 uM/kg),A,9615.0,,,,CHEMBL621466,4353,N,BAO_0000218,1,,In vivo,,,50588
6595,1,Canis lupus familiaris,Oral bioavailability in dog (mongrel),A,9615.0,,,,CHEMBL621467,17800,N,BAO_0000218,1,,In vivo,,,50588
6596,1,Canis lupus familiaris,Oral bioavailability in dog (dose 10 mg/kg),A,9615.0,,,,CHEMBL621468,3994,N,BAO_0000218,1,,In vivo,,,50588
6597,1,Canis lupus familiaris,Oral bioavailability in dog (dose 10 mg/kg),F,9615.0,,,,CHEMBL876734,3994,N,BAO_0000218,1,,In vivo,,,50588
6598,1,Canis lupus familiaris,Bioavailability in dog,A,9615.0,,,,CHEMBL618476,5145,N,BAO_0000218,1,,In vivo,,,50588
6599,1,Canis lupus familiaris,Bioavailability in dog (dose 1 mg/kg i.v.),A,9615.0,,,,CHEMBL618477,16452,N,BAO_0000218,1,,In vivo,,,50588
6600,1,Canis lupus familiaris,Pharmacokinetic data for dose given to dogs intravenously (oral PK study in parentheses),A,9615.0,,,,CHEMBL618478,16452,N,BAO_0000218,1,,In vivo,,,50588
6601,1,Canis lupus familiaris,Pharmacokinetic property (F) was measured in dog at the dose of 0.032 mg/kg,A,9615.0,,,,CHEMBL618479,5983,N,BAO_0000218,1,,In vivo,,,50588
6602,1,Canis lupus familiaris,Bioavailability in dog,A,9615.0,,,,CHEMBL618480,4273,N,BAO_0000218,1,,In vivo,,,50588
6603,1,Canis lupus familiaris,Bioavailability in dog (dose 3-10 mg/kg),A,9615.0,,,,CHEMBL618481,12500,N,BAO_0000218,1,,In vivo,,,50588
6604,1,Canis lupus familiaris,The compound was tested for bioavailability of compound in plasma of dog; Complete,A,9615.0,Plasma,,,CHEMBL618482,12500,N,BAO_0000218,1,1969.0,In vivo,,,50588
6605,1,Canis lupus familiaris,Oral bioavailability in dog,A,9615.0,,,,CHEMBL618483,3639,N,BAO_0000218,1,,In vivo,,,50588
6606,1,Canis lupus familiaris,Oral bioavailability in dog,A,9615.0,,,,CHEMBL618484,3880,N,BAO_0000218,1,,In vivo,,,50588
6607,1,Canis lupus familiaris,Bioavailability in dog,A,9615.0,,,,CHEMBL618485,4838,N,BAO_0000218,1,,In vivo,,,50588
6608,1,Canis lupus familiaris,oral bioavailability was measured in dogs,A,9615.0,,,,CHEMBL618486,15600,N,BAO_0000218,1,,In vivo,,,50588
6609,1,Canis lupus familiaris,Compound was tested for plasma protein binding in dog; Not determined,A,9615.0,,,,CHEMBL618487,17248,N,BAO_0000218,1,,,,,50588
6610,1,Canis lupus familiaris,Compound was tested for plasma protein binding of dog,A,9615.0,,,,CHEMBL618488,17248,N,BAO_0000218,1,,,,,50588
6611,1,Canis lupus familiaris,Compound was tested for plasma protein binding of dog; Not determined,A,9615.0,,,,CHEMBL876735,17248,N,BAO_0000218,1,,,,,50588
6612,1,Canis lupus familiaris,Concentration in dogs after oral administration at dose of 1 mg/kg after 180 min.,A,9615.0,,,,CHEMBL618489,17443,N,BAO_0000218,1,,,,,50588
6613,1,Canis lupus familiaris,Apparent terminal elimination half-life in dog after administration of 20 mg/kg dose through peroral route,A,9615.0,,,,CHEMBL618490,4186,N,BAO_0000218,1,,In vivo,,,50588
6614,1,Canis lupus familiaris,Half life was determined,A,9615.0,,,,CHEMBL618491,3749,N,BAO_0000218,1,,,,,50588
6615,1,Canis lupus familiaris,Half life by ''Cr'' assay in dog at a dose of 5 mg/kg,A,9615.0,,,,CHEMBL618492,3249,N,BAO_0000218,1,,In vivo,,,50588
6616,1,Canis lupus familiaris,Half life was evaluated in dog,A,9615.0,,,,CHEMBL873354,3022,N,BAO_0000218,1,,,,,50588
6617,1,Canis lupus familiaris,Half life was determined,A,9615.0,,,,CHEMBL618493,3749,N,BAO_0000218,1,,,,,50588
6618,1,Canis lupus familiaris,Biodistribution of compound was measured in bile at 2 hr post-injection in canine deep vein thrombosis model (DVT),A,9615.0,,,,CHEMBL618494,2517,N,BAO_0000218,1,,In vivo,,,50588
6619,1,Canis lupus familiaris,Biodistribution of compound was measured in heart at 2 hr post-injection in canine deep vein thrombosis model (DVT),A,9615.0,Heart,,,CHEMBL618495,2517,N,BAO_0000218,1,948.0,In vivo,,,50588
6620,1,Canis lupus familiaris,Biodistribution of compound was measured in kidney at 2 hr post-injection in canine deep vein thrombosis model (DVT),A,9615.0,Kidney,,,CHEMBL618496,2517,N,BAO_0000218,1,2113.0,In vivo,,,50588
6621,1,Canis lupus familiaris,Biodistribution of compound was measured in liver at 2 hr post-injection in canine deep vein thrombosis model (DVT),A,9615.0,Liver,,,CHEMBL618497,2517,N,BAO_0000218,1,2107.0,In vivo,,,50588
6622,1,Canis lupus familiaris,Biodistribution of compound was measured in lung at 2 hr post-injection in canine deep vein thrombosis model (DVT),A,9615.0,Lung,,,CHEMBL618498,2517,N,BAO_0000218,1,2048.0,In vivo,,,50588
6623,1,Canis lupus familiaris,Biodistribution of compound was measured in spleen at 2 hr post-injection in canine deep vein thrombosis model (DVT),A,9615.0,Spleen,,,CHEMBL618499,2517,N,BAO_0000218,1,2106.0,In vivo,,,50588
6624,1,Canis lupus familiaris,LogP in dog,A,9615.0,,,,CHEMBL876736,3639,N,BAO_0000218,1,,,,,50588
6625,1,Canis lupus familiaris,Partition coefficient (logP),A,9615.0,,,,CHEMBL618500,6227,N,BAO_0000218,1,,,,,50588
6626,1,Canis lupus familiaris,Partition coefficient in dog,A,9615.0,,,,CHEMBL857831,6227,N,BAO_0000218,1,,,,,50588
6627,1,Canis lupus familiaris,Mean-residence time of compound after intravenous administration in dogs at 1.2 uM/kg,A,9615.0,,,,CHEMBL618501,17764,N,BAO_0000218,1,,In vivo,,,50588
6628,1,Canis lupus familiaris,Pharmacokinetic parameter MRT was determined in Beagle dogs after (po) administration of a dose of 28 (uM/kg),A,9615.0,,,,CHEMBL618502,4809,N,BAO_0000218,1,,In vivo,,,50588
6629,1,Canis lupus familiaris,In vitro metabolic stability determined after 30 min of incubation in dog hepatic microsomes,A,9615.0,,,,CHEMBL618503,5600,N,BAO_0000218,1,,,,,50588
6630,1,Canis lupus familiaris,Metabolism of compound in dog S9 microsomes ('++''indicates 20-50% largest observed peak),A,9615.0,,,,CHEMBL618504,14294,N,BAO_0000218,1,,,,,50588
6631,1,Canis lupus familiaris,Metabolism of compound in dog S9 microsomes ('++++' indicates largest observed peak),A,9615.0,,,,CHEMBL618505,14294,N,BAO_0000218,1,,,,,50588
6632,1,Canis lupus familiaris,Metabolism of compound in dog S9 microsomes; Trace,A,9615.0,,,,CHEMBL618506,14294,N,BAO_0000218,1,,,,,50588
6633,1,Canis lupus familiaris,In vitro metabolic potential in dog liver microsomes,A,9615.0,Liver,,,CHEMBL618507,6251,N,BAO_0000218,1,2107.0,,,,50588
6634,1,Canis lupus familiaris,Oral bioavailability of perorally administered compound (10 mg/kg) was tested in dogs,A,9615.0,,,,CHEMBL876737,3748,N,BAO_0000218,1,,In vivo,,,50588
6635,1,Canis lupus familiaris,Oral bioavailability in dog,A,9615.0,,,,CHEMBL618508,2713,N,BAO_0000218,1,,In vivo,,,50588
6636,1,Canis lupus familiaris,Oral bioavailability in dog,A,9615.0,,,,CHEMBL618509,6512,N,BAO_0000218,1,,In vivo,,,50588
6637,1,Canis lupus familiaris,Oral bioavailability was determined after 1 mg/kg (i.v.) / 2 mg/kg (p.o.) of compound administration,A,9615.0,,,,CHEMBL618510,6679,N,BAO_0000218,1,,In vivo,,,50588
6638,1,Canis lupus familiaris,The compound was tested for bioavailability in dogs,A,9615.0,,,,CHEMBL618511,3749,N,BAO_0000218,1,,In vivo,,,50588
6639,1,Canis lupus familiaris,The compound was tested for oral bioavailability in dogs,A,9615.0,,,,CHEMBL618512,3749,N,BAO_0000218,1,,In vivo,,,50588
6640,1,Canis lupus familiaris,Oral bioavailability in dog,A,9615.0,,,,CHEMBL618513,6742,N,BAO_0000218,1,,In vivo,,,50588
6641,1,Canis lupus familiaris,Compound was tested for percent protein binding (PB) in dog,A,9615.0,,,,CHEMBL618514,6227,N,BAO_0000218,1,,,,,50588
6642,1,Canis lupus familiaris,Apparent permeability coefficient (Papp) for apical to basolateral flux was determined in MadinDarby Canine Kidney cells,A,9615.0,,,,CHEMBL620052,6874,N,BAO_0000218,1,,,,,50588
6643,1,Canis lupus familiaris,Compound was evaluated for plasma clearance.,A,9615.0,Plasma,,,CHEMBL620053,2877,N,BAO_0000218,1,1969.0,In vivo,,,50588
6644,1,Canis lupus familiaris,The compound was tested for plasma clearance in dog,A,9615.0,Plasma,,,CHEMBL620054,12500,N,BAO_0000218,1,1969.0,In vivo,,,50588
6645,1,Canis lupus familiaris,The compound was tested for plasma clearance in dog at dose of 3-10 mgkg,A,9615.0,Plasma,,,CHEMBL620055,12500,N,BAO_0000218,1,1969.0,In vivo,,,50588
6646,1,Canis lupus familiaris,Plasma protein binding was determined after intravenous administration of 1 mg/kg in dog,A,9615.0,,,,CHEMBL620056,4709,N,BAO_0000218,1,,,,,50588
6647,1,Canis lupus familiaris,In vitro relative rate of metabolism was determined in dog liver microsomes,A,9615.0,Liver,,,CHEMBL620057,5542,N,BAO_0000218,1,2107.0,,,,50588
6648,1,Canis lupus familiaris,Relative bioavailability after oral dose of compound at 3 mg/kg in dogs,A,9615.0,,,,CHEMBL618939,17594,N,BAO_0000218,1,,In vivo,,,50588
6649,1,Canis lupus familiaris,Compound was evaluated for half-life period in dogs at a dose of 5 mpk perorally,A,9615.0,,,,CHEMBL618940,2652,N,BAO_0000218,1,,In vivo,,,50588
6650,1,Canis lupus familiaris,Half life after intravenous administration in dogs at 1.2 uM/kg,A,9615.0,,,,CHEMBL618941,17764,N,BAO_0000218,1,,In vivo,,,50588
6651,1,Mus musculus,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/lung bearing S180 tumor cell line for 30 minutes,A,10090.0,Lung,,,CHEMBL624473,6599,N,BAO_0000218,1,2048.0,,,CCRF S-180,50594
6652,1,Mus musculus,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/lung bearing S180 tumor cell line for 4 hours,A,10090.0,Lung,,,CHEMBL624474,6599,N,BAO_0000218,1,2048.0,,,CCRF S-180,50594
6653,1,Mus musculus,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/lung bearing S180 tumor cell line for 8 hours,A,10090.0,Lung,,,CHEMBL624475,6599,N,BAO_0000218,1,2048.0,,,CCRF S-180,50594
6654,1,Mus musculus,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/muscle bearing S180 tumor cell line for 1 hour,A,10090.0,,,,CHEMBL624476,6599,N,BAO_0000218,1,,,,CCRF S-180,50594
6655,1,Mus musculus,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/muscle bearing S180 tumor cell line for 2 hours,A,10090.0,,,,CHEMBL623478,6599,N,BAO_0000218,1,,,,CCRF S-180,50594
6656,1,Mus musculus,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/muscle bearing S180 tumor cell line for 30 minutes,A,10090.0,,,,CHEMBL623479,6599,N,BAO_0000218,1,,,,CCRF S-180,50594
6657,1,Mus musculus,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/muscle bearing S180 tumor cell line for 4 hours,A,10090.0,,,,CHEMBL623480,6599,N,BAO_0000218,1,,,,CCRF S-180,50594
6658,1,Mus musculus,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/muscle bearing S180 tumor cell line for 8 hours,A,10090.0,,,,CHEMBL623481,6599,N,BAO_0000218,1,,,,CCRF S-180,50594
6659,1,Mus musculus,C2 in brain of mice at the oral dose of 50 mg/kg,A,10090.0,Brain,,,CHEMBL623482,17641,N,BAO_0000218,1,955.0,,,,50594
6660,1,Mus musculus,C2 in kidney of mice at the oral dose of 50 mg/kg,A,10090.0,Kidney,,,CHEMBL623483,17641,N,BAO_0000218,1,2113.0,,,,50594
6661,1,Mus musculus,C2 in liver of mice at the oral dose of 50 mg/kg,A,10090.0,Liver,,,CHEMBL623484,17641,N,BAO_0000218,1,2107.0,,,,50594
6662,1,Mus musculus,C2 in lungs of mice at the oral dose of 50 mg/kg,A,10090.0,Lung,,,CHEMBL623485,17641,N,BAO_0000218,1,2048.0,,,,50594
6663,1,Mus musculus,C2 in spleen of mice at the oral dose of 50 mg/kg,A,10090.0,Spleen,,,CHEMBL623486,17641,N,BAO_0000218,1,2106.0,,,,50594
6664,1,Mus musculus,Plasma clearance in mouse,A,10090.0,,,,CHEMBL623487,17852,N,BAO_0000218,1,,In vivo,,,50594
6665,1,Mus musculus,Clearance of compound after intravenous administration in mice at 24 uM/kg,A,10090.0,,,,CHEMBL623488,17764,N,BAO_0000218,1,,In vivo,,,50594
6666,1,Mus musculus,Clearance from mouse blood following i.v. administration of 10 mg/kg,A,10090.0,,,,CHEMBL623489,17837,N,BAO_0000218,1,,In vivo,,,50594
6667,1,Mus musculus,Clearance was evaluated in mice after intravenous administration,A,10090.0,,,,CHEMBL875157,2675,N,BAO_0000218,1,,In vivo,,,50594
6668,1,Mus musculus,Clearance was evaluated in mice after oral administration,A,10090.0,,,,CHEMBL623490,2675,N,BAO_0000218,1,,In vivo,,,50594
6669,1,Mus musculus,Pharmacokinetic property (Plasma clearance) was measured in mouse,A,10090.0,,,,CHEMBL623491,4239,N,BAO_0000218,1,,In vivo,,,50594
6670,1,Mus musculus,Plasma clearance of compound was determined at 40 mg/Kg,A,10090.0,,,,CHEMBL623492,17753,N,BAO_0000218,1,,In vivo,,,50594
6671,1,Mus musculus,Plasma clearance of at 24 mg/Kg,A,10090.0,,,,CHEMBL623493,17753,N,BAO_0000218,1,,In vivo,,,50594
6672,1,Mus musculus,Plasma clearance at 24 mg/Kg,A,10090.0,,,,CHEMBL623494,17753,N,BAO_0000218,1,,In vivo,,,50594
6673,1,Mus musculus,Plasma clearance at 5 mg/Kg,A,10090.0,,,,CHEMBL623495,17753,N,BAO_0000218,1,,In vivo,,,50594
6674,1,Mus musculus,Plasma clearance in mice,A,10090.0,,,,CHEMBL623496,5727,N,BAO_0000218,1,,In vivo,,,50594
6675,1,Mus musculus,Plasma clearance value upon iv administration in mouse,A,10090.0,,,,CHEMBL623497,2862,N,BAO_0000218,1,,In vivo,,,50594
6676,1,Mus musculus,Total plasma clearance in mice,A,10090.0,Plasma,,,CHEMBL623498,5980,N,BAO_0000218,1,1969.0,In vivo,,,50594
6677,1,Mus musculus,Clearance in mouse,A,10090.0,,,,CHEMBL623499,17592,N,BAO_0000218,1,,In vivo,,,50594
6678,1,Mus musculus,Clearance value was determined,A,10090.0,,,,CHEMBL623500,17718,N,BAO_0000218,1,,In vivo,,,50594
6679,1,Mus musculus,Plasma clearance at a dose of 10 mg/kg intravenous administration in mice.,A,10090.0,,,,CHEMBL623501,16597,N,BAO_0000218,1,,In vivo,,,50594
6680,0,,Calculated partition coefficient (clogP),P,,,,,CHEMBL875158,17384,U,BAO_0000100,1,,,,,22229
6681,1,Mus musculus,Plasma clearance for the compound was measured in mouse after an iv dose of 1 mg/kg,A,10090.0,,,,CHEMBL623502,6062,N,BAO_0000218,1,,In vivo,,,50594
6682,1,Mus musculus,Plasma clearance rate after intraperitoneal administration of 100 mg/kg in mice,A,10090.0,,,,CHEMBL623503,17734,N,BAO_0000218,1,,In vivo,,,50594
6683,1,Mus musculus,Plasma clearance was determined in mouse after 5 mg/kg (i.v.) and 6 mg/kg (p.o.) administration,A,10090.0,,,,CHEMBL623504,6348,N,BAO_0000218,1,,In vivo,,,50594
6684,1,Mus musculus,In vivo total clearance was determined in murine septicemia at dose of 100 mg/kg,A,10090.0,,,,CHEMBL623505,5969,N,BAO_0000218,1,,In vivo,,,50594
6685,1,Mus musculus,In vivo total clearance was determined in murine septicemia at dose of 50 mg/kg,A,10090.0,,,,CHEMBL623506,5969,N,BAO_0000218,1,,In vivo,,,50594
6686,1,Mus musculus,In vivo total clearance was determined in murine septicemia at dose of 50 mg/kg;ND=not determined,A,10090.0,,,,CHEMBL623507,5969,N,BAO_0000218,1,,In vivo,,,50594
6687,1,Mus musculus,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for Cmax,A,10090.0,,,,CHEMBL623508,16597,N,BAO_0000218,1,,In vivo,,,50594
6688,1,Mus musculus,Cmax after oral administration at 30 mg/kg in ICR mouse,A,10090.0,,,,CHEMBL623509,5781,N,BAO_0000218,1,,In vivo,,,50594
6689,1,Mus musculus,Cmax after peroral administration in mice at 2.4 uM/kg,A,10090.0,,,,CHEMBL875159,17764,N,BAO_0000218,1,,In vivo,,,50594
6690,1,Mus musculus,Cmax in brain of mice at the oral dose of 50 mg/kg,A,10090.0,Brain,,,CHEMBL623510,17641,N,BAO_0000218,1,955.0,In vivo,,,50594
6691,1,Mus musculus,Cmax in kidney of mice at the oral dose of 50 mg/kg,A,10090.0,Kidney,,,CHEMBL623511,17641,N,BAO_0000218,1,2113.0,In vivo,,,50594
6692,1,Mus musculus,Cmax in liver of mice at the oral dose of 50 mg/kg,A,10090.0,Liver,,,CHEMBL623512,17641,N,BAO_0000218,1,2107.0,In vivo,,,50594
6693,1,Mus musculus,Cmax in lungs of mice at the oral dose of 50 mg/kg,A,10090.0,Lung,,,CHEMBL623513,17641,N,BAO_0000218,1,2048.0,In vivo,,,50594
6694,1,Mus musculus,Cmax in mice at 18 uM/kg i.p. administration,F,10090.0,,,,CHEMBL623514,17764,N,BAO_0000218,1,,In vivo,,,50594
6695,1,Mus musculus,Cmax in mice at 23 uM/kg i.v. administration,F,10090.0,,,,CHEMBL622609,17764,N,BAO_0000218,1,,In vivo,,,50594
6696,1,Mus musculus,Cmax in mice at 24 uM/kg i.p. administration,F,10090.0,,,,CHEMBL622610,17764,N,BAO_0000218,1,,In vivo,,,50594
6697,1,Mus musculus,Cmax in mice at 25 uM/kg i.p. administration,F,10090.0,,,,CHEMBL621823,17764,N,BAO_0000218,1,,In vivo,,,50594
6698,1,Mus musculus,Cmax in mice at 26 uM/kg i.p. administration,F,10090.0,,,,CHEMBL621824,17764,N,BAO_0000218,1,,In vivo,,,50594
6699,1,Mus musculus,Cmax in spleen of mice at the oral dose of 50 mg/kg,A,10090.0,Spleen,,,CHEMBL621825,17641,N,BAO_0000218,1,2106.0,In vivo,,,50594
6700,1,Mus musculus,Cmax value at a dose of 10 mg/kg intravenous administration in mice.,A,10090.0,,,,CHEMBL621826,16597,N,BAO_0000218,1,,In vivo,,,50594
6701,1,Mus musculus,Cmax value at a dose of 10 mg/kg peroral administration in mice.,A,10090.0,,,,CHEMBL621827,16597,N,BAO_0000218,1,,In vivo,,,50594
6702,1,Mus musculus,Cmax value was determined,A,10090.0,,,,CHEMBL621828,5727,N,BAO_0000218,1,,In vivo,,,50594
6703,1,Mus musculus,Cmax value in IRC mice,A,10090.0,,,,CHEMBL621829,5951,N,BAO_0000218,1,,In vivo,,,50594
6704,1,Mus musculus,Cmax value was determined at a dose of 100 mg/kg (i.p.) in Mice,A,10090.0,,,,CHEMBL621830,5506,N,BAO_0000218,1,,In vivo,,,50594
6705,1,Mus musculus,Cmax value was determined at a dose of 200 mg/kg (i.p.) in Mice,A,10090.0,,,,CHEMBL621831,5506,N,BAO_0000218,1,,In vivo,,,50594
6706,1,Mus musculus,Compound was evaluated for maximum plasma concentration by administering orally at 25 mg/kg in mice,A,10090.0,Plasma,,,CHEMBL621832,14239,N,BAO_0000218,1,1969.0,In vivo,,,50594
6707,1,Mus musculus,"Compound was evaluated for the pharmacokinetic parameter, maximum plasma concentration",A,10090.0,Plasma,,,CHEMBL624579,4890,N,BAO_0000218,1,1969.0,In vivo,,,50594
6708,1,Mus musculus,Evaluated for pharmacokinetic parameter Cmax in mouse at the dose 20 mg/kg,A,10090.0,,,,CHEMBL624580,429,N,BAO_0000218,1,,In vivo,,,50594
6709,1,Acanthocheilonema viteae,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 50 mg/kg/day(5 days) dose,F,6277.0,,,,CHEMBL624581,10986,N,BAO_0000218,1,,,,,50535
6710,1,Acanthocheilonema viteae,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 6.25 mg/kg/day(5 days) dose,F,6277.0,,,,CHEMBL624582,10986,N,BAO_0000218,1,,,,,50535
6711,1,Acanthocheilonema viteae,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 75 mg/kg/day(5 days) dose,F,6277.0,,,,CHEMBL624583,10986,N,BAO_0000218,1,,,,,50535
6712,1,Homo sapiens,Inhibitory activity against human tumor cell line A0375 melanoma.,F,9606.0,,,,CHEMBL624584,13227,N,BAO_0000219,1,,,,A-375,80018
6713,9,Rattus norvegicus,Displacement of [3H]N6-PIA binding from A1 receptor in whole rat brain membranes,B,10116.0,,Brain membranes,,CHEMBL624585,4481,D,BAO_0000249,1,,,,,12512
6714,9,Homo sapiens,Forskolin-induced cAMP production at human A1 adenosine receptor,F,9606.0,,,,CHEMBL875165,16931,D,BAO_0000019,1,,,,,114
6715,8,,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 0.1; change of less than 5% of allosteric enhancement.,F,,,,,CHEMBL619490,3850,H,BAO_0000219,1,,,,CHO,114
6716,8,,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 0.1 uM; An increase of cAmp content of cells,F,,,,,CHEMBL619491,3850,H,BAO_0000219,1,,,,CHO,114
6717,8,,Percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 0.1 uM,F,,,,,CHEMBL619492,3850,H,BAO_0000219,1,,,,CHO,114
6718,8,,Percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 0.1 uM concentration,F,,,,,CHEMBL619493,3850,H,BAO_0000219,1,,,,CHO,114
6719,8,,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 0.1 uM concentration; An increase of cAmp content of cells,F,,,,,CHEMBL619494,3850,H,BAO_0000219,1,,,,CHO,114
6720,8,,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 0.1 uM concentration; change of less than 5% of allosteric enhancement,F,,,,,CHEMBL619495,3850,H,BAO_0000219,1,,,,CHO,114
6721,8,,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 0.1 uM concentration; change of less than 5% of allosteric enhancement.,F,,,,,CHEMBL619496,3850,H,BAO_0000219,1,,,,CHO,114
6722,9,Homo sapiens,Percent response to 10 uM PD-81723 on CHO cells expressing human A1-adenosine receptor at 0.1 uM; An increase of cAmp content of cells,F,9606.0,,,,CHEMBL619497,3850,D,BAO_0000219,1,,,,CHO,114
6723,8,,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 1 uM,F,,,,,CHEMBL619498,3850,H,BAO_0000219,1,,,,CHO,114
6724,8,,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 1 uM; change of less than 5% of allosteric enhancement.,F,,,,,CHEMBL619499,3850,H,BAO_0000219,1,,,,CHO,114
6725,8,,Percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 1 uM concentration,F,,,,,CHEMBL619500,3850,H,BAO_0000219,1,,,,CHO,114
6726,8,,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 1 uM concentration; change of less than 5% of allosteric enhancement.,F,,,,,CHEMBL619501,3850,H,BAO_0000219,1,,,,CHO,114
6727,8,,Percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 1 uM; An increase of cAmp content of cells,F,,,,,CHEMBL619502,3850,H,BAO_0000219,1,,,,CHO,114
6728,8,,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 10 uM,F,,,,,CHEMBL619503,3850,H,BAO_0000219,1,,,,CHO,114
6729,8,,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 10 uM; An increase of cAmp content of cells,F,,,,,CHEMBL619504,3850,H,BAO_0000219,1,,,,CHO,114
6730,8,,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 10 uM; change of less than 5% of allosteric enhancement.,F,,,,,CHEMBL621298,3850,H,BAO_0000219,1,,,,CHO,114
6731,8,,Percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 10 uM concentration,F,,,,,CHEMBL621299,3850,H,BAO_0000219,1,,,,CHO,114
6732,8,,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 10 uM concentration; An increase of cAmp content of cells,F,,,,,CHEMBL621300,3850,H,BAO_0000219,1,,,,CHO,114
6733,8,,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 10 uM concentration; change of less than 5% of allosteric enhancement.,F,,,,,CHEMBL621301,3850,H,BAO_0000219,1,,,,CHO,114
6734,8,,Percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 10 uM; An increase of cAmp content of cells,F,,,,,CHEMBL621302,3850,H,BAO_0000219,1,,,,CHO,114
6735,1,Oryctolagus cuniculus,Ability to inhibit [125I]ET1 binding to vascular smooth muscle (vsm)- A10 cells,F,9986.0,,,,CHEMBL621303,12680,N,BAO_0000219,1,,,,A10,80013
6736,0,Rattus norvegicus,In vitro potassium channel opening activity in A10 (smooth muscle) cells,F,10116.0,,,,CHEMBL621304,1313,U,BAO_0000219,1,,,,A10,22226
6737,0,Rattus norvegicus,In vitro potassium channel opening activity in A10 (smooth muscle) cells; Inactive,F,10116.0,,,,CHEMBL621305,1313,U,BAO_0000219,1,,,,A10,22226
6738,1,Rattus norvegicus,Effect on membrane potential of mitochondria in A10 smooth muscle cells from rats,F,10116.0,,,,CHEMBL621306,17567,N,BAO_0000219,1,,,,A10,80013
6739,1,Rattus norvegicus,Effect on membrane potential of mitochondria of A10 smooth muscle cells in rats,F,10116.0,,,,CHEMBL618444,17567,N,BAO_0000219,1,,,,A10,80013
6740,1,Rattus norvegicus,Percent decrease in fluorescence in a membrane potential assay using the A10 cell line derived from embryonic rat aorta at 0.001 uM,F,10116.0,,,,CHEMBL618445,11819,N,BAO_0000219,1,,,,A10,80013
6741,1,Cricetulus griseus,Compound was tested for aerobic growth inhibition against AA8 cells after 4 hr of exposure,F,10029.0,,,,CHEMBL618446,13436,N,BAO_0000219,1,,,,CHO-AA8,80089
6742,1,Cricetulus griseus,Concentration required to reduce AA8 cell numbers to 50% of controls in a growth inhibition microassay,F,10029.0,,,,CHEMBL618447,12687,N,BAO_0000219,1,,,,CHO-AA8,80089
6743,1,Cricetulus griseus,Concentration of the drug to inhibit chinese hamster ovary derived cell (AA8) growth in culture,F,10029.0,,,,CHEMBL618448,12651,N,BAO_0000219,1,,,,CHO-AA8,80089
6744,1,Cricetulus griseus,Cytotoxicity in a growth inhibition assay against aerobic cultures of AA8 cells was determined,F,10029.0,,,,CHEMBL618449,13300,N,BAO_0000219,1,,,,CHO-AA8,80089
6745,1,Cricetulus griseus,Cytotoxicity on AA8 cell growth (reduce cell number by 50%).,F,10029.0,,,,CHEMBL618637,15296,N,BAO_0000219,1,,,,CHO-AA8,80089
6746,1,Cricetulus griseus,"Cytotoxicity in chinese hamster ovary tumor cell line-AA8, by growth inhibition assay.",F,10029.0,,,,CHEMBL618638,15328,N,BAO_0000219,1,,,,CHO-AA8,80089
6747,1,Cricetulus griseus,Growth inhibition activity was measured in repair proficient AA8 cells under aerobic conditions (4 hours drug exposure),F,10029.0,,,,CHEMBL618639,13302,N,BAO_0000219,1,,,,CHO-AA8,80089
6748,1,Cricetulus griseus,"Growth inhibition of aerobic AA8 cells, after 18 hours exposure",F,10029.0,,,,CHEMBL618640,14367,N,BAO_0000219,1,,,,CHO-AA8,80089
6749,1,Cricetulus griseus,In vitro cellular toxicity against chinese hamster AA8 cell line after 4 hr of compound exposure,F,10029.0,,,,CHEMBL618641,17002,N,BAO_0000219,1,,,,CHO-AA8,80089
6750,1,Cricetulus griseus,Inhibitory activity against AA8 cell growth in aerobic condition after 4 hr of exposure,F,10029.0,,,,CHEMBL618642,13436,N,BAO_0000219,1,,,,CHO-AA8,80089
6751,1,Cricetulus griseus,Inhibitory activity against aerobic growth of AA8 cells.,F,10029.0,,,,CHEMBL618643,13435,N,BAO_0000219,1,,,,CHO-AA8,80089
6752,1,Cricetulus griseus,Tested for the in vitro cytotoxicity against transformed chinese hamster fibroblast line AA8,A,10029.0,,,,CHEMBL884013,10503,N,BAO_0000219,1,,,,CHO-AA8,80089
6753,1,Cricetulus griseus,In vitro cytotoxicity against transformed chinese hamster fibroblast line AA8,F,10029.0,,,,CHEMBL622723,10503,N,BAO_0000219,1,,,,CHO-AA8,80089
6754,1,Cricetulus griseus,Tested for the in vitro cytotoxicity against transformed chinese hamster fibroblast line AA8,F,10029.0,,,,CHEMBL622724,10503,N,BAO_0000219,1,,,,CHO-AA8,80089
6755,1,Cricetulus griseus,Tested for growth inhibition against AA8 tumor cell line(chinese hamster ovary).,F,10029.0,,,,CHEMBL622725,15090,N,BAO_0000219,1,,,,CHO-AA8,80089
6756,1,Cricetulus griseus,Cytotoxicity against AA8 cell line,F,10029.0,,,,CHEMBL622726,10368,N,BAO_0000219,1,,,,CHO-AA8,80089
6757,1,Cricetulus griseus,Hypersensitivity factor(HF) was determined as ratio of IC50(AA8) to IC50(UV4),F,10029.0,,,,CHEMBL622727,12651,N,BAO_0000219,1,,,,CHO-AA8,80089
6758,1,Cricetulus griseus,In vitro therapeutic index (aerobic IC50 / hypoxic C1.6),A,10029.0,,,,CHEMBL622728,12687,N,BAO_0000219,1,,,,CHO-AA8,80089
6759,1,Cricetulus griseus,In vitro therapeutic index (aerobic IC50 / hypoxic C1.6),F,10029.0,,,,CHEMBL622729,12687,N,BAO_0000219,1,,,,CHO-AA8,80089
6760,1,Cricetulus griseus,In vitro therapeutic index (aerobic IC50 / hypoxic C1.6),A,10029.0,,,,CHEMBL622730,12687,N,BAO_0000219,1,,,,CHO-AA8,80089
6761,1,Cricetulus griseus,Compound was evaluated for cytotoxicity against CHO AA8 cell lines for 4 hr at pH-7.4,F,10029.0,,,,CHEMBL622731,1890,N,BAO_0000219,1,,,,CHO-AA8,80089
6762,1,Cricetulus griseus,Compound was evaluated for in vitro cytotoxicities against Chinese hamster ovary derived AA8 cell lines.,F,10029.0,,,,CHEMBL622732,10747,N,BAO_0000219,1,,,,CHO-AA8,80089
6763,1,Cricetulus griseus,Compound was evaluated for in vitro cytotoxicities against Chinese hamster ovary derived AA8 cell lines.,F,10029.0,,,,CHEMBL622733,10747,N,BAO_0000219,1,,,,CHO-AA8,80089
6764,0,Cricetulus griseus,Maximum tolerated dose (MTD) in C3H/HeN mice (single ip dose),F,10029.0,,,,CHEMBL622734,11616,U,BAO_0000218,1,,,,,22224
6765,1,Cricetulus griseus,Concentration required to increase radiation sensitivity by 1.3 when AA8 cells are exposed to drug for 30 min before and during irradiation under hypoxic condition.,F,10029.0,,,,CHEMBL622735,11616,N,BAO_0000219,1,,,,CHO-AA8,80089
6766,0,Cricetulus griseus,Oxygen dependence of cytotoxicity was assessed by clonogenic assay using stirred suspension cultures of AA8 cells after 1 hr under anoxic conditions,F,10029.0,,,,CHEMBL618746,3471,U,BAO_0000219,1,,,,CHO-AA8,22224
6767,0,Cricetulus griseus,Oxygen dependence of cytotoxicity was assessed by clonogenic assay using stirred suspension cultures of AA8 cells after 3h under anoxic conditions,F,10029.0,,,,CHEMBL618747,3471,U,BAO_0000219,1,,,,CHO-AA8,22224
6768,0,Cricetulus griseus,Oxygen dependence of cytotoxicity was assessed by clonogenic assay using stirred suspension cultures of AA8 cells after 4 hr under anoxic conditions,F,10029.0,,,,CHEMBL620540,3471,U,BAO_0000219,1,,,,CHO-AA8,22224
6769,0,Cricetulus griseus,Oxygen dependence of cytotoxicity was assessed by clonogenic assay using stirred suspension cultures of AA8 cells after 1 hr under aerobic conditions,F,10029.0,,,,CHEMBL620541,3471,U,BAO_0000219,1,,,,CHO-AA8,22224
6770,0,Cricetulus griseus,Oxygen dependence of cytotoxicity was assessed by clonogenic assay using stirred suspension cultures of AA8 cells after 3h under aerobic conditions,F,10029.0,,,,CHEMBL620542,3471,U,BAO_0000219,1,,,,CHO-AA8,22224
6771,0,Cricetulus griseus,Oxygen dependence of cytotoxicity was assessed by clonogenic assay using stirred suspension cultures of AA8 cells after 4 hr under aerobic conditions,F,10029.0,,,,CHEMBL620543,3471,U,BAO_0000219,1,,,,CHO-AA8,22224
6772,0,Cricetulus griseus,Ratio of oxygen dependence of cytotoxicities of AA8 cells in aerobic condition to anoxic condition,F,10029.0,,,,CHEMBL618832,3471,U,BAO_0000219,1,,,,CHO-AA8,22224
6773,1,Cricetulus griseus,Concentration required to reduce AA8 cell survival by 10%,F,10029.0,,,,CHEMBL618833,11616,N,BAO_0000219,1,,,,CHO-AA8,80089
6774,0,Cricetulus griseus,"Concentration required to reduce cell survival to 10% of controls under hypoxic conditions, using the AA8 (chinese hamster) aerobic cells",F,10029.0,,,,CHEMBL618834,2656,U,BAO_0000219,1,,,,CHO-AA8,22224
6775,0,Cricetulus griseus,Tested for the product of the drug concentration to the exposure time needed to reduce cell survival to 10% of controls using AA8 cells at 10 E 6 /mL in the clonogenic assay,F,10029.0,,,,CHEMBL618835,10518,U,BAO_0000219,1,,,,CHO-AA8,22224
6776,0,Cricetulus griseus,CT10 (air/N2) ratio of the product of the drug concentration to the exposure time needed to reduce cell survival to 10% of controls using AA8 cells at 10 E 6 /mL in the clonogenic assay,F,10029.0,,,,CHEMBL618836,10518,U,BAO_0000219,1,,,,CHO-AA8,22224
6777,0,Cricetulus griseus,CT10 (air/N2) ratio of the product of the drug concentration to the exposure time needed to reduce cell survival to 10% of controls using AA8 cells at 10 E 6 /mL in the clonogenic assay; range is 0.8-1.5,F,10029.0,,,,CHEMBL618837,10518,U,BAO_0000219,1,,,,CHO-AA8,22224
6778,0,Cricetulus griseus,CT10 (air/N2) ratio of the product of the drug concentration to the exposure time needed to reduce cell survival to 10% of controls using AA8 cells at 10 E 6 /mL in the clonogenic assay; range is 1-2,F,10029.0,,,,CHEMBL618838,10518,U,BAO_0000219,1,,,,CHO-AA8,22224
6779,0,Cricetulus griseus,Ability to reduce cell density of AA8 cells to 50% after 4 hr of exposure to air,F,10029.0,,,,CHEMBL618839,16156,U,BAO_0000219,1,,,,CHO-AA8,22224
6780,0,Cricetulus griseus,Aerobic cytotoxic activity was evaluated by the growth inhibition of AA8 (chinese hamster) aerobic cells,F,10029.0,,,,CHEMBL618840,2656,U,BAO_0000219,1,,,,CHO-AA8,22224
6781,0,Cricetulus griseus,"Compound was evaluated for the inhibition of cell growth in culture against Chinese hamster ovary derived cell line, AA8",F,10029.0,,,,CHEMBL618841,11005,U,BAO_0000019,1,,,,,22224
6782,0,Cricetulus griseus,Concentration for 50% inhibition of AA8 cells growth under aerobic conditions after 18 hours exposure,F,10029.0,,,,CHEMBL618842,11942,U,BAO_0000219,1,,,,CHO-AA8,22224
6783,0,Cricetulus griseus,Concentration required for 50% inhibition of growth of AA8 cells following 4 hr drug exposure,F,10029.0,,,,CHEMBL618843,2128,U,BAO_0000219,1,,,,CHO-AA8,22224
6784,1,Canis lupus familiaris,Half life period after 15 mg/kg iv dose in Dogs,A,9615.0,,,,CHEMBL618844,16907,N,BAO_0000218,1,,In vivo,,,50588
6785,1,Canis lupus familiaris,Half life period after 30 mg/kg po dose in Dogs,A,9615.0,,,,CHEMBL618845,16907,N,BAO_0000218,1,,In vivo,,,50588
6786,1,Canis lupus familiaris,Half life was measured after oral 2b administration (tested in 6 dogs),A,9615.0,,,,CHEMBL618846,9579,N,BAO_0000218,1,,In vivo,,,50588
6787,1,Canis lupus familiaris,Half life was measured in dog after oral 17b administration,A,9615.0,,,,CHEMBL618847,9579,N,BAO_0000218,1,,In vivo,,,50588
6788,1,Canis lupus familiaris,Pharmacokinetic parameter T max determined in dog after oral administration of 17b,A,9615.0,,,,CHEMBL618848,9579,N,BAO_0000218,1,,In vivo,,,50588
6789,1,Canis lupus familiaris,Pharmacokinetic parameter T max determined in dog after oral administration of 2b,A,9615.0,,,,CHEMBL618849,9579,N,BAO_0000218,1,,In vivo,,,50588
6790,1,Canis lupus familiaris,Tmax value after 15 mg/kg iv dose in Dogs,A,9615.0,,,,CHEMBL618850,16907,N,BAO_0000218,1,,In vivo,,,50588
6791,1,Canis lupus familiaris,Tmax value after 30 mg/kg po dose in Dogs,A,9615.0,,,,CHEMBL618851,16907,N,BAO_0000218,1,,In vivo,,,50588
6792,1,Canis lupus familiaris,Compound was evaluated for its half life when administered intravenously in dog,A,9615.0,,,,CHEMBL873815,3184,N,BAO_0000218,1,,In vivo,,,50588
6793,1,Canis lupus familiaris,Compound was tested for plasma half life when administered in dog perorally (1 mg/kg) and intravenously (0.2 mg/kg),A,9615.0,Plasma,,,CHEMBL618852,5017,N,BAO_0000218,1,1969.0,In vivo,,,50588
6794,1,Canis lupus familiaris,Elimination Half-life of compound was determined in dog,A,9615.0,,,,CHEMBL618853,6821,N,BAO_0000218,1,,,,,50588
6795,1,Canis lupus familiaris,Half life of compound in dog following oral administration,A,9615.0,,,,CHEMBL618854,17839,N,BAO_0000218,1,,In vivo,,,50588
6796,1,Canis lupus familiaris,Half life of compound was determined in dog,A,9615.0,,,,CHEMBL618855,17267,N,BAO_0000218,1,,,,,50588
6797,1,Canis lupus familiaris,Half life of compound was determined in dog blood,A,9615.0,Blood,,,CHEMBL618856,4727,N,BAO_0000218,1,178.0,,,,50588
6798,1,Canis lupus familiaris,Half life after oral and iv dosing in dogs,A,9615.0,,,,CHEMBL875827,5238,N,BAO_0000218,1,,In vivo,,,50588
6799,1,Canis lupus familiaris,Half life in dogs in hours,A,9615.0,,,,CHEMBL618857,4942,N,BAO_0000218,1,,,,,50588
6800,1,Canis lupus familiaris,Half life on i.v. administration of 2 mg/kg was measured in dog,A,9615.0,,,,CHEMBL618858,6505,N,BAO_0000218,1,,In vivo,,,50588
6801,1,Canis lupus familiaris,t1/2 in dog after oral dose (1 mg/kg),A,9615.0,,,,CHEMBL618859,5130,N,BAO_0000218,1,,In vivo,,,50588
6802,1,Canis lupus familiaris,Half life was evaluated in dog,A,9615.0,,,,CHEMBL618860,1475,N,BAO_0000218,1,,,,,50588
6803,1,Canis lupus familiaris,Half life period of compound was determined after intravenous administration at 2 mg/kg,A,9615.0,,,,CHEMBL618861,17804,N,BAO_0000218,1,,In vivo,,,50588
6804,1,Canis lupus familiaris,Half life period of compound was determined after peroral administration at 2 mg/kg,A,9615.0,,,,CHEMBL622539,17804,N,BAO_0000218,1,,In vivo,,,50588
6805,1,Canis lupus familiaris,Half life period (10 mg/kg) was determined in dog,A,9615.0,,,,CHEMBL622540,6084,N,BAO_0000218,1,,In vivo,,,50588
6806,1,Canis lupus familiaris,Half life period (10 mg/kg) was determined in dog,A,9615.0,,,,CHEMBL873803,6084,N,BAO_0000218,1,,In vivo,,,50588
6807,1,Canis lupus familiaris,Half life period by iv administration in dog at a dose of 0.3 mg/kg,A,9615.0,,,,CHEMBL873804,5542,N,BAO_0000218,1,,In vivo,,,50588
6808,1,Canis lupus familiaris,Half life period by po administration in dog at a dose of 0.3 mg/kg,A,9615.0,,,,CHEMBL624311,5542,N,BAO_0000218,1,,In vivo,,,50588
6809,1,Canis lupus familiaris,Half life period in dog,A,9615.0,,,,CHEMBL624312,6084,N,BAO_0000218,1,,,,,50588
6810,1,Canis lupus familiaris,Half life period in dogs after oral administration at 1 mg/kg,A,9615.0,,,,CHEMBL624313,6241,N,BAO_0000218,1,,In vivo,,,50588
6811,1,Canis lupus familiaris,Half life period was evaluated against Beagle dog at a dose of 15 mg/kg after po administration,A,9615.0,,,,CHEMBL624314,1916,N,BAO_0000218,1,,In vivo,,,50588
6812,1,Canis lupus familiaris,Half-life of compound was determined in dogs,A,9615.0,,,,CHEMBL624315,6621,N,BAO_0000218,1,,,,,50588
6813,1,Canis lupus familiaris,Half-life in dog plasma,A,9615.0,Plasma,,,CHEMBL624316,1696,N,BAO_0000218,1,1969.0,,,,50588
6814,1,Canis lupus familiaris,Half-life in mongrel dogs was determined,A,9615.0,,,,CHEMBL624317,17800,N,BAO_0000218,1,,,,,50588
6815,1,Canis lupus familiaris,Half-life in dog upon oral administration,A,9615.0,,,,CHEMBL624318,17657,N,BAO_0000218,1,,In vivo,,,50588
6816,1,Canis lupus familiaris,Half-life in dog upon oral administration; Unable to calculate,A,9615.0,,,,CHEMBL624319,17657,N,BAO_0000218,1,,In vivo,,,50588
6817,1,Canis lupus familiaris,Half-life was measured in dog,A,9615.0,,,,CHEMBL624496,4239,N,BAO_0000218,1,,,,,50588
6818,1,Canis lupus familiaris,Half-life was measured in dog,A,9615.0,,,,CHEMBL624497,5985,N,BAO_0000218,1,,,,,50588
6819,1,Canis lupus familiaris,Half-recovery time (T1/2) of the vascular resistance decrease at ED30 in anesthetized dogs,A,9615.0,,,,CHEMBL624498,9932,N,BAO_0000218,1,,,,,50588
6820,1,Canis lupus familiaris,Oral half life was determined,A,9615.0,,,,CHEMBL624499,5199,N,BAO_0000218,1,,In vivo,,,50588
6821,1,Canis lupus familiaris,Plasma elimination half-life (08 h) was determined in canine following intravenous (iv) administration (1 mg/kg).,A,9615.0,Plasma,,,CHEMBL624500,5199,N,BAO_0000218,1,1969.0,In vivo,,,50588
6822,1,Canis lupus familiaris,Plasma half life was evaluated,A,9615.0,Plasma,,,CHEMBL624501,1475,N,BAO_0000218,1,1969.0,,,,50588
6823,1,Canis lupus familiaris,Plasma half life was evaluated in Dog,A,9615.0,Plasma,,,CHEMBL623666,1475,N,BAO_0000218,1,1969.0,,,,50588
6824,1,Canis lupus familiaris,Plasma half life was evaluated in dog,A,9615.0,Plasma,,,CHEMBL623667,1475,N,BAO_0000218,1,1969.0,,,,50588
6825,1,Canis lupus familiaris,T1/2 (Half-life) was after oral administration at 5 mg/kg,A,9615.0,,,,CHEMBL623668,6316,N,BAO_0000218,1,,In vivo,,,50588
6826,1,Canis lupus familiaris,Tested for the half life value in dog,A,9615.0,,,,CHEMBL623669,4883,N,BAO_0000218,1,,,,,50588
6827,1,Canis lupus familiaris,Maximum time at the dose of 2 mg/kg in dog,A,9615.0,,,,CHEMBL623670,4727,N,BAO_0000218,1,,In vivo,,,50588
6828,1,Canis lupus familiaris,Maximum time was evaluated against Beagle dog at a dose of 15 mg/kg after po administration,A,9615.0,,,,CHEMBL623671,1916,N,BAO_0000218,1,,In vivo,,,50588
6829,1,Canis lupus familiaris,Maximum time taken to reach maximum blood concentration was determined in dogs after oral administration (10 mg/kg) as a 0.05 M citric acid solution.,A,9615.0,Blood,,,CHEMBL875945,1337,N,BAO_0000218,1,178.0,In vivo,,,50588
6830,1,Canis lupus familiaris,Maximum time taken to reach maximum blood concentration was determined in dogs after oral administration (8 mg/kg) as a 0.05 M citric acid solution.,A,9615.0,Blood,,,CHEMBL623672,1337,N,BAO_0000218,1,178.0,In vivo,,,50588
6831,1,Canis lupus familiaris,Pharmacokinetic (PK) property (Tmax) was determined in dog at the single dose of 1 mg/kg,A,9615.0,,,,CHEMBL623673,6265,N,BAO_0000218,1,,In vivo,,,50588
6832,1,Canis lupus familiaris,Pharmacokinetic parameter Tmax was determined in Beagle dogs after (iv) administration of a dose of 28 (uM/kg),A,9615.0,,,,CHEMBL623674,4809,N,BAO_0000218,1,,In vivo,,,50588
6833,1,Canis lupus familiaris,Pharmacokinetic property (Tmax) was measured in dog at the dose of 0.032 mg/kg p.o.,A,9615.0,,,,CHEMBL623675,5983,N,BAO_0000218,1,,In vivo,,,50588
6834,1,Canis lupus familiaris,"Tested for the pharmacokinetic data, time required to reach Cmax (Tmax) in dog",A,9615.0,,,,CHEMBL872526,5313,N,BAO_0000218,1,,,,,50588
6835,1,Canis lupus familiaris,"Tested for the pharmacokinetic data, time required to reach Cmax (Tmax) in dog at dosage of 10 mpk",A,9615.0,,,,CHEMBL623676,5313,N,BAO_0000218,1,,In vivo,,,50588
6836,1,Canis lupus familiaris,Time for maximum plasma concentration was measured in dogs after an oral dose of 10 uM/kg,A,9615.0,Plasma,,,CHEMBL623677,17650,N,BAO_0000218,1,1969.0,In vivo,,,50588
6837,1,Canis lupus familiaris,Time taken by the compound to achieve maximum plasma concentration at a 1 mg/kg oral dose in male and female Beagle dogs.,A,9615.0,Plasma,,,CHEMBL623678,5199,N,BAO_0000218,1,1969.0,In vivo,,,50588
6838,1,Canis lupus familiaris,Time taken for maximum plasma concentration in dog,A,9615.0,Plasma,,,CHEMBL623679,933,N,BAO_0000218,1,1969.0,,,,50588
6839,1,Canis lupus familiaris,Time to reach Cmax after oral administration to dogs,A,9615.0,,,,CHEMBL623680,16367,N,BAO_0000218,1,,In vivo,,,50588
6840,1,Canis lupus familiaris,Time to reach maximum plasma concentration was determined in dog after 1 mg/kg (i.v.) and 5 mg/kg (p.o.) administration,A,9615.0,Plasma,,,CHEMBL623681,6348,N,BAO_0000218,1,1969.0,In vivo,,,50588
6841,1,Canis lupus familiaris,Tmax (time to reach maximum concentration) was after oral administration at 5 mg/kg,A,9615.0,,,,CHEMBL623682,6316,N,BAO_0000218,1,,In vivo,,,50588
6842,1,Canis lupus familiaris,Tmax after peroral administration (1 mg/kg) was determined in dog,A,9615.0,,,,CHEMBL623683,6215,N,BAO_0000218,1,,In vivo,,,50588
6843,1,Canis lupus familiaris,Tmax of compound determined in dog after iv administration at a dose of 10 mg/kg,A,9615.0,,,,CHEMBL623684,3598,N,BAO_0000218,1,,In vivo,,,50588
6844,1,Canis lupus familiaris,Tmax by oral administration at a dose of 10 uM/kg in dog was determined,A,9615.0,,,,CHEMBL622745,4527,N,BAO_0000218,1,,In vivo,,,50588
6845,1,Canis lupus familiaris,Tmax after peroral administration in dogs at 2.4 uM/kg,A,9615.0,,,,CHEMBL622746,17764,N,BAO_0000218,1,,In vivo,,,50588
6846,1,Mus musculus,In vivo Cmax in mice at dose of 100 mg/kg,A,10090.0,,,,CHEMBL622747,5969,N,BAO_0000218,1,,In vivo,,,50594
6847,1,Mus musculus,In vivo Cmax in mice at dose of 50 mg/kg,A,10090.0,,,,CHEMBL622748,5969,N,BAO_0000218,1,,In vivo,,,50594
6848,1,Mus musculus,Maximal concentration determined at a dose 10 mg/kg administered intraperitoneally to mice,A,10090.0,,,,CHEMBL622749,4573,N,BAO_0000218,1,,In vivo,,,50594
6849,1,Mus musculus,Maximum plasma concentration was determined in mice at a single subcutaneous administration of 40 mg/kg (n=4),A,10090.0,Plasma,,,CHEMBL622750,3277,N,BAO_0000218,1,1969.0,In vivo,,,50594
6850,1,Mus musculus,Maximum concentration in plasma was determined after intraperitoneal administration of 100 mg/kg in mice,A,10090.0,Plasma,,,CHEMBL623411,17734,N,BAO_0000218,1,1969.0,In vivo,,,50594
6851,1,Mus musculus,Maximum concentration obtained in mouse plasma was determined,A,10090.0,Plasma,,,CHEMBL875946,3132,N,BAO_0000218,1,1969.0,In vivo,,,50594
6852,1,Mus musculus,Maximum concentration obtained in mouse plasma was determined at dose 25 mg/kg,A,10090.0,Plasma,,,CHEMBL623412,3132,N,BAO_0000218,1,1969.0,In vivo,,,50594
6853,1,Mus musculus,Maximum plasma concentration of compound was determined in mouse after 5 mg/kg (i.v.) and 6 mg/kg (p.o.) administration,A,10090.0,Plasma,,,CHEMBL623413,6348,N,BAO_0000218,1,1969.0,In vivo,,,50594
6854,1,Mus musculus,Maximum plasma concentration when injected i.p. in mice at a dose of 50 mg/kg,A,10090.0,Plasma,,,CHEMBL623414,17729,N,BAO_0000218,1,1969.0,In vivo,,,50594
6855,1,Mus musculus,Maximum plasma concentration when injected intravenously in mice at a dose of 20 mg/kg,A,10090.0,Plasma,,,CHEMBL623415,17729,N,BAO_0000218,1,1969.0,In vivo,,,50594
6856,1,Mus musculus,Maximum plasma concentration when injected perorally in mice at a dose of 50 mg/kg,A,10090.0,Plasma,,,CHEMBL623416,17729,N,BAO_0000218,1,1969.0,In vivo,,,50594
6857,1,Mus musculus,Maximal plasma concentration in BALB/C mice after 20 mg/kg intraperitoneal dose,A,10090.0,Plasma,,,CHEMBL623417,17728,N,BAO_0000218,1,1969.0,In vivo,,,50594
6858,1,Mus musculus,Maximal plasma concentration in BALB/C mice after 20 mg/kg intravenous dose,A,10090.0,Plasma,,,CHEMBL623418,17728,N,BAO_0000218,1,1969.0,In vivo,,,50594
6859,1,Mus musculus,Maximal plasma concentration in BALB/C mice after 50 mg/kg oral dose,A,10090.0,Plasma,,,CHEMBL623419,17728,N,BAO_0000218,1,1969.0,In vivo,,,50594
6860,1,Mus musculus,Peak concentration at a single subcutaneous administration of 40 mg/kg in mice,A,10090.0,,,,CHEMBL622816,4066,N,BAO_0000218,1,,In vivo,,,50594
6861,1,Mus musculus,Pharmacokinetic property (C(max)) was determined after ip administration of 32 mg/kg in mice,A,10090.0,,,,CHEMBL623313,6178,N,BAO_0000218,1,,In vivo,,,50594
6862,1,Mus musculus,Pharmacokinetic property (C(max)) was determined after po administration of 32 mg/kg in mice,A,10090.0,,,,CHEMBL623314,6178,N,BAO_0000218,1,,In vivo,,,50594
6863,1,Mus musculus,Pharmacokinetic studies were carried out in vivo after administration of compound at 5 mg/kg intravenously in mice,A,10090.0,,,,CHEMBL876788,3760,N,BAO_0000218,1,,In vivo,,,50594
6864,1,Mus musculus,Pharmacokinetic studies were carried out in vivo after administration of compound at 5 mg/kg perorally in mice,A,10090.0,,,,CHEMBL623315,3760,N,BAO_0000218,1,,In vivo,,,50594
6865,1,Mus musculus,Pharmacokinetic studies were carried out in vivo after administration of compound at 50 mg/kg intravenously in mice,A,10090.0,,,,CHEMBL623316,3760,N,BAO_0000218,1,,In vivo,,,50594
6866,1,Mus musculus,Pharmacokinetic studies were carried out in vivo after administration of compound at 50 mg/kg perorally in mice,A,10090.0,,,,CHEMBL623317,3760,N,BAO_0000218,1,,In vivo,,,50594
6868,1,Mus musculus,Cmax in male mice after 2 mg/kg oral dose,A,10090.0,,,,CHEMBL623319,5961,N,BAO_0000218,1,,In vivo,,,50594
6869,1,Mus musculus,Plasma concentration of 5-FU in HT-3 (human cervical cancer) xenograft mice at 1.38 mg/kg oral dose co-administered with 135 mg/kg Capecitabine,A,10090.0,,,,CHEMBL623320,6137,N,BAO_0000218,1,,In vivo,,,50594
6870,1,Mus musculus,Tested for Cmax value at the dose of 10 mg/kg when administered perorally in mouse,A,10090.0,,,,CHEMBL623321,3802,N,BAO_0000218,1,,In vivo,,,50594
6871,1,Mus musculus,Concentration in plasma (systemic) following oral dose in mouse at 0.25 hr,A,10090.0,,,,CHEMBL623322,3535,N,BAO_0000218,1,,,,,50594
6872,1,Mus musculus,Concentration in plasma (systemic) following oral dose in mouse at 1 hr,A,10090.0,,,,CHEMBL623323,3535,N,BAO_0000218,1,,,,,50594
6873,1,Mus musculus,Concentration in plasma (systemic) following oral dose in mouse at 24 hr,A,10090.0,,,,CHEMBL623324,3535,N,BAO_0000218,1,,,,,50594
6874,1,Mus musculus,Concentration in plasma (systemic) following oral dose in mouse at 2 hr,A,10090.0,,,,CHEMBL623325,3535,N,BAO_0000218,1,,,,,50594
6875,1,Mus musculus,Concentration in plasma (systemic) following oral dose in mouse at 4 hr,A,10090.0,,,,CHEMBL623326,3535,N,BAO_0000218,1,,,,,50594
6876,1,Mus musculus,Concentration in plasma (systemic) following oral dose in mouse at 6 hr,A,10090.0,,,,CHEMBL623327,3535,N,BAO_0000218,1,,,,,50594
6877,1,Mus musculus,Maximum concentration in plasma upon oral administration in mouse,A,10090.0,Plasma,,,CHEMBL623328,2862,N,BAO_0000218,1,1969.0,,,,50594
6878,1,Mus musculus,Maximum plasma concentration was evaluated in mice after oral administration,A,10090.0,Plasma,,,CHEMBL623329,2675,N,BAO_0000218,1,1969.0,,,,50594
6879,1,Mus musculus,Maximum plasma concentration was evaluated in mice after intravenous administration; Cp max Not determined,A,10090.0,Plasma,,,CHEMBL623330,2675,N,BAO_0000218,1,1969.0,In vivo,,,50594
6880,1,Mus musculus,Dose at which the compound induced fecal excretion in mice,A,10090.0,,,,CHEMBL876789,5399,N,BAO_0000218,1,,,,,50594
6893,1,Rattus norvegicus,Percent decrease in fluorescence in a membrane potential assay using the A10 cell line derived from embryonic rat aorta at 0.01 uM,F,10116.0,,,,CHEMBL623333,11819,N,BAO_0000219,1,,,,A10,80013
6894,1,Rattus norvegicus,Percent decrease in fluorescence in a membrane potential assay using the A10 cell line derived from embryonic rat aorta at 0.1 uM,F,10116.0,,,,CHEMBL623334,11819,N,BAO_0000219,1,,,,A10,80013
6895,1,Rattus norvegicus,Percent decrease in fluorescence in a membrane potential assay using the A10 cell line derived from embryonic rat aorta at 1.0 uM,F,10116.0,,,,CHEMBL627536,11819,N,BAO_0000219,1,,,,A10,80013
6896,1,Rattus norvegicus,Percent decrease in fluorescence in a membrane potential assay using the A10 cell line derived from embryonic rat aorta at 10.0 uM,F,10116.0,,,,CHEMBL627537,11819,N,BAO_0000219,1,,,,A10,80013
6897,1,Rattus norvegicus,In vitro [14C]- creatine uptake (1 mM) was determined in rat A10 smooth muscle cells at a concentration of (1 mM),F,10116.0,,,,CHEMBL627538,16361,N,BAO_0000219,1,,,,A10,80013
6898,1,Homo sapiens,Cytotoxicity was evaluated against A121 ovarian carcinoma human cancer cell line,F,9606.0,,,,CHEMBL884106,2288,N,BAO_0000219,1,,,,A121,80655
6899,1,Homo sapiens,Anticancer activity against human ovarian carcinoma A121 cells,F,9606.0,,,,CHEMBL625294,10404,N,BAO_0000219,1,,,,A121,80655
6900,1,Homo sapiens,Cytotoxic effect (tumor cell growth inhibition) on the human cell line A121 ovarian carcinoma at the dose of of 16.6 mM,F,9606.0,,,,CHEMBL625295,14790,N,BAO_0000219,1,,,,A121,80655
6901,1,Homo sapiens,Cytotoxic effect (tumor cell growth inhibition) on the human cell line A121 ovarian carcinoma at the dose of of 83 mM,F,9606.0,,,,CHEMBL625296,14790,N,BAO_0000219,1,,,,A121,80655
6902,1,Homo sapiens,Growth inhibition of human ovarian carcinoma (A121) cell line,F,9606.0,,,,CHEMBL625297,14253,N,BAO_0000219,1,,,,A121,80655
6903,1,Homo sapiens,Concentration required to inhibit growth of human tumor A121 (ovarian) cell line.,F,9606.0,,,,CHEMBL625298,13617,N,BAO_0000219,1,,,,A121,80655
6904,1,Homo sapiens,Cytotoxicity against human A121 ovarian cells,F,9606.0,,,,CHEMBL625960,1003,N,BAO_0000219,1,,,,A121,80655
6905,1,Homo sapiens,Cytotoxicity was evaluated in vitro against A121 (ovarian carcinoma) human tumor cell lines,F,9606.0,,,,CHEMBL625961,830,N,BAO_0000219,1,,,,A121,80655
6906,1,Homo sapiens,In vitro cytotoxicity against human ovarian carcinoma A21,F,9606.0,,,,CHEMBL625962,12307,N,BAO_0000219,1,,,,A121,80655
6907,1,Homo sapiens,Inhibition of the growth against human Ovarian Carcinoma (A121) cell line after 72 hr exposure,F,9606.0,,,,CHEMBL624717,14254,N,BAO_0000219,1,,,,A121,80655
6908,1,Homo sapiens,Inhibitory activity of compound against human A121 ovarian cell line.,F,9606.0,,,,CHEMBL624718,13370,N,BAO_0000219,1,,,,A121,80655
6909,1,Homo sapiens,Dose at which compound exhibits cytotoxicity in the A121 ovarian carcinoma cell line.,F,9606.0,,,,CHEMBL624719,14790,N,BAO_0000219,1,,,,A121,80655
6910,1,Homo sapiens,Inhibition of growth of human ovarian tumor cell line (A121) after 72 hr of drug exposure,F,9606.0,,,,CHEMBL624720,3614,N,BAO_0000219,1,,,,A121,80655
6911,1,Homo sapiens,Compound was evaluated for in vitro antiproliferative activity against A172 human CNS cancer cell line,F,9606.0,,,,CHEMBL624721,2664,N,BAO_0000219,1,,,,A 172,80012
6912,1,Homo sapiens,In vitro cytotoxicity against A172 human tumor cell lines.,F,9606.0,,,,CHEMBL624722,2037,N,BAO_0000219,1,,,,A 172,80012
6913,1,Homo sapiens,Growth inhibition time for A172 Human Glioma cell growth at concentration 5 uM,F,9606.0,,,,CHEMBL877597,14539,N,BAO_0000219,1,,,,A 172,80012
6914,1,Homo sapiens,Compound was evaluated for cytotoxicity against human glioblastoma (A172) cell line,F,9606.0,,,,CHEMBL624723,2836,N,BAO_0000219,1,,,,A 172,80012
6915,1,Homo sapiens,Evaluated for the inhibitory concentration required to cause growth inhibition of A172Mer- cell line of central nervous system (CNS) using the MTT Cytotoxicity Assay,F,9606.0,,,,CHEMBL624724,10708,N,BAO_0000219,1,,,,A 172,80012
6916,4,Canis lupus familiaris,Association constant against A2 adenosine receptor,B,9615.0,,,,CHEMBL624725,8975,H,BAO_0000224,1,,,,,104729
6917,1,fish,In vitro effective dose that causes 50% inhibition of growth of A2 cell line - amelanotic melanoma,F,,,,,CHEMBL624726,7645,N,BAO_0000219,1,,,,A2,80656
6918,5,Rattus norvegicus,Ratio of Ki for adenosine A2 and A1 receptor binding,B,10116.0,,,,CHEMBL857535,11377,D,BAO_0000224,1,,,,,104713
6919,1,Homo sapiens,In vitro cytotoxicity against A204 human rhabdomyosarcoma cancer cell line,F,9606.0,,,,CHEMBL624727,13528,N,BAO_0000219,1,,,,A204,80014
6920,1,Homo sapiens,In vitro antitumor activity against A204 rhabdomyosarcoma tumor cell line was determined,F,9606.0,,,,CHEMBL624728,10160,N,BAO_0000219,1,,,,A204,80014
6921,1,Homo sapiens,The compound was tested in vitro for antiproliferative activity against A2058 tumor cell lines,F,9606.0,,,,CHEMBL624729,15144,N,BAO_0000219,1,,,,A2058,80015
6922,1,Homo sapiens,Growth inhibition against Human squamous cell line(A 253),F,9606.0,,,,CHEMBL624730,13160,N,BAO_0000219,1,,,,A253 cell line,80657
6923,1,Homo sapiens,Growth inhibition of human squamous carcinoma cell lines following continuous (120 hours) exposure to MTX and compound A253 cell line,F,9606.0,,,,CHEMBL624731,12898,N,BAO_0000219,1,,,,A253 cell line,80657
6924,1,Homo sapiens,The compound was tested for Growth inhibition of the human squamous cell carcinoma A253 cells,F,9606.0,,,,CHEMBL624732,13069,N,BAO_0000219,1,,,,A253 cell line,80657
6925,1,Homo sapiens,Growth inhibition of A253 cell lines.,F,9606.0,,,,CHEMBL883245,15984,N,BAO_0000219,1,,,,A253 cell line,80657
6926,1,Homo sapiens,Growth inhibition of human squamous cell carcinoma A253 cells during continuous Exposure (0-12 h),F,9606.0,,,,CHEMBL624733,15564,N,BAO_0000219,1,,,,A253 cell line,80657
6927,1,Homo sapiens,Growth inhibition of human squamous cell carcinoma A253 cells during continuous Exposure (0-12 h); ND means not determined,F,9606.0,,,,CHEMBL624734,15564,N,BAO_0000219,1,,,,A253 cell line,80657
6928,1,Homo sapiens,Growth inhibition of human squamous cell carcinoma A253 cells during continuous Exposure (0-12 h); ND means not determined,F,9606.0,,,,CHEMBL624735,15564,N,BAO_0000219,1,,,,A253 cell line,80657
6929,1,Homo sapiens,In vitro cytotoxicity causing 50% growth inhibition was determined against A270 (human ovarian cancer)cell line,F,9606.0,,,,CHEMBL621780,4720,N,BAO_0000219,1,,,,A2780,81034
6930,1,Homo sapiens,Antitumor activity of compound for 96-h exposure in A2780 human ovarian cell line,F,9606.0,,,,CHEMBL877598,16112,N,BAO_0000219,1,,,,A2780,81034
6931,1,Homo sapiens,Cytotoxic activity against A2780 human ovarian carcinoma cell line,F,9606.0,,,,CHEMBL621781,16597,N,BAO_0000219,1,,,,A2780,81034
6932,1,Homo sapiens,Cytotoxicity against human cancer cell lines A2780 (ovarian),F,9606.0,,,,CHEMBL621782,16378,N,BAO_0000219,1,,,,A2780,81034
6933,1,Homo sapiens,Growth and colony formation inhibition of A2780 ovarian cancer cell lines,F,9606.0,,,,CHEMBL621783,16085,N,BAO_0000219,1,,,,A2780,81034
6934,1,Homo sapiens,Inhibition of cell growth in human ovarian carcinoma cell line (A2780) using the 96 hour continuous exposure sulforhodamine B (SRB) growth delay assay,F,9606.0,,,,CHEMBL621784,16317,N,BAO_0000219,1,,,,A2780,81034
6935,1,Homo sapiens,The compound was tested for cytotoxic activity against A2780 cell line(human ovarian carcinoma ),F,9606.0,,,,CHEMBL621785,15748,N,BAO_0000219,1,,,,A2780,81034
6936,1,Homo sapiens,Inhibition of A2780 / DDP-R human ovarian carcinoma cell proliferation,F,9606.0,,,,CHEMBL621968,16597,N,BAO_0000219,1,,,,A2780,81034
6937,1,Homo sapiens,Inhibition of A2780 / TAX-R human ovarian carcinoma cell proliferation,F,9606.0,,,,CHEMBL621969,16597,N,BAO_0000219,1,,,,A2780,81034
6938,1,Homo sapiens,Inhibition of A2780 / TAX-S human ovarian carcinoma cell proliferation,F,9606.0,,,,CHEMBL621970,16597,N,BAO_0000219,1,,,,A2780,81034
6939,1,Homo sapiens,cytotoxic activity toward A2780 ovarian human cell line resistant (R) to cisplatin in experiment 2,F,9606.0,,,,CHEMBL621971,15608,N,BAO_0000219,1,,,,A2780,81034
6940,1,Homo sapiens,cytotoxic activity toward A2780 ovarian human cell line resistant (R) to cisplatin in experiment 3,F,9606.0,,,,CHEMBL621972,15608,N,BAO_0000219,1,,,,A2780,81034
6941,1,Homo sapiens,cytotoxic activity toward A2780 ovarian human cell line resistant (R) to cisplatin in experiment 5,F,9606.0,,,,CHEMBL884108,15608,N,BAO_0000219,1,,,,A2780,81034
6942,0,Cricetulus griseus,Cytotoxicity on AA8 cell growth (reduce cell number by 50%).,F,10029.0,,,,CHEMBL623826,15296,U,BAO_0000019,1,,,,,22224
6943,0,Cricetulus griseus,Evaluated for cytotoxicity under aerobic conditions against AA8 cells using microassay,A,10029.0,,,,CHEMBL623827,10251,U,BAO_0000219,1,,,,CHO-AA8,22224
6944,0,Cricetulus griseus,Evaluated for growth inhibition of AA8 cells under aerobic conditions,F,10029.0,,,,CHEMBL623828,10251,U,BAO_0000219,1,,,,CHO-AA8,22224
6945,0,Cricetulus griseus,Evaluated for growth inhibition of AA8 cells under aerobic or hypoxic conditions,F,10029.0,,,,CHEMBL623829,10251,U,BAO_0000219,1,,,,CHO-AA8,22224
6946,0,Cricetulus griseus,Evaluated for growth inhibition of AA8 cells under aerobic or hypoxic conditions (air/N2),F,10029.0,,,,CHEMBL623830,10251,U,BAO_0000219,1,,,,CHO-AA8,22224
6947,0,Cricetulus griseus,Growth inhibition against CHO-derived cell line AA8,F,10029.0,,,,CHEMBL623831,11858,U,BAO_0000019,1,,,,,22224
6948,0,Cricetulus griseus,Growth inhibition against CHO-derived cell line AA8 (Non toxic at solubility limit) [RB6145 used as positive control],F,10029.0,,,,CHEMBL623832,11858,U,BAO_0000219,1,,,,CHO-AA8,22224
6949,1,hampster,Growth inhibition in CHO subline AA8 cells exposed for 18 hr under aerobic(air) conditions,F,36483.0,,,,CHEMBL623833,11616,N,BAO_0000219,1,,,,CHO-AA8,80089
6950,1,Cricetulus griseus,Growth inhibitory activity against CHO subline AA8 cells exposed for 18 hr under aerobic conditions,F,10029.0,,,,CHEMBL623834,11616,N,BAO_0000219,1,,,,CHO-AA8,80089
6951,0,Cricetulus griseus,Tested for the concentration of the drug to reduce cell numbers to 50 percent of controls against AA8 cells in the microassay,F,10029.0,,,,CHEMBL623835,10518,U,BAO_0000219,1,,,,CHO-AA8,22224
6952,0,Cricetulus griseus,Growth inhibition of aerobic chinese hamster ovary fibroblast AA8 cell line using an exposure time of 18 hours,F,10029.0,,,,CHEMBL623836,11396,U,BAO_0000219,1,,,,CHO-AA8,22224
6953,0,Cricetulus griseus,IC50 (air/N2) ratio of the drug to reduce cell numbers to 50 percent of controls using AA8 cells in the microassay,F,10029.0,,,,CHEMBL623837,10518,U,BAO_0000219,1,,,,CHO-AA8,22224
6954,1,Cricetulus griseus,In vitro therapeutic index as ratio of CT10 and C1.3 calculated for AA8 cells.,F,10029.0,,,,CHEMBL623838,11616,N,BAO_0000219,1,,,,CHO-AA8,80089
6955,8,,compound was evaluated for association constant (Ka) of isolated serum protein AAG,F,,,,,CHEMBL623839,14837,H,BAO_0000019,1,,,,,12675
6956,8,,Number of binding sites (n) of isolated serum protein AAG,F,,,,,CHEMBL623840,14837,H,BAO_0000019,1,,,,,12675
6957,3,,Association constant for binding to AATT duplex,B,,,,,CHEMBL623841,16037,M,BAO_0000225,1,,,,,22222
6958,1,Homo sapiens,Inhibition of ABAE human fibroblast cell proliferation,F,9606.0,,,,CHEMBL623842,16597,N,BAO_0000219,1,,,,ABAE,100090
6959,1,Mus musculus,"Compound was evaluated for the antitumor activity against AC755 breast carcinoma for ip administration and daily x 10 schedule; Number of toxic deaths over total number of mice per group (T/C), 1/7 at dose of 25 mg/kg",F,10090.0,,,,CHEMBL623843,8831,N,BAO_0000218,1,,,,AC755,80668
6960,9,Oryctolagus cuniculus,Percent change in total cholesterol(TC) versus (T0)- at which drug intervention begins at a dose of 25 mg/kg in the chronic cholesterol-fed rabbit model,F,9986.0,,,,CHEMBL618669,13419,D,BAO_0000218,1,,,,,102444
6961,9,Oryctolagus cuniculus,Oral bioactivity expressed as %inhibition after 4 hours of drug administration (dose 25 mg/kg) in rabbit bioassay,F,9986.0,,,,CHEMBL618670,13419,D,BAO_0000218,1,,In vivo,,,102444
6962,8,,Inhibitory activity against angiotensin-converting enzyme (ACE).,B,,,,,CHEMBL618671,15778,H,BAO_0000357,1,,,,,69
6963,8,,oral activity against angiotensin -converting enzyme ( ACE) and neutral endopeptidase in mouse.,B,,,,,CHEMBL618672,15778,H,BAO_0000357,1,,,,,69
6964,1,Homo sapiens,Effect against HIV-1 chronically infected promonocytic cell line ACH-2 cells,F,9606.0,,,,CHEMBL618673,12988,N,BAO_0000219,1,,,,ACH-2 cell line,80669
6965,1,Homo sapiens,Effect against HIV-1 chronically infected promonocytic cell line ACH-2 cells in the presence of PMA(phorbol 12-myristate 13-acetate),F,9606.0,,,,CHEMBL618674,12988,N,BAO_0000219,1,,,,ACH-2 cell line,80669
6966,0,Human immunodeficiency virus 1,Effect against HIV-1 expression in a chronically infected human T cell line ACH-2,F,11676.0,,,,CHEMBL618675,12988,U,BAO_0000219,1,,,,T cell line,22224
6967,0,Human immunodeficiency virus 1,Effect against HIV-1 expression in a chronically infected human T cell line ACH-2 in the presence of PMA(phorbol 12-myristate 13-acetate),F,11676.0,,,,CHEMBL618676,12988,U,BAO_0000219,1,,,,T cell line,22224
6968,0,Human immunodeficiency virus 1,Effect against HIV-1 expression in a chronically infected human T cell line ACH-2i n the presence of PMA(phorbol 12-myristate 13-acetate),F,11676.0,,,,CHEMBL618677,12988,U,BAO_0000219,1,,,,T cell line,22224
6969,1,Homo sapiens,Inhibition of growth of renal cancer ACHN cell line,F,9606.0,,,,CHEMBL618678,11843,N,BAO_0000219,1,,,,ACHN,80025
6970,1,Homo sapiens,Inhibition of growth of ACHN renal cancer cell line,F,9606.0,,,,CHEMBL618679,16939,N,BAO_0000219,1,,,,ACHN,80025
6971,1,Homo sapiens,Inhibitory concentration required against ACHN renal cancer cell line,F,9606.0,,,,CHEMBL618680,4782,N,BAO_0000219,1,,,,ACHN,80025
6972,1,Homo sapiens,Concentration required to inhibit growth of human renal (ACHN) cell line,F,9606.0,,,,CHEMBL618681,6310,N,BAO_0000219,1,,,,ACHN,80025
6973,1,Homo sapiens,Concentration required to inhibit growth of human renal (ACHN) cell line; nt = not tested,F,9606.0,,,,CHEMBL618682,6310,N,BAO_0000219,1,,,,ACHN,80025
6974,1,Homo sapiens,Cytotoxic activity against ACHN Renal cancer cell line,F,9606.0,,,,CHEMBL618683,12858,N,BAO_0000219,1,,,,ACHN,80025
6975,1,Homo sapiens,Cytotoxicity evaluation against ACHN renal cancer cells,F,9606.0,,,,CHEMBL618684,17380,N,BAO_0000219,1,,,,ACHN,80025
6976,1,Homo sapiens,In vitro antitumor activity against human renal ACHN cell line,F,9606.0,,,,CHEMBL618685,5858,N,BAO_0000219,1,,,,ACHN,80025
6977,1,Homo sapiens,In vitro growth inhibition of compound was determined against ACHN cell lines of Renal cancer,F,9606.0,,,,CHEMBL876499,3838,N,BAO_0000219,1,,,,ACHN,80025
6978,1,Homo sapiens,In vitro growth inhibition of compound was determined against ACHN cell lines of Renal cancer,F,9606.0,,,,CHEMBL618686,3838,N,BAO_0000219,1,,,,ACHN,80025
6979,1,Homo sapiens,"Tested for the cytotoxicity against the Renal cancer cell line ACHN, growth inhibition by 50% is reported",F,9606.0,,,,CHEMBL618687,5406,N,BAO_0000219,1,,,,ACHN,80025
6980,1,Homo sapiens,The compound was tested in vitro for cytotoxicity against human tumor cell line ACHN (renal).,F,9606.0,,,,CHEMBL618688,4071,N,BAO_0000219,1,,,,ACHN,80025
6981,1,Homo sapiens,Tested in vitro for cytotoxicity against human tumor cell line ACHN (renal).,F,9606.0,,,,CHEMBL618689,4071,N,BAO_0000219,1,,,,ACHN,80025
6982,1,Homo sapiens,The compound was tested in vitro for cytotoxicity against human tumor cell line ACHN (renal); Not determined,F,9606.0,,,,CHEMBL618690,4071,N,BAO_0000219,1,,,,ACHN,80025
6983,1,Homo sapiens,Antitumor activity was evaluated against human renal adenocarcinoma cell line ACHN.,F,9606.0,,,,CHEMBL618691,15002,N,BAO_0000219,1,,,,ACHN,80025
6984,1,Homo sapiens,Compound was evaluated for in vitro activity against ACHN kidney cell lines (Human tumor cells ),F,9606.0,,,,CHEMBL619373,14769,N,BAO_0000219,1,,,,ACHN,80025
6985,1,Homo sapiens,"Compound was tested for antiproliferative activity against ACHN, human renal adenocarcinoma",F,9606.0,,,,CHEMBL884008,13958,N,BAO_0000219,1,,,,ACHN,80025
6986,1,Homo sapiens,Compound was tested for its effect on the proliferation of ACHN human kidney adenocarcinoma,F,9606.0,,,,CHEMBL619374,1665,N,BAO_0000219,1,,,,ACHN,80025
6987,1,Homo sapiens,Compound was tested for the growth inhibition of ACHN renal tumor cell line,F,9606.0,,,,CHEMBL619375,15354,N,BAO_0000219,1,,,,ACHN,80025
6988,1,Homo sapiens,Compound was tested for the growth inhibition of ACHN renal tumor cell line; ND=Not determined,F,9606.0,,,,CHEMBL619376,15354,N,BAO_0000219,1,,,,ACHN,80025
6989,1,Homo sapiens,In vitro Growth Inhibitory activity against ACHN Human kidney cancer cell line,F,9606.0,,,,CHEMBL619377,13978,N,BAO_0000219,1,,,,ACHN,80025
6990,1,Homo sapiens,In vitro cytotoxicity against human renal adenocarcinoma (ACHN) tumor cell line,F,9606.0,,,,CHEMBL619378,6798,N,BAO_0000219,1,,,,ACHN,80025
6991,1,Canis lupus familiaris,Tmax value after administration of 4 mg/Kg oral dose in dog,A,9615.0,,,,CHEMBL872527,2959,N,BAO_0000218,1,,In vivo,,,50588
6992,1,Canis lupus familiaris,"Time to peak response on lowering of vascular resistance, in dogs when administered intravenously",A,9615.0,,,,CHEMBL876500,9932,N,BAO_0000218,1,,,,,50588
6993,1,Canis lupus familiaris,Unbound plasma was determined in Beagle dog at a dose of 1 mg/kg by iv administration,A,9615.0,,,,CHEMBL619379,5546,N,BAO_0000218,1,,,,,50588
6994,1,Canis lupus familiaris,Volume distribution after 15 mg/kg iv dose in Dogs,A,9615.0,,,,CHEMBL619538,16907,N,BAO_0000218,1,,In vivo,,,50588
6995,1,Canis lupus familiaris,Volume distribution after 30 mg/kg po dose in Dogs,A,9615.0,,,,CHEMBL619539,16907,N,BAO_0000218,1,,In vivo,,,50588
6996,1,Canis lupus familiaris,Volume of distribution was determined in dog after a 3 mg/kg of iv dose,A,9615.0,,,,CHEMBL619540,4257,N,BAO_0000218,1,,In vivo,,,50588
6997,1,Canis lupus familiaris,Volume of distribution was determined by iv administration in dogs at a dose of 1 mg/kg,A,9615.0,,,,CHEMBL619541,4305,N,BAO_0000218,1,,In vivo,,,50588
6998,1,Canis lupus familiaris,Volume of distribution was evaluated in dog,A,9615.0,,,,CHEMBL619542,5472,N,BAO_0000218,1,,In vivo,,,50588
6999,1,Canis lupus familiaris,Terminal phase volume of distribution was measured in dog after an iv dose of 1 mg/kg,A,9615.0,,,,CHEMBL619543,6062,N,BAO_0000218,1,,In vivo,,,50588
7000,1,Canis lupus familiaris,Apparent volume of the central plasma compartment (Vc) of compound determined in dog after iv administration at a dose of 10 mg/kg,A,9615.0,,,,CHEMBL619544,3598,N,BAO_0000218,1,,,,,50588
7001,1,Canis lupus familiaris,The compound was tested for volume of distribution in dog,A,9615.0,,,,CHEMBL619545,12500,N,BAO_0000218,1,,In vivo,,,50588
7002,1,Canis lupus familiaris,The compound was tested for volume of distribution in dog at dose of 3-10 mgkg,A,9615.0,,,,CHEMBL619546,12500,N,BAO_0000218,1,,In vivo,,,50588
7003,1,Canis lupus familiaris,Vd (1 mg/kg) was determined in dog (in vivo),A,9615.0,,,,CHEMBL619547,6227,N,BAO_0000218,1,,In vivo,,,50588
7004,1,Canis lupus familiaris,Vd in dog,A,9615.0,,,,CHEMBL619548,6227,N,BAO_0000218,1,,In vivo,,,50588
7005,1,Canis lupus familiaris,Volume distribution was determined,A,9615.0,,,,CHEMBL619549,4219,N,BAO_0000218,1,,In vivo,,,50588
7006,1,Canis lupus familiaris,Volume of distribution in dog,A,9615.0,,,,CHEMBL619550,1696,N,BAO_0000218,1,,In vivo,,,50588
7007,1,Canis lupus familiaris,Volume of distribution by as 4 fold increase by iv administration in dogs,A,9615.0,,,,CHEMBL876501,5542,N,BAO_0000218,1,,In vivo,,,50588
7008,1,Canis lupus familiaris,Volume of distribution was determined in canine following intravenous (iv) administration of drug (1 mg/kg).,A,9615.0,,,,CHEMBL619551,5199,N,BAO_0000218,1,,In vivo,,,50588
7009,1,Canis lupus familiaris,Volume of distribution was determined in dog after 1 mg/kg (i.v.) and 5 mg/kg (p.o.) administration,A,9615.0,,,,CHEMBL619552,6348,N,BAO_0000218,1,,In vivo,,,50588
7010,1,Canis lupus familiaris,Volume distribution at the dose of 2 mg/kg in dog,A,9615.0,,,,CHEMBL619553,4727,N,BAO_0000218,1,,In vivo,,,50588
7011,1,Canis lupus familiaris,Steady state volume of distribution was determined,A,9615.0,,,,CHEMBL618722,16367,N,BAO_0000218,1,,In vivo,,,50588
7012,1,Canis lupus familiaris,Bioavailability as Vdss in dogs at 1 mg/kg intravenous dose,A,9615.0,,,,CHEMBL618723,2652,N,BAO_0000218,1,,In vivo,,,50588
7013,1,Canis lupus familiaris,Pharmacokinetic data at 0.5 mg/kg dose given to dogs intravenously.,A,9615.0,,,,CHEMBL618724,16452,N,BAO_0000218,1,,In vivo,,,50588
7014,1,Canis lupus familiaris,Pharmacokinetic data at 1 mg/kg dose given to dogs intravenously,A,9615.0,,,,CHEMBL618725,16452,N,BAO_0000218,1,,In vivo,,,50588
7015,1,Canis lupus familiaris,Bioavailability in dog (dose 1 mg/kg i.v.),A,9615.0,,,,CHEMBL618726,16452,N,BAO_0000218,1,,In vivo,,,50588
7016,1,Canis lupus familiaris,Pharmacokinetic parameter volume of distribution was reported after intravenous administration at a dose of 1 mg/kg in Beagle dog (male),A,9615.0,,,,CHEMBL618727,5334,N,BAO_0000218,1,,In vivo,,,50588
7017,1,Canis lupus familiaris,Pharmacokinetic property (vdss) was measured in dog,A,9615.0,,,,CHEMBL624233,4239,N,BAO_0000218,1,,In vivo,,,50588
7018,1,Canis lupus familiaris,Steady state volume of distribution for the compound after intravenous administration of 1 mg/kg in dog,A,9615.0,,,,CHEMBL624234,4709,N,BAO_0000218,1,,In vivo,,,50588
7019,1,Canis lupus familiaris,Vdss was determined after iv 0.1 mg/kg administration in dog,A,9615.0,,,,CHEMBL624235,5600,N,BAO_0000218,1,,In vivo,,,50588
7020,1,Canis lupus familiaris,Volume displacement was calculated in dog,A,9615.0,,,,CHEMBL624236,6057,N,BAO_0000218,1,,In vivo,,,50588
7021,1,Canis lupus familiaris,Volume distribution (Vdss) of compound was determined after intravenous administration in average of two dogs at a dose of 1 mg/kg,A,9615.0,,,,CHEMBL624237,5654,N,BAO_0000218,1,,In vivo,,,50588
7022,1,Canis lupus familiaris,Volume distribution constant was determined,A,9615.0,,,,CHEMBL624238,5505,N,BAO_0000218,1,,In vivo,,,50588
7023,1,Canis lupus familiaris,Volume distribution at a dose of 1 uM/kg in dog was determined,A,9615.0,,,,CHEMBL624239,4527,N,BAO_0000218,1,,In vivo,,,50588
7024,1,Canis lupus familiaris,Volume distribution in dog after 2 mg/kg by oral and 0.5 mg/kg by intravenous administration,A,9615.0,,,,CHEMBL875829,4521,N,BAO_0000218,1,,In vivo,,,50588
7025,1,Canis lupus familiaris,Volume distribution in dog after 2 mg/kg by oral and 0.5 mg/kg by intravenous administration; ND is not determined,A,9615.0,,,,CHEMBL624240,4521,N,BAO_0000218,1,,In vivo,,,50588
7026,1,Canis lupus familiaris,Volume distribution (Vdss) was measured in dog,A,9615.0,,,,CHEMBL624241,15660,N,BAO_0000218,1,,In vivo,,,50588
7027,1,Canis lupus familiaris,Volume distribution (Vdss) was measured in dog,A,9615.0,,,,CHEMBL624242,15660,N,BAO_0000218,1,,In vivo,,,50588
7028,1,Canis lupus familiaris,Volume of distribution at steady state was determined after 1 mg/kg (i.v.) / 2 mg/kg (p.o.) of compound administration,A,9615.0,,,,CHEMBL624243,6679,N,BAO_0000218,1,,In vivo,,,50588
7029,1,Canis lupus familiaris,Volume of distribution in steady state was determined in dog,A,9615.0,,,,CHEMBL624244,5145,N,BAO_0000218,1,,In vivo,,,50588
7030,1,Canis lupus familiaris,Volume of distribution of compound was determined in dog,A,9615.0,,,,CHEMBL624245,6821,N,BAO_0000218,1,,In vivo,,,50588
7031,1,Canis lupus familiaris,Volume of distribution after intravenous administration of 1 mg/kg/h in dog,A,9615.0,,,,CHEMBL624246,4137,N,BAO_0000218,1,,In vivo,,,50588
7032,1,Canis lupus familiaris,Volume of distribution was reported after oral administration at a dose of 2 mg/kg in Beagle dog (male),A,9615.0,,,,CHEMBL624247,5334,N,BAO_0000218,1,,In vivo,,,50588
7033,1,Canis lupus familiaris,Volume of distribution (Vdss) was measured in dog,A,9615.0,,,,CHEMBL624248,15660,N,BAO_0000218,1,,In vivo,,,50588
7034,1,Canis lupus familiaris,Volumes of distribution in dog (dosed as a mixture of five compounds at 0.5 mpk each via iv only),A,9615.0,,,,CHEMBL624249,6642,N,BAO_0000218,1,,In vivo,,,50588
7035,1,Canis lupus familiaris,Volumes of distribution in dog (dosed at 0.5 mpk iv and 2.0 mpk orally),A,9615.0,,,,CHEMBL624250,6641,N,BAO_0000218,1,,In vivo,,,50588
7036,1,Canis lupus familiaris,Volumes of distribution in dog (dosed at 0.5 mpk iv and 2.0 mpk orally),A,9615.0,,,,CHEMBL624251,6642,N,BAO_0000218,1,,In vivo,,,50588
7037,1,Canis lupus familiaris,Maximum rate of depolarization of the upstroke of the action potential,A,9615.0,,,,CHEMBL624252,11659,N,BAO_0000218,1,,,,,50588
7038,1,Canis lupus familiaris,Steady state volume distribution in dog,A,9615.0,,,,CHEMBL624253,6448,N,BAO_0000218,1,,In vivo,,,50588
7039,1,Canis lupus familiaris,Steady state volume of distribution at a dose of 0.2 mg/kg i.v.,A,9615.0,,,,CHEMBL624950,5474,N,BAO_0000218,1,,In vivo,,,50588
7040,1,Canis lupus familiaris,Tested for volume of distribution at steady state upon intravenous administration of 5.0 mg/Kg dose in dog,A,9615.0,,,,CHEMBL624951,1466,N,BAO_0000218,1,,In vivo,,,50588
7041,1,Canis lupus familiaris,Volume distribution in dog after administration of 0.25 mg/kg iv; ND = not determined,A,9615.0,,,,CHEMBL875830,6535,N,BAO_0000218,1,,In vivo,,,50588
7042,1,Canis lupus familiaris,Volume distribution in dog after administration of 1 mg/kg iv,A,9615.0,,,,CHEMBL624952,6535,N,BAO_0000218,1,,In vivo,,,50588
7043,1,Canis lupus familiaris,Volume of solubility in solution after intravenous administration in dogs at 1.2 uM/kg,A,9615.0,,,,CHEMBL624953,17764,N,BAO_0000218,1,,In vivo,,,50588
7044,1,Canis lupus familiaris,Vss after intravenous administration (0.5 mg/kg) was determined in dog,A,9615.0,,,,CHEMBL624954,6215,N,BAO_0000218,1,,In vivo,,,50588
7045,1,Canis lupus familiaris,Vss on i.v. administration of 2 mg/kg was measured in dog,A,9615.0,,,,CHEMBL624955,6505,N,BAO_0000218,1,,In vivo,,,50588
7046,1,Canis lupus familiaris,Vss was determined,A,9615.0,,,,CHEMBL624956,3639,N,BAO_0000218,1,,,,,50588
7047,1,Canis lupus familiaris,Vss in dog,A,9615.0,,,,CHEMBL625129,3639,N,BAO_0000218,1,,,,,50588
7048,1,Canis lupus familiaris,Volume of distribution was measured in dog after an iv dose of 1 mg/kg,A,9615.0,,,,CHEMBL625130,6062,N,BAO_0000218,1,,In vivo,,,50588
7049,1,Canis lupus familiaris,Volume distribution in dogs,A,9615.0,,,,CHEMBL625131,4942,N,BAO_0000218,1,,In vivo,,,50588
7050,1,Canis lupus familiaris,Volume of distribution in dog,A,9615.0,,,,CHEMBL625132,17796,N,BAO_0000218,1,,In vivo,,,50588
7051,1,Canis lupus familiaris,Tested for the oral bioavailability in dog,A,9615.0,,,,CHEMBL872263,4883,N,BAO_0000218,1,,In vivo,,,50588
7060,1,Mus musculus,Bioavailability of compound in mouse blood following p.o. administration of 30 mg/kg,A,10090.0,,,,CHEMBL624336,17837,N,BAO_0000218,1,,In vivo,,,50594
7061,1,Mus musculus,Bioavailability after i.p. administration of 50 mg/kg of dose in mice,A,10090.0,,,,CHEMBL624337,17729,N,BAO_0000218,1,,In vivo,,,50594
7062,1,Mus musculus,Bioavailability after peroral administration of 50 mg/kg of dose in mice,A,10090.0,,,,CHEMBL624338,17729,N,BAO_0000218,1,,In vivo,,,50594
7063,1,Mus musculus,Bioavailability was measured in mouse,A,10090.0,,,,CHEMBL624339,4239,N,BAO_0000218,1,,In vivo,,,50594
7064,1,Mus musculus,Bioavailability in mouse,A,10090.0,,,,CHEMBL624340,17592,N,BAO_0000218,1,,In vivo,,,50594
7065,1,Mus musculus,Bioavailability was determined in mouse after 5 mg/kg (i.v.) and 6 mg/kg (p.o.) administration,A,10090.0,,,,CHEMBL624341,6348,N,BAO_0000218,1,,In vivo,,,50594
7066,1,Mus musculus,Bioavailability in mouse,A,10090.0,,,,CHEMBL624342,2801,N,BAO_0000218,1,,In vivo,,,50594
7067,1,Mus musculus,Compound was evaluated for its bioavailability in mice at a dose of 1 mg/kg,A,10090.0,,,,CHEMBL624343,2801,N,BAO_0000218,1,,In vivo,,,50594
7068,1,Mus musculus,Oral bioavailability in mouse,A,10090.0,,,,CHEMBL624344,17718,N,BAO_0000218,1,,In vivo,,,50594
7069,1,Mus musculus,Oral availability at 50 mg/kg po in male mice,A,10090.0,,,,CHEMBL624345,5727,N,BAO_0000218,1,,In vivo,,,50594
7070,1,Mus musculus,Oral bioavailability in mouse (dose 10 mg/kg),A,10090.0,,,,CHEMBL624346,5302,N,BAO_0000218,1,,In vivo,,,50594
7071,1,Mus musculus,Oral bioavailability of compound determined in mouse after iv administration at a dose of 10 mg/kg,A,10090.0,,,,CHEMBL624347,3598,N,BAO_0000218,1,,In vivo,,,50594
7072,1,Mus musculus,"Bioavailability in male mice, 2mg/kg oral and 1 mg/kg intravenous dose",A,10090.0,,,,CHEMBL624348,5961,N,BAO_0000218,1,,In vivo,,,50594
7074,1,Mus musculus,Oral bioavailability in mouse,A,10090.0,,,,CHEMBL622754,6091,N,BAO_0000218,1,,In vivo,,,50594
7075,1,Mus musculus,Oral bioavailability in vivo in mice;ND=Not determined,A,10090.0,,,,CHEMBL622755,6091,N,BAO_0000218,1,,In vivo,,,50594
7076,1,Mus musculus,Oral bioavailability in mouse at 10 mg/kg of the compound,A,10090.0,,,,CHEMBL622756,5711,N,BAO_0000218,1,,In vivo,,,50594
7077,1,Mus musculus,Bioavailability in mouse (BALB/C) (dose 50 mg/kg i.p.),A,10090.0,,,,CHEMBL622757,17728,N,BAO_0000218,1,,In vivo,,,50594
7078,1,Mus musculus,Bioavailability in mouse (BALB/C) (dose 20 mg/kg i.v.),A,10090.0,,,,CHEMBL622758,17728,N,BAO_0000218,1,,In vivo,,,50594
7079,1,Mus musculus,Tested for bioavailability of the compound,A,10090.0,,,,CHEMBL622759,3802,N,BAO_0000218,1,,In vivo,,,50594
7080,1,Mus musculus,Tested for half life at the dose of 10 mg/kg when administered intravenously,A,10090.0,,,,CHEMBL622760,3802,N,BAO_0000218,1,,In vivo,,,50594
7081,1,Mus musculus,The plasma half life of compound was determined on EDTA prepared by mouse plasma. ,A,10090.0,Plasma,,,CHEMBL622761,14029,N,BAO_0000218,1,1969.0,,,,50594
7082,1,Mus musculus,The plasma half life of compound was determined on heparin prepared by human plasma. ,A,10090.0,Plasma,,,CHEMBL622762,14029,N,BAO_0000218,1,1969.0,,,,50594
7083,1,Mus musculus,The plasma half life of compound was determined on heparin prepared by human plasma; Not degraded,A,10090.0,Plasma,,,CHEMBL622763,14029,N,BAO_0000218,1,1969.0,,,,50594
7084,1,Mus musculus,The plasma half life of compound was determined on heparin prepared by mouse plasma. ,A,10090.0,Plasma,,,CHEMBL622764,14029,N,BAO_0000218,1,1969.0,,,,50594
7085,1,Mus musculus,The plasma half life of compound was determined on heparin prepared by mouse plasma; Not degraded,A,10090.0,Plasma,,,CHEMBL622765,14029,N,BAO_0000218,1,1969.0,,,,50594
7086,1,Mus musculus,Inhibitory concentration of compound was determined after intravenous administration in mice after 6 hours of exposure at 40 mg/Kg,F,10090.0,,,,CHEMBL622766,17753,N,BAO_0000218,1,,,,,50594
7087,1,Mus musculus,Inhibitory concentration of compound was determined after intravenous administration in mice after 8 hours of exposure at 24 mg/Kg,A,10090.0,,,,CHEMBL622767,17753,N,BAO_0000218,1,,,,,50594
7088,1,Mus musculus,Inhibitory concentration of compound was determined after intravenous administration in mice after 8 hours of exposure at 5 mg/Kg,A,10090.0,,,,CHEMBL622768,17753,N,BAO_0000218,1,,,,,50594
7089,1,Mus musculus,Biodistribution of intravenously injected [82Br]-labeled compound in blood of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,A,10090.0,Blood,,,CHEMBL875948,10107,N,BAO_0000218,1,178.0,In vivo,,,50594
7090,1,Mus musculus,Biodistribution of intravenously injected [82Br]-labeled compound in blood of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,A,10090.0,Blood,,,CHEMBL622769,10107,N,BAO_0000218,1,178.0,In vivo,,,50594
7091,1,Mus musculus,Biodistribution of intravenously injected [82Br]-labeled compound in blood of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,A,10090.0,Blood,,,CHEMBL622770,10107,N,BAO_0000218,1,178.0,In vivo,,,50594
7092,1,Mus musculus,Biodistribution of intravenously injected [82Br]-labeled compound in blood of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,A,10090.0,Blood,,,CHEMBL622771,10107,N,BAO_0000218,1,178.0,In vivo,,,50594
7093,1,Mus musculus,Biodistribution of intravenously injected [82Br]-labeled compound in blood of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,A,10090.0,Blood,,,CHEMBL622772,10107,N,BAO_0000218,1,178.0,In vivo,,,50594
7094,1,Mus musculus,Biodistribution of intravenously injected [82Br]-labeled compound in blood of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,A,10090.0,Blood,,,CHEMBL622773,10107,N,BAO_0000218,1,178.0,In vivo,,,50594
7095,1,Mus musculus,Biodistribution of intravenously injected [82Br]-labeled compound in blood of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,A,10090.0,Blood,,,CHEMBL622774,10107,N,BAO_0000218,1,178.0,In vivo,,,50594
7096,1,Mus musculus,Biodistribution of intravenously injected [82Br]-labeled compound in bone of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,A,10090.0,Bone,,,CHEMBL621725,10107,N,BAO_0000218,1,10000001.0,In vivo,,,50594
7097,1,Mus musculus,Biodistribution of intravenously injected [82Br]-labeled compound in bone of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.5 hours,A,10090.0,Bone,,,CHEMBL621726,10107,N,BAO_0000218,1,10000001.0,In vivo,,,50594
7098,1,Homo sapiens,cytotoxic activity toward A2780 ovarian human cell line resistant (R) to cisplatin in experiment 8,F,9606.0,,,,CHEMBL621727,15608,N,BAO_0000219,1,,,,A2780,81034
7099,1,Homo sapiens,In vitro cytotoxicity against human ovarian carcinoma cell line A2780 using sulforhodamine B (SRB) assay,F,9606.0,,,,CHEMBL622413,3290,N,BAO_0000219,1,,,,A2780,81034
7100,1,Homo sapiens,Compound was evaluated for cytotoxicity against A2780 cell line,F,9606.0,,,,CHEMBL622414,2859,N,BAO_0000219,1,,,,A2780,81034
7101,1,Homo sapiens,Inhibition of A2780 cell clonogenic assay,F,9606.0,,,,CHEMBL622415,15688,N,BAO_0000219,1,,,,A2780,81034
7102,1,Homo sapiens,Cytotoxic effect on ovarian cancer cell line (A2780),F,9606.0,,,,CHEMBL884001,5642,N,BAO_0000219,1,,,,A2780,81034
7103,1,Homo sapiens,Concentration required to inhibit A2780 cell growth when compared with control after incubation for 96 hr at 37 C,F,9606.0,,,,CHEMBL622416,6633,N,BAO_0000219,1,,,,A2780,81034
7104,1,Homo sapiens,"MDR-reversing activity was measured by vincristine accumulation in the multidrug resistant 2780AD, a subline of A2780 ovarian carcinoma cells at 10 mg/mL",F,9606.0,,,,CHEMBL622417,3906,N,BAO_0000219,1,,,,A2780,81034
7105,1,Homo sapiens,50% growth inhibition of A2780 (Human ovarian carcinoma) cell line compared with untreated control cells,F,9606.0,,,,CHEMBL622590,6788,N,BAO_0000219,1,,,,A2780,81034
7106,1,Homo sapiens,Antiproliferative activity against human A2780 cells,F,9606.0,,,,CHEMBL622591,17582,N,BAO_0000219,1,,,,A2780,81034
7107,1,Homo sapiens,Inhibition of human A2780 cell proliferation,F,9606.0,,,,CHEMBL622592,17764,N,BAO_0000219,1,,,,A2780,81034
7108,1,Homo sapiens,Antiproliferative effect against human A2780 cell line was determined in a whole cell 72 hr cytotoxicity assay,F,9606.0,,,,CHEMBL622593,17764,N,BAO_0000219,1,,,,A2780,81034
7109,1,Homo sapiens,Inhibition of human A2780 cell proliferation (No data),F,9606.0,,,,CHEMBL622594,17764,N,BAO_0000219,1,,,,A2780,81034
7110,1,Homo sapiens,Cell cytotoxicity was determined against human ovarian cancer (A2780) cell line,F,9606.0,,,,CHEMBL622595,2815,N,BAO_0000219,1,,,,A2780,81034
7111,1,Homo sapiens,Compound was evaluated against human Ovarian carcinoma cell line A2780,F,9606.0,,,,CHEMBL622596,16930,N,BAO_0000219,1,,,,A2780,81034
7112,1,Homo sapiens,Growth inhibition against A2780 wild-type ovarian cell lines,F,9606.0,,,,CHEMBL622597,17777,N,BAO_0000219,1,,,,A2780,81034
7113,1,Homo sapiens,Compound was evaluated for growth inhibition against A2780 wild-type ovarian cell lines; No data,F,9606.0,,,,CHEMBL622598,17777,N,BAO_0000219,1,,,,A2780,81034
7114,5,Homo sapiens,Inhibition of tubulin polymerization in human ovarian cancer cell lines,F,9606.0,,,,CHEMBL622599,16936,D,BAO_0000019,1,,,,,104766
7115,1,Homo sapiens,Compound was tested for in vitro growth inhibition of Ovarian carcinoma cell line panel A2780,F,9606.0,,,,CHEMBL622600,13759,N,BAO_0000219,1,,,,A2780,81034
7116,1,Homo sapiens,Compound was tested for in vitro growth inhibition of Ovarian carcinoma cell line panel A2780-R,F,9606.0,,,,CHEMBL622601,13759,N,BAO_0000219,1,,,,A2780,81034
7117,1,Homo sapiens,Compound was tested for in vitro growth inhibition of Ovarian carcinoma cell line panel A2780,F,9606.0,,,,CHEMBL622602,13759,N,BAO_0000219,1,,,,A2780,81034
7118,1,Homo sapiens,Compound was tested for in vitro growth inhibition of Ovarian carcinoma cell line panel A2780-R,F,9606.0,,,,CHEMBL622603,13759,N,BAO_0000219,1,,,,A2780,81034
7119,1,Homo sapiens,Compound was tested for inhibitory activity against A2780 human ovarian carcinoma cell line; activity expressed in Mean IC50 values,F,9606.0,,,,CHEMBL622604,15292,N,BAO_0000219,1,,,,A2780,81034
7120,1,Homo sapiens,Compound was tested for inhibitory activity against A2780cisR human ovarian carcinoma cell line; activity expressed in Mean IC50 values,F,9606.0,,,,CHEMBL622605,15292,N,BAO_0000219,1,,,,A2780,81034
7121,1,Homo sapiens,In vitro inhibition of human ovarian cell line A2780,F,9606.0,,,,CHEMBL622606,15069,N,BAO_0000219,1,,,,A2780,81034
7122,1,Homo sapiens,"In vitro inhibition of human ovarian cell line, resistant to cisplatin (A2780cisR).",F,9606.0,,,,CHEMBL619463,15069,N,BAO_0000219,1,,,,A2780,81034
7123,1,Homo sapiens,Concentration of compound to inhibit the growth of human A2780 ovarian carcinoma cells(in vitro),F,9606.0,,,,CHEMBL619464,14073,N,BAO_0000219,1,,,,A2780,81034
7124,1,Homo sapiens,Concentration required to inhibit A2780-cell growth by 50%,F,9606.0,,,,CHEMBL619465,14553,N,BAO_0000219,1,,,,A2780,81034
7125,1,Homo sapiens,Concentration required to inhibit the cell growth by 50 % after 96 hr A2780 leukemic cells.,F,9606.0,,,,CHEMBL619466,13040,N,BAO_0000219,1,,,,A2780,81034
7126,1,Homo sapiens,Cytotoxic effect on human ovarian (A2780) cancer cell line,F,9606.0,,,,CHEMBL619467,6891,N,BAO_0000219,1,,,,A2780,81034
7127,1,Homo sapiens,Cytotoxic activity in a panel of Human ovarian tumor A2780 cell line after 96h of drug exposure,F,9606.0,,,,CHEMBL619468,15569,N,BAO_0000219,1,,,,A2780,81034
7128,1,Homo sapiens,Cytotoxic potency required to inhibit A2780 cell growth by 50% after cell drug contact for 96 hrs,F,9606.0,,,,CHEMBL619469,14190,N,BAO_0000219,1,,,,A2780,81034
7129,1,Homo sapiens,Cytotoxicity measured in human ovarian cell line A2780 using sulforhodamine B (SRB) assay,F,9606.0,,,,CHEMBL619470,15014,N,BAO_0000219,1,,,,A2780,81034
7130,1,Homo sapiens,Cytotoxicity activity of the compound was measured in human ovarian cell line A2780 using sulforhodamine B (SRB) assay,F,9606.0,,,,CHEMBL619471,15014,N,BAO_0000219,1,,,,A2780,81034
7131,1,Homo sapiens,Cytotoxicity against human ovarian carcinoma A2780 cell line,F,9606.0,,,,CHEMBL619472,17496,N,BAO_0000219,1,,,,A2780,81034
7132,1,Homo sapiens,"Cytotoxicity against A2780-C25, oxaliplatin-resistant Ovarian carcinoma cell line",F,9606.0,,,,CHEMBL619473,13617,N,BAO_0000219,1,,,,A2780,81034
7133,1,Homo sapiens,"Cytotoxicity against A2780-CP3, cisplatin-resistant Ovarian carcinoma cell line",F,9606.0,,,,CHEMBL874368,13617,N,BAO_0000219,1,,,,A2780,81034
7134,1,Homo sapiens,"Cytotoxicity against A2780-DX5, Doxorubicin-resistant Ovarian carcinoma cell line",F,9606.0,,,,CHEMBL884003,13617,N,BAO_0000219,1,,,,A2780,81034
7135,1,Homo sapiens,"Cytotoxicity against A2780-WT, human ovarian carcinoma cell line",F,9606.0,,,,CHEMBL622690,13617,N,BAO_0000219,1,,,,A2780,81034
7136,1,Homo sapiens,Cytotoxicity against ovarian carcinoma A2780 tumor cell lines,F,9606.0,,,,CHEMBL622691,17672,N,BAO_0000219,1,,,,A2780,81034
7137,1,Homo sapiens,Dose of required to inhibit growth of cisplatin resistant human ovarian carcinoma (A2780 cisR) cell line with compound free controls as measured by the sulforhodamine B growth delay assay,F,9606.0,,,,CHEMBL622692,4544,N,BAO_0000219,1,,,,A2780,81034
7138,1,Homo sapiens,Dose of required to inhibit growth of human ovarian carcinoma (A2780) cell line with compound free controls as measured by the sulforhodamine B growth delay assay,F,9606.0,,,,CHEMBL623406,4544,N,BAO_0000219,1,,,,A2780,81034
7139,1,Homo sapiens,"Growth inhibition in human ovarian carcinoma cell line (A2780cisR,cisplatin-resistant) using the 96 hour exposure sulforhodamine B (SRB) growth delay assay",F,9606.0,,,,CHEMBL884004,16317,N,BAO_0000219,1,,,,A2780,81034
7140,1,Homo sapiens,In vitro Cytotoxic activity of compound in comparison with reference compounds in human cell line A2780,F,9606.0,,,,CHEMBL623407,15099,N,BAO_0000219,1,,,,A2780,81034
7141,1,Homo sapiens,In vitro Growth Inhibitory activity against A2780 Human ovarian cancer cell line,F,9606.0,,,,CHEMBL623408,13978,N,BAO_0000219,1,,,,A2780,81034
7142,1,Homo sapiens,In vitro antitumor activity against A2780 cell line.,F,9606.0,,,,CHEMBL623409,12989,N,BAO_0000219,1,,,,A2780,81034
7143,1,Homo sapiens,In vitro cytotoxic activity against human tumor cell line A2780 after incubation for 96 hours,F,9606.0,,,,CHEMBL623410,5574,N,BAO_0000219,1,,,,A2780,81034
7144,1,Homo sapiens,In vitro cytotoxicity against A2780 human ovarian cancer cell line,F,9606.0,,,,CHEMBL623576,13528,N,BAO_0000219,1,,,,A2780,81034
7145,1,Homo sapiens,Inhibitory activity against kidney A-CHN tumor cell growth in culture,F,9606.0,,,,CHEMBL623577,12782,N,BAO_0000219,1,,,,ACHN,80025
7146,1,Homo sapiens,The IC50 value was measured on ACHN cell line in renal tumor type.,F,9606.0,,,,CHEMBL623578,14255,N,BAO_0000219,1,,,,ACHN,80025
7147,1,Homo sapiens,Concentration required for killing 50% of cells of renal ACHN cell lines was determined in vitro,F,9606.0,,,,CHEMBL623579,16364,N,BAO_0000219,1,,,,ACHN,80025
7148,1,Homo sapiens,In vitro lethal concentration against most sensitive ACHN cell line,F,9606.0,,,,CHEMBL623580,17376,N,BAO_0000219,1,,,,ACHN,80025
7149,1,Homo sapiens,Tested for cytotoxic activity against renal cancer ACHN cell line,F,9606.0,,,,CHEMBL623581,12016,N,BAO_0000219,1,,,,ACHN,80025
7150,1,Homo sapiens,Compound tested for growth inhibition of renal cancer cell line ACHN,F,9606.0,,,,CHEMBL857456,6058,N,BAO_0000219,1,,,,ACHN,80025
7151,1,Homo sapiens,Compound was tested for 50% growth inhibition against human renal cancer ACHN cell line,F,9606.0,,,,CHEMBL623582,17708,N,BAO_0000219,1,,,,ACHN,80025
7152,1,Homo sapiens,Growth inhibition of the ACHN Renal cancer cell line for 2-day in vitro assay.,F,9606.0,,,,CHEMBL623583,15176,N,BAO_0000219,1,,,,ACHN,80025
7153,1,Homo sapiens,In vitro anticancer activity against ACHN renal cancer cell line,F,9606.0,,,,CHEMBL623584,2806,N,BAO_0000219,1,,,,ACHN,80025
7154,1,Homo sapiens,In vitro antitumor activity against Renal cancer ACHN cell lines by 6-day assay,F,9606.0,,,,CHEMBL623585,15300,N,BAO_0000219,1,,,,ACHN,80025
7155,1,Homo sapiens,Percent selectivity was evaluated in renal ACHN cell lines,F,9606.0,,,,CHEMBL623586,16364,N,BAO_0000219,1,,,,ACHN,80025
7156,1,Homo sapiens,In vitro inhibitory activity against renal ACHN cancer cell line,F,9606.0,,,,CHEMBL623587,13859,N,BAO_0000219,1,,,,ACHN,80025
7157,1,Homo sapiens,Tested for cytotoxicity against ACHN cell lines in renal cancer,F,9606.0,,,,CHEMBL875279,11970,N,BAO_0000219,1,,,,ACHN,80025
7158,1,Homo sapiens,Tested for the in vitro cytotoxicity against ACHN renal cancer cell line,F,9606.0,,,,CHEMBL623588,2450,N,BAO_0000219,1,,,,ACHN,80025
7159,1,Homo sapiens,In vitro anti tumor activity against human tumor Renal cancer cell lines was determined,F,9606.0,,,,CHEMBL623589,12696,N,BAO_0000219,1,,,,ACHN,80025
7160,1,Homo sapiens,Tested in vitro for cytotoxicity in ACHN cell line of Renal cancer,F,9606.0,,,,CHEMBL623590,12400,N,BAO_0000219,1,,,,ACHN,80025
7161,1,Homo sapiens,Cytotoxic effect on renal cancer line ACHN,F,9606.0,,,,CHEMBL623591,12888,N,BAO_0000219,1,,,,ACHN,80025
7162,1,Homo sapiens,In vitro anti-cancer activity against ACHN(Renal) human tumor cell line,F,9606.0,,,,CHEMBL623592,3156,N,BAO_0000219,1,,,,ACHN,80025
7163,1,Homo sapiens,In vitro inhibition of Renal Cancer ACHN cell lines,F,9606.0,,,,CHEMBL623593,3381,N,BAO_0000219,1,,,,ACHN,80025
7164,1,Homo sapiens,Antitumor activity against human renal adenocarcinoma ACHN cells,F,9606.0,,,,CHEMBL623594,16747,N,BAO_0000219,1,,,,ACHN,80025
7165,1,Homo sapiens,Antitumor activity against human renal adenocarcinoma ACHN cells.,F,9606.0,,,,CHEMBL621833,16748,N,BAO_0000219,1,,,,ACHN,80025
7166,1,Homo sapiens,Inhibitory concentration required to decrease cell viability in cell growth culture against kidney cells ACHN,F,9606.0,,,,CHEMBL621834,12062,N,BAO_0000219,1,,,,ACHN,80025
7167,1,Homo sapiens,Compound was evaluated for in vitro activity against ACHN kidney cell lines (Human tumor cells ),F,9606.0,,,,CHEMBL621835,14769,N,BAO_0000219,1,,,,ACHN,80025
7168,1,Homo sapiens,"Cytotoxicity against NCI tumor panel, ACHN renal cancer cell line",F,9606.0,,,,CHEMBL621836,15895,N,BAO_0000219,1,,,,ACHN,80025
7169,1,Homo sapiens,Concentration of compound that cause 50% cytotoxicity of ACHN renal cancer cell line,F,9606.0,,,,CHEMBL621837,17376,N,BAO_0000219,1,,,,ACHN,80025
7170,1,Homo sapiens,Compound was tested for antitumor activity against ACHN renal cancer cell line(molar concentration that inhibits 50% net cell growth).,F,9606.0,,,,CHEMBL875280,14882,N,BAO_0000219,1,,,,ACHN,80025
7171,1,Homo sapiens,Compound was tested for antitumor activity against ACHN renal cancer cell line(molar concentration leading to 50% net cell death).,F,9606.0,,,,CHEMBL621838,14882,N,BAO_0000219,1,,,,ACHN,80025
7172,1,Homo sapiens,Cytotoxicity was tested against renal cancer ACHN tumor cell lines.,F,9606.0,,,,CHEMBL621839,15661,N,BAO_0000219,1,,,,ACHN,80025
7173,0,,Keff is the effective biomolecular rate constant on paraxon for reactivation at pH 7.8 at 25 degree Centigrade,A,,,,,CHEMBL621840,9680,U,BAO_0000019,1,,,,,22224
7174,8,,Compound tested for relative response using 1 uM ACh as agonist against AChM1 receptor.,F,,,,,CHEMBL621841,14579,H,BAO_0000019,1,,,,,10647
7175,1,Cytomegalovirus,Antiviral activity against AD169 strain of cytomegalovirus (CMV) in HEL (human erythroleukemia) cells.,F,10358.0,,,,CHEMBL622979,17290,N,BAO_0000218,1,,,,HEL,50529
7176,1,Cytomegalovirus,Antiviral activity against AD169 strain of cytomegalovirus (CMV); ND=No data,F,10358.0,,,,CHEMBL876595,17290,N,BAO_0000218,1,,,,,50529
7177,8,,Compound was evaluated for its inhibitory activity against calf intestinal Adenosine deaminase (ADA),B,,,,,CHEMBL620221,15891,H,BAO_0000357,1,,,,,12159
7178,8,,Evaluated for the inhibition of calf intestinal Adenosine deaminase (ADA),B,,,,,CHEMBL620222,15890,H,BAO_0000357,1,,,,,12159
7179,1,Bos taurus,Inhibitory activity against ovarian tumor cell line ADDP after 72 hr continuous exposure to compound,F,9913.0,,,,CHEMBL620506,3801,N,BAO_0000219,1,,,,ADDP cell line,80670
7180,1,Mus musculus,Tumor growth inhibition activity after subcutaneous transplanted tumor in ADJ-PC6 plasmacytoma cells,F,10090.0,,,,CHEMBL620507,9222,N,BAO_0000219,1,,,,ADJ/PC6,80671
7181,1,Mus musculus,Tumor growth inhibition activity after subcutaneously transplanted tumor in ADJ-PC6 plasmacytoma cells,F,10090.0,,,,CHEMBL620508,9222,N,BAO_0000219,1,,,,ADJ/PC6,80671
7182,1,Mus musculus,"Compound was tested for dose producing 90% reduction in tumor weight, in ADJ/PC6 mouse plasma cell tumor",F,10090.0,,,,CHEMBL620509,7257,N,BAO_0000219,1,,,,ADJ/PC6,80671
7183,1,Mus musculus,Compound was tested for inhibition against ADJ/PC6 mouse plasma cell tumor at the dose of 320 mg/Kg,F,10090.0,,,,CHEMBL620510,7257,N,BAO_0000219,1,,,,ADJ/PC6,80671
7184,1,Mus musculus,Compound was tested for dose required to kill 50 % of ADJ/PC6 mouse plasma cell tumor in a group,A,10090.0,,,,CHEMBL620511,7257,N,BAO_0000219,1,,,,ADJ/PC6,80671
7185,1,Mus musculus,In vitro incorporation of the [3H]thymidine into the ADJ/PC6 Plasmacytoma cells,F,10090.0,,,,CHEMBL620512,8084,N,BAO_0000219,1,,,,ADJ/PC6,80671
7186,0,Mus musculus,Tested for cytotoxicity against ADJ/PC6 mouse plasmacytoma,F,10090.0,,,,CHEMBL620513,14943,U,BAO_0000019,1,,,,,22224
7187,0,Mus musculus,The compound was tested for cytotoxicity against ADJ/PC6 mouse plasmacytoma; Not determined,F,10090.0,,,,CHEMBL620514,14943,U,BAO_0000019,1,,,,,22224
7188,0,Mus musculus,Tested for cytotoxicity against ADJ/PC6 plasmacytoma,F,10090.0,,,,CHEMBL620515,14943,U,BAO_0000019,1,,,,,22224
7189,0,Bacillus subtilis,Maximum concentration determined against Bacillus subtilis ATCC 6633 after oral administration in dog(25 mg/kg),A,1423.0,,,,CHEMBL620516,10524,U,BAO_0000218,1,,In vivo,,,22224
7190,1,Canis lupus familiaris,AUC value in dog after IV administration at a dose of 5 mg/kg,A,9615.0,Plasma,,,CHEMBL620517,3546,N,BAO_0000218,1,1969.0,,,,50588
7191,1,Canis lupus familiaris,AUC value in dog after oral administration at a dose of 5 mg/kg,A,9615.0,Plasma,,,CHEMBL620518,3546,N,BAO_0000218,1,1969.0,,,,50588
7192,1,Canis lupus familiaris,Cmax value in dog after oral administration at a dose of 5 mg/kg,A,9615.0,,,,CHEMBL620519,3546,N,BAO_0000218,1,,In vivo,,,50588
7193,1,Canis lupus familiaris,Bioavailability in dog after oral administration at a dose of 5 mg/kg,A,9615.0,,,,CHEMBL621386,3546,N,BAO_0000218,1,,In vivo,,,50588
7194,1,Canis lupus familiaris,Tmax value in dog after oral administration at a dose of 5 mg/kg,A,9615.0,,,,CHEMBL621387,3546,N,BAO_0000218,1,,In vivo,,,50588
7195,1,Canis lupus familiaris,Compound was evaluated for its clearance when administered intravenously in dog,A,9615.0,,,,CHEMBL621388,3184,N,BAO_0000218,1,,In vivo,,,50588
7196,1,Canis lupus familiaris,Plasma clearance in Beagle dogs after intravenous administration at a dose of 10 mg/kg,A,9615.0,,,,CHEMBL621389,16456,N,BAO_0000218,1,,In vivo,,,50588
7197,1,Canis lupus familiaris,Plasma clearance was determined in Beagle dogs after (iv) administration of a dose of 12 (uM/kg),A,9615.0,,,,CHEMBL621390,4809,N,BAO_0000218,1,,In vivo,,,50588
7198,0,,Calculated partition coefficient (clogP),P,,,,,CHEMBL621391,4219,U,BAO_0000100,1,,,,,22229
7199,1,Canis lupus familiaris,Half life in dog,A,9615.0,,,,CHEMBL621392,3748,N,BAO_0000218,1,,,,,50588
7200,1,Canis lupus familiaris,Time taken for EC90 was determined when tested in dog,A,9615.0,,,,CHEMBL621393,3132,N,BAO_0000218,1,,,,,50588
7201,1,Canis lupus familiaris,Half life (iv) was determined,A,9615.0,,,,CHEMBL621394,4219,N,BAO_0000218,1,,,,,50588
7202,1,Canis lupus familiaris,Loss of compound (%metabolized) after 30 min exposure to human liver microsomes,A,9615.0,Liver,,,CHEMBL621395,16907,N,BAO_0000218,1,2107.0,,,,50588
7203,1,Canis lupus familiaris,Area under the curve was calculated in dog after iv administration,A,9615.0,,,,CHEMBL621396,6057,N,BAO_0000218,1,,,,,50588
7204,1,Canis lupus familiaris,Area under the curve was calculated in dog after peroral administration,A,9615.0,,,,CHEMBL621397,6057,N,BAO_0000218,1,,,,,50588
7205,1,Canis lupus familiaris,Dose-normalized area under curve in dog (p.o.) at 2.0 mpk,A,9615.0,,,,CHEMBL621398,17853,N,BAO_0000218,1,,,,,50588
7206,1,Canis lupus familiaris,pKa was evaluated in dog,A,9615.0,,,,CHEMBL618818,3639,N,BAO_0000218,1,,,,,50588
7207,1,Canis lupus familiaris,Compound was evaluated for pronounced GH response at 100 mg (n=6)(area under concentration curve was determined from 0-8 hr following morning and evening dosing with 25 mg of the compound,A,9615.0,,,,CHEMBL618819,14541,N,BAO_0000218,1,,,,,50588
7208,1,Canis lupus familiaris,Alpha-elimination half-life in Beagle dogs after intravenous administration at a dose of 10 mg/kg,A,9615.0,,,,CHEMBL618820,16456,N,BAO_0000218,1,,In vivo,,,50588
7209,1,Canis lupus familiaris,Beta-elimination half-life in Beagle dogs after intravenous administration at a dose of 10 mg/kg,A,9615.0,,,,CHEMBL873810,16456,N,BAO_0000218,1,,In vivo,,,50588
7210,1,Canis lupus familiaris,Compound was evaluated for half-life period in dogs at a dose of 5 mpk perorally,A,9615.0,,,,CHEMBL876606,2652,N,BAO_0000218,1,,In vivo,,,50588
7211,1,Canis lupus familiaris,Compound was evaluated for the half-life (t 1/2) in hours,A,9615.0,,,,CHEMBL618821,3624,N,BAO_0000218,1,,,,,50588
7212,1,Canis lupus familiaris,Half life to reach the blood concentration was determined in dogs after oral administration (10 mg/kg) as a 0.05 M citric acid solution.,A,9615.0,Blood,,,CHEMBL618822,1337,N,BAO_0000218,1,178.0,In vivo,,,50588
7213,1,Canis lupus familiaris,Half life to reach the blood concentration was determined in dogs after oral administration (8 mg/kg) as a 0.05 M citric acid solution.,A,9615.0,Blood,,,CHEMBL618823,1337,N,BAO_0000218,1,178.0,In vivo,,,50588
7214,1,Canis lupus familiaris,Half life after intravenous administration of 1 mg/kg in dog,A,9615.0,,,,CHEMBL618824,4709,N,BAO_0000218,1,,In vivo,,,50588
7215,1,Canis lupus familiaris,Half life was measured in dog,A,9615.0,,,,CHEMBL618825,15660,N,BAO_0000218,1,,,,,50588
7216,1,Canis lupus familiaris,Half life period in dog after 5 mg/kg dose,A,9615.0,,,,CHEMBL618826,5302,N,BAO_0000218,1,,In vivo,,,50588
7217,1,Canis lupus familiaris,Half life period was evaluated in dog; 4-4.8,A,9615.0,,,,CHEMBL618827,17791,N,BAO_0000218,1,,,,,50588
7218,1,Canis lupus familiaris,Half life was determined in dog after 1 mg/kg (i.v.) and 5 mg/kg (p.o.) administration,A,9615.0,,,,CHEMBL618828,6348,N,BAO_0000218,1,,In vivo,,,50588
7219,1,Canis lupus familiaris,Half-life was determined in dog after a3 mg/kg of iv dose,A,9615.0,,,,CHEMBL618829,4257,N,BAO_0000218,1,,In vivo,,,50588
7220,1,Canis lupus familiaris,Half-life was determined,A,9615.0,,,,CHEMBL618830,3771,N,BAO_0000218,1,,,,,50588
7221,1,Canis lupus familiaris,Half life in dogs,A,9615.0,,,,CHEMBL618831,6305,N,BAO_0000218,1,,,,,50588
7222,1,Canis lupus familiaris,Apparent Half life was determined from the linear portion of the log plasma concentration-time profile after oral administration of compound 18 at a dose of 2 mg/kg tp dog,A,9615.0,Plasma,,,CHEMBL619489,13501,N,BAO_0000218,1,1969.0,In vivo,,,50588
7223,1,Canis lupus familiaris,Apparent half-life after single intravenous bolus of 1 mg/kg in dogs,A,9615.0,,,,CHEMBL619649,17594,N,BAO_0000218,1,,In vivo,,,50588
7224,1,Canis lupus familiaris,Compound was evaluated for the half life period after iv administration in Beagle dog.,A,9615.0,,,,CHEMBL876607,3045,N,BAO_0000218,1,,In vivo,,,50588
7225,1,Canis lupus familiaris,Compound was evaluated for the half life period after oral administration in conscious dog.,A,9615.0,,,,CHEMBL619650,3043,N,BAO_0000218,1,,In vivo,,,50588
7226,1,Canis lupus familiaris,Compound was tested for half life in dog,A,9615.0,,,,CHEMBL619651,4839,N,BAO_0000218,1,,,,,50588
7227,1,Canis lupus familiaris,Compound was tested for its half life in dog,A,9615.0,,,,CHEMBL619652,4839,N,BAO_0000218,1,,,,,50588
7228,1,Canis lupus familiaris,Half life of compound after both po and iv administration at a dose of 5 mg/kg and 2 mg/kg resp in dog,A,9615.0,,,,CHEMBL619653,5802,N,BAO_0000218,1,,In vivo,,,50588
7229,1,Canis lupus familiaris,Half life of compound in dog was determined,A,9615.0,,,,CHEMBL619654,17839,N,BAO_0000218,1,,,,,50588
7230,1,Canis lupus familiaris,Half life (iv) was determined,A,9615.0,,,,CHEMBL619655,4219,N,BAO_0000218,1,,In vivo,,,50588
7231,1,Canis lupus familiaris,Half life following administration of 70 nM in canine whole blood (dose exceeding platelet binding capacity),A,9615.0,Blood,,,CHEMBL619656,13966,N,BAO_0000218,1,178.0,,,,50588
7232,1,Canis lupus familiaris,Half life in Dog plasma at a dosage 5 mg/kg after intravenous administration,A,9615.0,Plasma,,,CHEMBL873812,3994,N,BAO_0000218,1,1969.0,In vivo,,,50588
7233,1,Canis lupus familiaris,Half life in Dog plasma at a dosage 5 mg/kg after intravenous administration,F,9615.0,Plasma,,,CHEMBL621365,3994,N,BAO_0000218,1,1969.0,In vivo,,,50588
7234,1,Canis lupus familiaris,Half life in dog,A,9615.0,,,,CHEMBL621366,4453,N,BAO_0000218,1,,,,,50588
7235,1,Canis lupus familiaris,Half life in dog plasma,A,9615.0,Plasma,,,CHEMBL621367,6535,N,BAO_0000218,1,1969.0,,,,50588
7236,1,Canis lupus familiaris,Half life in dog plasma after administration of 0.25 mg/kg iv,A,9615.0,Plasma,,,CHEMBL621368,6535,N,BAO_0000218,1,1969.0,In vivo,,,50588
7237,1,Canis lupus familiaris,Half life in dog plasma after administration of 1 mg/kg iv,A,9615.0,Plasma,,,CHEMBL621369,6535,N,BAO_0000218,1,1969.0,In vivo,,,50588
7238,1,Canis lupus familiaris,Half life in dog plasma was determined at dose 10 mg/kg,A,9615.0,Plasma,,,CHEMBL621370,3132,N,BAO_0000218,1,1969.0,In vivo,,,50588
7239,1,Canis lupus familiaris,Half life in dog was determined,A,9615.0,,,,CHEMBL621371,5374,N,BAO_0000218,1,,,,,50588
7240,1,Canis lupus familiaris,Half life in dogs administered perorally (5 mg/kg) and intravenously (2 mg/kg),A,9615.0,,,,CHEMBL621372,5007,N,BAO_0000218,1,,In vivo,,,50588
7241,1,Canis lupus familiaris,Half life upon exposure to human plasma,A,9615.0,Plasma,,,CHEMBL621373,16907,N,BAO_0000218,1,1969.0,,,,50588
7242,1,Canis lupus familiaris,Half life was calculated in dog,A,9615.0,,,,CHEMBL621374,6057,N,BAO_0000218,1,,,,,50588
7243,1,Canis lupus familiaris,Half life was determined,A,9615.0,,,,CHEMBL621375,5006,N,BAO_0000218,1,,,,,50588
7244,1,Canis lupus familiaris,Half life was determined,A,9615.0,,,,CHEMBL621376,5473,N,BAO_0000218,1,,,,,50588
7245,1,Canis lupus familiaris,Half life by intravenous administration of 1.2 mg/kg in dog,A,9615.0,,,,CHEMBL619624,4368,N,BAO_0000218,1,,In vivo,,,50588
7246,1,Canis lupus familiaris,Half life in dog,A,9615.0,,,,CHEMBL875840,6448,N,BAO_0000218,1,,,,,50588
7247,1,Canis lupus familiaris,Half life in dog after intra venous administration of the compound,A,9615.0,,,,CHEMBL619625,4353,N,BAO_0000218,1,,,,,50588
7248,1,Canis lupus familiaris,Half life in dog after intra venous administration of the compound; ND means Not determined,A,9615.0,,,,CHEMBL619626,4353,N,BAO_0000218,1,,,,,50588
7249,1,Canis lupus familiaris,Half life in dog after po administration of the compound,A,9615.0,,,,CHEMBL619627,4353,N,BAO_0000218,1,,In vivo,,,50588
7250,1,Canis lupus familiaris,Half life in dog after po administration of the compound; ND means Not determined,A,9615.0,,,,CHEMBL873817,4353,N,BAO_0000218,1,,In vivo,,,50588
7251,1,Canis lupus familiaris,Half life in dog at the single oral dose of 1 mg/kg,A,9615.0,,,,CHEMBL619628,6265,N,BAO_0000218,1,,In vivo,,,50588
7252,1,Canis lupus familiaris,Half life in dogs,A,9615.0,,,,CHEMBL619629,5006,N,BAO_0000218,1,,,,,50588
7253,1,Canis lupus familiaris,Half life in dogs at 1 mg/kg oral dosing; 35-100 min,A,9615.0,,,,CHEMBL619630,5356,N,BAO_0000218,1,,In vivo,,,50588
7254,1,Canis lupus familiaris,Half life in rat,A,9615.0,,,,CHEMBL619631,405,N,BAO_0000218,1,,,,,50588
7255,1,Canis lupus familiaris,Half life in dog (dosed as a mixture of five compounds at 0.5 mpk each via iv only),A,9615.0,,,,CHEMBL619632,6642,N,BAO_0000218,1,,In vivo,,,50588
7256,1,Mus musculus,Biodistribution of intravenously injected [82Br]-labeled compound in bone of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,A,10090.0,Bone,,,CHEMBL619633,10107,N,BAO_0000218,1,10000001.0,In vivo,,,50594
7257,1,Mus musculus,Biodistribution of intravenously injected [82Br]-labeled compound in bone of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,A,10090.0,Bone,,,CHEMBL875841,10107,N,BAO_0000218,1,10000001.0,In vivo,,,50594
7258,1,Mus musculus,Biodistribution of intravenously injected [82Br]-labeled compound in bone of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,A,10090.0,Bone,,,CHEMBL619634,10107,N,BAO_0000218,1,10000001.0,In vivo,,,50594
7259,1,Mus musculus,Biodistribution of intravenously injected [82Br]-labeled compound in bone of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,A,10090.0,Bone,,,CHEMBL619635,10107,N,BAO_0000218,1,10000001.0,In vivo,,,50594
7260,1,Mus musculus,Biodistribution of intravenously injected [82Br]-labeled compound in bone of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,A,10090.0,Bone,,,CHEMBL619636,10107,N,BAO_0000218,1,10000001.0,In vivo,,,50594
7261,1,Mus musculus,Biodistribution of intravenously injected [82Br]-labeled compound in gut of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,A,10090.0,Gut,,,CHEMBL619637,10107,N,BAO_0000218,1,10000004.0,In vivo,,,50594
7262,1,Mus musculus,Biodistribution of intravenously injected [82Br]-labeled compound in gut of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,A,10090.0,Gut,,,CHEMBL619638,10107,N,BAO_0000218,1,10000004.0,In vivo,,,50594
7263,1,Mus musculus,Biodistribution of intravenously injected [82Br]-labeled compound in gut of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,A,10090.0,Gut,,,CHEMBL619639,10107,N,BAO_0000218,1,10000004.0,In vivo,,,50594
7264,1,Mus musculus,Biodistribution of intravenously injected [82Br]-labeled compound in gut of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,A,10090.0,Gut,,,CHEMBL619640,10107,N,BAO_0000218,1,10000004.0,In vivo,,,50594
7265,1,Mus musculus,Biodistribution of intravenously injected [82Br]-labeled compound in gut of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,A,10090.0,Gut,,,CHEMBL619641,10107,N,BAO_0000218,1,10000004.0,In vivo,,,50594
7266,1,Mus musculus,Biodistribution of intravenously injected [82Br]-labeled compound in gut of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,A,10090.0,Gut,,,CHEMBL619642,10107,N,BAO_0000218,1,10000004.0,In vivo,,,50594
7267,1,Mus musculus,Biodistribution of intravenously injected [82Br]-labeled compound in gut of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,A,10090.0,Gut,,,CHEMBL619643,10107,N,BAO_0000218,1,10000004.0,In vivo,,,50594
7268,1,Mus musculus,Biodistribution of intravenously injected [82Br]-labeled compound in heart of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,A,10090.0,Heart,,,CHEMBL619644,10107,N,BAO_0000218,1,948.0,In vivo,,,50594
7269,1,Mus musculus,Biodistribution of intravenously injected [82Br]-labeled compound in heart of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,A,10090.0,Heart,,,CHEMBL621112,10107,N,BAO_0000218,1,948.0,In vivo,,,50594
7270,1,Mus musculus,Biodistribution of intravenously injected [82Br]-labeled compound in heart of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,A,10090.0,Heart,,,CHEMBL621113,10107,N,BAO_0000218,1,948.0,In vivo,,,50594
7271,1,Mus musculus,Biodistribution of intravenously injected [82Br]-labeled compound in heart of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,A,10090.0,Heart,,,CHEMBL621114,10107,N,BAO_0000218,1,948.0,In vivo,,,50594
7272,1,Mus musculus,Biodistribution of intravenously injected [82Br]-labeled compound in heart of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,A,10090.0,Heart,,,CHEMBL621115,10107,N,BAO_0000218,1,948.0,In vivo,,,50594
7273,1,Mus musculus,Biodistribution of intravenously injected [82Br]-labeled compound in heart of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,A,10090.0,Heart,,,CHEMBL621116,10107,N,BAO_0000218,1,948.0,In vivo,,,50594
7274,1,Mus musculus,Biodistribution of intravenously injected [82Br]-labeled compound in heart of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,A,10090.0,Heart,,,CHEMBL621117,10107,N,BAO_0000218,1,948.0,In vivo,,,50594
7275,1,Mus musculus,Biodistribution of intravenously injected [82Br]-labeled compound in kidney of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,A,10090.0,Kidney,,,CHEMBL621118,10107,N,BAO_0000218,1,2113.0,In vivo,,,50594
7276,1,Mus musculus,Biodistribution of intravenously injected [82Br]-labeled compound in kidney of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.5 hours,A,10090.0,Kidney,,,CHEMBL621119,10107,N,BAO_0000218,1,2113.0,In vivo,,,50594
7277,1,Mus musculus,Biodistribution of intravenously injected [82Br]-labeled compound in kidney of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,A,10090.0,Kidney,,,CHEMBL621120,10107,N,BAO_0000218,1,2113.0,In vivo,,,50594
7278,1,Mus musculus,Biodistribution of intravenously injected [82Br]-labeled compound in kidney of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,A,10090.0,Kidney,,,CHEMBL621757,10107,N,BAO_0000218,1,2113.0,In vivo,,,50594
7279,1,Mus musculus,Biodistribution of intravenously injected [82Br]-labeled compound in kidney of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,A,10090.0,Kidney,,,CHEMBL621758,10107,N,BAO_0000218,1,2113.0,In vivo,,,50594
7280,1,Mus musculus,Biodistribution of intravenously injected [82Br]-labeled compound in kidney of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,A,10090.0,Kidney,,,CHEMBL621759,10107,N,BAO_0000218,1,2113.0,In vivo,,,50594
7281,1,Mus musculus,Biodistribution of intravenously injected [82Br]-labeled compound in kidney of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,A,10090.0,Kidney,,,CHEMBL621760,10107,N,BAO_0000218,1,2113.0,In vivo,,,50594
7282,1,Mus musculus,Biodistribution of intravenously injected [82Br]-labeled compound in liver of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,A,10090.0,Liver,,,CHEMBL621761,10107,N,BAO_0000218,1,2107.0,In vivo,,,50594
7283,1,Mus musculus,Biodistribution of intravenously injected [82Br]-labeled compound in liver of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,A,10090.0,Liver,,,CHEMBL621762,10107,N,BAO_0000218,1,2107.0,In vivo,,,50594
7284,1,Mus musculus,Biodistribution of intravenously injected [82Br]-labeled compound in liver of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,A,10090.0,Liver,,,CHEMBL621763,10107,N,BAO_0000218,1,2107.0,In vivo,,,50594
7285,1,Mus musculus,Biodistribution of intravenously injected [82Br]-labeled compound in liver of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,A,10090.0,Liver,,,CHEMBL624502,10107,N,BAO_0000218,1,2107.0,In vivo,,,50594
7286,1,Mus musculus,Biodistribution of intravenously injected [82Br]-labeled compound in liver of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,A,10090.0,Liver,,,CHEMBL624503,10107,N,BAO_0000218,1,2107.0,In vivo,,,50594
7287,1,Mus musculus,Biodistribution of intravenously injected [82Br]-labeled compound in liver of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,A,10090.0,Liver,,,CHEMBL624504,10107,N,BAO_0000218,1,2107.0,In vivo,,,50594
7288,1,Mus musculus,Biodistribution of intravenously injected [82Br]-labeled compound in liver of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,A,10090.0,Liver,,,CHEMBL624505,10107,N,BAO_0000218,1,2107.0,In vivo,,,50594
7289,1,Mus musculus,Biodistribution of intravenously injected [82Br]-labeled compound in lung of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,A,10090.0,Lung,,,CHEMBL624506,10107,N,BAO_0000218,1,2048.0,In vivo,,,50594
7290,1,Homo sapiens,In vitro cytotoxicity against A2780 (human ovarian cancer),F,9606.0,,,,CHEMBL624507,5895,N,BAO_0000219,1,,,,A2780,81034
7291,1,Homo sapiens,In vitro cytotoxicity against the paclitaxel sensitive human breast carcinoma cell line A2780,F,9606.0,,,,CHEMBL624508,6338,N,BAO_0000219,1,,,,A2780,81034
7292,1,Homo sapiens,In vitro cytotoxicity against. ovarian carcinoma cell line A2780.,F,9606.0,,,,CHEMBL624509,15163,N,BAO_0000219,1,,,,A2780,81034
7293,1,Homo sapiens,In vitro cytotoxicity against. ovarian carcinoma cell line A2780cisR (cisplatin resistant counter part of A2780).,F,9606.0,,,,CHEMBL624510,15163,N,BAO_0000219,1,,,,A2780,81034
7294,1,Homo sapiens,In vitro cytotoxicity was tested against human Ovarian carcinoma A2780 cell line,F,9606.0,,,,CHEMBL875956,15000,N,BAO_0000219,1,,,,A2780,81034
7295,1,Homo sapiens,In vitro cytotoxicity was tested against human Ovarian carcinoma A2780 cisplatin resistant cell line,F,9606.0,,,,CHEMBL839885,15000,N,BAO_0000219,1,,,,A2780,81034
7296,1,Homo sapiens,In vitro cytotoxicity against A2780 ovarian cells using the sulforhodamine B(SRB) assay.,F,9606.0,,,,CHEMBL624511,14729,N,BAO_0000219,1,,,,A2780,81034
7297,1,Homo sapiens,In vitro cytotoxicity against A2780 cell line,F,9606.0,,,,CHEMBL624512,17270,N,BAO_0000219,1,,,,A2780,81034
7298,1,Homo sapiens,In vitro growth inhibitory activity against A2780 human ovarium carcinoma cell line was determined,F,9606.0,,,,CHEMBL624513,5685,N,BAO_0000219,1,,,,A2780,81034
7299,1,Homo sapiens,In vitro inhibitory activity against human ovarian cancer A2780 cell line,F,9606.0,,,,CHEMBL624514,3563,N,BAO_0000219,1,,,,A2780,81034
7300,1,Homo sapiens,In vivo cytotoxic concentration of compound against A2780 cell line after 72 hr exposure,F,9606.0,,,,CHEMBL618547,17753,N,BAO_0000218,1,,,,A2780,81034
7301,1,Homo sapiens,"Inhibition of cell growth in human ovarian carcinoma cell line (A2780cisR,cisplatin-resistant)using the 96 hour continuous exposure sulforhodamine B (SRB) growth delay assay",F,9606.0,,,,CHEMBL618548,16317,N,BAO_0000219,1,,,,A2780,81034
7302,1,Homo sapiens,Inhibition of tubulin polymerization in analogy of ca.,F,9606.0,,,,CHEMBL618549,16936,N,BAO_0000219,1,,,,A2780,81034
7303,1,Homo sapiens,Inhibitory activity against ovarian tumor cell line A2780 after 72 hr continuous exposure to compound,F,9606.0,,,,CHEMBL618550,3801,N,BAO_0000219,1,,,,A2780,81034
7304,1,Homo sapiens,Cytotoxic effect in ovarian cancer cell line (A2780),F,9606.0,,,,CHEMBL618551,6181,N,BAO_0000219,1,,,,A2780,81034
7305,1,Homo sapiens,Tested for cytotoxicity against Ovarian carcinoma parental type A2780 cell line expressing MDR-1 (-) gene,F,9606.0,,,,CHEMBL618552,5318,N,BAO_0000219,1,,,,A2780,81034
7306,1,Homo sapiens,Tested for the cytotoxicity in A2780 ovarian cell line,F,9606.0,,,,CHEMBL618553,4840,N,BAO_0000219,1,,,,A2780,81034
7307,1,Homo sapiens,The compound was tested for cytotoxic activity against A2780 cell line(human ovarian carcinoma ),F,9606.0,,,,CHEMBL618554,15748,N,BAO_0000219,1,,,,A2780,81034
7308,1,Homo sapiens,The compound was tested for cytotoxic activity against A2780/Cs cell line(human ovarian carcinoma,F,9606.0,,,,CHEMBL618555,15748,N,BAO_0000219,1,,,,A2780,81034
7309,1,,The compound was tested for cytotoxic activity against A2780cisR cell line(human ovarian carcinoma,F,,,,,CHEMBL618556,15748,N,BAO_0000219,1,,,,A2780cisR,80017
7310,1,,The compound was tested for cytotoxic activity against A2780cisR cell line(human ovarian carcinoma ),F,,,,,CHEMBL618557,15748,N,BAO_0000219,1,,,,A2780cisR,80017
7311,1,,The compound was tested for cytotoxic activity against A2780cisR cell line(human ovarian carcinoma ); ND means no data,F,,,,,CHEMBL618558,15748,N,BAO_0000219,1,,,,A2780cisR,80017
7312,1,,The compound was tested for cytotoxic activity against A2780cisR cell line(human ovarian carcinoma),F,,,,,CHEMBL618559,15748,N,BAO_0000219,1,,,,A2780cisR,80017
7313,1,Homo sapiens,In vivo log of cells killed after administration of compound in A2780 cell line,F,9606.0,,,,CHEMBL618560,17753,N,BAO_0000218,1,,,,A2780,81034
7314,1,Homo sapiens,Compound was tested in vivo for maximum tolerated dose after i.v. administration twice a day for 5 days in A2780 cell line,F,9606.0,,,,CHEMBL618561,17753,N,BAO_0000218,1,,In vivo,,A2780,81034
7315,1,Homo sapiens,Compound was tested for Tubulin polymerization inhibition by using human ovarian carcinoma cell lines.;NA means not active,F,9606.0,,,,CHEMBL618562,16936,N,BAO_0000219,1,,,,A2780,81034
7316,1,Homo sapiens,Compound was tested for colchicine binding inhibition by using human ovarian carcinoma cell lines (at 5 uM );NA means not active,F,9606.0,,,,CHEMBL618563,16936,N,BAO_0000219,1,,,,A2780,81034
7317,1,Homo sapiens,Compound was tested for Tubulin polymerization inhibition by using human ovarian carcinoma cell lines; ND means no data,F,9606.0,,,,CHEMBL618564,16936,N,BAO_0000219,1,,,,A2780,81034
7318,1,Homo sapiens,Compound was tested for colchicine binding inhibition by using human ovarian carcinoma cell lines. (at 5 uM ); ND means no data,F,9606.0,,,,CHEMBL618565,16936,N,BAO_0000219,1,,,,A2780,81034
7319,1,Homo sapiens,Optimal dose required to inhibit human ovarian A2780 tumor growth after subcutaneous transplantation on athymic mice at 10 mg/kg (treatment schedule: q4dX2),F,9606.0,,,,CHEMBL618566,17528,N,BAO_0000218,1,,,,A2780,81034
7320,1,Homo sapiens,Resistance factor was determined as IC50 cisplatin-resistant/parent for human A2780 ovarian cell line,F,9606.0,,,,CHEMBL618567,6633,N,BAO_0000219,1,,,,A2780,81034
7321,1,Homo sapiens,Resistance index is IC50 ratio of A2780 cell line and A2780cisR cell line,F,9606.0,,,,CHEMBL618568,15000,N,BAO_0000219,1,,,,A2780,81034
7322,1,Homo sapiens,Percentage tumor growth inhibition was calculated in respect to controls one week after the end of the treatment,F,9606.0,,,,CHEMBL618569,17528,N,BAO_0000219,1,,,,A2780,81034
7323,1,Homo sapiens,Compound was tested for Tubulin polymerization inhibition by using human ovarian cancer cell lines.,F,9606.0,,,,CHEMBL621857,16936,N,BAO_0000219,1,,,,A2780,81034
7324,1,Homo sapiens,Compound was tested for Tubulin polymerization inhibition by using human ovarian carcinoma cell lines.,F,9606.0,,,,CHEMBL621858,16936,N,BAO_0000219,1,,,,A2780,81034
7325,1,Homo sapiens,Percent of Tubulin polymerization inhibition by using human ovarian cancer cell lines at a concentration of 5 uM,F,9606.0,,,,CHEMBL621859,16936,N,BAO_0000219,1,,,,A2780,81034
7326,1,Homo sapiens,"Colchicine Binding Inhibition ( CBI ) by using human ovarian cancer cell lines at 5 uM, (values are mean of 9 over 4 concentrations +/- SD)",F,9606.0,,,,CHEMBL621860,16936,N,BAO_0000219,1,,,,A2780,81034
7327,1,Homo sapiens,Compound tested for colchicine Binding Inhibition by using human ovarian cancer cell line (at 5 uM ),F,9606.0,,,,CHEMBL621861,16936,N,BAO_0000219,1,,,,A2780,81034
7328,1,Homo sapiens,"Tested for colchicine binding inhibition, using human ovarian cancer cell lines (at 5 uM )",F,9606.0,,,,CHEMBL621862,16936,N,BAO_0000219,1,,,,A2780,81034
7329,1,Homo sapiens,Compound tested for colchicine Binding Inhibition by using human ovarian carcinoma cell line (at 5 uM ),F,9606.0,,,,CHEMBL621863,16936,N,BAO_0000219,1,,,,A2780,81034
7330,1,Homo sapiens,Compound was tested for colchicine Binding Inhibition by using human ovarian carcinoma cell line (at 5 uM ),F,9606.0,,,,CHEMBL621864,16936,N,BAO_0000219,1,,,,A2780,81034
7331,1,Homo sapiens,Compound was tested for colchicine binding inhibition by using human ovarian carcinoma cell line (at 5 uM ),F,9606.0,,,,CHEMBL621865,16936,N,BAO_0000219,1,,,,A2780,81034
7332,1,Mus musculus,In vitro antiproliferative activity against A2780 cell line,F,10090.0,,,,CHEMBL621866,17737,N,BAO_0000219,1,,,,A2780,81034
7333,1,Mus musculus,Maximum tolerated dose in A2780 tumor in mice after intraperitoneal administration daily for 8 days,F,10090.0,,,,CHEMBL621867,17764,N,BAO_0000219,1,,,,A2780,81034
7334,1,Homo sapiens,In vitro cytotoxicity of compound was determined against A2780 cell lines at 37 degree C after 96 hr,F,9606.0,,,,CHEMBL621868,3830,N,BAO_0000219,1,,,,A2780,81034
7335,1,Homo sapiens,In vitro cytotoxicity of compound was determined against A2780 cell lines at 37 degree C for 96 hr,F,9606.0,,,,CHEMBL875282,3829,N,BAO_0000219,1,,,,A2780,81034
7336,1,Canis lupus familiaris,Vc value in dog after IV administration at a dose of 5 mg/kg,A,9615.0,,,,CHEMBL621869,3546,N,BAO_0000218,1,,,,,50588
7337,1,Canis lupus familiaris,Half life period in dog after IV administration at a dose of 5 mg/kg,A,9615.0,,,,CHEMBL621870,3546,N,BAO_0000218,1,,In vivo,,,50588
7338,0,Cercopithecidae,Area under curve was determine after peroral administration at 10 mpk in Rhesus,A,9527.0,,,,CHEMBL621871,5668,U,BAO_0000019,1,,,,,22224
7339,0,Cercopithecidae,AUC (area under curve) evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,A,9527.0,Plasma,,,CHEMBL621243,3443,U,BAO_0000218,1,1969.0,,,,22224
7340,0,Cercopithecidae,AUC (area under curve) compared to Cilastatin evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,A,9527.0,Plasma,,,CHEMBL621244,3443,U,BAO_0000218,1,1969.0,,,,22224
7341,0,Macaca fascicularis,Area under curve determined after intravenous administration at a dose of 3 mg/kg in cynomolgus monkey,A,9541.0,,,,CHEMBL621245,4256,U,BAO_0000218,1,,In vivo,,,22224
7342,0,Macaca fascicularis,Area under curve determined after peroral administration at a dose of 10 mg/kg in cynomolgus monkey,A,9541.0,,,,CHEMBL621246,4256,U,BAO_0000218,1,,In vivo,,,22224
7343,0,Macaca fascicularis,Area under curve determined after peroral administration at a dose of 3 mg/kg in cynomolgus monkey,A,9541.0,,,,CHEMBL621247,4256,U,BAO_0000218,1,,In vivo,,,22224
7344,0,Rattus norvegicus,Oral Bioavailability in rat,A,10116.0,,,,CHEMBL618386,4256,U,BAO_0000218,1,,In vivo,,,22224
7345,0,Cercopithecidae,Area under curve was evaluated against Cynomolgus monkey at a dose of 15 mg/kg after po administration,A,9527.0,,,,CHEMBL618387,1916,U,BAO_0000218,1,,,,,22224
7346,0,Cercopithecidae,Area under curve value in monkey at a dose of 5 mg/kg,A,9527.0,,,,CHEMBL618388,5302,U,BAO_0000218,1,,,,,22224
7347,0,Cercopithecidae,Area under curve was determined in monkey after a 3 mg/kg of oral dose,A,9527.0,,,,CHEMBL618389,4257,U,BAO_0000218,1,,,,,22224
7348,0,Cercopithecidae,Area under curve was determined using trapezoidal rule after intravenous administration in cynomolgus monkeys,A,9527.0,,,,CHEMBL618574,5355,U,BAO_0000019,1,,,,,22224
7349,0,Cercopithecidae,Area under curve was determined using trapezoidal rule after oral administration in cynomolgus monkeys,A,9527.0,,,,CHEMBL618575,5355,U,BAO_0000019,1,,,,,22224
7350,0,Cercopithecidae,Area under curve was determined using trapezoidal rule after oral administration in cynomolgus monkeys; ND means Not determined,A,9527.0,,,,CHEMBL618576,5355,U,BAO_0000019,1,,,,,22224
7351,0,Cercopithecidae,Area under the curve for the compound calculated from 0-24 hr after intravenous administration at a dose of 10 mg/kg in monkey,A,9527.0,,,,CHEMBL618577,6078,U,BAO_0000218,1,,,,,22224
7352,0,Cercopithecidae,Area under the curve for the compound calculated from 0-24 hr after oral administration at a dose of 10 mg/kg in monkey,A,9527.0,,,,CHEMBL876487,6078,U,BAO_0000218,1,,,,,22224
7353,0,Cercopithecidae,Area under the curve was measured in monkey after an iv dose of 1 mg/kg,A,9527.0,,,,CHEMBL618578,6062,U,BAO_0000218,1,,,,,22224
7354,0,Cercopithecidae,Compound was evaluated for AUC after treatment with iv dose of 1 mgkg to female cynomolgus monkey,A,9527.0,,,,CHEMBL618579,2661,U,BAO_0000218,1,,,,,22224
7355,0,Cercopithecidae,Compound was evaluated for AUC after treatment with oral dose of 2 mgkg to female cynomolgus monkey,A,9527.0,,,,CHEMBL618580,2661,U,BAO_0000019,1,,,,,22224
7356,0,Cercopithecidae,Pharmacokinetic parameter Cmax was measured after administration into monkey at 3 mg/kg,A,9527.0,,,,CHEMBL618581,5394,U,BAO_0000218,1,,,,,22224
7357,0,Cercopithecidae,Pharmacokinetic property at the dose of 10 mg/kg (20% HPbetaCD) concentration in cynomolgus monkeys (0 to 24 hr) p.o.,A,9527.0,,,,CHEMBL618582,4397,U,BAO_0000218,1,,,,,22224
7358,0,Cercopithecidae,Area under curve value 24 hr after 2 mg/kg iv administration in monkeys,A,9527.0,,,,CHEMBL618583,17509,U,BAO_0000218,1,,,,,22224
7359,0,Cercopithecidae,Area under curve value 24 hr after 2 mg/kg oral administration in monkeys,A,9527.0,,,,CHEMBL618584,17509,U,BAO_0000218,1,,,,,22224
7360,0,Cercopithecidae,Oral AUCN in monkey (dosed at 0.5 mpk iv ),A,9527.0,,,,CHEMBL618585,6641,U,BAO_0000218,1,,In vivo,,,22224
7361,0,Cercopithecidae,Bioavailability was reported in cynomolgus monkeys (ratio of AUC in oral administration to that of intravenous administration),A,9527.0,,,,CHEMBL618586,5355,U,BAO_0000218,1,,,,,22224
7362,0,Cercopithecidae,Half life compared to Cilastatin evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,A,9527.0,,,,CHEMBL618587,3443,U,BAO_0000218,1,,In vivo,,,22224
7363,0,Cercopithecidae,Half life evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,A,9527.0,,,,CHEMBL618588,3443,U,BAO_0000218,1,,In vivo,,,22224
7364,0,Cercopithecidae,Binding towards monkey plasma protein at 10 uM,A,9527.0,,,,CHEMBL618589,17409,U,BAO_0000019,1,,,,,22224
7365,0,Cercopithecidae,Binding towards monkey plasma protein at 100 uM,A,9527.0,,,,CHEMBL618590,17409,U,BAO_0000019,1,,,,,22224
7366,0,Cercopithecidae,Apparent bioavailability in squirrel monkey was determined,A,9527.0,,,,CHEMBL872262,1052,U,BAO_0000218,1,,In vivo,,,22224
7367,0,Cercopithecidae,Bioavailability was determined after oral administration of compound 18 at a dose of 1 mg/kg to rhesus monkey,A,9527.0,,,,CHEMBL618591,13501,U,BAO_0000218,1,,In vivo,,,22224
7368,0,monkey,Bioavailability in monkey (dose 2 mg/kg),A,9443.0,,,,CHEMBL618592,17509,U,BAO_0000218,1,,In vivo,,,22224
7369,0,Cercopithecidae,Compound at a dose 3 mg/kg was administered to monkey and was evaluated for bioavailability after administration into monkey at 3 mg/kg,A,9527.0,,,,CHEMBL876488,5394,U,BAO_0000218,1,,In vivo,,,22224
7370,0,Cercopithecidae,Compound was evaluated for bioavailability after treatment with oral dose of 2 mgkg to female cynomolgus monkey,A,9527.0,,,,CHEMBL618593,2661,U,BAO_0000218,1,,In vivo,,,22224
7371,0,monkey,Bioavailability in monkey (i.d. dosing),A,9443.0,,,,CHEMBL618594,11219,U,BAO_0000218,1,,In vivo,,,22224
7372,0,Cercopithecidae,Oral bioavailability after 5 mg/kg in cynomolgus monkey was determined,A,9527.0,,,,CHEMBL618595,3045,U,BAO_0000218,1,,In vivo,,,22224
7373,0,Cercopithecidae,Clearance of the drug was measured in cynomolgus,A,9527.0,,,,CHEMBL621469,17796,U,BAO_0000019,1,,,,,22224
7374,0,Cercopithecidae,Clearance was estimated in two squirrel monkeys after iv administration at 5 mg/kg,A,9527.0,,,,CHEMBL621470,1399,U,BAO_0000218,1,,In vivo,,,22224
7375,0,Cercopithecidae,Compound was evaluated for clearance after treatment with iv dose of 1 mgkg to female cynomolgus monkey,A,9527.0,,,,CHEMBL621471,2661,U,BAO_0000218,1,,In vivo,,,22224
7376,0,Macaca mulatta,Compound was tested for its plasma clearance rate in rhesus monkey at a dose of 0.75 mg/kg iv/ 1.5 mg/kg po,A,9544.0,Plasma,,,CHEMBL621472,5005,U,BAO_0000218,1,1969.0,In vivo,,,22224
7377,0,Cercopithecidae,Plasma clearance in rhesus monkey was determined,A,9527.0,,,,CHEMBL621473,17267,U,BAO_0000218,1,,In vivo,,,22224
7378,0,Cercopithecidae,Plasma clearance in monkey after administration of 1 mg/kg iv,A,9527.0,,,,CHEMBL621474,6535,U,BAO_0000218,1,,In vivo,,,22224
7379,0,Cercopithecidae,Plasma clearance in cynomolgus monkey,A,9527.0,,,,CHEMBL621475,5922,U,BAO_0000218,1,,In vivo,,,22224
7380,0,Cercopithecidae,Plasma clearance after oral administration (2.5 mg/kg) in monkey was determined,A,9527.0,,,,CHEMBL621476,6221,U,BAO_0000218,1,,In vivo,,,22224
7381,0,Cercopithecidae,Plasma clearance after peroral administration at 10 mpk in Rhesus,A,9527.0,,,,CHEMBL624290,5668,U,BAO_0000218,1,,In vivo,,,22224
7382,0,Cercopithecidae,The total clearance was determined after intravenous administration in cynomolgus monkeys,A,9527.0,,,,CHEMBL624291,5355,U,BAO_0000218,1,,In vivo,,,22224
7383,0,Cercopithecidae,The total clearance was determined after oral administration in cynomolgus monkeys; NA means Not applicable,A,9527.0,,,,CHEMBL624292,5355,U,BAO_0000218,1,,In vivo,,,22224
7384,0,Cercopithecidae,The total clearance was determined after oral administration in cynomolgus monkeys; NA means not applicable,A,9527.0,,,,CHEMBL624293,5355,U,BAO_0000218,1,,In vivo,,,22224
7385,0,Cercopithecidae,Tested for Clearance upon iv administration to african green monkey,A,9527.0,,,,CHEMBL624294,4578,U,BAO_0000218,1,,In vivo,,,22224
7386,0,Cercopithecidae,Clearance in monkey,A,9527.0,,,,CHEMBL624295,17592,U,BAO_0000218,1,,In vivo,,,22224
7387,1,Canis lupus familiaris,Half life in dog (dosed at 0.5 mpk iv and 2.0 mpk orally),A,9615.0,,,,CHEMBL624296,6641,N,BAO_0000218,1,,In vivo,,,50588
7388,1,Canis lupus familiaris,Half life in dog (dosed at 0.5 mpk iv and 2.0 mpk orally),A,9615.0,,,,CHEMBL624297,6642,N,BAO_0000218,1,,In vivo,,,50588
7389,1,Canis lupus familiaris,Half life was evaluated after intravenous administration to dogs,A,9615.0,,,,CHEMBL624298,16367,N,BAO_0000218,1,,In vivo,,,50588
7390,1,Canis lupus familiaris,Half life was evaluated in dog,A,9615.0,,,,CHEMBL624299,5472,N,BAO_0000218,1,,,,,50588
7391,1,Canis lupus familiaris,Half life was evaluated in dog,A,9615.0,,,,CHEMBL624300,5474,N,BAO_0000218,1,,,,,50588
7392,1,Canis lupus familiaris,Half life period (t1/2) of compound was determined after intravenous administration in average of two dogs at a dose of 1 mg/kg,A,9615.0,,,,CHEMBL624301,5654,N,BAO_0000218,1,,In vivo,,,50588
7393,1,Canis lupus familiaris,Half life period after intravenous administration (1 mg/kg) was determined in dog (in vivo),A,9615.0,,,,CHEMBL624302,6227,N,BAO_0000218,1,,In vivo,,,50588
7394,1,Canis lupus familiaris,Half life period after intravenous administration in dog,A,9615.0,,,,CHEMBL876026,6227,N,BAO_0000218,1,,In vivo,,,50588
7395,1,Canis lupus familiaris,Half life period after oral administration (2.5 mg/kg) in dog was determined,A,9615.0,,,,CHEMBL624303,6221,N,BAO_0000218,1,,In vivo,,,50588
7396,1,Canis lupus familiaris,Half life period at a dose of 1 uM/kg in dog was determined,A,9615.0,,,,CHEMBL624304,4527,N,BAO_0000218,1,,,,,50588
7397,1,Canis lupus familiaris,Half life period was determine after peroral administration at 10 mpk in dog,A,9615.0,,,,CHEMBL624305,5668,N,BAO_0000218,1,,In vivo,,,50588
7398,1,Canis lupus familiaris,Half life period was determine after peroral administration at 5 mpk in dog,A,9615.0,,,,CHEMBL624306,5668,N,BAO_0000218,1,,In vivo,,,50588
7399,1,Canis lupus familiaris,Half life period was determined,A,9615.0,,,,CHEMBL624307,3854,N,BAO_0000218,1,,,,,50588
7400,1,Canis lupus familiaris,Half life period was determined,A,9615.0,,,,CHEMBL624308,5505,N,BAO_0000218,1,,,,,50588
7401,1,Canis lupus familiaris,Half life period by iv administration in dog at a dose of 6 mg/kg,A,9615.0,,,,CHEMBL624309,6251,N,BAO_0000218,1,,In vivo,,,50588
7402,1,Canis lupus familiaris,Half life period was evaluated in dog,A,9615.0,,,,CHEMBL624310,1918,N,BAO_0000218,1,,,,,50588
7403,1,Canis lupus familiaris,Half life period was determined in Beagle dog at a dose of 1 mg/kg by iv administration,A,9615.0,,,,CHEMBL625003,5546,N,BAO_0000218,1,,In vivo,,,50588
7404,1,Canis lupus familiaris,Half life period was determined in Beagle dogs after (iv) administration of a dose of 12 (uM/kg),A,9615.0,,,,CHEMBL625004,4809,N,BAO_0000218,1,,In vivo,,,50588
7405,1,Canis lupus familiaris,Half life time after intravenous administration (0.5 mg/kg) was determined in dog,A,9615.0,,,,CHEMBL625005,6215,N,BAO_0000218,1,,In vivo,,,50588
7406,1,Canis lupus familiaris,Half-life period by oral administration at a dose of 10 uM/kg in dog was determined,A,9615.0,,,,CHEMBL873813,4527,N,BAO_0000218,1,,In vivo,,,50588
7407,1,Canis lupus familiaris,Half-life after oral dose of compound at 3 mg/kg in dogs,A,9615.0,,,,CHEMBL625006,17594,N,BAO_0000218,1,,In vivo,,,50588
7408,1,Canis lupus familiaris,Half-life of compound in dog following p.o. administration of 0.5 mg/kg,A,9615.0,,,,CHEMBL625007,17839,N,BAO_0000218,1,,In vivo,,,50588
7409,1,Canis lupus familiaris,Half-life of compound in dog following p.o. administration of 0.9 mg/kg,A,9615.0,,,,CHEMBL876027,17839,N,BAO_0000218,1,,In vivo,,,50588
7410,1,Canis lupus familiaris,Half-life of compound in dog following p.o. administration of 0.95 mg/kg,A,9615.0,,,,CHEMBL625008,17839,N,BAO_0000218,1,,In vivo,,,50588
7411,1,Canis lupus familiaris,Half-life of compound in dog following p.o. administration of 1 mg/kg,A,9615.0,,,,CHEMBL625009,17839,N,BAO_0000218,1,,In vivo,,,50588
7412,1,Canis lupus familiaris,Half-life of compound in plasma of dog was determined,A,9615.0,Plasma,,,CHEMBL625010,5210,N,BAO_0000218,1,1969.0,,,,50588
7413,1,Canis lupus familiaris,Half-life of compound was determined in dogs,A,9615.0,,,,CHEMBL625011,5210,N,BAO_0000218,1,,,,,50588
7414,1,Canis lupus familiaris,Half-life after administration of 4 mg/Kg oral dose in dog,A,9615.0,,,,CHEMBL621553,2959,N,BAO_0000218,1,,In vivo,,,50588
7415,1,Canis lupus familiaris,Half-life after intravenous administration of 1 mg/kg/h in dog,A,9615.0,,,,CHEMBL621554,4137,N,BAO_0000218,1,,In vivo,,,50588
7416,1,Canis lupus familiaris,Half-life in Dog,A,9615.0,,,,CHEMBL621555,5064,N,BAO_0000218,1,,,,,50588
7417,1,Canis lupus familiaris,Half-life in Dog,A,9615.0,,,,CHEMBL621556,5147,N,BAO_0000218,1,,,,,50588
7418,1,Canis lupus familiaris,Half-life in dog,A,9615.0,,,,CHEMBL621557,5145,N,BAO_0000218,1,,,,,50588
7419,1,Canis lupus familiaris,Half-life in dog after oral administration at 1 mg/kg,A,9615.0,,,,CHEMBL621558,6123,N,BAO_0000218,1,,In vivo,,,50588
7420,1,Canis lupus familiaris,Half-life in dog after oral administration at 1 mg/kg; nd is not determined,A,9615.0,,,,CHEMBL621559,6123,N,BAO_0000218,1,,In vivo,,,50588
7421,1,Canis lupus familiaris,Half-life in dogs,A,9615.0,,,,CHEMBL621560,4333,N,BAO_0000218,1,,,,,50588
7422,1,Canis lupus familiaris,Half-life in dogs; ND indicates not determined,A,9615.0,,,,CHEMBL876028,4333,N,BAO_0000218,1,,,,,50588
7423,1,Canis lupus familiaris,Half-life in plasma of dog,A,9615.0,Plasma,,,CHEMBL621561,12500,N,BAO_0000218,1,1969.0,,,,50588
7424,1,Canis lupus familiaris,Half-life in plasma of dog at dose of 3-10 mgkg,A,9615.0,Plasma,,,CHEMBL621562,12500,N,BAO_0000218,1,1969.0,,,,50588
7425,1,Canis lupus familiaris,Half-life was evaluated after i.v. administration in dog at a dose of 1 mg/kg,A,9615.0,,,,CHEMBL621563,6005,N,BAO_0000218,1,,In vivo,,,50588
7426,1,Canis lupus familiaris,Half-life was measured in dog after an iv dose of 1 mg/kg,A,9615.0,,,,CHEMBL621564,6062,N,BAO_0000218,1,,In vivo,,,50588
7427,1,Canis lupus familiaris,Half-life was measured in dogs after an oral dose of 10 uM/kg,A,9615.0,,,,CHEMBL621565,17650,N,BAO_0000218,1,,In vivo,,,50588
7428,1,Canis lupus familiaris,Half-life in vivo in dog by intravenous administration at a dose of 0.2 mg/kg,A,9615.0,,,,CHEMBL621566,5530,N,BAO_0000218,1,,In vivo,,,50588
7429,1,Canis lupus familiaris,Half-life in vivo in dog by intravenous administration at a dose of 1 mg/kg,A,9615.0,,,,CHEMBL621567,5530,N,BAO_0000218,1,,In vivo,,,50588
7430,1,Canis lupus familiaris,Half-life of the compound after 0.3 mg/kg po administration in dog,A,9615.0,,,,CHEMBL622978,5600,N,BAO_0000218,1,,In vivo,,,50588
7431,1,Canis lupus familiaris,Half-life period after intravenous administration of 0.5 mg/kg in dog was determined,A,9615.0,,,,CHEMBL873814,6039,N,BAO_0000218,1,,In vivo,,,50588
7432,1,Canis lupus familiaris,Half-life period after intravenous administration of 1.0 mg/kg in dog was determined,A,9615.0,,,,CHEMBL623219,6039,N,BAO_0000218,1,,In vivo,,,50588
7433,1,Canis lupus familiaris,Half-life period after peroral administration of 0.2 mg/kg in dog was determined,A,9615.0,,,,CHEMBL624477,6039,N,BAO_0000218,1,,In vivo,,,50588
7434,1,Canis lupus familiaris,t1/2 in dog,A,9615.0,,,,CHEMBL624478,6227,N,BAO_0000218,1,,,,,50588
7435,1,Canis lupus familiaris,Half-life period measured in dogs,A,9615.0,,,,CHEMBL624479,14541,N,BAO_0000218,1,,,,,50588
7436,1,Canis lupus familiaris,Half-life period in dog after 2 mg/kg by oral and 0.5 mg/kg by intravenous administration,A,9615.0,,,,CHEMBL624480,4521,N,BAO_0000218,1,,In vivo,,,50588
7437,1,Canis lupus familiaris,Half-life period in dog after 2 mg/kg by oral and 0.5 mg/kg by intravenous administration; ND is not determined,A,9615.0,,,,CHEMBL623595,4521,N,BAO_0000218,1,,In vivo,,,50588
7438,1,Canis lupus familiaris,Half-life period was determined after 1 mg/kg (i.v.) / 2 mg/kg (p.o.) of compound administration,A,9615.0,,,,CHEMBL623596,6679,N,BAO_0000218,1,,In vivo,,,50588
7439,1,Canis lupus familiaris,"In vitro half life at 1.5 -5.6ug/mL, 37 degree C in dog plasma",A,9615.0,Plasma,,,CHEMBL623597,1116,N,BAO_0000218,1,1969.0,In vitro,,,50588
7440,1,Canis lupus familiaris,In vivo half life period was calculated at 1 mg/kg in dog,A,9615.0,,,,CHEMBL623598,5444,N,BAO_0000218,1,,In vivo,,,50588
7441,1,Canis lupus familiaris,In vivo half life period was calculated at 1 mg/kg in dog; ND=Not determined,A,9615.0,,,,CHEMBL623599,5444,N,BAO_0000218,1,,In vivo,,,50588
7442,1,Canis lupus familiaris,Longer half-life in dog (i.v.) at 0.5 mpk,A,9615.0,,,,CHEMBL623600,17853,N,BAO_0000218,1,,In vivo,,,50588
7443,1,Canis lupus familiaris,Oral bioavailability in dog (dose 5 uM/kg),A,9615.0,,,,CHEMBL623601,4353,N,BAO_0000218,1,,In vivo,,,50588
7444,1,Canis lupus familiaris,Pharmacokinetic data at 0.5 mg/kg dose given to dogs intravenously.,A,9615.0,,,,CHEMBL623602,16452,N,BAO_0000218,1,,In vivo,,,50588
7445,1,Canis lupus familiaris,Pharmacokinetic data at 1 mg/kg dose given to dogs intravenously,A,9615.0,,,,CHEMBL623603,16452,N,BAO_0000218,1,,In vivo,,,50588
7446,1,Canis lupus familiaris,Bioavailability in dog (dose 1 mg/kg i.v.),A,9615.0,,,,CHEMBL623604,16452,N,BAO_0000218,1,,In vivo,,,50588
7447,1,Mus musculus,Biodistribution of intravenously injected [82Br]-labeled compound in lung of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.5 hours,A,10090.0,Lung,,,CHEMBL623605,10107,N,BAO_0000218,1,2048.0,In vivo,,,50594
7448,1,Mus musculus,Biodistribution of intravenously injected [82Br]-labeled compound in lung of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,A,10090.0,Lung,,,CHEMBL623606,10107,N,BAO_0000218,1,2048.0,In vivo,,,50594
7449,1,Mus musculus,Biodistribution of intravenously injected [82Br]-labeled compound in lung of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,A,10090.0,Lung,,,CHEMBL623607,10107,N,BAO_0000218,1,2048.0,In vivo,,,50594
7450,1,Mus musculus,Biodistribution of intravenously injected [82Br]-labeled compound in lung of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,A,10090.0,Lung,,,CHEMBL623608,10107,N,BAO_0000218,1,2048.0,In vivo,,,50594
7451,1,Mus musculus,Biodistribution of intravenously injected [82Br]-labeled compound in lung of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,A,10090.0,Lung,,,CHEMBL623609,10107,N,BAO_0000218,1,2048.0,In vivo,,,50594
7452,1,Mus musculus,Biodistribution of intravenously injected [82Br]-labeled compound in lung of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,A,10090.0,Lung,,,CHEMBL623610,10107,N,BAO_0000218,1,2048.0,In vivo,,,50594
7453,1,Mus musculus,Biodistribution of intravenously injected [82Br]-labeled compound in muscle of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,A,10090.0,Muscle tissue,,,CHEMBL623611,10107,N,BAO_0000218,1,2385.0,In vivo,,,50594
7454,1,Mus musculus,Biodistribution of intravenously injected [82Br]-labeled compound in muscle of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.5 hours,A,10090.0,Muscle tissue,,,CHEMBL623612,10107,N,BAO_0000218,1,2385.0,In vivo,,,50594
7455,1,Mus musculus,Biodistribution of intravenously injected [82Br]-labeled compound in muscle of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,A,10090.0,Muscle tissue,,,CHEMBL623613,10107,N,BAO_0000218,1,2385.0,In vivo,,,50594
7456,1,Mus musculus,Biodistribution of intravenously injected [82Br]-labeled compound in muscle of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,A,10090.0,Muscle tissue,,,CHEMBL623614,10107,N,BAO_0000218,1,2385.0,In vivo,,,50594
7457,1,Mus musculus,Biodistribution of intravenously injected [82Br]-labeled compound in muscle of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,A,10090.0,Muscle tissue,,,CHEMBL623615,10107,N,BAO_0000218,1,2385.0,In vivo,,,50594
7458,1,Mus musculus,Biodistribution of intravenously injected [82Br]-labeled compound in muscle of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,A,10090.0,Muscle tissue,,,CHEMBL623616,10107,N,BAO_0000218,1,2385.0,In vivo,,,50594
7459,1,Mus musculus,Biodistribution of intravenously injected [82Br]-labeled compound in muscle of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,A,10090.0,Muscle tissue,,,CHEMBL623617,10107,N,BAO_0000218,1,2385.0,In vivo,,,50594
7460,1,Mus musculus,Biodistribution of intravenously injected [82Br]-labeled compound in skin of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,A,10090.0,Zone of skin,,,CHEMBL875944,10107,N,BAO_0000218,1,14.0,In vivo,,,50594
7461,1,Mus musculus,Biodistribution of intravenously injected [82Br]-labeled compound in skin of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,A,10090.0,Zone of skin,,,CHEMBL623618,10107,N,BAO_0000218,1,14.0,In vivo,,,50594
7462,1,Mus musculus,Biodistribution of intravenously injected [82Br]-labeled compound in skin of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,A,10090.0,Zone of skin,,,CHEMBL623619,10107,N,BAO_0000218,1,14.0,In vivo,,,50594
7463,1,Mus musculus,Biodistribution of intravenously injected [82Br]-labeled compound in skin of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,A,10090.0,Zone of skin,,,CHEMBL623620,10107,N,BAO_0000218,1,14.0,In vivo,,,50594
7464,1,Mus musculus,Biodistribution of intravenously injected [82Br]-labeled compound in skin of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,A,10090.0,Zone of skin,,,CHEMBL623621,10107,N,BAO_0000218,1,14.0,In vivo,,,50594
7465,1,Mus musculus,Biodistribution of intravenously injected [82Br]-labeled compound in skin of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,A,10090.0,Zone of skin,,,CHEMBL623622,10107,N,BAO_0000218,1,14.0,In vivo,,,50594
7466,1,Mus musculus,Biodistribution of intravenously injected [82Br]-labeled compound in skin of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,A,10090.0,Zone of skin,,,CHEMBL623623,10107,N,BAO_0000218,1,14.0,In vivo,,,50594
7467,1,Mus musculus,Biodistribution of intravenously injected [82Br]-labeled compound in spleen of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,A,10090.0,Spleen,,,CHEMBL623624,10107,N,BAO_0000218,1,2106.0,In vivo,,,50594
7468,1,Mus musculus,Biodistribution of intravenously injected [82Br]-labeled compound in spleen of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,A,10090.0,Spleen,,,CHEMBL618521,10107,N,BAO_0000218,1,2106.0,In vivo,,,50594
7469,1,Mus musculus,Biodistribution of intravenously injected [82Br]-labeled compound in spleen of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,A,10090.0,Spleen,,,CHEMBL618522,10107,N,BAO_0000218,1,2106.0,In vivo,,,50594
7470,1,Mus musculus,Biodistribution of intravenously injected [82Br]-labeled compound in spleen of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,A,10090.0,Spleen,,,CHEMBL618523,10107,N,BAO_0000218,1,2106.0,In vivo,,,50594
7471,1,Mus musculus,Biodistribution of intravenously injected [82Br]-labeled compound in spleen of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,A,10090.0,Spleen,,,CHEMBL618524,10107,N,BAO_0000218,1,2106.0,In vivo,,,50594
7472,1,Mus musculus,Biodistribution of intravenously injected [82Br]-labeled compound in spleen of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,A,10090.0,Spleen,,,CHEMBL618525,10107,N,BAO_0000218,1,2106.0,In vivo,,,50594
7473,1,Mus musculus,Biodistribution of intravenously injected [82Br]-labeled compound in spleen of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,A,10090.0,Spleen,,,CHEMBL624586,10107,N,BAO_0000218,1,2106.0,In vivo,,,50594
7474,1,Mus musculus,Biodistribution of intravenously injected [82Br]-labeled compound in stomach of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,A,10090.0,Stomach,,,CHEMBL624587,10107,N,BAO_0000218,1,945.0,In vivo,,,50594
7475,1,Mus musculus,Biodistribution of intravenously injected [82Br]-labeled compound in stomach of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,A,10090.0,Stomach,,,CHEMBL624588,10107,N,BAO_0000218,1,945.0,In vivo,,,50594
7476,1,Mus musculus,Biodistribution of intravenously injected [82Br]-labeled compound in stomach of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,A,10090.0,Stomach,,,CHEMBL624589,10107,N,BAO_0000218,1,945.0,In vivo,,,50594
7477,1,Mus musculus,Biodistribution of intravenously injected [82Br]-labeled compound in stomach of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,A,10090.0,Stomach,,,CHEMBL624590,10107,N,BAO_0000218,1,945.0,In vivo,,,50594
7478,1,Mus musculus,Biodistribution of intravenously injected [82Br]-labeled compound in stomach of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,A,10090.0,Stomach,,,CHEMBL624591,10107,N,BAO_0000218,1,945.0,In vivo,,,50594
7479,1,Mus musculus,Biodistribution of intravenously injected [82Br]-labeled compound in stomach of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,A,10090.0,Stomach,,,CHEMBL624592,10107,N,BAO_0000218,1,945.0,In vivo,,,50594
7480,1,Mus musculus,Biodistribution of intravenously injected [82Br]-labeled compound in stomach of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,A,10090.0,Stomach,,,CHEMBL624593,10107,N,BAO_0000218,1,945.0,In vivo,,,50594
7481,1,Rattus norvegicus,Oral bioavailability in rat,A,10116.0,,,,CHEMBL624594,4689,N,BAO_0000218,1,,In vivo,,,50597
7482,1,Rattus norvegicus,Tested for the bioavailability in rat,A,10116.0,,,,CHEMBL624595,4950,N,BAO_0000218,1,,In vivo,,,50597
7483,1,Rattus norvegicus,Bioavailability in rat (dose 1 mg/kg i.v. and 2 mg/kg p.o.),A,10116.0,,,,CHEMBL624596,5328,N,BAO_0000218,1,,In vivo,,,50597
7484,1,Rattus norvegicus,Bioavailability in rat,A,10116.0,,,,CHEMBL624597,406,N,BAO_0000218,1,,In vivo,,,50597
7485,1,Rattus norvegicus,Bioavailability in rat,A,10116.0,,,,CHEMBL624598,12500,N,BAO_0000218,1,,In vivo,,,50597
7486,1,Rattus norvegicus,Bioavailability in rat (dose 3-10 mg/kg),A,10116.0,,,,CHEMBL624599,12500,N,BAO_0000218,1,,In vivo,,,50597
7487,1,Rattus norvegicus,Bioavailability in rat,A,10116.0,,,,CHEMBL875166,5247,N,BAO_0000218,1,,In vivo,,,50597
7488,1,Rattus norvegicus,Apparent terminal elimination half-life in rat plasma after administration of 3.5 mg/kg dose through subcutaneous route,A,10116.0,Plasma,,,CHEMBL624600,4186,N,BAO_0000218,1,1969.0,In vivo,,,50597
7489,1,Rattus norvegicus,Apparent terminal elimination half-life in rat plasma after administration of 50 mg/kg dose through subcutaneous route,A,10116.0,Plasma,,,CHEMBL624601,4186,N,BAO_0000218,1,1969.0,In vivo,,,50597
7490,1,Rattus norvegicus,Half life after oral administration was determined in rats at 6 mg/kg,A,10116.0,,,,CHEMBL624602,6647,N,BAO_0000218,1,,In vivo,,,50597
7491,1,Rattus norvegicus,Half life was determined,A,10116.0,,,,CHEMBL624603,6484,N,BAO_0000218,1,,,,,50597
7492,1,Rattus norvegicus,Half life the of compound was determined by ''Cr'' assay in rat at a dose of 10 mg/kg,A,10116.0,,,,CHEMBL624604,3249,N,BAO_0000218,1,,In vivo,,,50597
7493,1,Rattus norvegicus,Plasma half life in rat at oral dose 2.8 mg/mk body weight,A,10116.0,Plasma,,,CHEMBL624605,6281,N,BAO_0000218,1,1969.0,In vivo,,,50597
7494,1,Rattus norvegicus,Half life in rats,A,10116.0,,,,CHEMBL624606,3307,N,BAO_0000218,1,,,,,50597
7495,1,Rattus norvegicus,Half-lives were estimated from the elimination phase of the blood conc-time curve after oral administration,A,10116.0,Blood,,,CHEMBL624607,12058,N,BAO_0000218,1,178.0,In vivo,,,50597
7496,1,Rattus norvegicus,Hill coefficient of the compound,A,10116.0,,,,CHEMBL624608,8833,N,BAO_0000218,1,,,,,50597
7497,1,Rattus norvegicus,Compound was tested for percent hydrolysis in whole blood after a time interval of 0.5 min,A,10116.0,Blood,,,CHEMBL624609,3193,N,BAO_0000218,1,178.0,,,,50597
7498,1,Rattus norvegicus,Compound was tested for percent hydrolysis in whole blood after a time interval of 180.0 min,A,10116.0,Blood,,,CHEMBL624610,3193,N,BAO_0000218,1,178.0,,,,50597
7499,1,Rattus norvegicus,Compound was tested for percent hydrolysis in whole blood after a time interval of 2.0 min,A,10116.0,Blood,,,CHEMBL624611,3193,N,BAO_0000218,1,178.0,,,,50597
7500,1,Rattus norvegicus,Compound was tested for percent hydrolysis in whole blood after a time interval of 5.0 min,A,10116.0,Blood,,,CHEMBL624612,3193,N,BAO_0000218,1,178.0,,,,50597
7501,1,Rattus norvegicus,Compound was tested for percent hydrolysis in whole blood after a time interval of 60.0 min,A,10116.0,Blood,,,CHEMBL875167,3193,N,BAO_0000218,1,178.0,,,,50597
7502,1,Rattus norvegicus,Compound was tested for percent hydrolysis in whole blood after a time interval of 7.0 min,A,10116.0,Blood,,,CHEMBL624613,3193,N,BAO_0000218,1,178.0,,,,50597
7503,1,Rattus norvegicus,"Compound was tested for percent hydrolysis in whole blood, after a time interval of 15.0 min",A,10116.0,Blood,,,CHEMBL624614,3193,N,BAO_0000218,1,178.0,,,,50597
7504,1,Rattus norvegicus,Plasma concentration at 4 hr after 30 mg/kg post dosing in rat using HPLC/MS,A,10116.0,,,,CHEMBL624392,5960,N,BAO_0000218,1,,,,,50597
7505,1,Rattus norvegicus,Biodistribution of [123I]-label in rat brain was reported at 0.33 hr post injection. Value shown is %ID/organ,A,10116.0,Brain,,,CHEMBL624393,13950,N,BAO_0000218,1,955.0,In vivo,,,50597
7506,1,Rattus norvegicus,Biodistribution of [123I]-label in rat brain was reported at 1 hr post injection. Value shown is %ID/organ,A,10116.0,Brain,,,CHEMBL624394,13950,N,BAO_0000218,1,955.0,In vivo,,,50597
7507,1,Rattus norvegicus,Biodistribution of [123I]-label in rat brain was reported at 2 hr post injection. Value shown is %ID/organ,A,10116.0,Brain,,,CHEMBL624395,13950,N,BAO_0000218,1,955.0,In vivo,,,50597
7508,1,Rattus norvegicus,Biodistribution of [123I]-label in rat brain was reported at 24 hr post injection. Value shown is %ID/organ,A,10116.0,Brain,,,CHEMBL624396,13950,N,BAO_0000218,1,955.0,In vivo,,,50597
7509,1,Rattus norvegicus,Biodistribution of [123I]-label in rat brain was reported at 4 hr post injection. Value shown is %ID/organ,A,10116.0,Brain,,,CHEMBL624397,13950,N,BAO_0000218,1,955.0,In vivo,,,50597
7510,1,Rattus norvegicus,Biodistribution of [123I]-label in rat thyroid was reported at 0.33 hr post injection. Value shown is %ID/organ,A,10116.0,Thyroid gland,,,CHEMBL624398,13950,N,BAO_0000218,1,2046.0,In vivo,,,50597
7511,1,Rattus norvegicus,Biodistribution of [123I]-label in rat thyroid was reported at 1 hr post injection. Value shown is %ID/organ,A,10116.0,Thyroid gland,,,CHEMBL624399,13950,N,BAO_0000218,1,2046.0,In vivo,,,50597
7512,1,Rattus norvegicus,Biodistribution of [123I]-label in rat thyroid was reported at 2 hr post injection. Value shown is %ID/organ,A,10116.0,Thyroid gland,,,CHEMBL624400,13950,N,BAO_0000218,1,2046.0,In vivo,,,50597
7513,1,Rattus norvegicus,Biodistribution of [123I]-label in rat thyroid was reported at 24 hr post injection. Value shown is %ID/organ,A,10116.0,Thyroid gland,,,CHEMBL624401,13950,N,BAO_0000218,1,2046.0,In vivo,,,50597
7514,1,Rattus norvegicus,Biodistribution of [123I]-label in rat thyroid was reported at 4 hr post injection. Value shown is %ID/organ,A,10116.0,Thyroid gland,,,CHEMBL624402,13950,N,BAO_0000218,1,2046.0,In vivo,,,50597
7515,1,Rattus norvegicus,Biodistribution in normal rat blood in the presence of 0.005 M Gd/0.01 M lig at 2 hr,A,10116.0,Blood,,,CHEMBL624403,9866,N,BAO_0000218,1,178.0,In vivo,,,50597
7516,1,Rattus norvegicus,Biodistribution in normal rat blood in the presence of 0.01 M Gd/0.05 M lig,A,10116.0,Blood,,,CHEMBL624404,9866,N,BAO_0000218,1,178.0,In vivo,,,50597
7517,1,Rattus norvegicus,Biodistribution in normal rat blood in the presence of NAC Gd 0.01 M lig at 2 hr,A,10116.0,Blood,,,CHEMBL624405,9866,N,BAO_0000218,1,178.0,In vivo,,,50597
7518,1,Rattus norvegicus,Biodistribution in normal rat bone in the presence of 0.005 M Gd/0.01 M lig at 2 hr,A,10116.0,Bone,,,CHEMBL624406,9866,N,BAO_0000218,1,10000001.0,In vivo,,,50597
7519,1,Rattus norvegicus,Biodistribution in normal rat bone in the presence of 0.01 M Gd/0.05 M lig,A,10116.0,Bone,,,CHEMBL624407,9866,N,BAO_0000218,1,10000001.0,In vivo,,,50597
7520,1,Rattus norvegicus,Biodistribution in normal rat bone in the presence of NAC Gd 0.01 M lig at 2 hr,A,10116.0,Bone,,,CHEMBL624408,9866,N,BAO_0000218,1,10000001.0,In vivo,,,50597
7521,1,Rattus norvegicus,Biodistribution in normal rat heart in the presence of 0.005 M Gd/0.01 M lig at 2 hr,A,10116.0,Heart,,,CHEMBL618644,9866,N,BAO_0000218,1,948.0,In vivo,,,50597
7522,1,Rattus norvegicus,Biodistribution in normal rat heart in the presence of 0.01 M Gd/0.05 M lig,A,10116.0,Heart,,,CHEMBL618645,9866,N,BAO_0000218,1,948.0,In vivo,,,50597
7523,1,Rattus norvegicus,Biodistribution in normal rat heart in the presence of NAC Gd 0.01 M lig at 2 hr,A,10116.0,Heart,,,CHEMBL618646,9866,N,BAO_0000218,1,948.0,In vivo,,,50597
